PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P				Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P			Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IRON OVERLOAD	Background and Methods Hereditary hemochromatosis in adults is usually characterized by mutations in the hemochromatosis (HFE) gene on the short arm of chromosome 6. Most patients have a substitution of tyrosine for cysteine at position 282 (C282Y). We studied a large family from Italy that includes persons who have a hereditary iron-overload condition indistinguishable from hemochromatosis but without apparent pathogenic mutations in the HFE gene. We performed biochemical, histologic, and genetic studies of 53 living members of the family, including microsatellite analysis of chromosome 6 and direct sequencing of the HFE gene, Results Of the 53 family members, 15 had abnormal serum ferritin levels, values for transferrin saturation that were higher than 50 percent, or both. Thirteen of the 15 had elevated body iron levels, diagnosed on the basis of the clinical evaluation and liver biopsy, and underwent iron-removal therapy. The other two, both children, did not undergo liver biopsy or iron-removal therapy. None of the 15 members had the C282Y mutation of the HFE gene; 5 of the 15 (as well as 5 healthy relatives) had another mutation of this gene, a substitution of aspartate for histidine at position 63, but none were homozygous for it. No other mutations were found after sequencing of the entire HFE gene for all family members. Microsatellite analysis showed no linkage of the hemochromatosis phenotype with the short arm of chromosome 6, the site of the HFE gene. Conclusions Hereditary hemochromatosis can occur in adults who do not have pathogenic mutations in the hemochromatosis gene. (N Engl J Med 1999;341:725-32,) (C)1999, Massachusetts Medical Society.	Univ Modena, Policlin, Dept Internal Med, I-41100 Modena, Italy; Osped San Giovanni Rotondo, Foggia, Italy; Univ Milan, Dept Gastroenterol, Milan, Italy	Universita di Modena e Reggio Emilia; University of Milan	Pietrangelo, A (corresponding author), Univ Modena, Policlin, Dept Internal Med, Via Pozzo 71, I-41100 Modena, Italy.		Gasparini, Paolo/B-6173-2014; Cassanelli, Stefano/D-7631-2015; Pietrangelo, Antonello/K-1517-2016	Cassanelli, Stefano/0000-0001-5929-4689; Pietrangelo, Antonello/0000-0002-7411-935X; Gasparini, Paolo/0000-0002-0859-0856	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Beutler E, 1997, AM J HUM GENET, V61, P762; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; Carella M, 1997, AM J HUM GENET, V60, P828; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; McNamara L, 1998, BRIT J HAEMATOL, V102, P1176; PERKINS KW, 1965, AM J MED, V39, P118, DOI 10.1016/0002-9343(65)90251-2; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; ROCCHI E, 1986, J LAB CLIN MED, V107, P36; Sanchez M, 1998, GENE, V225, P77, DOI 10.1016/S0378-1119(98)00519-8; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; VONRECKLINGHAUS.FD, 1889, HAEMOCHROMATOSE, P324	16	209	220	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					725	732		10.1056/NEJM199909023411003	http://dx.doi.org/10.1056/NEJM199909023411003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471458				2022-12-28	WOS:000082291900003
J	Yusuf, S				Yusuf, S			Randomised controlled trials in cardiovascular medicine: past achievements, future challenges	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REQUIRING PROLONGED OBSERVATION; ACUTE MYOCARDIAL-INFARCTION; DISEASE; PATIENT; DESIGN; RISK		McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University	Yusuf, S (corresponding author), Hamilton Gen Hosp, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				ADAMS DH, 1986, LANCET, V1, P57; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; COLLINS R, 1995, LANCET, V345, P669; FLATHER MD, 1995, ACUTE CORONARY CARE, P131; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; MELDRUM M, 1998, BMJ-BRIT MED J, V317, P233; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Montague T, 1996, CAN J CARDIOL, V12, P995; Perry G, 1997, NEW ENGL J MED, V336, P525; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Reddy KS, 1998, CIRCULATION, V97, P596; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	29	16	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					564	568		10.1136/bmj.319.7209.564	http://dx.doi.org/10.1136/bmj.319.7209.564			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463903	Green Published			2022-12-28	WOS:000082347200032
J	Nosten, F; McGready, R; Simpson, JA; Thwai, KL; Balkan, S; Cho, T; Hkirijaroen, L; Looareesuwan, S; White, NJ				Nosten, F; McGready, R; Simpson, JA; Thwai, KL; Balkan, S; Cho, T; Hkirijaroen, L; Looareesuwan, S; White, NJ			Effects of Plasmodium vivax malaria in pregnancy	LANCET			English	Article							HUMAN PLACENTA; FALCIPARUM	Background Plasmodium vivax is more common than P falciparum as a cause of malaria in many parts of the tropics outside Africa. P falciparum infection has harmful effects in pregnancy, but the effects of P vivax have not been characterised. We investigated the effects of P vivax infection during pregnancy. Methods Since 1986, pregnant Karen women living in camps for displaced people on the western border of Thailand have been encouraged to attend antenatal clinics. Karen women were screened for malaria and anaemia at each week of pregnancy until delivery, and pregnancy outcome recorded. We compared the effects of P vivax infection on anaemia and pregnancy outcome with those of P falciparum and no malaria infection in the first pregnancy recorded at the antenatal clinics. Findings There were 634 first episodes of pure P vivax malaria in 9956 women. P vivax malaria was more common in primigravidae than in multigravidae and was associated with mild anaemia and an increased risk of low birthweight (odds ratio 1.64 [95% CI 1.29-2.08], p<0.001). The birthweight was a mean of 107 g (95% CI 61-154) lower in women with P vivax infection than in uninfected women, By contrast with P falciparum malaria, the decrease in birthweight was greater in multigravidae. P vivax malaria was not associated with miscarriage, stillbirth, or with a shortened duration of pregnancy. Interpretation P vivax malaria during pregnancy is associated with maternal anaemia and low birthweight, The effects of P vivax infection are less striking than those of P falciparum infection, but antimalarial prophylaxis against P vivax in pregnancy may be justified.	Shoklo Malaria Res Unit, Mae Sot 63110, Thailand; Mahidol Univ, Fac Trop Med, Bangkok, Thailand; John Radcliffe Hosp, Nuffield Dept Med, Ctr Trop Med, Oxford, England; Med Sans Frontieres, Paris, France	Mahidol University; Mahidol University; University of Oxford; Doctors Without Borders	Nosten, F (corresponding author), Shoklo Malaria Res Unit, POB 46, Mae Sot 63110, Thailand.		Simpson, Julie A/P-7299-2014; McGready, Rose/A-3290-2014; White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012; Nosten, Francois/AAC-5509-2019	McGready, Rose/0000-0003-1621-3257; White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; Simpson, Julie/0000-0002-2660-2013	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bloland P, 1996, AM J TROP MED HYG, V55, P82, DOI 10.4269/ajtmh.1996.55.82; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Dubowitz L, 1977, GESTATIONAL AGE NEWB; Fried M, 1998, J IMMUNOL, V160, P2523; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Luxemburger C, 1996, T ROY SOC TROP MED H, V90, P105, DOI 10.1016/S0035-9203(96)90102-9; Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2; NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D; Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0; WATKINSON M, 1983, BMJ-BRIT MED J, V287, P251, DOI 10.1136/bmj.287.6387.251; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	11	259	264	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					546	549		10.1016/S0140-6736(98)09247-2	http://dx.doi.org/10.1016/S0140-6736(98)09247-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470698				2022-12-28	WOS:000081991000011
J	Orr, GW; Barbour, LJ; Atwood, JL				Orr, GW; Barbour, LJ; Atwood, JL			Controlling molecular self-organization: Formation of nanometer-scale spheres and tubules	SCIENCE			English	Article							CALIX<4>ARENES; ENCAPSULATION; DENDRIMERS; COMPLEXES; DESIGN; SHAPE; CORE	Amphiphilic polyhedron-shaped p-sulfonatocalix[4]arene building blocks, which have been previously shown to assemble into bilayers in an antiparallel fashion, have been assembled in a parallel alignment into spherical and helical tubular structures by the addition of pyridine N-oxide and Lanthanide ions. Crystallographic studies revealed how metal ion coordination and substrate recognition direct the formation of these supramolecular assemblies. The addition of greater amounts of pyridine N-oxide changed the curvature of the assembling surface and resulted in the formation of extended tubules.	Univ Missouri, Dept Chem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Atwood, JL (corresponding author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.		atwood, jerry/ABA-8947-2021					ATWOOD JL, 1989, J INCLUSION PHENOM, V7, P203, DOI 10.1007/BF01060722; ATWOOD JL, 1991, J AM CHEM SOC, V113, P2760, DOI 10.1021/ja00007a064; ATWOOD JL, 1992, INORG CHEM, V31, P603, DOI 10.1021/ic00030a015; Balagurusamy VSK, 1997, J AM CHEM SOC, V119, P1539, DOI 10.1021/ja963295i; Barbour LJ, 1998, NATURE, V393, P671, DOI 10.1038/31441; CASJENS S, 1995, VIRUS STRUCTURE ASSE, P75; Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Huang HY, 1998, CHEM COMMUN, P1415, DOI 10.1039/a708686e; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Israelachvili JN, 1985, INTERMOLECULAR SURFA; Jenekhe SA, 1998, SCIENCE, V279, P1903, DOI 10.1126/science.279.5358.1903; Jones M.N., 1995, MICELLES MONOLAYERS; KHAZANOVICH N, 1994, J AM CHEM SOC, V116, P6011, DOI 10.1021/ja00092a079; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; MANN S, 1996, BIOMIMETIC MAT CHEM; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; Percec V, 1998, NATURE, V391, P161, DOI 10.1038/34384; Shimizu KD, 1995, P NATL ACAD SCI USA, V92, P12403, DOI 10.1073/pnas.92.26.12403; Tanford C., 1973, HYDROPHOBIC EFFECT; Terfort A, 1997, NATURE, V386, P162, DOI 10.1038/386162a0; TIMASHEFF SN, 1978, PHYSICAL ASPECTS PRO, P219; Vreekamp RH, 1996, ANGEW CHEM INT EDIT, V35, P1215, DOI 10.1002/anie.199612151; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095	27	530	533	2	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1049	1052		10.1126/science.285.5430.1049	http://dx.doi.org/10.1126/science.285.5430.1049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446047				2022-12-28	WOS:000082033100040
J	Banner, AS				Banner, AS			Emerging role of corticosteroids in chronic obstructive pulmonary disease	LANCET			English	Editorial Material							CONTROLLED TRIAL		Harvard Univ, Sch Med, Manchester, NH 03104 USA; Vet Affairs Med Ctr, Manchester, NH 03104 USA	Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Banner, AS (corresponding author), Harvard Univ, Sch Med, Manchester, NH 03104 USA.							ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; Bourbeau J, 1998, THORAX, V53, P477, DOI 10.1136/thx.53.6.477; *BRIT THOR SOC, 1997, THORAX S5, V52; Bullard MJ, 1996, AM J EMERG MED, V14, P139, DOI 10.1016/S0735-6757(96)90120-5; Burge PS, 1999, THORAX, V54, P287, DOI 10.1136/thx.54.4.287; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; Centers for Disease Control and Prevention, 2007, AM J RESP CRIT CARE, V55; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nishimura K, 1999, CHEST, V115, P31, DOI 10.1378/chest.115.1.31; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Van Andel AE, 1999, CHEST, V115, P703; van Grunsven PM, 1999, THORAX, V54, P7, DOI 10.1136/thx.54.1.7; VESBO J, 1999, LANCET, V353, P1819	15	4	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					440	441		10.1016/S0140-6736(99)90119-8	http://dx.doi.org/10.1016/S0140-6736(99)90119-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465162				2022-12-28	WOS:000081896100002
J	Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA				Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA			Creation of human tumour cells with defined genetic elements	NATURE			English	Article							LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN-FIBROBLASTS; TRANSFORMATION; EXPRESSION; SENESCENCE; ONCOGENE; SARCOMA; CANCER	During malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling: cellular proliferation. Primary rodent cells are efficiently converted into tumorigenic cells by the coexpression of cooperating oncogenes(1,2). However, similar experiments with human cells have consistently failed to yield tumorigenic transformants(3-5), indicating a fundamental difference in the biology of human and rodent cells. The few reported successes in the creation of human tumour cells have depended on the use of chemical or physical agents to achieve immortalization(6), the selection of rare, spontaneously arising immortalized cells(7-10), or the use of an entire viral genome(11). We show here that the ectopic expression of the telomerase catalytic subunit (hTERT)(12) in combination with two oncogenes (the simian virus 40 large-T oncoprotein and an oncogenic allele of H-ras) results in direct tumorigenic conversion of normal human epithelial and fibroblast cells. These results demonstrate that disruption of the intracellular pathways regulated by large-T, oncogenic ras and telomerase suffices to create a human tumor cell.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu		Counter, Christopher M/0000-0003-0748-3079; Beijersbergen, Roderick/0000-0003-0116-4130				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kang KS, 1998, MOL CARCINOGEN, V21, P225, DOI 10.1002/(SICI)1098-2744(199804)21:4<225::AID-MC1>3.0.CO;2-J; Kim JW, 1997, INFORM SYST RES, V8, P25, DOI 10.1287/isre.8.1.25; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	30	1866	1948	1	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					464	468		10.1038/22780	http://dx.doi.org/10.1038/22780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440377				2022-12-28	WOS:000081715000054
J	Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM				Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM			Missing lithotroph identified as new planctomycete	NATURE			English	Article							ANAEROBIC AMMONIUM OXIDATION; ORDER PLANCTOMYCETALES; BUDDING BACTERIA; REACTOR; DIVERSITY; EVOLUTION; PIRELLA	With the increased use of chemical fertilizers in agriculture, many densely populated countries face environmental problems associated with high ammonia emissions. The process of anaerobic ammonia oxidation ('anammox') is one of the most innovative technological advances in the removal of ammonia nitrogen from waste water(1,2). This new process combines ammonia and nitrite directly into dinitrogen gas(3). Until now, bacteria capable of anaerobically oxidizing ammonia had never been found and were known as "lithotrophs missing from nature"(4). Here we report the discovery of this missing lithotroph and its identification as a new, autotrophic member of the order Planctomycetales, one of the major distinct divisions of the Bacteria(5). The new planctomycete grows extremely slowly, dividing only once every two weeks. At present, it cannot be cultivated by conventional microbiological techniques. The identification of this bacterium as the one responsible for anaerobic oxidation of ammonia makes an important contribution to the problem of unculturability.	Delft Univ Technol, Dept Biotechnol, NL-2628 BC Delft, Netherlands; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Netherlands Inst Sea Res, NL-1790 AB Den Burg, Netherlands	Delft University of Technology; University of Queensland; University of Queensland; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Jetten, MSM (corresponding author), Delft Univ Technol, Dept Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.		Strous, Marc/B-4064-2017; Muyzer, Gerard/A-3161-2013; Jetten, Mike/B-8834-2011; Fuerst, John/I-8649-2012; Muyzer, Gerard/ABE-5834-2020; Curto, Ana Q/O-6849-2015	Strous, Marc/0000-0001-9600-3828; Jetten, Mike/0000-0002-4691-7039; Fuerst, John/0000-0002-6451-8533; Muyzer, Gerard/0000-0002-2422-0732; Curto, Ana Q/0000-0003-3568-9322				BRODA E, 1977, Z ALLG MIKROBIOL, V17, P491, DOI 10.1002/jobm.3630170611; Byers HK, 1998, FEMS MICROBIOL ECOL, V25, P391, DOI 10.1016/S0168-6496(98)00013-0; DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924, DOI 10.4319/lo.1993.38.5.0924; FUERST JA, 1995, MICROBIOL-UK, V141, P1493, DOI 10.1099/13500872-141-7-1493; FUERST JA, 1991, P NATL ACAD SCI USA, V88, P8184, DOI 10.1073/pnas.88.18.8184; Fuerst JA, 1997, APPL ENVIRON MICROB, V63, P254, DOI 10.1128/AEM.63.1.254-262.1997; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Jetten MSM, 1997, WATER SCI TECHNOL, V35, P171, DOI 10.2166/wst.1997.0341; KONIG E, 1984, ARCH MICROBIOL, V138, P200, DOI 10.1007/BF00402120; LIESACK W, 1986, ARCH MICROBIOL, V145, P361, DOI 10.1007/BF00470872; Lindsay MR, 1997, MICROBIOL-UK, V143, P739, DOI 10.1099/00221287-143-3-739; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neef A, 1998, MICROBIOL-UK, V144, P3257, DOI 10.1099/00221287-144-12-3257; SCHLESNER H, 1986, SYST APPL MICROBIOL, V8, P174, DOI 10.1016/S0723-2020(86)80072-8; Strous M, 1997, WATER RES, V31, P1955, DOI 10.1016/S0043-1354(97)00055-9; Strous M, 1998, APPL MICROBIOL BIOT, V50, P589, DOI 10.1007/s002530051340; Van De Graaf Astrid A., 1996, Microbiology (Reading), V142, P2187; vandeGraaf AA, 1997, MICROBIOL-SGM, V143, P2415, DOI 10.1099/00221287-143-7-2415; Vergin KL, 1998, APPL ENVIRON MICROB, V64, P3075; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Zarda B, 1997, ARCH MICROBIOL, V168, P185, DOI 10.1007/s002030050486	22	1103	1300	40	776	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					446	449		10.1038/22749	http://dx.doi.org/10.1038/22749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440372				2022-12-28	WOS:000081715000049
J	Cohen, LR; Hahn, RW				Cohen, LR; Hahn, RW			Science and regulation - A solution to concerns over public access to scientific data	SCIENCE			English	Article									Univ Calif Irvine, Dept Econ, Irvine, CA 92697 USA; Amer Enterprise Inst Publ Policy Res, Brookings Joint Ctr Regulatory Studies, Washington, DC 20036 USA	University of California System; University of California Irvine; American Enterprise Institute for Public Policy Research	Cohen, LR (corresponding author), Univ Calif Irvine, Dept Econ, Irvine, CA 92697 USA.							COHEN L, 1999, 991 AEI BROOK JOINT; DEWALD WG, 1986, AM ECON REV, V76, P587; *ENV PROT AG, 1997, REG IMP AN PART MATT; FUMENTO M, 1998, REASON           AUG; Godlee F, 1998, JAMA-J AM MED ASSOC, V280, P237, DOI 10.1001/jama.280.3.237; HAHN RW, 1996, RISKS COSTS LIVES SA, pCH10; Kaiser J, 1997, SCIENCE, V277, P467, DOI 10.1126/science.277.5325.467; LAVE LB, 1981, SCIENCE, V212, P893, DOI 10.1126/science.212.4497.893; LEAMER EE, 1983, AM ECON REV, V73, P31; LUTTER R, 1999, 995 AEI BROOK JOINT; MORRALL JF, 1986, REGULATION, V10, P25; *OFF MAN BUDG, 1998, REPORT CONGRESS COST; TENGS TO, 1996, RISKS COSTS LIVES SA, pCH8; VISCUSI W, 1999, 992 BROOK JOINT CTR; Viscusi WK, 1996, J ECON PERSPECT, V10, P119, DOI 10.1257/jep.10.3.119	15	10	10	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					535	536		10.1126/science.285.5427.535	http://dx.doi.org/10.1126/science.285.5427.535			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219LV	10447485				2022-12-28	WOS:000081609500020
J	Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR				Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR			First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons	LANCET			English	Article							HIV-INFECTION	Background We assessed a programme of tuberculosis control in a prison setting in Baku, Azerbaijan. The programme used first-line therapy and DOTS (directly observed treatment, short course). Methods 467 patients had sputum-positive tuberculosis. Their treatment regimens followed WHO guidelines, and they had regular clinical examinations and dietary supplements. Isolates were tested by standard methods for resistance to isoniazid, rifampicin, ethambutol, and streptomycin in three laboratories. Treatment success was defined as three consecutive negative sputum smears at end of treatment. Factors independently associated with treatment failure were estimated by logistic regression. Findings Drug-resistance data on admission were available for 131 patients. 55% of patients had strains of Mycobacterium tuberculosis resistant to two or more antibiotics. Mortality during treatment was 11%, and 13% of patients defaulted. Overall, treatment was successful in 54% of patients, and in 71% of those completing treatment. 104 patients completed a full treatment regimen and remained sputum-positive. Resistance to two or more antibiotics, a positive sputum result at the end of initial treatment, cavitary disease, and poor compliance were independently associated with treatment failure. Interpretation The effectiveness of a DOTS programme with first-line therapy fell short of the 85% target set by WHO. First-line therapy may not be sufficient in settings with a high degree of resistance to antibiotics.	Int Comm Red Cross, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Republ Stadyum, Baku, Azerbaijan		Coninx, R (corresponding author), Int Comm Red Cross, 19 Ave Paix, CH-1202 Geneva, Switzerland.	rconinx@icrc.org		Mirzayev, Fuad/0000-0001-6658-0325				BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; Coninx R, 1998, BRIT MED J, V316, P1423, DOI 10.1136/bmj.316.7142.1423; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; *EUR CTR EP MON AI, 1996, 52 EUR CTR EP MON AI, P11; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Siddiqi SH, 1989, BACTEC TB SYSTEM PRO; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; *WHO, 1997, GLOB TUB CONTR, P66; *WHO, 1995, WKLY EPIDEMIOL REC, V70, P21; *WHO, 1997, ANT DRUG RES WORLD W, P117; *WHO, 1997, TUB CONTR REF SIT; *WHO, 1997, TREATM TUB DISTR LEV; World Health Organization, 1995, WHO REP TUB EP 1995	16	90	99	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					969	973		10.1016/S0140-6736(98)08341-X	http://dx.doi.org/10.1016/S0140-6736(98)08341-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459906				2022-12-28	WOS:000079421600012
J	Kirkpatrick, PJ				Kirkpatrick, PJ			Time to reconsider treatment options for intracranial aneurysms	LANCET			English	Editorial Material									Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Kirkpatrick, PJ (corresponding author), Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.							INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	4	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					942	943		10.1016/S0140-6736(98)00278-5	http://dx.doi.org/10.1016/S0140-6736(98)00278-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459898				2022-12-28	WOS:000079421600004
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					851	851		10.1016/S0140-6736(05)76679-4	http://dx.doi.org/10.1016/S0140-6736(05)76679-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10460000				2022-12-28	WOS:000079089100073
J	Forsythe, M; Calnan, M; Wall, B				Forsythe, M; Calnan, M; Wall, B			Doctors as patients: postal survey examining consultants and general practitioners adherence to guidelines	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; DEPRESSION; ANXIETY; STRESS	Objectives To examine the adherence by senior NHS medical staff to the BMA guidelines on the ethical responsibilities of doctors towards themselves and their families. Design Postal semistructured questionnaire. Setting Four randomly selected NHS trusts and three local medical committees in South Thames region. Subjects Consultants and principals in general practice. Main outcome measures Personal use of health services. Results The response rate was 64% (724) for general practitioners and 72% (427) for consultants after three mailings. Most (1106, 96%) respondents were registered with a general practitioner, although little use was made of their services. 159 (26%) general practitioners were registered with a general practitioner in their own practice and 80 (11%) admitted to looking after members of their family. 73 (24%) consultants would never see their general practitioner before obtaining consultant advice. Most consultants and general practitioners admitted to prescribing for themselves and their family. Responses to vignettes for different health problems indicated a general reluctance to take time off, but there were differences between consultants and general practitioners and by sex. Views on improvements needed included the possibility of a "doctor's doctor," access to out of area secondary care, an occupational health service for general practitioners, and regular health check ups. Conclusion The guidelines are largely not being followed, perhaps because of the difficulties of obtaining access to general practitioners outside working hours. The occupational health service should be expanded and a general practitioner service for NHS staff piloted.	Univ Kent, Ctr Hlth Serv Studies, Canterbury CT2 7NF, Kent, England	University of Kent	Forsythe, M (corresponding author), Univ Kent, Ctr Hlth Serv Studies, George Allen Wing, Canterbury CT2 7NF, Kent, England.							Academy of Royal Medical Colleges, 1998, REP WORK PART; Allen I., 1994, DOCTORS THEIR CAREER; Baldwin PJ, 1997, SOC SCI MED, V45, P35, DOI 10.1016/S0277-9536(96)00306-1; British Medical Association, 1995, ETH RESP INV TREAT D; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; Chambers R, 1996, FAM PRACT, V13, P170, DOI 10.1093/fampra/13.2.170; FIRTHCOZENS J, 1995, STRESS DOCTORS LONGI; McKevitt C, 1995, DOCTORS HLTH NEEDS S; *OFF POP CENS SURV, 1986, OCC MORT 1979 80 198; *OFF POP CENS SURV, 1995, OCC HLTH DEC S; *OFF POP CENS SURV, 1992, 4 NAT STUD MORB STAT; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; SYLVESTER S, 1994, PROVISION MED SERVIC; 1998, GMC NEWS, V3, P5	14	81	83	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					605	608		10.1136/bmj.319.7210.605	http://dx.doi.org/10.1136/bmj.319.7210.605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473473	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000082460300015
J	Mortimer, PP				Mortimer, PP			The other Dr Finlay	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					618	618		10.1136/bmj.319.7210.618	http://dx.doi.org/10.1136/bmj.319.7210.618			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473479	Green Published			2022-12-28	WOS:000082460300023
J	Wilson, CJF				Wilson, CJF			My years with Lyme disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Navy, Northwood, Middx, England		Wilson, CJF (corresponding author), Royal Navy, Northwood, Middx, England.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					649	649		10.1136/bmj.319.7210.649	http://dx.doi.org/10.1136/bmj.319.7210.649			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473502	Green Published			2022-12-28	WOS:000082460300063
J	Goy, JJ				Goy, JJ			Contemporary approach to management of unstable angina	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION		Univ Lausanne Hosp, Dept Cardiol, CH-1003 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Goy, JJ (corresponding author), Univ Lausanne Hosp, Dept Cardiol, CH-1003 Lausanne, Switzerland.							Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; CHIERCHIA S, 1999, EUR HEART J SUPPL, V1, P2; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; THEROUX P, 1993, CURR PROB CARDIOLOGY, V18, P159; Wallentin L, 1996, LANCET, V347, P561; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X	9	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					694	695		10.1016/S0140-6736(99)00264-0	http://dx.doi.org/10.1016/S0140-6736(99)00264-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475174				2022-12-28	WOS:000082233000002
J	Hansen, D; Moller, H; Olsen, J				Hansen, D; Moller, H; Olsen, J			Severe periconceptional life events and the sex ratio in offspring: follow up study based on five national registers	BRITISH MEDICAL JOURNAL			English	Article							BIRTH		John F Kennedy Inst, DK-2600 Glostrup, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark; Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danmarks Grundforskningsfond; Aarhus University	Hansen, D (corresponding author), John F Kennedy Inst, G1 Landevej 7, DK-2600 Glostrup, Denmark.			Moller, Henrik/0000-0001-8200-5929				Fenster L, 1997, J ANDROL, V18, P194; Fukuda M, 1998, HUM REPROD, V13, P2321, DOI 10.1093/humrep/13.8.2321; James WH, 1996, J THEOR BIOL, V180, P271, DOI 10.1006/jtbi.1996.0102; LYSTER WR, 1974, J OBSTET GYN BR COMM, V81, P626; PRATT NC, 1989, J REPROD FERTIL, V87, P736	5	112	113	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					548	549		10.1136/bmj.319.7209.548	http://dx.doi.org/10.1136/bmj.319.7209.548			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463895	Green Published, Bronze			2022-12-28	WOS:000082347200022
J	Marquis, D				Marquis, D			How to resolve an ethical dilemma concerning randomized clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EQUIPOISE		Univ Kansas, Lawrence, KS 66045 USA	University of Kansas	Marquis, D (corresponding author), Univ Kansas, Lawrence, KS 66045 USA.							ALTMAN L, 1986, NY TIMES        0829, pB6; CHALMERS TC, 1967, 14 C CARD TRAIN GRAN, P87; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1992, J Clin Ethics, V3, P231; GIFFORD F, 1995, BIOETHICS, V9, P127, DOI 10.1111/j.1467-8519.1995.tb00306.x; GIFFORD F, 1986, J MED PHILOS, V11, P347, DOI 10.1093/jmp/11.4.347; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; KOLATA GB, 1977, SCIENCE, V198, P1127, DOI 10.1126/science.11643424; Markman M, 1992, J Clin Ethics, V3, P193; MARQUIS D, 1983, HASTINGS CENT REP, V13, P40, DOI 10.2307/3561721; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; SHAW LW, 1970, ANN NY ACAD SCI, V169, P487, DOI 10.1111/j.1749-6632.1970.tb54759.x; SPODICK DH, 1983, NEW ENGL J MED, V308, P343; WIKLER D, 1981, SEMIN ONCOL, V8, P437	17	22	22	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					691	693		10.1056/NEJM199908263410912	http://dx.doi.org/10.1056/NEJM199908263410912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	229JY	10460824	Green Published			2022-12-28	WOS:000082192500012
J	Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO				Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO			Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene	LANCET			English	Article							DOMINANT CEREBELLAR-ATAXIA; CAG REPEAT; MEN; CHROMOSOME; DISEASE; SPERM; TRANSACTIVATION; INSENSITIVITY; AZOOSPERMIA; MUTATIONS	Background Androgens acting via the androgen receptor bring about stimulation and maintenance of spermatogenesis. If mutations in the androgen-receptor gene interfere with the receptor's function, this effect may partly account for impaired spermatogenesis. We aimed to find out whether expansion of a trinucleotide repeat in the androgen-receptor gene is associated with male infertility. Methods We analysed 67 coded semen and blood samples from a predominantly white group of male infertility patients and controls. Clinical analyses included cause of infertility, sperm count, and reproductive hormone concentrations. Analysis of trinucleotide (CAG) repeal length and point mutations in the androgen-receptor gene was done by PCR, single-stranded conformational polymorphism, and DNA sequencing. Findings Screening and characterisation of the androgen-receptor gene in 35 patients and 32 controls showed no point mutations in the gene. 30 of the infertile patients had idiopathic azoospermia or oligozoospermia, and these men had significantly longer CAG repeat tracts than controls (mean 23.2 [SE 0.7] vs 20.5 [0.3], p=0.0001). The odds of having CAG repeat lengths of 20 were six-fold higher for fertile men than for men with a spermatogenic disorder. Interpretation Our results indicate a relation between CAG repeat length in the androgen-receptor gene and the risk of defective spermatogenesis. With the use of intracytoplasmic sperm injection, this mutation could be inherited. possibly leading to an increase in male infertility in future generations. Should further elongation of the CAG repeat occur in these future generations, there is an added risk of increased severity of male infertility, and potentially an increased incidence of neurodegenerative disease.	Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Dept Math & Stat, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore, Singapore	Monash University; Monash University; Monash University; Prince Henry's Institute of Medical Research; National University of Singapore	Trounson, AO (corresponding author), Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Level 5,246 Clayton Rd, Clayton, Vic 3168, Australia.			Yong, Eu-Leong/0000-0001-6511-770X; Trounson, Alan/0000-0001-5469-0500				AIMAN J, 1982, J CLIN ENDOCR METAB, V54, P725, DOI 10.1210/jcem-54-4-725; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIU DY, 1994, HUM REPROD, V9, P1694, DOI 10.1093/oxfordjournals.humrep.a138776; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; McLachlan RI, 1996, J ENDOCRINOL, V148, P1, DOI 10.1677/joe.0.1480001; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PUSCHECK EE, 1994, FERTIL STERIL, V62, P1035; Tincello DG, 1997, MOL HUM REPROD, V3, P941, DOI 10.1093/molehr/3.11.941; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; *WHO, 1987, INT J ANDROL S, V7, P3; *WHO, 1996, 2 WHO LAB MAN EX HUM; YONG EL, 1994, FERTIL STERIL, V61, P856; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	25	217	222	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					640	643		10.1016/S0140-6736(98)08413-X	http://dx.doi.org/10.1016/S0140-6736(98)08413-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466666				2022-12-28	WOS:000082214500013
J	Kerstjens, HAM				Kerstjens, HAM			Clinical evidence - Stable chronic obstructive pulmonary disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IPRATROPIUM BROMIDE; LUNG-FUNCTION; CORTICOSTEROID-THERAPY; CHRONIC-BRONCHITIS; AIR-POLLUTION; COPD; SALMETEROL; BRONCHODILATOR; SALBUTAMOL; DECLINE		Univ Groningen Hosp, Dept Pulm Dis, NL-9700 RB Groningen, Netherlands	University of Groningen	Kerstjens, HAM (corresponding author), Univ Groningen Hosp, Dept Pulm Dis, POB 30001, NL-9700 RB Groningen, Netherlands.	h.a.m.kerstjens@int.azg.nl	Kerstjens, Huib/N-4754-2017	Kerstjens, Huib/0000-0001-7705-7927	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Auerbach D, 1997, CHEST, V112, P1514; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Boyd G, 1997, EUR RESPIR J, V10, P815; BRAUN SR, 1989, ARCH INTERN MED, V149, P544, DOI 10.1001/archinte.149.3.544; BRUNEKREEF B, 1985, INT J EPIDEMIOL, V14, P227, DOI 10.1093/ije/14.2.227; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CALVERLEY PMA, 1995, CHRONIC OBSTRUCTIVE, P419; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; *COMB INH AER STUD, 1994, CHEST, V5, P1411; Dockery DW, 1996, AM J RESP CRIT CARE, V154, pS250, DOI 10.1164/ajrccm/154.6_Pt_2.S250; Grove A, 1996, THORAX, V51, P689, DOI 10.1136/thx.51.7.689; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HALL IP, 1992, ASTHMA, P341; HIGGINS BG, 1991, EUR RESPIR J, V4, P415; IKEDA A, 1995, CHEST, V107, P401, DOI 10.1378/chest.107.2.401; IKEDA A, 1995, THORAX, V50, P62, DOI 10.1136/thx.50.1.62; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; Kerstjens HAM, 1996, AM J RESP CRIT CARE, V154, pS266, DOI 10.1164/ajrccm/154.6_Pt_2.S266; Levin DC, 1996, AM J MED, V100, pS40, DOI 10.1016/S0002-9343(96)80073-8; Matera MG, 1995, PULM PHARMACOL, V8, P267, DOI 10.1006/pulp.1995.1036; McEvoy CE, 1997, CHEST, V111, P732, DOI 10.1378/chest.111.3.732; *MED RES COUNC WOR, 1981, LANCET, V4, P681; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; POOLE PJ, 1998, COCHRANE LIB; Rennard SI, 1996, CHEST, V110, P62, DOI 10.1378/chest.110.1.62; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; ROBERTSON AS, 1986, EUR J RESPIR DIS, V69, P565; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; SHIM CS, 1985, AM J MED, V78, P655, DOI 10.1016/0002-9343(85)90409-7; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; ULRIK CS, 1995, THORAX, V50, P750, DOI 10.1136/thx.50.7.750; van Grunsven PM, 1999, THORAX, V54, P7, DOI 10.1136/thx.54.1.7; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112; WHITTEMORE AS, 1995, AM J PUBLIC HEALTH, V85, P702, DOI 10.2105/AJPH.85.5.702	41	14	14	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	1999	319	7208					495	500		10.1136/bmj.319.7208.495	http://dx.doi.org/10.1136/bmj.319.7208.495			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454405	Green Published			2022-12-28	WOS:000082199600027
J	Ni, M; Tepperman, JM; Quail, PH				Ni, M; Tepperman, JM; Quail, PH			Binding of phytochrome B to its nuclear signalling partner PIF3 is reversibly induced by light	NATURE			English	Article							REGULATORY ACTIVITY; TERMINAL-DOMAIN; TRANSDUCTION; PROTEIN	The phytochrome photoreceptor family directs plant gene expression by switching between biologically inactive and active conformers in response to the sequential absorption of red and far-red photons(1,2). Several intermediates that act late in the phytochrome signalling pathway have been identified, but fewer have been identified that act early in the pathway(3,4). We have cloned a nuclear basic helix-loop-helix protein, PIF3, which can bind to non-photoactive carboxy-terminal fragments of phytochromes A and B and functions in phytochrome signalling in vivo(5). Here we show that full-length photoactive phytochrome B binds PIF3 in vitro only upon light-induced conversion to its active form, and that photoconversion back to its inactive form causes dissociation from PIF3. We conclude that photosensory signalling by phytochrome B involves light-induced, conformer-specific recognition of the putative transcriptional regulator PIF3, providing a potential mechanism for direct photoregulation of gene expression.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Ni, Maria/GVT-4942-2022					Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; DENG XW, IN PRESS SEMIN CELL; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Quail PH, 1998, PHILOS T R SOC B, V353, P1399, DOI 10.1098/rstb.1998.0294; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; Scheer H., 1984, TECHNIQUES PHOTOMORP, P227, DOI [10.5282/ubm/epub.2167, DOI 10.5282/UBM/EPUB.2167]; SOMERS DE, 1991, PLANT CELL, V3, P1263, DOI 10.1105/tpc.3.12.1263; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Tobin Elaine M., 1994, Seminars in Cell Biology, V5, P335, DOI 10.1006/scel.1994.1040; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Wei N, 1996, PLANT PHYSIOL, V112, P871, DOI 10.1104/pp.112.3.871; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	17	350	388	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					781	784		10.1038/23500	http://dx.doi.org/10.1038/23500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466729				2022-12-28	WOS:000082131100054
J	Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J				Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J			Dynamics of disease resistance polymorphism at the Rpm1 locus of Arabidopsis	NATURE			English	Article							MOLECULAR POPULATION-GENETICS; PSEUDOMONAS-SYRINGAE; THALIANA; RECOMBINATION; EPIDEMIOLOGY; PARASITES; SELECTION; GENES	The co-evolutionary 'arms race'(1) is a widely accepted model for the evolution of host-pathogen interactions. This model predicts that variation for disease resistance will be transient, and that host populations generally will be monomorphic at disease-resistance (R-gene) loci. However, plant populations show considerable polymorphism at R-gene loci involved in pathogen recognition(2). Here we have tested the arms-race model in Arabidopsis thaliana by analysing sequences flanking Rpm1, a gene conferring the ability to recognize Pseudomonas pathogens carrying AvrRpm1 or AvrB (ref. 3). We reject the arms-race hypothesis: resistance and susceptibility alleles at this locus have co-existed for millions of years. To account for the age of alleles and the relative levels of polymorphism within allelic classes, we use coalescence theory to model the long-term accumulation of nucleotide-polymorphism in the context of the short-term ecological dynamics of disease resistance. This analysis supports a 'trench warfare' hypothesis, in which advances and retreats of resistance-allele frequency maintain variation for disease resistance as a dynamic polymorphism(4,5).	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Bergelson, J (corresponding author), Univ Chicago, Comm Genet, Chicago, IL 60637 USA.	jbergels@midway.uchicago.edu	Dwyer, Greg/L-1134-2015	Dwyer, Greg/0000-0002-7387-2075; Bergelson, Joy/0000-0001-7893-7387	NIGMS NIH HHS [R01 GM057994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergelson J, 1998, GENETICS, V148, P1311; Bergelson J, 1996, AM NAT, V148, P536, DOI 10.1086/285938; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; DAWKINS R, 1979, PROC R SOC SER B-BIO, V205, P489, DOI 10.1098/rspb.1979.0081; Grant MR, 1998, P NATL ACAD SCI USA, V95, P15843, DOI 10.1073/pnas.95.26.15843; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Hamilton W.D., 1982, Life Sciences Research Report, P269; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HIRANO SS, 1990, ANNU REV PHYTOPATHOL, V28, P155, DOI 10.1146/annurev.py.28.090190.001103; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1988, GENETICS, V120, P831; Innan H, 1996, GENETICS, V143, P1761; JAYAKAR S D, 1970, Theoretical Population Biology, V1, P140, DOI 10.1016/0040-5809(70)90032-8; JUDSON OP, 1995, GENET RES, V65, P175, DOI 10.1017/S0016672300033267; Kawabe A, 1997, MOL BIOL EVOL, V14, P1303, DOI 10.1093/oxfordjournals.molbev.a025740; Kimura M., 1983, NEUTRAL THEORY MOL E; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; May R.M., 1985, Linnean Society Symposium Series, P243; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; McDonald JH, 1998, MOL BIOL EVOL, V15, P377, DOI 10.1093/oxfordjournals.molbev.a025934; NEI M, 1986, MOL BIOL EVOL, V3, P418; OKane SL, 1997, NOVON, V7, P323, DOI 10.2307/3391949; Purugganan MD, 1999, GENETICS, V151, P839; Purugganan MD, 1998, P NATL ACAD SCI USA, V95, P8130, DOI 10.1073/pnas.95.14.8130; REDEI GP, 1975, ANNU REV GENET, V9, P111, DOI 10.1146/annurev.ge.09.120175.000551; Rozas J, 1997, COMPUT APPL BIOSCI, V13, P307; TAJIMA F, 1989, GENETICS, V123, P585; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204	30	450	462	0	65	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					667	671		10.1038/23260	http://dx.doi.org/10.1038/23260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458161				2022-12-28	WOS:000082032900054
J	Grace, AA				Grace, AA			Brugada syndrome	LANCET			English	Editorial Material							UNEXPLAINED-DEATH-SYNDROME; ST-SEGMENT ELEVATION; BUNDLE-BRANCH BLOCK; VENTRICULAR-FIBRILLATION; HEART-DISEASE; SUDDEN-DEATH; MARKER		Papworth Hosp, Cambridge CB3 8RE, England; Univ Cambridge, Dept Biochem, Sect Cardiovasc Biol, Cambridge CB2 1QW, England	Papworth Hospital; University of Cambridge	Grace, AA (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.							Alings M, 1999, CIRCULATION, V99, P666, DOI 10.1161/01.CIR.99.5.666; Brugada J, 1998, CIRCULATION, V97, P457; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Corrado D, 1996, J AM COLL CARDIOL, V27, P443, DOI 10.1016/0735-1097(95)00485-8; Gussak I, 1999, J AM COLL CARDIOL, V33, P5, DOI 10.1016/S0735-1097(98)00528-2; Kasanuki H, 1997, CIRCULATION, V95, P2277, DOI 10.1161/01.CIR.95.9.2277; Matsuo K, 1999, EUR HEART J, V20, P465, DOI 10.1053/euhj.1998.1332; Nademanee K, 1997, CIRCULATION, V96, P2595, DOI 10.1161/01.CIR.96.8.2595; Priori SG, 1999, EUR HEART J, V20, P174, DOI 10.1053/euhj.1998.1220; Priori SG, 1997, CIRCULATION, V95, P265; SAUMAREZ RC, 1995, CIRCULATION, V92, P2565, DOI 10.1161/01.CIR.92.9.2565; WEVER EFD, 1993, CIRCULATION, V88, P1021, DOI 10.1161/01.CIR.88.3.1021; WONG ML, 1992, TROP GEOGR MED, V44, pS1; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	14	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					445	446		10.1016/S0140-6736(99)90032-6	http://dx.doi.org/10.1016/S0140-6736(99)90032-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465166				2022-12-28	WOS:000081896100006
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1966: Francis Peyton Rous (1879-1970) and Charles Brenton Huggins (1901-97)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					520	520		10.1016/S0140-6736(05)75563-X	http://dx.doi.org/10.1016/S0140-6736(05)75563-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465213				2022-12-28	WOS:000081896100069
J	Mollica, RF; McInnes, K; Sarajlic, N; Lavelle, J; Sarajlic, I; Massagli, MP				Mollica, RF; McInnes, K; Sarajlic, N; Lavelle, J; Sarajlic, I; Massagli, MP			Disability associated with psychiatric comorbidity and health status in Bosnian refugees living in Croatia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SOUTHEAST-ASIAN REFUGEES; GENERAL-POPULATION; PSYCHOLOGICAL SEQUELAE; FORMER PRISONERS; MENTAL-DISORDERS; WAR VETERANS; TORTURE; TRAUMA; DEPRESSION	Context The relationship between psychiatric symptoms and disability in refugee survivors of mass violence is not known. Objective To determine if risk factors, such as demographics, trauma, health status, and psychiatric illness, are associated with disability in Bosnian refugees. Design, Setting, and Participants Cross-sectional survey conducted in 1996 of Bosnian refugee adults living in a camp established by the Croatian government near the city of Varazdin. One adult aged 18 years or older was randomly selected from each of 573 camp families; 534 (93%) agreed to participate (mean age, 50 years; 41% male). Main Outcome Measures Culturally validated measures for depression and posttraumatic stress disorder (PTSD) included the Hopkins Symptom Checklist 25 and the Harvard Trauma Questionnaire, respectively. Disability measures included the Medical Outcomes Study Short-Form 20, a physical functioning scale based on World Health Organization criteria, and self-reports of socioeconomic activity, levels of physical energy, and perceived health status. Results Respondents reported a mean (SD) of 6.5 (4.7) unduplicated trauma events; 18% (n = 95) had experienced 1 or more torture events. While 55.2% reported no psychiatric symptoms, 39.2% and 26.3% reported symptoms that meet DSM-IV criteria for depression and PTSD, respectively; 20.6% reported symptoms comorbid for both disorders. A total of 25.5% reported having a disability. Refugees who reported symptoms comorbid for both depression and PTSD were associated with an increased risk for disability compared with asymptomatic refugees (unadjusted odds ratio [OR], 5.02; 95% confidence interval [CI], 3.05-8.26; adjusted OR, 2.06; 95% CI, 1.10-3.86). Older age, cumulative trauma, and chronic medical illness were also associated with disability. Conclusions In a population of Bosnian refugees who had recently fled from the war in Bosnia and Herzegovina, psychiatric comorbidity was associated with disability independent of the effects of age, trauma, and health status.	Harvard Univ, Program Refugee Trauma, Sch Med, Cambridge, MA 02138 USA; Univ Zagreb, Sch Med, Zagreb 41001, Croatia; Picker Inst, Boston, MA USA	Harvard University; University of Zagreb	Mollica, RF (corresponding author), Harvard Univ, Program Refugee Trauma, Sch Med, 8 Story St,3rd Floor, Cambridge, MA 02138 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057806] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57806-02] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1996, GLOBAL BURDEN DIS CO; BASOGLU M, 1994, JAMA-J AM MED ASSOC, V272, P357, DOI 10.1001/jama.272.5.357; Bleich A, 1997, BRIT J PSYCHIAT, V170, P479, DOI 10.1192/bjp.170.5.479; CARLSON EB, 1991, AM J PSYCHIAT, V148, P1548; CASPIYAVIN Y, 1995, PSYCHIAT FUNCTIONAL; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Dahl S, 1998, J TRAUMA STRESS, V11, P137, DOI 10.1023/A:1024417401973; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; de Girolamo G., 1996, ETHNOCULTURAL ASPECT, P33, DOI [DOI 10.1037/10555-002, 10.1037/10555-002]; Drozdek B, 1997, J NERV MENT DIS, V185, P690, DOI 10.1097/00005053-199711000-00007; Engdahl B, 1998, AM J PSYCHIAT, V155, P1740, DOI 10.1176/ajp.155.12.1740; Favaro A, 1999, J NERV MENT DIS, V187, P306, DOI 10.1097/00005053-199905000-00007; Fawzi MCS, 1997, ACTA PSYCHIAT SCAND, V95, P87, DOI 10.1111/j.1600-0447.1997.tb00379.x; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; Gorst-Unsworth C, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/bjp.172.1.90; *HARV PROGR REF TR, 1996, MAJ FIND RUK PHAS 1; Havelka Mladen, 1995, Croatian Medical Journal, V36, P262; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Holtz TH, 1998, J NERV MENT DIS, V186, P24, DOI 10.1097/00005053-199801000-00005; Hurry J, 1981, WHAT IS CASE PROBLEM, P202; Jankovic S, 1998, MIL MED, V163, P331, DOI 10.1093/milmed/163.5.331; Jenkins JH, 1997, PSYCHIATRY, V60, P40, DOI 10.1080/00332747.1997.11024784; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KINZIE JD, 1990, AM J PSYCHIAT, V147, P913; KROLL J, 1989, AM J PSYCHIAT, V146, P1592; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Marmar, 1988, NATL VIETNAM VET REA; MELLINGER GD, 1983, PSYCHOL MED, V13, P607, DOI 10.1017/S0033291700048029; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; MOLLICA R, 1991, PSYCHOL ASSESSMENT, V3, P1; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; Mollica RF, 1998, J NERV MENT DIS, V186, P543, DOI 10.1097/00005053-199809000-00005; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; Mollica RF, 1998, ADVERSITY, STRESS AND PSYCHOPATHOLOGY, P34; Mollica RF, 1998, BRIT J PSYCHIAT, V173, P482, DOI 10.1192/bjp.173.6.482; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; MOLLICA RF, 1996, TORTURE S, V1, P19; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; RASMUSSEN OV, 1984, DAN MED B, V37, P1; Reynell J., 1989, POLITICAL PAWNS REFU; SAS Institute Inc, 1989, SAS STAT US GUID, V2; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280, P443, DOI 10.1001/jama.280.5.443; Sinnerbrink I, 1997, J PSYCHOL, V131, P463, DOI 10.1080/00223989709603533; Skodol AE, 1996, BRIT J PSYCHIAT, V169, P717, DOI 10.1192/bjp.169.6.717; SOLOMON Z, 1994, AM J PSYCHIAT, V151, P554; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Thulesius H, 1999, J TRAUMA STRESS, V12, P167, DOI 10.1023/A:1024758718971; UHLENHUTH EH, 1983, ARCH GEN PSYCHIAT, V40, P1167; *US COMM REF, 1997, WORLD REF STAT WORLD; VonKorff M, 1996, J CLIN EPIDEMIOL, V49, P297, DOI 10.1016/0895-4356(95)00512-9; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1993, SF 36 HLTH SURVEY; WEINE SM, 1995, AM J PSYCHIAT, V152, P536; WELLS KB, 1988, AM J PSYCHIAT, V145, P712; WESTERMEYER J, 1985, AM J PSYCHIAT, V142, P798; Willis GB, 1998, J NERV MENT DIS, V186, P283, DOI 10.1097/00005053-199805000-00004; World Bank Group, 1998, WORLD BANK GROUP COU; World Health Organization, 1980, INT CLASS IMP DIS HA; [No title captured]	63	304	310	3	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					433	439		10.1001/jama.282.5.433	http://dx.doi.org/10.1001/jama.282.5.433			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442658	Bronze			2022-12-28	WOS:000081784900019
J	Wiktor, SZ; Ekpini, E; Karon, JM; Nkengasong, J; Maurice, C; Severin, ST; Roels, TH; Kouassi, MK; Lackritz, EM; Coulibaly, IM; Greenberg, AE				Wiktor, SZ; Ekpini, E; Karon, JM; Nkengasong, J; Maurice, C; Severin, ST; Roels, TH; Kouassi, MK; Lackritz, EM; Coulibaly, IM; Greenberg, AE			Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; REDUCTION	Background In Africa, the risk of mother-to-child transmission of HIV-1 infection is high. Short-course perinatal oral zidovudine might decrease the rate of transmission, We assessed the safety and efficacy of such a regimen among HIV-1-seropositive breastfeeding women in Abidjan, Cote d'Ivoire. Methods From April, 1996, to February, 1998, all consenting, eligible HIV-1-seropositive pregnant women attending a public antenatal clinic in Abidjan were enrolled at 36 weeks' gestation and randomly assigned placebo or zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery. We used HIV-1-DNA PCR to test the infection status of babies at birth, 4 weeks, and 3 months. We stopped the study on Feb 18, 1998, when efficacy results were available from a study in Bangkok, Thailand, in which the same regimen was used in a non-breast-feeding population. Findings 280 women were enrolled (140 in each group). The median duration of the prenatal drug regimen was 27 days (range 1-80) and the median duration of labour was 7-5 h. Treatment was well tolerated with no withdrawals because of adverse events. All babies were breastfed. Among babies with known infection status at age 3 months, 30 (26.1%) of 115 babies in the placebo group and 19 (16.5%) of 115 in the zidovudine group were identified as HIV-1 infected, The estimated risk of HIV-1 transmission in the placebo and zidovudine groups were 21.7% and 12.2% (p=0.05) at 4 weeks, and 24.9% and 15.7% (p=0.07) at 3 months. Efficacy was 44% (95% CI -1 to 69) at age 4 weeks and 37% (-5 to 63) at 3 months, Interpretation Short-course oral zidovudine was safe, well tolerated, and decreased mother-to-child transmission of HIV-1 at age 3 months. Substantial efforts will be needed to ensure successful widespread implementation of such a regimen.	Projet RETRO CI, Abidjan 01, Cote Ivoire; Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; Cote dIvoire Minist Publ Hlth, Natl AIDS STD TB Control Program, Abidjan, Cote Ivoire	Centers for Disease Control & Prevention - USA	Wiktor, SZ (corresponding author), Projet RETRO CI, 01 BP 1712, Abidjan 01, Cote Ivoire.	szw0@cdc.gov		Roels, Thierry/0000-0002-0886-5645; Lackritz, Eve/0000-0002-5397-7291				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; BISHOP YM, 1995, DISCRETE MULTIVARIAT; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Janini LM, 1996, VIRUS GENES, V13, P69, DOI 10.1007/BF00576981; *JOINT UN PROGR HI, 1996, PEDIAT AIDS HIV, V7, P476; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LINDEGREN ML, 1998, 12 WORLD AIDS C 28 J; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Nkengasong JN, 1999, AIDS, V13, P109, DOI 10.1097/00002030-199901140-00015; Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123, DOI 10.1128/JCM.36.1.123-127.1998; NKENGASONG JN, 1997, 10 INT C AIDS STD AF; *REG OP CTR DIV AI, 1998, SER ADV EXP REP MAN; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; *UNAIDS, 1998, REP GLOB HIV AIDS EP	23	398	406	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					781	785		10.1016/S0140-6736(98)10412-9	http://dx.doi.org/10.1016/S0140-6736(98)10412-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459958				2022-12-28	WOS:000079089100008
J	Wilfert, CM; Ammann, A; Bayer, R; Curran, JW; del Rio, C; Faden, RR; Feinberg, MB; Karlin, PD; Levine, RJ; Luo, C; Sessions, K; Aldrovandi, G; Allen, S; Arras, J; Bassett, M; Chokani, K; DeCock, K; Fawzi, WW; Fleming, T; Fowler, MG; Gayle, H; Glantz, L; Greco, DB; Jackson, RE; Karim, SA; Kass, N; Keusch, G; Kreiss, J; Kunanusont, C; Lamptey, P; Marseille, E; Mofenson, L; Kamenga, CM; Nieburg, P; Robb, M; Rogers, MF; Samuel, NM; Schulz, KF; Stein, Z; Thomas, SB; Westmoreland, TM; Wilson, CM				Wilfert, CM; Ammann, A; Bayer, R; Curran, JW; del Rio, C; Faden, RR; Feinberg, MB; Karlin, PD; Levine, RJ; Luo, C; Sessions, K; Aldrovandi, G; Allen, S; Arras, J; Bassett, M; Chokani, K; DeCock, K; Fawzi, WW; Fleming, T; Fowler, MG; Gayle, H; Glantz, L; Greco, DB; Jackson, RE; Karim, SA; Kass, N; Keusch, G; Kreiss, J; Kunanusont, C; Lamptey, P; Marseille, E; Mofenson, L; Kamenga, CM; Nieburg, P; Robb, M; Rogers, MF; Samuel, NM; Schulz, KF; Stein, Z; Thomas, SB; Westmoreland, TM; Wilson, CM		Perinatal HIV Intervention Res Dev Countires Wo	Science, ethics, and the future of research into maternal infant transmission of HIV-1	LANCET			English	Article								Effective, feasible Interventions to prevent perinatal transmission of HIV-1 in developing nations are an urgent necessity. Scientific issues of concern include a need to identify other effective antiretroviral agents; to define the shortest effective course of therapy; to assess interventions other than antiretroviral agents; and to investigate interventions that may reduce HIV-1 transmission via breastfeeding. Sound scientific design is fundamental to all research studies. Ethical standards must guide such studies and include the necessity that the problem studied be a health priority in the host country; that the highest standard of care attainable in the country be assured to participants; that the health-care resources of the country not be harmed; that the informed consent of participants be obtained; and that a process of discussion ensure that a successful intervention will be considered for implementation. There are circumstances in which a no-antiretroviral comparison may be ethically justified.	EGPAF, Santa Monica, CA 90405 USA		Wilfert, CM (corresponding author), EGPAF, 2950 31st St,Suite 125, Santa Monica, CA 90405 USA.	wilfert@mindspring.com	del Rio, Carlos/B-3763-2012; Karim, Salim Abdool/AAE-7118-2019; Greco, Dirceu/AAR-4714-2020; Karim, Salim Safurdeen Abdool/N-5947-2013; Mofenson, Lynne/P-9631-2019	del Rio, Carlos/0000-0002-0153-3517; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Mofenson, Lynne/0000-0002-2818-9808				Bayer R, 1998, AM J PUBLIC HEALTH, V88, P567, DOI 10.2105/AJPH.88.4.567; BIRKHEAD GS, 1998, 5 C RETR OPP INF CHI; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1086; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; CULNANE M, 1997, CLIN INFECT DIS, P25; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; de Zoysa I, 1998, AM J PUBLIC HEALTH, V88, P571, DOI 10.2105/AJPH.88.4.571; Faden R, 1998, AM J PUBLIC HEALTH, V88, P548, DOI 10.2105/AJPH.88.4.548; FISCUS SA, 1997, 4 C RETR OPP INF WAS; Karim SSA, 1998, AM J PUBLIC HEALTH, V88, P564, DOI 10.2105/AJPH.88.4.564; LEVINE RJ, 1998, BEST PROVEN THERAPEU, P5; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MOFENSON LM, 1997, P 37 INT C ANT AG CH; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; Susser M, 1998, AM J PUBLIC HEALTH, V88, P547, DOI 10.2105/AJPH.88.4.547; *UNAIDS, 1998, HIV INF FEED; *UNAIDS WHO, 1998, PREV HIV TRANSM MOTH; *US DEPT HHS, 1998, HIV AIDS SURV REP, V9, P1; 1998, LANCET, V351, P225	22	46	46	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					832	835						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	175JC	10459979				2022-12-28	WOS:000079089100047
J	McEvoy, P; Cavanagh, V				McEvoy, P; Cavanagh, V			Peter Thomas Fallen - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					645	645		10.1136/bmj.319.7210.645	http://dx.doi.org/10.1136/bmj.319.7210.645			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473497	Green Published			2022-12-28	WOS:000082460300055
J	Hafeez, A; Mirza, Z				Hafeez, A; Mirza, Z			Responses from pharmaceutical companies to doctors' requests for more drug information in Pakistan: postal survey	BRITISH MEDICAL JOURNAL			English	Article							PROMOTION		Khan Res Labs Hosp, Dept Paediat, Islamabad, Pakistan; Network Rat Use Medicat Pakistan, Islamabad, Pakistan		Hafeez, A (corresponding author), Khan Res Labs Hosp, Dept Paediat, Islamabad, Pakistan.							AVORN J, 1987, AM J MED, V73, P4; Dikshit RK, 1996, BRIT MED J, V313, P855; LEXCHIN J, 1992, J DRUG ISSUES, V22, P417, DOI 10.1177/002204269202200218; LEXCHIN J, 1987, INT J HEALTH SERV, V17, P77, DOI 10.2190/4W1H-E70T-TL9X-VGGC; WHO, 1988, ETH CRIT MED DRUG PR	5	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					547	547		10.1136/bmj.319.7209.547	http://dx.doi.org/10.1136/bmj.319.7209.547			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463894	Bronze, Green Published			2022-12-28	WOS:000082347200021
J	Ishii, M; Tromp, J				Ishii, M; Tromp, J			Normal-mode and free-air gravity constraints on lateral variations in velocity and density of Earth's mantle	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; BOUNDARY; CORE; HETEROGENEITY; TOPOGRAPHY; TOMOGRAPHY; INVERSION; SHEAR; FLOW	With the use of a Large collection of free-oscillation data and additional constraints imposed by the free-air gravity anomaly, Lateral variations in shear velocity, compressional velocity, and density within the mantle; dynamic topography on the free surface; and topography on the 660-km discontinuity and the core-mantle boundary were determined. The velocity models are consistent with existing models based on travel-time and waveform inversions. In the Lowermost mantle, near the core-mantle boundary, denser than average material is found beneath regions of upwellings centered on the Pacific Ocean and Africa that are characterized by slow shear velocities. These anomalies suggest the existence of compositional heterogeneity near the core-mantle boundary.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Ishii, M (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA.		Tromp, Jeroen/B-6185-2015	Tromp, Jeroen/0000-0002-2742-8299				ANDERSON DL, 1987, PHYS EARTH PLANET IN, V45, P307, DOI 10.1016/0031-9201(87)90039-2; ANDERSON DL, 1989, THEORY EARTH; ANDERSON OL, 1968, REV GEOPHYS, V6, P491, DOI 10.1029/RG006i004p00491; BACKUS G, 1968, GEOPHYS J ROY ASTR S, V16, P169, DOI 10.1111/j.1365-246X.1968.tb00216.x; Bolton H., 1996, THESIS U CALIFORNIA; CAZENAVE A, 1989, NATURE, V340, P54, DOI 10.1038/340054a0; CHRISTENSEN U, 1984, ANN GEOPHYS, V2, P311; Dahlen F. A, 1998, THEORETICAL GLOBAL S; DAVIES GF, 1986, GEOPHYS RES LETT, V13, P1517, DOI 10.1029/GL013i013p01517; Dziewonski AM, 1997, EARTHS DEEP INTERIOR, P11; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P2673, DOI 10.1029/97JB03212; Flanagan MP, 1999, GEOPHYS RES LETT, V26, P549, DOI 10.1029/1999GL900036; FORTE AM, 1994, J GEOPHYS RES-SOL EA, V99, P21857, DOI 10.1029/94JB01467; FORTE AM, 1987, J GEOPHYS RES-SOLID, V92, P3645, DOI 10.1029/JB092iB05p03645; FORTE AM, 1995, GEOPHYS RES LETT, V22, P1013, DOI 10.1029/95GL01065; Forte AM, 1997, J GEOPHYS RES-SOL EA, V102, P17981, DOI 10.1029/97JB01276; GIARDINI D, 1987, NATURE, V325, P405, DOI 10.1038/325405a0; Grand SP., 1997, GSA TODAY, V7, P1; Gu Y, 1998, EARTH PLANET SC LETT, V157, P57, DOI 10.1016/S0012-821X(98)00027-2; GWINN CR, 1986, J GEOPHYS RES-SOLID, V91, P4755, DOI 10.1029/JB091iB05p04755; HAGER BH, 1984, J GEOPHYS RES, V89, P6003, DOI 10.1029/JB089iB07p06003; HAGER BH, 1989, MANTLE CONVECTION, P657; HANSEN U, 1988, NATURE, V334, P237, DOI 10.1038/334237a0; He X, 1996, J GEOPHYS RES-SOL EA, V101, P20053, DOI 10.1029/96JB01783; INOUE H, 1990, PHYS EARTH PLANET IN, V59, P294, DOI 10.1016/0031-9201(90)90236-Q; KARASON H, 1998, EOS S, V79, pF656; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; Lemoine F., 1998, DEV JOINT NASA GSFC; LEMOINE FG, 1997, INT ASS GEODESY S, V117, P462; LEMOINE FG, 1998, EOS T AGU, V79, P117; LI XD, 1991, J GEOPHYS RES-SOLID, V96, P551, DOI 10.1029/90JB02009; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; MASTERS G, 1999, EOS T AGU S, V80, pS14; Mooney WD, 1998, J GEOPHYS RES-SOL EA, V103, P727, DOI 10.1029/97JB02122; MORELLI A, 1987, NATURE, V325, P678, DOI 10.1038/325678a0; Resovsky JS, 1999, J GEOPHYS RES-SOL EA, V104, P993, DOI 10.1029/1998JB900025; Resovsky JS, 1998, J GEOPHYS RES-SOL EA, V103, P783, DOI 10.1029/97JB02482; RESOVSKY JS, 1995, GEOPHYS RES LETT, V22, P2301, DOI 10.1029/95GL01996; RICARD Y, 1989, J GEOPHYS RES-SOLID, V94, P13739, DOI 10.1029/JB094iB10p13739; RICARD Y, 1993, J GEOPHYS RES-SOL EA, V98, P21895, DOI 10.1029/93JB02216; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; RITZWOLLER M, 1988, J GEOPHYS RES-SOLID, V93, P6369, DOI 10.1029/JB093iB06p06369; RITZWOLLER MH, 1995, GEOPHYS RES LETT, V22, P2305, DOI 10.1029/95GL02231; ROBERTSON GS, 1995, GEOPHYS J INT, V123, P85, DOI 10.1111/j.1365-246X.1995.tb06663.x; Su WJ, 1997, PHYS EARTH PLANET IN, V100, P135, DOI 10.1016/S0031-9201(96)03236-0; Tackley PJ, 1998, GEODYNAMICS, V28, P231; TANIMOTO T, 1991, J GEOPHYS RES-SOLID, V96, P8167, DOI 10.1029/91JB00196; TROMP J, 1995, GEOPHYS RES LETT, V22, P2297, DOI 10.1029/95GL01810; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0	52	378	386	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1231	1236		10.1126/science.285.5431.1231	http://dx.doi.org/10.1126/science.285.5431.1231			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455043				2022-12-28	WOS:000082130200033
J	Spearow, JL; Doemeny, P; Sera, R; Leffler, R; Barkley, M				Spearow, JL; Doemeny, P; Sera, R; Leffler, R; Barkley, M			Genetic variation in susceptibility to endocrine disruption by estrogen in mice	SCIENCE			English	Article							OVULATION RATE; INDUCTION; CANCER	Large (more than 16-fold) differences in susceptibility to disruption of juvenile male reproductive development by 17 beta-estradiol (E-2) were detected between strains of mice. Effects of strain, E-2 dose, and the interaction of strain and E-2 dose on testes weight and spermatogenesis were all highly significant (P < 0.0001). Spermatid maturation was eliminated by low doses of E-2 in strains such as C57BL/6J and C17/Jls. In contrast, mice of the widely used CD-1 line, which has been selected for large litter size, showed Little or no inhibition of spermatid maturation even in response to 16 times as much E-2. Product safety bioassays conducted with animals selected for fecundity may greatly underestimate disruption of male reproductive development by estradiol and environmental estrogenic compounds.	Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA	University of California System; University of California Davis	Spearow, JL (corresponding author), Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA.		Spearow, Jimmy/AAL-2798-2020					BEHRE HM, 1995, J CLIN ENDOCR METAB, V80, P2394, DOI 10.1210/jc.80.8.2394; BlancoRodriguez J, 1997, J REPROD FERTIL, V110, P61, DOI 10.1530/jrf.0.1100061; BRADFORD GE, 1968, GENETICS, V58, P283; BRADFORD GE, 1969, GENETICS, V61, P905; BRADFORD GE, 1991, REPROD DOMEST ANIM, P605; CLARINGBOLD PJ, 1955, J ENDOCRINOL, V12, P9, DOI 10.1677/joe.0.0120009; Davis DL, 1997, ENVIRON HEALTH PERSP, V105, P571; ERICKSON S, 1995, BIOL REPROD S1, V52, P70; Inano H, 1996, CARCINOGENESIS, V17, P355, DOI 10.1093/carcin/17.2.355; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Kirkpatrick BW, 1998, MAMM GENOME, V9, P97, DOI 10.1007/s003359900696; LAND RB, 1973, NATURE, V241, P208, DOI 10.1038/241208a0; LAND RB, 1969, GENET RES, V13, P25, DOI 10.1017/S0016672300002718; MUNRO C, 1984, J ENDOCRINOL, V101, P41, DOI 10.1677/joe.0.1010041; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; Pollard JW, 1999, ENDOCRINOLOGY, V140, P553, DOI 10.1210/en.140.2.553; Roper RJ, 1999, ENDOCRINOLOGY, V140, P556, DOI 10.1210/en.140.2.556; Shibata A, 1998, J NATL CANCER I, V90, P1230, DOI 10.1093/jnci/90.16.1230; SILBERBERG M, 1951, P SOC EXP BIOL MED, V78, P161; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; SOTO AM, 1996, COMMENTS TOXICOLOGY, V5, P329; SPEAROW JL, 1983, J REPROD FERTIL, V69, P529, DOI 10.1530/jrf.0.0690529; Spearow JL, 1999, BIOL REPROD, V61, P851, DOI 10.1095/biolreprod61.4.851; SPEAROW JL, 1988, J REPROD FERTIL, V82, P787, DOI 10.1530/jrf.0.0820787; Spearow JL, 1999, BIOL REPROD, V61, P857, DOI 10.1095/biolreprod61.4.857; SPEAROW JL, 1987, J ANIM SCI S1, V65, P399; SPEAROW JL, 1996, POLYCYSTIC OVARY SYN, P1; Swan SH, 1999, BIOESSAYS, V21, P614; TOELLE VD, 1984, J ANIM SCI, V59, P967, DOI 10.2527/jas1984.594967x; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239, DOI 10.1177/074823379801400115; WAITES GMH, 1990, LANCET, V336, P955; WHITSETT JM, 1984, J REPROD FERTIL, V72, P277, DOI 10.1530/jrf.0.0720277	32	207	209	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1259	1261		10.1126/science.285.5431.1259	http://dx.doi.org/10.1126/science.285.5431.1259			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455051				2022-12-28	WOS:000082130200041
J	Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS				Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS			The prevalence of hepatitis C virus infection in the United States, 1988 through 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	IX Triennial International Symposium on Viral Hepatitis and Liver Disease	APR 21-25, 1996	ROME, ITALY				NON-B-HEPATITIS; SEXUALLY-TRANSMITTED DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-A; RISK-FACTORS; VIRAL-HEPATITIS; LIVER-DISEASE; BLOOD-DONORS; EPIDEMIOLOGY; TRANSFUSION	Background Because many persons with chronic hepatitis C virus (HCV) infection are asymptomatic, population-based serologic studies are needed to estimate the prevalence of the infection and to develop and evaluate prevention efforts. Methods We performed tests for antibody to HCV (anti-HCV) on serum samples from 21,241 persons six years old or older who participated in the third National Health and Nutrition Examination Survey, conducted during 1988 through 1994. We determined the prevalence of HCV RNA by means of nucleic acid amplification and the genotype by means of sequencing. Results The overall prevalence of anti-HCV was 1.8 percent, corresponding to an estimated 3.9 million persons nationwide (95 percent confidence interval, 3.1 million to 4.8 million) with HCV infection. Sixty-five percent of the persons with HCV infection were 30 to 49 years old. Seventy-four percent were positive for HCV RNA, indicating that an estimated 2.7 million persons in the United States (95 percent confidence interval, 2.4 million to 3.0 million) were chronically infected, of whom 73.7 percent were infected with genotype 1 (56.7 percent with genotype la, and 17.0 percent with genotype Ib). Among subjects 17 to 59 years of age, the strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior. Other factors independently associated with infection included poverty, having had 12 or fewer years of education, and having been divorced or separated. Neither sex nor racial-ethnic group was independently associated with HCV infection. Conclusions In the United States, about 2.7 million persons are chronically infected with HCV. People who use illegal drugs or engage in high-risk sexual behavior account for most persons with HCV infection. (N Engl J Med 1999;341:556-62.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; NIAID, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Alter, MJ (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop G37, Atlanta, GA 30333 USA.							ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; EZZATI T, 1993, 1992 P SURV RES METH, P339; FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6; Kahn HA, 1989, STAT METHODS EPIDEMI; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MANSELL CJ, 1995, SEMIN LIVER DIS, V15, P15, DOI 10.1055/s-2007-1007260; Mast EE, 1997, SEMIN PEDIAT INFECT, V8, P17; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; Mosley J W, 1965, Tech Bull Regist Med Technol, V35, P183; Nainan OV, 1996, J VIROL METHODS, V61, P127, DOI 10.1016/0166-0934(96)02077-0; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1; *NIH CONS DEV C PA, 1997, HEPATOLOGY S1, V26, P25; PANLILIO AL, 1995, J AM COLL SURGEONS, V180, P16; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SEEFF LB, 1975, AM J MED SCI, V270, P355, DOI 10.1097/00000441-197509000-00018; SHAH BV, 1991, SUDAAN USERS MANUAL; Shapiro CN, 1996, J BONE JOINT SURG AM, V78A, P1791, DOI 10.2106/00004623-199612000-00001; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; THOMAS DL, 1994, J INFECT DIS, V169, P990, DOI 10.1093/infdis/169.5.990; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; Thomas SL, 1997, EUR J CLIN MICROBIOL, V16, P711, DOI 10.1007/BF01709250; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x	41	2100	2158	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					556	562		10.1056/NEJM199908193410802	http://dx.doi.org/10.1056/NEJM199908193410802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	227CV	10451460				2022-12-28	WOS:000082061500002
J	Atiyah, M				Atiyah, M			Science for evil: the scientist's dilemma	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Dept Math & Stat, Edinburgh EH9 3JZ, Midlothian, Scotland	University of Edinburgh	Atiyah, M (corresponding author), Univ Edinburgh, Dept Math & Stat, Edinburgh EH9 3JZ, Midlothian, Scotland.							1997, PRINCIPLES STRUCTURE	1	2	2	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					448	449		10.1136/bmj.319.7207.448	http://dx.doi.org/10.1136/bmj.319.7207.448			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445933	Green Published			2022-12-28	WOS:000082098900029
J	Howard, ER				Howard, ER			John Leonard Dawson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					456	456		10.1136/bmj.319.7207.456	http://dx.doi.org/10.1136/bmj.319.7207.456			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445945	Green Published			2022-12-28	WOS:000082098900046
J	Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD				Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD			X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli	SCIENCE			English	Article							MACROMOLECULAR STRUCTURES; ANOMALOUS DIFFRACTION; PROTEIN STRUCTURES; TYPE-1 FIMBRIAE; PILUS; ENTEROBACTERIACEAE; RECOGNITION; REFINEMENT; ALIGNMENT	Type 1 pili-adhesive fibers expressed in most members of the Enterobacteriaceae family-mediate binding to mannose receptors on host cells through the FimH adhesin. Pilus biogenesis proceeds by way of the chaperone/usher pathway. The x-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli at 2.5 angstrom resolution reveals the basis for carbohydrate recognition and for pilus assembly. The carboxyl-terminal pilin domain of FimH has an immunoglobulin-like fold, except that the seventh strand is missing, leaving part of the hydrophobic core exposed. A donor strand complementation mechanism in which the chaperone donates a strand to complete the pilin domain explains the basis for both chaperone function and pilus biogenesis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Mol Biol, S-75324 Uppsala, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France; European Synchrotron Radiat Facil, F-38400 Grenoble, France; Medimmune Inc, Gaithersburg, MD 20878 USA	Washington University (WUSTL); Swedish University of Agricultural Sciences; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); AstraZeneca; Medimmune	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	hullgren@borcim.wustl.edu; stefan@xray.bmc.uu.se	stojanoff, vivian/I-7290-2012; Knight, Stefan/D-4315-2015	stojanoff, vivian/0000-0002-6650-512X; Knight, Stefan/0000-0002-7180-8758; Pinkner, Jerome/0000-0002-7389-7440	NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Brunger A. T, 1993, XPLOR MANUAL VERSION; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; HANSON MS, 1988, J BACTERIOL, V170, P3350, DOI 10.1128/jb.170.8.3350-3358.1988; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Knight S, 1997, ACTA CRYSTALLOGR D, V53, P207, DOI 10.1107/S0907444996011511; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KNIGHT SD, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LANGERMANN S, UNPUB; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellecchia M, 1998, NAT STRUCT BIOL, V5, P885, DOI 10.1038/2325; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	504	525	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1061	1066		10.1126/science.285.5430.1061	http://dx.doi.org/10.1126/science.285.5430.1061			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446051				2022-12-28	WOS:000082033100044
J	Wyncoll, DLA; Evans, TW				Wyncoll, DLA; Evans, TW			Acute respiratory distress syndrome	LANCET			English	Article							INHALED NITRIC-OXIDE; END-EXPIRATORY PRESSURE; CRITICALLY ILL PATIENTS; MECHANICAL VENTILATION; LUNG INJURY; COMPUTED-TOMOGRAPHY; IMPROVED SURVIVAL; FLUID MANAGEMENT; CLINICAL-TRIAL; PRONE POSITION	Outcome in acute respiratory distress syndrome (ARDS) is influenced by a number of factors, including the nature of the precipitating condition and the extent to which multiorgan failure ensues. Most studies of potential therapeutic interventions have been unsuccessful due to the enrollment of limited numbers of patients with a wide variety of pathologies of varying severity. Moreover, the value of initiating single-agent interventions at varying time points in what is an evolving and complex inflammatory process must be questioned. Mortality may therefore represent an inappropriate end-point for clinical trials, which are increasingly focusing on ventilator-free days. Despite these uncertainties, survival appears to be improving, possibly due to the application of supportive techniques in a protocol-driven fashion to patients in whom the underlying condition has been rigorously treated.	Royal Brompton Hosp, Imperial Coll Sch Med, Crit Care Unit, London SW3 6NP, England	Imperial College London; Royal Brompton Hospital	Evans, TW (corresponding author), Royal Brompton Hosp, Imperial Coll Sch Med, Crit Care Unit, London SW3 6NP, England.							Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERNARD GR, 1987, NEW ENGL J MED, V317, P991; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cuthbertson BH, 1997, INTENS CARE MED, V23, P1212, DOI 10.1007/s001340050488; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; DELL, 1998, GILLART T, V45, P402; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Desai SR, 1999, RADIOLOGY, V210, P29, DOI 10.1148/radiology.210.1.r99ja2629; Desai SR, 1997, INTENS CARE MED, V23, P7, DOI 10.1007/s001340050284; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Frost P, 1997, INTENS CARE MED, V23, P243, DOI 10.1007/s001340050322; GADEK J, 1998, AM J RESP CRIT CARE, V157, pA677; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; Lewandowski K, 1997, INTENS CARE MED, V23, P819, DOI 10.1007/s001340050418; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MESSENT M, 1992, ANAESTHESIA, V47, P267, DOI 10.1111/j.1365-2044.1992.tb02134.x; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; OWENS CM, 1994, CHEST, V106, P1815, DOI 10.1378/chest.106.6.1815; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Pelosi P, 1996, EUR RESPIR J, V9, P1055, DOI 10.1183/09031936.96.09051055; PEOLAERT JI, 1993, CHEST, V104, P214; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; SCHUSTER DP, 1995, INTENS CARE MED, V21, P101, DOI 10.1007/BF01726530; SINCLAIR DG, 1994, CHEST, V106, P535, DOI 10.1378/chest.106.2.535; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SNOW N, 1990, CHEST, V97, P1467, DOI 10.1378/chest.97.6.1467; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Suter PM, 1998, UPD INT CAR, V30, P41; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; Verbrugge SJC, 1998, INTENS CARE MED, V24, P172, DOI 10.1007/s001340050541; Walmrath D, 1996, AM J RESP CRIT CARE, V153, P991, DOI 10.1164/ajrccm.153.3.8630585; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WEG JG, 1994, JAMA-J AM MED ASSOC, V272, P1433, DOI 10.1001/jama.272.18.1433	47	88	91	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					497	501		10.1016/S0140-6736(98)08129-X	http://dx.doi.org/10.1016/S0140-6736(98)08129-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465189				2022-12-28	WOS:000081896100041
J	Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM				Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM			Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; FIBER-TYPE; GROWTH; PROLIFERATION; ACTIVATION; CELLS	Skeletal muscle hypertrophy and regeneration are important adaptive responses to both physical activity and pathological stimuli(1). Failure to maintain these processes underlies the loss of skeletal muscle mass and strength that occurs with ageing and in myopathies(2). Here we show that stable expression of a gene encoding insulin-like growth factor 1 (IGF-1) in C2C12 skeletal muscle cells, or treatment of these cells with recombinant IGF-1 or with insulin and dexamethasone, results in hypertrophy of differentiated myotubes and a switch to glycolytic metabolism. Treatment with IGF-1 or insulin and dexamethasone mobilizes intracellular calcium, activates the Ca2+/calmodulin-dependent phosphatase calcineurin, and induces the nuclear translocation of the transcription factor NF-ATc1. Hypertrophy is suppressed by the calcineurin inhibitors cyclosporin A or FK506, but not by inhibitors of the MAP-kinase or phosphatidylinositol-3-OH kinase pathways. Injecting rat latissimus dorsi muscle with a plasmid encoding IGF-1 also activates calcineurin, mobilizes satellite cells and causes a switch to glycolytic metabolism. We propose that growth-factor-induced skeletal-muscle hypertrophy and changes in myofibre phenotype are mediated by calcium mobilization and are critically regulated by the calcineurin/NF-ATc1 signalling pathway.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of Sydney; University of New South Wales Sydney	Graham, RM (corresponding author), St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia.	b.graham@victorchang.unsw.edu.au		Harvey, Richard/0000-0002-9950-9792				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; Ju YK, 1998, J PHYSIOL-LONDON, V508, P153, DOI 10.1111/j.1469-7793.1998.153br.x; KAZAKI M, 1997, J BIOL CHEM, V272, P4964; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montano MM, 1997, ENDOCR RES, V23, P37, DOI 10.1080/07435809709031841; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Renganathan M, 1998, J BIOL CHEM, V273, P28845, DOI 10.1074/jbc.273.44.28845; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Semsarian C, 1999, BIOCHEM J, V339, P443, DOI 10.1042/0264-6021:3390443; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TESCH PA, 1984, J APPL PHYSIOL, V56, P35, DOI 10.1152/jappl.1984.56.1.35; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	30	360	379	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					576	581		10.1038/23054	http://dx.doi.org/10.1038/23054			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448861				2022-12-28	WOS:000081854800059
J	Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N				Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N			Munc13-1 is essential for fusion competence of glutamatergic synoptic vesicles	NATURE			English	Article							TRANSMITTER RELEASE; CENTRAL SYNAPSE; RECEPTOR; PROBABILITY; EXOCYTOSIS; CULTURE; FAMILY; POOL	Neurotransmitter release at synapses between nerve cells is mediated by calcium-triggered exocytotic fusion of synaptic vesicles'. Before fusion, vesicles dock at the presynaptic release site where they mature to a fusion-competent state(1,2). Here we identify Munc13-1, a brain-specific presynaptic phorbol ester receptor(3,4), as an essential protein for synaptic vesicle maturation. We show that glutamatergic hippocampal neurons from mice lacking Munc13-1 form ultrastructurally normal synapses whose synaptic-vesicle cycle is arrested at the maturation step. Transmitter release from mutant synapses cannot be triggered by action potentials, calcium-ionophores or hypertonic sucrose solution. In contrast, release evoked by alpha-latrotolrin is indistinguishable from wild-type controls, indicating that the toxin can bypass Munc13-1-mediated vesicle maturation. A small subpopulation of synapses of any given glutamatergic neuron as well as all synapses of GABA (gamma-aminobutyric acid)-containing neurons are unaffected by Munc13-1 loss, demonstrating the existence of multiple and transmitter-specific synaptic vesicle maturation processes in synapses.	Max Planck Inst Expt Med, AG Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, Dallas, TX 75235 USA	Max Planck Society; Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brose, N (corresponding author), Max Planck Inst Expt Med, AG Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Boyer C, 1998, J NEUROSCI, V18, P5294, DOI 10.1523/JNEUROSCI.18-14-05294.1998; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Martin TFJ, 1998, VITAM HORM, V54, P207, DOI 10.1016/S0083-6729(08)60926-7; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	17	535	551	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					457	461		10.1038/22768	http://dx.doi.org/10.1038/22768			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440375				2022-12-28	WOS:000081715000052
J	Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH				Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH			Structure of cytochrome c nitrite reductase	NATURE			English	Article							WOLINELLA-SUCCINOGENES; DESULFOVIBRIO-DESULFURICANS; NITROSOMONAS-EUROPAEA; ENTERIC BACTERIA; ESCHERICHIA-COLI; NITROGEN-CYCLE; AMMONIA; PURIFICATION; OXYGEN; ENZYME	The enzyme cytochrome c nitrite reductase catalyses the six-electron reduction of nitrite to ammonia as one of the key steps in the biological nitrogen cycle(1), where it participates in the anaerobic energy metabolism of dissimilatory nitrate ammonification(2). Here we report on the crystal structure of this enzyme from the microorganism Sulfurospirillum deleyianum, which we solved by multiwavelength anomalous dispersion methods. We propose a reaction scheme for the transformation of nitrite based on structural and spectroscopic information. Cytochrome c nitrite reductase is a functional dimer, with 10 dose-packed haem groups of type c and an unusual lysine-coordinated high-spin haem at the active site. By comparing the haem arrangement of this nitrite reductase with that of other multihaem cytochromes, we have been able to identify a family of proteins in which the orientation of haem groups is conserved whereas structure and function are not.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; DESY, Arbeitsgrp Prot Dynam, MPG ASMB, D-22603 Hamburg, Germany	University of Konstanz; Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Kroneck, PMH (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.	einsle@biochem.mpg.de	Messerschmidt, Albrecht/A-8337-2008; Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920; Einsle, Oliver/0000-0001-8722-2893				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; COLE JA, 1980, FEMS MICROBIOL LETT, V7, P65, DOI 10.1111/j.1574-6941.1980.tb01578.x; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; LAFORTELLE ED, 1997, CRYSTALLOGR COMPUT, V7, P1; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; MORENO C, 1993, EUR J BIOCHEM, V212, P79, DOI 10.1111/j.1432-1033.1993.tb17635.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHRODER I, 1985, ARCH MICROBIOL, V140, P380, DOI 10.1007/BF00446982; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751; Schumacher W, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P329; SCHUMACHER W, 1991, ARCH MICROBIOL, V156, P70, DOI 10.1007/BF00418190; Strehlitz B, 1996, ANAL CHEM, V68, P807, DOI 10.1021/ac950692n; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Vijgenboom, 1998, BIOL ELECT TRANSFER, P197, DOI 10.1007/978-94-011-5133-7_14; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	30	274	283	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					476	480		10.1038/22802	http://dx.doi.org/10.1038/22802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440380				2022-12-28	WOS:000081715000057
J	Seckl, MJ; Mulholland, PJ; Bishop, AE; Teale, JD; Hales, CN; Glaser, M; Watkins, S; Seckl, JR				Seckl, MJ; Mulholland, PJ; Bishop, AE; Teale, JD; Hales, CN; Glaser, M; Watkins, S; Seckl, JR			Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GASTROINTESTINAL-TRACT; GROWTH FACTOR-II; TUMOR HYPOGLYCEMIA; GENE-EXPRESSION; ANTIBODY; BINDING; THERAPY; MARKER		Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Canc Med, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Histochem, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Radiotherapy, London, England; Royal Surrey Cty Hosp, Clin Lab, Suprareg Assay Serv, Peptide Ctr, Guildford, Surrey, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; N Herts Natl Hlth Serv Trust, Dept Oncol, Stevenage, Herts, England; Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh, Midlothian, Scotland	Imperial College London; Imperial College London; Imperial College London; Royal Surrey County Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Seckl, MJ (corresponding author), Charing Cross Hosp, Dept Canc Med, Fulham Palace Rd, London W6 8RF, England.	m.seckl@ic.ac.uk	Seckl, Jonathan R/C-3555-2013	Mulholland, Paul/0000-0002-7926-824X				DAUGHADAY WH, 1989, P NATL ACAD SCI USA, V86, P6778, DOI 10.1073/pnas.86.17.6778; ERNESTI M, 1965, LANCET, V1, P628; FACER P, 1985, GASTROENTEROLOGY, V89, P1366, DOI 10.1016/0016-5085(85)90657-2; FACER P, 1992, GASTROENTEROLOGY, V102, P47, DOI 10.1016/0016-5085(92)91783-Z; GORDEN P, 1981, NEW ENGL J MED, V305, P1452, DOI 10.1056/NEJM198112103052405; HAMID QA, 1986, HISTOPATHOLOGY, V10, P119, DOI 10.1111/j.1365-2559.1986.tb02468.x; HAMID QA, 1987, VIRCHOWS ARCH A, V411, P185, DOI 10.1007/BF00712743; HAYES DM, 1961, METABOLISM, V10, P183; HOSKINS PJ, 1995, GYNECOL ONCOL, V56, P218, DOI 10.1006/gyno.1995.1035; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KIANG DT, 1973, CANCER-AM CANCER SOC, V31, P801, DOI 10.1002/1097-0142(197304)31:4<801::AID-CNCR2820310407>3.0.CO;2-J; LYALL SS, 1975, ARCH INTERN MED, V135, P865, DOI 10.1001/archinte.135.6.865; Marks V, 1998, ENDOCR-RELAT CANCER, V5, P111, DOI 10.1677/erc.0.0050111; MCFADZEAN AJ, 1969, AM J MED, V47, P220, DOI 10.1016/0002-9343(69)90148-X; OHANLAN KA, 1991, GYNECOL ONCOL, V43, P167, DOI 10.1016/0090-8258(91)90066-E; OLEESKY S, 1962, LANCET, V2, P378; REDMON B, 1992, NEW ENGL J MED, V326, P994, DOI 10.1056/NEJM199204093261505; REMICK SC, 1987, MEDICINE, V66, P457, DOI 10.1097/00005792-198711000-00004; Seckl MJ, 1998, RESP PHARM & PHARMAC, P129; SHAMES JM, 1968, AM J MED, V44, P632, DOI 10.1016/0002-9343(68)90065-X; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; TEALE JD, 1992, ANN CLIN BIOCHEM, V29, P314, DOI 10.1177/000456329202900312; WALTERS EG, 1987, LANCET, V1, P241; Yau JLW, 1997, NEUROSCIENCE, V78, P111, DOI 10.1016/S0306-4522(96)00497-6	25	42	42	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					733	736		10.1056/NEJM199909023411004	http://dx.doi.org/10.1056/NEJM199909023411004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471459				2022-12-28	WOS:000082291900004
J	Tanne, JH				Tanne, JH			Study gives reassurance on safety of xenotransplantation	BRITISH MEDICAL JOURNAL			English	News Item																		Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					533	533						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463880	Green Published			2022-12-28	WOS:000082347200005
J	Blondel, J; Dias, PC; Ferret, P; Maistre, M; Lambrechts, MM				Blondel, J; Dias, PC; Ferret, P; Maistre, M; Lambrechts, MM			Selection-based biodiversity at a small spatial scale in a low-dispersing insular bird	SCIENCE			English	Article							TIT PARUS-CAERULEUS; MEDITERRANEAN BLUE TITS; LIFE-HISTORY TRAITS; ISLAND POPULATION; LAYING-DATE; GENE FLOW; DIFFERENTIATION; SPECIALIZATION; EVOLUTION; SIZE	The blue tit is a highly mobile small passerine found in deciduous and evergreen oaks. In mainland populations, gene flow results in Local maladaptive timing of breeding in evergreen oak forests, the rarer habitat. However, on the island of Corsica, two populations only 25 kilometers apart are highly specialized and differ between the two habitat types in breeding and morphological traits. In contrast to theoretical predictions about the homogenizing effects of gene flow, this highlights evolutionary consequences of habitat diversification and isolation at a small spatial scale in insular organisms, which should be taken into account in conservation policies.	CNRS, Ctr Ecol Fonct & Evolut, F-34293 Montpellier 5, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier	Blondel, J (corresponding author), CNRS, Ctr Ecol Fonct & Evolut, 1919 Route Mende, F-34293 Montpellier 5, France.	blondel@cefe.cnrs-mop.fr						AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.es.18.110187.002421; BERVEN KA, 1983, AM ZOOL, V23, P85; BLONDEL J, 1988, ECOLOGY, V69, P1899, DOI 10.2307/1941167; Blondel J, 1998, OECOLOGIA, V117, P80, DOI 10.1007/s004420050634; BLONDEL J, 1990, J EVOLUTION BIOL, V3, P469, DOI 10.1046/j.1420-9101.1990.3050469.x; BLONDEL J, 1993, AUK, V110, P511, DOI 10.2307/4088415; DHONDT AA, 1982, EVOLUTION, V36, P418, DOI 10.1111/j.1558-5646.1982.tb05061.x; DHONDT AA, 1990, NATURE, V348, P723, DOI 10.1038/348723a0; DIAMOND JM, 1981, NATURE, V293, P507, DOI 10.1038/293507a0; Dias PC, 1996, OECOLOGIA, V107, P79, DOI 10.1007/BF00582237; Dias PC, 1996, J EVOLUTION BIOL, V9, P965, DOI 10.1046/j.1420-9101.1996.9060965.x; Endler J.A., 1977, Monographs in Population Biology, pi; ENDLER JA, 1995, TRENDS ECOL EVOL, V10, P22, DOI 10.1016/S0169-5347(00)88956-9; FUTUYMA DJ, 1988, ANNU REV ECOL SYST, V19, P207, DOI 10.1146/annurev.es.19.110188.001231; GARLAND T, 1991, ANNU REV ECOL SYST, V22, P193, DOI 10.1146/annurev.es.22.110191.001205; Holt RD, 1987, EVOL ECOL, V1, P331, DOI 10.1007/BF02071557; Lambrechts MM, 1997, EVOL ECOL, V11, P599, DOI 10.1007/s10682-997-1515-0; Lambrechts MM, 1997, P NATL ACAD SCI USA, V94, P5153, DOI 10.1073/pnas.94.10.5153; Linhart YB, 1996, ANNU REV ECOL SYST, V27, P237, DOI 10.1146/annurev.ecolsys.27.1.237; Lynch C.B., 1986, P497; MARTIN JL, 1991, AUK, V108, P820; Merila J, 1998, GENETICS, V148, P1233; NEVO E, 1986, VARIABILITY BEHAV EV, P39; PARTRIDGE L, 1976, J ZOOL LONDON, V179, P125; REZNICK DA, 1990, NATURE, V346, P357, DOI 10.1038/346357a0; *SAS I INC, 1988, SAS LANG GUID REL 6; Schluter D, 1996, AM NAT, V148, pS40, DOI 10.1086/285901; Singer MC, 1996, AM NAT, V148, pS9, DOI 10.1086/285900; SLATKIN M, 1987, SCIENCE, V236, P787, DOI 10.1126/science.3576198; Smith TB, 1997, SCIENCE, V276, P1855, DOI 10.1126/science.276.5320.1855; Stearns S.C., 1992, pi; Thompson JD., 1994, COEVOLUTIONARY PROCE; Verhulst S, 1996, J EVOLUTION BIOL, V9, P771, DOI 10.1046/j.1420-9101.1996.9060771.x	33	127	129	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	1999	285	5432					1399	1402		10.1126/science.285.5432.1399	http://dx.doi.org/10.1126/science.285.5432.1399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464098				2022-12-28	WOS:000082233500042
J	Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ				Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ			HIV transmission through breastfeeding - A study in Malawi	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; BREAST-MILK; POSTNATAL TRANSMISSION; HIV-1-INFECTED WOMEN; P24 ANTIGEN; MOTHER; TYPE-1; INFECTION; COHORT	Context Understanding the risk of human immunodeficiency virus (HIV) transmission through breastfeeding is essential for advising HIV-infected mothers and formulating public health policy recommendations. Objective To measure the frequency, timing, and risk factors of HIV transmission through breast milk. Design Prospective cohort study conducted between 1994 and 1997, with follow-up of infants through 24 months of age. Setting Postnatal clinic of tertiary care hospital, Blantyre, Malawi. Participants A total of 672 infants (HIV-negative at birth) born to HIV-infected women who had not received antiretroviral drugs during or after pregnancy. Main Outcome Measure Incidence of HIV in breastfed infants by age and maternal and infant risk factors for HIV transmission, using proportional hazard models to derive risk ratios (RRs) and 95% confidence intervals (Cls). Results Forty-seven children became HIV-infected while breastfeeding but none after breastfeeding had stopped. The cumulative infection rate while breastfeeding, from month 1 to the end of months 5, 11, 17, and 23, was 3.5%, 7.0%, 8.9%, and 10.3 %, respectively. Incidence per month was 0.7% during age 1 to 5 months, 0.6% during age 6 to 11 months, and 0.3% during age 12 to 17 months (P = .01 for trend). The only factors significantly associated with low risk of postnatal HIV transmission in a multivariate model were high maternal parity (RR, 0.23; 95% CI, 0.09-0.56) and older maternal age (RR, 0.44; 95% CI, 0.23-0.84), Conclusions Our data suggest that the risk of HIV infection is highest in the early months of breastfeeding, which should be considered in formulating breastfeeding policy recommendations.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Malawi Coll Med, Blantyre, Malawi; NCI, NIH, Bethesda, MD USA	Johns Hopkins University; University of Malawi; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miotti, PG (corresponding author), NIAID, Div Aids, NIH, Room 4109,6700 B Rockledge Dr,MSC 7626, Bethesda, MD 20892 USA.	pm122m@nih.gov	Kumwenda, Newton/ADL-6890-2022	Kumwenda, Newton/0000-0003-2622-4339; Taha, Taha/0000-0001-9814-4894	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173, Z01AI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-35173-117] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; BULTERYS M, 1995, AIDS, V9, P93; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Guay LA, 1996, PEDIATRICS, V98, P438; John GC, 1996, EPIDEMIOL REV, V18, P149, DOI 10.1093/oxfordjournals.epirev.a017922; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LAWRENCE R, 1994, BREASTFEEDING GUIDE, P28; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Lewis P, 1998, J INFECT DIS, V177, P34, DOI 10.1086/513816; NAGELKERKE NJD, 1995, J ACQ IMMUN DEF SYND, V8, P176; NDUATI RW, 1995, J INFECT DIS, V172, P1461, DOI 10.1093/infdis/172.6.1461; NDUATI RW, 1994, LANCET, V344, P1432, DOI 10.1016/S0140-6736(94)90596-7; NDUATI RW, 1998, 12 WORLD AIDS C JUN; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RUFF AJ, 1994, J ACQ IMMUN DEF SYND, V7, P68; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Southern S O, 1998, J Hum Virol, V1, P328; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; *UNICEF UNAIDS WHO, 1998, HIV INF FEED IMPL GU; VANDEPERRE P, 1993, LANCET, V341, P914, DOI 10.1016/0140-6736(93)91210-D; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VandePerre P, 1997, LANCET, V350, P221, DOI 10.1016/S0140-6736(05)62390-2	33	232	241	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					744	749		10.1001/jama.282.8.744	http://dx.doi.org/10.1001/jama.282.8.744			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463709	Bronze			2022-12-28	WOS:000082118800025
J	Barzilay, JI; Spiekerman, CF; Wahl, PW; Kuller, LH; Cushman, M; Furberg, CD; Dobs, A; Polak, JF; Savage, PJ				Barzilay, JI; Spiekerman, CF; Wahl, PW; Kuller, LH; Cushman, M; Furberg, CD; Dobs, A; Polak, JF; Savage, PJ			Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria	LANCET			English	Article							HEALTH	Background The new fasting American Diabetes Association (ADA) criteria for the diagnosis of diabetes mellitus rely mainly on fasting blood glucose concentrations and use a lower cutoff value for diagnosis than the WHO criteria. We aimed to assess the sensitivity of these criteria for the detection of cardiovascular disease, the main complication of diabetes mellitus in the elderly. Methods We did a cross-sectional and prospective analysis of 4515 participants of the Cardiovascular Health Study, an 8-year longitudinal study designed to identify factors related to the onset and course of cardiovascular disease in adults aged at least 65 years. We calculated the prevalence and incidence of cardiovascular disease for the ADA and WHO criteria. Findings There was a higher prevalence of cardiovascular disease among individuals with impaired glucose or newly diagnosed diabetes by both criteria than among those with normal glucose concentrations. However, because fewer individuals had abnormal glucose states by the fasting ADA criteria (22.3%) than by the WHO criteria (46.8%), the number of cases of cardiovascular disease attributable to abnormal glucose stales was a third of that attributable by the WHO criteria (53 vs 159 cases per 10 000), For the two sets of criteria, the relative risk for incident cardiovascular disease (mean follow-up 5.9 years) was higher in individuals with impaired glucose and newly diagnosed diabetes than in those with normal glucose. Individuals classified as normal by the fasting ADA criteria had a higher absolute number of incident events (455 of 581 events) than those classified as normal by the WHO criteria (269 of 581 events). Fasting ADA criteria were therefore less sensitive than the WHO criteria for predicting cardiovascular disease among individuals with abnormal glucose (sensitivity, 28% vs 54%), Interpretation The new fasting ADA criteria seem to be less predictive than the WHO criteria for the burden of cardiovascular disease associated with abnormal glucose in the elderly.	Kaiser Permanente Georgia, Div Endocrinol, Tucker, GA 30084 USA; Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Vermont, Sch Med, Dept Med, Colchester, VT USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA	Kaiser Permanente; Emory University; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Vermont; Wake Forest University; Wake Forest Baptist Medical Center; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Barzilay, JI (corresponding author), Kaiser Permanente Georgia, Div Endocrinol, 200 Crescent Ctr Pkwy, Tucker, GA 30084 USA.			Cushman, Mary/0000-0002-7871-6143	NHLBI NIH HHS [N01-HC-97079] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett-Connor E, 1998, DIABETES CARE, V21, P1236, DOI 10.2337/diacare.21.8.1236; Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; CUSHMAN M, 1995, CLIN CHEM, V41, P264; De Vegt F, 1998, DIABETES CARE, V21, P1686, DOI 10.2337/diacare.21.10.1686; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gavin JR, 1997, DIABETES CARE, V20, P1183; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Keen H, 1998, LANCET, V352, P1000, DOI 10.1016/S0140-6736(98)00021-X; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wahl PW, 1998, LANCET, V352, P1012, DOI 10.1016/S0140-6736(98)04055-0; WHO, 1980, WHO TECHN REP SER, V646	13	156	164	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					622	625		10.1016/S0140-6736(98)12030-5	http://dx.doi.org/10.1016/S0140-6736(98)12030-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466662				2022-12-28	WOS:000082214500009
J	Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G				Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G			Structural basis of chaperone function and pilus biogenesis	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD CHAPERONE; SUBUNIT RECOGNITION; OUTER-MEMBRANE; PROTEIN; CRYSTALLOGRAPHY; ASSOCIATION; SUPERFAMILY; REFINEMENT; URINARY	Many Gram-negative pathogens assemble architecturally and functionally diverse adhesive pill on their surfaces by the chaperone-usher pathway, Immunoglobulin-like periplasmic chaperones escort pilus subunits to the usher, a large protein complex that facilitates the translocation and assembly of subunits across the outer membrane. The crystal structure of the PapD-PapK chaperone-subunit complex, determined at 2.4 angstrom resolution, reveals that the chaperone functions by donating its G(1) beta strand to complete the immunoglobulin-like fold of the subunit via a mechanism termed donor strand complementation. The structure of the PapD-PapK complex also suggests that during pilus biogenesis, every subunit completes the immunoglobulin-like fold of its neighboring subunit via a mechanism termed donor strand exchange.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Futterer, Klaus/0000-0001-7445-5372	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NIGMS NIH HHS [R01GM54033] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1996, ACTA CRYSTALLOGR D, V52, P32; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Bullitt E, 1996, P NATL ACAD SCI USA, V93, P12890, DOI 10.1073/pnas.93.23.12890; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1996, ESCHERICHIA COLI SAL, P2730; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P23; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; STRIKER R, 1995, MOL MICROBIOL, V16, P1021, DOI 10.1111/j.1365-2958.1995.tb02327.x; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146	36	326	340	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1058	1061		10.1126/science.285.5430.1058	http://dx.doi.org/10.1126/science.285.5430.1058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446050				2022-12-28	WOS:000082033100043
J	Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC				Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC			Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization	NATURE			English	Article							V(D)J RECOMBINATION; TRANSGENIC MICE; BONE-MARROW; RECEPTOR; GENE; LYMPHOCYTES; TOLERANCE; ANTIBODY; MOUSE; ELIMINATION	Models of B-cell-development in the immune system suggest that only those immature B cells in the bone marrow that undergo receptor editing express V(D)J-recombination-activating genes (RAGs)(1-3). Here we investigate the regulation of RAG expression in transgenic mice carrying a bacterial artificial chromosome that encodes a green fluorescent. protein reporter instead of RAG2 (ref. 4). We find that the reporter is expressed in all immature B cells in the bone marrow and spleen. Endogenous RAG messenger RNA is expressed in immature beeps in bone marrow and spleen and decreases by two orders of magnitude as they acquire higher levels of surface immunoglobulin M (IgM). Once RAG expression is stopped it is not re-induced during immune responses. Our findings may help to reconcile a series of apparently contradictory observations, and suggest a new model for the mechanisms that regulate allelic exclusion, receptor editing and tolerance.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Inst Mol Genet & Genet Engn, YU-11001 Belgrade, Yugoslavia; Basel Inst Immunol, CH-4005 Basel, Switzerland	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockvax.rockfeller.edu	Nussenzweig, Michel/AAE-7292-2019					ALLMAN DM, 1992, J IMMUNOL, V149, P2533; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; STORB U, 1995, IMMUNOGLOBULIN GENES, P345; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	30	318	323	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					682	687		10.1038/23287	http://dx.doi.org/10.1038/23287			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458165				2022-12-28	WOS:000082032900058
J	Uwaifo, GI; Muzzammil, A; Shoukri, K; Whitaker-Worth, DL				Uwaifo, GI; Muzzammil, A; Shoukri, K; Whitaker-Worth, DL			Diabetes but not psoriasis	LANCET			English	Article									Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	University of Connecticut	Muzzammil, A (corresponding author), Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA.		Uwaifo, Gabriel I/M-2361-2016	Uwaifo, Gabriel I/0000-0002-6962-9304				BLOOM SR, 1995, PRINCIPLES PRACTICE, P1512; Frankton S, 1996, BAILLIERE CLIN GASTR, V10, P697, DOI 10.1016/S0950-3528(96)90019-6; Krejs GJ, 1998, WILLIAMS TXB ENDOCRI, P1663; Schwartz RA, 1997, INT J DERMATOL, V36, P81, DOI 10.1046/j.1365-4362.1997.00042.x; Soga J, 1998, J Hepatobiliary Pancreat Surg, V5, P312, DOI 10.1007/s005340050052	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					480	480		10.1016/S0140-6736(99)06298-4	http://dx.doi.org/10.1016/S0140-6736(99)06298-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465174				2022-12-28	WOS:000081896100014
J	Hodgkin, J				Hodgkin, J			Sex, cell death, and the genome of C-elegans	CELL			English	Review							CAENORHABDITIS-ELEGANS; DETERMINING GENE; ZINC FINGERS; TRA-1; PROTEINS; NEURONS		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Hodgkin, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; BERGERON L, 1998, SCIENCE, V282, P2012; CHEN PJ, 1999, IN PRESS DEV BIOL; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1998, NATURE, V391, P691; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; Kuwabara PE, 1999, CURR TOP DEV BIOL, V41, P99; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MEYER BJ, 1997, C ELEGANS, V2, P209; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	17	12	29	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					277	280		10.1016/S0092-8674(00)81956-X	http://dx.doi.org/10.1016/S0092-8674(00)81956-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458602	Bronze			2022-12-28	WOS:000081950300002
J	Kidd, FL; Isaac, JTR				Kidd, FL; Isaac, JTR			Developmental and activity-dependent regulation of kainate receptors at thalamocortical synapses	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL INTERNEURONS; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; CRITICAL PERIOD; AMPA RECEPTORS; ACTIVATION; NEURONS; CORTEX; RECTIFICATION	Most of the fast excitatory synaptic transmission in the mammalian brain is mediated by ionotrophic glutamate receptors, of which there are three subtypes: AMPA (alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate), NMDA (N-methyl-D-aspartate) and kainate. Although kainate-receptor subunits (GluR5-7, KA1 and 2) are widely expressed in the mammalian central nervous system(1,2), little is known about their function. The development of pharmacological agents that distinguish between AMPA and kainate receptors has now allowed the functions of kainate receptors to be investigated(3,4). The modulation of synaptic transmission by kainate receptors(5-7) and their synaptic activation(8-14) in a variety of brain regions have been reported. The expression of kainate receptor subunits is developmentally regulated(1,2) but their role in plasticity and development is unknown. Here we show that developing thalamocortical synapses express postsynaptic kainate receptors as well as AMPA receptors; however, the two receptor subtypes do not colocalize. During the critical period for experience-dependent plasticity, the kainate-receptor contribution to transmission decreases; a similar decrease occurs when long-term potentiation is induced in vitro. This indicates that during development there is activity-dependent regulation of the expression of kainate receptors at thalamocortical synapses.	Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Isaac, JTR (corresponding author), Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DeVries SH, 1999, NATURE, V397, P157, DOI 10.1038/16462; Feldman DE, 1998, NEURON, V21, P347, DOI 10.1016/S0896-6273(00)80544-9; FOX K, 1995, NEURON, V15, P485, DOI 10.1016/0896-6273(95)90136-1; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li P, 1999, NATURE, V397, P161, DOI 10.1038/16469; Paternain AV, 1998, NEUROPHARMACOLOGY, V37, P1249, DOI 10.1016/S0028-3908(98)00098-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Washburn MS, 1997, J NEUROSCI, V17, P9393; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	187	189	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					569	573		10.1038/23040	http://dx.doi.org/10.1038/23040			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448859				2022-12-28	WOS:000081854800057
J	Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR				Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR			The medical costs of gunshot injuries in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARM-RELATED INJURIES; WOUNDS; HOSPITALIZATION; CHARGES	Context The cost of treating gunshot injuries imposes a financial burden on society. Estimates of such costs are relevant to evaluation of gun violence reduction programs and may help guide reimbursement policies. Objectives To develop reliable US estimates of the medical costs of treating gunshot injuries and to present national estimates for the sources of payment for treating these injuries. Design and Setting Cost analysis using E-coded discharge data from hospitals in Maryland for 1994-1995 and New York for 1994 and from emergency departments in South Carolina for 1997, Other sources of data included the National Electronic Injury Surveillance System for 1994 incidence of nonfatal gun injuries, the National Spinal Cord Injury Statistical Center database for 1988-1992 estimates of lifetime medical costs of gun injuries, and the 1994 Vital Statistics census for incidence of fatal gun injuries. Main Outcome Measures Estimated national acute-care and follow-up treatment costs and payment sources for gunshot injuries. Results At a mean medical cost per injury of about $17 000, the 134 445 (95% confidence interval [CI], 109 465-159 425) gunshot injuries in the United States in 1994 produced $2.3 billion (95% CI, $2.1 billion-$2.5 billion) in lifetime medical costs (in 1994 dollars, using a 3% real discount rate), of which $1.1 billion (49%) was paid by US taxpayers. Gunshot injuries due to assaults accounted for 74% of total costs. Conclusions Gunshot injury costs represent a substantial burden to the medical care system. Nearly half this cost is borne by US taxpayers.	Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA; Natl Publ Serv Res Inst, Landoven, MD USA; Georgetown Univ, Georgetown Publ Policy Inst, Washington, DC USA	Duke University; Georgetown University	Cook, PJ (corresponding author), Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA.			Miller, Ted/0000-0002-0958-2639; Cook, Philip/0000-0001-5094-9052				ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRICK M, 1992, STAT EVALUATION COST; *BUR CENS, 1998, 1994 VIT STAT CENS D, P109; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; DISCHINGER PC, 1992, AM PUBL HLTH ASS NOV; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HLTH AFF MILLWOOD, V12, P17; Miller TR, 1997, ACCIDENT ANAL PREV, V29, P329, DOI 10.1016/S0001-4575(97)00007-9; MILLER TR, 1989, ACCIDENT ANAL PREV, V21, P303, DOI 10.1016/0001-4575(89)90022-5; MILLER TR, 1995, DATABOOK NONFATAL IN; Miller TR, 1996, TXB PENETRATING TRAU, P49; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; MORABITO D, 1989, REPORT CALIFORNIA DE; *NAT CTR HLTH CAR, 1992, NAT HOSP DISCH SURV; *NAT HIGHW TRANSP, 1983, EC COSTS SOC MOT VEH; Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644; U. S. Bureau of the Census, 1996, STAT ABSTR US 1996; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, ARCH SURG-CHICAGO, V127, P694; WEISSMAN JS, 1992, HEALTH AFFAIR, V11, P148, DOI 10.1377/hlthaff.11.2.148; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; [No title captured]	26	104	104	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					447	454		10.1001/jama.282.5.447	http://dx.doi.org/10.1001/jama.282.5.447			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442660	Bronze			2022-12-28	WOS:000081784900021
J	Watanabe, Y; Nurse, P				Watanabe, Y; Nurse, P			Cohesin Rec8 is required for reductional chromosome segregation at meiosis	NATURE			English	Article							SISTER-CHROMATID COHESION; YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; ANAPHASE TRANSITION; GENE; RECOMBINATION; CENTROMERES; METAPHASE; NUCLEAR; RAD21	When cells exit from mitotic cell division, their sister chromatids lose cohesion and separate to opposite poles of the dividing cell, resulting in equational chromosome segregation. In contrast, the reductional segregation of the first stage of meiotic cell division (meiosis I) requires that sister chromatids remain associated through their centromeres and move together to the same pole. Centromeric cohesion is lost as cells exit from meiosis II and sister chromatids can then separate(1-4). The fission yeast cohesin protein Reed is specific to and required for meiosis(5-8). Here we show that Rec8 appears in the centromeres and adjacent chromosome arms during the pre-meiotic S phase. Centromeric Red persists throughout meiosis I and disappears at anaphase of meiosis II. When the rec8 gene is deleted, sister chromatids separate at meiosis I, resulting in equational rather than reductional chromosome segregation. We propose that the persistence of Rec8 at centromeres during meiosis I maintains sister-chromatid cohesion, and that its presence in the centromere-adjacent regions orients the kinetochores so that sister chromatids move to the same pole. This results in the reductional pattern of chromosome segregation necessary to reduce a diploid zygote to haploid gametes.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan.	ywatanab@ims.u-tokyo.ac.jp		Watanabe, Yoshinori/0000-0002-5488-4812				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NAKASEKO Y, 1984, J BACTERIOL, V157, P334, DOI 10.1128/JB.157.1.334-336.1984; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4	29	419	435	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					461	464		10.1038/22774	http://dx.doi.org/10.1038/22774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440376				2022-12-28	WOS:000081715000053
J	Goldman, WE				Goldman, WE			Microbiology - Looking for a few good mutants	SCIENCE			English	Editorial Material							VIRULENCE GENES; HISTOPLASMA-CAPSULATUM; IDENTIFICATION; MUTAGENESIS; EXPRESSION		Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Goldman, WE (corresponding author), Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA.	goldman@borcim.wustl.edu		Goldman, William/0000-0002-1551-6718				Brandhorst TT, 1999, J EXP MED, V189, P1207, DOI 10.1084/jem.189.8.1207; Brown JS, 1998, MOL GEN GENET, V259, P327, DOI 10.1007/s004380050819; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; Cormack BP, 1999, SCIENCE, V285, P578, DOI 10.1126/science.285.5427.578; Cormack BP, 1999, GENETICS, V151, P979; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; Del Poeta M, 1999, INFECT IMMUN, V67, P1812; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Morschhauser J, 1999, MOL MICROBIOL, V32, P547, DOI 10.1046/j.1365-2958.1999.01393.x; Patel JB, 1998, J BACTERIOL, V180, P1786, DOI 10.1128/JB.180.7.1786-1792.1998; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Varma A, 1998, CURR GENET, V34, P60, DOI 10.1007/s002940050366; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; Woods JP, 1998, INFECT IMMUN, V66, P1697, DOI 10.1128/IAI.66.4.1697-1707.1998	16	3	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					539	+		10.1126/science.285.5427.539	http://dx.doi.org/10.1126/science.285.5427.539			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10447486				2022-12-28	WOS:000081609500023
J	Diwan, VK; Thorson, A				Diwan, VK; Thorson, A			Sex, gender, and tuberculosis	LANCET			English	Article									Nord Sch Publ Hlth, S-40242 Gothenburg, Sweden		Diwan, VK (corresponding author), Nord Sch Publ Hlth, Box 12133, S-40242 Gothenburg, Sweden.			Thorson, Anna/0000-0002-8703-6561				DIWAN VK, 1998, GENDER TUBERCULOSIS; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; KUMARESAN JA, 1996, GLOBAL BURDEN DIS RI; Kurasawa T, 1990, Kekkaku, V65, P47; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; SHAABAN MA, 1990, EUR RESPIR J, V3, P187; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	7	98	104	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1000	1001		10.1016/S0140-6736(99)01318-5	http://dx.doi.org/10.1016/S0140-6736(99)01318-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459926				2022-12-28	WOS:000079421600047
J	Wales, DJ; Scheraga, HA				Wales, DJ; Scheraga, HA			Review: Chemistry - Global optimization of clusters, crystals, and biomolecules	SCIENCE			English	Review							LENNARD-JONES CLUSTERS; DIFFUSION EQUATION METHOD; MULTIPLE-MINIMA PROBLEM; CLASSICAL DENSITY DISTRIBUTION; MODIFIED GENETIC ALGORITHM; LOWEST-ENERGY STRUCTURES; PROTEIN-FOLDING PROBLEM; MONTE-CARLO METHOD; ATOMIC CLUSTERS; GEOMETRY OPTIMIZATION	Finding the optimal solution to a complex optimization problem is of great importance in many fields, ranging from protein structure prediction to the design of microprocessor circuitry. Some recent progress in finding the global minima of potential energy functions is described, focusing on applications of the simple "basin-hopping" approach to atomic and molecular clusters and more complicated hypersurface deformation techniques for crystals and biomolecules. These methods have produced promising results and should enable Larger and more complex systems to be treated in the future.	Univ Chem Labs, Cambridge CB2 1EW, England; Cornell Univ, Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA	University of Cambridge; Cornell University	Wales, DJ (corresponding author), Univ Chem Labs, Lensfield Rd, Cambridge CB2 1EW, England.							Aakeroy CB, 1998, J AM CHEM SOC, V120, P8986, DOI 10.1021/ja981122i; AMARA P, 1995, J PHYS CHEM-US, V99, P14840, DOI 10.1021/j100040a039; Andricioaei I, 1997, J CHEM PHYS, V107, P9117, DOI 10.1063/1.475203; Barhen J, 1997, SCIENCE, V276, P1094, DOI 10.1126/science.276.5315.1094; Barron C, 1996, APPL MATH LETT, V9, P75, DOI 10.1016/0893-9659(96)00076-6; Barron C, 1997, APPL MATH LETT, V10, P25, DOI 10.1016/S0893-9659(97)00078-5; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CLARK DA, 1991, PROTEIN ENG, V4, P751, DOI 10.1093/protein/4.7.751; CVIJOVIC D, 1995, SCIENCE, V267, P664, DOI 10.1126/science.267.5198.664; DEAVEN DM, 1995, PHYS REV LETT, V75, P288, DOI 10.1103/PhysRevLett.75.288; Deaven DM, 1996, CHEM PHYS LETT, V256, P195, DOI 10.1016/0009-2614(96)00406-X; DeCamp W. H, 1996, ACS P SERIES; Derreumaux P, 1997, J CHEM PHYS, V106, P5260, DOI 10.1063/1.473525; Desiraju GR, 1997, SCIENCE, V278, P404, DOI 10.1126/science.278.5337.404; Dittes FM, 1996, PHYS REV LETT, V76, P4651, DOI 10.1103/PhysRevLett.76.4651; Doye JPK, 1997, Z PHYS D ATOM MOL CL, V40, P194, DOI 10.1007/s004600050192; Doye JPK, 1996, J CHEM PHYS, V105, P8428, DOI 10.1063/1.472697; DOYE JPK, 1995, J CHEM PHYS, V103, P4234, DOI 10.1063/1.470729; Doye JPK, 1998, PHYS REV LETT, V80, P1357, DOI 10.1103/PhysRevLett.80.1357; Doye JPK, 1998, NEW J CHEM, V22, P733, DOI 10.1039/a709249k; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; FISHER D, 1996, FASEB J, V10, P126; Gavezzotti A, 1996, J AM CHEM SOC, V118, P7153, DOI 10.1021/ja9540637; Gavezzotti A, 1997, FARADAY DISCUSS, V106, P63, DOI 10.1039/a701436h; GAVEZZOTTI A, 1991, J AM CHEM SOC, V113, P4622, DOI 10.1021/ja00012a034; GAVEZZOTTI A, 1994, ACCOUNTS CHEM RES, V27, P309, DOI 10.1021/ar00046a004; Goldberg D.E., 1989, GENETIC ALGORITHMS S; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P9029, DOI 10.1073/pnas.89.19.9029; Hansmann UHE, 1997, PHYS REV E, V56, P2228, DOI 10.1103/PhysRevE.56.2228; HAO MH, 1994, J PHYS CHEM-US, V98, P9882, DOI 10.1021/j100090a024; Hartke B, 1996, CHEM PHYS LETT, V258, P144, DOI 10.1016/0009-2614(96)00629-X; HEADGORDON T, 1991, P NATL ACAD SCI USA, V88, P11076, DOI 10.1073/pnas.88.24.11076; HOLLAND J, 1975, ADAPTATION NATURAL A; Horst R., 1995, INTRO GLOBAL OPTIMIZ; Huber GA, 1997, PHYS REV E, V55, P4822, DOI 10.1103/PhysRevE.55.4822; Huber T, 1998, J PHYS CHEM A, V102, P5937, DOI 10.1021/jp9806258; JOHNSON MS, 1993, J MOL BIOL, V231, P735, DOI 10.1006/jmbi.1993.1323; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KARFUNKEL HR, 1992, J COMPUT CHEM, V13, P1171, DOI 10.1002/jcc.540131002; Kariuki BM, 1997, CHEM PHYS LETT, V280, P189, DOI 10.1016/S0009-2614(97)01156-1; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOLINSKI A, 1994, PROTEINS, V18, P338, DOI 10.1002/prot.340180405; Koretke KK, 1996, PROTEIN SCI, V5, P1043; KOSTROWICKI J, 1991, J PHYS CHEM-US, V95, P4113, DOI 10.1021/j100163a040; Lee J, 1998, BIOPOLYMERS, V46, P103, DOI 10.1002/(SICI)1097-0282(199808)46:2&lt;103::AID-BIP5&gt;3.0.CO;2-Q; Lee J, 1999, P NATL ACAD SCI USA, V96, P2025, DOI 10.1073/pnas.96.5.2025; Lee J, 1997, J COMPUT CHEM, V18, P1222, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1222::AID-JCC10>3.0.CO;2-7; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; Li Z., 1988, J MOL STRUC-THEOCHEM, V179, P333; Liwo A, 1999, P NATL ACAD SCI USA, V96, P5482, DOI 10.1073/pnas.96.10.5482; Liwo A, 1998, J COMPUT CHEM, V19, P259, DOI 10.1002/(SICI)1096-987X(199802)19:3<259::AID-JCC1>3.0.CO;2-S; MA JP, 1993, J CHEM PHYS, V99, P4024, DOI 10.1063/1.466098; MA JP, 1994, J CHEM PHYS, V101, P533, DOI 10.1063/1.468163; MARANAS CD, 1994, J CHEM PHYS, V100, P1247, DOI 10.1063/1.467236; MARKHAM A, UNPUB; Moret MA, 1998, J COMPUT CHEM, V19, P647, DOI 10.1002/(SICI)1096-987X(19980430)19:6<647::AID-JCC6>3.0.CO;2-R; Mousseau N, 1998, PHYS REV E, V57, P2419, DOI 10.1103/PhysRevE.57.2419; Niesse JA, 1997, J COMPUT CHEM, V18, P1233, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1233::AID-JCC11>3.0.CO;2-6; Niesse JA, 1996, J CHEM PHYS, V105, P4700, DOI 10.1063/1.472311; NORTHBY JA, 1987, J CHEM PHYS, V87, P6166, DOI 10.1063/1.453492; ORESIC M, 1994, J CHEM PHYS, V101, P9844, DOI 10.1063/1.468485; Parks EK, 1997, J CHEM PHYS, V107, P1861, DOI 10.1063/1.474536; PIELA L, 1989, J PHYS CHEM-US, V93, P3339, DOI 10.1021/j100345a090; Pillardy J, 1997, J COMPUT CHEM, V18, P2040, DOI 10.1002/(SICI)1096-987X(199712)18:16<2040::AID-JCC8>3.0.CO;2-L; PILLARDY J, 1992, J MOL STRUCT, V270, P277, DOI 10.1016/0022-2860(92)85034-E; Pillardy J, 1999, J PHYS CHEM B, V103, P7353, DOI 10.1021/jp991014y; PILLARDY J, 1995, J PHYS CHEM-US, V99, P11805, DOI 10.1021/j100031a003; Rabow AA, 1996, PROTEIN SCI, V5, P1800, DOI 10.1002/pro.5560050906; Reva BA, 1998, FOLD DES, V3, P141, DOI 10.1016/S1359-0278(98)00019-4; ROOMAN MJ, 1992, BIOCHEMISTRY-US, V31, P10239, DOI 10.1021/bi00157a010; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Schelstraete S, 1997, J PHYS CHEM A, V101, P310, DOI 10.1021/jp9621181; Scheraga HA, 1996, BIOPHYS CHEM, V59, P329, DOI 10.1016/0301-4622(95)00126-3; SCHERAGA HA, 1992, INT J QUANTUM CHEM, V42, P1529, DOI 10.1002/qua.560420526; Schmidt M, 1997, PHYS REV LETT, V79, P99, DOI 10.1103/PhysRevLett.79.99; Schneider J, 1998, PHYS REV E, V58, P5085, DOI 10.1103/PhysRevE.58.5085; Skolnick J, 1997, J MOL BIOL, V265, P217, DOI 10.1006/jmbi.1996.0720; SKOLNICK J, 1993, CURR BIOL, V3, P414, DOI 10.1016/0960-9822(93)90348-R; Stanton AF, 1997, J COMPUT CHEM, V18, P594, DOI 10.1002/(SICI)1096-987X(199703)18:4<594::AID-JCC12>3.0.CO;2-G; STILLINGER FH, 1990, J CHEM PHYS, V93, P6106, DOI 10.1063/1.459003; STILLINGER FH, 1988, J STAT PHYS, V52, P1429, DOI 10.1007/BF01011658; Tsallis C, 1996, PHYSICA A, V233, P395, DOI 10.1016/S0378-4371(96)00271-3; TSOO C, 1994, J CHEM PHYS, V101, P6405, DOI 10.1063/1.468397; VANEIJCK BP, 1995, ACTA CRYSTALLOGR B, V51, P99, DOI 10.1107/S0108768194009651; Venkatesh PK, 1997, PHYS REV E, V55, P6219, DOI 10.1103/PhysRevE.55.6219; Wales D.J, CAMBRIDGE CLUSTER DA; WALES DJ, 1990, J AM CHEM SOC, V112, P7908, DOI 10.1021/ja00178a010; Wales DJ, 1997, J PHYS CHEM A, V101, P5111, DOI 10.1021/jp970984n; Wales DJ, 1998, NATURE, V394, P758, DOI 10.1038/29487; Wales DJ, 1998, CHEM PHYS LETT, V286, P65, DOI 10.1016/S0009-2614(98)00065-7; WARME PK, 1974, BIOCHEMISTRY-US, V13, P768, DOI 10.1021/bi00701a020; Wawak RJ, 1998, J PHYS CHEM A, V102, P2904, DOI 10.1021/jp972424u; Wawak RJ, 1996, P NATL ACAD SCI USA, V93, P1743, DOI 10.1073/pnas.93.5.1743; WAWAK RJ, 1992, J PHYS CHEM-US, V96, P5138, DOI 10.1021/j100191a071; Wenzel W, 1999, PHYS REV LETT, V82, P3003, DOI 10.1103/PhysRevLett.82.3003; White RP, 1998, CHEM PHYS LETT, V289, P463, DOI 10.1016/S0009-2614(98)00431-X; WILLE LT, 1987, CHEM PHYS LETT, V133, P405, DOI 10.1016/0009-2614(87)87091-4; WILLE LT, IN PRESS ANN REV COM, V7; Williams DE, 1996, ACTA CRYSTALLOGR A, V52, P326, DOI 10.1107/S0108767395016679; Wolf MD, 1998, J PHYS CHEM A, V102, P6129, DOI 10.1021/jp9814597; XUE G, 1991, J GLOBAL OPTIM, V1, P187; ZWANZIG R, 1992, P NATL ACAD SCI USA, V89, P20, DOI 10.1073/pnas.89.1.20	102	883	889	5	243	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1368	1372		10.1126/science.285.5432.1368	http://dx.doi.org/10.1126/science.285.5432.1368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464088				2022-12-28	WOS:000082233500032
J	Ward, S; Brown, B; Hill, A; Kelley, J; Downs, W				Ward, S; Brown, B; Hill, A; Kelley, J; Downs, W			Equatorius: A new hominoid genus from the Middle Miocene of Kenya	SCIENCE			English	Article							BODY-WEIGHT; EVOLUTION; ORIGINS; EXTANT	A partial hominoid skeleton just older than 15 million years from sediments in the Tugen Hills of north central Kenya mandates a revision of the hominoid genus Kenyapithecus, a possible early member of the great ape-human clade, The Tugen Hills specimen represents a new genus, which also incorporates all material previously referable to Kenyapithecus africanus. The new taxon is derived with respect to earlier Miocene hominoids but is primitive with respect to the younger species Kenyapithecus wickeri and therefore is a Late member of the stem hominoid radiation in the East African Miocene.	NE Ohio Univ, Coll Med, Dept Anat, Rootstown, OH 44272 USA; Kent State Univ, Div Biomed Sci, Kent, OH 44242 USA; NE Ohio Univ, Coll Med, Dept Orthopaed Surg, Rootstown, OH 44272 USA; Yale Univ, Dept Anthropol, New Haven, CT 06520 USA; Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; No Arizona Univ, Bilby Res Ctr, Flagstaff, AZ 86011 USA	Northeast Ohio Medical University (NEOMED); University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; Northeast Ohio Medical University (NEOMED); Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northern Arizona University	Ward, S (corresponding author), NE Ohio Univ, Coll Med, Dept Anat, POB 95, Rootstown, OH 44272 USA.							ALPAGUT B, 1990, J HUM EVOL, V19, P397, DOI 10.1016/0047-2484(90)90052-D; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Andrews P., 1996, P168; ANDREWS P, 1987, J HUM EVOL, V16, P101, DOI 10.1016/0047-2484(87)90062-5; Andrews P., 1976, HUMAN ORIGINS L LEAK, P279; Begun David R., 1994, Yearbook of Physical Anthropology, V37, P11; Begun David R., 1997, P389; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; HARRISON T, 1992, PRIMATES, V33, P501, DOI 10.1007/BF02381152; Ishida H., 1984, AFR STUD MONOGR, V2, P73; KELLEY J, 1995, AM J PHYS ANTHROPOL, V96, P365, DOI 10.1002/ajpa.1330960405; Kelley J., 1995, AM J PHYS ANTHROPOL, V96, P390; KELLEY JL, UNPUB; LEAKEY LSB, 1962, ANN MAG NAT HIST, V13, P689; MARTIN L, 1986, MAJOR TOPICS PRIMATE, P151; Martin Lawrence B., 1993, P393; McCrossin M.L., 1997, AM J PHYS ANTHR S, VS24, P164; McCrossin M.L., 1994, INTEGRATIVE PATHS PA, P95; MCCROSSIN ML, 1993, P NATL ACAD SCI USA, V90, P1962, DOI 10.1073/pnas.90.5.1962; McCrossin Monte L., 1997, P241; Nakatsukasa M, 1998, J HUM EVOL, V34, P657, DOI 10.1006/jhev.1998.0228; PICKFORD M, 1986, Zeitschrift fuer Morphologie und Anthropologie, V76, P117; PICKFORD M, 1985, J HUM EVOL, V14, P113, DOI 10.1016/S0047-2484(85)80002-6; PICKFORD M, 1986, PRIMATE EVOLUTION, V1, P163; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; RAFFERTY KL, 1995, AM J PHYS ANTHROPOL, V97, P391, DOI 10.1002/ajpa.1330970406; Rose Michael D., 1997, P79; Rose Michael D., 1996, African Study Monographs Supplementary Issue, V24, P3; RUFF C, 1988, J HUM EVOL, V17, P687, DOI 10.1016/0047-2484(88)90025-5; Ward Carol V., 1997, P101; WARD SC, 1983, NEW INTERPRETATIONS, P325	31	94	97	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1382	1386		10.1126/science.285.5432.1382	http://dx.doi.org/10.1126/science.285.5432.1382			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464093				2022-12-28	WOS:000082233500037
J	Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ				Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ			Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOTHYROIDISM; IMMUNOGLOBULINS; BINDING; WOMEN	Background When thyroid deficiency occurs simultaneously in a pregnant woman and her fetus, the child's neuropsychological development is adversely affected. Whether developmental problems occur when only the mother has hypothyroidism during pregnancy is not known. Methods In 1996 and 1997,we measured thyrotropin in stored serum samples collected from 25,216 pregnant women between January 1987 and March 1990. We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percentile of the values for all the pregnant women, 15 women with values between the 98th and 99.6th percentiles, inclusive, in combination with low thyroxine levels, and 124 matched women with normal values. Their seven-to-nine-year-old children, none of whom had hypothyroidism as newborns, underwent 15 tests relating to intelligence, attention, language, reading ability, school performance, and visual-motor performance. Results The children of the 62 women with high serum thyrotropin concentrations performed slightly less well on all 15 tests. Their full-scale IQ scares on the Wechsler Intelligence Scale for Children, third edition, averaged 4 points lower than those of the children of the 124 matched control women (P=0.06); 15 percent had scores of 85 or less, as compared with 5 percent of the matched control children. Of the 62 women with thyroid deficiency, 48 were not treated for the condition during the pregnancy under study. The full-scale IQ scores of their children averaged 7 points lower than those of the 124 matched control children (P=0.005); 19 percent had scores of 85 or less. Eleven years after the pregnancy under study, 64 percent of the untreated women and 4 percent of the matched control women had confirmed hypothyroidism. Conclusions Undiagnosed hypothyroidism in pregnant women may adversely affect their fetuses; therefore, screening for thyroid deficiency during pregnancy may be warranted. (N Engl J Med 1999;341:549-55.) (C)1999, Massachusetts Medical Society.	Fdn Blood Res, Scarborough, ME 04074 USA; New England Newborn Screening Program, Jamaica Plain, MA USA; Childrens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Dartmouth Med Sch, Hanover, NH USA	Foundation for Blood Research (FBR); Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	Haddow, JE (corresponding author), Fdn Blood Res, 69 US Rte 1, Scarborough, ME 04074 USA.		Fahimifar, Sepideh/M-5303-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031183] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD31183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; CHO BY, 1988, ENDOCRINOL JAPON, V35, P819; CONNERS CK, 1994, CPT COMPUTER PROGRAM; CONNORS MH, 1986, PEDIATRICS, V78, P287; Dussault JH, 1999, OBSTET GYNECOL, V93, P15, DOI 10.1016/S0029-7844(98)00369-X; FORT P, 1988, J CLIN ENDOCR METAB, V66, P645, DOI 10.1210/jcem-66-3-645; Gardner LI, 1975, ENDOCRINE GENETIC DI, P234; GOLDSMITH RE, 1973, J CLIN ENDOCR METAB, V37, P265, DOI 10.1210/jcem-37-2-265; HADDOW JE, 1983, OBSTET GYNECOL, V62, P556; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; KLEIN RZ, 1991, CLIN ENDOCRINOL, V35, P41, DOI 10.1111/j.1365-2265.1991.tb03494.x; MAN EB, 1969, AM J OBSTET GYNECOL, V104, P898, DOI 10.1016/0002-9378(69)90644-9; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MARKWARDT F, 1989, PEABODY INDIVIDUAL A; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, P369; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, pA767; MITCHELL ML, 1976, CLIN CHEM, V22, P1912; NEWCOMER P, 1991, TEST LANGUAGE DEV, V2; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; SUTHERLAND JM, 1960, NEW ENGL J MED, V263, P336, DOI 10.1056/NEJM196008182630703; Trites R., 1989, GROOVED PEGBOARD TES; Volpe J., 1995, NEUROLOGY NEWBORN, P43; Wechsler D., 1991, WISC 3 WECHSLER INTE	26	1590	1718	1	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					549	555		10.1056/NEJM199908193410801	http://dx.doi.org/10.1056/NEJM199908193410801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451459				2022-12-28	WOS:000082061500001
J	Gardner, K; Chapple, A				Gardner, K; Chapple, A			Barriers to referral in patients with angina: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY; REVASCULARIZATION; ACCESS; RATES; CARE; UK	Objectives To explore barriers to patients being referred for possible revascularisation. Design Qualitative study using semi-structured interviews. Participants 16 patients aged under 75 years with stable angina and their doctors. Setting General practice in Toxteth, Liverpool. Results Fear of both hospitals and medical tests was common and largely hidden from the doctors. Patients felt they were old, had low expectations of treatment, viewed angina as a chronic illness, and knew little about new developments in angina treatment Patients and doctors had difficulty in recognising angina symptoms that were not textbook definitions amid multiple comorbidity. Patients saw doctors as busy and did not want to bother them with their condition. Cultural gaps and communication difficulties existed despite all but one patient having English as their first language. Conclusions Listening to patients is vital to address inequitable access to health services: how patients are treated by doctors today affects acceptability of referral tomorrow. Primary care groups in deprived areas should work With communities to address local fears. This will involve collaboration between primary, secondary, and tertiary care. Cultural gaps exist between patients and doctors in deprived areas, and diagnostic confusion can occur particularly in die presence of other psychological and physical morbidity. Adequate time and resources-for example, education for doctors and patients and provision of interpreters-need to he provided if inequitable access to revascularisation procedures is to be addressed.	Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Gardner, K (corresponding author), Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England.							ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; BEERY TA, 1995, HEART LUNG, V24, P427, DOI 10.1016/S0147-9563(95)80020-4; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; BLACK N, 1995, J EPIDEMIOL COMMUN H, V49, P408, DOI 10.1136/jech.49.4.408; Chapple A, 1998, J Health Serv Res Policy, V3, P153; FORREST D, 1995, HEART DIS PREVENTION; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; Kee F, 1993, Qual Health Care, V2, P87, DOI 10.1136/qshc.2.2.87; LEAR JT, 1994, J R SOC MED, V84, P661; Morse JM, 1999, QUAL HEALTH RES, V9, P5, DOI 10.1177/104973299129121622; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PENDLETON D, 1984, CONSULTATOIN APPROAC; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; Popay J, 1996, SOC SCI MED, V42, P759, DOI 10.1016/0277-9536(95)00341-X; Ruston A, 1998, BRIT MED J, V316, P1060; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; Tesch R, 1990, ANAL TYPES SOFTWARE	19	59	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					418	421		10.1136/bmj.319.7207.418	http://dx.doi.org/10.1136/bmj.319.7207.418			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445924	Green Published, Bronze			2022-12-28	WOS:000082098900018
J	Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M				Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M		Meningococcal Res Grp	4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; PROTEIN-C; PURPURA FULMINANS; SEPTIC SHOCK; PLASMA ENDOTOXIN; ASSOCIATION; COAGULATION; CHILDREN; INTERLEUKIN-1; ANTITHROMBIN	Background Intravascular coagulation with infarction of skin, digits, and limbs is a characteristic feature of meningococcal sepsis. Children with meningococcal sepsis have higher than normal concentrations of plasminogen activator inhibitor 1 (PAI-1) in plasma. Combined with the widespread venous thrombosis, this finding suggests an impairment of fibrinolysis. A common functional insertion/deletion (4G/5G) polymorphism exists in the promoter region of the PAI-1. gene. We tested the hypothesis that children with the 4G/4G genotype produce higher concentrations of PAI-1, develop more severe coagulopathy, and are at greater risk of death during meningococcal sepsis. Methods The relation between meningococcal disease outcome, PAI-1 concentration, ana PAI-1 genotype was investigated in 175 children with meningococcal disease (37 from Rotterdam, the Netherlands, and 138 from London, UK) and 226 controls (137 from Rotterdam, 89 from London). PAI-1 concentrations in plasma were measured by ELISA, and the 4G/5G PAI-1 polymorphism was detected by PCR and hybridisation. Findings Concentrations of PAI-1 on admission correlated with presentation (sepsis or meningitis) and outcome. The median PAI-1 concentration in children who died was substantially higher than that in survivors (2448 [IQR 1115-3191] vs 370 [146-914] ng/mL; p<0.0001). Patients with the 4G/4G genotype had significantly higher PAI-1 concentrations than those with the 4G/5G or 5G/5G genotype (1051 [550-2440] vs 436 [198-1225] ng/mL; p=0.03), and had an increased risk of death (relative risk 2.0 [1.0-3.8] for the two cohorts combined, and 4.8 [1.8-13] for the London cohort). Interpretation A genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis. This finding suggests that impaired fibrinolysis is an important factor in the pathophysiology of meningococcal sepsis.	Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat, London, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Imperial College London; University of London; University College London	Hermans, PWM (corresponding author), Erasmus Univ, Lab Paediat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hazelzet, Jan A/L-2888-2015; Hermans, Peter W.M./H-8042-2014; Hermans, Peter P.W.M./F-4655-2010; Hibberd, Martin L/D-5050-2009	Levin, Michael/0000-0003-2767-6919; Hibberd, Martin/0000-0001-8587-1849; Hazelzet, Jan/0000-0002-9414-5539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achtman M, 1995, MENINGOCOCCAL DIS, P159; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DAY KC, 1990, BLOOD, V76, P1538; Derkx B, 1999, CLIN INFECT DIS, V28, P770, DOI 10.1086/515184; DRAPKIN MS, 1989, PEDIATR INFECT DIS J, V8, P399, DOI 10.1097/00006454-198906000-00015; Duncan A, 1997, LANCET, V350, P1565, DOI 10.1016/S0140-6736(05)64007-X; ENGEBRETSEN LF, 1986, THROMB RES, V42, P713, DOI 10.1016/0049-3848(86)90351-8; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; GLADSON CL, 1989, BLOOD, V74, P173; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; HEYDERMAN RS, 1991, ARCH DIS CHILD, V66, P1296, DOI 10.1136/adc.66.11.1296; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; KUPPERMANN N, 1994, PEDIATR INFECT DIS J, V13, P867, DOI 10.1097/00006454-199410000-00004; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NADEL S, 1995, MENINGOCOCCAL DIS, P207; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POWARS DR, 1987, NEW ENGL J MED, V317, P571; Ryan MP, 1996, BIOCHEM J, V314, P1041, DOI 10.1042/bj3141041; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; SPEER CP, 1987, J PEDIATR-US, V111, P667, DOI 10.1016/S0022-3476(87)80240-8; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; ZENZ W, 1995, PEDIATRICS, V96, P144	30	218	226	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					556	560		10.1016/S0140-6736(99)02220-5	http://dx.doi.org/10.1016/S0140-6736(99)02220-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470700				2022-12-28	WOS:000081991000013
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The TRA-1A sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REGULATION; CUBITUS INTERRUPTUS; SIGNALING PATHWAY; IN-VITRO; APOPTOSIS; DROSOPHILA; NUCLEUS; FAMILY; DIFFERENTIATION	The hermaphrodite-specific neurons (HSNs) of the nematode Caenorhabditis elegans are generated embryonically in both hermaphrodites and males but undergo programmed cell death in males. The gene egl-1 encodes a BH3-containing cell death activator that is required for programmed cell death in C. elegans. Gain-of-function (gf) mutations in egl-1 cause the inappropriate programmed cell death of the HSNs in hermaphrodites. These mutations lie 5.6 kb downstream of the egl-1 transcription unit and disrupt the binding of the TRA-1A zinc finger protein, the terminal global regulator of somatic sexual fate. This disruption results in the activation of the egl-1 gene in the HSNs not only in males but also in hermaphrodites. Our findings suggest that in hermaphrodites TRA-1A represses egl-1 transcription in the HSNs to prevent these neurons from undergoing programmed cell death.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02319 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	horvitz@mit.edu	Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BREEDLOVE SM, 1986, J NEUROBIOL, V17, P157, DOI 10.1002/neu.480170304; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CLARK SG, 1994, GENETICS, V137, P987; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/0006-8993(96)00298-3; DEBONO M, 1995, GENE DEV, V9, P155, DOI 10.1101/gad.9.2.155; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DESAI C, 1989, GENETICS, V121, P703; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KIM RJ, 1989, J NEUROSCI, V9, P3176; KONISHI M, 1985, NATURE, V315, P145, DOI 10.1038/315145a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MEYER BJ, 1997, C ELEGANS, V2, P209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NORDEEN EJ, 1985, SCIENCE, V229, P671, DOI 10.1126/science.4023706; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERRY MD, 1994, GENETICS, V138, P317; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Priess J. R., 1997, C ELEGANS 2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasaki H, 1997, DEVELOPMENT, V124, P1313; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORN RS, 1994, J NEUROBIOL, V25, P1039, DOI 10.1002/neu.480250902; TRENT C, 1983, GENETICS, V104, P619; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRUMAN JW, 1984, ANNU REV NEUROSCI, V7, P171; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	55	171	185	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					317	327		10.1016/S0092-8674(00)81961-3	http://dx.doi.org/10.1016/S0092-8674(00)81961-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458607	Bronze			2022-12-28	WOS:000081950300007
J	Ritchie, ME; Olff, H				Ritchie, ME; Olff, H			Spatial scaling laws yield a synthetic theory of biodiversity	NATURE			English	Article							BODY-SIZE; FRACTAL LANDSCAPES; DIVERSITY; ABUNDANCE; PLANT	Ecologists still search for common principles that predict well-known responses of biological diversity to different factors(1-4) Such factors include the number of available niches in space(5-7), productivity(8-10), area(10), species' body size(11-14) and habitat fragmentation. Here we show that all these patterns can arise from simple constraints on how organisms acquire resources in space. We use spatial scaling laws to describe how species of different sizes find food in patches of varying size and resource concentration. We then derive a mathematical rule for the minimum similarity in size of species that share these resources. This packing rule yields a theory of species diversity that predicts relations between diversity and productivity more effectively than previous models(8-10). Size and diversity patterns for locally coexisting East African grazing mammals and North American savanna plants strongly support these predictions. The theory also predicts relations between diversity and area and between diversity and habitat fragmentation. Thus, spatial scaling laws provide potentially unifying first principles that may explain many important patterns of species diversity.	Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA; Agr Univ Wageningen, Dept Environm Sci, Trop Nat Conservat & Vertebrate Ecol Grp, NL-6708 PD Wageningen, Netherlands	Utah System of Higher Education; Utah State University; Wageningen University & Research	Ritchie, ME (corresponding author), Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA.	ritchie@cc.usu.edu	Olff, Han/A-8516-2008	Olff, Han/0000-0003-2154-3576				[Anonymous], 2001, PLANT STRATEGIES VEG; Belovsky GE, 1997, EVOL ECOL, V11, P641, DOI 10.1023/A:1018430201230; BROWN JH, 1993, AM NAT, V142, P573, DOI 10.1086/285558; BROWN JH, 1981, AM ZOOL, V21, P877; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; Huston M. A., 1994, BIOL DIVERSITY; HUTCHINSON GE, 1959, AM NAT, V93, P117, DOI 10.1086/282063; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; JONES CG, 1991, J ANIM ECOL, V60, P767, DOI 10.2307/5413; KINGDON J, 1979, E AFRICAN MAMMALS AT, V1; MACARTHUR RH, 1964, AM NAT, V98, P387, DOI 10.1086/282334; Mandelbrot B, 1983, FRACTAL GEOMETRY NAT; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; MILNE BT, 1992, AM NAT, V139, P32, DOI 10.1086/285312; Milne BT, 1997, WILDLIFE AND LANDSCAPE ECOLOGY, P32; MORSE DR, 1985, NATURE, V314, P731, DOI 10.1038/314731a0; O'Neill RV, 1988, LANDSCAPE ECOL, V2, P63, DOI 10.1007/BF00138908; PALMER MW, 1992, AM NAT, V139, P375, DOI 10.1086/285332; Prins H.H.T., 1998, P449; Ritchie ME, 1998, ECOLOGY, V79, P165, DOI 10.1890/0012-9658(1998)079[0165:HEOPAN]2.0.CO;2; Ritchie ME, 1998, EVOL ECOL, V12, P309, DOI 10.1023/A:1006552200746; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG ML, 1994, SPECIES DIVERSITY EC, P52; SCHLUTER D, 1994, SPECIES DIVERSITY EC; SCHOENER TW, 1974, THEOR POPUL BIOL, V6, P265, DOI 10.1016/0040-5809(74)90013-6; Siemann E, 1996, NATURE, V380, P704, DOI 10.1038/380704a0; SINCLAIR ARE, 1979, SERENGCTI DYNAMICS E; TILMAN D, 1994, SPECIES DIVERSITY EC, P13; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109	30	291	302	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					557	560		10.1038/23010	http://dx.doi.org/10.1038/23010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448857	Green Published			2022-12-28	WOS:000081854800053
J	Amado, RG; Chen, ISY				Amado, RG; Chen, ISY			Biomedicine - Lentiviral vectors - the promise of gene therapy within reach?	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; NONDIVIDING CELLS; IN-VIVO; TRANSDUCTION; INTEGRATION; EXPRESSION; DELIVERY; HIV		Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Amado, RG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA.	ramado@ucla.edu						Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; AN DS, IN PRESS J VIROL; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; DONAHUE RE, 1998, BLOOD S1, V92; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Poeschla EM, 1998, NAT MED, V4, P354, DOI 10.1038/nm0398-354; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; TAKAHASHI M, IN PRESS J VIROL; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	21	132	163	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					674	676		10.1126/science.285.5428.674	http://dx.doi.org/10.1126/science.285.5428.674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454923				2022-12-28	WOS:000081765100031
J	Tyler, CW				Tyler, CW			Neuroscience - Is art lawful?	SCIENCE			English	Editorial Material									Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Tyler, CW (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							Arnheim R., 1988, POWER CTR STUDY COMP; BRENNAN SE, 1985, LEONARDO, V18, P170, DOI 10.2307/1578048; HANSON HM, 1959, J EXP PSYCHOL, V58, P321, DOI 10.1037/h0042606; Kandinsky W., 1947, POINT LINE PLANE; Martindale C., 1990, CLOCKWORK MUSE PREDI; Ramachandran V.S., 1999, J CONSCIOUSNESS STUD, V6, P15, DOI [10.1179/174327908X392906, DOI 10.1179/174327908X392906]	6	13	13	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					673	674		10.1126/science.285.5428.673	http://dx.doi.org/10.1126/science.285.5428.673			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454922				2022-12-28	WOS:000081765100030
J	Harnden, P; Mahmood, N; Southgate, J				Harnden, P; Mahmood, N; Southgate, J			Expression of cytokeratin 20 redefines urothelial papillomas of the bladder	LANCET			English	Article							CARCINOMA; CANCER	Background Most non-invasive urothelial tumours of the bladder are diagnosed as papillary carcinomas in accordance with the WHO classification and because the identification of papillomas is difficult by routine histology; some patients are therefore misdiagnosed. This practice is associated with psychological morbidity for the patient and may also skew cancer statistics. Cytokeratin 20 (CK20) is a sensitive marker of urothelial differentiation. We investigated whether this marker could be used in the identification of urothelial papillomas and used the rate of recurrence as an indicator to assess the biological behaviour of such tumours. Methods In a prospective study, immunocytochemistry for CK20 was done on tumours of all patients who presented for the first time with non-invasive papillary bladder tumours. We classified the expression pattern of CK20 as normal or abnormal at the time of initial diagnosis. We recorded time to first biopsy-proven recurrence or length of follow-up when no recurrence was observed. Findings Of 58 consecutive patients, ten had tumours with a normal pattern of CK20 expression. No patients developed further tumours during the follow-up (median 18 [range 13-28] months). By contrast, 30 (73%) of the 41 evaluable patients with tumours that showed abnormal CK20 expression developed further tumours; the median time to a second tumour was 6 (2-24) months. The only factor that had a significant effect on the outcome of patients in terms of recurrence was expression of CK20 (p<0.0001). Interpretation Normal urothelial differentiation, as evidenced by a normal pattern of CK20 expression, is retained in a proportion of non-invasive papillary urothelial tumours and thus justifies use of the term urothelial papilloma. A large-scale study is needed to investigate the outcome of patients with such tumours.	Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England	Leeds General Infirmary; Saint James's University Hospital	Harnden, P (corresponding author), St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England.		Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				DEMING CL, 1950, J UROLOGY, V63, P815, DOI 10.1016/S0022-5347(17)68833-5; GREENE LF, 1973, J UROLOGY, V110, P205, DOI 10.1016/S0022-5347(17)60161-7; HALL RR, 1994, BMJ-BRIT MED J, V308, P257, DOI 10.1136/bmj.308.6923.257; Harnden P, 1996, BRIT J UROL, V78, P870, DOI 10.1046/j.1464-410X.1996.23511.x; HARNDEN P, 1996, CURR DIAGN PATHOL, V3, P109; HARNDEN P, 1995, HISTOPATHOLOGY, V27, P167; JORDAN AM, 1987, CANCER, V60, P2766, DOI 10.1002/1097-0142(19871201)60:11<2766::AID-CNCR2820601129>3.0.CO;2-0; KIEMENEY LALM, 1994, EUR J CANCER, V30A, P1134, DOI 10.1016/0959-8049(94)90472-3; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Murphy WM, 1994, TUMORS KIDNEY BLADDE; OOMS ECM, 1983, HUM PATHOL, V14, P140, DOI 10.1016/S0046-8177(83)80242-1; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; READING J, 1995, BRIT J UROL, V75, P604, DOI 10.1111/j.1464-410X.1995.tb07417.x; REUTER VE, 1994, DIAGNOSTIC SURG PATH; *WHO, 1973, HIST TYP UR BLADD TU, V10; [No title captured]	16	95	98	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					974	977		10.1016/S0140-6736(98)05383-5	http://dx.doi.org/10.1016/S0140-6736(98)05383-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459907				2022-12-28	WOS:000079421600013
J	Mofenson, LM				Mofenson, LM			Short-course zidovudine for prevention of perinatal infection	LANCET			English	Editorial Material							CLINICAL-TRIAL; TRANSMISSION; AFRICA		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; MOFENSON LM, IN PRESS AIDS; Rouse DJ, 1997, AM J OBSTET GYNECOL, V176, P617, DOI 10.1016/S0002-9378(97)70557-X; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SEMBA R, 1998, 3 INT S GLOB STRAT P; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; World Health Organization, 1997, COV MAT CAR LIST AV	16	50	51	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					766	767		10.1016/S0140-6736(99)90028-4	http://dx.doi.org/10.1016/S0140-6736(99)90028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459952				2022-12-28	WOS:000079089100002
J	Bush, A				Bush, A			A positive response from the GP	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					573	573		10.1136/bmj.319.7209.573	http://dx.doi.org/10.1136/bmj.319.7209.573			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463907	Green Published			2022-12-28	WOS:000082347200035
J	Baron, DN				Baron, DN			A memorable experience - The qat party	BRITISH MEDICAL JOURNAL			English	Article																			0	5	5	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					500	500		10.1136/bmj.319.7208.500	http://dx.doi.org/10.1136/bmj.319.7208.500			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454406	Green Published			2022-12-28	WOS:000082199600028
J	Wickware, P				Wickware, P			Data explosion fuels search for drugs	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					799	800		10.1038/23532	http://dx.doi.org/10.1038/23532			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466732				2022-12-28	WOS:000082131100060
J	Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ				Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ		Multicenter Hemophilia Cohort Study	Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: A measure of current immune suppression	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA LEVELS; ANTIRETROVIRAL THERAPY; LYMPHOCYTE COUNTS; TYPE-1 INFECTION; PROGNOSTIC VALUE; IN-VIVO; AIDS; MACROPHAGES; PROGRESSION	Background: For patients infected with HIV, plasma HIV viral load in early disease predicts long-term prognosis. However, the implications of viral load measurements late in HIV disease are uncertain. Objective: To evaluate the relation between plasma HIV viral load and subsequent risk for disease progression in patients with late-stage HIV disease. Design: Retrospective cohort study. Setting: 16 treatment centers for patients with hemophilia. Patients: 389 patients with hemophilia and late-stage HIV disease (CD4 count < 200 cells/mm(3)). Measurements: Plasma HIV viral load was measured at baseline. Patients were followed for AIDS-related illnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome). Results: HIV viral load strongly predicted AIDS-related illness. For patients with viral loads less than 4.00 log(10) copies/mL, the 1-year actuarial risk was 0% and the 5-year risk was 25%. For patients with viral loads of at least 6.00 log(10) copies/mL, the 1-year actuarial risk was 42% and the 5-year risk was 78%. A linear relation existed between viral load a nd risk for AIDS-related illness (hazard ratio, 2.37 per log(10) copies/mL; P < 0.001). In addition, viral load most strongly predicted risk for illness immediately after viral load testing; this predictive relation attenuated over time (P = 0.002). These findings changed little after adjustment for CD4 cell counts that were updated during follow-up. In the first year after viral load was measured, it predicted occurrence of P, carinii pneumonia (hazard ratio, 4.69 per log(10) copies/mL; P < 0.001). Conclusions: In patients with hemophilia and late-stage HIV disease, viral load predicts disease progression independently of CD4 cell counts. Because viral load most strongly predicts progression immediately after load is measured, it seems to reflect the current level of immunosuppression.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA; NCI, Biostat Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Engels, EA (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8005, Rockville, MD 20822 USA.	engelse@exchange.nih.gov		Rosenberg, Philip/0000-0001-6349-9126	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP033002, Z01CP010115] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-33002] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHATURVEDI S, 1995, J INFECT DIS, V171, P320, DOI 10.1093/infdis/171.2.320; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Council of State and Territorial Epidemiologists, 1987, MMWR MORB MORTAL S1, V36, p1S; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P52; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P69; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GalettoLacour A, 1996, J INFECT DIS, V173, P1388, DOI 10.1093/infdis/173.6.1388; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HARRISON TS, 1995, J INFECT DIS, V172, P665, DOI 10.1093/infdis/172.3.665; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P22; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; KLEIN JP, 1997, KSURVIVAL ANAL TECHN, P83; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; KRONER BL, 1994, J ACQ IMMUN DEF SYND, V7, P279; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; LYLES R, 1999, 6 C RETR OPP INF 31; Maas JJ, 1998, J INFECT DIS, V178, P1024, DOI 10.1086/515655; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; MURDER J, 1994, J CLIN MICROBIOL, V32, P292; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Read C, 1983, ENCY STAT SCI, V3, P86; SHIRATSUCHI H, 1994, J CLIN INVEST, V93, P885, DOI 10.1172/JCI117044; TOLLERUD DJ, 1991, J CLIN LAB ANAL, V5, P255; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; WAGNER RP, 1992, AM REV RESPIR DIS, V146, P1434, DOI 10.1164/ajrccm/146.6.1434	36	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					256	+		10.7326/0003-4819-131-4-199908170-00004	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454946				2022-12-28	WOS:000082012500003
J	Javedan, SP; Dickman, CA				Javedan, SP; Dickman, CA			Cause of adjacent-segment disease after spinal fusion	LANCET			English	Editorial Material							ANTERIOR; INSTRUMENTATION		Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Javedan, SP (corresponding author), Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.							AOTA Y, 1995, J SPINAL DISORD, V8, P464, DOI 10.1097/00002517-199512000-00008; Cunningham BW, 1997, SPINE, V22, P2655, DOI 10.1097/00007632-199711150-00014; Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163; FRYMOYER J W, 1978, Spine, V3, P1, DOI 10.1097/00007632-197803000-00001; GOFFIN J, 1995, J SPINAL DISORD, V8, P500; Hilibrand AS, 1997, SPINE, V22, P1574, DOI 10.1097/00007632-199707150-00009; Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009; LEE CK, 1981, SPINE, V6, P118, DOI 10.1097/00007632-198103000-00002; LUNSFORD LD, 1980, J NEUROSURG, V53, P1, DOI 10.3171/jns.1980.53.1.0001; PENTA M, 1995, SPINE, V20, P743, DOI 10.1097/00007632-199503150-00018; ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223; Shono Y, 1998, SPINE, V23, P1550, DOI 10.1097/00007632-199807150-00009; WHITEHILL R, 1987, SPINE, V12, P959, DOI 10.1097/00007632-198712000-00001; Wimmer C, 1997, ACTA ORTHOP SCAND, V68, P269, DOI 10.3109/17453679708996699; Wu W, 1996, ACTA RADIOL, V37, P614; YANG SW, 1986, SPINE, V11, P937	16	36	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					530	531		10.1016/S0140-6736(99)00201-9	http://dx.doi.org/10.1016/S0140-6736(99)00201-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470693				2022-12-28	WOS:000081991000006
J	van der Cammen, TJM; Tanis, AA; Maes, RM; de Man, RA				van der Cammen, TJM; Tanis, AA; Maes, RM; de Man, RA			Stopping the pills	LANCET			English	Article									Dept Internal Med 1 & Geriatr Med, NL-3000 CA Rotterdam, Netherlands; Erasmus Univ Hosp, NL-3000 CA Rotterdam, Netherlands; Ziekenhuis Walcheren, Vlissingen, Netherlands; St Antonius Ziekenhuis, Nieuwegein, Netherlands	Erasmus University Rotterdam; Erasmus MC; St. Antonius Hospital Utrecht	de Man, RA (corresponding author), Dept Internal Med 1 & Geriatr Med, NL-3000 CA Rotterdam, Netherlands.							BERNARD G, 1993, GASTROENTEROLOGY, V105, P482, DOI 10.1016/0016-5085(93)90723-P; FAGEL WJ, 1988, AM J MED, V85, P858; JENNER PN, 1992, INT CLIN PSYCHOPHARM, V6, P69, DOI 10.1097/00004850-199206004-00013; MICHAELI D, 1968, GASTROENTEROLOGY, V54, P929; PEPPER W, 1981, NY STATE J MED, V81, P209	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					564	564		10.1016/S0140-6736(99)06508-3	http://dx.doi.org/10.1016/S0140-6736(99)06508-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470702				2022-12-28	WOS:000081991000015
J	Daniele, A; Moro, E; Bentivoglio, AR				Daniele, A; Moro, E; Bentivoglio, AR			Zolpidem in progressive supranuclear palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Catholic Univ, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Daniele, A (corresponding author), Catholic Univ, I-00168 Rome, Italy.		Daniele, Antonio/I-4516-2012; Bentivoglio, Anna Rita/K-3752-2018; Daniele, Antonio/AFQ-9918-2022; Daniele, Antonio/AAD-1935-2022	Bentivoglio, Anna Rita/0000-0002-9663-095X				Daniele A, 1997, LANCET, V349, P1222, DOI 10.1016/S0140-6736(05)62416-6; Langer SZ, 1988, IMIDAZOPYRIDINES SLE, P55; LEVY R, 1995, NEUROLOGY, V45, P127, DOI 10.1212/WNL.45.1.127; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Schwarz J., 1993, Neurology, V43, pS17	5	56	58	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					543	544		10.1056/NEJM199908123410721	http://dx.doi.org/10.1056/NEJM199908123410721			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10447452	Bronze			2022-12-28	WOS:000081962600034
J	Durham, SR; Walker, SM; Varga, EM; Jacobson, MR; O'Brien, F; Noble, W; Till, SJ; Hamid, QA; Nouri-Aria, KT				Durham, SR; Walker, SM; Varga, EM; Jacobson, MR; O'Brien, F; Noble, W; Till, SJ; Hamid, QA; Nouri-Aria, KT			Long-term clinical efficacy of grass-pollen immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED IMMUNOTHERAPY; T-CELL CLONES; DOUBLE-BLIND; HAY-FEVER; ALLERGEN IMMUNOTHERAPY; MESSENGER-RNA; FOLLOW-UP; RAGWEED IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; RUSH IMMUNOTHERAPY	Background Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment. Methods We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge; Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (T(H)2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease. Results Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression. Conclusions immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity. (N Engl J Med 1999; 341:468-75.) (C) 1999 Massachusetts Medical Society.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, London SW3 6LY, England; Royal Brompton & Harefield Batl Hlth Serv Trust, Allergy Clin, London, England; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; McGill University	Durham, SR (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013; Noble, Wendy/C-3756-2009	Walker, Samantha/0000-0001-5503-8258; Noble, Wendy/0000-0002-7898-4295; Till, Stephen/0000-0003-4518-3093; Jacobson, Mikila/0000-0002-2921-6169				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; ARMITAGE P, 1994, STAT METHODS MED RES, P448; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Chanez P, 1996, ALLERGY, V51, P850; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; FRANKLAND AW, 1954, LANCET, V1, P1055; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; IMADA M, 1995, IMMUNOLOGY, V85, P373; *INT RHIN MAN WORK, 1994, ALLERGY S19, V49, P34; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; McKean J. W., 1977, ACM Transactions on Mathematical Software, V3, P183, DOI 10.1145/355732.355740; MOQBEL R, 1995, J IMMUNOL, V155, P4939; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P88, DOI 10.1016/0091-6749(90)90227-U; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; 1998, ALLERGY S, V44, P1	48	1027	1076	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					468	475		10.1056/NEJM199908123410702	http://dx.doi.org/10.1056/NEJM199908123410702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441602	Bronze			2022-12-28	WOS:000081962600002
J	Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW				Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW			Neuroimmune appendicitis	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASOACTIVE INTESTINAL POLYPEPTIDE; GROWTH-ASSOCIATED PROTEIN-43; RECEPTOR-BINDING SITES; CHRONIC-PANCREATITIS; SUBSTANCE-P; ULCERATIVE-COLITIS; CROHNS-DISEASE; NERVE-FIBERS; INNERVATION	Background 15-25% of appendices removed from patients with suspected appendicitis appear normal on histological examination. The cause of pain in such patients is unknown. Since the content of neuropeptides seems to be altered in chronic inflammation, we investigated possible changes in peptidergic innervation for substance P (SP), vasoactive intestinal peptide (VIP), and growth-associated protein-43 (GAP-43). Methods Appendices classified as showing acute appendicitis, non-acute appendicitis (clinical signs of acute appendicitis, but histologically not inflamed), or normal were processed for SP, VIP, and GAP-43 immunocytochemistry. The density of SP immunostaining was assessed by digitised morphometry. Findings 31 appendix specimens were studied (16 acute, 15 non-acute). 16 specimens were used as controls. Expression of GAP-43 was increased in the non-acute appendices. We observed larger amounts of SP-immunoreactive and VIP-immunoreactive nerves in the mucosal layer of the appendix in patients with non-acute appendicitis than in controls and patients with acute appendicitis (mean % area SP-immunoreactive 0.0496 [SD 0.0113] non-acute, 0.0221 [0.0049] acute, 0.0229 [0.0068] controls). In addition, a close spatial relation between SP-immunoreactive and VIP-immunoreactive nerve fibres and lymphoid cells was detected in the outer zone of lymph follicles. Interpretation Neuroproliferation in the appendix, in association with an increase in neurotransmitters SP and VIP, may be involved in the pathophysiology of acute right abdominal pain in the absence of an acute inflammation of the appendix. Our data, together with increasing knowledge about the way in which the nervous system and immune cells interact, suggest that neuroimmune appendicitis is a distinct pathological entity.	Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland; Univ G DAnnunzio, Surg Unit, Chieti, Italy; Univ Mainz, Inst Legal Med, D-6500 Mainz, Germany; Univ Marburg, Dept Anat & Cell Biol, D-35032 Marburg, Germany	University of Bern; G d'Annunzio University of Chieti-Pescara; Johannes Gutenberg University of Mainz; Philipps University Marburg	Buchler, MW (corresponding author), Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland.		di Mola, Fabio Francesco/J-3082-2018; di sebastiano, pierluigi/I-9851-2018	di Mola, Fabio Francesco/0000-0001-9877-2946; di sebastiano, pierluigi/0000-0002-9386-8241				AUBOCK L, 1982, J PATHOL, V136, P217, DOI 10.1002/path.1711360305; BISHOP AE, 1980, GASTROENTEROLOGY, V79, P853; BUCHLER M, 1992, PANCREAS, V7, P183; CHONG MS, 1992, EUR J NEUROSCI, V4, P883, DOI 10.1111/j.1460-9568.1992.tb00115.x; DiSebastiano P, 1997, GASTROENTEROLOGY, V112, P1648, DOI 10.1016/S0016-5085(97)70047-7; DISEBASTIANO P, 1995, DIGEST DIS SCI, V4, P333; FINK T, 1994, NEUROSCIENCE, V63, P249, DOI 10.1016/0306-4522(94)90020-5; GOLDIN E, 1989, DIGEST DIS SCI, V34, P754, DOI 10.1007/BF01540348; HORSCH D, 1993, J COMP NEUROL, V335, P381, DOI 10.1002/cne.903350308; KUBOTA Y, 1992, GASTROENTEROLOGY, V102, P1242; LAU WY, 1986, SURG GYNECOL OBSTET, V162, P256; LEMBECK F, 1985, SUBSTANCE P METABOLI, P137; MAGGI CA, 1990, NEUROSCIENCE, V39, P833, DOI 10.1016/0306-4522(90)90266-7; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MANTYH PW, 1989, PEPTIDES, V10, P627, DOI 10.1016/0196-9781(89)90154-X; MANTYH PW, 1988, NEUROSCIENCE, V25, P817, DOI 10.1016/0306-4522(88)90038-3; MASSON P, 1921, PARIS, V173, P262; MEYERMARCOTTY W, 1986, LANGENBECK ARCH CHIR, V369, P187, DOI 10.1007/BF01274349; MIETTINEN P, 1995, ANN CHIR GYNAECOL FE, V84, P267; OLSEN BS, 1987, HISTOPATHOLOGY, V11, P843, DOI 10.1111/j.1365-2559.1987.tb01887.x; OMORAIN C, 1984, GUT, V25, P57, DOI 10.1136/gut.25.1.57; PERNOW B, 1985, SUBSTANCE P METABOLI, P187; SAMELSON SL, 1987, ARCH SURG-CHICAGO, V122, P691; SHAW PAV, 1990, HISTOPATHOLOGY, V17, P117, DOI 10.1111/j.1365-2559.1990.tb00681.x; SJOLUND K, 1983, GUT, V24, P724, DOI 10.1136/gut.24.8.724; STEAD RH, 1990, J PATHOL, V161, P209, DOI 10.1002/path.1711610307; Wang Y, 1996, LANCET, V347, P1076, DOI 10.1016/S0140-6736(96)90279-2; WEIHE E, 1988, AGENTS ACTIONS, V25, P255, DOI 10.1007/BF01965027; WEIHE E, 1991, ANN NY ACAD SCI, V632, P283, DOI 10.1111/j.1749-6632.1991.tb33116.x; 1987, LANCET, V1, P198	30	97	98	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					461	466		10.1016/S0140-6736(98)10463-4	http://dx.doi.org/10.1016/S0140-6736(98)10463-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465170				2022-12-28	WOS:000081896100010
J	Shaffer, N; Chuachoowong, R; Mock, PA; Bhadrakom, C; Siriwasin, W; Young, NL; Chotpitayasunondh, T; Chearskul, S; Roongpisuthipong, A; Chinayon, P; Karon, J; Mastro, TD; Simonds, RJ				Shaffer, N; Chuachoowong, R; Mock, PA; Bhadrakom, C; Siriwasin, W; Young, NL; Chotpitayasunondh, T; Chearskul, S; Roongpisuthipong, A; Chinayon, P; Karon, J; Mastro, TD; Simonds, RJ		Bangkok Collaborative Perinatal HIV	Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CLINICAL-TRIALS; INFANT; INFECTION; RISK	Background Many developing countries have not implemented the AIDS Clinical Trials Group 076 zidovudine regimen for prevention of perinatal HIV-1 transmission because of its complexity and cost. We investigated the safety and efficacy of short-course oral zidovudine administered during late pregnancy and labour. Methods In a randomised, double-blind, placebo-controlled trial, HIV-1-infected pregnant women at two Bangkok hospitals were randomly assigned placebo or one zidovudine 300 mg tablet twice daily from 36 weeks' gestation and every 3 h from onset of labour until delivery. Mothers were given infant formula and asked not to breastfeed. The main endpoint was babies' HIV-1-infection status, tested with HIV-1-DNA PCR at birth, 2 months, and 6 months. We measured maternal plasma viral concentrations by RNA PCR. Findings Between May, 1996, and December, 1997, 397 women were randomised; 393 gave birth to 395 live-born babies. Median duration of antenatal treatment was 25 days, and median number of doses during labour was three. 99% of women took at least 90% of scheduled antenatal doses. Adverse events were similar in the study groups. Of 392 babies with at least one PCR lest, 55 tested positive: 18 in the zidovudine group and 37 in the placebo group. The estimated transmission risks were 9.4% (95% CI 5.2-13.5) on zidovudine and 18.9% (13.2-24.2) on placebo (p=0.006; efficacy 50.1% [15.4-70.6]). Between enrolment and delivery, women in the zidovudine group had a mean decrease in viral load of 0.56 log. About 80% of the treatment effect was explained by lowered maternal Viral concentrations at delivery. Interpretation A short course of twice-daily oral zidovudine was safe and well tolerated and, in the absence of breastfeeding, can. lessen the risk for mother-to-child HIV-1 transmission by half. This regimen could prevent many HIV-1 infections during late pregnancy and labour in less-developed countries unable to implement the full 076 regimen.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; HIV AIDS Collaborat, Nonthaburi, Thailand; Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok 10700, Thailand; Minist Publ Hlth, Rajavithi Hosp, Bangkok, Thailand; Minist Publ Hlth, Childrens Hosp, Dept Med Serv, Bangkok, Thailand	Centers for Disease Control & Prevention - USA; Mahidol University; Ministry of Public Health - Thailand; Rajavithi Hospital; Ministry of Public Health - Thailand	Shaffer, N (corresponding author), Ctr Dis Control & Prevent, Mailstop E-50,1600 Clifton Rd, Atlanta, GA 30333 USA.	nas4@cdc.gov						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Breslow N E, 1980, IARC Sci Publ, P5; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; CHEARSKUL S, 1997, THAIL C GLOB STRAT P; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; Kuhn L, 1997, AIDS, V11, P429, DOI 10.1097/00002030-199704000-00005; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; Moodley J, 1998, J INFECT DIS, V178, P1327, DOI 10.1086/314431; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; READ J, 1998, GEN 12 WORLD AIDS C; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Shaffer N, 1999, J INFECT DIS, V179, P590, DOI 10.1086/314641; SHAFFER N, 1996, 11 INT C AIDS VANC C; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Siriwasin W, 1998, JAMA-J AM MED ASSOC, V280, P49, DOI 10.1001/jama.280.1.49; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *US NAT I ALL INF, 1998, SER ADV EXP REP MAN; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P313; World Health Organization, 1997, Weekly Epidemiological Record, V72, P357; Young N, 1997, J ACQ IMMUN DEF SYND, V15, P391, DOI 10.1097/00042560-199708150-00011	35	564	585	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					773	780		10.1016/S0140-6736(98)10411-7	http://dx.doi.org/10.1016/S0140-6736(98)10411-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459957				2022-12-28	WOS:000079089100007
J	Hart, PD				Hart, PD			A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s	BRITISH MEDICAL JOURNAL			English	Article									Natl Inst Med Res, London NW7 1AA, England	MRC National Institute for Medical Research	Hart, PD (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.							[Anonymous], 1948, BMJ-BRIT MED J, V2, P769; ARMITAGE P, 1992, Pharmaceutical Medicine (London), V6, P23; CLARK M, 1998, MED RES COUNCIL NEWS, V79, P24; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; *MRC PAT CLIN TRIA, 1944, LANCET, V2, P373; SUTHERLAND I, 1998, ENCY BIOSTATISTICS, P2559; THOMSON AL, 1975, HALF CENTURY MED RES, P238	7	34	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					572	573		10.1136/bmj.319.7209.572	http://dx.doi.org/10.1136/bmj.319.7209.572			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463905	Green Published			2022-12-28	WOS:000082347200034
J	Dixon, RN; Hwang, DW; Yang, XF; Harich, S; Lin, JJ; Yang, X				Dixon, RN; Hwang, DW; Yang, XF; Harich, S; Lin, JJ; Yang, X			Chemical "double slits": Dynamical interference of photodissociation pathways in water	SCIENCE			English	Article							ROTATIONAL STATE DISTRIBUTIONS; A-STATE; DISSOCIATION; MOLECULES; PRODUCTS; AMMONIA; H2O	Photodissociation of water at a wavelength of 121.6 nanometers has been investigated by using the H-atom Rydberg tagging technique. A striking even-odd intensity oscillation was observed in the OH(X) product rotational distribution. Model calculations attribute this oscillation to an unusual dynamical interference brought about by two dissociation pathways that pass through dissimilar conical intersections of potential energy surfaces, but result in the same products. The interference pattern and the OH product rotational distribution are sensitive to the positions and energies of the conical intersections, one with the atoms collinear as H-OH and the other as H-HO. An accurate simulation of the observations would provide a detailed test of global H2O potential energy surfaces for the three ((X) over tilde/(A) over tilde/(B) over tilde) contributing states. The interference observed from the two conical intersection pathways provides a chemical analog of Young's well-known double-slit experiment.	Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Acad Sinica, Inst Atom & Mol Sci, Taipei 106, Taiwan; Dalian Univ Technol, Lab Plasma Phys Chem, Dalian 116024, Peoples R China	University of Bristol; Academia Sinica - Taiwan; Dalian University of Technology	Dixon, RN (corresponding author), Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8 1TS, Avon, England.		Yang, Xueming/C-8764-2013; Hwang, Dennis W./F-2911-2017; Hwang, Dennis W./ABE-2158-2020	Hwang, Dennis W./0000-0001-9974-4728; Hwang, Dennis W./0000-0001-9974-4728				ANDRESEN P, 1984, J CHEM PHYS, V80, P2548, DOI 10.1063/1.447049; BIESNER J, 1989, J CHEM PHYS, V91, P2901, DOI 10.1063/1.457644; COMBEN ER, 1988, CHEM PHYS, V119, P443, DOI 10.1016/0301-0104(88)87203-3; DIEKE GH, 1962, J QUANT SPECTROSC RA, V2, P97, DOI 10.1016/0022-4073(62)90061-4; DIXON R, UNPUB; DIXON RN, 1995, J CHEM PHYS, V102, P301, DOI 10.1063/1.469403; DIXON RN, 1985, MOL PHYS, V54, P333, DOI 10.1080/00268978500100271; GUO H, 1988, J CHEM SOC FARAD T 2, V84, P949, DOI 10.1039/f29888400949; Ho TS, 1996, J CHEM PHYS, V105, P10472, DOI 10.1063/1.472977; KABLE SH, 1991, J PHYS CHEM-US, V95, P8013, DOI 10.1021/j100174a006; MARANGOS JP, 1990, J OPT SOC AM B, V7, P1254, DOI 10.1364/JOSAB.7.001254; MORDAUNT DH, 1994, J CHEM PHYS, V100, P7360, DOI 10.1063/1.466880; Mordaunt DH, 1996, J CHEM PHYS, V104, P6460, DOI 10.1063/1.471367; Murrell J.N., 1984, MOL POTENTIAL ENERGY; SCHATZ GC, 1985, J CHEM PHYS, V83, P5677, DOI 10.1063/1.449862; SCHINKE R, 1991, J CHEM PHYS, V94, P283, DOI 10.1063/1.460395; SCHINKE R, 1985, J CHEM PHYS, V83, P4522, DOI 10.1063/1.449021; Schnieder L, 1997, J CHEM PHYS, V107, P6175, DOI 10.1063/1.474283; THEODORAKOPOULOS G, 1985, CHEM PHYS, V96, P217, DOI 10.1016/0301-0104(85)85086-2; WEIDE K, 1987, J CHEM PHYS, V87, P4627, DOI 10.1063/1.452824; Yarkony DR, 1998, MOL PHYS, V93, P971, DOI 10.1080/002689798168673	21	103	106	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1249	1253		10.1126/science.285.5431.1249	http://dx.doi.org/10.1126/science.285.5431.1249			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455048				2022-12-28	WOS:000082130200038
J	Kim, KK; Yokota, H; Kim, SH				Kim, KK; Yokota, H; Kim, SH			Four-helical-bundle structure of the cytoplasmic domain of a serine chemotaxis receptor	NATURE			English	Article							DISULFIDE CROSS-LINKING; LIGAND-BINDING DOMAIN; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; ALPHA-HELIX; CHEMORECEPTOR; MODEL; DIMER; MUTAGENESIS	The bacterial chemotaxis receptors are transmembrane receptors with a simple signalling pathway which has elements relevant to the general understanding of signal recognition and transduction across membranes, how signals are relayed between molecules in a pathway, and how adaptation to a persistent signal is achieved(1). In contrast to many mammalian receptors which signal by oligomerizing upon ligand binding(2), the chemotaxis receptors are dimeric even in the absence of their ligands, and their signalling does not depend on a monomer-dimer equilibrium(3). Bacterial chemotaxis receptors are composed of a ligand-binding domain, a transmembrane domain consisting of two helices TM1 and TM2, and a cytoplasmic domain. All known bacterial chemotaxis receptors have a highly conserved cytoplasmic domain, which unites signals from different ligand domains into a single signalling pathway to flagella motors. Here we report the crystal structure of the cytoplasmic domain of a serine chemotaxis receptor of Escherichia coli, which reveals a 200 Angstrom-long coiled-coil of two antiparallel helices connected by a 'U-turn'. Two of these domains form a long, supercoiled, four-helical bundle in the cytoplasmic portion of the receptor.	Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Phys Biosci Div, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA.	shkim@LBL.gov						AMES P, 1988, COLD SPRING HARB SYM, V53, P59, DOI 10.1101/SQB.1988.053.01.010; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass RB, 1998, J BIOL CHEM, V273, P25006, DOI 10.1074/jbc.273.39.25006; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRUNGER AT, 1993, X PLOR VERSION 3 1; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1994, PROTEIN SCI, V3, P159; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	30	381	386	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					787	792		10.1038/23512	http://dx.doi.org/10.1038/23512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466731				2022-12-28	WOS:000082131100056
J	DeFronzo, RA				DeFronzo, RA			Pharmacologic therapy for type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Review							HEPATIC GLUCOSE-PRODUCTION; CORONARY HEART-DISEASE; INTENSIVE INSULIN THERAPY; SECONDARY SULFONYLUREA FAILURE; CARDIOVASCULAR RISK-FACTORS; ORAL ANTIDIABETIC AGENTS; PLACEBO-CONTROLLED TRIAL; POOR GLYCEMIC CONTROL; NIDDM PATIENTS; DOUBLE-BLIND	Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. An elevated rate of basal hepatic glucose production in the presence of hyperinsulinemia is the primary cause of fasting hyperglycemia; after a meal, impaired suppression of hepatic glucose production by insulin and decreased insulin-mediated glucose uptake by muscle contribute almost equally to postprandial hyperglycemia. In the United States, five classes of oral agents, each of which works through a different mechanism of action, are currently available to improve glycemic control in patients with type 2 diabetes. The recently completed United Kingdom Prospective Diabetes Study (UKPDS) has shown that type 2 diabetes mellitus is a progressive disorder that can be treated initially with oral agent monotherapy but will eventually require the addition of other oral agents, and that in many patients, insulin therapy will be needed to achieve targeted glycemic levels. In the UKPDS, improved glycemic control, irrespective of the agent used (sulfonylureas, metformin, or insulin), decreased the incidence of microvascular complications (retinopathy, neuropathy, and nephropathy). This review examines the goals of antihyperglycemic therapy and reviews the mechanism of action, efficacy, nonglycemic benefits, cost, and safety profile of each of the five approved classes of oral agents. A rationale for the use of these oral agents as monotherapy, in combination with each other, and in combination with insulin is provided.	Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	DeFronzo, RA (corresponding author), Univ Texas, Hlth Sci Ctr, Diabet Div, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; American Diabetes Association, 1998, DIABETES CARE, V21, pS23, DOI [10.2337/diacare.21.1.S23, DOI 10.2337/DIACARE.21.1.S23]; [Anonymous], 1996, DIABETES, V45, P1289; ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; Aviles-Santa L, 1998, DIABETES, V47, pA89; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BALODIMOS MC, 1966, METABOLIS, V15, P957, DOI 10.1016/0026-0495(66)90044-8; Bayraktar M, 1996, DIABETES CARE, V19, P252, DOI 10.2337/diacare.19.3.252; BECKNIELSEN H, 1988, DIABETIC MED, V5, P613, DOI 10.1111/j.1464-5491.1988.tb01068.x; Bell D S, 1997, Endocr Pract, V3, P73; BELL DSH, 1997, ENDOCR PRACT, P373; Bergenstal R, 1998, DIABETES, V47, pA89; Berger S, 1998, DIABETES, V47, pA18; BERGER W, 1986, SCHWEIZ MED WSCHR, V116, P145; BEST JD, 1982, DIABETES, V31, P333, DOI 10.2337/diabetes.31.4.333; Blaum CS, 1997, DIABETES CARE, V20, P7, DOI 10.2337/diacare.20.1.7; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; BURGE MR, 1998, JAMA-J AM MED ASSOC, V14, P137; Buse JB, 1998, DIABETES CARE, V21, P1455, DOI 10.2337/diacare.21.9.1455; CAMERINIDAVALOS R, 1962, METABOLISM S, V11, P74; CAMPBELL IW, 1995, DIABETES METAB REV, V11, pS57, DOI 10.1002/dmr.5610110509; CAMPBELL IW, 1985, HORM METAB RES, V15, P105; CEFALU WT, 1996, DIABETES S2, V45, pA201; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; CHOW CC, 1995, DIABETES CARE, V18, P307, DOI 10.2337/diacare.18.3.307; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; CLISSOLD SP, 1988, DRUGS, V35, P214, DOI 10.2165/00003495-198835030-00003; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; CONIFF RF, 1995, DIABETES CARE, V18, P817, DOI 10.2337/diacare.18.6.817; CONIFF RF, 1995, AM J MED, V98, P443, DOI 10.1016/S0002-9343(99)80343-X; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Cusi K, 1998, DIABETES REV, V6, P89; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; DEFRONZO RA, 1978, J CLIN INVEST, V62, P204, DOI 10.1172/JCI109108; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DeFronzo RA, 1997, DIABETES REV, V5, P177; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DUNN CJ, 1995, DRUGS, V49, P721, DOI 10.2165/00003495-199549050-00007; EDELMAN SV, 1995, DIABETES REV, V3, P308; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; FERRANNINI E, 1988, METABOLISM, V37, P79, DOI 10.1016/0026-0495(88)90033-9; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; FONESCA VA, 1998, J CLIN ENDOCR METAB, V83, P3169; Fontbonne A, 1996, DIABETES CARE, V19, P920, DOI 10.2337/diacare.19.9.920; Fuhlendorff J, 1998, DIABETES, V47, P345, DOI 10.2337/diabetes.47.3.345; Garber AJ, 1997, AM J MED, V103, P491, DOI 10.1016/S0002-9343(97)00254-4; Gavin JR, 1997, DIABETES CARE, V20, P1183; GENUTH S, 1990, DIABETES CARE, V13, P1240, DOI 10.2337/diacare.13.12.1240; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Gitlin N, 1998, ANN INTERN MED, V129, P36, DOI 10.7326/0003-4819-129-1-199807010-00008; GIUGLIANO D, 1993, EUR J CLIN PHARMACOL, V44, P107, DOI 10.1007/BF00315466; Gregersen G, 1968, Diabetologia, V4, P273, DOI 10.1007/BF01309900; GROOP L, 1987, DIABETES, V36, P1320, DOI 10.2337/diabetes.36.11.1320; GROOP L, 1991, DIABETES METAB, V17, P218; GROOP L, 1989, DIABETOLOGIA, V32, P599; GROOP L, 1987, DIABETES CARE, V10, P671, DOI 10.2337/diacare.10.6.671; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; Grossman S L, 1997, Expert Opin Investig Drugs, V6, P1025, DOI 10.1517/13543784.6.8.1025; GUSTAFSON A, 1971, ACTA MED SCAND, V190, P491; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HAUPT E, 1991, DIABETES METAB, V17, P224; HAUPT E, 1977, MED KLIN, V72, P1529; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; HILLEBRAND I, 1979, RES EXP MED, V175, P81, DOI 10.1007/BF01851236; Horton ES, 1998, DIABETES CARE, V21, P1462, DOI 10.2337/diacare.21.9.1462; Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Iwamoto Y, 1996, DIABETIC MED, V13, P365, DOI 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M; Iwamoto Y, 1996, DIABETES CARE, V19, P151, DOI 10.2337/diacare.19.2.151; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; JEPPESEN J, 1994, DIABETES CARE, V17, P1093, DOI 10.2337/diacare.17.10.1093; JEPPESEN J, 1994, DIABETOLOGIA, V37, P781, DOI 10.1007/s001250050179; Johansen K, 1999, DIABETES CARE, V22, P33, DOI 10.2337/diacare.22.1.33; JOHNSON AB, 1993, METABOLISM, V42, P1217, DOI 10.1016/0026-0495(93)90284-U; Johnson JL, 1996, ARCH INTERN MED, V156, P259, DOI 10.1001/archinte.156.3.259; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KAYASHIMA T, 1995, DIABETES RES CLIN PR, V28, P119, DOI 10.1016/0168-8227(95)01066-M; Kelley D.E., 1995, DIABETES REV, V3, P366; Kelley DE, 1998, DIABETES CARE, V21, P2056, DOI 10.2337/diacare.21.12.2056; KILO C, 1980, DIABETOLOGIA, V18, P179, DOI 10.1007/BF00251913; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KLEIN W, 1991, DIABETES METAB, V17, P235; KLIMT CR, 1970, DIABETES, V19, P747; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; KRENTZ AJ, 1994, DRUG SAFETY, V11, P223, DOI 10.2165/00002018-199411040-00002; KUDLACEK S, 1992, HORM METAB RES, V24, P478, DOI 10.1055/s-2007-1003367; Kumar S, 1996, DIABETOLOGIA, V39, P701; LANDSTEDTHALLIN L, 1995, DIABETES CARE, V18, P1183, DOI 10.2337/diacare.18.8.1183; Lebovitz Harold E., 1995, Clinical Diabetes, V13, P99; LEBOVITZ HE, 1994, DIABETES CARE, V17, P1542, DOI 10.2337/diacare.17.12.1542; LEBOVITZ HE, 1997, INT TXB DIABETES MEL, P817; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; Leibowitz G, 1996, DIABETOLOGIA, V39, P503, DOI 10.1007/BF00403296; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Marbury T, 1999, DIABETES RES CLIN PR, V43, P155, DOI 10.1016/S0168-8227(99)00002-9; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MEINERT CL, 1970, DIABETES, V19, P789; Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; Moses R, 1999, DIABETES CARE, V22, P119, DOI 10.2337/diacare.22.1.119; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATHAN DM, 1995, DIABETES CARE, V18, P251, DOI 10.2337/diacare.18.2.251; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OHNEDA A, 1978, TOHOKU J EXP MED, V124, P205, DOI 10.1620/tjem.124.205; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; PAASIKIV.J, 1971, DIABETOLOGIA, V7, P323, DOI 10.1007/BF01219465; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; Patel J., 1997, DIABETES S1, V46, p150A; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; REAVEN GM, 1992, J CLIN ENDOCR METAB, V74, P1020, DOI 10.1210/jc.74.5.1020; REAVEN GM, 1994, DIABETOLOGIA, V37, P948, DOI 10.1007/s001250050202; RIDDLE MC, 1990, DIABETES CARE, V13, P676, DOI 10.2337/diacare.13.6.676; RODGER NW, 1995, CLIN INVEST MED, V18, P318; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rosenstock J, 1996, DIABETES CARE, V19, P1194, DOI 10.2337/diacare.19.11.1194; Rosenstock J, 1998, DIABETES CARE, V21, P2050, DOI 10.2337/diacare.21.12.2050; ROSSETTI L, 1995, CLIN INVEST MED, V18, P255; ROSSETTI L, 1990, METABOLISM, V39, P425, DOI 10.1016/0026-0495(90)90259-F; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SAAD MF, 1989, LANCET, V1, P1356; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; SCHNEIDER SH, 1995, DIABETES REV, V3, P378; SCHOR S, 1971, J AMER MED ASSOC, V217, P1671, DOI 10.1001/jama.217.12.1671; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Schwartz SL, 1998, DIABETES, V47, pA98; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHANK ML, 1995, DIABETES, V44, P165, DOI 10.2337/diabetes.44.2.165; Shorr RI, 1996, J AM GERIATR SOC, V44, P751, DOI 10.1111/j.1532-5415.1996.tb03729.x; SICONOLFIBAEZ L, 1990, DIABETES CARE, V13, P2, DOI 10.2337/diacare.13.3.2; SIMA AAF, 1988, J CLIN INVEST, V81, P349, DOI 10.1172/JCI113327; Simonson DC, 1997, DIABETES CARE, V20, P597, DOI 10.2337/diacare.20.4.597; SIMONSON DC, 1984, DIABETES, V33, P838, DOI 10.2337/diabetes.33.9.838; Sinha A, 1996, DIABETIC MED, V13, P40, DOI 10.1002/(SICI)1096-9136(199601)13:1<40::AID-DIA991>3.3.CO;2-L; Sironi AM, 1997, CLIN PHARMACOL THER, V62, P194, DOI 10.1016/S0009-9236(97)90068-0; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; STERN MP, 1992, DIABETES, V41, P484, DOI 10.2337/diabetes.41.4.484; Stith BJ, 1996, ENDOCRINOLOGY, V137, P2990, DOI 10.1210/en.137.7.2990; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TEUTSCH S, 1989, AM J KIDNEY DIS, V13, P11, DOI 10.1016/S0272-6386(89)80106-4; TRISCHITTA V, 1992, DIABETES CARE, V15, P539, DOI 10.2337/diacare.15.4.539; Turner R, 1997, LANCET, V350, P1288, DOI 10.1016/S0140-6736(97)03062-6; Turner RC, 1998, LANCET, V352, P1934, DOI 10.1016/S0140-6736(05)60426-6; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VAGUE P, 1987, THROMB HAEMOSTASIS, V57, P326; VAGUE P, 1994, DIABETOLOGIA S1, V37, P236; vanStaa T, 1997, J CLIN EPIDEMIOL, V50, P735, DOI 10.1016/S0895-4356(97)00024-3; VIGNERI R, 1991, DIABETES METAB, V17, P232; VORA JP, 1993, DIABETOLOGIA, V36, P734, DOI 10.1007/BF00401144; WHITEHOUSE FW, 1979, DIABETES CARE, V2, P453, DOI 10.2337/diacare.2.5.453; WIDEN EIM, 1992, DIABETES, V41, P354, DOI 10.2337/diabetes.41.3.354; WIHOLM BE, 1993, EUR J CLIN PHARMACOL, V44, P589, DOI 10.1007/BF02440866; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Wright AD, 1998, DIABETES CARE, V21, P87; Yki-Jarvinen H, 1997, J CLIN ENDOCR METAB, V82, P4037, DOI 10.1210/jc.82.12.4037; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087; 1996, DIABETES CARE S1, V19, P553	175	830	877	2	93	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					281	303		10.7326/0003-4819-131-4-199908170-00008	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00008			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454950				2022-12-28	WOS:000082012500006
J	Lenski, RE; Ofria, C; Collier, TC; Adami, C				Lenski, RE; Ofria, C; Collier, TC; Adami, C			Genome complexity, robustness and genetic interactions in digital organisms	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; FITNESS; POPULATIONS; ADAPTATION	Digital organisms are computer programs that self-replicate, mutate and adapt by natural selection(1-3). They offer an opportunity to test generalizations about living systems that may extend beyond the organic life that biologists usually study. Here we have generated two classes of digital organism: simple programs selected solely for rapid replication, and complex programs selected to perform mathematical operations that accelerate replication through a set of defined 'metabolic' rewards., To examine the differences in their genetic architecture, we introduced millions of single and multiple mutations into each organism and measured the effects on the organism's fitness. The complex organisms are more robust than the simple ones with respect to the average effects of single mutations. Interactions among mutations are common and usually yield higher fitness than predicted from the component mutations assuming multiplicative effects; such interactions are especially important in the complex organisms. Frequent interactions among mutations have also been seen in bacteria, fungi and fruitflies(4-6). Our findings support the view that interactions are a general feature of genetic systems(7-9).	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; CALTECH, Kellogg Radiat Lab, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA	Michigan State University; California Institute of Technology; University of California System; University of California Los Angeles	Lenski, RE (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	lenski@pilot.msu.edu; chalres@krl.caltech.edu	Adami, Chris/A-9675-2011; Adami, Christoph/A-5181-2009	Adami, Chris/0000-0002-2915-9504; Lenski, Richard/0000-0002-1064-8375; Ofria, Charles/0000-0003-2924-1732				ADAMI C, 1995, PHYSICA D, V80, P154, DOI 10.1016/0167-2789(95)90073-X; Adami C., 1998, INTRO ARTIFICIAL LIF; Burch CL, 1999, GENETICS, V151, P921; Clark AG, 1997, GENETICS, V147, P157; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; deVisser JAGM, 1997, EVOLUTION, V51, P1499, DOI 10.1111/j.1558-5646.1997.tb01473.x; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Frank Steven A., 1996, P451; Holland J. H., 1992, ADAPTATION NATURAL A, DOI 10.7551/mitpress/1090.001.0001; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; Kauffman S. A., 1993, ORIGINS ORDER; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KOZA JR, 1998, EVOLUTIONARY ROBOTIC, P37; Koza JR, 1992, GENETIC PROGRAMMING; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; MAYNARD SMITH J., 1978, EVOLUTION SEX; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; PAQUIN CE, 1983, NATURE, V306, P368, DOI 10.1038/306368a0; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; RAY T., 1992, ARTIF LIFE, P371, DOI DOI 10.1016/S0040-4039(01)97473-8; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SMITH JM, 1992, NATURE, V355, P772; SOKAL RR, 1994, BIOMETRY; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Wright S., 1977, EVOLUTION GENETICS P, V3	29	197	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					661	664		10.1038/23245	http://dx.doi.org/10.1038/23245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458160				2022-12-28	WOS:000082032900052
J	Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S				Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S			Intussusception among recipients of rotavirus vaccine - United States, 1998-1999 (Reprinted from MMWR, vol 48, pg 577, 1999)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Minnesota Dept Hlth, Minneapolis, MN 55414 USA; Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA; US FDA, Div Biostat & Epidemiol, Rockville, MD 20857 USA; Natl Ctr Infect Dis, Viral Gastroenteritis Sect, Resp & Enter Viruses Br, Atlanta, GA USA; Natl Ctr Infect Dis, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA USA; CDC, Vaccine Safety Datalink Team, Atlanta, GA 30333 USA; CDC, Stat Anal Br, Data Management Div, Atlanta, GA 30333 USA; CDC, Vaccine Safety & Dev Activ, Atlanta, GA 30333 USA; CDC, Child Vaccine Prevent Dis Br, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA	Minnesota Department of Health (MHD); Kaiser Permanente; US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Ehresman, K (corresponding author), Minnesota Dept Hlth, Minneapolis, MN 55414 USA.							Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577	1	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					520	521						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450702				2022-12-28	WOS:000081919100010
J	Allmers, H				Allmers, H			Manfred Freiherr von Richthofen's medical record - was the "Red Baron" fit to fly?	LANCET			English	Article											Allmers, H (corresponding author), Hohe Str 133, D-44139 Dortmund, Germany.							BODENSCHATZ K, 1935, JAGD FLANDERNS HIMME; CARISELLA PJ, 1969, WHO KILLED RED BARON; GOLDSTEIN K, 1917, MILITARISCHE SACHVER; ITALIAANDER R, 1938, MF VONRICHTHOFEN BES; NEWTON D, 1986, J AUSTR WAR MEMO OCT; SKAWRAN PR, 1940, PSYCHOL JAGDFLIEGERS; Udet E., 1935, MEIN FLIEGERLEBEN; von Richtofen M, 1917, ROTE KAMPFFLIEGER; VONRICHTHOFEN KF, 1937, MEIN KRIEGSTAGEBUCH; VONRICHTHOFEN M, 1937, ROTE KAMPFFLIEGER; 1909, DIENST BEURTEILUNG M; 1954, FEHLERTABELLEN CHEM	12	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					502	504		10.1016/S0140-6736(98)11106-6	http://dx.doi.org/10.1016/S0140-6736(98)11106-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465190				2022-12-28	WOS:000081896100042
J	Mariotto, A; De Leo, D; Dello Buono, M; Favaretti, C; Austin, P; Naylor, CD				Mariotto, A; De Leo, D; Dello Buono, M; Favaretti, C; Austin, P; Naylor, CD			Will elderly patients stand aside for younger patients in the queue for cardiac services?	LANCET			English	Article							BRIEF-SYMPTOM-INVENTORY	Background Fair management of queues for hospital-based services requires consideration of clinical need, but there is no information on public attitudes towards non-clinical factors such as age or work status as determinants of priority. Methods We asked elderly residents of Padova, Italy, whether, if they were awaiting cardiac surgery or an outpatient cardiology consultant, they would give up their place in line for a younger or self-employed individual. We also elicited responses from a convenience sample of younger health workers asked to imagine themselves as elderly persons facing the same choices. Findings The eligible response rate was 72% (443/616). About half deemed it right to give up their place in line for cardiac surgery to a 45-year-old (51%, 95% CI 46-56) or self-employed person (47%, 95% CI 42-51) Proportions were significantly higher for an outpatient consultation (68%, 95% CI 63-72), In multivariate analyses, married respondents, those closer to age 65, university graduates, and those who were formerly self-employed were significantly less likely to respond affirmatively. In significant contrast for all four scenarios (p<0.0001), the overwhelming majority of non-elderly respondents refused to give up their places in line. Interpretation The majority of elderly citizens were hypothetically willing to cede priority in accessing cardiac care to younger or self-employed persons, but this willingness was attenuated among the "young" elderly and more privileged respondents. Non-elderly respondents were much less self-sacrificing, suggesting that ageing baby-boomers may be more assertive about their continuing rights to health care.	Med Directorate, Unit Technol Assessment & Qual Assurance, I-35100 Padua, Italy; Griffith Univ, Fac Hlth Sci, Brisbane, Qld, Australia; Griffith Univ, Fac Hlth Sci, Brisbane, Qld, Australia; Univ Padua, Psychogeriatr Serv, Padua, Italy; Italian Soc Qual Assuranve, Veneto Reg Sect, Venice, Italy; Univ Toronto, Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON, Canada	Griffith University; Griffith University; University of Padua; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Mariotto, A (corresponding author), Med Directorate, Unit Technol Assessment & Qual Assurance, LHU 16,Via Palme 15, I-35100 Padua, Italy.			Austin, Peter/0000-0003-3337-233X				Crowne DP, 1964, APPROVAL MOTIVE STUD; DELEO D, 1993, BRIT J CLIN PSYCHOL, V32, P209; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIGGLE P, 1994, ANAL LONGITUDINAL DA, P143; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heitman E, 1996, INT J TECHNOL ASSESS, V12, P657, DOI 10.1017/S0266462300010953; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; NAYLOR CD, 1992, J GEN INTERN MED, V7, P492, DOI 10.1007/BF02599450; *SAS I INC, 1997, SAS STAT SOFTW CHANG, P293	10	27	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					467	470		10.1016/S0140-6736(98)12192-X	http://dx.doi.org/10.1016/S0140-6736(98)12192-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224KB	10465171				2022-12-28	WOS:000081896100011
J	Mole, SE				Mole, SE			Batten's disease: eight genes and still counting?	LANCET			English	Editorial Material							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; MUTATIONS		UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England	University of London; University College London; UCL Medical School	Mole, SE (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England.		Mole, Sara/C-2024-2008	Mole, Sara/0000-0003-4385-4957				BERKOVIC SF, 1988, BRAIN, V111, P27, DOI 10.1093/brain/111.1.27; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Das AK, 1998, J CLIN INVEST, V102, P361, DOI 10.1172/JCI3112; Goebel H, 1999, NEURONAL CEROID LIPO; Greene NDE, 1999, MOL GENET METAB, V66, P309, DOI 10.1006/mgme.1999.2828; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; LU JY, 1996, P NATL ACAD SCI USA, V93, P1046; Mitchison HM, 1998, HUM MOL GENET, V7, P291, DOI 10.1093/hmg/7.2.291; MOLE SE, IN PRESS HUM MUTAT; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Ranta S, 1997, GENOME RES, V7, P887, DOI 10.1101/gr.7.9.887; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Wheeler RB, 1999, MOL GENET METAB, V66, P337, DOI 10.1006/mgme.1999.2804	19	45	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					443	445		10.1016/S0140-6736(99)00173-7	http://dx.doi.org/10.1016/S0140-6736(99)00173-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465165				2022-12-28	WOS:000081896100005
J	Sattar, N; Perera, M; Small, M; Lumsden, MA				Sattar, N; Perera, M; Small, M; Lumsden, MA			Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes	LANCET			English	Article								C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 mu g with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.	Glasgow Royal Infirm Univ NHS Trust, Clin Biochem, Glasgow G4 0SF, Lanark, Scotland; Gartnavel Gen Hosp, Ctr Diabet, Glasgow G4 0SF, Lanark, Scotland; Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow G4 0SF, Lanark, Scotland		Sattar, N (corresponding author), Glasgow Royal Infirm Univ NHS Trust, Clin Biochem, Glasgow G4 0SF, Lanark, Scotland.							CANTATORE FP, 1995, CLIN RHEUMATOL, V14, P157, DOI 10.1007/BF02214935; KAFONEK SD, 1994, DRUGS, V47, P16, DOI 10.2165/00003495-199400472-00005; Kluft C, 1999, LANCET, V353, P1274, DOI 10.1016/S0140-6736(05)66951-6; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; SITTERI PK, 1977, ANN NY ACAD SCI, V286, P384	5	77	79	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					487	488		10.1016/S0140-6736(99)02079-6	http://dx.doi.org/10.1016/S0140-6736(99)02079-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465182				2022-12-28	WOS:000081896100022
J	Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA				Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA			Nuclear trafficking of cubitus interruptus in the transcriptional regulation of hedgehog target gene expression	CELL			English	Article							KINESIN-RELATED PROTEIN; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYOS; KINASE-A; WINGLESS; PROTEOLYSIS; PATHWAYS; COMPLEX; PHOSPHORYLATION; PROTEASOME	Transcriptional activation of Hedgehog (Hh) target genes requires Cubitus interruptus, a 155 kDa cytoplasmic zinc finger protein (Ci155), which in the absence of Hh signaling is processed to form a nuclear repressor (Ci75). We show that Hh signaling reduces phosphorylation of Ci155, and this reduction in turn appears to decrease processing. Blocking processing with proteasome inhibitors or altered Ci proteins, however, is insufficient for activation of Hh targets. We find that Hh signaling increases the rate of Ci155 nuclear import, resulting in significant nuclear accumulation. Even in the absence of signaling, nuclear accumulation of Ci155 suffices for significant induction of Hh targets, and active nuclear export of Ci155 is an essential mechanism for maintenance of the unstimulated state.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FORBES AJ, 1993, DEVELOPMENT, P115; Hepker J, 1997, DEVELOPMENT, V124, P549; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; ZHANG J, 1991, J BIOL CHEM, V266, P2290	35	213	219	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					305	316		10.1016/S0092-8674(00)81960-1	http://dx.doi.org/10.1016/S0092-8674(00)81960-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458606	hybrid			2022-12-28	WOS:000081950300006
J	Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG				Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG			The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum	NATURE			English	Article							MALARIA; GENE; DNA; GENOME; CENTROMERE; DOMAINS; CONSTRUCTION; EXPRESSION; LIBRARIES; PROTEINS	Analysis of Plasmodium falciparum chromosome 3, and comparison with chromosome 2, highlights novel features of chromosome organization and gene structure. The sub-telomeric regions of chromosome 3 show a conserved order of features, including repetitive DNA sequences, members of multigene families involved in pathogenesis and antigenic variation, a number of conserved pseudogenes, and several genes of unknown function. A putative centromere has been identified that has a core region of about 2 kilobases with an extremely high (adenine + thymidine) composition and arrays of tandem repeats. We have predicted 215 protein-coding genes and two transfer RNA genes In the 1,060,106-base-pair chromosome sequence. The predicted protein-coding genes can be divided into three main classes: 52.6% are not spliced, 45.1% have a large exon with short additional 5' or 3' exons, and 2.3% have a multiple exon structure more typical of higher eukaryotes.	Sanger Ctr, Pathogen Sequencing Unit, Hinxton CB10 1SA, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	Wellcome Trust Sanger Institute; University of Oxford	Bowman, S (corresponding author), Sanger Ctr, Pathogen Sequencing Unit, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	sharen@sanger.ac.uk	Horrocks, Paul/C-2615-2009; Quail, michael/ABE-6131-2020	Horrocks, Paul/0000-0003-3981-0732; Murphy, Lee/0000-0001-6467-7449; Craig, Alister/0000-0003-0914-6164; Lawson, Daniel/0000-0001-7765-983X; Davies, Robert/0000-0002-9983-1378; Newbold, Chris/0000-0002-9274-3789; Jassal, Bijay/0000-0002-5039-5405	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aston C, 1999, TRENDS BIOTECHNOL, V17, P297, DOI 10.1016/S0167-7799(99)01326-8; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; Berriman M, 1998, BIOCHEM J, V334, P437, DOI 10.1042/bj3340437; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARCY B, 1997, MOL BIOCHEM PARASIT, V68, P221; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; ENEA V, 1984, SCIENCE, V225, P628, DOI 10.1126/science.6204384; Fischer K, 1997, MOL CELL BIOL, V17, P3679, DOI 10.1128/MCB.17.7.3679; Garcia A, 1999, PARASITOL TODAY, V15, P90, DOI 10.1016/S0169-4758(99)01393-9; Gardiner K, 1995, SOMAT CELL MOLEC GEN, V21, P399, DOI 10.1007/BF02310207; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Hoffman SL, 1997, NATURE, V387, P647, DOI 10.1038/42571; HOLT DC, IN PRESS INT J PARAS; Horrocks P, 1998, MOL BIOCHEM PARASIT, V95, P171, DOI 10.1016/S0166-6851(98)00110-8; KYES S, IN PRESS P NATL ACAD; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; Soldati D, 1999, PARASITOL TODAY, V15, P5, DOI 10.1016/S0169-4758(98)01363-5; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Thompson JK, 1997, MOL BIOCHEM PARASIT, V90, P537, DOI 10.1016/S0166-6851(97)00203-X; Thompson JK, 1997, MOL BIOCHEM PARASIT, V87, P49, DOI 10.1016/S0166-6851(97)00041-8; TRIGLIA T, 1991, MOL BIOCHEM PARASIT, V44, P207, DOI 10.1016/0166-6851(91)90006-R; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; World Health Organization, 1993, GLOB STRAT MAL CONTR	45	269	297	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					532	538		10.1038/22964	http://dx.doi.org/10.1038/22964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448855				2022-12-28	WOS:000081854800046
J	Rodriguez, MA; Bauer, HM; McLoughlin, E; Grumbach, K				Rodriguez, MA; Bauer, HM; McLoughlin, E; Grumbach, K			Screening and intervention for intimate partner abuse - Practices and attitudes of primary care physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TREATING WIFE ABUSE; DOMESTIC VIOLENCE; FAMILY VIOLENCE; WOMEN; PREVALENCE; EMERGENCY; COMMUNICATION; EDUCATION; SEX	Context Although practice guidelines encouraging the screening of patients for intimate partner abuse have been available for several years, it is unclear how well and in which circumstances physicians adhere to them. Objective To describe the practices and perceptions of primary care physicians regarding intimate partner abuse screening and interventions. Design, Setting, and Participants Cross-sectional survey of a stratified probability sample of 900 physicians practicing family medicine, general internal medicine, and obstetrics/gynecology in California. After meeting exclusion criteria, 582 were eligible for participation in the study. Main Outcome Measure Reported abuse screening practices in a variety of clinic settings, based on a 24-item questionnaire, with responses compared by physician sex, practice setting, and intimate partner abuse training. Results Surveys were completed by 400 (69%) of the 582 eligible physicians, including 149 family physicians, 115 internists, and 136 obstetrician/gynecologists. Data were weighted to estimate the practices of primary care physicians in California. An estimated majority (79%; 95% confidence interval [CI], 75%-83%) of these primary care physicians routinely screen injured patients for intimate partner abuse. However, estimated routine screening was less common for new patient visits (10%; 95% CI, 7%-13%), periodic checkups (9%; 95% CI, 6%-12%), and prenatal care (11%; 95% CI, 7%-15%), Neither physician sex nor recent intimate partner abuse training had significant effects on reported new patient screening practices. Obstetrician/gynecologists (17%) and physicians practicing in public clinic settings (37%) were more likely to screen new patients. Internists (6%) and physicians practicing in health maintenance organizations (1%) were least likely to screen new patients. Commonly reported routine interventions included relaying concern for safety (91%), referral to shelters (79%) and counseling (88%), and documentation in the medical chart (89%). Commonly cited barriers to identification and referral included the patients' fear of retaliation (82%) and police involvement (55%), lack of patient disclosure (78%) and follow-up (52%), and cultural differences (56%). Conclusions These findings suggest that primary care physicians are missing opportunities to screen patients for intimate partner abuse in a variety of clinical situations. Further studies are needed to identify effective intervention strategies and improve adherence to intimate partner abuse practice guidelines.	Univ Calif San Francisco, Ctr Aging Diverse Communities, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Effect Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Primary Care Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Pacific Ctr Violence Prevent, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rodriguez, MA (corresponding author), San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94110 USA.	rodrigu@itsa.ucsf.edu	Grumbach, Kevin/L-9222-2016					ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; Alpert EJ, 1998, AM J PREV MED, V14, P273, DOI 10.1016/S0749-3797(98)00008-7; *AM COLL OBST GYN, 1989, ACOG TECHN B, V124; *AM PUBL HLTH ASS, 1993, AM J PUBLIC HEALTH, V83, P458; [Anonymous], 1994, AM FAM PHYSICIAN, V50, P1636; Bailey JE, 1997, ARCH INTERN MED, V157, P777, DOI 10.1001/archinte.157.7.777; BAUER HM, 1995, CAMB Q HEALTHC ETHIC, V4, P459, DOI 10.1017/S0963180100006289; Brown J B, 1996, Fam Med, V28, P422; BROWN JB, 1993, J FAM PRACTICE, V36, P185; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Caralis PV, 1997, SOUTH MED J, V90, P1075, DOI 10.1097/00007611-199711000-00003; CASCARDI M, 1992, ARCH INTERN MED, V152, P1178, DOI 10.1001/archinte.152.6.1178; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P428; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P670; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; FERRIS LE, 1994, MED CARE, V32, P1163, DOI 10.1097/00005650-199412000-00001; Flitcraft A.H., 1992, DIAGNOSTIC TREATMENT; Freund KM, 1996, J GEN INTERN MED, V11, P44, DOI 10.1007/BF02603485; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; Gremillion DH, 1996, ANN EMERG MED, V27, P769, DOI 10.1016/S0196-0644(96)70200-7; Hamberger L K, 1992, Fam Med, V24, P283; Harwell TS, 1998, AM J PREV MED, V15, P235, DOI 10.1016/S0749-3797(98)00070-1; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; Johnson M, 1997, J FAM PRACTICE, V44, P391; LURIE N, 1993, NEW ENGL J MED, V329, P478, DOI 10.1056/NEJM199308123290707; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCLEER SV, 1989, ANN EMERG MED, V18, P651, DOI 10.1016/S0196-0644(89)80521-9; MERCY JA, 1989, AM J PUBLIC HEALTH, V79, P595, DOI 10.2105/AJPH.79.5.595; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3132, DOI 10.1001/jama.267.23.3132; Olson L, 1996, ANN EMERG MED, V27, P741, DOI 10.1016/S0196-0644(96)70193-2; Pan H S, 1997, Fam Med, V29, P492; PARSONS LH, 1995, AM J OBSTET GYNECOL, V173, P381, DOI 10.1016/0002-9378(95)90256-2; Plichta SB, 1996, AM J PREV MED, V12, P297, DOI 10.1016/S0749-3797(18)30282-4; PLICHTA SB, 1996, WOMENS HLTH COMMONWE, P237; Rodriguez MA, 1999, AM J PUBLIC HEALTH, V89, P575, DOI 10.2105/AJPH.89.4.575; Rodriguez MA, 1998, WESTERN J MED, V169, P337; Rodriguez MA, 1996, ARCH FAM MED, V5, P153, DOI 10.1001/archfami.5.3.153; ROTER D, 1991, MED CARE, V29, P1083; Saltzman L E, 1996, J Am Med Womens Assoc (1972), V51, P83; SALTZMAN LE, 1992, JAMA-J AM MED ASSOC, V267, P3143; Sansone R A, 1997, Violence Vict, V12, P165; SAUNDERS DG, 1993, J GEN INTERN MED, V8, P606, DOI 10.1007/BF02599714; Sherin K M, 1998, Fam Med, V30, P508; *SPSS INC, 1997, SPSS COMP PROGR VERS; Stark E, 1998, MAXCY ROSENAU LAST P, P1231; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; The AAFP Commission on Special Issues and Clinical Interests, 1994, AM FAM PHYSICIAN, V50, P1644; TILDEN VP, 1994, AM J PUBLIC HEALTH, V84, P628, DOI 10.2105/AJPH.84.4.628; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P555; Wagner P J, 1995, Arch Fam Med, V4, P956; Warshaw C, 1996, J Am Med Womens Assoc (1972), V51, P87; WARSHAW C, 1996, J AM MED WOMEN ASSOC, V51, P100	56	329	334	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					468	474		10.1001/jama.282.5.468	http://dx.doi.org/10.1001/jama.282.5.468			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442663	Bronze			2022-12-28	WOS:000081784900024
J	Gollub, SB				Gollub, SB			Is intensive drug therapy appropriate for older patients?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; WOMEN		Univ Kansas, Sch Med, Div Cardiovasc Dis, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Gollub, SB (corresponding author), Univ Kansas, Sch Med, Div Cardiovasc Dis, Kansas City, KS 66160 USA.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826	6	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					940	941		10.1016/S0140-6736(99)90024-7	http://dx.doi.org/10.1016/S0140-6736(99)90024-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459896				2022-12-28	WOS:000079421600002
J	Nicholson, S; Gallop, JL; Law, P; Thomas, H; George, AJT				Nicholson, S; Gallop, JL; Law, P; Thomas, H; George, AJT			Monitoring antibody responses to cancer vaccination with a resonant mirror biosensor	LANCET			English	Article									Hammersmith Hosp, Imperial Coll Sch Med, Div Med, Imperial Canc Res Fund,Mol Oncol Unit, London W12 0HS, England; Hammersmith Hosp, Imperial Coll Sch Med, Dept Clin Oncol & Immunol, Div Med, London, England	Cancer Research UK; Imperial College London; Imperial College London	Nicholson, S (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Div Med, Imperial Canc Res Fund,Mol Oncol Unit, London W12 0HS, England.			George, Andrew/0000-0002-2866-0241; Gallop, Jennifer Louise/0000-0002-9978-1382				CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; KARLSSON R, 1997, PRINCIPLES PRACTICE, P99; LUNDKVIST I, 1993, CLIN IMMUNOL IMMUNOP, V67, P192, DOI 10.1006/clin.1993.1064; NICHOLSON S, 1997, P R COLL PHYSICIANS, V27, P145; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69	5	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					808	808		10.1016/S0140-6736(98)04907-1	http://dx.doi.org/10.1016/S0140-6736(98)04907-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459965				2022-12-28	WOS:000079089100015
J	Briggs, AH; Gray, AM				Briggs, AH; Gray, AM			Methods in health service research - Handling uncertainty in economic evaluations of healthcare interventions	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS RATIOS; CONFIDENCE-INTERVALS; TRIAL		Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of Oxford	Briggs, AH (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997				ANDERSON MH, 1993, BRIT HEART J, V69, P83; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; BRIGGS AH, 1995, 32 OHE; BRIGGS AH, IN PRESS STAT MED; Canadian Co-ordinating Office for Health Technology Assessment , 1997, GUID EC EV PHARM CAN; Chaudhary MA, 1996, STAT MED, V15, P1447; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; DRUMMOND MF, 1997, METHODS EC EV HLTH C; FENN P, 1995, MED CARE, V33, P851, DOI 10.1097/00005650-199508000-00009; Gold MR, 1996, COST EFFECTIVENESS H; Gray AM, 1999, HLTH TECHNOL ASSESS, V3; MANNING WG, 1996, COST EFFECTIVENESS H, P247; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; Polsky D, 1997, HEALTH ECON, V6, P243, DOI 10.1002/(SICI)1099-1050(199705)6:3<243::AID-HEC269>3.0.CO;2-Z; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; WAKKER P, 1995, HEALTH ECON, V4, P373, DOI 10.1002/hec.4730040503	16	146	151	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					635	638		10.1136/bmj.319.7210.635	http://dx.doi.org/10.1136/bmj.319.7210.635			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	234AJ	10473486	Green Published			2022-12-28	WOS:000082460300032
J	Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N				Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N			Acquired immunoparalysis in paediatric intensive care: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTE		Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England; Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, London WC1N 3JH, England; Inst Child Hlth, Immunobiol Unit, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Peters, M (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England.			Inwald, David/0000-0001-9518-7821; Klein, Nigel/0000-0003-3925-9258; Peters, Mark/0000-0003-3653-4808; Dixon, Garth/0000-0001-8165-3094				ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Schinkel C, 1998, J TRAUMA, V44, P743, DOI 10.1097/00005373-199805000-00001; WILKINSON JD, 1986, CRIT CARE MED, V14, P271, DOI 10.1097/00003246-198604000-00002; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609	5	20	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					609	610		10.1136/bmj.319.7210.609	http://dx.doi.org/10.1136/bmj.319.7210.609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473475	Bronze, Green Published			2022-12-28	WOS:000082460300019
J	Fox, AJ; Rowbotham, DJ				Fox, AJ; Rowbotham, DJ			Anaesthesia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EVOKED POTENTIAL INDEX; NITROUS-OXIDE; LEVERING LARYNGOSCOPE; GENERAL-ANESTHESIA; BUPIVACAINE; ROPIVACAINE; DESFLURANE; SEVOFLURANE; ISOFLURANE; S(-)-BUPIVACAINE		Univ Leicester, Leicester Royal Infirm, Dept Anaesthesia, Leicester LE1 5WW, Leics, England	University of Leicester	Rowbotham, DJ (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Anaesthesia, Leicester LE1 5WW, Leics, England.	David.Rowbotham@leicester.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRIGHT GA, 1979, ANESTHESIOLOGY, V51, P285, DOI 10.1097/00000542-197910000-00001; BENUMOF JL, 1992, ANESTH ANALG, V74, P313, DOI 10.1213/00000539-199202000-00034; Biebuyck JF, 1994, ANESTHESIOLOGY, V80, P906; Brain AIJ, 1997, BRIT J ANAESTH, V79, P699, DOI 10.1093/bja/79.6.699; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; Capouet V, 1996, BRIT J ANAESTH, V76, P54, DOI 10.1093/bja/76.1.54; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Cox CR, 1998, BRIT J ANAESTH, V80, P594, DOI 10.1093/bja/80.5.594; Cox CR, 1998, BRIT J ANAESTH, V80, P289, DOI 10.1093/bja/80.3.289; CRISTWOOD R, 1994, EXPERT OPINION INVES, V3, P1209; Diemunsch P, 1999, BRIT J ANAESTH, V82, P274, DOI 10.1093/bja/82.2.274; Doi M, 1997, BRIT J ANAESTH, V78, P180, DOI 10.1093/bja/78.2.180; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Elton CD, 1997, BRIT J ANAESTH, V79, P551, DOI 10.1093/bja/79.5.551; Gepts E, 1998, ANAESTHESIA, V53, P4, DOI 10.1111/j.1365-2044.1998.53s111.x; GHOURI AF, 1991, ANESTHESIOLOGY, V74, P419, DOI 10.1097/00000542-199103000-00005; Goto T, 1997, ANESTHESIOLOGY, V86, P1273, DOI 10.1097/00000542-199706000-00007; Gray JM, 1998, ANAESTHESIA, V53, P22, DOI 10.1111/j.1365-2044.1998.53s114.x; HOWELL CJ, 1999, COCHRANE LIB; JONES RM, 1990, BRIT J ANAESTH, V64, P3; KENNY G N C, 1992, Anesthesiology (Hagerstown), V77, pA328, DOI 10.1097/00000542-199209001-00328; Knudsen K, 1997, BRIT J ANAESTH, V78, P507, DOI 10.1093/bja/78.5.507; Lee DJH, 1996, BRIT J ANAESTH, V76, P780, DOI 10.1093/bja/76.6.780; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; MATHER LE, 1996, ANESTHESIOLOGY, V137, pF135; MAZOIT JX, 1993, ANESTH ANALG, V77, P477; McClure JH, 1996, BRIT J ANAESTH, V76, P300, DOI 10.1093/bja/76.2.300; MCCOY EP, 1993, ANAESTHESIA, V48, P516, DOI 10.1111/j.1365-2044.1993.tb07075.x; Mirakhur RK, 1998, ANAESTHESIA, V53, P1, DOI 10.1111/j.1365-2044.1998.53s170.x; Morton CPJ, 1997, BRIT J ANAESTH, V79, P3, DOI 10.1093/bja/79.1.3; Paris ST, 1997, BRIT J ANAESTH, V79, P280, DOI 10.1093/bja/79.3.280; PATEL SS, 1995, DRUGS, V50, P742, DOI 10.2165/00003495-199550040-00010; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; ROSENBERG PH, 1983, ANESTHESIOLOGY, V58, P95, DOI 10.1097/00000542-198301000-00014; RUSSELL D, 1995, BRIT J ANAESTH, V75, P562, DOI 10.1093/bja/75.5.562; Shende D, 1997, ANAESTHESIA, V52, P496, DOI 10.1111/j.1365-2044.1997.101-az0098.x; SILK JM, 1991, EUR J ANAESTH, P47; Smith I, 1996, BRIT J ANAESTH, V76, P435, DOI 10.1093/bja/76.3.435; Thompson JP, 1996, BRIT J ANAESTH, V76, P341, DOI 10.1093/bja/76.3.341; Tuckey JP, 1996, ANAESTHESIA, V51, P71, DOI 10.1111/j.1365-2044.1996.tb07658.x; ZWASS MS, 1992, ANESTHESIOLOGY, V76, P373, DOI 10.1097/00000542-199203000-00009	41	7	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					557	560		10.1136/bmj.319.7209.557	http://dx.doi.org/10.1136/bmj.319.7209.557			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463900	Green Published			2022-12-28	WOS:000082347200029
J	Mousa, A; Jones, S; Toft, A; Perros, P				Mousa, A; Jones, S; Toft, A; Perros, P			Spontaneous rupture of Achilles tendon: missed presentation of Cushing's syndrome	BRITISH MEDICAL JOURNAL			English	Article									Freeman Hosp, Endocrine Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Royal Infirm, Endocrine Unit, Edinburgh EH3 9YW, Midlothian, Scotland	Newcastle Freeman Hospital; Royal Infirmary of Edinburgh	Mousa, A (corresponding author), Freeman Hosp, Endocrine Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.			Perros, Petros/0000-0001-7320-5574				Baruah D R, 1984, Br J Sports Med, V18, P128; Cirincione R J, 1975, J Bone Joint Surg Am, V57, P852; HAACKE H, 1979, KLIN WOCHENSCHR, V57, P397, DOI 10.1007/BF01480478; HAINES JF, 1983, ANN RHEUM DIS, V42, P652, DOI 10.1136/ard.42.6.652; HANLON D P, 1992, Journal of Emergency Medicine, V10, P559, DOI 10.1016/0736-4679(92)90136-H; MAHONEY PG, 1981, ANN RHEUM DIS, V40, P416, DOI 10.1136/ard.40.4.416; MOREIN G, 1977, CLIN ORTHOP RELAT R, P209; PLOTZ CM, 1952, AM J MED, V13, P597, DOI 10.1016/0002-9343(52)90027-2; PRESTON ET, 1972, J AMER MED ASSOC, V221, P406, DOI 10.1001/jama.221.4.406; PRICE AE, 1986, CLIN ORTHOP RELAT R, P249; RASCHER JJ, 1974, J BONE JOINT SURG AM, VA 56, P821, DOI 10.2106/00004623-197456040-00020; RASK MR, 1978, JAMA-J AM MED ASSOC, V239, P435, DOI 10.1001/jama.239.5.435; ROSS EJ, 1982, LANCET, V2, P646; SMAILL GB, 1961, BRIT MED J, V1, P1657, DOI 10.1136/bmj.1.5240.1657; VONWERDER K, 1998, CLIN ENDOCRINOL, P415	15	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					560	561		10.1136/bmj.319.7209.560	http://dx.doi.org/10.1136/bmj.319.7209.560			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463901	Green Published			2022-12-28	WOS:000082347200030
J	Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B				Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B			Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODERATE HYPOGLYCEMIA; AWARENESS; ADULTS; IDDM	Context Laboratory studies have shown impairments in driving performance among subjects with type 1 diabetes mellitus when their blood glucose (BG) level is between 2.6 and 3.6 mmol/L (47-65 mg/dL), However, to our knowledge, no data exist examining subjects' decisions to drive at various BC levels during their daily routine, Objective To examine type 1 diabetic subjects' decisions to drive during their daily routine based on perception of BG levels compared with actual measured BC; levels. Design and Setting Two separate groups of patients were recruited 2 years apart from 4 academic medical centers. Participants All subjects were adults with type 1 diabetes who were drivers and who performed at least 2 BC tests per day. Group 1 (initial) subjects (n = 65) had a mean (SD) age of 38.6 (8.9) years with a mean (SD) diabetes duration of 20.5 (10.6) years, were taking 38.8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA(1)) level of 10.0% (1.9%), Group 2 (replication) subjects (n = 93) were 35.8 (8.0) years old with a mean diabetes duration of 17.0 (10.6) years, were taking 40.0 (15.5) U/d of insulin, and had a mean (SD) HbA(1) level of 8.5% (1.6%). Each subject used a handheld computer to record data on symptoms, cognitive function, insulin dosage, food, activity, estimated and actual BC levels, and whether he/she would drive. Data were entered 3 to 6 times per day for a total of 50 to 70 collections per subject during a 3- to 4-week period. Main outcome Measures Decisions to drive when subjects estimated their BC level to be less than 2.2 mmol/L (40 mg/dL), 2.2 to 2.8 mmol/L (40-50 mg/dL), 2.8 to 3.3 mmol/L (50-60 mg/dL), 3.3 to 3.9 mmol/L (60-70 mg/dL), 3.9 to 10 mmol/L (70-180 mg/dL), and more than 10 mmol/L (>180 mg/dL), and driving decisions when actual BG levels were in these ranges. Results Subjects stated they would drive 43% to 44% of the time when they estimated their BG level to be 3.3 to 3.9 mmol/L (60-70 mg/dL), and 38% to 47% of the time when their actual BC level was less than 2.2 mmol/L (40 mg/dL), Logistic regression analysis demonstrated that number of autonomic symptoms, degree of impairment on cognitive function tests, and BC level estimate predicted 76% to 80% of decisions to drive (P < .01 for all). Approximately 50% of subjects in each group decided to drive at least 50% of the time when their BG level was less than 3.9 mmol/L (70 mg/dL), Conclusions Our data suggest that persons with type 1 diabetes may not judge correctly when their BC level is too low to permit safe driving and may consider driving with a low BC level even when they are aware of the low level. Health care professionals should counsel their patients about the risk of driving with hypoglycemia and the importance of measuring BG level before driving.	Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Psychiat Med, Behav Med Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Clarke, WL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Box 386, Charlottesville, VA 22908 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028288] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00847] Funding Source: Medline; NIDDK NIH HHS [R01-DK-28288] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM DIAB ASS NAT C, 1996, PROV REC PROGR; Clarke WL, 1997, DIABETES EDUCATOR, V23, P55, DOI 10.1177/014572179702300107; COX D, 1995, DIABETES CARE, V18, P523, DOI 10.2337/diacare.18.4.523; COX D, IN PRESS DIABETES CA; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; COX DJ, 1993, DIABETES, V42, P239, DOI 10.2337/diabetes.42.2.239; COX DJ, 1994, DIABETES CARE, V17, P1, DOI 10.2337/diacare.17.1.1; Kovatchev B, 1998, HEALTH PSYCHOL, V17, P277, DOI 10.1037/0278-6133.17.3.277; QUILLIAN WC, 1994, DIABETES CARE, V17, P1367, DOI 10.2337/diacare.17.11.1367	9	50	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					750	754		10.1001/jama.282.8.750	http://dx.doi.org/10.1001/jama.282.8.750			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463710				2022-12-28	WOS:000082118800026
J	Nousari, HC; Anhalt, GJ				Nousari, HC; Anhalt, GJ			Pemphigus and bullous pemphigoid	LANCET			English	Article							FOLIACEUS FOGO SELVAGEM; PARANEOPLASTIC PEMPHIGUS; VULGARIS ANTIGEN; EXTRACELLULAR DOMAIN; NEONATAL MICE; CELL-ADHESION; SKIN DISEASES; AUTOANTIBODIES; ACANTHOLYSIS; BACULOVIRUS	Pemphigus and bullous pemphigoid are distinct autoimmune blistering diseases that are characterised by the presence of autoantibodies directed against specific adhesion molecules of the skin and mucous membranes. The comparison and contrast of molecular mechanism of blister formation of these two diseases provide a rational diagnostic and therapeutic approach to affected patients.	Johns Hopkins Med Inst, Dept Dermatol, Div Dermatoimmunol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Nousari, HC (corresponding author), Johns Hopkins Med Inst, Dept Dermatol, Div Dermatoimmunol, Richard S Ross Res Bldg,Room 771,720 Rutland Ave, Baltimore, MD 21205 USA.							AHMED AR, 1990, P NATL ACAD SCI USA, V87, P7658, DOI 10.1073/pnas.87.19.7658; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Anhalt G J, 1997, Adv Dermatol, V12, P77; ANHALT GJ, 1986, J IMMUNOL, V137, P2835; ANHALT GJ, 1986, J IMMUNOL, V136, P113; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; ANHALT GJ, 1995, CONNS CURRENT THERAP, P766; BLACK MM, 1994, DERMATOLOGY, V189, P50, DOI 10.1159/000246929; DIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394; Ding X, 1997, J INVEST DERMATOL, V109, P592, DOI 10.1111/1523-1747.ep12337524; GUIDICE GJ, 1992, J INVEST DERMATOL, V99, P243; Ishii K, 1997, J IMMUNOL, V159, P2010; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Liu Z, 1997, J CLIN INVEST, V100, P1256, DOI 10.1172/JCI119639; LIU Z, 1995, J CLIN INVEST, V95, P1539, DOI 10.1172/JCI117826; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Moraes ME, 1997, TISSUE ANTIGENS, V49, P35, DOI 10.1111/j.1399-0039.1997.tb02707.x; MULLER S, 1989, J INVEST DERMATOL, V92, P33; Nousari HC, 1995, CURR OPIN IMMUNOL, V7, P844, DOI 10.1016/0952-7915(95)80058-1; Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805; Nousari HC, 1999, J AM ACAD DERMATOL, V40, P265, DOI 10.1016/S0190-9622(99)70203-3; NOUSARI HC, IN PRESS J AM ACAD D; ROBLEDO MA, 1988, BRIT J DERMATOL, V118, P737, DOI 10.1111/j.1365-2133.1988.tb02590.x; SINHA AA, 1988, SCIENCE, V139, P10026; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; STANLEY JR, 1995, J EXP MED, V181, P1, DOI 10.1084/jem.181.1.1; Zillikens D, 1997, J INVEST DERMATOL, V109, P679, DOI 10.1111/1523-1747.ep12338088	30	141	143	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					667	672		10.1016/S0140-6736(99)03007-X	http://dx.doi.org/10.1016/S0140-6736(99)03007-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466686				2022-12-28	WOS:000082214500046
J	Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T				Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T			Nucleosome mobilization catalysed by the yeast SWI/SNF complex	NATURE			English	Article							REMODELING FACTOR; HOLLIDAY JUNCTION; MOBILITY; BINDING; TRANSCRIPTION; RESOLUTION; ISWI; RSC; DNA	The generation of a local chromatin topology conducive to transcription is a key step in gene regulation(1). The yeast SWI/SNF complex is the founding member of a family of ATP-dependent remodelling activities capable of altering chromatin structure both in vitro and in vivo(2). Despite its importance, the pathway by which the SWI/SNF complex disrupts chromatin structure is unknown. Here we use a model system to demonstrate that the yeast SWI/SNF complex can reposition nucleosomes in an ATP-dependent reaction that favours attachment of the histone octamer to an acceptor site on the same molecule of DNA (in cis), We show that SWI/SNF-mediated displacement of the histone octamer is effectively blocked by a barrier introduced into the DNA, suggesting that this redistribution involves sliding or tracking of nucleosomes along DNA, and that it is achieved by a catalytic mechanism. We conclude that SWI/SNF catalyses the redistribution of nucleosomes along DNA in cis, which may represent a general mechanism by which ATP-dependent chromatin remodelling occurs.	Univ Dundee, Div Gene Regulat, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Huntsman Canc Inst, Salt Lake City, UT 84108 USA; Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Dundee; University of Dundee; Huntsman Cancer Institute; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Owen-Hughes, T (corresponding author), Univ Dundee, Div Gene Regulat, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.		White, Malcolm F/A-6055-2010; Flaus, Andrew/D-5076-2011	White, Malcolm F/0000-0003-1543-9342; Flaus, Andrew/0000-0002-5720-7139; Whitehouse, Iestyn/0000-0003-0385-3116; Owen-Hughes, Tom/0000-0002-0618-8185	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grigoriev M, 1997, MOL CELL BIOL, V17, P7139, DOI 10.1128/MCB.17.12.7139; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; van Holde KE, 1985, STRUCTURE FUNCTION G, P35, DOI DOI 10.1007/978-1-4684-5024-8_4; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	29	268	275	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					784	787		10.1038/23506	http://dx.doi.org/10.1038/23506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466730				2022-12-28	WOS:000082131100055
J	Coupland, RM; Meddings, DR				Coupland, RM; Meddings, DR			Mortality associated with use of weapons in armed conflicts, wartime atrocities, and civilian mass shootings: literature review	BRITISH MEDICAL JOURNAL			English	Article							WAR; MANAGEMENT	Objective To determine the implications of variation in mortality associated with use of weapons in different contexts. Design Literature review. Setting Armed conflicts and civilian mass shootings, 1929-96. Main outcome measure Mortality from wounds. Results During the fighting of war the number of people wounded is at least twice the number killed and may be 13 times as high; this ratio of the number wounded to the number killed results from the impact of a weapon system on human beings in the particular context of war. When firearms are used against people who are immobilised, in a confined space, or unable to defend themselves the wounded to killed ratio has been lower than 1 or even 0, Conclusions Mortality fr om firearms depends not only on the technology of die weapon or its ammunition but also on the context in which it is used. The increased mortality resulting from the use of firearms in situations other than war requires a complex interaction of factors explicable in terms of wound ballistics and the psychology of the user. Understanding these factors has implications for recognition of war crimes. In addition, the lethality of conventional weapons may be increased if combatants are disabled by the new non-lethal weapons beforehand; this possibility requires careful legal examination within the framework of the Geneva Conventions.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, RM (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							[Anonymous], 1996, NONL WEAP EM REQ SEC; ARKIN WM, 1997, MED CONFLICT SURVIVA, V14, P314; BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; Bellamy RF, 1996, ANESTHESIA PERIOPERA; Beyersdorf SR, 1996, AM J SURG, V171, P467, DOI 10.1016/S0002-9610(96)00005-0; BRINDED PMJ, 1995, AUST NZ J PSYCHIAT, V29, P316, DOI 10.3109/00048679509075928; BROOME G, 1988, INJURY, V19, P313, DOI 10.1016/0020-1383(88)90101-5; BUTKOVICSOLDO S, 1995, MIL MED, V160, P408, DOI 10.1093/milmed/160.8.408; CLYNE A J, 1955, J R Army Med Corps, V101, P33; Coupland RM, 1997, BRIT MED J, V315, P72, DOI 10.1136/bmj.315.7100.72; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; COUPLAND RM, 1994, RECENT ADV SURG, P121; Coupland Robin, 1997, SIRUS PROJECT DETERM; Curry J L, 1990, J Emerg Nurs, V16, p42A; Dando M., 1996, NEW FORM WARFARE RIS; DICE WH, 1991, ANN EMERG MED, V20, P1336, DOI 10.1016/S0196-0644(05)81077-7; Early E, 1992, J Emerg Nurs, V18, P316; ECKERT WG, 1980, AM J FOREN MED PATH, V1, P67, DOI 10.1097/00000433-198003000-00011; Gofrit ON, 1997, MIL MED, V162, P24, DOI 10.1093/milmed/162.1.24; Grossman Dave, 1995, KILLING PSYCHOL COST; KNEUBUEHL BP, 1994, EXP M CERT WEAP SYST, P26; Kovacevic S, 1991, Lijec Vjesn, V113, P205; Lewer Nick, 1997, NONLETHAL WEAPONS FA; Marcikic M, 1991, Lijec Vjesn, V113, P208; Marcikic M, 1991, Lijec Vjesn, V113, P202; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Meloy JR, 1997, J FORENSIC SCI, V42, P326; MELSOM MA, 1975, ANN R COLL SURG ENGL, V56, P287; MITCHELL TJ, 1931, CASUALTIES MED STAT, P108; PENGELLY R, 1994, INT DEFENCE REV, V27, P1; RASZEJA S, 1994, FORENSIC SCI INT, V68, P1, DOI 10.1016/0379-0738(94)90373-5; REAY DT, 1986, AM J FOREN MED PATH, V7, P330, DOI 10.1097/00000433-198612000-00013; REISTER FA, 1975, MED STAT WORLD WAR 2, P76; SELLIER KG, 1994, WOUND BALLISTICS; SMITH MSO, 1981, J R ARMY MED CORPS, V127, P31; SPINNELY L, 1997, NEW SCI         1018, P26	36	55	60	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					407	410		10.1136/bmj.319.7207.407	http://dx.doi.org/10.1136/bmj.319.7207.407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445920	Green Published, Bronze			2022-12-28	WOS:000082098900014
J	Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD				Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD			Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years	LANCET			English	Article							LUNG-FUNCTION; EARLY-CHILDHOOD; 1ST YEAR; AIRWAY RESPONSIVENESS; TRACT ILLNESS; SERUM IGE; ASTHMA; BRONCHIOLITIS; CHILDREN; RESPONSES	Background The relation between lower respiratory tract illnesses in early life caused by the respiratory syncytial virus (RSV) and the subsequent development of wheezing acid atopy in childhood is not well understood. We studied this relation in children who had lower respiratory tract illnesses that occurred before 3 years of age. Methods Children were enrolled at birth and cases of lower respiratory tract illness were ascertained by a physician. Viral tests were done for specimens collected at the time of the illness. Children were classified into five groups according to type and cause of lower respiratory tract illness. Children were then followed prospectively up to age 13, and we measured frequency of wheezing, pulmonary function, and atopic status (allergy skin-prick tests, serum IgE concentrations). Findings RSV lower respiratory tract illnesses were associated with an increased risk of infrequent wheeze (odds ratio 3.2 [95% CI 2.0-5.0], p<0.001), and an increased risk of frequent wheeze (4.3 [2.2-8.7], p less than or equal to 0.001) by age 6, Risk decreased markedly with age and was not significant by age 13. There was no association between RSV lower respiratory tract illnesses and subsequent atopic status. RSV lower respiratory tract illnesses were associated with significantly lower measurements of forced expiratory volume (2.11 [2.05-2.15], p less than or equal to 0.001) when compared with those of children with no lower respiratory tract illnesses, but there was no difference in forced expiratory volume after inhalation of salbutamol. Interpretation RSV lower respiratory tract illnesses in early childhood are an independent risk factor for the subsequent development of wheezing up to age 11 years but not at ape 13. This association is not caused by an increased risk of allergic sensitisation.	Pontiflcia Univ Catolica RS, Dept Pediat, Pediat Pulm Sect, Porto Alegre, RS, Brazil; Univ Arizona, Resp Sci Ctr, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Martinez, FD (corresponding author), POB 245030, Tucson, AZ 85724 USA.		Stein, Renato T/G-2975-2012; Stein, Renato Tetelbom/K-2568-2014	Halonen, Marilyn/0000-0001-9606-935X; STEIN, RENATO/0000-0003-0269-0757	NHLBI NIH HHS [R01 HL-56177, HL-03154] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1302, DOI 10.1164/ajrccm.152.4.7551386; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Colasurdo GN, 1998, AM J RESP CRIT CARE, V157, P1506, DOI 10.1164/ajrccm.157.5.9705026; COLASURDO GN, 1995, AM J PHYSIOL-LUNG C, V268, pL1006, DOI 10.1152/ajplung.1995.268.6.L1006; GLEZEN WP, 1981, J PEDIATR, V98, P702; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HALONEN M, 1999, IN PRESS AM J RESP C; Hanrahan JP, 1996, AM J RESP CRIT CARE, V154, P670, DOI 10.1164/ajrccm.154.3.8810604; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Larsen GL., 1998, RSV ASTHMA IS THERE, P17; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MCCONNOCHIE KM, 1985, AM J DIS CHILD, V139, P625, DOI 10.1001/archpedi.1985.02140080095042; MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PULLAN CR, 1982, BRIT MED J, V284, P165; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SIGURS N, 1995, PEDIATRICS, V95, P500; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655, DOI 10.1164/ajrccm/144.3_Pt_1.655; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1993, AM REV RESPIR DIS, V147, pA375; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; VOTER KZ, 1988, AM REV RESPIR DIS, V137, P302, DOI 10.1164/ajrccm/137.2.302; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WELLIVER RC, 1998, RSV ASTHMA IS THERE, P21; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	34	1104	1150	4	57	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					541	545		10.1016/S0140-6736(98)10321-5	http://dx.doi.org/10.1016/S0140-6736(98)10321-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470697				2022-12-28	WOS:000081991000010
J	Mira, JP; Cariou, A; Grall, F; Delclaux, C; Losser, MR; Heshmati, F; Cheval, C; Monchi, M; Teboul, JL; Riche, F; Leleu, G; Arbibe, L; Mignon, A; Delpech, M; Dhainaut, JF				Mira, JP; Cariou, A; Grall, F; Delclaux, C; Losser, MR; Heshmati, F; Cheval, C; Monchi, M; Teboul, JL; Riche, F; Leleu, G; Arbibe, L; Mignon, A; Delpech, M; Dhainaut, JF			Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality - A multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; GRADIENT GEL-ELECTROPHORESIS; MONOCLONAL-ANTIBODY; GENE PROMOTER; CONTROLLED TRIAL; TISSUE-INJURY; DOUBLE-BLIND; SEPSIS; INTERLEUKIN-1; DISEASE	Context Tumor necrosis factor alpha (TNF-alpha) is believed to be a cytokine central to pathogenesis of septic shock. TNF2, a polymorphism within the TNF-alpha gene pro meter, has been associated with enhanced TNF-alpha production and negative outcome in some severe infections. Objectives To investigate the frequency of the TNF2 allele in patients with septic shock and to determine whether the allele is associated with the occurrence and outcome of septic shock. Design Multicenter case-control study conducted from March 1996 to June 1997, Setting Seven medical intensive care units in university hospitals. Subjects Eighty-nine patients with septic shock and 87 healthy unrelated blood donors. Main Outcome Measures Frequency of the TNF2 allele among patients with septic shock and among those who died and the level of corresponding TNF-alpha concentrations. Results Mortality among patients with septic shock was 54%, consistent with the predicted mortality from the Simplified Acute Physiologic Score (SAPS II) value. The polymorphism frequencies of the controls and the patients with septic shock differed only at the TNF2 allele (39% vs 18% in the septic shock and control groups, respectively, P =.002). Among the septic shock patients, TNF2 polymorphism frequency was significantly greater among those who had died (52% vs 24% in the survival group. P =.008). Concentrations of TNF-alpha were higher in 68% and 52% with the TNF2 and TNF1 polymorphisms, respectively, but their median Values (48 pg/mL vs 29 pg/mL) were not statistically different (P =.31). After controlling for age and the probability of death, derived by the SAPS II score, multiple logistic regression analysis showed that, for the same rank of SAPS ii value, patients with the TNF2 allele had a 3.7-fold risk of death (95% confidence interval, 1.37-20.24). Conclusion The TNF2 allele is strongly associated with susceptibility to septic shock and death due to septic shock.	Cochin Port Royal Univ Hosp, Intens Care Unit, F-75679 Paris, France; Cochin Port Royal Univ Hosp, Lab Biochem Genet, F-75679 Paris 14, France; Lariboisiere Univ Hosp, Intens Care Unit, Paris, France; St Joseph Univ Hosp, Paris, France; Kremlin Bicetre Univ Hosp, Paris, France; St Louis Univ Hosp, Paris, France; Cochin Hosp, Blood Bank, Paris, France; Mondor Univ Hosp, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Mira, JP (corresponding author), Cochin Port Royal Univ Hosp, Med Intens Care Unit, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.		Losser, Marie-Reine/AHB-0522-2022; Connor, Toni R/C-6964-2012	Teboul, Jean-Louis/0000-0002-5748-7820; Arbibe, Laurence/0000-0001-7102-346X				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; Abraham E, 1998, LANCET, V351, P929; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Andrejko KM, 1996, CRIT CARE MED, V24, P1947, DOI 10.1097/00003246-199612000-00004; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; Bouma G, 1996, SCAND J IMMUNOL, V43, P456, DOI 10.1046/j.1365-3083.1996.d01-65.x; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; Cohen J, 1996, CRIT CARE MED, V24, P1431, DOI 10.1097/00003246-199609000-00002; COLOMBANI J, 1993, EUROTEXT, P100; Conway DJ, 1997, INFECT IMMUN, V65, P1003, DOI 10.1128/IAI.65.3.1003-1006.1997; COSTES B, 1993, HUM MOL GENET, V2, P393, DOI 10.1093/hmg/2.4.393; DHAINAUT JFA, 1995, CRIT CARE MED, V23, P1461, DOI 10.1097/00003246-199509000-00004; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; Goldfeld AE, 1998, JAMA-J AM MED ASSOC, V279, P226, DOI 10.1001/jama.279.3.226; GUSTAFSON S, 1987, ANAL BIOCHEM, V165, P294, DOI 10.1016/0003-2697(87)90272-7; HAMANN A, 1995, BIOCHEM BIOPH RES CO, V211, P833, DOI 10.1006/bbrc.1995.1887; Hurme M, 1998, ANN MED, V30, P469, DOI 10.3109/07853899809002488; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; Keel M, 1996, J TRAUMA, V40, P907, DOI 10.1097/00005373-199606000-00008; KNAUS WA, 1989, CRIT CARE CLIN, V5, P221; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Louis E, 1998, CLIN EXP IMMUNOL, V113, P401; LYNN WA, 1995, CLIN INFECT DIS, V20, P143, DOI 10.1093/clinids/20.1.143; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MITCHIE HR, 1988, NEW ENGL J MED, V318, P1481; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P705, DOI 10.1111/j.1365-3083.1988.tb02404.x; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Pellegrini JD, 1996, SHOCK, V6, P389, DOI 10.1097/00024382-199612000-00001; POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x; Rink L, 1996, INT ARCH ALLERGY IMM, V111, P199, DOI 10.1159/000237369; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; STRUBER F, 1996, J INFLAMM, V46, P42; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VERJANS GMGM, 1994, CLIN EXP IMMUNOL, V97, P45; Vinasco J, 1997, TISSUE ANTIGENS, V49, P74, DOI 10.1111/j.1399-0039.1997.tb02715.x; WAKABAYASHI G, 1991, J CLIN INVEST, V87, P1925, DOI 10.1172/JCI115218; Warzocha K, 1998, BLOOD, V91, P3574; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; WILSON AG, 1995, J INFLAMM, V45, P1	50	538	573	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					561	568		10.1001/jama.282.6.561	http://dx.doi.org/10.1001/jama.282.6.561			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450718	Bronze			2022-12-28	WOS:000081919100030
J	Brown, M				Brown, M			Do vitamin E and fish oil protect against ischaemic heart disease?	LANCET			English	Editorial Material							CORONARY-DISEASE; ATHEROSCLEROSIS; INCREASE; TRIAL; RISK		Univ Cambridge, Clin Pharmacol Unit, Cambridge CB2 2QQ, England	University of Cambridge	Brown, M (corresponding author), Univ Cambridge, Clin Pharmacol Unit, Cambridge CB2 2QQ, England.							BURR ML, 1989, LANCET, V2, P757; Gey K F, 1989, Int J Vitam Nutr Res Suppl, V30, P224; HIGORANI AD, IN PRESS CIRCULATION; HINGORANI AD, 1997, CLIN SCI COLCH, V932, pP18; Kinlay S, 1999, CIRCULATION, V100, P219, DOI 10.1161/01.CIR.100.3.219; MITCHINSON MJ, 1983, MED HYPOTHESES, V12, P171, DOI 10.1016/0306-9877(83)90079-8; Philip I, 1999, CIRCULATION, V99, P3096, DOI 10.1161/01.CIR.99.24.3096; Rodriguez BL, 1996, CIRCULATION, V94, P952, DOI 10.1161/01.CIR.94.5.952; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1	12	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					441	442		10.1016/S0140-6736(99)00253-6	http://dx.doi.org/10.1016/S0140-6736(99)00253-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465163				2022-12-28	WOS:000081896100003
J	Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N				Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N			IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; NF-AT; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; TRANSGENIC MICE; GROWTH-FACTORS; MUSCLE-CELLS; ACTIVATION; MORPHOGENESIS	Localized synthesis of insulin-like growth factors (IGFs) has been broadly implicated in skeletal muscle growth, hypertrophy and regeneration(1). Virally delivered IGF-1 genes induce local skeletal muscle hypertrophy and attenuate age-related skeletal muscle atrophy, restoring and improving muscle mass and strength in mice(2), Here we show that the molecular pathways underlying the hypertrophic action of IGF-1 in skeletal muscle are similar to those responsible for cardiac hypertrophy, Transfected IGF-1 gene expression in postmitotic skeletal myocytes activates calcineurin-mediated calcium signalling by inducing calcineurin transcripts and nuclear localization of calcineurin protein. Expression of activated calcineurin mimics the effects of IGF-1, whereas expression of a dominant-negative calcineurin mutant or addition of cyclosporin, a calcineurin inhibitor, represses myocyte differentiation and hypertrophy. Either IGF-1 or activated calcineurin induces expression of the transcription factor GATA-2, which accumulates in a subset of myocyte nuclei, where it associates with calcineurin and a specific dephosphorylated isoform of the transcription factor NF-ATc1. Thus, IGF-1 induces calcineurin-mediated signalling and activation of GATA-2, a marker of skeletal muscle hypertrophy, which cooperates with selected NF-ATc isoforms to activate gene expression programs.	Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75225 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenthal, N (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Musaro, Antonio/P-2953-2019; Musarò, Antonio/K-9598-2016	Musaro, Antonio/0000-0002-2944-9739; Musarò, Antonio/0000-0002-2944-9739; Rosenthal, Nadia/0000-0002-7599-7365				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MITSUMOTO Y, 1992, FEBS LETT, V301, P94, DOI 10.1016/0014-5793(92)80217-5; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Muramatsu T, 1996, BIOCHEM BIOPH RES CO, V218, P466, DOI 10.1006/bbrc.1996.0083; Musaro A, 1999, MOL CELL BIOL, V19, P3115; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	30	530	547	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					581	585		10.1038/23060	http://dx.doi.org/10.1038/23060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448862				2022-12-28	WOS:000081854800060
J	Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP				Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP			Ethnic differences in use of hormone replacement therapy: community based survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England	St Georges University London; St Georges University London; St Georges University London	Cook, DG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Cappuccio, Francesco/D-3028-2009; Cappuccio, Francesco Paolo/ABF-1094-2020	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Cook, Derek/0000-0002-9723-5759; Harris, Tess/0000-0002-8671-1553				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; GRIFFITHS F, 1995, FAM PRACT, V12, P163, DOI 10.1093/fampra/12.2.163; TOBIAS JH, 1994, CLIN SCI, V87, P587, DOI 10.1042/cs0870587	5	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					610	611		10.1136/bmj.319.7210.610	http://dx.doi.org/10.1136/bmj.319.7210.610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473476	Bronze, Green Published			2022-12-28	WOS:000082460300020
J	Fisk, DT; Saint, S; Tierney, LM				Fisk, DT; Saint, S; Tierney, LM			Back to the basics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPINAL-CORD INJURY; URINARY-TRACT INFECTION; APPENDICITIS; ABDOMEN		Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Hlth Serv, Ann Arbor, MI USA; Res Field Program, Ann Arbor, MI USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Saint, S (corresponding author), Univ Michigan, Dept Internal Med, Taubman Ctr 3116, Box 0376, Ann Arbor, MI 48109 USA.	saint@umich.edu	Saint, Sanjay/AAF-5126-2019					CALDER JDF, 1995, BRIT J HOSP MED, V54, P129; CARDENAS DD, 1995, ARCH PHYS MED REHAB, V76, P272, DOI 10.1016/S0003-9993(95)80615-6; JULER GL, 1985, PARAPLEGIA, V23, P118, DOI 10.1038/sc.1985.20; Kamitsuka P F, 1993, Curr Clin Top Infect Dis, V13, P1; KUHN W, 1991, PARAPLEGIA, V29, P222, DOI 10.1038/sc.1991.33; Lightner DJ, 1998, MAYO CLIN PROC, V73, P434; McColl I, 1998, NEW ENGL J MED, V338, P190, DOI 10.1056/NEJM199801153380309; MILLER LS, 1975, ARCH PHYS MED REHAB, V56, P405; National Institute on Disability and Reha- bilitation Research Consensus Statement, 1992, J AM PARAPLEGIA SOC, V15, P194, DOI DOI 10.1080/01952307.1992.11735873; NEUMAYER LA, 1990, ANN SURG, V212, P561, DOI 10.1097/00000658-199011000-00002; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; Saint S, 1998, AM J MED, V105, P236, DOI 10.1016/S0002-9343(98)00240-X; Saint S, 1999, ARCH INTERN MED, V159, P800, DOI 10.1001/archinte.159.8.800; SAINT S, IN PRESS AM J INFECT; SILEN W, 1991, COPES EARLY DIAGNOSI; VELANOVICH V, 1992, AM SURGEON, V58, P264; Warren JW, 1997, INFECT DIS CLIN N AM, V11, P609, DOI 10.1016/S0891-5520(05)70376-7	17	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					747	750		10.1056/NEJM199909023411007	http://dx.doi.org/10.1056/NEJM199909023411007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471462				2022-12-28	WOS:000082291900007
J	Brennand, JK				Brennand, JK			"I wish I'd got my new ears last year, mum"'	LANCET			English	Editorial Material									Perth Royal Infirm, Perth PH1 1NX, Scotland		Brennand, JK (corresponding author), Perth Royal Infirm, Taymount Terrace, Perth PH1 1NX, Scotland.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					676	676		10.1016/S0140-6736(99)04026-X	http://dx.doi.org/10.1016/S0140-6736(99)04026-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466688				2022-12-28	WOS:000082214500048
J	Maiden, MCJ; Spratt, BG				Maiden, MCJ; Spratt, BG			Meningococcal conjugate vaccines: new opportunities and new challenges	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; ET-37 COMPLEX; VACCINATION; CARRIAGE; DISEASE		Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England	University of Oxford	Maiden, MCJ (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3FY, England.		Spratt, Brian G/A-1676-2009; Maiden, Martin C J/C-5055-2014; Maiden, Martin/N-6805-2019	Maiden, Martin C J/0000-0001-6321-5138; Maiden, Martin/0000-0001-6321-5138				CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; Gupta S, 1999, PHILOS T R SOC B, V354, P711, DOI 10.1098/rstb.1999.0424; Kwara A, 1998, TROP MED INT HEALTH, V3, P742, DOI 10.1046/j.1365-3156.1998.00300.x; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Slack MPE, 1998, PEDIATR INFECT DIS J, V17, pS204, DOI 10.1097/00006454-199809001-00026; Stephens DS, 1999, LANCET, V353, P941, DOI 10.1016/S0140-6736(98)00279-7; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010; VEDROS NA, 1987, EVOLUTION MENINGOCOC, P33; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320	16	87	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					615	616						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466659				2022-12-28	WOS:000082214500006
J	Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L				Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L			Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme	NATURE			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; SERINE PROTEASES; SULFATE; MOUSE; BIOSYNTHESIS; EXPRESSION; PROTEOGLYCANS; DROSOPHILA	Heparin is a sulphated polysaccharide, synthesized exclusively by connective-tissue-type mast cells(1) and stored in the secretory granules in complex with histamine and various mast-cell proteases(2). Although heparin has long been used as an antithrombotic drug, endogenous heparin is not present in the blood, so it cannot have a physiological role in regulating blood coagulation. The biosynthesis of heparin involves a series of enzymatic reactions, including sulphation at various positions(1,3). The initial modification step, catalysed by the enzyme glucosaminyl N-deacetylase/N-sulphotransferase-2, NDST-2 (refs 4-7), is essential for the subsequent reactions. Here we report that mice carrying a targeted disruption of the gene encoding NDST-2 are unable to synthesize sulphated heparin. These NDST-2-deficient mice are viable and fertile but have fewer connective-tissue-type mast cells; these cells have an altered morphology and contain severely reduced amounts of histamine and mast-cell proteases. Our results indicate that one site of physiological action for heparin could be inside connective-tissue-type mast cells, where its absence results in severe defects in the secretory granules.	Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Cell & Mol Biol, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Uppsala University	Kjellen, L (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.		Kusche-Gullberg, Marion/P-4466-2016; Kjellen, Lena/F-1362-2011	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ledin, Johan/0000-0002-7319-7735				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PASSLER R, 1995, GENE DEV, V9, P1896; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458	25	393	397	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					773	776		10.1038/23488	http://dx.doi.org/10.1038/23488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466727				2022-12-28	WOS:000082131100052
J	Connelly, MT; Ferrari, N; Hagen, N; Inui, TS				Connelly, MT; Ferrari, N; Hagen, N; Inui, TS			Patient-identified needs for hormone replacement therapy counseling: A qualitative study	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN	Background: Numerous medical organizations, including the American College of Physicians, have recommended that women be counseled about postmenopausal hormone replacement therapy (HRT). Patients' perspectives on their counseling needs, however, have not been integrated into most counseling guides. Objective: To use patient self-reports to identify needs for HRT counseling. Design: Individual, in-depth patient interviews. Setting: Managed care organization. Patients: 26 women who had received an initial prescription for HRT. Measurements: Qualitative, consensus review of the content of interview transcripts. Results: On average, women reported 15 factors (range, 6 to 24 factors) as critical to their decision-making process. Although most women cited their physician's opinion (96%), reports in the media (81%), and experiences and opinions of friends (77%) as critical to their decisions about HRT, counseling recommendations address none of these concerns. Conclusions: Many women in a managed care organization who accepted a prescription for HRT identified counseling needs that are not included in widely used HRT guidelines.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Hlth Publicat Grp, Boston, MA 02215 USA; Brown & Toland Phys Serv Org, San Francisco, CA 94109 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Connelly, MT (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 203, Boston, MA 02215 USA.				AHRQ HHS [1F32HS00107-01] Funding Source: Medline; BHP HRSA HHS [2T32PE11001-06, 5T32PE11001-07] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		*AM COLL OBST GYN, 1998, AM COLL OBST GYN ED, V247, P1; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Chan ECY, 1998, AM J MED, V105, P266, DOI 10.1016/S0002-9343(98)00257-5; CRABTREE BF, 1992, DOING QUALITATIVE RE, P41; Daley J, 1999, ANN INTERN MED, V130, P602, DOI 10.7326/0003-4819-130-7-199904060-00021; FEASLEY J, 1996, HLTH OUTCOMES OLDER; GRADY D, 1992, ANN INTERN MED, V117, P1038; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; MANSFIELD PK, 1998, HEALTH CARE WOMEN IN, V18, P55; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Saver BG, 1997, AM J PREV MED, V13, P358, DOI 10.1016/S0749-3797(18)30155-7; Seto TB, 1996, J GEN INTERN MED, V11, P197, DOI 10.1007/BF02642475; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P829	18	37	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					265	268		10.7326/0003-4819-131-4-199908170-00005	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454947				2022-12-28	WOS:000082012500004
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					605	605		10.1016/S0140-6736(05)77968-X	http://dx.doi.org/10.1016/S0140-6736(05)77968-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470741				2022-12-28	WOS:000081991000074
J	Whittick, WK				Whittick, WK			Crossed lines	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					406	406		10.1136/bmj.319.7207.406	http://dx.doi.org/10.1136/bmj.319.7207.406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445918	Green Published			2022-12-28	WOS:000082098900013
J	Silvian, LF; Wang, JM; Steitz, TA				Silvian, LF; Wang, JM; Steitz, TA			Insights into editing from an Ile-tRNA synthetase structure with tRNA(Ile) and mupirocin	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; DNA-POLYMERASE-I; ESCHERICHIA-COLI; KLENOW FRAGMENT; AMINOACYLATION; REFINEMENT; MECHANISM; SITES; GENE	Isoleucyl-transfer RNA (tRNA) synthetase (IleRS) joins Ire to tRNA(Ile) at its synthetic active site and hydrolyzes incorrectly acylated amino acids at its editing active site. The 2.2 angstrom resolution crystal structure of Staphylococcus aureus IleRS complexed with tRNA(Ile) and Mupirocin shows the acceptor strand of the tRNA(Ile) in the continuously stacked, A-form conformation with the 3' terminal nucleotide in the editing active site. To position the 3' terminus in the synthetic active site, the acceptor strand must adopt the hairpinned conformation seen in tRNA(Gln) complexed with its synthetase, The amino acid editing activity of the IleRS may result from the incorrect products shuttling between the synthetic and editing active sites, which is reminiscent of the editing mechanism of DNA polymerases.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Silvian, LF (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Steitz, Thomas A./C-6559-2009	Silvian, Laura/0000-0002-5299-5201	NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDMAN AM, 1994, AM CRYST ASS ANN M A; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HECK JD, 1988, J BIOL CHEM, V263, P868; JONES TA, 1994, O MANUAL; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SILVIAN LF, UNPUB; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WANG JC, UNPUB	28	344	358	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1074	1077		10.1126/science.285.5430.1074	http://dx.doi.org/10.1126/science.285.5430.1074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446055				2022-12-28	WOS:000082033100048
J	Veenstra, DL; Saint, S; Sullivan, SD				Veenstra, DL; Saint, S; Sullivan, SD			Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED TRIAL; PULMONARY-ARTERY CATHETERS; CRITICALLY ILL PATIENTS; BACTERIAL-COLONIZATION; INTENSIVE-CARE; SILVER-SULFADIAZINE; MORTALITY; SEPSIS; CHLORHEXIDINE	Context A recent randomized controlled trial and meta-analysis indicated that central venous catheters impregnated with an antiseptic combination of chlorhexidine and silver sulfadiazine are efficacious in reducing the incidence of catheter-related bloodstream infection (CR-BSI); however, the ultimate clinical and economic consequences of their use have not been formally evaluated. Objective To estimate the incremental clinical and economic outcomes associated with the use of antiseptic-impregnated vs standard catheters. Design Decision analytic model using data from randomized controlled trials, meta-analyses, and case-control studies, as well as safety data from the US Food and Drug Administration. Setting and Patients A hypothetical cohort of hospitalized patients at high risk for catheter-related infections leg, patients in intensive care units, immunosuppressed patients, and patients receiving total parenteral nutrition) requiring use of a central venous catheter. Intervention Short-term use (2-10 days) of chlorhexidine-silver sulfadiazine-impregnated multilumen central venous catheters and nonimpregnated catheters. Main Outcome Measures Expected incidence of CR-BSI and death attributable to antiseptic-impregnated and standard catheter use; direct medical costs for both types of catheters. Results In the base-case analysis, use of antiseptic-impregnated catheters resulted in a decrease in the incidence of CR-BSI of 2.2% (5.2% for standard vs 3.0% for antiseptic-impregnated catheters), a decrease in the incidence of death of 0.33% (0.78% for standard vs 0.45% for antiseptic-impregnated), and a decrease in costs of $196 per catheter used ($532 for standard vs $336 for antiseptic-impregnated). The decrease in CR-BSI ranged from 1.2% to 3.4%, the decrease in death ranged from 0.09% to 0.78%, and the costs saved ranged from $68 to $391 in a multivariate sensitivity analysis. Conclusion Our analyses suggest that use of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in patients at high risk for catheter-related infections reduces the incidence of CR-BSI and death and provides significant saving in costs. Use of these catheters should be considered as part of a comprehensive nosocomial infection control program.	Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; Univ Washington, Sch Pharm, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle	Veenstra, DL (corresponding author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, POB 357630, Seattle, WA 98195 USA.		Saint, Sanjay/AAF-5126-2019		AHRQ HHS [HS/HL08368-01A1, HS07834-03S1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Appavu S. K., 1994, Chest, V106, p176S; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; Bach A, 1996, J ANTIMICROB CHEMOTH, V37, P315, DOI 10.1093/jac/37.2.315; Bach A, 1995, ZBL BAKT-INT J MED M, V283, P208; BACH A, 1994, ANESTHESIOLOGY, V81, pA261; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; *BUR LAB STAT, 1998, CONS PRIC IND MED CA; *CDCP, 1996, EPI INF COMP PROGR V; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; Collin GR, 1999, CHEST, V115, P1632, DOI 10.1378/chest.115.6.1632; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; *CTR DEV RAD HLTH, 1998, POT HYP REACT CHLORH; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Drummond MF, 2015, METHODS EC EVALUATIO; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; George SJ, 1997, EUR J ANAESTH, V14, P428, DOI 10.1046/j.1365-2346.1997.00168.x; GILLUM BS, 1998, VITAL HLTH STAT, V13, P133; Hannan M, 1996, CLIN INTENSIVE CARE, V7, P56; Hasaniya NWMA, 1996, CHEST, V109, P1030, DOI 10.1378/chest.109.4.1030; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; *HLTH CAR FIN ADM, 1998, PROSP PAYM SYST STAN; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Logghe C, 1997, J HOSP INFECT, V37, P145, DOI 10.1016/S0195-6701(97)90184-5; Maki Dennis G., 1994, P155; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, CRIT CARE MED, V22, P1729; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; MODAK SM, 1992, COMPLICATION SURG, V11, P23; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; NYSTROM B, 1994, INFECT CONT HOSP EP, V15, P435; Oda T, 1997, ANESTHESIOLOGY, V87, P1242, DOI 10.1097/00000542-199711000-00031; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pearson ML, 1997, ANN INTERN MED, V127, P304, DOI 10.7326/0003-4819-127-4-199708150-00009; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Pittet D, 1994, JAMA-J AM MED ASSOC, V272, P1819; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; Ramsay J, 1994, CRIT CARE MED, V22, pA115; SMITH RL, 1991, CHEST, V100, P164, DOI 10.1378/chest.100.1.164; Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348; Torrance GW., 1996, COST EFFECTIVENESS H, P54; TRAZZERA S, 1995, CRIT CARE MED, V23, pA152; vanHeerden PV, 1996, ANAESTH INTENS CARE, V24, P330, DOI 10.1177/0310057X9602400305; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; *WHO, 1997, INF EXCH SYST	57	194	202	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					554	560		10.1001/jama.282.6.554	http://dx.doi.org/10.1001/jama.282.6.554			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450717				2022-12-28	WOS:000081919100029
J	Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E				Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E			The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene	CELL			English	Article							RNA SPLICE JUNCTIONS; MESSENGER-RNA; DROSOPHILA PERIOD; SEQUENCE; CATAPLEXY; SYSTEMS; SUSCEPTIBILITY; HYPOTHALAMUS; CHROMOSOMES; EXPRESSION	Narcolepsy is a disabling sleep disorder affecting humans and animals. It is characterized by daytime sleepiness, cataplexy, and striking transitions from wakefulness into rapid eye movement (REM) sleep. In this study, we used positional cloning to identify an autosomal recessive mutation responsible for this sleep disorder in a well-established canine model. We have determined that canine narcolepsy is caused by disruption of the hypocretin (orexin) receptor 2 gene (Hcrtr2). This result identifies hypocretins as major sleep-modulating neurotransmitters and opens novel potential therapeutic approaches for narcoleptic patients.	Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Stanford University; Roswell Park Cancer Institute	Mignot, E (corresponding author), Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA.		Kadotani, Hiroshi/A-7908-2015	Kadotani, Hiroshi/0000-0001-7474-3315	NHLBI NIH HHS [HL59601] Funding Source: Medline; NINDS NIH HHS [NS33797, NS23724] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033797, R37NS033797, P01NS023724, P50NS023724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ALDRICH MS, 1993, PROG NEUROBIOL, V41, P533, DOI 10.1016/0301-0082(93)90042-Q; ALDRICH MS, 1989, NEUROLOGY, V39, P1505, DOI 10.1212/WNL.39.11.1505; Baker TL, 1985, BRAIN MECH SLEEP, P199; Barch MJ, 1997, AGT CYTOGENETICS LAB; Beck B, 1999, BIOCHEM BIOPH RES CO, V258, P119, DOI 10.1006/bbrc.1999.0605; Borbely AA, 1994, PRINCIPLES PRACTICE, P309; Broberger C, 1998, J COMP NEUROL, V402, P460; Cederberg R, 1998, VET REC, V142, P31, DOI 10.1136/vr.142.2.31; COLTMAN DW, 1994, NUCLEIC ACIDS RES, V22, P2726, DOI 10.1093/nar/22.14.2726; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; Dutra AS, 1996, CYTOGENET CELL GENET, V74, P113, DOI 10.1159/000134395; Edwards CMB, 1999, J ENDOCRINOL, V160, pR7, DOI 10.1677/joe.0.160R007; FOUTZ AS, 1979, SLEEP, V1, P413; Francisco LV, 1996, MAMM GENOME, V7, P359, DOI 10.1007/s003359900104; Green E D, 1991, PCR Methods Appl, V1, P77; Honda Y., 1990, HDB SLEEP DISORDERS, P217; Horvath TL, 1999, J NEUROSCI, V19, P1072; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kastin AJ, 1999, J PHARMACOL EXP THER, V289, P219; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li R, 1999, GENOMICS, V58, P9, DOI 10.1006/geno.1999.5772; Lin L, 1997, TISSUE ANTIGENS, V50, P507, DOI 10.1111/j.1399-0039.1997.tb02907.x; Lubkin M, 1998, BIOCHEM BIOPH RES CO, V253, P241, DOI 10.1006/bbrc.1998.9750; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MATSUKI K, 1992, LANCET, V339, P1052, DOI 10.1016/0140-6736(92)90571-J; McGrory J, 1999, CLIN GENET, V55, P118, DOI 10.1034/j.1399-0004.1999.550208.x; MIGNOT E, 1993, PSYCHOPHARMACOLOGY, V113, P76, DOI 10.1007/BF02244337; MIGNOT E, 1995, ADV NEUROIMMUNOL, V5, P23, DOI 10.1016/0960-5428(94)00043-N; MIGNOT E, 1993, J NEUROSCI, V13, P1057; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; MIGNOT E, 1991, P NATL ACAD SCI USA, V88, P3475, DOI 10.1073/pnas.88.8.3475; MIGNOT E, 1994, SLEEP, V17, pS68, DOI 10.1093/sleep/17.suppl_8.S68; MILLER JD, 1990, BRAIN RES, V509, P169, DOI 10.1016/0006-8993(90)90328-9; MINNICK MF, 1992, GENE, V110, P235, DOI 10.1016/0378-1119(92)90654-8; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Moore RY, 1998, CHRONOBIOL INT, V15, P475, DOI 10.3109/07420529808998703; Moriguchi T, 1999, NEUROSCI LETT, V264, P101, DOI 10.1016/S0304-3940(99)00177-9; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Neff MW, 1999, GENETICS, V151, P803; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; OSTRANDER EA, 1995, MAMM GENOME, V6, P192, DOI 10.1007/BF00293011; Ott J., 1991, ANAL HUMAN GENETIC L; Peyron C, 1998, J NEUROSCI, V18, P9996; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; Reid MS, 1996, BRAIN RES, V733, P83, DOI 10.1016/0006-8993(96)00541-0; Riehl J, 1998, EXP NEUROL, V152, P292, DOI 10.1006/exnr.1998.6847; Ryder EJ, 1999, ANIM GENET, V30, P63, DOI 10.1046/j.1365-2052.1999.00424.x; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Sweet DC, 1999, BRAIN RES, V821, P535, DOI 10.1016/S0006-8993(99)01136-1; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Wakefield MJ, 1996, MAMM GENOME, V7, P715, DOI 10.1007/s003359900221; Yamamoto Y, 1999, MOL BRAIN RES, V65, P14, DOI 10.1016/S0169-328X(98)00320-9	73	1896	1995	5	162	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					365	376		10.1016/S0092-8674(00)81965-0	http://dx.doi.org/10.1016/S0092-8674(00)81965-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458611	Bronze			2022-12-28	WOS:000081950300011
J	Sniderman, AD				Sniderman, AD			Clinical trials, consensus conferences, and clinical practice	LANCET			English	Editorial Material							AVERAGE CHOLESTEROL LEVELS; CORONARY HEART-DISEASE; APOLIPOPROTEIN-B; PREVENTION; MEN; PRAVASTATIN; EVENTS; WOMEN; RISK		McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Sniderman, AD (corresponding author), McGill Univ, Royal Victoria Hosp, 687 Pine Ave W,Room H7-22, Montreal, PQ H3A 1A1, Canada.	asniderm@is.rvh.mcgill.ca						DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; McIntyre KM, 1998, CHEST, V114, p742S, DOI 10.1378/chest.114.5_Supplement.742S; Packard CJ, 1998, CIRCULATION, V97, P1440; *PATH DET ATH YOUT, 1993, ARTERIOSCLEROSIS, V13, P291; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; ZHAO XQ, 1993, CIRCULATION, V88, P2744, DOI 10.1161/01.CIR.88.6.2744	18	43	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					327	330		10.1016/S0140-6736(98)11185-6	http://dx.doi.org/10.1016/S0140-6736(98)11185-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440326				2022-12-28	WOS:000081646000047
J	McCormick, DA				McCormick, DA			Developmental neuroscience - Spontaneous activity: Signal or noise?	SCIENCE			English	Editorial Material							GENE-EXPRESSION; VISUAL-CORTEX; OCULAR DOMINANCE; OSCILLATIONS; EXPERIENCE; SPECIFICITY; COMPETITION; MECHANISMS; FREQUENCY; FEEDBACK		Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University	McCormick, DA (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA.		Kobelt, Liza/F-5926-2011; McCormick, David A/J-2649-2015	McCormick, David A/0000-0002-9803-8335				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Catalano SM, 1998, SCIENCE, V281, P559, DOI 10.1126/science.281.5376.559; Contreras D, 1996, SCIENCE, V274, P771, DOI 10.1126/science.274.5288.771; Craig AM, 1998, NEURON, V21, P459, DOI 10.1016/S0896-6273(00)80555-3; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DAW N, 1995, VISUAL DEVELOPMENT; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Erwin E, 1998, J NEUROSCI, V18, P9870; Fields RD, 1997, J NEUROSCI, V17, P7252; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; Huntsman MM, 1999, SCIENCE, V283, P541, DOI 10.1126/science.283.5401.541; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KORNORO H, 1998, J NEUROBIOL, V37, P110; Kudrimoti HS, 1999, J NEUROSCI, V19, P4090; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; Meissirel C, 1997, P NATL ACAD SCI USA, V94, P5900, DOI 10.1073/pnas.94.11.5900; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; RAKIC P, 1981, SCIENCE, V214, P928, DOI 10.1126/science.7302569; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; Rittenhouse CD, 1999, NATURE, V397, P347, DOI 10.1038/16922; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; Skaggs WE, 1996, SCIENCE, V271, P1870, DOI 10.1126/science.271.5257.1870; Snider CJ, 1999, J NEUROSCI, V19, P220, DOI 10.1523/JNEUROSCI.19-01-00220.1999; Steriade M, 1998, J SLEEP RES, V7, P30, DOI 10.1046/j.1365-2869.7.s1.4.x; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STRETAVAN DW, 1988, NATURE, V336, P468; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978	45	52	54	2	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					541	543		10.1126/science.285.5427.541	http://dx.doi.org/10.1126/science.285.5427.541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10447487				2022-12-28	WOS:000081609500024
J	Kappos, L; Moeri, D; Radue, EW; Schoetzau, A; Schweikert, K; Barkhof, F; Miller, D; Guttmann, CRG; Weiner, HL; Gasperini, C; Filippi, M				Kappos, L; Moeri, D; Radue, EW; Schoetzau, A; Schweikert, K; Barkhof, F; Miller, D; Guttmann, CRG; Weiner, HL; Gasperini, C; Filippi, M		Gadolinium MRI Metaanal Grp	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis	LANCET			English	Article							DISEASE-ACTIVITY; SPINAL-CORD; MRI; BRAIN; GUIDELINES; LESIONS; TRIALS	Background Reliable prognostic factors are lacking for multiple sclerosis (MS). Gadolinium enhancement in magnetic resonance imaging (MRI) of the brain detects with high sensitivity disturbance of the blood-brain barrier, an early event in the development of inflammatory lesions in MS. To investigate the prognostic value of gadolinium-enhanced MRI, we did a meta-analysis of longitudinal MRI studies. Methods From the members of MAGNIMS (European Magnetic Resonance Network in Multiple Sclerosis) and additional centres in the USA, we collected data from five natural-course studies and four placebo groups of clinical trials completed between 1992 and 1995. We included a total of 307 patients, 237 with relapsing disease course and 70 with secondary progressive disease course. We investigated by regression analysis the relation between initial count of gadolinium-enhancing lesions and subsequent worsening of disability or impairment as measured by the expanded disability status scale (EDSS) and relapse rate. Findings The relapse rate in the first year was predicted with moderate ability by the mean number of gadolinium-enhancing lesions in monthly scans during the first 6 months (relative risk per five lesions 1.13, p=0.023). The predictive value of the number of gadolinium-enhancing lesions in one baseline scan was less strong. The best predictor for relapse rate was the variation (SD) of lesion counts in the first six monthly scans which allowed an estimate of relapse in the first year (relative risk 1.2, p=0.020) and in the second year (risk ratio=1.59, p=0.010). Neither the initial scan nor monthly scans over six months were predictive of change in the EDSS in the subsequent 12 months or 24 months. The mean of gadolinium-enhancing-lesion counts in the first six monthly scans was weakly predictive of EDSS change after 1 year (odds ratio=1.34, p=0.082) and 2 years (odds ratio=1.65, p=0.049). Interpretation Although disturbance of the blood-brain barrier as shown by gadolinium enhancement in MRI is a predictor of the occurrence of relapses, it is not a strong predictor of the development of cumulative impairment or disability. This discrepancy supports the idea that variant pathogenetic mechanisms are operative in the occurrence of relapses and in the development of long-term disability in MS.	Kantonsspital, Dept Neurol, CH-4031 Basel, Switzerland; Kantonsspital, Dept Neuroradiol, CH-4031 Basel, Switzerland; Free Univ Amsterdam, Dept Diagnost Radiol, Amsterdam, Netherlands; Inst Neurol, NMR Res Unit, London WC1N 3BG, England; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Univ Rome La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, S Camillo Hosp, Rome, Italy; Univ Milan, Sci Inst Osped San Raffaele, Dept Neurol, I-20122 Milan, Italy	Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; Vrije Universiteit Amsterdam; University of London; University College London; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Sapienza University Rome; Sapienza University Rome; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Kappos, L (corresponding author), Kantonsspital, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland.	Kappos@ubaclu.unibas.ch	Guttmann, Charles RG/J-3093-2018; Barkhof, Frederik/AAJ-6226-2020; Filippi, Massimo/K-1755-2018; gasperini, claudio/K-5093-2016	Barkhof, Frederik/0000-0003-3543-3706; Filippi, Massimo/0000-0002-5485-0479; Guttmann, Charles/0000-0002-7006-9762; gasperini, claudio/0000-0002-3959-4067	Multiple Sclerosis Society [491] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Barkhof F, 1997, J NEUROL, V244, P76, DOI 10.1007/s004150050053; BARKHOF F, 1992, AM J ROENTGENOL, V159, P1041, DOI 10.2214/ajr.159.5.1414773; Bruck W, 1997, ANN NEUROL, V42, P783, DOI 10.1002/ana.410420515; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; FILIPPI M, 1995, NEUROLOGY, V45, P255, DOI 10.1212/WNL.45.2.255; Filippi M, 1997, AM J NEURORADIOL, V18, P1549; GROSSMAN RI, 1986, RADIOLOGY, V161, P721, DOI 10.1148/radiology.161.3.3786722; Hohol Marika, 1997, Neurology, V48, pA174; KAPPOS L, 1988, NEURORADIOLOGY, V30, P299, DOI 10.1007/BF00328179; KAPPOS L, 1987, NEUROSURG REV, V10, P133, DOI 10.1007/BF01741450; Kappos L., 1996, Neurology, V46, pA410; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; KHOURY SJ, 1994, NEUROLOGY, V44, P2120, DOI 10.1212/WNL.44.11.2120; Kidd D, 1996, J NEUROL NEUROSUR PS, V60, P15, DOI 10.1136/jnnp.60.1.15; Koudriatseva T, 1997, J NEUROSURG PSYCHIAT, V67, P285; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Losseff N A, 1996, Mult Scler, V1, P218; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MCCULLAGH P, 1989, MONOGRAPHS STAT APPL, V37, P48; MILLER DH, 1993, BRAIN, V116, P1077, DOI 10.1093/brain/116.5.1077; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; Miller DH, 1998, BRAIN, V121, P3, DOI 10.1093/brain/121.1.3; Molyneux PD, 1998, ANN NEUROL, V43, P332, DOI 10.1002/ana.410430311; NOSEWORTHY JH, 1994, ANN NEUROL, V36, pS80, DOI 10.1002/ana.410360718; O'Riordan JI, 1998, BRAIN, V121, P495, DOI 10.1093/brain/121.3.495; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Pozzilli C, 1996, J NEUROL NEUROSUR PS, V61, P251, DOI 10.1136/jnnp.61.3.251; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114; SMITH ME, 1993, ANN NEUROL, V33, P480, DOI 10.1002/ana.410330511; Thorpe JW, 1996, NEUROLOGY, V46, P373, DOI 10.1212/WNL.46.2.373; Truyen L, 1997, Mult Scler, V2, P283; Truyen L, 1996, NEUROLOGY, V47, P1469, DOI 10.1212/WNL.47.6.1469; vanOosten BW, 1997, NEUROLOGY, V49, P351, DOI 10.1212/WNL.49.2.351; WEINSHENKER BG, 1995, NEUROL CLIN, V13, P119, DOI 10.1016/S0733-8619(18)30064-1; Weinshenker BG, 1996, NEUROLOGY, V46, P1613, DOI 10.1212/WNL.46.6.1613; Whitaker J N, 1995, Mult Scler, V1, P37	36	379	388	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					964	969		10.1016/S0140-6736(98)03053-0	http://dx.doi.org/10.1016/S0140-6736(98)03053-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459905				2022-12-28	WOS:000079421600011
J	Pitt, B; Zannad, F; Remme, WJ; Cody, R; Castaigne, A; Perez, A; Palensky, J; Wittes, J				Pitt, B; Zannad, F; Remme, WJ; Cody, R; Castaigne, A; Perez, A; Palensky, J; Wittes, J		Randomized Aldactone Evaluation Study Investiga	The effect of spironolactone on morbidity and mortality in patients with severe heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIOTENSIN-ALDOSTERONE SYSTEM; CONVERTING ENZYME-INHIBITOR; CLINICAL-TRIALS; ACE-INHIBITORS; BLOCKADE; THERAPY; HYPERTENSION; SECONDARY; POTASSIUM; EFFICACY	Background and Methods Aldosterone is important in the pathophysiology of heart failure, In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an a agiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. Results The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious, There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001). In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients. Conclusions Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. (N Engl J Med 1999:341:709-17.) (C)1999, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA; Clin Nancy, Ctr Invest, Nancy, France; Cardiovasc Res Fdn, STICARES, Rotterdam, Netherlands; Hop Henri Mondor, Serv Cardiol, F-94010 Creteil, France; Searle, Global Med Operat, Skokie, IL USA; Stat Collaborat, Washington, DC USA	University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Pitt, B (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, 3910 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.		ALMEIDA, FERNANDO/S-1880-2019; Zannad, Faiez/K-4649-2019; Arnold, Malcolm/G-2869-2011	ALMEIDA, FERNANDO/0000-0002-9404-9707; MELCHOR, LORENZO/0000-0002-8685-268X				BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BIOLLAZ J, 1982, J CARDIOVASC PHARM, V4, P966, DOI 10.1097/00005344-198211000-00014; BORGHI C, 1993, J CLIN PHARMACOL, V33, P40, DOI 10.1002/j.1552-4604.1993.tb03901.x; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; BRILLA CG, 1993, AM J CARDIOL, V71, pA12, DOI 10.1016/0002-9149(93)90239-9; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; CLELAND JGF, 1984, BRIT HEART J, V52, P530; Cleland JGF, 1998, LANCET, V352, P19; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; COX DR, 1972, J R STAT SOC B, V34, P187; DEGASPARO M, 1987, J PHARMACOL EXP THER, V240, P650; Duprez DA, 1998, EUR HEART J, V19, P1371, DOI 10.1053/euhj.1998.1099; DZAU VJ, 1981, CIRCULATION, V63, P645, DOI 10.1161/01.CIR.63.3.645; HAJNOCZKY G, 1991, ENDOCRINOLOGY, V128, P2639, DOI 10.1210/endo-128-5-2639; Hobbs RE, 1998, CLEV CLIN J MED, V65, P539, DOI 10.3949/ccjm.65.10.539; JEUNEMAITRE X, 1987, AM J CARDIOL, V60, P820, DOI 10.1016/0002-9149(87)91030-7; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLUG D, 1993, AM J CARDIOL, V71, pA46, DOI 10.1016/0002-9149(93)90245-8; LAKATOS E, 1988, BIOMETRICS, V44, P229, DOI 10.2307/2531910; LAKATOS E, 1988, BIOMETRICS, V44, P923; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lechat P, 1999, LANCET, V353, P9; MacFadyen RJ, 1997, CARDIOVASC RES, V35, P30, DOI 10.1016/S0008-6363(97)00091-6; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; *MED EC, 1998, PHYS DESK REF, P784; *MED EC, 1998, PHYS DESK REF, P1771; *MED EC, 1998, PHYS DESK REF, P2928; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Okubo S, 1997, J CLIN INVEST, V99, P855, DOI 10.1172/JCI119249; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Perry G, 1997, NEW ENGL J MED, V336, P525; Pitt B, 1996, AM J CARDIOL, V78, P902; PITT B, 1995, CARDIOVASC DRUG THER, V9, P145, DOI 10.1007/BF00877755; Rocha R, 1998, HYPERTENSION, V31, P451, DOI 10.1161/01.HYP.31.1.451; STAESSEN J, 1981, J ENDOCRINOL, V91, P457, DOI 10.1677/joe.0.0910457; Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; Szalay KS, 1998, LIFE SCI, V62, P1845, DOI 10.1016/S0024-3205(98)00150-7; WANG W, 1994, HYPERTENSION, V24, P571, DOI 10.1161/01.HYP.24.5.571; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZANNAD F, 1993, AM J CARDIOL, V71, pA34, DOI 10.1016/0002-9149(93)90243-6	45	6186	6487	9	256	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					709	717		10.1056/NEJM199909023411001	http://dx.doi.org/10.1056/NEJM199909023411001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471456				2022-12-28	WOS:000082291900001
J	Borch-Johnsen, K; Neil, A; Balkau, B; Larsen, S; Borch-Johnsen, K; Nissinen, A; Pekkanen, J; Tuomilehto, J; Keinanen-Kiukaanniemi, S; Hiltunen, L; Kivela, SL; Tuomilehto, J; Jousilahti, P; Lindstrom, J; Pyorala, M; Pyorala, K; Balkau, B; Eschwege, E; Gallus, G; Garancini, MP; Schranz, A; Heine, RJ; Dekker, JM; Feskens, E; Lithell, H; Zethelius, B; Peltonen, M; Unwin, N; Ahmad, N; Alberti, KGMM; Alberti, MM; Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Qiao, Q; Balkau, B; Tuomilehto, J; Qiao, Q; Borch-Johnsen, K; Balkau, B				Borch-Johnsen, K; Neil, A; Balkau, B; Larsen, S; Borch-Johnsen, K; Nissinen, A; Pekkanen, J; Tuomilehto, J; Keinanen-Kiukaanniemi, S; Hiltunen, L; Kivela, SL; Tuomilehto, J; Jousilahti, P; Lindstrom, J; Pyorala, M; Pyorala, K; Balkau, B; Eschwege, E; Gallus, G; Garancini, MP; Schranz, A; Heine, RJ; Dekker, JM; Feskens, E; Lithell, H; Zethelius, B; Peltonen, M; Unwin, N; Ahmad, N; Alberti, KGMM; Alberti, MM; Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Qiao, Q; Balkau, B; Tuomilehto, J; Qiao, Q; Borch-Johnsen, K; Balkau, B		DECODE Study Grp; European Diabet Epidemiology Grp	Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria	LANCET			English	Article							CORONARY HEART-DISEASE; FASTING BLOOD-GLUCOSE; RISK FACTOR; FOLLOW-UP; ASYMPTOMATIC HYPERGLYCEMIA; CARDIOVASCULAR-DISEASES; HELSINKI POLICEMEN; MEN BORN; POPULATION; STROKE	Background The American Diabetes Association (ADA) recommend that fasting glucose alone with the oral glucose tolerance test should be used to diagnose diabetes mellitus. We assessed mortality associated with the ADA fasting-glucose criteria compared with the WHO 2 h post-challenge glucose criteria. Methods We assessed baseline data on glucose concentrations at fasting and 2 h after the 75 g oral glucose tolerance test from 13 prospective European cohort studies, which included 18 048 men and 7316 women aged 30 years or older. Mean follow-up was 7.3 years. We assessed the risk of death according to the different diagnostic glucose categories. Findings Compared with men who had normal fasting glucose (<6.1 mmol/L), men with newly diagnosed diabetes mellitus by the ADA fasting criteria(greater than or equal to 7.0 mmol/L) had a hazard ratio for death of 1.81 (95% Cl 1.49-2.20); for women the hazard ratio was 1.79 (1.18-2.69). For impaired fasting glucose (6.1-6.9 mmol/L), the hazard ratios were 1.21 (1.05-1.41) and 1.08 (0.70-1.66). For the WHO criteria (greater than or equal to 11.1 mmol/L), the ratios for newly diagnosed diabetes were 2.02 (1.66-2.46) in men and 2.77 (1.96-3.92) in women, and for impaired glucose tolerance (7.8-11.1 mmol/L) were 1.51 (1.32-1.72) and 1.60 (1.22-2.10). Within each fasting-glucose classification, mortality increased with increasing 2 h glucose. However, for 2 h glucose classifications of impaired glucose tolerance, and diabetes, there was no trend for increasing fasting glucose concentrations. Interpretation Fasting-glucose concentrations alone do not identify individuals at increased risk of death associated with hyperglycaemia. The oral glucose tolerance test provides additional prognostic information and enables detection of individuals with impaired glucose tolerance, who have the greatest attributable risk of death.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Tuomilehto, J (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Mannerheimintie 16, FIN-00300 Helsinki, Finland.	jaakko.tuomilehto@ktl.fi	Peltonen, Markku/F-3037-2015; Feskens, Edith JM/A-3757-2012; Feskens, Edith/ABI-1446-2020	Peltonen, Markku/0000-0002-3767-4223; Feskens, Edith/0000-0001-5819-2488; Eriksson, Johan/0000-0002-2516-2060				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; CRUZVIDAL M, 1983, DIABETES CARE, V6, P556, DOI 10.2337/diacare.6.6.556; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FESKENS EJM, 1992, J CLIN EPIDEMIOL, V45, P1327, DOI 10.1016/0895-4356(92)90173-K; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; OHLSON LO, 1986, DIABETIC MED, V3, P33, DOI 10.1111/j.1464-5491.1986.tb00702.x; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PYORALA K, 1979, J CHRON DIS, V32, P729, DOI 10.1016/0021-9681(79)90052-3; REUNANEN A, 1979, J CHRON DIS, V32, P747, DOI 10.1016/0021-9681(79)90053-5; SCHEIDTNAVE C, 1991, AM J EPIDEMIOL, V133, P565, DOI 10.1093/oxfordjournals.aje.a115928; SCHROLL M, 1979, J CHRON DIS, V32, P699, DOI 10.1016/0021-9681(79)90049-3; STAMLER R, 1979, J CHRON DIS, V32, P805, DOI 10.1016/0021-9681(79)90060-2; STEGMAYR B, 1995, DIABETOLOGIA, V38, P1061, DOI 10.1007/BF00402176; TUOMILEHTO J, 1994, DIABETIC MED, V11, P170, DOI 10.1111/j.1464-5491.1994.tb02015.x; VACCARO O, 1992, DIABETES CARE, V15, P1328, DOI 10.2337/diacare.15.10.1328; VALLE T, 1997, INT TXB DIABETES MEL, P125; WEI M, 1998, CVD PREV, V1, P123; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; *WHO EXP COMM, 1980, WHO TECHN REP SER, V646; *WHO STUD GROUP, 1985, WHO TECHN REP SER, V727; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; YANO K, 1982, AM J MED, V72, P71, DOI 10.1016/0002-9343(82)90580-0; YARNELL JWG, 1994, J CLIN EPIDEMIOL, V47, P383, DOI 10.1016/0895-4356(94)90159-7	30	1384	1471	0	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					617	621						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466661				2022-12-28	WOS:000082214500008
J	Plaisance, P; Lurie, KG; Vicaut, E; Adnet, F; Petit, JL; Epain, D; Ecollan, P; Gruat, R; Cavagna, P; Biens, J; Payen, D				Plaisance, P; Lurie, KG; Vicaut, E; Adnet, F; Petit, JL; Epain, D; Ecollan, P; Gruat, R; Cavagna, P; Biens, J; Payen, D		French Active Compression-Decompression Card	A comparison of standard cardiopulmonary resuscitation and active compression-decompression resuscitation for out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR-FIBRILLATION; CPR; INSTRUCTOR; SURVIVAL; STUDENT; SYSTEM; TRIAL; MODEL	Background We previously observed that shortterm survival after out-of-hospital cardiac arrest was greater with active compression-decompression cardiopulmonary resuscitation (CPR) than with standard CPR. In the current study, we assessed the effects of the active compression-decompression method on one-year survival. Methods Patients who had cardiac arrest in the Paris metropolitan area or in Thionville, France, more than 80 percent of whom had asystole, were assigned to receive either standard CPR (377 patients) or active compression-decompression CPR (373 patients) according to whether their arrest occurred on an even or odd day of the month, respectively. The primary end point was survival at one year. The rate of survival to hospital discharge without neurologic impairment and the neurologic outcome were secondary end points. Results Both the rate of hospital discharge without neurologic impairment (6 percent vs. 2 percent, P = 0.01) and the one-year survival rate (5 percent vs. 2 percent, P = 0.03) were significantly higher among patients who received active compression-decompression CPR than among those who received stand ard CPR. AII patients who survived to one year had cardiac arrests that were witnessed. Nine of 17 one-year survivors in the active compression-decompression group and 2 of 7 in the standard group, respectively, initially had asystole or pulseless electrical activity. In 12 of the 17 survivors who had received active compression-decompression CPR, neurologic status returned to base line, as compared with 3 of 7 survivors who had received standard CPR (P = 0.34). Conclusions Active compression-decompression CPR performed during advanced life support significantly improved long-term survival rates among patients who had cardiac arrest outside the hospital. (N Engl J Med 1999;341:569-75.) (C)1999, Massachusetts Medical Society.	Lariboisiere Univ Hosp, Dept Anesthesiol & Crit Care, F-75475 Paris 10, France; Lariboisiere Univ Hosp, Serv Mobile Urgence & Reanimat, F-75475 Paris, France; Univ Minnesota, Cardiac Arrhythmia Ctr, Minneapolis, MN USA; Fernand Widal Hosp, Biophys Lab, Paris, France; Thionville Hosp, SMUR 57, Thionville, France; Lagny Hosp, Serv Aide Med Urgente, SMUR, SAMU 77, Lagny, France; La Pitie Salpetriere Univ Hosp, SMUR, Paris, France; La Pitie Salpetriere Univ Hosp, Dept Anesthesiol & Crit Care, SAMU 75, Paris, France; Pontoise Hosp, SMUR, SAMU 95, Pontoise, France; Montfermeil Hosp, SMUR, SAMU 93, Montfermeil, France; Aulnay Bois Hosp, SMUR, SAMU 93, Aulnay Sous Bois, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Minnesota System; University of Minnesota Twin Cities; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier Rene Dubos, Pontoise	Plaisance, P (corresponding author), Lariboisiere Univ Hosp, Dept Anesthesiol & Crit Care, 2 Rue Ambroise Pare, F-75475 Paris 10, France.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; CARLI PA, 1993, TXB TRAUMA ANESTHESI, P199; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2184; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; JANNIERE D, 1993, J EUR URGENCES, V6, P76; KIMMAN GP, 1994, RESUSCITATION, V28, P227, DOI 10.1016/0300-9572(94)90068-X; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; Luiz T, 1996, J CARDIOTHOR VASC AN, V10, P178, DOI 10.1016/S1053-0770(96)80234-5; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; Mauer D, 1996, RESUSCITATION, V33, P125, DOI 10.1016/S0300-9572(96)01006-4; MULLIE A, 1989, RESUSCITATION, V17, pS23, DOI 10.1016/0300-9572(89)90088-9; Nolan J, 1998, RESUSCITATION, V37, P119, DOI 10.1016/S0300-9572(98)00045-8; Panzer W, 1996, RESUSCITATION, V33, P117, DOI 10.1016/S0300-9572(96)01021-0; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; Plaisance P, 1997, CIRCULATION, V95, P955; Schneider T, 1996, RESUSCITATION, V32, P203, DOI 10.1016/0300-9572(96)00946-X; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHULTZ JJ, 1995, RESUSCITATION, V29, P23, DOI 10.1016/0300-9572(94)00812-T; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; SILFVAST T, 1990, AM J EMERG MED, V8, P359, DOI 10.1016/0735-6757(90)90097-J; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; THEURY O, 1997, REV SAMU, V6, P211; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; Wik L, 1996, RESUSCITATION, V32, P206, DOI 10.1016/0300-9572(96)82051-X	28	123	129	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					569	575		10.1056/NEJM199908193410804	http://dx.doi.org/10.1056/NEJM199908193410804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451462				2022-12-28	WOS:000082061500004
J	Lehmann, ED				Lehmann, ED			Clinical value of aortic pulse-wave velocity measurement	LANCET			English	Editorial Material							ATHEROSCLEROSIS		St Bartholomews Hosp, Acad Dept Radiol, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Imaging, London, England	University of London; Queen Mary University London; Imperial College London	Lehmann, ED (corresponding author), St Bartholomews Hosp, Acad Dept Radiol, London EC1A 7BE, England.							Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Bramwell JC, 1922, LANCET, V1, P891; Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022; de Simone G, 1999, HYPERTENSION, V33, P800, DOI 10.1161/01.HYP.33.3.800; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOPKINS KD, 1994, LANCET, V343, P1447, DOI 10.1016/S0140-6736(94)92577-1; KAGAN AR, 1976, B WORLD HEALTH ORGAN, V53, P485; Lehmann ED, 1998, HYPERTENSION, V32, P565, DOI 10.1161/01.HYP.32.3.565; LEHMANN ED, 1997, RADIOLOGY S, V205, P500; LEHMANN ED, IN PRESS PATHOL BIOL; LEHMANN ED, 1997, LANCET S1, V350, P14; Mallick NP, 1999, LANCET, V353, P737, DOI 10.1016/S0140-6736(97)09411-7	12	180	192	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					528	529		10.1016/S0140-6736(99)00179-8	http://dx.doi.org/10.1016/S0140-6736(99)00179-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470691				2022-12-28	WOS:000081991000004
J	Lipkin, DP				Lipkin, DP			Sleep-disordered breathing in chronic stable heart failure	LANCET			English	Editorial Material							CHEYNE-STOKES RESPIRATION; SYMPATHETIC ACTIVITY; APNEA		Royal Free Hosp, Dept Cardiol, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lipkin, DP (corresponding author), Royal Free Hosp, Dept Cardiol, London NW3 2PF, England.							ANCOLIISRAEL S, 1994, CHEST, V106, P780, DOI 10.1378/chest.106.3.780; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; Cheyne J, 1818, DUBLIN HOSP REP, V12, p[216, 317]; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; JAHAVERI S, 1995, ANN INTERN MED, V122, P487; KAVERI S, 1995, ANN INTERN MED, V122, P487; Lanfranchi PA, 1999, CIRCULATION, V99, P1435, DOI 10.1161/01.CIR.99.11.1435; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; Staniforth AD, 1998, EUR HEART J, V19, P922, DOI 10.1053/euhj.1997.0861; Staniforth AD, 1998, HEART, V79, P394, DOI 10.1136/hrt.79.4.394; STOKES W, 1854, DIS HEART AORTA, P302; Tkacova R, 1997, J AM COLL CARDIOL, V30, P739, DOI 10.1016/S0735-1097(97)00199-X	13	13	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					531	532		10.1016/S0140-6736(99)00138-5	http://dx.doi.org/10.1016/S0140-6736(99)00138-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470694				2022-12-28	WOS:000081991000007
J	Giancotti, FG; Ruoslahti, E				Giancotti, FG; Ruoslahti, E			Transduction - Integrin signaling	SCIENCE			English	Review							FOCAL ADHESION KINASE; CELL-CYCLE PROGRESSION; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR PTEN; PHOSPHOINOSITIDE 3-OH KINASE; TYROSINE-PHOSPHATASE 1B; HUMAN ENDOTHELIAL-CELLS; MAP KINASE; EXTRACELLULAR-MATRIX; GROWTH-FACTOR	Cells reside in a protein network, the extracellular matrix (ECM), which they secrete and mold into the intercellular space. The ECM exerts profound control over cells. The effects of the matrix are primarily mediated by integrins, a family of cell surface receptors that attach cells to the matrix and mediate mechanical and chemical signals from it. These signals regulate the activities of cytoplasmic kinases, growth factor receptors, and ion channels and control the organization of the intracellular actin cytoskeleton. Many integrin signals converge on cell cycle regulation, directing cells to live or die, to proliferate, or to exit the cell cycle and differentiate.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Burnham Inst, Ctr Canc Res, La Jolla, CA 92027 USA	Memorial Sloan Kettering Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	f-giancotti@ski.mskcc.org; ruoslahti@burnham.inst.org						ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CYBULSKY AV, 1994, J CLIN INVEST, V94, P68, DOI 10.1172/JCI117350; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pozzi M, 1998, J CELL BIOL, V142, P587; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Woodard AS, 1998, J CELL SCI, V111, P469; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	128	3607	3772	15	523	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1028	1032		10.1126/science.285.5430.1028	http://dx.doi.org/10.1126/science.285.5430.1028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446041				2022-12-28	WOS:000082033100034
J	Udey, MC; Stanley, JR				Udey, MC; Stanley, JR			Pemphigus - Diseases of antidesmosomal autoimmunity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARANEOPLASTIC PEMPHIGUS; VULGARIS ANTIGEN; FOGO-SELVAGEM; PATHOGENIC AUTOANTIBODIES; PASSIVE TRANSFER; NEONATAL MICE; FOLIACEUS; SUSCEPTIBILITY; BACULOVIRUS; ANTIBODIES		NCI, Dermatol Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania	Udey, MC (corresponding author), NCI, Dermatol Branch, Div Clin Sci, NIH, Bldg 10,Room 12B238, Bethesda, MD 20892 USA.							AMAGAI M, 1995, J INVEST DERMATOL, V104, P895, DOI 10.1111/1523-1747.ep12606168; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Amagai M, 1996, Adv Dermatol, V11, P319; Anhalt G J, 1997, Adv Dermatol, V12, P77; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Bystryn JC, 1996, ARCH DERMATOL, V132, P203, DOI 10.1001/archderm.132.2.203; Chowdhury MMU, 1998, BRIT J DERMATOL, V139, P500; COHEN PL, 1999, FUNDAMENTAL IMMUNOLO, P1067; Ding X, 1997, J INVEST DERMATOL, V109, P592, DOI 10.1111/1523-1747.ep12337524; Eaton DP, 1998, J MED ENTOMOL, V35, P120, DOI 10.1093/jmedent/35.2.120; Enk AH, 1999, ARCH DERMATOL, V135, P54, DOI 10.1001/archderm.135.1.54; HASHIMOTO K, 1983, J EXP MED, V157, P259, DOI 10.1084/jem.157.1.259; HUILGOL SC, 1995, CLIN EXP DERMATOL, V20, P283, DOI 10.1111/j.1365-2230.1995.tb01327.x; Ishii K, 1997, J IMMUNOL, V159, P2010; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Lin MS, 1997, J CLIN INVEST, V99, P31, DOI 10.1172/JCI119130; LIN MS, 1997, CLIN EXP IMMUNOL  S1, V107, pS9; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MARINKOVICH MP, 1999, DERMATOLOGY GEN MED, P690; Moraes ME, 1997, TISSUE ANTIGENS, V49, P35, DOI 10.1111/j.1399-0039.1997.tb02707.x; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; SAMPAIO SAP, 1994, DERMATOL CLIN, V12, P765, DOI 10.1016/S0733-8635(18)30140-2; SAMS WM, 1971, BRIT J DERMATOL, V84, P7; SCHLITZ JR, 1976, J INVEST DERMATOL, V67, P254; SHEVACH EM, 1999, FUNDAMENTAL IMMUNOLO, P1089; Stanley JR, 1999, ARCH DERMATOL, V135, P76, DOI 10.1001/archderm.135.1.76; STANLEY JR, 1999, DERMATOLOGY GEN MED, P654; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935	33	67	71	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					572	576		10.1001/jama.282.6.572	http://dx.doi.org/10.1001/jama.282.6.572			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450720				2022-12-28	WOS:000081919100032
J	Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE				Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE			Stat3 as an oncogene	CELL			English	Article							TRANSCRIPTIONALLY ACTIVE STAT1; EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; ACUTE-PHASE REACTION; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; INTERFERON-GAMMA; GENE-REGULATION	STATs are latent transcription factors that mediate cytokine- and growth factor-directed transcription. In many human cancers and transformed cell lines, Stat3 is persistently activated, and in cell culture, active Stat3 is either required for transformation, enhances transformation, or blocks apoptosis. We report that substitution of two cysteine residues within the C-terminal loop of the SH2 domain of Stat3 produces a molecule that dimerizes spontaneously, binds to DNA, and activates transcription. The Stat3-C molecule in immortalized fibroblasts causes cellular transformation scored by colony formation in soft agar and tumor formation in nude mice. Thus, the activated Stat3 molecule by itself can mediate cellular transformation and the experiments focus attention on the importance of constitutive Stat3 activation in human tumors.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Rockefeller University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.			Zhao, Yanxiang/0000-0002-9408-9979	NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA70897, R01CA75503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; Besser D, 1999, MOL CELL BIOL, V19, P1401; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cory S, 1999, CANCER RES, V59, p1685S; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heinrich PC, 1998, Z ERNAHRUNGSWISS, V37, P43; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LODISH H, 1995, MOL CELL BIOL, P1247; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weber-Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	49	2410	2593	3	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					295	303		10.1016/S0092-8674(00)81959-5	http://dx.doi.org/10.1016/S0092-8674(00)81959-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458605	Bronze			2022-12-28	WOS:000081950300005
J	Kramer, AF; Hahn, S; Cohen, NJ; Banich, MT; McAuley, E; Harrison, CR; Chason, J; Vakil, E; Bardell, L; Boileau, RA; Colcombe, A				Kramer, AF; Hahn, S; Cohen, NJ; Banich, MT; McAuley, E; Harrison, CR; Chason, J; Vakil, E; Bardell, L; Boileau, RA; Colcombe, A			Ageing, fitness and neurocognitive function	NATURE			English	Letter							PREFRONTAL CORTEX; BRAIN		Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel	University of Illinois System; University of Illinois Urbana-Champaign; Bar Ilan University	Kramer, AF (corresponding author), Univ Illinois, Beckman Inst, 405 N Mathews Ave, Urbana, IL 61801 USA.		McAuley, Edward/A-9508-2008; Kramer, Arthur/AAB-2937-2019	McAuley, Edward/0000-0002-4574-3292; Kramer, Arthur/0000-0001-5870-2724; BANICH, MARIE/0000-0001-9373-9194; Colcombe, Stan/0000-0001-5051-2491				AZARI NP, 1992, BRAIN RES, V589, P279, DOI 10.1016/0006-8993(92)91288-P; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; COFFEY CE, 1992, NEUROLOGY, V42, P527, DOI 10.1212/WNL.42.3.527; Dustman R. E., 1994, Journal of Aging and Physical Activity, V2, P143; Hanes DP, 1998, J NEUROPHYSIOL, V79, P817, DOI 10.1152/jn.1998.79.2.817; KRAMER AF, 1999, ATTENTION PERFORMANC, V17; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Rafal R, 1996, NEUROPSYCHOLOGIA, V34, P1197, DOI 10.1016/0028-3932(96)00045-0; Rogers RD, 1998, BRAIN, V121, P815, DOI 10.1093/brain/121.5.815; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272	10	943	967	1	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					418	419		10.1038/22682	http://dx.doi.org/10.1038/22682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440369				2022-12-28	WOS:000081715000035
J	Gleissberg, V				Gleissberg, V			The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?	LANCET			English	Article									Newham Healthcare NHS Trust, Shrrewsbury Ctr, London E7, England		Gleissberg, V (corresponding author), Newham Healthcare NHS Trust, Shrrewsbury Ctr, Shrewsbury Rd, London E7, England.	ginig@ibm.net						BENNETT DE, 1996, THORAX S3, V51, pSA32; Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3; *DEP HLTH NT WORK, 1996, PREV CONTR TUB UK RE; FARMER F, 1998, BRIT MED J, V317, P671; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAYWARD A, 1998, TUBERCULOSIS CONTROL; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; Snider DE, 1998, NEW ENGL J MED, V338, P1689, DOI 10.1056/NEJM199806043382309; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; WHO, 1997, TREATM TUB GUID NAT, V2; *WHO, 1997, ANT DRUG RES WORLD W	12	14	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					998	999		10.1016/S0140-6736(99)01439-7	http://dx.doi.org/10.1016/S0140-6736(99)01439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459924				2022-12-28	WOS:000079421600045
J	Rao, J; Ramaiah, S				Rao, J; Ramaiah, S			Diversity to divinity	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					629	629		10.1136/bmj.319.7210.629	http://dx.doi.org/10.1136/bmj.319.7210.629			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473484	Green Published			2022-12-28	WOS:000082460300029
J	McElwain, JC; Beerling, DJ; Woodward, FI				McElwain, JC; Beerling, DJ; Woodward, FI			Fossil plants and global warming at the Triassic-Jurassic boundary	SCIENCE			English	Article							KAP STEWART FORMATION; SEA-LEVEL CHANGE; STOMATAL DENSITY; ENVIRONMENTAL-CHANGE; ATMOSPHERIC CO2; CARBON-DIOXIDE; EAST GREENLAND; RECORD; EXTINCTION; PALYNOLOGY	The Triassic-Jurassic boundary marks a major faunal mass extinction, but records of accompanying environmental changes are Limited. Paleobotanical evidence indicates a fourfold increase in atmospheric carbon dioxide concentration and suggests an associated 3 degrees to 4 degrees C "greenhouse" warming across the boundary. These environmental conditions are calculated to have raised leaf temperatures above a highly conserved Lethal Limit, perhaps contributing to the >95 percent species-level turnover of Triassic-Jurassic megaflora.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	McElwain, JC (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.		Woodward, Ian F/B-7762-2008; McElwain, Jennifer/B-1735-2009; Beerling, David J/C-2840-2009; Woodward, Frank Ian/P-4530-2019; McElwain, Jennifer/AAX-1605-2020	McElwain, Jennifer/0000-0002-1729-6755; Beerling, David J/0000-0003-1869-4314; 				[Anonymous], 1937, MEDDELELSER GRONLAND; Barrera E, 1997, GEOLOGY, V25, P715, DOI 10.1130/0091-7613(1997)025<0715:EFTCRC>2.3.CO;2; Beerling DJ, 1997, BOT J LINN SOC, V124, P137, DOI 10.1006/bojl.1997.0098; BEERLING DJ, 1993, P ROY SOC B-BIOL SCI, V251, P133, DOI 10.1098/rspb.1993.0019; BEERLING DJ, 1993, ANN BOT-LONDON, V71, P431, DOI 10.1006/anbo.1993.1056; BEERLING DJ, 1995, GLOB CHANGE BIOL, V1, P289, DOI 10.1111/j.1365-2486.1995.tb00027.x; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Berner RA, 1997, SCIENCE, V276, P544, DOI 10.1126/science.276.5312.544; CALDEIRA K, 1991, GEOPHYS RES LETT, V18, P987, DOI 10.1029/91GL01237; Colbert E.H., 1986, P49; DAM G, 1992, GEOLOGY, V20, P749, DOI 10.1130/0091-7613(1992)020<0749:FRIALW>2.3.CO;2; DAM G, 1993, SPEC PUBL INT ASS SE, V18, P4189; Fowell S.J., 1994, GEOLOGICAL SOC AM SP, V288, P197, DOI [DOI 10.1130/SPE288-P197, 10.1130/SPE288-p197]; GAUSLAA Y, 1984, HOLARCTIC ECOL, V7, P1; GRANDSTEIN FM, 1994, J GEOPHYS RES, V99, P24051; GUYOHLSON D, 1981, GEOL FOREN STOCK FOR, V103, P233, DOI 10.1080/11035898109454520; Hallam A., 1995, Historical Biology, V10, P247; Hallam A, 1997, J GEOL SOC LONDON, V154, P773, DOI 10.1144/gsjgs.154.5.0773; HALLAM A, 1997, MASS EXTINCTIONS THE; KIMURA T, 1983, Bulletin of the National Science Museum Series C (Geology and Paleontology), V9, P91; Kothavala Z, 1999, GEOPHYS RES LETT, V26, P209, DOI 10.1029/1998GL900275; Larcher W., 1994, ECOPHYSIOLOGY PHOTOS, P261; LUNDBLAD ANNA BIRGITTA, 1959, K SVENSKA VETENSKAPSAKAD HANDL, V6, P1; MANSFIELD TA, 1990, ANNU REV PLANT PHYS, V41, P55, DOI 10.1146/annurev.pp.41.060190.000415; Marzoli A, 1999, SCIENCE, V284, P616, DOI 10.1126/science.284.5414.616; McElwain JC, 1996, PALAIOS, V11, P376, DOI 10.2307/3515247; MCELWAIN JC, 1995, ANN BOT-LONDON, V76, P389, DOI 10.1006/anbo.1995.1112; McElwain JC, 1998, PHILOS T R SOC B, V353, P83, DOI 10.1098/rstb.1998.0193; McRoberts CA, 1997, PALAEOGEOGR PALAEOCL, V136, P79, DOI 10.1016/S0031-0182(97)00074-6; Morante R, 1996, GEOLOGY, V24, P391, DOI 10.1130/0091-7613(1996)024<0391:OCIRAT>2.3.CO;2; PEDERSEN KR, 1980, REV PALAEOBOT PALYNO, V31, P1; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; SARMIENTO JL, 1984, NATURE, V308, P621, DOI 10.1038/308621a0; SCHUURMAN WML, 1977, REV PALAEOBOT PALYNO, V23, P159, DOI 10.1016/0034-6667(77)90007-0; VANDERBURGH J, 1993, SCIENCE, V260, P1788, DOI 10.1126/science.260.5115.1788; VANDEWATER PK, 1994, SCIENCE, V264, P239, DOI 10.1126/science.264.5156.239; VISSCHER H, 1981, REV PALAEOBOT PALYNO, V34, P115, DOI 10.1016/0034-6667(81)90069-5; WILSON KM, 1994, GEOL SOC AM SPEC PAP, V288, P91; WOODWARD FI, 1987, NATURE, V327, P617, DOI 10.1038/327617a0; WOODWARD FI, 1988, J EXP BOT, V39, P1771, DOI 10.1093/jxb/39.12.1771; Yapp CJ, 1996, EARTH PLANET SC LETT, V137, P71, DOI 10.1016/0012-821X(95)00213-V	41	464	495	2	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1386	1390		10.1126/science.285.5432.1386	http://dx.doi.org/10.1126/science.285.5432.1386			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464094				2022-12-28	WOS:000082233500038
J	Alevizaki, M; Papamichael, C; Koutras, DA; Stamatelopoulos, SF				Alevizaki, M; Papamichael, C; Koutras, DA; Stamatelopoulos, SF			One swollen hand	LANCET			English	Article							PRETIBIAL MYXEDEMA; DISEASE		Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11528, Greece	Alexandra Hospital; Athens Medical School; National & Kapodistrian University of Athens	Alevizaki, M (corresponding author), Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, 80 Vass Sofias Ave, Athens 11528, Greece.							FATOURECHI V, 1994, MEDICINE, V73, P1; FATOURECHI V, 1996, WERNER INGBARS THYRO, P553; LYNCH PJ, 1973, ARCH DERMATOL, V107, P107, DOI 10.1001/archderm.107.1.107; SALVI M, 1994, EUR J ENDOCRINOL, V131, P113, DOI 10.1530/eje.0.1310113; WORTSMAN J, 1981, ARCH DERMATOL, V117, P635, DOI 10.1001/archderm.117.10.635	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					644	644						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466667				2022-12-28	WOS:000082214500014
J	Dobson, R				Dobson, R			Global health gap widens says World Bank	BRITISH MEDICAL JOURNAL			English	News Item																		Gwatkin DR, 1999, LANCET, V354, P586, DOI 10.1016/S0140-6736(99)02108-X	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					470	470		10.1136/bmj.319.7208.470	http://dx.doi.org/10.1136/bmj.319.7208.470			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454395	Green Published			2022-12-28	WOS:000082199600012
J	Haucke, V; De Camilli, P				Haucke, V; De Camilli, P			AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs	SCIENCE			English	Article							COATED VESICLE FORMATION; SORTING SIGNALS; SYNAPTIC VESICLES; RECEPTOR; MEMBRANE; PROTEINS; BINDING; DOMAIN; COMPLEXES; LIPOSOMES	Clathrin-mediated endocytosis is initiated by the recruitment of the clathrin adaptor protein AP-2 to the plasma membrane where the membrane protein synaptotagmin is thought to act as a docking site. AP-2 also interacts with endocytic motifs present in other cargo proteins. Peptides with a tyrosine-based endocytic motif stimulated binding of AP-2 to synaptotagmin and enhanced AP-2 recruitment to the plasma membrane of neuronal and non-neuronal cells. This suggests a mechanism by which nucleation of clathrin-coated pits is stimulated by the loading of cargo proteins.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36252] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R41NS036252, R42NS036252] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P1651; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	145	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1268	1271		10.1126/science.285.5431.1268	http://dx.doi.org/10.1126/science.285.5431.1268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455054				2022-12-28	WOS:000082130200044
J	Ioffe, LB; Millis, AJ				Ioffe, LB; Millis, AJ			Superconductivity and the c axis spectral weight of high-T-c superconductors	SCIENCE			English	Article							PHASE FLUCTUATIONS; CHARGE DYNAMICS; NORMAL-STATE; PSEUDOGAP; CONDUCTIVITY; MODEL; GAP; BI2SR2CACU2O8+DELTA; YBA2CU3O6+X; DEPENDENCE	The temperature dependence of the c axis spectral weight (frequency integral of the interplane conductivity) of high transition temperature (high-T-c) superconductors is shown to be a probe of thermal and quantal fluctuations of the phase of the superconducting order parameter. The behavior of underdoped cuprates is shown to be a natural consequence of superconducting pairing without long-ranged phase coherence. Very underdoped cuprates are found to have strong phase fluctuations, even for temperatures much less than the transition temperature.	Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Ioffe, LB (corresponding author), Rutgers State Univ, Dept Phys & Astron, POB 849, Piscataway, NJ 08854 USA.	ioffe@physics.rutgers.edu; millis@physics.rutgers.edu						Abrikosov AA, 1996, PHYS REV B, V54, P12003, DOI 10.1103/PhysRevB.54.12003; ANDERSEN OK, 1994, PHYS REV B, V49, P4145, DOI 10.1103/PhysRevB.49.4145; Andersen OK, 1995, J PHYS CHEM SOLIDS, V56, P1573, DOI 10.1016/0022-3697(95)00269-3; Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; BASOV DN, 1994, PHYS REV B, V50, P3511, DOI 10.1103/PhysRevB.50.3511; Basov DN, 1999, SCIENCE, V283, P49, DOI 10.1126/science.283.5398.49; Chakravarty S, 1998, EUR PHYS J B, V5, P337, DOI 10.1007/s100510050451; Chakravarty S, 1999, PHYS REV LETT, V82, P2366, DOI 10.1103/PhysRevLett.82.2366; COOPER SL, 1994, PHYSICAL PROPERTIES, V4, P61; Das Sarma S, 1998, PHYS REV LETT, V80, P4753, DOI 10.1103/PhysRevLett.80.4753; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; Franz M, 1998, PHYS REV B, V58, P14572, DOI 10.1103/PhysRevB.58.14572; Geshkenbein VB, 1997, PHYS REV B, V55, P3173, DOI 10.1103/PhysRevB.55.3173; HOMES CC, 1995, PHYSICA C, V254, P265, DOI 10.1016/0921-4534(95)00579-X; Ioffe LB, 1998, PHYS REV B, V58, P11631, DOI 10.1103/PhysRevB.58.11631; Kim EH, 1998, PHYS REV B, V58, P2452, DOI 10.1103/PhysRevB.58.2452; KOHN W, 1964, PHYS REV, V133, pA171, DOI 10.1103/PhysRev.133.A171; Kumar N, 1998, PHYS REV B, V57, P13399, DOI 10.1103/PhysRevB.57.13399; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; MILLIS AJ, 1990, PHYS REV B, V42, P10807, DOI 10.1103/PhysRevB.42.10807; Miyakawa N, 1998, PHYS REV LETT, V80, P157, DOI 10.1103/PhysRevLett.80.157; ORENSTEIN J, 1990, PHYS REV B, V42, P6342, DOI 10.1103/PhysRevB.42.6342; Pines D., 1966, THEORY QUANTUM LIQUI; Puchkov AV, 1996, J PHYS-CONDENS MAT, V8, P10049, DOI 10.1088/0953-8984/8/48/023; RADTKE RJ, 1995, PHYSICA C, V250, P282, DOI 10.1016/0921-4534(95)00359-2; Renner C, 1998, PHYS REV LETT, V80, P149, DOI 10.1103/PhysRevLett.80.149; SCHREIFFER JR, 1983, THEORY SUPERCONDUCTI; Tajima S, 1997, PHYS REV B, V55, P6051, DOI 10.1103/PhysRevB.55.6051; TAKIGAWA M, 1991, PHYS REV B, V43, P247, DOI 10.1103/PhysRevB.43.247; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Uchida S, 1996, PHYS REV B, V53, P14558, DOI 10.1103/PhysRevB.53.14558; WARREN WW, 1989, PHYS REV LETT, V62, P1193, DOI 10.1103/PhysRevLett.62.1193	34	87	88	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1999	285	5431					1241	1244		10.1126/science.285.5431.1241	http://dx.doi.org/10.1126/science.285.5431.1241			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455045				2022-12-28	WOS:000082130200035
J	Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB				Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB			Interaction of glutamic-acid-rich proteins with the cGMP signalling pathway in rod photoreceptors	NATURE			English	Article							GATED CHANNEL; OUTER SEGMENTS; BETA-SUBUNIT; LOCALIZATION; CALMODULIN; CELLS; PHOTOTRANSDUCTION; MEMBRANE; DOMAIN; LIGHT	The assembly of signalling molecules into macromolecular complexes (transducisomes) provides specificity, sensitivity and speed in intracellular signalling pathways(1,2). Rod photoreceptors in the eye contain an unusual set of glutamic-acid-rich proteins (GARPs) of unknown function(3-7). GARPs exist as two soluble forms, GARP1 and GARP2, and as a large cytoplasmic domain (GARP' part) of the beta-subunit of the cyclic GMP-gated channel(3-7). Here we identify GARPs as multivalent proteins that interact with the key players of cGMP signalling, phosphodiesterase and guanylate cyclase, and with a retina-specific ATP-binding cassette transporter (ABCR)(8,9), through four, short, repetitive sequences. In electron micrographs, GARPs are restricted to the rim region and incisures of discs in dose proximity to the guanylate cyclase and ABCR, whereas the phosphodiesterase is randomly distributed. GARP2, the most abundant splice form, associates more strongly with light-activated than with inactive phosphodiesterase, and GARP2 potently inhibits phosphodiesterase activity. Thus, the GARPs organize a dynamic protein complex near the disc rim that may control cGMP turnover and possibly other light-dependent processes. Because there are no similar GARPs in cones, we propose that GARPs may prevent unnecessary cGMP turnover during daylight, when rods are held in saturation by the relatively high light levels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10998 Berlin, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Karlsruhe, Inst Zool, D-76128 Karlsruhe, Germany	Helmholtz Association; Research Center Julich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	A.eckert@fz-juelich.de	Mueller, Frank/I-7196-2013; Koch, Karl-Wilhelm/C-9551-2015	Mueller, Frank/0000-0001-7264-1227; Koch, Karl-Wilhelm/0000-0003-1501-0044				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; Eckmiller MS, 1998, ACTA ANAT, V162, P133; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KOCH KW, 1992, SIGNAL TRANSDUCTION, P259; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PEDLER CMH, 1967, VISION RES, V7, P829, DOI 10.1016/0042-6989(67)90003-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; Schrem A, 1999, J BIOL CHEM, V274, P6244, DOI 10.1074/jbc.274.10.6244; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	29	105	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					761	766		10.1038/23468	http://dx.doi.org/10.1038/23468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466724				2022-12-28	WOS:000082131100049
J	Thacher, TD; Fischer, PR; Pettifor, JM; Lawson, JO; Isichei, CO; Reading, JC; Chan, GM				Thacher, TD; Fischer, PR; Pettifor, JM; Lawson, JO; Isichei, CO; Reading, JC; Chan, GM			A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	South African Nutrition Congress	MAY 25-29, 1998	PILANESBURG, SOUTH AFRICA				DEFICIENCY; ETIOLOGY	Background Nutritional rickets remains prevalent in many tropical countries despite the fact that such countries have ample sunlight. Some postulate that a deficiency of dietary calcium, rather than vitamin D, is often responsible for rickets after infancy. Methods We enrolled 123 Nigerian children (median age, 46 months) with rickets in a randomized, double-blind, controlled trial of 24 weeks of treatment with vitamin D (600,000 U intramuscularly at enrollment and at 12 weeks), calcium (1000 mg daily), or a combination of vitamin D and calcium. We compared the calcium intake of the children at enrollment with that of control children without rickets who were matched for sex, age, and weight. We measured serum calcium and alkaline phosphatase and used a 10-point radiographic score to assess the response to treatment at 24 weeks. Results The daily dietary calcium intake was low in the children with rickets and the control children (median, 203 mg and 196 mg, respectively; P=0.64). Treatment produced a smaller increase in the mean (+/-SD) serum calcium concentration in the vitamin D group (from 7.8+/-0.8 mg per deciliter [2.0+/-0.2 mmol per liter] at base line to 8.3+/-0.7 mg per deciliter [2.1+/-0.2 mmol per liter] at 24 weeks) than in the calcium group (from 7.5+/-0.8 mg per deciliter [1.9+/-0.2 mmol per liter] to 9.0+/-0.6 mg per deciliter [2.2+/-0.2 mmol per liter], P<0.001) or the combination-therapy group (from 7.7+/-1.0 mg per deciliter [1.9+/-0.25 mmol per liter] to 9.1+/-0.6 mg per deciliter [2.3+/-0.2 mmol per liter], P<0.001). A greater proportion of children in the calcium and combination-therapy groups than in the vitamin D group reached the combined end point of a serum alkaline phosphatase concentration of 350 U per liter or less and radiographic evidence of nearly complete healing of rickets (61 percent, 58 percent, and 19 percent, respectively; P<0.001). Conclusions Nigerian children with rickets have a low intake of calcium and have a better response to treatment with calcium alone or in combination with vitamin D than to treatment with vitamin D alone. (N Engl J Med 1999;341:563-8.) (C)1999, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Univ Jos, Teaching Hosp, Dept Family Med, Jos, Nigeria; Univ Jos, Teaching Hosp, Dept Paediat, Jos, Nigeria; Univ Jos, Teaching Hosp, Dept Chem Pathol, Jos, Nigeria; Univ Witwatersrand, Dept Pediat, MRC, Mineral Metab Res Unit, Johannesburg, South Africa; Chris Hani Baragwanath Hosp, Johannesburg, South Africa; Univ Utah, Hlth Sci Ctr, Dept Family & Prevent Med, Salt Lake City, UT USA; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA	Mayo Clinic; University of Jos; University of Jos; University of Jos; University of Witwatersrand; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Fischer, PR (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.		Thacher, Tom/B-3356-2009; Isichei, Christian/AAG-9282-2021; Pettifor, John/M-4579-2019	Isichei, Christian/0000-0001-7703-7635; Pettifor, John/0000-0003-1155-0334; Thacher, Tom/0000-0002-7644-8173				*AGR EXT RES LIAIS, 1985, EXT B AHM BELL U, V21, P62; Barness LA, 1996, J PEDIATR-US, V129, P941, DOI 10.1016/S0022-3476(96)70045-8; Bhattacharyya A K, 1992, World Rev Nutr Diet, V67, P140; CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0; DAVID L, 1991, RICKETS, V21, P107; ELIDRISSY AWT, 1991, RICKETS, V21, P223; GLORIEUX FH, 1991, RICKETS, V21, pR7; Gouws E, 1986, NRIND FOOD COMPOSITI; KOOH SW, 1977, NEW ENGL J MED, V297, P1264, DOI 10.1056/NEJM197712082972307; LATHAM MC, 1979, FAO FOOD NUTR SERIES, V11, P264; MALTZ H E, 1970, Pediatrics, V46, P865; Muhe L, 1997, LANCET, V349, P1801, DOI 10.1016/S0140-6736(96)12098-5; *NIH, 1994, NIH CONSENSUS STATE, V12, P1; Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5; Oginni LM, 1999, LANCET, V353, P296, DOI 10.1016/S0140-6736(05)74931-X; OKONOFUA F, 1991, METABOLISM, V40, P209, DOI 10.1016/0026-0495(91)90177-X; PETTIFOR JM, 1978, J PEDIATR-US, V92, P320, DOI 10.1016/S0022-3476(78)80035-3; PRENTICE A, 1991, EUR J CLIN NUTR, V45, P611; Thacher T, 1999, J TROP PEDIATRICS, V45, P202, DOI 10.1093/tropej/45.4.202; Thacher T, 1997, J PEDIATR-US, V130, P332, DOI 10.1016/S0022-3476(97)70370-6; Thacher TD, 1997, AMBULATORY CHILD HLT, V3, P56; THACHER TD, IN PRESS J TROP PEDI; Walker ARP, 1997, J PEDIATR-US, V130, P501, DOI 10.1016/S0022-3476(97)70226-9; ZHOU H, 1991, RICKETS, V21, P253	24	201	211	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					563	568		10.1056/NEJM199908193410803	http://dx.doi.org/10.1056/NEJM199908193410803			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451461				2022-12-28	WOS:000082061500003
J	Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR				Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR			Increased affiliative response to vasopressin in mice expressing the V-1a receptor from a monogamous vole	NATURE			English	Article							MICROTUS-OCHROGASTER; PRAIRIE VOLES; SPECIES-DIFFERENCES; PATERNAL BEHAVIOR; COHABITATION; INNERVATION; HAMSTERS; BRAIN; GENE	Arginine vasopressin influences male reproductive and social behaviours in several vertebrate taxa(1) through its actions at the V-1a receptor in the brain, The neuroanatomical distribution of vasopressin V-1a receptors varies greatly between species with different forms of social organization(2,3). Here we show that centrally administered arginine vasopressin increases affiliative behaviour in the highly social, monogamous prairie vole, but not in the relatively asocial, promiscuous montana vole. Molecular analyses indicate that gene duplication and/or changes in promoter structure of the prairie vole receptor gene may contribute to the species differences in vasopressin-receptor expression. We further show that mice that are transgenic for the prairie vole receptor gene have a neuroanatomical pattern of receptor binding that is similar to that of the prairie vole, and exhibit increased affiliative behaviour after injection with arginine vasopressin. These data indicate that the pattern of V-1a-receptor gene expression in the brain may be functionally associated with species-typical social behaviours in male vertebrates.	Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University; Emory University	Young, LJ (corresponding author), Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.		Young, Larry/HGE-5031-2022					BAMSHAD M, 1994, PHYSIOL BEHAV, V56, P751, DOI 10.1016/0031-9384(94)90238-0; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BESTERMEREDITH JK, IN PRESS HORM BEHAV; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; FERRIS CF, 1988, PHYSIOL BEHAV, V44, P235, DOI 10.1016/0031-9384(88)90144-8; Ferris CF, 1997, J NEUROSCI, V17, P4331; INSEL TR, 1994, J NEUROSCI, V14, P5381; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Meloni R, 1998, HUM MOL GENET, V7, P423, DOI 10.1093/hmg/7.3.423; MOORE FL, 1983, PEPTIDES, V4, P97, DOI 10.1016/0196-9781(83)90173-0; RITTERS LV, 1997, ANN NY ACAD SCI, V807, P478; SHAPIRO LE, 1990, J COMP PSYCHOL, V104, P268, DOI 10.1037/0735-7036.104.3.268; WANG ZX, 1994, BRAIN RES, V650, P212, DOI 10.1016/0006-8993(94)91784-1; WANG ZX, 1994, P NATL ACAD SCI USA, V91, P400, DOI 10.1073/pnas.91.1.400; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Young LJ, 1998, TRENDS NEUROSCI, V21, P71, DOI 10.1016/S0166-2236(97)01167-3; Young LJ, 1997, BEHAV NEUROSCI, V111, P599, DOI 10.1037/0735-7044.111.3.599	18	363	378	0	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					766	768		10.1038/23475	http://dx.doi.org/10.1038/23475			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466725				2022-12-28	WOS:000082131100050
J	Burkle, FM				Burkle, FM			Fortnightly review - Lessons learnt and future expectations of complex emergencies	BRITISH MEDICAL JOURNAL			English	Review							PUBLIC-HEALTH; WAR		Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA	University of Hawaii System; World Health Organization	Burkle, FM (corresponding author), Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA.		Burkle, Frederick/AAE-5423-2020					[Anonymous], 1997, REFUGEE HLTH APPROAC; BLECHMAN BM, 1994, TRAINING PEACEKEEPIN, P1; Borton J, 1996, DISASTERS, V20, P305, DOI 10.1111/j.1467-7717.1996.tb01046.x; BRADSHAW AL, 1998, INT ENV SECURITY REG; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; Burkle F M Jr, 1995, Prehosp Disaster Med, V10, P48; BURKLE FM, 1999, HUMANITARIAN CRISES, P293; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; *DIV EM HUM ACT, 1999, APPL HLTH RES EM SET; Garshnek V, 1998, SPACE POLICY, V14, P223, DOI 10.1016/S0265-9646(98)00023-X; *INT FED RED CROSS, 1997, WORLD DIS REP 1997; KANE H, 1995, WORLDWATCH       JUN, P18; MINEAR L, 1991, HUMANITARIANISM WAR; *NAT DEF COUNC FDN, 1998, NAT DEF COUNC FDN WO; Palmer CA, 1998, DISASTERS, V22, P236, DOI 10.1111/1467-7717.00089; Perrin P., 1996, HDB WAR PUBLIC HLTH; *PUBL BROADC SYST, 1997, ALL THINGS CONS CULT; *REPR HLTH REF CON, 1998, REF REPR HLTH CAR NE; *SPHER PROJ, 1998, HUM CHART MIN STAND, pCH6; THAROOR S, 1998, WASHINGTON POST 0216, P34; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; *UN HIGH COMM REF, 1999, STAT WORLDS REF HUM; ZWI A, 1991, HEALTH POLICY PLANN, V6, P203, DOI 10.1093/heapol/6.3.203; 1998, ECONOMIST       0502, P21	25	48	49	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					422	426		10.1136/bmj.319.7207.422	http://dx.doi.org/10.1136/bmj.319.7207.422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445925	Green Published			2022-12-28	WOS:000082098900020
J	Cooper-Patrick, L; Gallo, JJ; Gonzales, JJ; Vu, HT; Powe, NR; Nelson, C; Ford, DE				Cooper-Patrick, L; Gallo, JJ; Gonzales, JJ; Vu, HT; Powe, NR; Nelson, C; Ford, DE			Race, gender, and partnership in the patient-physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	21st Annual Meeting of the Society-of-General-Internal-Medicine	APR 23-25, 1998	CHICAGO, ILLINOIS	Soc Gen Internal Med			LONGITUDINAL DATA-ANALYSIS; PRIMARY-CARE PHYSICIANS; DECISION-MAKING; HEALTH-CARE; MENTAL-HEALTH; WHITE AMERICANS; UNITED-STATES; COMMUNICATION; BLACK; OUTCOMES	Context Many studies have documented race and gender differences in health care received by patients. However, few studies have related differences in the quality of interpersonal care to patient and physician race and gender. Objective To describe how the race/ethnicity and gender of patients and physicians are associated with physicians' participatory decision-making (PDM) styles. Design, Setting, and Participants Telephone survey conducted between November 1996 and June 1998 of 1816 adults aged 18 to 65 years (mean age, 41 years) who had recently attended 1 of 32 primary care practices associated with a large mixed-model managed care organization in an urban setting. Sixty-six percent of patients surveyed were female, 43% were white, and 45% were African American. The physician sample (n = 64) was 63% male, with 56% white, and 25% African American. Main Outcome Measure Patients' ratings of their physicians' PDM style on a 100-point scale. Results African American patients rated their visits as significantly less participatory than whites in models adjusting for patient age, gender, education, marital status, health status, and length of the patient-physician relationship (mean [SE] PDM score, 58.0 [1.2] vs 60.6 [3.3]; P=.03). Ratings of minority and white physicians did not differ with respect to PDM style (adjusted mean [SE] PDM score for African Americans, 59.2 [1.7] vs whiles, 61.7 [3.1]; P =.13). Patients in race-concordant relationships with their physicians rated their visits as significantly more participatory than patients in race-discordant relationships (difference [SEI, 2.6 [1.1]; P=.02), Patients of female physicians had more participatory visits (adjusted mean [SE] PDM score for female, 62.4 [1.3] vs male, 59.5 [3.1]; P=.03), but gender concordance between physicians and patients was not significantly related to PDM score (unadjusted mean [SEI PDM score, 76.0 [1.0] for concordant vs 74.5 [0.9] for discordant; P =.12). Patient satisfaction was highly associated with PDM score within all race/ethnicity groups. Conclusions Our data suggest that African American patients rate their visits with physicians as less participatory than whites. However, patients seeing physicians of their own race rate their physicians' decision-making styles as more participatory. Improving crosscultural communication between primary care physicians and patients and providing patients with access to a diverse group of physicians may lead to more patient involvement in care, higher levels of patient satisfaction, and better health outcomes.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mental Hyg, Baltimore, MD USA; Georgetown Univ, Med Ctr, Dept Psychiat, Washington, DC 20007 USA; NYLCare Hlth Plans MidAtlantic, Greenbelt, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Georgetown University	Cooper-Patrick, L (corresponding author), Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.				NIMH NIH HHS [5U01MH54443] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH054443] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARSKY AJ, 1980, SOC SCI MED-MED SOC, V14, P653, DOI 10.1016/0160-7979(80)90070-3; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Carlisle DM, 1998, J NATL MED ASSOC, V90, P466; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; Elderkin-Thompson V, 1999, J GEN INTERN MED, V14, P112, DOI 10.1046/j.1525-1497.1999.00296.x; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HOOPER EM, 1982, MED CARE, V20, P630, DOI 10.1097/00005650-198206000-00009; HU TW, 1991, AM J PUBLIC HEALTH, V81, P1429, DOI 10.2105/AJPH.81.11.1429; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; KAPLAN SH, 1992, CLIN RES, V40, pA614; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; LavizzoMourey R, 1996, ANN INTERN MED, V124, P919, DOI 10.7326/0003-4819-124-10-199605150-00010; LEE JA, 1997, MED CARE, V35, P1173; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LEVY DR, 1985, PEDIATRICS, V75, P639; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIN EHB, 1983, J FAM PRACTICE, V16, P91; LURIE N, 1990, J GEN INTERN MED, V5, P527; MATHEWS JJ, 1983, SOC SCI MED, V17, P1371, DOI 10.1016/0277-9536(83)90197-1; McKinlay JB, 1996, SOC SCI MED, V42, P769, DOI 10.1016/0277-9536(95)00342-8; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; MULL JD, 1993, WESTERN J MED, V159, P609; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PENDLETON DA, 1980, SOC SCI MED-MED SOC, V14, P669, DOI 10.1016/S0271-7123(80)80077-0; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; ROTER D, 1991, MED CARE, V29, P1083; Roter D.L., 1992, DOCTORS TALKING PATI; ROTER DL, 1988, PATIENT EDUC COUNS, V12, P99, DOI 10.1016/0738-3991(88)90057-2; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; SCHEFFLER RM, 1989, INQUIRY-J HEALTH CAR, V26, P202; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SUSSMAN LK, 1987, SOC SCI MED, V24, P187, DOI 10.1016/0277-9536(87)90046-3; van den Brink-Muinen A, 1998, MED CARE, V36, P100, DOI 10.1097/00005650-199801000-00012; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; VERNON SW, 1982, SOC SCI MED, V16, P1575, DOI 10.1016/0277-9536(82)90168-X; WASSERMAN RC, 1984, PEDIATRICS, V74, P1047; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WILLIAMS SJ, 1979, MED CARE, V17, P139, DOI 10.1097/00005650-197902000-00004; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	53	1407	1409	3	106	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					583	589		10.1001/jama.282.6.583	http://dx.doi.org/10.1001/jama.282.6.583			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224UV	10450723	Bronze			2022-12-28	WOS:000081919100035
J	Klein, G				Klein, G			The tale of the great cuckoo egg	NATURE			English	Editorial Material									Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden	Karolinska Institutet	Klein, G (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, POB 280, S-17177 Stockholm, Sweden.								0	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					515	515		10.1038/22906	http://dx.doi.org/10.1038/22906			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448850	Bronze			2022-12-28	WOS:000081854800034
J	Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K				Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K			Inner-arm dynein c of Chlamydomonas flagella is a single-headed processive motor	NATURE			English	Article							KINESIN MOLECULES; MICROTUBULES; PROTEINS; PURIFICATION; MICROSCOPY; MOVEMENT; MUTANTS; TUBULIN; DOMAIN; ASSAY	Axonemal dyneins are force-generating ATPases that produce movement of eukaryotic cilia and flagella(1,2). Several studies indicate that inner-arm dyneins mainly produce bending moments in flagella(3,4) and that these motors have inherent oscillations in force and motility(5-8). Processive motors such as kinesins have high duty ratios of attached to total ATPase cycle (attached plus detached) times(9) compared to sliding motors such as myosin(10). Here we provide evidence that subspecies-c, a single-headed axonemal inner-arm dynein, is processive but has a low duty ratio. Ultrastructurally it is similar to other dyneins(11-14), with a single globular head, long stem and a slender stalk that attaches to microtubules. In vitro studies of microtubules sliding over surfaces coated with subspecies-c at low densities (measured by single-molecule fluorescence) show that a single molecule is sufficient to move a microtubule more than 1 mu m at 0.7 mu m s(-1). When many motors interact the velocity is 5.1 mu m s(-1), fitting a duty ratio of 0.14. Using optical trap nanometry, we show that beads carrying a single subspecies-c motor move processively along the microtubules in 8-nm steps but slip backwards under high loads. These results indicate that dynein subspecies-c functions in a very different way from conventional motor proteins, and has properties that could produce self-oscillation in vivo.	Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan	National Institute of Information & Communications Technology (NICT) - Japan; University of Tokyo	Oiwa, K (corresponding author), Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan.	oiwa@crl.go.jp	Oiwa, Kazuhiro/D-7721-2011	Oiwa, Kazuhiro/0000-0002-1281-113X				AMOS LA, 1989, J CELL SCI, V93, P19; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; KAGAMI O, 1992, J CELL SCI, V103, P653; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KING SM, 1986, METHOD ENZYMOL, V134, P291; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Oiwa K., 1997, Biophysical Journal, V72, pA180; OIWA K, 1988, CELL STRUCT FUNCT, V13, P193, DOI 10.1247/csf.13.193; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1983, J SUBMICR CYTOL PATH, V15, P1; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89	28	149	152	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					586	590		10.1038/23066	http://dx.doi.org/10.1038/23066			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448863				2022-12-28	WOS:000081854800061
J	Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M				Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M			Dynamic measurement of myosin light-chain-domain tilt and twist in muscle contraction	NATURE			English	Article							SKELETAL-MUSCLE; FLUORESCENCE POLARIZATION; FORCE GENERATION; STRIATED-MUSCLE; SCALLOP MYOSIN; MOTOR DOMAIN; LEVER-ARM; FIBERS; ORIENTATION; ACTIN	A new method is described for measuring motions of protein domains in their native environment on the physiological timescale. pairs of cysteines are introduced Into the domain at sites chosen from its static structure and are crosslinked by a bifunctional rhodamine. Domain orientation in a reconstituted macromolecular complex is determined by combining fluorescence polarization data from a small number of such labelled cysteine pairs. This approach bridges the gap between in vitro studies of protein structure and cellular studies of protein function and is used here to measure the tilt and twist of the myosin light-chain domain with respect to actin filaments in single muscle cells. The results reveal the structural basis for the lever-arm action of the light-chain domain of the myosin motor during force generation in muscle.	Univ London Kings Coll, Randall Inst, London WC2B 5RL, England; Natl Inst Med Res, London NW7 1AA, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of London; King's College London; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	Irving, M (corresponding author), Univ London Kings Coll, Randall Inst, 26-29 Drury Lane, London WC2B 5RL, England.			, Seth/0000-0003-3999-2281	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; Corrie JET, 1998, BIOCONJUGATE CHEM, V9, P160, DOI 10.1021/bc970174e; Dale RE, 1999, BIOPHYS J, V76, P1606, DOI 10.1016/S0006-3495(99)77320-0; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JANSCO A, 1994, P NATL ACAD SCI USA, V91, P8762; KABASCH W, 1990, NATURE, V347, P37; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOSS RL, 1982, J BIOL CHEM, V257, P8588; OKI M, 1983, TOP STEREOCHEM, V14, P1; PENZKOFER A, 1980, OPT COMMUN, V35, P81, DOI 10.1016/0030-4018(80)90364-8; Press W., 1992, NUMERICAL RECIPES FO; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; Sabido-David C, 1998, BIOPHYS J, V74, P3083, DOI 10.1016/S0006-3495(98)78015-4; Sabido-David C, 1998, J MOL BIOL, V279, P387, DOI 10.1006/jmbi.1998.1771; SIMMONS RM, 1980, NATURE, V286, P626, DOI 10.1038/286626a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Warshaw DM, 1998, P NATL ACAD SCI USA, V95, P8034, DOI 10.1073/pnas.95.14.8034; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	44	172	173	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					425	430		10.1038/22704	http://dx.doi.org/10.1038/22704			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440371				2022-12-28	WOS:000081715000043
J	Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A				Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A			How should age affect management of acute myocardial infarction? A prospective cohort study	LANCET			English	Article							THROMBOLYTIC THERAPY; RISK; SURVIVAL; TRIAL	Background About 75% of patients with acute myocardial infarction are older than 70 years, but patients in this age group are commonly treated less vigorously than younger patients. This differential treatment may partly reflect clinicians' misconceptions about the outlook of such patients, and the importance of age in clinical decisions. We examined how age does and should affect the management of patients and risk stratification in acute myocardial infarction. Methods In this prospective cohort study, we recruited 1225 consecutive patients admitted with acute myocardial infarction to a district general hospital in east London. The primary endpoint was death. We used tabulation and regression methods to analyse the association between age group and clinical variables. Findings Patients aged 70 years or older took a longer time to arrive in hospital and were less likely to receive thrombolysis or discharge beta-blockers than patients younger than 60 years: odds ratio 0.63 (95% CI 9.45-0.88) for thrombolysis and 0.25 (0.16-0.37) for beta-blockade, adjusted for sex, diabetes, previous acute myocardial infarction, Q wave infarction, and left-ventricular failure. Left-ventricular failure was the strongest independent predictor of death within 1 year of infarction with a hazard ratio of 4.76 (3.53-6.43), adjusted for age, sex, diabetes, and Q wave infarction. Patients aged 70 years or older without left-ventricular failure had significantly better survival at 1 year after acute myocardial infarction than patients under 60 years with left-ventricular failure. 70.8% (62.2-78.2) of the older patients who survived to hospital discharge were still alive 3 years later. Interpretation Elderly patients with acute myocardial infarction were treated less vigorously than younger patients. The prognosis of acute myocardial infarction, however, was substantially affected by the development of left-ventricular failure and other clinical indices, such that many older patients had a better outlook than younger patients with adverse clinical factors. In planning risk-based management, consideration of age independently of clinical status is inappropriate.	London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England; Newman Healthcare Trust, London, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine	Timmis, A (corresponding author), London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England.	adam@timmis-lch.demon.co.uk		Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; COLEMAN MP, 1989, 89006 INT AG RES CAN; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HANNAFORD PC, 1994, BRIT MED J, V309, P573, DOI 10.1136/bmj.309.6954.573; HAWKINS CM, 1983, CIRCULATION, V67, P94; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; McMechan SR, 1998, BMJ-BRIT MED J, V317, P1334, DOI 10.1136/bmj.317.7169.1334; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NORRIS RM, 1969, LANCET, V1, P274; *OFF NAT STAT, 1997, MORT STAT DH2, V22; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525	23	103	109	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					955	959		10.1016/S0140-6736(98)07114-1	http://dx.doi.org/10.1016/S0140-6736(98)07114-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459903				2022-12-28	WOS:000079421600009
J	Culpepper, L; Gilbert, TT				Culpepper, L; Gilbert, TT			Evidence and ethics	LANCET			English	Article									Boston Univ, Med Ctr, Dept Family Med, Boston, MA 02118 USA	Boston University	Culpepper, L (corresponding author), Boston Univ, Med Ctr, Dept Family Med, 1 Boston Med Ctr Pl, Boston, MA 02118 USA.			Culpepper, Larry/0000-0002-7655-0477				[Anonymous], 1987, J ROY COLL GEN PRACT, V37, P400; BECKER LA, 1993, J FAM PRACTICE, V37, P129; CULPEPPER L, 1995, J AM BOARD FAM PRACT, V8, P1; Donaldson M, 1996, PRIMARY CARE AM HLTH; George JN, 1997, ANN INTERN MED, V126, P317, DOI 10.7326/0003-4819-126-4-199702150-00009; Mant D, 1999, LANCET, V353, P743, DOI 10.1016/S0140-6736(98)09102-8; Rosser WW, 1999, LANCET, V353, P661, DOI 10.1016/S0140-6736(98)09103-X; STOOL SE, 1994, CLIN PRACTICE GUIDEL, V12; VANWEEL C, 1995, LANCET, V345, P1549, DOI 10.1016/S0140-6736(95)91091-3; VANWEEL C, IN PRESS LANCET	10	43	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					829	831		10.1016/S0140-6736(98)09101-6	http://dx.doi.org/10.1016/S0140-6736(98)09101-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459978	hybrid			2022-12-28	WOS:000079089100046
J	Light, DW				Light, DW			Here we go again: repeating implementation errors	BRITISH MEDICAL JOURNAL			English	Article							AMERICAN PERSPECTIVE		Univ Med & Dent New Jersey, Div Social & Behav Med, Stratford, NJ 08084 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Light, DW (corresponding author), Univ Med & Dent New Jersey, Div Social & Behav Med, Stratford, NJ 08084 USA.							ABBOTT S, 1998, CONTINUING CHALLENGE; DAWSON D, 1995, REGULATING COMPETITI; GOULD M, 1999, HLTH SERV J     0401, P2; HIGGINS J, 1999, HLTH SERV J     0128, P22; HUNTER D, 1999, HLTH SERV J      JUN, P16; KLEIN RE, 1998, IMPLEMENTING WHITE P; KNOWLES D, 1998, IMPLEMENTING WHITE P, P74; LIGHT DW, 1991, BRIT MED J, V303, P568, DOI 10.1136/bmj.303.6802.568; Light DW, 1997, MILBANK Q, V75, P297, DOI 10.1111/1468-0009.00058; Light DW, 1998, BRIT MED J, V316, P217; LIGHT DW, 1998, EFFECTIVE COMMISSION; MAYS N, 1998, LEARNING NHS INTERNA, P84; *NHS EX, 1998, NEWS NHS 1998 REF CO; REGAN E, 1999, FIRST OFF STARTING B; Williams S, 1998, IMPROVING HLTH NHS W	15	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					616	618		10.1136/bmj.319.7210.616	http://dx.doi.org/10.1136/bmj.319.7210.616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473478	Green Published, Bronze			2022-12-28	WOS:000082460300022
J	Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA				Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA			Gene expression profile of aging and its retardation by caloric restriction	SCIENCE			English	Article							MESSENGER-RNA EXPRESSION; CAENORHABDITIS-ELEGANS; LIFE-SPAN; TRANSCRIPTION FACTOR; PROTEIN; MUSCLE; STRESS; LONGEVITY; EXTENSION; DAF-16	The gene expression profile of the aging process was analyzed in skeletal muscle of mice. Use of high-density oligonucleotide arrays representing 6347 genes revealed that aging resulted in a differential gene expression pattern indicative of a marked stress response and Lower expression of metabolic and biosynthetic genes. Most alterations were either completely or partially prevented by caloric restriction, the only intervention known to retard aging in mammals. Transcriptional patterns of calorie-restricted animals suggest that caloric restriction retards the aging process by causing a metabolic shift toward increased protein turnover and decreased macromolecular damage.	VA Hosp, Dept Med, GRECC 4D, Madison, WI 53705 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Inst Aging, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Weindruch, R (corresponding author), VA Hosp, Dept Med, GRECC 4D, 2500 Overlook Terrace, Madison, WI 53705 USA.	rhweindr@facstaff.wisc.edu; taprolla@facstaff.wisc.edu	Lee, Cheol-Koo/F-2103-2013	Lee, Cheol-Koo/0000-0003-3927-9195	NATIONAL CANCER INSTITUTE [R01CA078723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78723] Funding Source: Medline; NIA NIH HHS [P01 AG11915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Copray JCVM, 1997, NEUROSCI LETT, V236, P41, DOI 10.1016/S0304-3940(97)00747-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dutta C, 1997, MUSCLE NERVE, V5, P55; Goyns MH, 1998, MECH AGEING DEV, V101, P73, DOI 10.1016/S0047-6374(97)00166-8; HOEK JB, 1988, BIOCHEM J, V254, P1; JACKMAN J, 1994, CANCER RES, V54, P5656; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; Lexell J, 1997, J NUTR, V127, pS1011, DOI 10.1093/jn/127.5.1011S; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LISOWSKY T, 1994, CURR GENET, V26, P15, DOI 10.1007/BF00326299; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; LUDATSCHER R, 1983, EXP GERONTOL, V18, P113, DOI 10.1016/0531-5565(83)90004-9; MARAZZI G, 1993, DEV DYNAM, V197, P115, DOI 10.1002/aja.1001970205; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peterson CA, 1997, J NUTR, V127, pS1007; Pugh TD, 1999, CANCER RES, V59, P1642; Schwartz AL, 1999, ANNU REV MED, V50, P57; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Wang S, 1996, MECH AGEING DEV, V92, P121, DOI 10.1016/S0047-6374(96)01814-3; Weindruch R., 1988, RETARDATION AGING DI; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	40	1188	1252	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	1999	285	5432					1390	1393		10.1126/science.285.5432.1390	http://dx.doi.org/10.1126/science.285.5432.1390			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464095				2022-12-28	WOS:000082233500039
J	Manson, JE; Hu, FB; Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Speizer, FE; Hennekens, CH				Manson, JE; Hu, FB; Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Speizer, FE; Hennekens, CH			A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICAL-ACTIVITY; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; DEATH; MORTALITY; RISK; MEN; HEALTH	Background The role of walking, as compared with vigorous exercise, in the prevention of coronary heart disease remains controversial, and data for women on this topic are sparse. Methods We prospectively examined the associations between the score for total physical activity, walking, and vigorous exercise and the incidence of coronary events among 72,488 female nurses who were 40 to 65 years old in 1986. Participants were free of diagnosed cardiovascular disease or cancer at the time of entry and completed serial detailed questionnaires about physical activity. During eight years of follow-up, we documented 645 incident coronary events (nonfatal myocardial infarction or death from coronary disease). Results There was a strong, graded inverse association between physical activity and the risk of coronary events. As compared with women in the lowest quintile group for energy expenditure (expressed as the metabolic-equivalent [MET] score), women in increasing quintile groups had age-adjusted relative risks of 0.77 0.65, 0.54, and 0.46 for coronary events (P for trend <0.001). In multivariate analyses, the inverse gradient remained strong (relative risks, 0.88, 0.81, 0.74, and 0.66 for women in increasing quintile groups as compared with those in the lowest quintile group; P for trend = 0.002). Walking was inversely associated with the risk of coronary events; women in the highest quintile group for walking, who walked the equivalent of three or more hours per week at a brisk pace, had a multivariate relative risk of 0.65 (95 percent confidence interval, 0.47 to 0.91) as compared with women who walked infrequently. Regular vigorous exercise (greater than or equal to 6 MET) was associated with similar risk reductions (30 to 40 percent). Sedentary women who became active in middle adulthood or later had a lower risk of coronary events than their counterparts who remained sedentary. Conclusions These prospective data indicate that brisk walking and vigorous exercise are associated with substantial and similar reductions in the incidence of coronary events among women. (N Engl J Med 1999;341:650-8.) (C) 1999, Massachusetts Medical Society.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Manson, JE (corresponding author), Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; American College of Sports Medicine, 1986, GUID GRAD EX TEST EX, V3rd; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BRUNNER D, 1974, J CHRON DIS, V27, P217, DOI 10.1016/0021-9681(74)90047-2; DAGOSTINO RB, 1990, STAT MED, V9, P14501; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; MAGNUS K, 1979, AM J EPIDEMIOL, V110, P724, DOI 10.1093/oxfordjournals.aje.a112853; Manson JE, 1996, NEW ENGL J MED, V334, P1325, DOI 10.1056/NEJM199605163342010; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; *NAT CTR HLTH STAT, 1967, DHEW PUBL PHS; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SCRAGG R, 1987, AM J EPIDEMIOL, V126, P77, DOI 10.1093/oxfordjournals.aje.a114664; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; Smith JK, 1999, JAMA-J AM MED ASSOC, V281, P1722, DOI 10.1001/jama.281.18.1722; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Williams PT, 1996, NEW ENGL J MED, V334, P1298, DOI 10.1056/NEJM199605163342004; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	29	660	680	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					650	658		10.1056/NEJM199908263410904	http://dx.doi.org/10.1056/NEJM199908263410904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460816				2022-12-28	WOS:000082192500004
J	Payne, D				Payne, D			Irish doctors protest over pay and conditions	BRITISH MEDICAL JOURNAL			English	News Item																		1999, IRISH MED TIMES, V33, P25	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					468	468		10.1136/bmj.319.7208.468	http://dx.doi.org/10.1136/bmj.319.7208.468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454390	Green Published			2022-12-28	WOS:000082199600008
J	Ross, JA; Coppes, MJ; Robison, LL				Ross, JA; Coppes, MJ; Robison, LL			Population density and risk of childhood acute lymphoblastic leukaemia	LANCET			English	Editorial Material							LEUKEMIA		Univ Minnesota, Sch Med, Div Pediat Epidemiol & Clin Res, Minneapolis, MN 55455 USA; Univ Calgary, Dept Oncol, Calgary, AB, Canada; Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Calgary; University of Calgary	Ross, JA (corresponding author), Univ Minnesota, Sch Med, Div Pediat Epidemiol & Clin Res, Minneapolis, MN 55455 USA.		Robison, Leslie/N-8122-2018					Alexander FE, 1998, BRIT J CANCER, V77, P818, DOI 10.1038/bjc.1998.133; Alexander FE, 1999, EUR J CANCER, V35, P439, DOI 10.1016/S0959-8049(98)00385-2; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1	4	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					532	532		10.1016/S0140-6736(99)00140-3	http://dx.doi.org/10.1016/S0140-6736(99)00140-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470695				2022-12-28	WOS:000081991000008
J	Deppisch, LM; Centeno, JA; Gemmel, DJ; Torres, NL				Deppisch, LM; Centeno, JA; Gemmel, DJ; Torres, NL			Andrew Jackson's exposure to mercury and lead - Poisoned president?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HAIR; BODY	Historians have suggested that US president Andrew Jackson (1767-1845) experienced lead and mercury poisoning following his therapeutic use of calomel (mercurous chloride) and sugar of lead (lead acetate), To evaluate these claims, we performed direct physical measurement of 2 samples of Jackson's hair(1 from 1815, 1 from 1839), Following pretreatment and acid digestion, mercury was measured using cold vapor generation techniques, while lead levels were measured by electrothermal atomic absorption spectrophotometry, Mercury levels of 6.0 and 5.6 ppm were obtained from the 1815 and 1839 hair specimens, respectively, Lead levels were significantly elevated in both the 1815 sample (mean lead level, 130.5 ppm) and the 1839 sample (mean lead level, 44 ppm). These results suggest that Jackson had mercury and lead exposure, the tatter compatible with symptomatic plumbism in the 1815 sample. However, Jackson's death was probably not due to heavy metal poisoning.	NE Ohio Univ, Coll Med, Dept Pathol, Rootstown, OH 44272 USA; Youngstown State Univ, Dept Pathol, Youngstown, OH 44555 USA; Youngstown State Univ, Dept Res, Youngstown, OH 44555 USA; Youngstown State Univ, Forum Hlth, Youngstown, OH 44555 USA; Youngstown State Univ, Dept Hlth & Human Serv, Youngstown, OH 44555 USA; Armed Forces Inst Pathol, Dept Environm & Toxicol Pathol, Washington, DC 20306 USA	Northeast Ohio Medical University (NEOMED); University System of Ohio; Youngstown State University; University System of Ohio; Youngstown State University; University System of Ohio; Youngstown State University; University System of Ohio; Youngstown State University; United States Department of Defense	Deppisch, LM (corresponding author), Northside Hosp, Dept Pathol, 500 Gypsy Ln, Youngstown, OH 44501 USA.							BASSETT JS, 1926, CORRES A JACKSON, V1; BLINDERMAN A, 1972, NEW YORK STATE J MED, V72, P405; BUMGARNER JR, 1994, HLTH PRESIDENTS 41 U, P43; BURKE PW, 1941, E DONELSON TENNESSEE, V1, P64; Caravati C M, 1983, Va Med, V110, P194; CASTELLINO P, 1995, INORGANIC LEAD EXPOS, P287; COXE JR, 1818, AM DISPENSATORY, P437; DALE PM, 1952, MED BIOGRAPHIES AILM, P136; DILLMAN RO, 1979, AM J MED, V66, P509, DOI 10.1016/0002-9343(79)91083-0; FOO SC, 1993, INT ARCH OCCUP EN S1, V65, P583; FRITZ M, 1985, THESIS U TOLEDO TOLE; GARDNER FT, 1949, SURG GYNECOL OBSTET, V30, P404; IYENGAR V, 1988, CLIN CHEM, V34, P474; Janin Y, 1985, Surg Annu, V17, P287; KATZ SA, 1992, J APPL TOXICOL, V12, P79, DOI 10.1002/jat.2550120203; KOPITO L, 1969, J AMER MED ASSOC, V209, P243, DOI 10.1001/jama.209.2.243; LENIHAN JMA, 1971, LANCET, V2, P1030; MARX R, 1960, HLTH PRESIDENTS; MOORE MR, 1980, FOOD COSMET TOXICOL, V18, P399, DOI 10.1016/0015-6264(80)90197-2; PAINE M, 1948, MAT MED THERAPEUTICS, P321; PARTON J, 1860, LIFE A JACKSON 3 VOL; Remini R V, 1980, Tenn Hist Q, V39, P167; REMINI RV, 1981, A JACKSON COURSE AM; REMINI RV, 1977, A JACKSON COURSE AM, V1; REMINI RV, 1984, A JACKSON COURSE AM; ROSENBERG JC, 1969, AM J SURG, V117, P721, DOI 10.1016/0002-9610(69)90414-0; SUZUKI T, 1984, SCI TOTAL ENVIRON, V39, P81, DOI 10.1016/0048-9697(84)90026-3; WEISS D, 1972, SCIENCE, V178, P69, DOI 10.1126/science.178.4056.69; WINSHIP KA, 1985, ADVERSE DRUG REACT T, V4, P129	29	20	21	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					569	571		10.1001/jama.282.6.569	http://dx.doi.org/10.1001/jama.282.6.569			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450719				2022-12-28	WOS:000081919100031
J	Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL				Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL			Trends in perinatal transmission of HIV/AIDS in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; PREGNANT-WOMEN; VERTICAL TRANSMISSION; ZIDOVUDINE TREATMENT; CHILDREN; AIDS; PREVALENCE; REDUCTION; TYPE-1	Context Since 1994, the US Public Health Service (PHS) has recommended routine, voluntary prenatal human immunodeficiency virus (HIV)testing and zidovudine therapy to reduce perinatal HIV transmission. Objective To describe trends in incidence of perinatal AIDS and factors contributing to these trends, particularly the effect of PHS perinatal HIV recommendations. Design, Setting, and Participants Analysis of nationwide AIDS surveillance data and data from HIV-reporting states through June 1998. Main Outcome Measures Trends in AIDS by year of diagnosis, incidence rates of AIDS and Pneumocystis carinii pneumonia (PCP) among infants younger than 1 year from US natality data for birth cohorts 1988 to 1996; expected number of infants with AIDS from national serosurvey data; and zidovudine use data from selected HIV-reporting states. Results Perinatal AIDS cases peaked in 1992 and then declined 67% from 1992 through 1997, including an 80% decline in infants and a 66% decline in children aged 1 to 5 years. Rates of AIDS among infants (per 100 000 births) declined 69%, from 8.9 in 1992 to 2.8 in 1996 compared with a 17% decline in births to HIV-infected women from 1992 (n = 6990) to 1995 (n = 5797). Among infants, PCP rates per 100 000 declined 67% (from 4.5 in 1992 to 1,5 in 1996), similar to the decline in other AIDS conditions. The percentage of perinatally exposed children born from 1993 through 1997 whose mothers were tested for HIV before giving birth increased from 70% to 94%; the percentage who received zidovudine increased from 7% to 91%. Conclusions According to these data, substantial declines in AIDS incidence were temporally associated with an increase in zidovudine use to reduce perinatal HIV transmission, demonstrating substantial success in implementing PHS guidelines. Reductions in the numbers of births and effects of therapy in delaying AIDS do not explain the decline.	New York City Dept Hlth, New York, NY 10013 USA; Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA USA; Ctr Dis Control & Prevent, Program Epidemiol, Off Sci & Hlth Commun, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Lindegren, ML (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Sueveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Mailstop E-47,1600 Clifton Rd, Atlanta, GA 30333 USA.	mll3@cdc.gov						Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; Barnhart HX, 1996, PEDIATRICS, V97, P710; Blanche S, 1997, J ACQ IMMUN DEF SYND, V14, P442, DOI 10.1097/00042560-199704150-00008; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; Byers RH, 1998, STAT MED, V17, P169, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;169::AID-SIM759&gt;3.0.CO;2-8; BYERS RH, 1993, 9 INT AIDS C JUN 6 1; *CDCP, 1985, MMWR-MORBID MORTAL W, V34, P731; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P688; Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S; Centers for Disease Control (CDC), 1985, MMWR Morb Mortal Wkly Rep, V34, P721; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR EM, 1993, PEDIATR INFECT DIS J, V12, P513, DOI 10.1097/00006454-199306000-00011; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Green TA, 1998, STAT MED, V17, P143, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;143::AID-SIM757&gt;3.0.CO;2-Y; *I MED NAT RES COU, 1999, RED ODDS PREV PER TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1989, LECTURE NOTES BIOMAT, V83, P58; KROGSTAD P, 1998, 5 C RETR OPP INF FEB; Lansky A, 1998, J ACQ IMMUN DEF SYND, V18, P289, DOI 10.1097/00042560-199807010-00014; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; MUELLER BU, 1997, 4 C RETR OPP INF JAN; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIMONDS RJ, 1995, NEW ENGL J MED, V332, P786, DOI 10.1056/NEJM199503233321206; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Simpson BJ, 1997, J ACQ IMMUN DEF SYND, V14, P145, DOI 10.1097/00042560-199702010-00007; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilfert C, 1998, PEDIATRICS, V101, P315, DOI 10.1542/peds.101.2.315; WORTLEY P, 1997, JAMA-J AM MED ASSOC, V298, P911	48	197	204	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					531	538		10.1001/jama.282.6.531	http://dx.doi.org/10.1001/jama.282.6.531			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450714	Bronze			2022-12-28	WOS:000081919100026
J	Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A				Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A			Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study	LANCET			English	Article							MITOCHONDRIAL-FUNCTION; IRON ACCUMULATION; OXIDATIVE STRESS; FRATAXIN; HOMOLOG; DEFICIENCY; ACONITASE; CHAIN; GENE	Background Friedreich's ataxia is caused by a deficiency of frataxin, a protein involved in regulation of mitochondrial iron content. We have reported a combined deficiency of a Krebs-cycle enzyme, aconitase, and three mitochondrial respiratory-chain complexes in endomyocardial biopsy samples from patients with this disorder. All four enzymes share iron-sulphur cluster-containing proteins that are damaged by iron overload through generation of oxygen free radicals. We used an in-vitro system to elucidate the mechanism of iron-induced injury and to test the protective effects of various substances. On the basis of these results, we assessed the effect of idebenone (a free-radical scavenger) in three patients with Friedreich's ataxia. Methods Heart homogenates from patients with valvular stenosis were tested for respiratory-chain complex II activity, lipoperoxidation, and aconitase activity by spectrophotometric assays, in the presence of reduced iron (Fe2+), oxidised iron (Fe3+), desferrioxamine, ascorbic acid, and idebenone. The Friedreich's ataxia patients (aged 11 years, 19 years, and 21 years) underwent ultrasonographic heart measurements at baseline and after 4-9 months of idebenone (5 mg/kg daily). Findings Fe2+ (but not Fe3+) decreased complex II activity and increased lipoperoxidation in heart homogenate. Addition of ascorbate or desferrioxamine increased some of the iron-induced adverse effects. Idebenone protected against these effects. In the three patients, left-ventricular mass index decreased from baseline to 4-9 months of idebenone treatment (patient 1, 145 g to 114 g; patient 2, 215 g to 151 g; patient 3, 408 g to 279 g). Interpretation Our in-vitro data suggest that both iron chelators and antioxidant drugs that may reduce iron are potentially harmful in patients with Friedreich's ataxia. Conversely, our preliminary findings in patients suggest that idebenone protects heart muscle from iron-induced injury.	Hop Necker Enfants Malad, INSERM, U393,, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Munnich, A (corresponding author), Hop Necker Enfants Malad, INSERM, U393,, Tour Lavoisler,149 Rue Sevres, F-75743 Paris, France.		Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHAMBERLAIN S, 1989, AM J HUM GENET, V44, P518; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; HARDING AE, 1981, BRAIN, V104, P598; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; NZNAGY I, 1990, ARCH GERONTOL GERIAT, V11, P177; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SANCHEZCASIS G, 1977, CAN J NEUROL SCI, V3, P349; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	18	284	301	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					477	479		10.1016/S0140-6736(99)01341-0	http://dx.doi.org/10.1016/S0140-6736(99)01341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465173				2022-12-28	WOS:000081896100013
J	Wintemute, GJ				Wintemute, GJ			The future of firearm violence prevention - Building on success	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; GUN MARKETS; LAWS; CRIME; HOMICIDE; INJURIES; HANDGUNS; POLICY; RATES		Univ Calif Davis, Med Ctr, Violence Prevent Res Program, Sacramento, CA 95817 USA	University of California System; University of California Davis	Wintemute, GJ (corresponding author), Univ Calif Davis, Med Ctr, Violence Prevent Res Program, 2315 Stockton Blvd, Sacramento, CA 95817 USA.							Black DA, 1998, J LEGAL STUD, V27, P209, DOI 10.1086/468019; *BUR ALC TOB FIR, 1999, CRIM GUN TRAC AN REP; *BUR ALC TOB FIR, 1999, 105825 BUR ALC TOB F; Caruso RP, 1999, J TRAUMA, V46, P462, DOI 10.1097/00005373-199903000-00021; Cherry D, 1998, ANN EMERG MED, V32, P51, DOI 10.1016/S0196-0644(98)70099-X; Cook PJ, 1995, J CRIM LAW CRIM, V86, P59, DOI 10.2307/1144000; Cummings P, 1997, JAMA-J AM MED ASSOC, V278, P1084, DOI 10.1001/jama.278.13.1084; DECKER SH, 1997, NATL I JUSTICE PUBLI; DIAZ T, 1999, MAKING KILLING; Fagan J, 1998, J CRIM LAW CRIM, V88, P1277, DOI 10.2307/1144257; Fingerhut LA, 1998, JAMA-J AM MED ASSOC, V280, P423, DOI 10.1001/jama.280.5.423; KASSIRER JP, 1995, NEW ENGL J MED, V333, P793, DOI 10.1056/NEJM199509213331209; Kellermann AL, 1996, NEW ENGL J MED, V335, P1438, DOI 10.1056/NEJM199611073351906; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KENNEDY D, 1998, HOMICIDE STUDIES, V0002, P00263; Kennedy DM, 1996, LAW CONTEMP PROBL, V59, P147, DOI 10.2307/1192213; Lott JR, 1997, J LEGAL STUD, V26, P1, DOI 10.1086/467988; Ludwig J, 1998, INT REV LAW ECON, V18, P239, DOI 10.1016/S0144-8188(98)00012-X; MANSON DA, 1999, US BUREAU JUSTIC STA; McDowall D, 1995, J CRIM LAW CRIM, V86, P193, DOI 10.2307/1144006; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; *OFF JUV JUST DEL, 1999, OFF JUST PROGR PUBL; PIERCE GL, 1998, 50 ANN M AM SOC CRIM; PIERCE GL, 1998, NATL REPORT FIREARM; Romero M P, 1998, Inj Prev, V4, P206; ROSENFELD R, 1996, FIRE GUN BUY BACKS E, P1; SHELEY JF, 1995, NATL I JUSTICE PUBLI; SHERMAN LW, 1995, NATL I JUSTICE PUBLI; SHERMAN LW, 1997, NATL I JUSTICE PUBLI; SUGARMANN J, 1992, MORE GUN DEALERS GAS; Teret SP, 1998, NEW ENGL J MED, V339, P813, DOI 10.1056/NEJM199809173391206; *US FED BUR INV, 1998, CRIM US 1997; *US FED BUR INV, 1999, UN CRIM REP 1998 PRE; *US GEN ACC OFF, 1991, US GEN ACC OFF PUBL; VERNICK JS, 1998, 126 ANN M AM PUBL HL; Wachtel J., 1998, POLICING INT J POLIC, V21, P220; WEBSTER DW, 1992, ARCH SURG-CHICAGO, V127, P694; Webster DW, 1997, AM J PUBLIC HEALTH, V87, P918, DOI 10.2105/AJPH.87.6.918; WEBSTER DW, 1998, 126 ANN M AM PUBL HL; Weil DS, 1996, JAMA-J AM MED ASSOC, V275, P1759, DOI 10.1001/jama.275.22.1759; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; WINTEMUTE GJ, 1987, J TRAUMA, V27, P532, DOI 10.1097/00005373-198705000-00013; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; Wright MA, 1999, AM J PUBLIC HEALTH, V89, P88, DOI 10.2105/AJPH.89.1.88; 1999, FIREARMS BUSINE 0401, V8, P3; 1999, FIREARMS BUSINE 0415, V8, P6; 1994, MONTHLY VITAL STAT R, V42, P1; 1999, HUNTING SHOOTING SPO, V2, P1	49	23	23	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					475	478		10.1001/jama.282.5.475	http://dx.doi.org/10.1001/jama.282.5.475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442664				2022-12-28	WOS:000081784900025
J	Kirtley, JR; Tsuei, CC; Moler, KA				Kirtley, JR; Tsuei, CC; Moler, KA			Temperature dependence of the half-integer magnetic flux quantum	SCIENCE			English	Article							SUPERCONDUCTING GAP ANISOTROPY; TIME-REVERSAL SYMMETRY; ORDER-PARAMETER; PAIRING SYMMETRY; YBA2CU3O7-DELTA; BI2SR2CACU2O8; JUNCTIONS; VORTICES; STATE	The temperature dependence of the half-integer magnetic flux quantum effect in thin-film tricrystal samples of the high-critical-temperature cuprate superconductor YBa2Cu3O7-delta was measured and found to persist from a temperature of 0.5 kelvin through a critical temperature of about 90 kelvin, with no change in total flux. This result implies that d-wave symmetry pairing predominates in this cuprate, with a small component of time-reversal symmetry breaking, if any over the entire temperature range.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA	International Business Machines (IBM); Stanford University	Kirtley, JR (corresponding author), IBM Corp, Thomas J Watson Res Ctr, POB 218, Yorktown Hts, NY 10598 USA.	kirtley@us.ibm.com	Moler, Kathryn A/F-2541-2011	Moler, Kathryn/0000-0002-0233-8123				ANLAGE SM, 1994, PHYS REV B, V50, P523, DOI 10.1103/PhysRevB.50.523; BICKERS NE, 1989, PHYS REV LETT, V62, P961, DOI 10.1103/PhysRevLett.62.961; BRAWNER DA, 1994, PHYS REV B, V50, P6530, DOI 10.1103/PhysRevB.50.6530; Bulut N, 1996, PHYS REV B, V54, P14971, DOI 10.1103/PhysRevB.54.14971; Covington M, 1997, PHYS REV LETT, V79, P277, DOI 10.1103/PhysRevLett.79.277; Kendziora C, 1996, PHYS REV LETT, V77, P727, DOI 10.1103/PhysRevLett.77.727; Kirtley JR, 1999, APPL PHYS LETT, V74, P4011, DOI 10.1063/1.123244; Kirtley JR, 1996, PHYS REV LETT, V76, P1336, DOI 10.1103/PhysRevLett.76.1336; KIRTLEY JR, 1995, NATURE, V373, P225, DOI 10.1038/373225a0; Koren G, 1998, APPL PHYS LETT, V73, P3763, DOI 10.1063/1.122887; Krishana K, 1997, SCIENCE, V277, P83, DOI 10.1126/science.277.5322.83; MA J, 1995, SCIENCE, V267, P862, DOI 10.1126/science.267.5199.862; MATHAI A, 1995, PHYS REV LETT, V74, P4523, DOI 10.1103/PhysRevLett.74.4523; MILLER JH, 1995, PHYS REV LETT, V74, P2347, DOI 10.1103/PhysRevLett.74.2347; MONTHOUX P, 1992, PHYS REV B, V46, P14803, DOI 10.1103/PhysRevB.46.14803; Pashitskii EA, 1997, PHYSICA C, V282, P1843, DOI 10.1016/S0921-4534(97)01081-2; ROTH BJ, 1989, J APPL PHYS, V65, P361, DOI 10.1063/1.342549; SCALAPINO DJ, 1995, PHYS REP, V250, P330; SIGRIST M, 1995, PHYS REV LETT, V74, P3249, DOI 10.1103/PhysRevLett.74.3249; SPIELMAN S, 1992, PHYS REV LETT, V68, P3472, DOI 10.1103/PhysRevLett.68.3472; SUBOKI K, 1996, J PHYS SOC JPN, V65, P3611; Tsuei CC, 1997, PHYSICA C, V282, P4, DOI 10.1016/S0921-4534(97)00193-7; TSUEI CC, 1994, PHYS REV LETT, V73, P593, DOI 10.1103/PhysRevLett.73.593; WOLLMAN DA, 1993, PHYS REV LETT, V71, P2134, DOI 10.1103/PhysRevLett.71.2134	24	67	67	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	1999	285	5432					1373	1375		10.1126/science.285.5432.1373	http://dx.doi.org/10.1126/science.285.5432.1373			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464089				2022-12-28	WOS:000082233500033
J	Muller, JR; Metha, AB; Krauskopf, J; Lennie, P				Muller, JR; Metha, AB; Krauskopf, J; Lennie, P			Rapid adaptation in visual cortex to the structure of images	SCIENCE			English	Article							CONTRAST GAIN-CONTROL; CAT STRIATE CORTEX; SYNAPTIC DEPRESSION; RECEPTIVE-FIELDS; CORTICAL-NEURONS; SINGLE UNITS; MACAQUE; CELLS; NORMALIZATION; SELECTIVITY	Complex cells in striate cortex of macaque showed a rapid pattern-specific adaptation. Adaptation made cells more sensitive to orientation change near the adapting orientation. It reduced correlations among the responses of populations of cells, thereby increasing the information transmitted by each action potential. These changes were brought about by brief exposures to stationary patterns, on the time scale of a single fixation. Thus, if successive fixations expose neurons' receptive fields to images with similar but not identical structure, adaptation will remove correlations and improve discriminability.	Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA; Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	University of Rochester; University of Rochester; New York University	Muller, JR (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Fairchild D209, Stanford, CA 94305 USA.		; Metha, Andrew/H-2401-2015	Lennie, Peter/0000-0002-2561-6368; Metha, Andrew/0000-0003-2997-4362	NEI NIH HHS [EY01319, EY06638, EY04440] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY004440, P30EY001319, R01EY004440] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BAHILL AT, 1975, INVEST OPHTH VISUAL, V14, P468; BARLOW HB, 1976, VISION RES, V16, P1043, DOI 10.1016/0042-6989(76)90241-8; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Blakemore C., 2010, VISION CODING EFFICI, P363, DOI 10.1017/cbo9780511626197.034; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; Carandini M, 1997, PHILOS T R SOC B, V352, P1149, DOI 10.1098/rstb.1997.0098; Carandini M, 1997, J NEUROSCI, V17, P8621; CARANDINI M, COMMUNICATION; Chance FS, 1998, J NEUROSCI, V18, P4785; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREENLEE MW, 1988, VISION RES, V28, P791, DOI 10.1016/0042-6989(88)90026-0; Hawken MJ, 1996, VISUAL NEUROSCI, V13, P477, DOI 10.1017/S0952523800008154; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; Land MF, 1997, PHILOS T ROY SOC B, V352, P1231, DOI 10.1098/rstb.1997.0105; Lankheet MJM, 1998, VISUAL NEUROSCI, V15, P37, DOI 10.1017/S0952523898151027; LENNIE P, 1990, J NEUROSCI, V10, P649; LENNIE P, 1994, INVEST OPHTH VIS SCI, V35, P1662; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; REGAN D, 1985, J OPT SOC AM A, V2, P147, DOI 10.1364/JOSAA.2.000147; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; SAUL AB, 1989, VISUAL NEUROSCI, V2, P609, DOI 10.1017/S0952523800003539; SCLAR G, 1989, VISION RES, V29, P747, DOI 10.1016/0042-6989(89)90087-4; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SIMONCELLI EP, 1999, ADV NEURAL INFORMATI, V11; TOLHURST DJ, 1980, EXP BRAIN RES, V38, P431; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	38	343	345	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1405	1408		10.1126/science.285.5432.1405	http://dx.doi.org/10.1126/science.285.5432.1405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464100				2022-12-28	WOS:000082233500044
J	Ferris, FL; Davis, MD; Aiello, LM				Ferris, FL; Davis, MD; Aiello, LM			Treatment of diabetic retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RETINAL MICROANEURYSM COUNTS; ALDOSE REDUCTASE INHIBITORS; GALACTOSE-FED DOGS; EYE-CARE; MICROVASCULAR COMPLICATIONS; VITREOUS SURGERY; COST-EFFECTIVENESS; INSULIN INFUSION; HARD EXUDATE; RISK-FACTORS		NEI, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Wisconsin System; University of Wisconsin Madison; Harvard University; Joslin Diabetes Center, Inc.	Ferris, FL (corresponding author), Div Biometry & Epidemiol, 31 Ctr Dr,MSC 2510,Bldg 31,Rm 6A52, Bethesda, MD 20892 USA.	rickferris@nei.nih.gov		Ferris, Frederick/0000-0002-4933-0639				ACKERMAN SJ, 1992, DIABETES CARE, V15, P580, DOI 10.2337/diacare.15.4.580; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Albers JW, 1995, ANN NEUROL, V38, P869, DOI 10.1002/ana.410380607; ANDERSON B, 1980, OPHTHALMOLOGY, V87, P173; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1988, OPHTHALMOLOGY, V95, P1307; [Anonymous], 1990, Arch Ophthalmol, V108, P958; [Anonymous], 1988, JAMA, V260, P37; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1988, Ophthalmology, V95, P1321; [Anonymous], 1976, Am J Ophthalmol, V81, P383; [Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1990, ARCH OPHTHALMOL-CHIC, V108, P1452; Aubert R., 1995, NIH PUBLICATION; Beetham W P, 1969, Trans Am Ophthalmol Soc, V67, P39; BEETHAM W P, 1963, Br J Ophthalmol, V47, P611, DOI 10.1136/bjo.47.10.611; British Multicentre Study Group, 1984, DIABETOLOGIA, V26, P109; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CAIRD FI, 1968, DIABETES, V17, P121, DOI 10.2337/diab.17.3.121; CARLISON S, 1993, NEUROLOGY, V43, P1141; Carroll W W, 1972, Ann Ophthalmol, V4, P1019; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004; CHEW EY, 1995, ARCH OPHTHALMOL-CHIC, V113, P52, DOI 10.1001/archopht.1995.01100010054020; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DANEMAN D, 1981, DIABETES CARE, V4, P360, DOI 10.2337/diacare.4.3.360; DAVIS MD, 1965, ARCH OPHTHALMOL-CHIC, V74, P741; DAVIS MD, 1997, INT TXB DIABETES MEL, V2, P1413; DAVIS MD, 1967, VASCULAR COMPLICATIO, P139; DCCT Res Grp, 1986, DIABETES, V35, P530; DECKERT T, 1967, DIABETES, V16, P728, DOI 10.2337/diab.16.10.728; *DIAB CONTR COMPL, 1998, ARCH OPHTHALMOL-CHIC, V116, P1469; *DIAB RET STUD RES, 1981, DEV OPHTHALMOL, V2, P248; Diabet Contr Complicat Trial Res Grp, 1998, ARCH OPHTHALMOL-CHIC, V116, P874; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Diabetic Retinopathy Study Research Group, 1981, INVEST OPHTH VIS SCI, V21, P149; Diabetic Retinopathy Vitrectomy Study Research Group, 1985, OPHTHALMOLOGY, V92, P492; Dobbie J G, 1973, Trans Am Acad Ophthalmol Otolaryngol, V77, pOP43; DOBREE JH, 1964, BRIT J OPHTHALMOL, V48, P637, DOI 10.1136/bjo.48.12.637; *EARL TREATM DIAB, 1987, INT OPHTHALMOL CLIN, V27, P265; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Ederer F, 1975, Surv Ophthalmol, V19, P267; ENGERMAN RL, 1984, DIABETES, V33, P97, DOI 10.2337/diabetes.33.1.97; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Ferris F, 1996, Trans Am Ophthalmol Soc, V94, P505; FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761; FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; FRANK RN, 1994, DIABETES, V43, P169, DOI 10.2337/diab.43.2.169; FRANK RN, 1989, RETINA, V2, P301; GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513; GOLDBERG MF, 1969, USPHS PUBLICATION, V1890; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; HENNEKENS, 1990, ARCH OPHTHALMOL-CHIC, V108, P1234; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; KADOR PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1099, DOI 10.1001/archopht.1988.01060140255036; KADOR PF, 1990, ARCH OPHTHALMOL-CHIC, V108, P1301, DOI 10.1001/archopht.1990.01070110117035; KAHN HA, 1974, AM J OPHTHALMOL, V78, P58, DOI 10.1016/0002-9394(74)90010-5; KAHN HA, 1975, BRIT J OPHTHALMOL, V59, P345, DOI 10.1136/bjo.59.7.345; KING R C, 1963, Br J Ophthalmol, V47, P666, DOI 10.1136/bjo.47.11.666; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; Klein B E, 1995, Ophthalmic Epidemiol, V2, P49, DOI 10.3109/09286589509071451; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P1356; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P295, DOI 10.1016/S0002-9394(14)71170-5; KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173; KLEIN R, 1989, DIABETES METAB REV, V5, P559, DOI 10.1002/dmr.5610050703; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1780, DOI 10.1001/archopht.1989.01070020862028; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P1386, DOI 10.1001/archopht.1995.01100110046024; Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; Klein R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1073, DOI 10.1001/archopht.1997.01100160243018; KLEIN R, 1994, DIABETES CARE, V17, P614, DOI 10.2337/diacare.17.6.614; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER EM, 1986, OPHTHALMOLOGY, V93, P586; Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297; KUPFER C, 1989, OPHTHALMOLOGY, V96, P737; KUWABARA T, 1960, ARCH OPHTHALMOL-CHIC, V64, P904, DOI 10.1001/archopht.1960.01840010906012; LARSEN H W, 1960, Acta Ophthalmol Suppl, VSuppl 60, P1; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LAURITZEN T, 1983, LANCET, V1, P200; MACHEMER R, 1972, AM J OPHTHALMOL, V74, P1034, DOI 10.1016/0002-9394(72)90720-9; MACHEMER R, 1972, AM J OPHTHALMOL, V73, P1; MACHEMER R, 1972, AM J OPHTHALMOL, V74, P1022, DOI 10.1016/0002-9394(72)90719-2; Meyer-Schwickerath G., 1960, LIGHT COAGULATION; Moss S E, 1995, Arch Fam Med, V4, P529, DOI 10.1001/archfami.4.6.529; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Patz A, 1973, Trans Am Acad Ophthalmol Otolaryngol, V77, pOP34; POWELL EDU, 1964, LANCET, V2, P17; PUKLIN JE, 1982, OPHTHALMOLOGY, V89, P735; RAND LI, 1985, INVEST OPHTH VIS SCI, V26, P983; REGNAULT F, 1972, SEM HOP PARIS, V48, P893; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROBISON WG, 1989, INVEST OPHTH VIS SCI, V30, P2285; Robison WG, 1996, INVEST OPHTH VIS SCI, V37, P1149; SAGEL J, 1975, ANN INTERN MED, V82, P733, DOI 10.7326/0003-4819-82-6-733; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SIGURDSSON R, 1980, BRIT J OPHTHALMOL, V64, P392, DOI 10.1136/bjo.64.6.392; Smiddy WE, 1998, INT OPHTHALMOL CLIN, V38, P155, DOI 10.1097/00004397-199838020-00011; SMIDDY WE, 1995, OPHTHALMOLOGY, V102, P1688; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; SPRAFKA JM, 1990, ARCH INTERN MED, V150, P857, DOI 10.1001/archinte.150.4.857; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tasman W, 1979, Mod Probl Ophthalmol, V20, P413; The Diabetes Control and Complications Trial Research Group, 1997, JAMA-J AM MED ASSOC, V278, P25; The Diabetic Retinopathy Study Research Group, 1979, ARCH OPHTHALMOL-CHIC, V97, P654; The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644; The Early Treatment Diabetic Retinopathy Study Research Group, 1987, INT OPHTHALMOL CLIN, V27, P254, DOI DOI 10.1097/00004397-198702740-00005; TOLENTIN.FI, 1966, ARCH OPHTHALMOL-CHIC, V75, P238; TURNER RC, 1993, J HYPERTENS, V11, P309; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UK PROSP DIAB STU, 1998, LANCET, V352, P1557; WILL JC, 1994, AM J PUBLIC HEALTH, V84, P1669, DOI 10.2105/AJPH.84.10.1669; WISE G N, 1956, Trans Am Ophthalmol Soc, V54, P729; YANKO L, 1983, BRIT J OPHTHALMOL, V67, P759, DOI 10.1136/bjo.67.11.759; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796	132	127	135	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					667	678		10.1056/NEJM199908263410907	http://dx.doi.org/10.1056/NEJM199908263410907			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460819				2022-12-28	WOS:000082192500007
J	Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH				Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH			Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY PULMONARY-HYPERTENSION; DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; CHOLESTEROL REDUCTION; PRIMARY PREVENTION; CLINICAL-TRIALS; EVENTS; COMPLICATIONS; DEXFENFLURAMINE; FENFLURAMINE		Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98101 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Group Health Cooperative	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Suite 1360,1730 Minor Ave, Seattle, WA 98101 USA.		Kaplan, Robert/A-2526-2011; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NHLBI NIH HHS [HL40628, HL60739, HL43201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040628, R01HL043201, R01HL040628, R01HL060739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; [Anonymous], 1991, JAMA, V265, P3255; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; *FDA, 1999, EV US DRUG LAW; Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GUYGRAND B, 1989, LANCET, V2, P1142; Imura H, 1998, NEW ENGL J MED, V338, P908, DOI 10.1056/NEJM199803263381311; LIPICKY RJ, 1993, AM J CARDIOL, V22, pA179; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; McCann UD, 1997, JAMA-J AM MED ASSOC, V278, P666, DOI 10.1001/jama.278.8.666; MEINERT CL, 1970, DIABETES, V19, P789; Mitchell P, 1997, LANCET, V350, P1685, DOI 10.1016/S0140-6736(05)64289-4; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sobel BE, 1997, CIRCULATION, V95, P1661; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Temple Robert J., 1995, P3; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	41	122	123	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					786	790		10.1001/jama.282.8.786	http://dx.doi.org/10.1001/jama.282.8.786			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463718	Green Published			2022-12-28	WOS:000082118800034
J	Temple, R				Temple, R			Are surrogate markers adequate to assess cardiovascular disease drugs?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; BLOOD-PRESSURE; HYPERTENSION; MORTALITY; FAILURE; MORBIDITY; THERAPIES		US FDA, Ctr Drug Evaluat & Res Policy, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, Ctr Drug Evaluat & Res Policy, 5600 Fishers Ln,HFD 101, Rockville, MD 20857 USA.	Temple@CDER.fda.gov						Alderman M, 1997, J HYPERTENS, V15, P105; [Anonymous], 1992, Fed Regist, V57, P58942; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Forker AD, 1996, J CLIN PHARMACOL, V36, P973, DOI 10.1177/009127009603601101; FREIS ED, 1990, HYPERTENSION, V16, P472, DOI 10.1161/01.HYP.16.4.472; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PACKER M, 1993, CIRCULATION S1, V88, P1; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Sobel BE, 1997, CIRCULATION, V95, P1661; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TEMPLE R, 1990, DEV CARDIOVASC MED, P139; TEMPLE R, 1988, P179; TEMPLE R, 1987, CONGESTIVE HEART FAI, P155; Temple Robert J., 1995, P3; US Government Printing Office, 1992, FED REGISTER, V57, P13234; *VET ADM COOP STUD, 1967, JAMA-J AM MED ASSOC, V202, P1228; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	30	220	222	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					790	795		10.1001/jama.282.8.790	http://dx.doi.org/10.1001/jama.282.8.790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463719				2022-12-28	WOS:000082118800035
J	Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T				Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T			Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Univ Kuopio, Res Inst Publ Hlth, Kuopio 70211, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, Kuopio 70211, Finland	University of Eastern Finland; University of Eastern Finland	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, POB 1627, Kuopio 70211, Finland.		Lehtimäki, Terho/AAD-1094-2022	Lehtimäki, Terho/0000-0002-2555-4427; Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Sanghera DK, 1998, ATHEROSCLEROSIS, V136, P217, DOI 10.1016/S0021-9150(97)00206-2	5	58	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					487	488		10.1136/bmj.319.7208.487	http://dx.doi.org/10.1136/bmj.319.7208.487			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454401	Bronze, Green Published			2022-12-28	WOS:000082199600020
J	Moore, MAS				Moore, MAS			"Turning brain into blood" - Clinical applications of stem-cell research in neurobiology and hematology	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADULT		Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Moore, MAS (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							Belaoussoff M, 1998, DEVELOPMENT, V125, P5009; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Thomson JA, 1998, SCIENCE, V282, P1827; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 1998, NAT BIOTECHNOL, V16, P478, DOI 10.1038/nbt0598-478; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0	10	25	26	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					605	607		10.1056/NEJM199908193410811	http://dx.doi.org/10.1056/NEJM199908193410811			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451469				2022-12-28	WOS:000082061500011
J	Montecalvo, MA; Jarvis, WR; Uman, J; Shay, DK; Petrullo, C; Rodney, K; Gedris, C; Horowitz, HW; Wormser, GP				Montecalvo, MA; Jarvis, WR; Uman, J; Shay, DK; Petrullo, C; Rodney, K; Gedris, C; Horowitz, HW; Wormser, GP			Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting	ANNALS OF INTERNAL MEDICINE			English	Article							FAECIUM BACTEREMIA; RISK-FACTORS; OUTBREAK; UNIT	Background: Vancomycin-resistant enterococci (VRE) are nosocomial pathogens in many U.S. hospitals. Objective: To determine whether enhanced infection-control strategies reduce transmission of VRE in an endemic setting. Design: Prospective cohort study. Setting: Adult oncology inpatient unit. Patients: 259 patients evaluated during use of enhanced infection-control strategies and 184 patients evaluated during use of standard infection-control practices. Interventions: Patient surveillance cultures were taken, patients were assigned to geographic cohorts, nurses were assigned to patient cohorts, gowns and gloves were worn on room entry, compliance with infection-control procedures was monitored, patients were educated about VRE transmission, patients taking antimicrobial agents were evaluated by an infectious disease specialist, and environmental surveillance was performed. Measurements: VRE infection rates, VRE colonization rates, and changes in antimicrobial use. Results: During use of enhanced infection-control strategies, incidence of VRE bloodstream infections decreased significantly (0.45 patients per 1000 patient-days compared with 2.1 patients per 1000 patient-days; relative rate ratio, 0.22 [95% CI, 0.05 to 0.92]; P = 0.04), as did VRE colonization (10.3 patients per 1000 patient-days compared with 20.7 patients per 1000 patient-days; relative rate ratio, 0.5 [CI, 0.33 to 0.75]; P < 0.001). Use of all antimicrobial agents except clindamycin and amikacin was significantly reduced. Conclusion: Enhanced infection-control strategies reduced VRE transmission in an oncology unit in which VRE were endemic.	New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Westchester Cty Med Ctr, Dept Microbiol, Valhalla, NY 10595 USA	New York Medical College; Centers for Disease Control & Prevention - USA; Westchester Medical Center	Montecalvo, MA (corresponding author), New York Med Coll, Div Infect Dis, Macy Pavil 209SE, Valhalla, NY 10595 USA.			Shay, David/0000-0001-9619-4820	PHS HHS [200-94-0860] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson RL, 1997, INFECT CONT HOSP EP, V18, P195; [Anonymous], 1993, MMWR-MORBID MORTAL W, V42, P597; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; *CONTR PRACT ADV C, 1995, MMWR-MORBID MORTAL W, V44, P1; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; Quale J, 1996, CLIN INFECT DIS, V23, P1020, DOI 10.1093/clinids/23.5.1020; Sahm D.H., 1991, MANUAL CLIN MICROBIO; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Tornieporth NG, 1996, CLIN INFECT DIS, V23, P767, DOI 10.1093/clinids/23.4.767; VanHorn KG, 1996, J CLIN MICROBIOL, V34, P924, DOI 10.1128/JCM.34.4.924-927.1996; WELLS CL, 1995, CLIN INFECT DIS, V21, P45, DOI 10.1093/clinids/21.1.45	17	136	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					269	272		10.7326/0003-4819-131-4-199908170-00006	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454948				2022-12-28	WOS:000082012500005
J	Westendorp, RGJ; Hottenga, JJ; Slagboom, PE				Westendorp, RGJ; Hottenga, JJ; Slagboom, PE			Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; INTRAVASCULAR COAGULATION; ENDOTOXIN; SEPSIS; POLYMORPHISM; DIAGNOSIS; MORTALITY; PROMOTER; INCREASE; DISEASE	Background Some patients infected with Neisseria meningitidis develop septic shock accompanied by fibrin deposition and microthrombus formation in various organs, whereas others develop bacteraemia or meningitis without septic shock. We investigated whether genetic differences in the fibrinolytic system influence the development of meningococcal septic shock. Methods We investigated 50 patients who survived meningococcal infection, and 131 controls from the same geographical region. Because we had no information on genotypes of patients who died, we also genotyped 183 first-degree relatives of a consecutive series of patients with meningococcal infection for the 4G/5G deletion/insertion polymorphism in the promoter region of the plasminogen-activator-inhibitor-1 gene (PAI-1), The 4G allele is associated with increased gene transcription in cell lines in vitro and with increased PAI-1 concentrations in carriers in vivo. Findings The allele frequencies of 4G and 5G were similar between patients and controls. However, the 4G/4G genotype was present in only 9% of relatives of patients with meningitis compared with 36% of relatives of patients with septic shock. The 5G/5G genotype was more common among relatives of patients with meningitis (31 vs 11%, p=0.001). Patients whose relatives were carriers of the 4G/4G genotype had a six-fold higher risk of developing septic shock than meningitis (odds ratio 5.9 [95% CI 1.9-18.0]) compared with all other genotypes, Interpretation Variation in the PAI-1 gene does not affect the probability of contracting meningococcal infection, but does influence the development of septic shock.	Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; TNO, Gaubius Lab, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Westendorp, RGJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, CO-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Slagboom, P. Eline/R-4790-2016	Slagboom, P. Eline/0000-0002-2875-4723				ANDERSEN BM, 1987, SCAND J INFECT DIS, V19, P409, DOI 10.3109/00365548709021673; BOHM N, 1982, PATHOL RES PRACT, V174, P92; BRANDTZAEG P, 1990, THROMB RES, V57, P271, DOI 10.1016/0049-3848(90)90326-8; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; MANSFIELD MW, 1995, THROMB HAEMOSTASIS, V74, P1032; Mesters RM, 1996, THROMB HAEMOSTASIS, V75, P902; Mohanty D, 1997, AM J HEMATOL, V54, P23, DOI 10.1002/(SICI)1096-8652(199701)54:1&lt;23::AID-AJH4&gt;3.0.CO;2-6; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Paloma MJ, 1995, THROMB HAEMOSTASIS, V74, P1578; PARAMO JA, 1990, THROMB HAEMOSTASIS, V64, P3; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; VANDEUREN M, 1993, BMJ-BRIT MED J, V306, P1229, DOI 10.1136/bmj.306.6887.1229; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WESTENDORP RGJ, 1992, AM J MED, V92, P577, DOI 10.1016/0002-9343(92)90761-Y; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1996, THROMB HAEMOSTASIS, V75, P899; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	23	147	152	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					561	563		10.1016/S0140-6736(98)09376-3	http://dx.doi.org/10.1016/S0140-6736(98)09376-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470701				2022-12-28	WOS:000081991000014
J	Yakshinskiy, BV; Madey, TE				Yakshinskiy, BV; Madey, TE			Photon-stimulated desorption as a substantial source of sodium in the lunar atmosphere	NATURE			English	Article							MERCURY; SURFACE; POTASSIUM; ATOMS; EXOSPHERE; DISCOVERY; ORIGIN; IONS; MOON	Mercury and the Moon both have tenuous atmospheres that contain atomic sodium and potassium. These chemicals must be continuously resupplied, as neither body can retain the atoms for more than a few hours (refs 1-6). The mechanisms proposed to explain the resupply include sputtering of the surface by the solar wind(3,4), micrometeorite impacts(5), thermal desorption(6-8) and photon-stimulated desorption(6-10). But there are few data and no general agreement about which processes. dominate(5,10-14). Here we report laboratory studies of photon-stimulated desorption of sodium from Surfaces that simulate lunar silicates. We find that bombardment of such surfaces at temperatures of similar to 250 K by ultraviolet photons (wavelength lambda < 300 nm) causes very efficient desorption of sodium atoms, induced by electronic excitations rather than by thermal processes or momentum transfer. The flux at the lunar surface of ultraviolet photons from the Sun is sufficient to ensure that photon-stimulated desorption of sodium contributes substantially to the Moon's atmosphere. On Mercury, solar heating of the surface implies that thermal desorption(7) will also be an important source of atmospheric sodium.	Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Rutgers State Univ, Surface Modificat Lab, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Madey, TE (corresponding author), Rutgers State Univ, Dept Phys & Astron, POB 849, Piscataway, NJ 08854 USA.							AGEEV VN, 1995, NUCL INSTRUM METH B, V101, P69, DOI 10.1016/0168-583X(95)00286-3; Ageev VN, 1998, PHYS REV B, V58, P2248, DOI 10.1103/PhysRevB.58.2248; FLYNN B, 1995, J GEOPHYS RES-PLANET, V100, P23271, DOI 10.1029/95JE01747; HEATH DF, 1977, SOLAR OUTPUT ITS VAR, P193; Hellsing B, 1997, J CHEM PHYS, V106, P982, DOI 10.1063/1.473177; Hunten DM, 1997, ADV SPACE RES-SERIES, V19, P1551, DOI 10.1016/S0273-1177(97)00368-2; IP WH, 1986, GEOPHYS RES LETT, V13, P423, DOI 10.1029/GL013i005p00423; KIVELSON MG, 1995, INTRO SPACE PHYSICS, V92; KNOTEK ML, 1983, SPRINGER SER CHEM PH, V24, P139; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; Madey TE, 1998, J GEOPHYS RES-PLANET, V103, P5873, DOI 10.1029/98JE00230; MASCHHOFF BL, 1991, SURF SCI, V259, P190, DOI 10.1016/0039-6028(91)90537-3; MCGRATH MA, 1986, NATURE, V323, P694, DOI 10.1038/323694a0; MENDILLO M, 1995, NATURE, V377, P404, DOI 10.1038/377404a0; Mendillo M, 1999, ICARUS, V137, P13, DOI 10.1006/icar.1998.6042; MENDILLO M, 1997, ADV SPACE RES, V19, P1557; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1987, ICARUS, V71, P472, DOI 10.1016/0019-1035(87)90041-8; Potter AE, 1998, J GEOPHYS RES-PLANET, V103, P8581, DOI 10.1029/98JE00059; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; Sprague AL, 1997, ICARUS, V129, P506, DOI 10.1006/icar.1997.5784; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; SPRAGUE AL, 1992, ICARUS, V96, P7; Verani S, 1998, PLANET SPACE SCI, V46, P1003, DOI 10.1016/S0032-0633(98)00024-5; Wilde M, 1997, SURF SCI, V390, P186, DOI 10.1016/S0039-6028(97)00547-5; XU XP, 1993, SURF SCI, V282, P323, DOI 10.1016/0039-6028(93)90937-F; ZHOU XL, 1991, SURF SCI REP, V13, P73, DOI 10.1016/0167-5729(91)90009-M	29	138	138	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					642	644		10.1038/23204	http://dx.doi.org/10.1038/23204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458159				2022-12-28	WOS:000082032900045
J	Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE				Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE			Myosin-V is a processive actin-based motor	NATURE			English	Article							SINGLE KINESIN MOLECULES; MOVEMENT; FORCE; TRANSPORT; MECHANICS; STEPS; ATP	Class-V myosins, one of 15 known classes of actin-based molecular motors, have been implicated in several forms of organelle transport(1-5), perhaps working with microtubule-based motors such as kinesin(2-4,6). Such movements may require a motor with mechanochemical properties distinct from those of myosin-II, which operates in large ensembles to drive high-speed motility as in muscle contraction(7). Based on its function and biochemistry, it has been suggested that myosin-V may be a processive motor(7,8) like kinesing(9,10). Processivity means that the motor undergoes multiple catalytic cycles and coupled mechanical advances for each diffusional encounter with its track. This allows single motors to support movement of an organelle along its track Here we provide direct evidence that myosin-V is indeed a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament.	Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Stanford University; Yale University; University of North Carolina; University of North Carolina Chapel Hill	Mehta, AD (corresponding author), Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA.			Cheney, Richard/0000-0001-6565-7888	NIDCD NIH HHS [R29 DC003299] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003299] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Evans LL, 1998, J CELL SCI, V111, P2055; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Mehta AD, 1998, METHOD ENZYMOL, V298, P436, DOI 10.1016/S0076-6879(98)98039-9; Mehta AD, 1998, ADV STR BIO, V5, P229; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Reck-Peterson SL, 1999, MOL BIOL CELL, V10, P1001, DOI 10.1091/mbc.10.4.1001; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tabb JS, 1998, J CELL SCI, V111, P3221; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	30	648	663	1	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					590	593		10.1038/23072	http://dx.doi.org/10.1038/23072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448864				2022-12-28	WOS:000081854800062
J	Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V				Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V			Virginity examinations in turkey - Role of forensic physicians in controlling female sexuality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYMEN; GIRLS	Context Although the Turkish Medical Association has deemed "virginity examinations" a form of gender-based violence, women in Turkey are often subjected to such examinations by forensic physicians for both legal and social reasons. Little is known about these physicians' role and attitudes in this practice. Objectives To assess forensic physicians' experiences and attitudes regarding virginity examinations in Turkey and suggest potential solutions to the problems identified, Design Cross-sectional self-administered survey. Setting Surveys were completed during the Forensic Science Congress held in Kusadasi in April 1998 as well as in urban academic and medical practice settings between April and October 1998. Participants Of 158 physicians who practice, are formally trained in, or are in training for forensic medicine, 118 completed the survey (response rate, 74.7%). Main Outcome Measures Frequency and circumstances of conducting virginity examinations, opinions regarding beneficial and adverse consequences of these examinations, and recommendations for changing the practice, as measured by a 100-item questionnaire. Results Overall, survey respondents reported conducting 5901 examinations in the previous 12 months; 4045 were conducted because of alleged sexual assault and 1856 for social reasons, Although 68% of forensic physicians indicated that they believed virginity examinations are inappropriate in the absence of an allegation of sexual assault, 45% had conducted examinations for social reasons. The majority of the respondents (93%) agreed that the examinations are psychologically traumatic for the patient. In addition, more than half (58%) reported that at least 50% of patients undergo examinations against their will. Conclusions Nearly half of forensic physicians in Turkey conduct virginity examinations for social reasons despite beliefs that such examinations are inappropriate, traumatic to the patient, and often performed against the patient's will. Physicians' participation in such practices is inconsistent with principles of bioethics and international human rights.	Phys Human Rights, Boston, MA 02116 USA; Columbia Univ, Ctr Populat & Family Hlth, Joseph L Mailman Sch Publ Hlth, Program Forced Migrat & Hlth, New York, NY 10027 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Istanbul, Dept Forens Med, Istanbul, Turkey	Columbia University; University of California System; University of California San Francisco; Istanbul University	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.		Fincanci, Sebnem Korur/F-6684-2010; ARICAN, Nadir/G-2778-2012	Fincanci, Sebnem Korur/0000-0003-4484-4961; ARICAN, Nadir/0000-0002-9736-0277				BERENSON AB, 1992, PEDIATRICS, V89, P387; BERENSON AB, 1994, CURR OPIN OBSTET GYN, V6, P526; BUROSU E, 1992, CUMHURIYET      0509; Copelon Rhonda, 1998, WOMEN WAR READER, P63; Das V, 1996, DAEDALUS, V125, P67; FAHRI I, 1984, TOPLUMUMUZDA KADIN C, P152; Finkel MA, 1994, CHILD ABUSE MED DIAG, P185; GIARDINO AP, 1992, PRACTICAL GUIDE EVAL; GODDARD V, 1987, CULTURAL CONSTRUCTIO; Goodyear-Smith FA, 1998, FORENSIC SCI INT, V94, P147, DOI 10.1016/S0379-0738(98)00053-X; ISLAMI U, 1992, TURKIYE KAD N OLGUSU, P131; MATTHEWS CD, 1994, REPROD FERT DEVELOP, V6, P1; Onderoglu Selda, 1993, Okajimas Folia Anatomica Japonica, V70, P35; ORTNER SB, 1978, FEMINIST STUD, V4, P19; OZBAY F, 1992, TURKIYE KAD N OLGUSU, P151; OZUGURLU K, 1985, EVLILIK RAPORU ALTIN, P46; PETERSON VS, 1998, WOMEN WAR READER, P44; Reich, 1990, ORIGINS TERRORISM PS, P161; SCHEGEL A, 1991, AM ETHNOL, V18, P719; *SPSS INC, 1998, SPSS BAS 8 0 WIND; Staub E., 1990, PSYCHOL TORTURE, P49; XIAO Z, 1989, FEMINIST STUD, V15, P279; YUKSEL S, 1992, TURKIYE KAD N OLGUSU, P115; 1994, CUMHURIYET      0325; 1999, LOS ANGELES TIM 0106; [No title captured]	26	19	20	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					485	490		10.1001/jama.282.5.485	http://dx.doi.org/10.1001/jama.282.5.485			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442667				2022-12-28	WOS:000081784900029
J	Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED				Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED			Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide	NATURE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; ISOLATED MESENTERIC-ARTERY; GENE-RELATED PEPTIDE; RAT HEPATIC-ARTERY; CANNABINOID RECEPTOR; CAPSAICIN RECEPTOR; CB1; NEUROTRANSMITTER; ANTAGONIST; INHIBITION	The endogenous cannabinoid receptor agonist anandamide(1) is a powerful vasodilator of isolated vascular preparations(2-4), but its mechanism of action is unclear. Here we show that the vasodilator response to anandamide in isolated arteries is capsaicin-sensitive and accompanied by release of calcitonin-gene-related peptide (CGRP), The selective CGRP-receptor antagonist 8-37 CGRP (ref. 5), but not the cannabinoid CB1 receptor blocker SR141716A (ref. 7), inhibited the vasodilator effect of anandamide, Other endogenous (2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP 55,940) CB1 and CB2 receptor agonists' could not mimic the action of anandamide. The selective 'vanilloid receptor' antagonist capsazepine(6,7) inhibited anandamide-induced vasodilation and release of CGRP. In patch-clamp experiments on cells expressing the cloned vanilloid receptor (VR1)(8), anandamide induced a capsazepine-sensitive current in whale cells and isolated membrane patches. Our results indicate that anandamide induces vasodilation by activating: vanilloid receptors on perivascular sensory nerves and causing release of CGRP. The vanilloid receptor may thus be another molecular target for endogenous anandamide, besides cannabinoid receptors, in the nervous and cardiovascular systems.	Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice, Napoli, Italy	Lund University; University of California System; University of California San Francisco; Consiglio Nazionale delle Ricerche (CNR)	Hogestatt, ED (corresponding author), Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden.		Di Marzo, Vincenzo/AAD-7742-2019; Andersson, David A/C-3435-2008; Petersson, Jesper/I-2546-2016	Di Marzo, Vincenzo/0000-0002-1490-3070; Andersson, David A/0000-0001-7451-8548; Zygmunt, Peter/0000-0002-5102-8199				BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HAN SP, 1990, BIOCHEM BIOPH RES CO, V168, P786, DOI 10.1016/0006-291X(90)92390-L; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; KAWASAKI H, 1988, NATURE, V335, P164, DOI 10.1038/335164a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Petersson J, 1998, J VASC RES, V35, P285, DOI 10.1159/000025595; Plane F, 1997, BRIT J PHARMACOL, V121, P1509, DOI 10.1038/sj.bjp.0701361; Pratt PF, 1998, AM J PHYSIOL-HEART C, V274, pH375, DOI 10.1152/ajpheart.1998.274.1.H375; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; White R, 1998, BRIT J PHARMACOL, V125, P533, DOI 10.1038/sj.bjp.0702111; White R, 1998, BRIT J PHARMACOL, V125, P689, DOI 10.1038/sj.bjp.0702127; ZYGMENT PM, 1996, BRIT J PHARMACOL, V118, P1149; ZYGMUNT PM, 1994, ACTA PHYSIOL SCAND, V152, P107, DOI 10.1111/j.1748-1716.1994.tb09789.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V122, P1679, DOI 10.1038/sj.bjp.0701601	30	1729	1796	4	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					452	457		10.1038/22761	http://dx.doi.org/10.1038/22761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440374				2022-12-28	WOS:000081715000051
J	Stephens, DS				Stephens, DS			Uncloaking the meningococcus: dynamics of carriage and disease	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; POPULATION; SPREAD		Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA; Vet Affairs Med Ctr, Res Serv, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Stephens, DS (corresponding author), Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA.		Stephens, David S/A-8788-2012					ACHTMAN M, 1994, MOL MICROBIOL, V11, P15, DOI 10.1111/j.1365-2958.1994.tb00285.x; Andersen J, 1998, EPIDEMIOL INFECT, V121, P85, DOI 10.1017/S0950268898008930; [Anonymous], 1805, J MED CHIR PHARM; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; Jones GR, 1998, J INFECT DIS, V178, P451, DOI 10.1086/515622; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; NORTH E, 1980, REV INFECT DIS, V2, P811; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998	14	132	139	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					941	942		10.1016/S0140-6736(98)00279-7	http://dx.doi.org/10.1016/S0140-6736(98)00279-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459897				2022-12-28	WOS:000079421600003
J	Black, J				Black, J			Claude Bernard on the action of curare	BRITISH MEDICAL JOURNAL			English	Article																		BERNARD C, 1938, M CHOISIS PREFACES, P70	1	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					622	622		10.1136/bmj.319.7210.622	http://dx.doi.org/10.1136/bmj.319.7210.622			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473481	Green Published			2022-12-28	WOS:000082460300025
J	Leino-Arjas, P; Liira, J; Mutanen, P; Malmivaara, A; Matikainen, E				Leino-Arjas, P; Liira, J; Mutanen, P; Malmivaara, A; Matikainen, E			Predictors and consequences of unemployment among construction workers: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; ALCOHOL-CONSUMPTION; BODY-WEIGHT; HEALTH; IMPACT; MEN	Objective To study predictors and consequences of unemployment. Design Prospective cohort study. Setting TI construction companies in southern Finland. Participants 586 male employees, aged 40-59 years at baseline in 1991 and not retired during a 4 year follow up. Main outcome measures Long term unemployment, stress symptoms, disease, alcohol consumption, exercise activity and body mass index. Results In a multiple logistic regression model, long term unemployment (> 24 months v less than or equal to 24 months) was predicted by age 50-54 years v 40-44 years (odds ratio 2.0, 95% confidence interval 1.1 to 3.7), less than or equal to 3 years' employment in the present job (3.1, 1.9 to 5.1), previous unemployment (2.1, 1.2 to 3.8), being single (1.8, 1.1 to 3.1), current smoking (2.6, 1.4 to 4.7), high alcohol consumption (2.1, 1.1 to 4.3), body mass index <23 kg/m(2) v 23-29 kg/m(2) (2.4, 1.3 to 4.4), frequent stress symptoms (2.0, 1.2, to 3.2), mental disorders (7.8, 1.5 to 40.0), and skin diseases (2.0, 1.0 to 3.9). Workers who were unemployed long term reported increased stress (2.1, 1.2 to 3.5) but fewer incident diseases (0.6, 0.4 to 0.9), decreased alcohol consumption (2.9, 1.6 to 5.2), increased exercise (1.9, 1.2 to 3.0), and increased; body mass index (2.3, 1.3 to 4.0) compared with the rest of the cohort. Conclusions The workers' perceptions of work did not predict unemployment Health based selection to long term unemployment was shown. Smoking and high alcohol consumption predated unemployment, but favourable lifestyle changes were observed among the unemployed workers. Stress predicted unemployment, which further increased the stress.	Finnish Inst Occupat Hlth, Dept Epidemiol & Biostat, FIN-00250 Helsinki, Finland; Finnish Inst Occupat Hlth, Work Abil Ctr, FIN-00250 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Occupat Med, FIN-00250 Helsinki, Finland; Local Govt Pens Inst Finland, FIN-00100 Helsinki, Finland	Finnish Institute of Occupational Health; Finnish Institute of Occupational Health; Finnish Institute of Occupational Health	Leino-Arjas, P (corresponding author), Finnish Inst Occupat Hlth, Dept Epidemiol & Biostat, FIN-00250 Helsinki, Finland.			Leino-Arjas, Paivi/0000-0001-9534-7071				Avery AJ, 1998, PUBLIC HEALTH, V112, P169, DOI 10.1016/S0033-3506(98)00223-6; BARTLEY M, 1994, J EPIDEMIOL COMMUN H, V48, P333, DOI 10.1136/jech.48.4.333; Bethune A, 1996, Popul Trends, P37; *DAT AN PROD, 1997, S PLUS 4 GUID STAT; Dooley D, 1991, WHO Reg Publ Eur Ser, V37, P313; ELKELES T, 1993, EUR J PUBLIC HEALTH, V3, P28; EZZY D, 1993, SOC SCI MED, V37, P41, DOI 10.1016/0277-9536(93)90316-V; HALLSTEN L, 1998, ARBETE HALSA, V7; JANLERT U, 1992, BRIT J ADDICT, V87, P703; JIN RL, 1995, CAN MED ASSOC J, V153, P529; LEE AJ, 1991, SOC SCI MED, V33, P1309, DOI 10.1016/0277-9536(91)90080-V; LEINOARJAS P, 1998, TYO JA IHMINEN, V12, P139; Liira J, 1999, SCAND J WORK ENV HEA, V25, P42, DOI 10.5271/sjweh.382; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; Martikainen PT, 1996, LANCET, V348, P909, DOI 10.1016/S0140-6736(96)03291-6; Mathers CD, 1998, MED J AUSTRALIA, V168, P178, DOI 10.5694/j.1326-5377.1998.tb126776.x; MATIKAINEN E, 1998, TYO JA IHMINEN, V12, P85; Montgomery SM, 1998, EUR J PUBLIC HEALTH, V8, P21, DOI 10.1093/eurpub/8.1.21; MORRIS JK, 1992, BRIT MED J, V304, P536, DOI 10.1136/bmj.304.6826.536; MORRIS JK, 1991, BRIT J IND MED, V48, P1; Ryan J, 1996, J OCCUP ENVIRON MED, V38, P928, DOI 10.1097/00043764-199609000-00017; Weich S, 1998, BMJ-BRIT MED J, V317, P115, DOI 10.1136/bmj.317.7151.115	22	102	103	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					600	605		10.1136/bmj.319.7210.600	http://dx.doi.org/10.1136/bmj.319.7210.600			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	234AJ	10473472	Bronze, Green Published			2022-12-28	WOS:000082460300014
J	Ramsay, LE; Williams, B; Johnston, GD; MacGregor, GA; Poston, L; Potter, JF; Poulter, NR; Russell, G				Ramsay, LE; Williams, B; Johnston, GD; MacGregor, GA; Poston, L; Potter, JF; Poulter, NR; Russell, G			British Hypertension Society guidelines for hypertension management 1999: summary	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISOLATED SYSTOLIC HYPERTENSION; BLOOD-PRESSURE; ANTIHYPERTENSIVE TREATMENT; MILD HYPERTENSION; WORKING PARTY; TRIAL; METAANALYSIS; PLACEBO; THERAPY; AGENTS		Univ Leicester, Leicester Royal Infirm, Sch Med, Leicester LE2 7LX, Leics, England; Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England; Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland; Univ London St Georges Hosp, Dept Med, London SW17 0RE, England; St Thomas Hosp, Dept Obstet & Gynaecol, London SE1 7EH, England; Imperial Coll Sch Med, London W2 1NY, England; N Staffordshire Royal Infirm, Stoke On Trent ST4 7LN, Staffs, England	University of Leicester; University of Sheffield; Queens University Belfast; St Georges University London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; Keele University; University Hospital of North Staffordshire NHS Trust	Williams, B (corresponding author), Univ Leicester, Leicester Royal Infirm, Sch Med, Leicester LE2 7LX, Leics, England.	bw17@leicester.ac.uk		Williams, Bryan/0000-0002-8094-1841				ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; Andersson OK, 1998, BMJ-BRIT MED J, V317, P167, DOI 10.1136/bmj.317.7152.167; [Anonymous], 1991, JAMA, V265, P3255; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Colhoun HM, 1998, J HYPERTENS, V16, P747, DOI 10.1097/00004872-199816060-00005; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; *JOINT BRIT REC PR, 1998, HEART, V80, pS1; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; Meade TW, 1998, LANCET, V351, P233; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; O'Brien E., 1997, BLOOD PRESSURE MEASU; Philipp T, 1997, BMJ-BRIT MED J, V315, P154, DOI 10.1136/bmj.315.7101.154; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; *SCOTT INT GUID NE, 1999, LIP PRIM PREV COR HE; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; *STAND MED ADV COM, 1997, US STAT; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; THIJS L, 1992, J HYPERTENS, V10, P1103, DOI 10.1097/00004872-199210000-00001; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	29	271	278	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	1999	319	7210					630	635		10.1136/bmj.319.7210.630	http://dx.doi.org/10.1136/bmj.319.7210.630			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473485	Green Published			2022-12-28	WOS:000082460300031
J	Eloubeidi, MAS; Fowler, VG				Eloubeidi, MAS; Fowler, VG			Emphysematous pyelonephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Eloubeidi, MAS (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.		Fowler, Vance/AAW-2017-2021						0	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					737	737		10.1056/NEJM199909023411005	http://dx.doi.org/10.1056/NEJM199909023411005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471460				2022-12-28	WOS:000082291900005
J	Singer, AJ; Clark, RAF				Singer, AJ; Clark, RAF			Mechanisms of disease - Cutaneous wound healing	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; COLLAGEN MATRICES; VENOUS ULCERS; SKIN ULCERS; EPIDERMAL-KERATINOCYTES; EXTRACELLULAR-MATRIX; PROVISIONAL MATRIX; GRANULATION-TISSUE; HYPERTROPHIC SCARS; MOLECULAR-BASIS		SUNY Stony Brook, Univ Med Ctr, Dept Emergency Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Dermatol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Singer, AJ (corresponding author), SUNY Stony Brook, Univ Med Ctr, Dept Emergency Med, Stony Brook, NY 11794 USA.		Singer, Adam/ABG-4506-2021					Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; BABU M, 1992, J INVEST DERMATOL, V99, P650, DOI 10.1111/1523-1747.ep12668146; BAILEY AJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P412, DOI 10.1016/0005-2795(75)90106-3; BOYCE ST, 1995, WOUNDS, V7, P24; Brigham Peter A., 1996, Journal of Burn Care and Rehabilitation, V17, P95, DOI 10.1097/00004630-199603000-00003; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Bullard KM, 1997, J PEDIATR SURG, V32, P1023, DOI 10.1016/S0022-3468(97)90391-2; Clark, 1996, MOL CELLULAR BIOL WO, P355; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CLARK RAF, 1995, J CELL SCI, V108, P1251; CLARK RAF, 1989, J CLIN INVEST, V84, P1036, DOI 10.1172/JCI114227; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; CLARK RAF, 1982, J EXP MED, V156, P646, DOI 10.1084/jem.156.2.646; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; CUONO C, 1986, LANCET, V1, P1123, DOI 10.1016/S0140-6736(86)91838-6; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; EAGLSTEIN WH, 1995, DERMATOL SURG, V21, P839, DOI 10.1111/j.1524-4725.1995.tb00709.x; FAHEY TJ, 1991, J SURG RES, V50, P308, DOI 10.1016/0022-4804(91)90196-S; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Folkman J, 1997, EXS, V79, P1; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; GILCHREST BA, 1983, J CELL PHYSIOL, V117, P235, DOI 10.1002/jcp.1041170215; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; GRAY AJ, 1993, J CELL SCI, V104, P409; Greiling D, 1997, J CELL SCI, V110, P861; Guo NH, 1997, CANCER RES, V57, P1735; HEFTON JM, 1986, J AM ACAD DERMATOL, V14, P399, DOI 10.1016/S0190-9622(86)70048-0; HEFTON JM, 1983, LANCET, V2, P428; HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008; Heldin CH., 1996, MOL CELLULAR BIOL WO, P249; HUNT TK, 1980, WOUND HEALING WOUND; Ilan N, 1998, J CELL SCI, V111, P3621; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LEIGH IM, 1987, BRIT J DERMATOL, V117, P591, DOI 10.1111/j.1365-2133.1987.tb07491.x; LEVENSON SM, 1965, ANN SURG, V161, P293, DOI 10.1097/00000658-196502000-00019; Loots MAM, 1998, J INVEST DERMATOL, V111, P850, DOI 10.1046/j.1523-1747.1998.00381.x; Machesney M, 1998, AM J PATHOL, V152, P1133; MADDEN MR, 1986, J TRAUMA, V26, P955, DOI 10.1097/00005373-198611000-00001; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; MARTIN P, 1992, NATURE, V360, P179, DOI 10.1038/360179a0; McClain SA, 1996, AM J PATHOL, V149, P1257; *MED DAT INT, 1997, US MARK WOUND MAN PR; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; Nissen NN, 1998, AM J PATHOL, V152, P1445; NOLAN CM, 1978, DIABETES, V27, P889, DOI 10.2337/diab.27.9.889; OCONNOR NE, 1981, LANCET, V1, P75; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PHILLIPS TJ, 1989, J AM ACAD DERMATOL, V21, P191, DOI 10.1016/S0190-9622(89)70160-2; PIERCE GF, 1995, ANNU REV MED, V46, P467; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Pintucci Giuseppe, 1996, Seminars in Thrombosis and Hemostasis, V22, P517, DOI 10.1055/s-2007-999054; Purdue Gary F., 1997, Journal of Burn Care and Rehabilitation, V18, pS13, DOI 10.1097/00004630-199701001-00007; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; ROBSON MC, 1992, LANCET, V339, P23, DOI 10.1016/0140-6736(92)90143-Q; ROBSON MC, 1992, ANN SURG, V216, P401, DOI 10.1097/00000658-199210000-00002; RUE LW, 1993, J TRAUMA, V34, P662, DOI 10.1097/00005373-199305000-00008; Saed GM, 1998, ARCH DERMATOL, V134, P963, DOI 10.1001/archderm.134.8.963; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHAH M, 1995, J CELL SCI, V108, P985; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; SULLIVAN KM, 1995, J PEDIATR SURG, V30, P198, DOI 10.1016/0022-3468(95)90560-X; TEEPE RGC, 1990, BRIT J DERMATOL, V122, P81, DOI 10.1111/j.1365-2133.1990.tb08243.x; THIVOLET J, 1986, TRANSPLANTATION, V42, P274, DOI 10.1097/00007890-198609000-00010; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Tredget EE, 1997, SURG CLIN N AM, V77, P701, DOI 10.1016/S0039-6109(05)70576-4; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; ZHANG K, 1995, J INVEST DERMATOL, V104, P750, DOI 10.1111/1523-1747.ep12606979	86	4285	4496	40	967	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					738	746		10.1056/NEJM199909023411006	http://dx.doi.org/10.1056/NEJM199909023411006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471461				2022-12-28	WOS:000082291900006
J	Hamilton, W; Bradley, N				Hamilton, W; Bradley, N			Self regulation at work: a case study	BRITISH MEDICAL JOURNAL			English	Editorial Material														Hamilton, William/0000-0003-1611-1373					0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					585	585		10.1136/bmj.319.7209.585	http://dx.doi.org/10.1136/bmj.319.7209.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463928	Green Published			2022-12-28	WOS:000082347200067
J	Markel, H				Markel, H			Charles Dickens' work to help establish Great Ormond Street Hospital, London	LANCET			English	Editorial Material									Hist Ctr Hlth Sci, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Simpson Mem Inst 100, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Hist Ctr Hlth Sci, Dept Pediat & Communicable Dis, Box 0725,102 Observ, Ann Arbor, MI 48109 USA.							ACKROYD P, 1990, DICKENS, P56; DICKENS C, 1850, D COPPERFIELD, P183; DICKENS C, 1865, OUR MUTUAL FRIEND, P246; DICKENS C, 1852, HOUSEHOLD WORDS 0403, P47; DICKENS C, 1852, HOUSEHOLD WORDS 0403, P45; DICKENS C, 1862, ALL YEAR ROUND  0201, P454; DICKENS Charles, 1860, UNCOMMERCIAL TRAVELL; FIELDING KJ, 1960, SPEECHES C DICKENS, P40; FORSTER J, 1966, LIFE C DICKENS, V1, P21; JOHNSON E, 1952, C DICKENS HIS TRAGED, V1, P27; KITTON FG, 1890, C DICKENS PEN PENC S, P46; KOSKY J, 1989, MUTUAL FRIENDS C DIC, P143; Kosky Jules, 1989, MUTUAL FRIENDS C DIC; MARKEL H, 1984, ANN INTERN MED, V101, P408, DOI 10.7326/0003-4819-101-3-408; Markel H, 1985, Pharos Alpha Omega Alpha Honor Med Soc, V48, P5; POYNTER FNL, 1962, P ROY SOC MED, V55, P381, DOI 10.1177/003591576205500513; STONE H, 1969, UNCOLLECTED WRITINGS, V2, P401; STOREY G, 1995, LETT C DICKENS, V8, P649	18	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					673	675		10.1016/S0140-6736(98)10108-3	http://dx.doi.org/10.1016/S0140-6736(98)10108-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466687				2022-12-28	WOS:000082214500047
J	Meddings, DR; O'Connor, SM				Meddings, DR; O'Connor, SM			Circumstances around weapon injury in Cambodia after departure of a peacekeeping force: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							WAR; EPIDEMIOLOGY; INTERVENTION; HEALTH	Objective To examine the circumstances surrounding weapon injury and combatant status of those injured by weapons. Design Prospective cohort study Setting Northwestern Cambodia after departure of United Nations peacekeeping force, Subjects 863 people admitted to hospital for weapon injuries over 12 months. Main outcome measures Annual incidence of Weapon injury by time period; proportions of injuries inflicted as a result of interfactional combat (combat injuries) and outside such combat (non-combat injuries) by combatant status and weapon type. Results The annual incidence of weapon injuries was higher than the rate observed before the peacekeeping operation. 30%, of weapon injuries occurred in contexts other than inter-factional combat. Most commonly these were firearm injuries inflicted intentionally on civilians, Civilians accounted for 71% of those with non-combat injuries, 42% of those with combat related injuries, and 51% of those with weapon injuries of either type. Conclusions The incidence of weapon injuries remained high when the disarmament component of a peacekeeping operation achieved only limited success. Furthermore, injuries occurring outside the context of interfactional combat accounted for a substantial proportion of all weapon injuries, were experienced disproportionately by civilians, and were most likely to entail the intentional use of a firearm against a civilian.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Div Hlth Operat, CH-1202 Geneva, Switzerland		Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; *AS WATCH PHYS HUM, 1991, LAND MIN CAMB COW WA; COBEY JC, 1993, JAMA-J AM MED ASSOC, V270, P632, DOI 10.1001/jama.270.5.632; COMNINELLIS N, 1994, TROP DOCT, V24, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Grossman Dave, 1995, KILLING PSYCHOL COST; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; WANG J, 1996, MANAGING ARMS PEACE, P32; WEINBERG J, 1995, SOC SCI MED, V40, P1663, DOI 10.1016/0277-9536(95)00022-Y; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	14	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					412	415		10.1136/bmj.319.7207.412	http://dx.doi.org/10.1136/bmj.319.7207.412			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445922	Green Published, Bronze			2022-12-28	WOS:000082098900016
J	Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA				Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA			Giant eyes in Xenopus laevis by overexpression of XOptx2	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; HOMEOBOX GENE SIX3; S-PHASE; LENS INDUCTION; DROSOPHILA EYE; NERVOUS-SYSTEM; EYELESS GENE; SINE OCULIS; EXPRESSION; DIFFERENTIATION	Overexpression of XOptx2, a homeodomain-containing transcription factor expressed in the Xenopus embryonic eye field, results in a dramatic increase in eye size. An XOptx2-Engrailed repressor gives a similar phenotype, while an XOptx2-VP16 activator reduces eye size. XOptx2 stimulates bromodeoxyuridine incorporation, and XOptx2-induced eye enlargement is dependent on cellular proliferation. Moreover, retinoblasts transfected with XOptx2 produce clones of cells approximately twice as large as control clones. Pax6, which does not increase eye size alone, acts synergistically with XOptx2. Our results suggest that XOptx2, in combination with other genes expressed in the eye field, is crucially involved in the proliferative state of retinoblasts and thereby the size of the eye.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge CB3 2QQ, England; Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	University of Cambridge; University of Cambridge; Salk Institute	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Perron, Muriel/F-6795-2019	Perron, Muriel/0000-0002-1558-8236; Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; EAGLESON G, 1995, J NEUROBIOL, V28, P146, DOI 10.1002/neu.480280203; Faber J., 1994, NORMAL TABLE XENOPUS, P2; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harris W. A., 1979, SOC NEUROSCI S, V4, P228; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kobayashi M, 1998, DEVELOPMENT, V125, P2973; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Li HS, 1997, DEVELOPMENT, V124, P603; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; Lopez-Rios J, 1999, MECH DEVELOP, V83, P155, DOI 10.1016/S0925-4773(99)00017-9; MARDON G, 1994, DEVELOPMENT, V120, P3473; Mariani FV, 1998, DEVELOPMENT, V125, P5019; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; PITTACK C, 1991, DEVELOPMENT, V113, P577; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROTMANN ECKHARD, 1940, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V140, P124, DOI 10.1007/BF00576250; Rotmann Eckhard, 1939, Wilhelm Roux Arch Entwickl Mech Org, V139, P1, DOI 10.1007/BF00576382; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Shen WP, 1997, DEVELOPMENT, V124, P45; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Stone LS, 1930, J EXP ZOOL, V55, P193, DOI 10.1002/jez.1400550112; Toy J, 1999, MECH DEVELOP, V83, P183, DOI 10.1016/S0925-4773(99)00049-0; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TWITTY V, 1955, ANAL DEV, P402; TWITTY VC, 1940, GROWTH, V4, P109	46	169	169	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					341	352		10.1016/S0092-8674(00)81963-7	http://dx.doi.org/10.1016/S0092-8674(00)81963-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458609	Bronze			2022-12-28	WOS:000081950300009
J	Clancy, CE; Rudy, Y				Clancy, CE; Rudy, Y			Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia	NATURE			English	Article							LONG-QT SYNDROME; DYNAMIC-MODEL; ION CHANNELS; MUTATIONS; HEART; AFTERDEPOLARIZATIONS; MECHANISM; MYOCYTES	Advances in genetics and molecular biology have provided an extensive body of information on the structure and function of the elementary building blocks of living systems. Genetic defects in membrane ion channels can disrupt the delicate balance of dynamic interactions between the ion channels and the cellular environment, leading to altered cell function(1-3). As ion-channel defects are typically studied in isolated expression systems, away from the cellular environment where they function physiologically, a connection between molecular findings and the physiology and pathophysiology of the cell is rarely established. Here we describe a single-channel-based Markovian modelling approach that bridges this gap. We achieve this by determining the cellular arrhythmogenic consequences of a mutation in the cardiac sodium channel that can lead to a clinical arrhythmogenic disorder (the long-QT syndrome) and sudden cardiac death.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rudy, Y (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	yxr@po.cwru.edu	Clancy, Colleen/B-2528-2010					Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; BALSER JR, 1990, BIOPHYS J, V57, P433, DOI 10.1016/S0006-3495(90)82560-1; Barinaga M, 1998, SCIENCE, V281, P32, DOI 10.1126/science.281.5373.32; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Hanck D. A., 1995, CARDIAC ELECTROPHYSI, P65; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; MITSUIYE T, 1995, J PHYSIOL-LONDON, V485, P581, DOI 10.1113/jphysiol.1995.sp020754; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; Wang DW, 1997, J CLIN INVEST, V99, P1714, DOI 10.1172/JCI119335; WELSH MJ, 1995, NATURE, V376, P640, DOI 10.1038/376640a0; YUE DT, 1989, SCIENCE, V244, P349, DOI 10.1126/science.2540529; ZENG J, 1997, BIOMEDICAL ENG; ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140; ZENG JL, 1995, BIOPHYS J, V68, P949, DOI 10.1016/S0006-3495(95)80271-7	21	324	332	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					566	569		10.1038/23034	http://dx.doi.org/10.1038/23034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448858				2022-12-28	WOS:000081854800056
J	Brener, ND; Simon, TR; Krug, EG; Lowy, R				Brener, ND; Simon, TR; Krug, EG; Lowy, R			Recent trends in violence-related behaviors among high school students in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUTH	Context Violence-related behaviors such as fighting and weapon carrying are associated with serious physical and psychosocial consequences for adolescents. Objective To measure trends in nonfatal violent behaviors among adolescents in the United States between 1991 and 1997. Design, Setting, and Participants Nationally representative data from the 1991, 1993, 1995, and 1997 Youth Risk Behavior Surveys were analyzed to describe the percentage of students in grades 9 through 12 who engaged in behaviors related to violence. Overall response rates for each of these years were 68%, 70%, 60%, and 69%, respectively. To assess the statistical significance of time trends for these variables, logistic regression analyses were conducted that controlled for sex, grade, and race or ethnicity and simultaneously assessed linear and higher-order effects. Main Outcome Measures Self-reported weapon carrying, physical fighting, fighting-related injuries, feeling unsafe, and damaged or stolen property. Results Between 1991 and 1997, the percentage of students in a physical fight decreased 14%, from 42.5% (95% confidence interval [CI], 40.1%-44.9%) to 36.6% (95% CI, 34.6%-38.6%); the percentage of students injured in a physical fight decreased 20%, from 4.4% (95% CI, 3.6%-5.2%) to 3.5% (95% CI, 2.9%-4.1%); and the percentage of students who carried a weapon decreased 30%, from 26.1% (95% CI, 23.8%-28.4%) to 18.3% (95% CI, 16.5%-20.1%). Between 1993 and 1997, the percentage of students who carried a gun decreased 25%, from 7.9% (95% CI, 6.6%-9.2%) to 5.9% (95% CI, 5.1%-6.7%); the percentage of students in a physical fight on school property decreased 9%, from 16.2% (95% CI, 15.0%-17.4%) to 14.8% (95% CI, 13.5%-16.1%); and the percentage of students who carried a weapon on school property decreased 28%, from 11.8% (95% CI, 10.4%-13.2%) to 8.5% (95% CI, 7.0%-10.0%). All of these changes represent significant linear decreases. Conclusions Declines in fighting and weapon carrying among US adolescents between 1991 and 1997 are encouraging and consistent with declines in homicide, nonfatal victimization, and school crime rates. Further research should explore why behaviors related to interpersonal violence are decreasing and what types of interventions are most effective.	Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Brener, ND (corresponding author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-33,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 1995, MMWR Recomm Rep, V44, P1; BRENER ND, 1995, AM J EPIDEMIOL, V141, P575, DOI 10.1093/oxfordjournals.aje.a117473; *BUR JUST STAT, 1996, CRIM VICT US 1993; *BUR JUST STAT, 1997, CRIM VICT 1996 CHANG; *BUR JUST STAT, 1993, HIGHL 20 YEARS SURV; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P129; Cole TB, 1999, JAMA-J AM MED ASSOC, V281, P25, DOI 10.1001/jama.281.1.25; Dahlberg LL, 1998, AM J PREV MED, V14, P259, DOI 10.1016/S0749-3797(98)00009-9; Fox JA., 1999, HOMICIDE TRENDS US; Jensen G F, 1986, Violence Vict, V1, P85; Kachur SP, 1996, JAMA-J AM MED ASSOC, V275, P1729, DOI 10.1001/jama.275.22.1729; Kann L, 1993, PUBLIC HLTH REP S1, V108, P1; KAUFMAN P, 1998, PUBLICATION US DEP E; KOLBE LJ, 1993, PUBLIC HEALTH REP, V108, P2; Lowry R, 1998, AM J PREV MED, V14, P122, DOI 10.1016/S0749-3797(97)00020-2; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; MOORE MH, 1998, CRIME JUSTICE REV RE, V24; *NAT CTR ED STAT, 1997, DIG ED STAT 1997; *PHS, 1991, HLTH PEOPLE 2000 NAT; Shah BV, 1996, SUDAAN SOFTWARE STAT; Simon TR, 1999, J ADOLESCENT HEALTH, V24, P340, DOI 10.1016/S1054-139X(98)00121-9	23	111	111	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					440	446		10.1001/jama.282.5.440	http://dx.doi.org/10.1001/jama.282.5.440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442659	Bronze			2022-12-28	WOS:000081784900020
J	Essex-Lopresti, M				Essex-Lopresti, M			Operating theatre design	LANCET			English	Article											Essex-Lopresti, M (corresponding author), 14 Oakwood Pk Rd, London N14 6QG, England.							Boott F., 1847, LANCET, V49, P5; BRIAN V, 1978, NURISNG MIRRO S 0315, pR4; BURDETT HC, 1893, HOSP ASYLUMS WORLD, V4, P72; BURDETT HC, 1880, COTTAGE HOSP THEIR P, P223; *C PLANN OP THEATR, 1963, P ROY SOC MED, V56, P733; *COMM DES OP THEAT, 1964, ANN R COLL SURG ENGL, V34, P217; *DEP COMM COST HOS, 1937, REP DEP COMM COST HO, P28; ESSEXLOPRESTI M, 1962, BMJ-BRIT MED J, P1470, DOI 10.1136/bmj.1.5290.1470; ESSEXLOPRESTI M, 1963, BRIT J ANAESTH, V35, P649, DOI 10.1093/bja/35.10.649; FLUKE K, 1995, OLD OPERATING THEATR; HUBERT D, 1963, ARCHITECTS J, V137, P247; HUMPHREYS H, 1993, J HOSP INFECT, V23, P61, DOI 10.1016/0195-6701(93)90132-J; Lister J, 1867, LANCET, V90, P353, DOI [10.1016/S0140-6736(02)51827-4, DOI 10.1016/S0140-6736(02)51827-4]; *MIN HLTH, 1967, 26 MIN HLTH OP DEP, V26; *MIN HLTH DEP HLTH, 1957, HOSP BUILD B, V1; *NHS EST DEP HLTH, 1991, 26 NHS EST DEP HLTH; *NUFF PROV HOSP TR, 1955, STUD FUNCT DES HOSP, P57; Simpson J.Y., 1847, LANCET, V2, P549, DOI 10.1016/S0140-6736(00)63271-3; SMYLIE HG, 1961, SCOT MED J, V6, P588; SUTHERLAND DA, 1990, H V ENG, V63, P12; WILLIAMS REO, 1960, HOSP INFECTION CAUSE, P164; 1962, BMJ, V1, P1465; 1965, LANCET, V1, P151	23	24	25	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1007	1010		10.1016/S0140-6736(98)11356-9	http://dx.doi.org/10.1016/S0140-6736(98)11356-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459931				2022-12-28	WOS:000079421600052
J	Heger, S; Maier, C; Otter, K; Helwig, U; Suttorp, M				Heger, S; Maier, C; Otter, K; Helwig, U; Suttorp, M			Morphine induced allodynia in a child with brain tumour	BRITISH MEDICAL JOURNAL			English	Article							PARADOXICAL PAIN; HYPERALGESIA; MORPHINE-3-GLUCURONIDE; METABOLISM; ANTAGONIST; TOLERANCE		Univ Kiel, Dept Paediat, D-24105 Kiel, Germany; Univ Kiel, Dept Anaesthesiol, D-24105 Kiel, Germany; Univ Kiel, Dept Pharmacol, D-24105 Kiel, Germany	University of Kiel; University of Kiel; University of Kiel	Heger, S (corresponding author), Oregon Hlth Sci Univ, Oregon Reg Primate Res Ctr, Div Neurosci, 595 NW 185th Ave, Beaverton, OR 97066 USA.		Heger, Sabine/AAW-5360-2020; Suttorp, Meinolf/D-1968-2010	Suttorp, Meinolf/0000-0002-9522-8838				BERDE C, 1990, Pediatrics, V86, P818; BOWSHER D, 1993, BRIT MED J, V306, P473, DOI 10.1136/bmj.306.6876.473; CHOONARA I, 1992, BRIT J CLIN PHARMACO, V34, P434, DOI 10.1111/j.1365-2125.1992.tb05652.x; CHOONARA IA, 1989, BRIT J CLIN PHARMACO, V28, P599, DOI 10.1111/j.1365-2125.1989.tb03548.x; Christrup LL, 1997, ACTA ANAESTH SCAND, V41, P116, DOI 10.1111/j.1399-6576.1997.tb04625.x; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MORLEY JS, 1992, LANCET, V340, P1045, DOI 10.1016/0140-6736(92)93067-W; Savage SR, 1996, J PAIN SYMPTOM MANAG, V11, P274, DOI 10.1016/0885-3924(95)00202-2; SAWE J, 1987, EUR J CLIN PHARMACOL, V32, P377, DOI 10.1007/BF00543973; SJOGREN P, 1994, PAIN, V59, P313, DOI 10.1016/0304-3959(94)90084-1; Sjogren P, 1998, ACTA ANAESTH SCAND, V42, P1070, DOI 10.1111/j.1399-6576.1998.tb05378.x; SMITH GD, 1995, PAIN, V62, P51, DOI 10.1016/0304-3959(94)00228-7; SMITH MT, 1990, LIFE SCI, V47, P579, DOI 10.1016/0024-3205(90)90619-3; SVENSSON JO, 1982, J CHROMATOGR, V230, P427, DOI 10.1016/S0378-4347(00)80494-6; VENN RF, 1990, PAIN S5, V43, P188; Warncke T, 1997, PAIN, V72, P99, DOI 10.1016/S0304-3959(97)00006-7	17	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					627	628		10.1136/bmj.319.7210.627	http://dx.doi.org/10.1136/bmj.319.7210.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473483	Green Published			2022-12-28	WOS:000082460300028
J	Campbell, J; Blakey, R				Campbell, J; Blakey, R			Henry Hasted Dale Anderson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					582	582		10.1136/bmj.319.7209.582	http://dx.doi.org/10.1136/bmj.319.7209.582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463923	Green Published			2022-12-28	WOS:000082347200062
J	Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E				Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E			Familial clustering of Helicobacter pylori infection: population based study	BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL SYMPTOMS; CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; HEALTHY-INDIVIDUALS; IMMUNE-RESPONSE; CHILDREN; GASTRITIS; PREVALENCE; CHILDHOOD; IDENTIFICATION	Objectives To assess the rate of intrafamilial transmission of Helicobacter pylori infection in the general population and the role of a family's social background. Design Population survey. Setting Campogalliano, a town in northern Italy with about 5000 residents. Participants 3289 residents, accounting for 416 families. Main outcome measures Prevalence of H pylori infection assessed by presence of IgG antibodies to H pylori. Results The overall prevalence of H pylori infection was 58%. Children belonging to families with both parents infected had a significantly higher prevalence of H pylori infection (44%) than children from families with only one (30%) or no parents (21%) infected (P < 0.001). Multivariate analyses confirmed that children with both parents positive had double the risk of being infected by H pylori than those from families in which both parents were negative. Family social status was independently related to infection in children, with those from blue collar or farming families showing an increased risk of infection compared with children of white collars workers (odds ratio 2.02, 95% confidence interval 1.16 to 3.49). Conclusions H pylori infection clusters within families belonging to the same population. Social status may also be a risk factor. This suggests either a person to person transmission or a common source of exposure for H pylori infection.	Bracco SpA, Dept Med, I-20134 Milan, Italy; Fondo Studio Malattie Fegato ONLUS, I-34121 Trieste, Italy; Univ Modena & Reggio Emilia, Dept Gynaecol Obstet & Paediat Sci, I-41100 Modena, Italy	Bracco; Universita di Modena e Reggio Emilia	Bellentani, S (corresponding author), Fondo Studi Fegato, Sez Modena, I-41100 Ferrara, Italy.		Grossi, Enzo/AAF-7765-2020; Grilli, Roberto/K-1444-2016; Bellentani, Stefano/L-3600-2019; Grilli, Roberto/AAN-9249-2021; Tiribelli, Claudio/A-4716-2014	Grilli, Roberto/0000-0001-9425-7170; Grilli, Roberto/0000-0001-9425-7170; Tiribelli, Claudio/0000-0001-6596-7595; Bellentani, Stefano/0000-0003-2836-8870				ALFONSO V, 1995, REV ESP ENFERM DIG, V87, P109; ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BEST LM, 1994, J CLIN MICROBIOL, V32, P1193, DOI 10.1128/JCM.32.5.1193-1196.1994; Bonamico M, 1996, ITAL J GASTROENTEROL, V28, P512; CARRICK J, 1989, GUT, V30, P790, DOI 10.1136/gut.30.6.790; CONTINIBALI S, 1988, RIV ITAL PED S1, V14, P87; DASKALOPOULOS G, 1987, GASTROENTEROLOGY, V92, P1363; DEGIACOMA C, 1991, J PEDIATR-US, V119, P205, DOI 10.1016/S0022-3476(05)80728-0; DEGIACOMO C, 1995, ACTA GASTROENTEROL S, P87; DOOLEY CP, 1993, GASTROENTEROL CLIN N, V22, P1; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1526; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIEDOREK SC, 1991, PEDIATRICS, V88, P578; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HOSMER DW, 1983, APPL LOGISTIC REGRES; JOHNSTON BJ, 1986, GUT, V27, P11532; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KATELARIS PH, 1991, ITALIAN J GASTROE S2, V23, P12; LANGENBERG ML, 1984, LANCET, V1, P1348; LIN SK, 1991, ITAL J GASTROENTE S2, V23, P10; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALATY HM, 1994, GUT, V35, P742, DOI 10.1136/gut.35.6.742; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; Mendall M A, 1997, Semin Gastrointest Dis, V8, P113; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; NWOKOLO CU, 1992, GUT, V33, P1323, DOI 10.1136/gut.33.10.1323; ODERDA G, 1991, DIGEST DIS SCI, V36, P572, DOI 10.1007/BF01297021; Palli D, 1997, ALIMENT PHARM THERAP, V11, P719, DOI 10.1046/j.1365-2036.1997.00215.x; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1	38	79	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					537	540		10.1136/bmj.319.7209.537	http://dx.doi.org/10.1136/bmj.319.7209.537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463891	Green Published, Bronze			2022-12-28	WOS:000082347200017
J	McManus, IC; Richards, P; Winder, BC				McManus, IC; Richards, P; Winder, BC			Intercalated degrees, learning styles, and career preferences: prospective longitudinal study of UK medical students	BRITISH MEDICAL JOURNAL			English	Article							BSC; PERFORMANCE	Objectives To assess the effects of taking an intercalated degree (BSc)on the study habits and learning styles of medical students and on their interest in a career in medical research. Design Longitudinal questionnaire study of medical students at application to medical school and in their final year. Setting All UK medical schools. Participants 6901 medical school applicants for admission in 1991 were studied in the autumn of 1990. 3333 entered medical school in 1991 or 1992, and 2695 who were due to qualify in 1996 or 1997 were studied 3 months before the end of their clinical course. Response rates were 92% for applicants and 56% for final year students. Main outcome measures Study habits (surface, deep, and strategic learning style) and interest in different medical careers, including medical research. Identical questions were used at time of application and in final year. Results Students who had taken an intercalated degree had higher deep and strategic learning scores than at application to medical school. Those with highest degree classes had higher strategic and deep learning scores and lower surface learning scores. Students taking intercalated degrees showed greater interest in careers in medical research and laboratory medicine and less interest in general practice than their peas. The effects of the course on interest in medical research and learning styles were independent The effect of the intercalated degree was greatest in schools where relatively few students took intercalated degrees. Conclusions Intercalated degrees result in a greater interest in research careers and higher deep and strategic learning scores. However, the effects are much reduced in schools where most students intercalate a degree. Introduction of intercalated degrees for all medical students without sufficient resources may not therefore achieve its expected effects.	UCL, Royal Free & Univ Coll Med Sch, Ctr Hlth Informat & Multiprofessional Educ, Res Ctr Med Educ, London N19 3UA, England; Hughes Hall, Cambridge CB1 2EW, England	University of London; University College London; University of Cambridge	McManus, IC (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Ctr Hlth Informat & Multiprofessional Educ, Res Ctr Med Educ, London N19 3UA, England.	i.mcmanus@ucl.ac.uk		McManus, Ian/0000-0003-3510-4814; Winder, Belinda/0000-0002-9118-679X				ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; Attwell D, 1996, LANCET, V348, P198, DOI 10.1016/S0140-6736(05)66145-4; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BIGGS J, 1993, BRIT J EDUC PSYCHOL, V63, P3, DOI 10.1111/j.2044-8279.1993.tb01038.x; Biggs J. B, 1987, STUDENT APPROACHES L; Biggs JB, 1987, STUDY PROCESS QUESTI; COLES CR, 1985, MED EDUC, V19, P308, DOI 10.1111/j.1365-2923.1985.tb01327.x; Committee of Vice Chancellors and Principals, 1997, CLIN AC CAR REP IND; CRIMLISK HL, 1987, MED EDUC, V21, P464, DOI 10.1111/j.1365-2923.1987.tb01403.x; EATON DG, 1985, MED EDUC, V19, P445, DOI 10.1111/j.1365-2923.1985.tb01352.x; Entwistle N, 1981, STYLES LEARNING TEAC; EVERED DC, 1987, BRIT MED J, V295, P241, DOI 10.1136/bmj.295.6592.241; General Medical Council, 1993, TOM DOCT REC UND MED, P1; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; MARTENSON DF, 1986, MED EDUC, V20, P532, DOI 10.1111/j.1365-2923.1986.tb01395.x; McManus IC, 1998, BRIT MED J, V316, P345, DOI 10.1136/bmj.316.7128.345; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; MCMANUS IC, 1985, THESIS U LONDON LOND; NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; ONEIL MJ, 1984, BRIT J EDUC PSYCHOL, V54, P228, DOI 10.1111/j.2044-8279.1984.tb02584.x; SMITH R, 1986, BRIT MED J, V292, P1619, DOI 10.1136/bmj.292.6536.1619-a; TAIT N, 1995, MED EDUC, V29, P216, DOI 10.1111/j.1365-2923.1995.tb02833.x; Tamber PS, 1996, BRIT MED J, V312, P1117; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; WOODHOUSE G, 1990, MULTILEVEL MODELLING; WYLLIE AH, 1986, BRIT MED J, V292, P1646, DOI 10.1136/bmj.292.6536.1646	26	99	100	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					542	546		10.1136/bmj.319.7209.542	http://dx.doi.org/10.1136/bmj.319.7209.542			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463892	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000082347200019
J	Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L				Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L			Dual function of the selenoprotein PHGPx during sperm maturation	SCIENCE			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; RAT SPERM; MITOCHONDRIAL CAPSULES; SELENIUM DEFICIENCY; PROTEIN; EXPRESSION; SELENOCYSTEINE; ENZYME; CELLS; CDNA	The selenoprotein phospholipid hydroperoxide glutathione peroxidase (PHGPx) changes its physical characteristics and biological functions during sperm maturation. PHGPx exists as a Soluble peroxidase in spermatids but persists in mature spermatozoa as an enzymatically inactive, oxidatively cross-linked, insoluble protein. in the midpiece of mature spermatozoa, PHGPx protein represents at least 50 percent of the capsule material that embeds the helix of mitochondria. The role of PHGPx as a structural protein may explain the mechanical instability of the mitochondrial midpiece that is observed in selenium deficiency.	Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Natl Res Ctr Biotechnol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; University of Padua	Flohe, L (corresponding author), Tech Univ Braunschweig, Dept Biochem, Mascheroder Weg 1, D-38124 Braunschweig, Germany.		Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				Adham IM, 1996, DNA CELL BIOL, V15, P159, DOI 10.1089/dna.1996.15.159; ANDREESE.JR, 1973, J BACTERIOL, V116, P867, DOI 10.1128/JB.116.2.867-873.1973; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BAUCHE F, 1994, FEBS LETT, V349, P392, DOI 10.1016/0014-5793(94)00709-8; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CALVIN HI, 1981, GAMETE RES, V4, P139, DOI 10.1002/mrd.1120040208; Cataldo L, 1996, MOL REPROD DEV, V45, P320, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;320::AID-MRD9&gt;3.0.CO;2-U; Fisher HM, 1997, J EXP ZOOL, V277, P390, DOI 10.1002/(SICI)1097-010X(19970401)277:5&lt;390::AID-JEZ5&gt;3.0.CO;2-K; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe Leopold, 1997, P415; Giannattasio A, 1997, J ENDOCRINOL INVEST, V20, P439, DOI 10.1007/BF03347999; Gobom J, 1997, INT J MASS SPECTROM, V169, P153, DOI 10.1016/S0168-1176(97)00216-4; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; Nam Sang-Yoon, 1997, Journal of Reproduction and Development, V43, P227, DOI 10.1262/jrd.43.227; National Research Council (US) Subcommittee on Selenium: 7, 1983, SELENIUM NUTR REVISE; PALLINI V, 1979, J SUBMICR CYTOL PATH, V11, P165; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sandstrom PA, 1998, FREE RADICAL BIO MED, V24, P1485, DOI 10.1016/S0891-5849(98)00023-9; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SELIGMAN J, 1992, BIOL REPROD, V46, P301, DOI 10.1095/biolreprod46.2.301; SHALGI R, 1989, BIOL REPROD, V40, P1037, DOI 10.1095/biolreprod40.5.1037; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; TURNER DC, 1973, ARCH BIOCHEM BIOPHYS, V154, P366, DOI 10.1016/0003-9861(73)90069-6; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wallace E, 1987, SELENIUM BIOL MED A, P181; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793	39	636	680	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1393	1396		10.1126/science.285.5432.1393	http://dx.doi.org/10.1126/science.285.5432.1393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464096				2022-12-28	WOS:000082233500040
J	Gilbert, RE; Tookey, PA				Gilbert, RE; Tookey, PA			Perinatal mortality and morbidity among babies delivered in water: surveillance study and postal survey	BRITISH MEDICAL JOURNAL			English	Article							BIRTHING POOLS; TERM INFANTS; LABOR; ENCEPHALOPATHY; INFECTION	Aim To compare perinatal morbidity and mortality for babies delivered in water with rates for babies delivered conventionally (not in water). Design Surveillance study (of all consultant paediatricians) and postal survey (of all NHS maternity units). Setting British Isles (surveillance study); England and Wales (postal survey). Subjects Babies born in the British Isles between April 1994 and March 1996 who died perinatally or were admitted for special care within 48 hours of birth after delivery in water or after labour in water followed by conventional delivery (surveillance study); babies delivered in water in England and Wales in the same period (postal survey). Main outcome measures Number of deliveries in water in the British Isles that resulted in perinatal death or in admission to special care within 48 hours of birth; and proportions (of such deliveries) of all water births in England and Wales. Results 4032 deliveries (0.6% of all deliveries) in England and Wales occurred in water. Perinatal mortality was 1.2/1000 (95% confidence interval 0.4 to 2.9) live births; 8.4/1000 (5.8 to 11.8) live births were admitted for special care. No deaths were directly attributable to delivery in water, but 2 admissions were for water aspiration. UK reports of mortality and special care admission rates for babies of women considered to be at low risk of complications during delivery who delivered conventionally ranged from 0.8/1000 (0.2 to 4.2) to 4.6/1000 (0.1 to 25) live births and from 9.2 (1.1 to 33) to 64/1000 (58 to 10) live births respectively. Compared with regional data for low risk, spontaneous, normal vaginal deliveries at term, the relative risk for perinatal mortality associated with delivery in water was 0.9 (99% confidence interval 0.2 to 3.6). Conclusions Perinatal mortality is not substantially higher among babies delivered in water than among those born to low risk women who delivered conventionally. The data are compatible with a small increase or decrease in perinatal mortality for babies delivered in water.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Gilbert, RE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gilbert, Ruth/0000-0001-9347-2709				ALDERDICE F, 1995, BRIT MED J, V310, P837, DOI 10.1136/bmj.310.6983.837; ALDERDICE F, 1995, BRIT J MIDWIFERY, V3, P375; Arya R, 1996, ARCH DIS CHILD-FETAL, V75, pF97, DOI 10.1136/fn.75.2.F97; Barron SL, 1996, BRIT MED J, V313, P1306; BARRY CN, 1995, BRIT MED J, V310, P1602, DOI 10.1136/bmj.310.6994.1602b; CAMMU H, 1994, ACTA OBSTET GYN SCAN, V73, P468, DOI 10.3109/00016349409013433; CHURCH LK, 1989, J NURSE-MIDWIFERY, V34, P165, DOI 10.1016/0091-2182(89)90076-1; Cleary R, 1996, BRIT J OBSTET GYNAEC, V103, P223, DOI 10.1111/j.1471-0528.1996.tb09710.x; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; HALL S, 1997, CHILD CARE HLTH DEV, V24, P129; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; Johnson P, 1996, BRIT J OBSTET GYNAEC, V103, P202, DOI 10.1111/j.1471-0528.1996.tb09706.x; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; Middle C, 1995, BRIT J OBSTET GYNAEC, V102, P970, DOI 10.1111/j.1471-0528.1995.tb10904.x; NIKODEM V, 1998, COCHRANE LIB; ODENT M, 1983, LANCET, V2, P1476, DOI 10.1016/S0140-6736(83)90816-4; PAGE L, 1995, MATERNAL CHILD H JAN, P22; Parker PC, 1997, PEDIATRICS, V99, P653, DOI 10.1542/peds.99.4.653a; RAWAL J, 1994, BRIT MED J, V309, P511, DOI 10.1136/bmj.309.6953.511; Roome APCH, 1996, LANCET, V348, P274, DOI 10.1016/S0140-6736(05)65590-0; ROSEVEAR SK, 1993, LANCET, V342, P1048, DOI 10.1016/0140-6736(93)92902-6; Rosser J, 1994, MIDIRS MIDWIFERY DIG, V4, P4; Rush J, 1996, BIRTH-ISS PERINAT C, V23, P136, DOI 10.1111/j.1523-536X.1996.tb00474.x; SCHORN MN, 1993, J NURSE-MIDWIFERY, V38, P336, DOI 10.1016/0091-2182(93)90014-8	24	65	69	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					483	487		10.1136/bmj.319.7208.483	http://dx.doi.org/10.1136/bmj.319.7208.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454400	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000082199600019
J	Jones, SB				Jones, SB			Cancer in the developing world: a call to action	BRITISH MEDICAL JOURNAL			English	Article									Int Agcy Res Canc, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Jones, SB (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.			Jones, Sinead/0000-0002-1364-4150				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; PISANI P, 1999, IN PRESS INT J CANC; SANKARANARAYANA.R, 1998, CANC SURVIVAL DEV CO; *UNAIDS WHO, 1998, EP SHEET HIV AIDS SE; WALBOOMERS JMM, 1999, IN PRESS JPATHOL; *WHO EXP PROGR IMM, 1997, HEP B VACC MAK GLOB; *WHO PROGR CANC CO, 1998, P C HELD ROYAL COLL	9	67	69	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					505	508		10.1136/bmj.319.7208.505	http://dx.doi.org/10.1136/bmj.319.7208.505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454408	Green Published			2022-12-28	WOS:000082199600030
J	Spence, SA				Spence, SA			A memorable patient - The screaming man	BRITISH MEDICAL JOURNAL			English	Article													Spence, Sean A/A-6218-2008						0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					489	489		10.1136/bmj.319.7208.489	http://dx.doi.org/10.1136/bmj.319.7208.489			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454402	Green Published			2022-12-28	WOS:000082199600023
J	Peterson, AT; Soberon, J; Sanchez-Cordero, V				Peterson, AT; Soberon, J; Sanchez-Cordero, V			Conservatism of ecological niches in evolutionary time	SCIENCE			English	Article							HETEROGENEOUS ENVIRONMENTS	Theory predicts low niche differentiation between species over evolutionary time scales, but little empirical evidence is available. Reciprocal geographic predictions based on ecological niche models of sister taxon pairs of birds, mammals, and butterflies in southern Mexico indicate niche conservatism over several million years of independent evolution (between putative sister taxon pairs) but little conservatism at the level of families. Niche conservatism over such time scales indicates that speciation takes place in geographic, not ecological, dimensions and that ecological differences evolve later.	Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA; Univ Nacl Autonoma Mexico, Inst Ecol, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biol, Dept Zool, Mexico City 04510, DF, Mexico	University of Kansas; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Peterson, AT (corresponding author), Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA.		Soberon, Jorge/N-7444-2015; Peterson, A. Townsend/I-5697-2013; Soberon, Jorge/ABF-1306-2021	Soberon, Jorge/0000-0003-2160-4148; Peterson, A. Townsend/0000-0003-0243-2379; Soberon, Jorge/0000-0003-2160-4148				American Ornithologists Union, 1998, CHECK LIST N AM BIRD, V7th; BRADSHAW AD, 1991, PHILOS T R SOC B, V333, P289, DOI 10.1098/rstb.1991.0079; BROWN JS, 1992, EVOL ECOL, V6, P360, DOI 10.1007/BF02270698; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; FUTUYMA DJ, 1997, EVOLUTIONARY BIOL; Graham A., 1993, Biological diversity of Mexico: origins and distribution., P109; HOLT RD, 1992, EVOL ECOL, V6, P433, DOI 10.1007/BF02270702; HOUSTON AI, 1992, EVOL ECOL, V6, P243, DOI 10.1007/BF02214164; HUNTLEY B, 1989, J BIOGEOGR, V16, P551, DOI 10.2307/2845210; KAWECKI TJ, 1993, EVOL ECOL, V7, P155, DOI 10.1007/BF01239386; Mayr E., 1963, ANIMAL SPECIES EVOLU; Musser G G, 1993, MAMMAL SPECIES WORLD; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; PETERSON AS, UNPUB; Ramamoorthy TP., 1994, BIOL DIVERSITY MEXIC; RICKLEFS RE, 1992, AM NAT, V139, P1305, DOI 10.1086/285388; ROSENZWEIG ML, EVOL ECOL, V1, P15; ROSS H H, 1972, Taxon, V21, P253, DOI 10.2307/1218192; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; STOCKWELL DRB, 1992, MATH COMPUT SIMULAT, V33, P385, DOI 10.1016/0378-4754(92)90126-2; TYLER, 1994, SWALLOWTAIL BUTTERFL; Vargas-F. Isabel, 1996, Journal of the Lepidopterists' Society, V50, P97; Wendt T., 1989, Anales del Instituto de Biologia. Serie Botanica, V58, P29	23	1087	1142	4	271	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1265	1267		10.1126/science.285.5431.1265	http://dx.doi.org/10.1126/science.285.5431.1265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455053				2022-12-28	WOS:000082130200043
J	Trimble, SW				Trimble, SW			Decreased rates of alluvial sediment storage in the Coon Creek Basin, Wisconsin, 1975-93	SCIENCE			English	Article							STREAM CHANNEL EROSION; DRIFTLESS AREA; UNITED-STATES; RIVER BASIN; BUDGET; MANAGEMENT; IMPACTS	The total measured rate of alluvial sediment accretion in the agricultural Coon Creek Basin for the period 1975-93 was only about 6 percent of the rate that occurred in the 1930s, but the distributed changes within the basin were highly variable and systematic. Sediment yield (efflux), however, remained relatively constant despite Large stream and valley changes within the basin. These observations demonstrate (i) that sediment sources, sinks, and fluxes vary widely over time and space and (ii) that, although improved soil conservation measures have decreased soil erosion, the downstream effects are complex.	Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Environm, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Trimble, SW (corresponding author), Univ Calif Los Angeles, Dept Geog, 1255 Bunche Hall, Los Angeles, CA 90095 USA.							ASHMORE P, 1993, PROG PHYS GEOG, V17, P190, DOI 10.1177/030913339301700206; BRUNE GUNNAR M., 1950, TRANS AMER GEOPHYS UNION, V31, P587; CHURCH M, 1989, NATURE, V337, P352; Dietrich W.E., 1978, ZIETSCHRIFT GEOMORPH, V29, P191, DOI [10.1130/0091-7613(2001)029, DOI 10.1130/0091-7613(2001)029]; Gebert WA, 1996, WATER RESOUR BULL, V32, P733; KELSEY HM, 1980, GEOL SOC AM BULL, V91, P190, DOI 10.1130/0016-7606(1980)91<190:ASBAAA>2.0.CO;2; KNOX JC, 1987, ANN ASSOC AM GEOGR, V77, P224, DOI 10.1111/j.1467-8306.1987.tb00155.x; KNOX JC, 1977, ANN ASSOC AM GEOGR, V67, P323, DOI 10.1111/j.1467-8306.1977.tb01145.x; MEADE RH, 1982, J GEOL, V90, P235, DOI 10.1086/628677; OWEN OS, 1998, NATURAL RESOURCE CON; PATTON PC, 1986, GEOL SOC AM BULL, V97, P369, DOI 10.1130/0016-7606(1986)97<369:PAROFO>2.0.CO;2; PHILLIPS JD, 1987, AM J SCI, V287, P780, DOI 10.2475/ajs.287.8.780; POTTER KW, 1991, WATER RESOUR RES, V27, P845, DOI 10.1029/91WR00076; SCHICK AP, 1993, PHYS GEOGR, V14, P225, DOI 10.1080/02723646.1993.10642477; SLAYMAKER O, 1993, PHYSICAL GEOGR, V14, P305; Steiner F. R., 1990, SOIL CONSERVATION US; Swanson F. J., 1982, SEDIMENT BUDGETS ROU; TRIBLE S, 1975, LANDSCAPES WISCONSIN, P24; Trimble S. W., 1976, P 3 FED INT SED C WA, P100; Trimble S.W., 1995, CHANGING RIVER CHANN, P201; TRIMBLE SW, 1993, PHYS GEOGR, V14, P285, DOI 10.1080/02723646.1993.10642481; TRIMBLE SW, 1983, AM J SCI, V283, P454, DOI 10.2475/ajs.283.5.454; TRIMBLE SW, 1975, SCIENCE, V188, P1207, DOI 10.1126/science.188.4194.1207; Trimble SW, 1997, GEOLOGY, V25, P467, DOI 10.1130/0091-7613(1997)025<0467:SCEACR>2.3.CO;2; TRIMBLE SW, 1981, SCIENCE, V214, P181, DOI 10.1126/science.214.4517.181; Trimble SW, 1997, SCIENCE, V278, P1442, DOI 10.1126/science.278.5342.1442; Trimble SW, 1997, ENVIRON GEOL, V32, P230, DOI 10.1007/s002540050211; WALLING DE, 1983, J HYDROL, V65, P209, DOI 10.1016/0022-1694(83)90217-2	28	290	297	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1244	1246		10.1126/science.285.5431.1244	http://dx.doi.org/10.1126/science.285.5431.1244			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455046				2022-12-28	WOS:000082130200036
J	Bruderlein, C; Leaning, J				Bruderlein, C; Leaning, J			New challenges for humanitarian protection	BRITISH MEDICAL JOURNAL			English	Article									Harvard Ctr Populat & Dev Studies, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health	Bruderlein, C (corresponding author), Harvard Ctr Populat & Dev Studies, Cambridge, MA 02138 USA.							*AFR RIGHTS, 1994, GEN RWAND; BOUTROUE J, 1998, MISSED OPPORTUNITIES; Brett R., 1998, CHILDREN INVISIBLE S; *BRIT MED ASS, 1992, MED BETR; *BRIT MED ASS, 1986, TORT REP; DEWAAL A, 1992, NO MERCY MOGADISHU H; DEWAAL A, 1994, CURRENT DILEMMAS FAC; GEIGER HJ, 1988, CASUALTIES CONFLICT; HANSEN G, 1997, CHRISTIAN SCI M 1231, P19; HART M, 1997, WORLD CRISIS POLITIC, P181; Hoang R., 2019, PROLONGED FIELD CARE; IACOPINO V, 1998, TALIBANS WAR WOMEN H; Ignatieff M., 1997, WARRIORS HONOR ETHNI; JEAN F, 1996, CENTRAL ASIAN SURVEY, V15, P255; KALDOR M, 1997, RESTRUCTURING GLOBAL, V1; LEANING J, 1993, FRAMEWORK FOR SURVIVAL, P103; Minear Larry., 1993, HUMANITARIAN ACTION; O'Donnell D., 1998, INT REV RED CROSS, V324, P481; PERRIN P, 1999, HUMANITARIAN CRISIS, P309; *PHYS HUM RIGHTS, 1999, WAR CRIM KOS 1998 19; *PHYS HUM RIGHTS, 1998, MED GROUP DOC SYST P; *PHYS HUM RIGHTS, 1996, MED SIEG FORM YUG 19; PORTER K, 1996, STUDENT BMJ, V4, P146; RAMSBOTHAM O, 1996, HUMANITARIAN INTERVE, P167; Russbach R., 1994, MED GLOBAL SURVIVAL, V1, P188; SANDOZ Y, 1995, INT LEGAL ISSUES ARI, P899; Sivard R. L., 1996, WORLD MILITARY SOCIA; Stremlau J., 1998, PEOPLE PERIL HUMAN R; *US MISS UN, 1998, GLOB HUM EM 1998; WEISS TG, 1999, MILITARY CIVILIAN IN; [No title captured]	31	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					430	435		10.1136/bmj.319.7207.430	http://dx.doi.org/10.1136/bmj.319.7207.430			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445928	Green Published			2022-12-28	WOS:000082098900022
J	Lee, DC; Halliday, AN; Hein, JR; Burton, KW; Christensen, JN; Gunther, D				Lee, DC; Halliday, AN; Hein, JR; Burton, KW; Christensen, JN; Gunther, D			Hafnium isotope stratigraphy of ferromanganese crusts	SCIENCE			English	Article							CENTRAL PACIFIC SEAWATER; DEEP-OCEAN WATER; FE-MN CRUSTS; PB ISOTOPES; HF; ND; DEPOSITS; NODULES; MANTLE; EVOLUTION	A Cenozoic record of hafnium isotopic compositions of central Pacific deep water has been obtained from two ferromanganese crusts. The crusts are separated by more than 3000 kilometers but display similar secular variations. Significant fluctuations in hafnium isotopic composition occurred in the Eocene and Oligocene, possibly related to direct advection from the Indian and Atlantic oceans. Hafnium isotopic compositions have remained approximately uniform for the past 20 million years, probably reflecting increased isolation of the central Pacific. The mechanisms responsible for the increase in Sr-87/Sr-86 in seawater through the Cenozoic apparently had no effect on central Pacific deep-water hafnium.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; ETH Zentrum, Dept Erdwissensch, Inst Isotopengeol & Mineral Rohstoffe, CH-8092 Zurich, Switzerland; US Geol Survey, Menlo Park, CA 94025 USA; Univ Blaise Pascal, Dept Sci Terre, F-63038 Clermont Ferrand, France; ETH Zurich, Inst Analyt Chem & Spurenanalyt, Anorgan Chem Lab, CH-8092 Zurich, Switzerland	University of Michigan System; University of Michigan; Swiss Federal Institutes of Technology Domain; ETH Zurich; United States Department of the Interior; United States Geological Survey; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Swiss Federal Institutes of Technology Domain; ETH Zurich	Lee, DC (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.		Lee, Der-Chuen/N-9225-2013; Hein, James/R-7123-2019; Christensen, John N/D-1475-2015	Burton, Kevin/0000-0002-3381-7004; Lee, Der-Chuen/0000-0001-8855-9594				Abouchami W, 1997, GEOCHIM COSMOCHIM AC, V61, P3957, DOI 10.1016/S0016-7037(97)00218-4; ALBAREDE F, 1992, GEOLOGY, V20, P761, DOI 10.1130/0091-7613(1992)020<0761:WMONII>2.3.CO;2; Albarede F, 1997, GEOCHIM COSMOCHIM AC, V61, P1277, DOI 10.1016/S0016-7037(96)00404-8; Albarede F, 1998, GEOPHYS RES LETT, V25, P3895, DOI 10.1029/1998GL900008; APLIN A, 1986, EARTH PLANET SC LETT, V81, P7, DOI 10.1016/0012-821X(86)90096-8; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; BURKE WH, 1982, GEOLOGY, V10, P516, DOI 10.1130/0091-7613(1982)10<516:VOSSTP>2.0.CO;2; Burton KW, 1997, NATURE, V386, P382, DOI 10.1038/386382a0; Christensen JN, 1997, SCIENCE, V277, P913, DOI 10.1126/science.277.5328.913; Frank M, 1998, EARTH PLANET SC LETT, V158, P121, DOI 10.1016/S0012-821X(98)00055-7; FRANK M, IN PRESS GEOCHIM COS; Godfrey LV, 1997, EARTH PLANET SC LETT, V151, P91, DOI 10.1016/S0012-821X(97)00106-4; GOLDSTEIN SL, 1981, NATURE, V292, P324, DOI 10.1038/292324a0; HALLIDAY AN, 1992, GEOPHYS RES LETT, V19, P761, DOI 10.1029/92GL00393; Hay WW, 1996, GEOL RUNDSCH, V85, P409, DOI 10.1007/BF02369000; Hein J. R., 1990, 90407 US GEOL SURV, P90; HEIN JR, 1993, PALEOCEANOGRAPHY, V8, P293, DOI 10.1029/93PA00320; HEIN JR, 1987, 87663 US GEOL SURV; HENDERSON GM, IN PRESS EARTH PLANE; INGRAM BL, 1990, GEOCHIM COSMOCHIM AC, V54, P1709, DOI 10.1016/0016-7037(90)90402-7; KAIHO K, 1994, TERRA NOVA, V6, P376, DOI 10.1111/j.1365-3121.1994.tb00510.x; Koschinsky A, 1997, GEOCHIM COSMOCHIM AC, V61, P4079, DOI 10.1016/S0016-7037(97)00231-7; LEE DC, 1994, EARTH PLANET SC LETT, V123, P119, DOI 10.1016/0012-821X(94)90262-3; LEE DC, 1995, INT J MASS SPECTROM, V146, P35, DOI 10.1016/0168-1176(95)04201-U; LEE DC, 1998, EOS, V79, pF443; Ling HF, 1997, EARTH PLANET SC LETT, V146, P1, DOI 10.1016/S0012-821X(96)00224-5; LYLE M, 1987, GEOPHYS RES LETT, V14, P595, DOI 10.1029/GL014i006p00595; Macdonald AM, 1996, NATURE, V382, P436, DOI 10.1038/382436a0; Maier-Reimer E, 1990, PALEOCEANOGRAPHY, V5, P349, DOI 10.1029/PA005i003p00349; MIKOLAJEWICZ U, 1993, PALEOCEANOGRAPHY, V8, P409, DOI 10.1029/93PA00893; O'Nions RK, 1998, EARTH PLANET SC LETT, V155, P15, DOI 10.1016/S0012-821X(97)00207-0; PATCHETT PJ, 1983, GEOCHIM COSMOCHIM AC, V47, P81, DOI 10.1016/0016-7037(83)90092-3; PATCHETT PJ, 1984, EARTH PLANET SC LETT, V69, P365, DOI 10.1016/0012-821X(84)90195-X; PIOTROWSKI A, 1999, EOS, V80, pS184; RICHTER FM, 1988, EARTH PLANET SC LETT, V90, P382, DOI 10.1016/0012-821X(88)90137-9; SALTERS VJM, 1991, EARTH PLANET SC LETT, V104, P364, DOI 10.1016/0012-821X(91)90216-5; von Blanckenburg F, 1996, GEOCHIM COSMOCHIM AC, V60, P4957, DOI 10.1016/S0016-7037(96)00310-9; von Blanckenburg F, 1996, EARTH PLANET SC LETT, V141, P213, DOI 10.1016/0012-821X(96)00059-3; WHITE WM, 1986, EARTH PLANET SC LETT, V79, P46, DOI 10.1016/0012-821X(86)90039-7	40	57	63	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1052	1054		10.1126/science.285.5430.1052	http://dx.doi.org/10.1126/science.285.5430.1052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446048				2022-12-28	WOS:000082033100041
J	van Oudenaarden, A; Boxer, SG				van Oudenaarden, A; Boxer, SG			Brownian ratchets: Molecular separations in lipid bilayers supported on patterned arrays	SCIENCE			English	Article							PARTICLES; POLYELECTROLYTES; MACROMOLECULES; MEMBRANES; PROTEINS; MOTION; SIEVE	Brownian ratchets use a time-varying asymmetric potential that can be applied to separate diffusing particles or molecules. A new type of Brownian ratchet, a geometrical Brownian ratchet, has been realized, Charged, fluorescently labeled phospholipids in a two-dimensional fluid bilayer were driven in one direction by an electric field through a two-dimensional periodic array of asymmetric barriers to lateral diffusion fabricated from titanium oxide on silica, Diffusion spreads the phospholipid molecules in the orthogonal direction, and the asymmetric barriers rectify the Brownian motion, causing a directional transport of molecules. The geometrical ratchet can be used as a continuous molecular sieve to separate mixtures of membrane-associated molecules that differ in electrophoretic mobility and diffusion coefficient.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Boxer, SG (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		van Oudenaarden, Alexander/AAA-1705-2019	Boxer, Steven/0000-0001-9167-4286				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 1998, CHAOS, V8, P533, DOI 10.1063/1.166334; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Derenyi I, 1998, PHYS REV E, V58, P7781, DOI 10.1103/PhysRevE.58.7781; Duke TAJ, 1998, PHYS REV LETT, V80, P1552, DOI 10.1103/PhysRevLett.80.1552; Ertas D, 1998, PHYS REV LETT, V80, P1548, DOI 10.1103/PhysRevLett.80.1548; FAUCHEUX LP, 1995, J CHEM SOC FARADAY T, V91, P3163, DOI 10.1039/ft9959103163; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYSICS, V1; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1995, BIOPHYS J, V69, P1972, DOI 10.1016/S0006-3495(95)80067-6; Groves JT, 1998, LANGMUIR, V14, P3347, DOI 10.1021/la9711701; Groves JT, 1997, SCIENCE, V275, P651, DOI 10.1126/science.275.5300.651; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KONIG BW, 1996, LANGMUIR, V12, P1343; KUNG LA, UNPUB; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; Shimizu S, 1997, SYNTHETIC MET, V85, P1337, DOI 10.1016/S0379-6779(97)80260-3; Slater GW, 1997, PHYS REV LETT, V78, P1170, DOI 10.1103/PhysRevLett.78.1170; Stora T, 1999, ANGEW CHEM INT EDIT, V38, P389, DOI 10.1002/(SICI)1521-3773(19990201)38:3<389::AID-ANIE389>3.0.CO;2-U; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	209	212	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1046	1048		10.1126/science.285.5430.1046	http://dx.doi.org/10.1126/science.285.5430.1046			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446046				2022-12-28	WOS:000082033100039
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1946: Hermann Joseph Muller (1890-1967)	LANCET			English	Biographical-Item									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	13	13	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1023	1023		10.1016/S0140-6736(05)70742-X	http://dx.doi.org/10.1016/S0140-6736(05)70742-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459949				2022-12-28	WOS:000079421600075
J	Andrews, G				Andrews, G			Randomised controlled trials in psychiatry: important but poorly accepted	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ New S Wales, St Vincents Hosp, Sch Psychiat, Sydney, NSW, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney	Andrews, G (corresponding author), Anxiety Disorders Unit, Darlinghurst, NSW 2010, Australia.	gavina@crufad.unsw.edu.au	Andrews, Gavin/J-6537-2012	Andrews, Gavin/0000-0002-4315-2173				ABE O, 1992, LANCET, V339, P71; ACKNER B, 1957, LANCET, V1, P607; Amer Psychiat Assoc, 1998, AM J PSYCHIAT, V155, P1; Andrews G, 1996, BRIT MED J, V313, P1501, DOI 10.1136/bmj.313.7071.1501; ANDREWS G, 1993, BRIT J PSYCHIAT, V162, P447, DOI 10.1192/bjp.162.4.447; ANDREWS G, 1993, EPIDEMIOL PSICHIAT S, V2, P161; [Anonymous], 1992, Lancet, V339, P1; Cochrane AL., 1989, EFFECTIVENESS EFFICI; COLLINS R, 1997, NONRANDOM REFLECTION, P197; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; GREGORY S, 1985, BRIT J PSYCHIAT, V146, P520, DOI 10.1192/bjp.146.5.520; KAVANAGH DJ, 1993, AUST PSYCHOL, V28, P181, DOI 10.1080/00050069308258899; KLERMAN GL, 1990, AM J PSYCHIAT, V147, P409; MARI JD, 1994, PSYCHOL MED, V24, P565, DOI 10.1017/S0033291700027720; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT HLTH COMM NZ, 1998, GUID ASS TREAT ANX D; NATHAN PE, 1998, GUIDE TREATMENTS WOR; Wells J, 1998, BRIT MED J, V317, P1224, DOI 10.1136/bmj.317.7167.1224; Wells KB, 1999, AM J PSYCHIAT, V156, P5, DOI 10.1176/ajp.156.1.5	19	23	23	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					562	564		10.1136/bmj.319.7209.562	http://dx.doi.org/10.1136/bmj.319.7209.562			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463902	Green Published			2022-12-28	WOS:000082347200031
J	Vincent, P				Vincent, P			A memorable patient - The accordionist	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					556	556		10.1136/bmj.319.7209.556	http://dx.doi.org/10.1136/bmj.319.7209.556			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463899	Green Published			2022-12-28	WOS:000082347200028
J	Norwitz, ER; Robinson, JN; Challis, JRG				Norwitz, ER; Robinson, JN; Challis, JRG			The control of labor	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPONTANEOUS PRETERM BIRTH; FETAL FIBRONECTIN; PREMATURE DELIVERY; TOCOLYTIC THERAPY; MAGNESIUM-SULFATE; RISK ASSESSMENT; AMNIOTIC-FLUID; PARTURITION; INFECTION; TRIAL		Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Toronto, Dept Physiol, Toronto, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Toronto	Norwitz, ER (corresponding author), Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, 75 Francis St, Boston, MA 02115 USA.	ernorwitz@bics.bwh.harvard.edu	Challis, John RG/E-7419-2014		NICHD NIH HHS [5K12 HD00849] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen SR, 1998, CLIN OBSTET GYNECOL, V41, P842, DOI 10.1097/00003081-199812000-00008; ANDERSEN LF, 1989, AM J PERINAT, V6, P196, DOI 10.1055/s-2007-999575; Bernal AL, 1995, ADV EXP MED BIOL, V395, P435; Besinger R E, 1990, Obstet Gynecol Surv, V45, P415, DOI 10.1097/00006254-199007000-00002; CLARK IM, 1994, OBSTET GYNECOL, V83, P532, DOI 10.1097/00006250-199404000-00008; COPPER RL, 1994, OBSTET GYNECOL, V84, P490; CREASY RK, 1980, OBSTET GYNECOL, V55, P692; CUNNINGHAM FG, 1993, WILLIAMS OBSTET, P298; Dudley DJ, 1997, J REPROD IMMUNOL, V36, P93, DOI 10.1016/S0165-0378(97)00065-X; DUFF P, 1984, OBSTET GYNECOL, V63, P697; ELOVITZ M, 1999, AM J OBSTET GYNECOL, V180; FERGUSON JE, 1984, AM J OBSTET GYNECOL, V148, P166, DOI 10.1016/S0002-9378(84)80170-2; FLINT APF, 1975, BIOCHEM SOC T, V3, P1189, DOI 10.1042/bst0031189; FUCHS AR, 1981, SEMIN PERINATOL, V5, P236; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; GARRIOCH DB, 1978, BRIT J OBSTET GYNAEC, V85, P47, DOI 10.1111/j.1471-0528.1978.tb15825.x; Gibb, 1996, PRENAT NEONAT MED, V1, P283; Gibbs RS, 1997, AM J OBSTET GYNECOL, V177, P375, DOI 10.1016/S0002-9378(97)70201-1; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GLOCK JL, 1993, AM J OBSTET GYNECOL, V169, P960, DOI 10.1016/0002-9378(93)90035-H; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Goodwin TM, 1996, AM J PERINAT, V13, P143, DOI 10.1055/s-2007-994312; Goodwin TM, 1999, AM J OBSTET GYNECOL, V180, pS208, DOI 10.1016/S0002-9378(99)70702-7; Goodwin TM, 1998, CLIN PERINATOL, V25, P859, DOI 10.1016/S0095-5108(18)30087-3; Guinn DK, 1998, AM J OBSTET GYNECOL, V179, P874, DOI 10.1016/S0002-9378(98)70181-4; HANSSENS MCAJA, 1985, BRIT J OBSTET GYNAEC, V92, P698, DOI 10.1111/j.1471-0528.1985.tb01451.x; Heath VCF, 1998, ULTRASOUND OBST GYN, V12, P312, DOI 10.1046/j.1469-0705.1998.12050312.x; Heine RP, 1999, AM J OBSTET GYNECOL, V180, pS214, DOI 10.1016/S0002-9378(99)70703-9; HIGBY K, 1993, AM J OBSTET GYNECOL, V168, P1247, DOI 10.1016/0002-9378(93)90376-T; HILL WC, 1995, CLIN OBSTET GYNECOL, V38, P725, DOI 10.1097/00003081-199538040-00008; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Hobel CJ, 1999, AM J OBSTET GYNECOL, V180, pS257, DOI 10.1016/S0002-9378(99)70712-X; HONNEBIER MBOM, 1994, EUR J OBSTET GYN R B, V55, P193, DOI 10.1016/0028-2243(94)90038-8; IAMS JD, 1988, AM J OBSTET GYNECOL, V159, P595, DOI 10.1016/S0002-9378(88)80016-4; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; IAMS JD, 1995, AM J OBSTET GYNECOL, V173, P141, DOI 10.1016/0002-9378(95)90182-5; Korebrits C, 1998, J CLIN ENDOCR METAB, V83, P1585, DOI 10.1210/jc.83.5.1585; Liggins G C, 1973, Recent Prog Horm Res, V29, P111; LIGGINS GC, 1989, BIOL NEONATE, V55, P366, DOI 10.1159/000242940; LIGGINS GC, 1988, ONSET LABOR CELLULAR, P1; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; Matthijs G, 1996, EUR J HUM GENET, V4, P46; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P1337, DOI 10.1016/0002-9378(95)91383-1; Mercer BM, 1996, AM J OBSTET GYNECOL, V174, P1885, DOI 10.1016/S0002-9378(96)70225-9; MOLLER M, 1984, LANCET, V2, P69; MORRISON JJ, 1993, AM J OBSTET GYNECOL, V169, P1277, DOI 10.1016/0002-9378(93)90294-S; MORTENSEN OA, 1987, ACTA OBSTET GYN SCAN, V66, P507, DOI 10.3109/00016348709015725; MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; MYERS DA, 1993, CLIN PERINATOL, V20, P9, DOI 10.1016/S0095-5108(18)30409-3; Nathanielsz P W, 1997, Equine Vet J Suppl, P83; Nathanielsz PW, 1998, EUR J OBSTET GYN R B, V78, P127, DOI 10.1016/S0301-2115(98)00058-X; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; Norwitz Errol R., 1999, Current Problems in Obstetrics Gynecology and Fertility, V22, P41; Papatsonis DNM, 1997, OBSTET GYNECOL, V90, P230, DOI 10.1016/S0029-7844(97)00182-8; PAUERSTEIN CJ, 1970, OBSTET GYNECOL SURV, V25, P617; PETERSEN LK, 1992, BRIT J OBSTET GYNAEC, V99, P292, DOI 10.1111/j.1471-0528.1992.tb13725.x; PETRAGLIA F, 1995, J CLIN ENDOCR METAB, V80, P558, DOI 10.1210/jc.80.2.558; Petraglia F, 1997, PLACENTA, V18, P3, DOI 10.1016/S0143-4004(97)90065-5; RAJABI M, 1987, OBSTET GYNECOL, V69, P179; ROMERO R, 1987, AM J OBSTET GYNECOL, V157, P1461, DOI 10.1016/S0002-9378(87)80245-4; ROMERO R, 1993, AM J OBSTET GYNECOL, V169, P839, DOI 10.1016/0002-9378(93)90014-A; ROMERO R, 1991, ANN NY ACAD SCI, V622, P355; RUSH RW, 1976, BRIT MED J, V2, P965, DOI 10.1136/bmj.2.6042.965; Rust OA, 1996, AM J OBSTET GYNECOL, V175, P838, DOI 10.1016/S0002-9378(96)80009-3; SWEET RL, 1987, AM J OBSTET GYNECOL, V156, P824, DOI 10.1016/0002-9378(87)90338-3; THORBURN GD, 1991, J DEV PHYSIOL, V15, P71; VALENZUELA G, 1982, AM J OBSTET GYNECOL, V143, P718, DOI 10.1016/0002-9378(82)90122-3; VILLAR J, 1994, RES CLIN FORUMS, V16, P9; Voss HF, 1999, AM J OBSTET GYNECOL, V180, pS226, DOI 10.1016/S0002-9378(99)70706-4; ZUCKERMAN H, 1984, J PERINAT MED, V12, P25, DOI 10.1515/jpme.1984.12.1.25	70	272	282	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					660	666		10.1056/NEJM199908263410906	http://dx.doi.org/10.1056/NEJM199908263410906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460818				2022-12-28	WOS:000082192500006
J	Rayner, C				Rayner, C			Personal view - A patient's eye view of quality	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					525	525		10.1136/bmj.319.7208.525	http://dx.doi.org/10.1136/bmj.319.7208.525			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454424	Green Published			2022-12-28	WOS:000082199600069
J	Spiegelhalter, DJ; Myles, JP; Jones, DR; Abrams, KR				Spiegelhalter, DJ; Myles, JP; Jones, DR; Abrams, KR			Methods in health service research - An introduction to bayesian methods in health technology assessment	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; METAANALYSIS; DESIGN		Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	MRC Biostatistics Unit; University of Cambridge; University of Leicester	Spiegelhalter, DJ (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.		Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				Abrams K, 1995, IMA J MATH APPL MED, V12, P297; ASHBY D, 1993, STATISTICIAN, V42, P385; BERRY DA, 1994, CONTROL CLIN TRIALS, V15, P360, DOI 10.1016/0197-2456(94)90033-7; BERRY DA, 1996, BAYESIAN BIOSTATITIC; Breslow N., 1990, STAT SCI, V5, P269; CHALONER K, 1993, STATISTICIAN, V42, P341, DOI 10.2307/2348469; CORNFIELD J, 1976, AM J EPIDEMIOL, V104, P408, DOI 10.1093/oxfordjournals.aje.a112313; DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N; DIXON DO, 1992, STAT MED, V11, P13, DOI 10.1002/sim.4780110104; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; EDDY DM, 1992, EMTAANALYSIS CONFIDE; Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO;2-U; FREEDMAN LS, 1994, STAT MED, V13, P1371, DOI 10.1002/sim.4780131312; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GROSSMAN J, 1994, STAT MED, V13, P1815, DOI 10.1002/sim.4780131804; KADANE JB, 1995, CONTROL CLIN TRIALS, V16, P313, DOI 10.1016/0197-2456(95)00072-0; LEWIS RJ, 1993, ANN EMERG MED, V22, P1328, DOI 10.1016/S0196-0644(05)80119-2; Lilford RJ, 1996, BRIT MED J, V313, P603; LOUIS TA, 1991, STAT MED, V10, P811, DOI 10.1002/sim.4780100604; ONEILL RT, 1994, STAT MED, V13, P1493, DOI 10.1002/sim.4780131327; Parmar MKB, 1996, J NATL CANCER I, V88, P1645, DOI 10.1093/jnci/88.22.1645; PARMAR MKB, 1994, STAT MED, V13, P1297, DOI 10.1002/sim.4780131304; PARMIGIANI G, 1996, BAYESIAN BIOSTATISTI, P207; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P1015, DOI 10.1136/bmj.305.6860.1015; SACKETT DL, 1991, CLIN EPDIEMIOLOGY BA; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Wolfson L., 1996, BAYESIAN BIOSTATISTI, P261; 1999, INT C HARM STAT PRIN	29	213	221	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					508	512		10.1136/bmj.319.7208.508	http://dx.doi.org/10.1136/bmj.319.7208.508			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454409	Green Published			2022-12-28	WOS:000082199600031
J	Coupland, R				Coupland, R			Clinical and legal significance of fragmentation of bullets in relation to size of wounds: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							WAR WOUNDS; CLASSIFICATION; MANAGEMENT; DISRUPTION; BALLISTICS	Objective To examine the relation between fragmentation of bullets and size of wounds clinically and in the context of the Hague Declaration of 1899. Design Retrospective analysis of prospectively collected data on hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 5215 people wounded by bullets in armed conflicts (5933 wounds). Main outcome measures Grade of wound computed from the Red Cross wound classification and presence of bullet fragments on radiography. Results Of the 347 wounds with fragmentation of bullets, 251 (72%) were large wounds (grade 2 or 3)that is, those with a clinically detectable cavity. Of the 5586 wounds without fragmentation of bullets, 2915 (52.1%) were large wounds. Only 7.9% (251/3166) of large wounds were associated with fragmentation of bullets. Conclusions Fragmentation of bullets is associated with large wounds, but most large wounds do not contain bullet fragments. In addition, bullet fragments may occur in wounds that are not defined as large. Fragmentation of bullets is neither a necessary nor sufficient cause of large wounds, and surgeons should not diagnose extensive tissue damage because of the presence of fragments on radiography Such findings also do not necessarily represent the use of bullets which contravene the law of war. Future legislation should take into account not only the construction of bullets but also their potential to transfer energy to the human body.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, R (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							BOWYER GW, 1995, J TRAUMA, V38, P64, DOI 10.1097/00005373-199501000-00018; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; Coupland R.M., 1991, RED CROSS WOUND CLAS, P18; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1992, LANCET, V339, P35, DOI 10.1016/0140-6736(92)90152-S; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1994, RECENT ADV SURG, P121; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; Coupland Robin, 1997, SIRUS PROJECT DETERM; Davis H J, 1897, Br Med J, V2, P1789; FACKLER ML, 1984, J TRAUMA, V24, P35, DOI 10.1097/00005373-198401000-00005; FACKLER ML, 1984, J TRAUMA, V24, P263, DOI 10.1097/00005373-198403000-00014; KNEUBUEHL BP, 1994, EXP M CERT WEAP SYST, P26; KNUDSEN PJT, 1993, INT J LEGAL MED, V106, P61, DOI 10.1007/BF01225042; LINDSEY D, 1980, J TRAUMA, V20, P1068, DOI 10.1097/00005373-198012000-00012; Ogston A, 1898, Br Med J, V2, P813; Ogston Alex, 1899, BMJ, V2, P278; SELLER KG, 1994, WOUND BALLISTICS; SMITH MSO, 1981, HIGH VELOCITY MISSIL; Spencer CG, 1908, GUNSHOT WOUNDS	20	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					403	406		10.1136/bmj.319.7207.403	http://dx.doi.org/10.1136/bmj.319.7207.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445917	Green Published, Bronze			2022-12-28	WOS:000082098900012
J	Coupland, RM; Samnegaard, HO				Coupland, RM; Samnegaard, HO			Effect of type and transfer of conventional weapons on civilian injuries: retrospective analysis of prospective data from Red Cross hospitals	BRITISH MEDICAL JOURNAL			English	Article							ANTIPERSONNEL MINES; LAND MINES; MOZAMBIQUE; MANAGEMENT; HEALTH	Objective To examine the link between different weapons used in modern wars and their potential to injury civilians. Design Retrospective analysis of prospectively collected data about hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 18 877 people wounded by bullets, fragmentation munitions, or mines. Of these, 2012 had been admitted to the hospital in Kabul within six hours of injury. Main outcome measures Age and sex of wounded people according to cause of injury and whether they were civilians (women and girls, boys under 16 years old, or men of 50 or more). Results 18.7% of those injured by bullets, 34.1% of those injured by fragments, and 30.8% of those injured by mines were civilians. Of those admitted to the Red Cross hospital in Kabul within six hours of injury, 39.1% of those injured by bullets, 60.6% of those injured by fragments, and 55.0% of those injured by mines were civilians. Conclusions The proportion of civilians injured differs between weapon systems. The higher proportion injured by fragments and mines is explicable in terms of the military efficiency of weapons, the distance between user and victim, and the effect that the kind of weapon has on the psychology of the user.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, RM (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; Bowyer GW, 1997, ANN ROY COLL SURG, V79, P175; CARFIELD RM, 1991, JAMA-J AM MED ASSOC, V226, P688; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1996, LANCET, V347, P450, DOI 10.1016/S0140-6736(96)90017-3; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; Grossman Dave, 1995, KILLING PSYCHOL COST; *INT COMM RED CROS, 1996, MED PROF EFF WEAP S; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; Prokosch E., 1995, TECHNOLOGY KILLING; SELLIER KG, 1994, WOUND BALLISTICS; Sidel VW, 1995, BRIT MED J, V311, P1677, DOI 10.1136/bmj.311.7021.1677	14	29	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					410	412		10.1136/bmj.319.7207.410	http://dx.doi.org/10.1136/bmj.319.7207.410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445921	Green Published, Bronze			2022-12-28	WOS:000082098900015
J	Andretic, R; Chaney, S; Hirsh, J				Andretic, R; Chaney, S; Hirsh, J			Requirement of circadian genes for cocaine sensitization in Drosophila	SCIENCE			English	Article							CLOCK GENE; BEHAVIORAL SENSITIZATION; PERIOD PROTEIN; DOUBLE-TIME; MELANOGASTER; ADDICTION; MUTANTS; RHYTHMS; TRANSCRIPTION; RESPONSES	The circadian clock consists of a feedback loop in which clock genes are rhythmically expressed, giving rise to cycling Levels of RNA and proteins. Four of the five circadian genes identified to date influence responsiveness to free-base cocaine in the fruit fly, Drosophila melanogaster, Sensitization to repeated cocaine exposures, a phenomenon also seen in humans and animal models and associated with enhanced drug craving, is eliminated in flies mutant for period, clock, cycle, and doubletime, but not in flies lacking the gene timeless. Flies that do not sensitize owing to lack of these genes do not show the induction of tyrosine decarboxylase normally seen after cocaine exposure. These findings indicate unexpected roles for these genes in regulating cocaine sensitization and indicate that they function as regulators of tyrosine decarboxylase.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Virginia	Hirsh, J (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.		Andretic, Rozi/M-5666-2013; Jansen, Heiko T./A-5770-2008	Andretic, Rozi/0000-0003-0375-0520; Jansen, Heiko T./0000-0003-0178-396X; Chaney, Sarah/0000-0002-4734-7576	NIDA NIH HHS [DA05942] Funding Source: Medline; NIGMS NIH HHS [GM/DA 27318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRETIC R, UNPUB; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; GOODMAN A, 1990, PHARMACOL BASIS THER, P417; Hamblen MJ, 1998, GENETICS, V149, P165; HENRY DJ, 1995, J NEUROSCI, V15, P6287; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; MCCLUNG C, IN PRESS CURR BIOL; MCCLUNG C, UNPUB; MORSE AC, 1995, PHYSIOL BEHAV, V58, P891, DOI 10.1016/0031-9384(95)00144-8; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1; TOLLIVER BK, 1994, J PHARMACOL EXP THER, V270, P1230; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHITE FJ, 1995, NEUROBIOLOGY COCAINE, P81; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135	29	214	228	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1066	1068		10.1126/science.285.5430.1066	http://dx.doi.org/10.1126/science.285.5430.1066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446052				2022-12-28	WOS:000082033100045
J	Davies, L; Angus, RM; Calverley, PMA				Davies, L; Angus, RM; Calverley, PMA			Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial	LANCET			English	Article							CHRONIC-BRONCHITIS; GLOBAL BURDEN; COPD; METHYLPREDNISOLONE; MORTALITY	Background The role of oral corticosteroids in treating patients with exacerbations of chronic obstructive pulmonary disease (COPD) remains contentious. We assessed in a prospective, randomised, double-blind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of COPD requiring hospital admission. Methods We recruited patients with non-acidotic exacerbations of COPD who were randomly assigned oral prednisolone 30 mg once daily (n=29) or identical placebo (n=27) for 14 days, in addition to standard treatment with nebulised bronchodilators, antibiotics, and oxygen. We did spirometry and recorded symptom scores daily in inpatients. Time to discharge and withdrawals were noted in each group. We recalled patients at 6 weeks to repeat spirometry and collect data on subsequent exacerbations and treatment. Hospital stay was analysed by intention to treat and forced expiratory volume in 1 s (FEV1) according to protocol. Findings FEV1 after bronchodilation increased more rapidly and to a greater extent in the corticosteroid-treated group: percentage predicted FEV1 after bronchodilation rose from 25.7% (95% CI 21.0-30.4) to 32.2% (27.3-27.1) in the placebo group (p<0.0001) compared with 28.2% (23.5-32.9) to 41.5% (35.8-47.2) in the corticosteroid-treated group (p<0.0001). Up to day 5 of hospital stay, FEV1 after bronchodilation increased by 90 mL daily (50.8-129.2) and by 30 mt daily (10.4-49.6) in the placebo group (p=0.039). Hospital stays were shorter in the corticosteroid-treated group. Groups did not differ at 6-week follow-up. Interpretation These data provide evidence to support the current practice of prescribing low-dose oral corticosteroids to all patients with non-acidotic exacerbations of COPD requiring hospital admission.	Univ Liverpool, Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England; Univ Liverpool, Univ Hosp Aintree, Dept Med, Liverpool L9 7AL, Merseyside, England	University of Liverpool; University of Liverpool	Calverley, PMA (corresponding author), Univ Liverpool, Univ Hosp Aintree, Clin Dept, Liverpool L9 7AL, Merseyside, England.							ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; Angus RM, 1995, THORAX, V50, P445; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bullard MJ, 1996, AM J EMERG MED, V14, P139, DOI 10.1016/S0735-6757(96)90120-5; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; Decramer M, 1996, AM J RESP CRIT CARE, V153, P1958, DOI 10.1164/ajrccm.153.6.8665061; EMERMAN CL, 1989, CHEST, V95, P563, DOI 10.1378/chest.95.3.563; Gibson P G, 1998, J Qual Clin Pract, V18, P125; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; MOAYYEDI P, 1995, THORAX, V50, P834, DOI 10.1136/thx.50.8.834; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Osman LM, 1997, THORAX, V52, P67; Pearson MG, 1997, THORAX, V52, pS1; Poole PJ, 1997, NEW ZEAL MED J, V110, P272; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814	23	353	375	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					456	460		10.1016/S0140-6736(98)11326-0	http://dx.doi.org/10.1016/S0140-6736(98)11326-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465169				2022-12-28	WOS:000081896100009
J	Newell, ML				Newell, ML			Infant feeding and HIV-1 transmission	LANCET			English	Editorial Material							TO-CHILD TRANSMISSION; HIV-1-INFECTED WOMEN; RISK		UCL, Inst Child Hlth, Dept Epidemiol, London WC1N 1EH, England	University of London; University College London	Newell, ML (corresponding author), UCL, Inst Child Hlth, Dept Epidemiol, London WC1N 1EH, England.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699				Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; DUNN DT, 1995, AIDS, V9, P7; LAWRENCE RA, 1994, BREASTFEEDING GUIDE; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; VANDEPERRE P, 1993, LANCET, V341, P914, DOI 10.1016/0140-6736(93)91210-D	7	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					442	443		10.1016/S0140-6736(99)90118-6	http://dx.doi.org/10.1016/S0140-6736(99)90118-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465164				2022-12-28	WOS:000081896100004
J	Semenza, GL				Semenza, GL			Perspectives on oxygen sensing	CELL			English	Review							NITRIC-OXIDE; ERYTHROPOIETIN PRODUCTION; HYPOXIA; INDUCTION; SENSOR; GENE		Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA	Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA.							Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gupte SA, 1999, AM J PHYSIOL-HEART C, V276, pH1535, DOI 10.1152/ajpheart.1999.276.5.H1535; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 1998, J BIOL CHEM, V273, P18019, DOI 10.1074/jbc.273.29.18019; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	20	307	338	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					281	284		10.1016/S0092-8674(00)81957-1	http://dx.doi.org/10.1016/S0092-8674(00)81957-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458603	hybrid			2022-12-28	WOS:000081950300003
J	Summons, RE; Jahnke, LL; Hope, JM; Logan, GA				Summons, RE; Jahnke, LL; Hope, JM; Logan, GA			2-Methylhopanoids as biomarkers for cyanobacterial oxygenic photosynthesis	NATURE			English	Article							PROKARYOTIC TRITERPENOIDS; METHYLOBACTERIUM-ORGANOPHILUM; HOPANE SERIES; 2-BETA-METHYLHOPANOIDS; LOCALIZATION; BIOSYNTHESIS; ANTIQUITY; ORIGIN	Oxygenic photosynthesis is widely accepted as the most important bioenergetic process happening in Earth's surface environment(1). It is thought to have evolved within the cyanobacterial lineage, but it has been difficult to determine when it began. Evidence based on the occurrence and appearance of stromatolites(2) and microfossils' indicates that phototrophy occurred as long ago as 3,465 Myr although no definite physiological inferences can be he made from these objects. Carbon isotopes and other geological phenomena(4,5) provide clues but are also equivocal, Biomarkers are potentially useful because the three domains of extant life-Bacteria, Archaea and Eukarya-have signature membrane lipids with recalcitrant carbon skeletons. These lipids turn into hydrocarbons in sediments and can be found wherever the record is sufficiently well preserved. Here we show that 2-methylbacteriohopanepolyols occur in a high proportion of cultured cyanobacteria and cyanobacterial mats, Their 2-methylhopane hydrocarbon derivatives are abundant in organic-rich sediments as old as 2,500 Myr. These biomarkers may help constrain the age of the oldest cyanobacteria and the advent of oxygenic photosynthesis. They could also be used to quantify the ecological importance of cyanobacteria through geological time.	Australian Geol Survey Org, Canberra, ACT 2601, Australia; NASA, Ames Res Ctr, Exobiol Biol Branch, Moffett Field, CA 94035 USA	Geoscience Australia; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Summons, RE (corresponding author), Australian Geol Survey Org, GPO Box 378, Canberra, ACT 2601, Australia.		Summons, Roger Everett/AAL-3789-2020					[Anonymous], 1994, EARLY LIFE EARTH; Bauld J., 1984, MBL LECT BIOL, V3, P39; BISSERET P, 1985, EUR J BIOCHEM, V150, P29, DOI 10.1111/j.1432-1033.1985.tb08982.x; Blankenship RE, 1998, TRENDS BIOCHEM SCI, V23, P94, DOI 10.1016/S0968-0004(98)01186-4; BUICK R, 1992, SCIENCE, V255, P74, DOI 10.1126/science.11536492; Buick R, 1998, AAPG BULL, V82, P50; GOLUBIC S, 1994, EARLY LIFE EARTH, P220; Haug GH, 1998, PALEOCEANOGRAPHY, V13, P427, DOI 10.1029/98PA01976; HERMANN D, 1995, THESIS U HAUTE ALSAC; JURGENS UJ, 1992, FEMS MICROBIOL LETT, V92, P285; JW, 1992, PROTEROZOIC BIOSPHER, P81; KENIG F, 1995, GEOCHIM COSMOCHIM AC, V59, P2999, DOI 10.1016/0016-7037(95)00190-5; KNANI M, 1994, MICROBIOL-UK, V140, P2755, DOI 10.1099/00221287-140-10-2755; Llopiz P, 1996, FEMS MICROBIOL LETT, V140, P199; PETERS KE, 1992, BIOMARKER GUIDE INTE; PRICE LC, 1993, GEOCHIM COSMOCHIM AC, V57, P3261, DOI 10.1016/0016-7037(93)90539-9; RENOUX JM, 1985, EUR J BIOCHEM, V151, P405, DOI 10.1111/j.1432-1033.1985.tb09116.x; ROHMER M, 1984, J GEN MICROBIOL, V130, P1137; ROHMER M, 1993, PURE APPL CHEM, V65, P1293, DOI 10.1351/pac199365061293; SCHOPF J.W., 1992, PROTEROZOIC BIOSPHER; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Simonin P, 1996, EUR J BIOCHEM, V241, P865, DOI 10.1111/j.1432-1033.1996.00865.x; SUMMONS RE, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P182; Summons RE, 1996, CIBA F SYMP, V202, P174; SUMMONS RE, 1990, AM J SCI, V290A, P212; VILCHEZE C, 1994, MICROBIOLOGY, V140, P2794; ZHAO N, 1996, TETRAHEDRON, V52, P2772; ZUNDEL M, 1985, EUR J BIOCHEM, V150, P35, DOI 10.1111/j.1432-1033.1985.tb08984.x	28	679	732	4	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					554	557		10.1038/23005	http://dx.doi.org/10.1038/23005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448856				2022-12-28	WOS:000081854800052
J	Hogarth, MB; Qureshi, T; Lloyd, J; Rees, RG				Hogarth, MB; Qureshi, T; Lloyd, J; Rees, RG			A blistering rash and swollen knees	LANCET			English	Article							VASCULITIS		St Marys Hosp, Rheumatol Unit, London W2 1NY, England; St Marys Hosp, Dept Histopathol, London W2 1NY, England	Imperial College London; Imperial College London	Hogarth, MB (corresponding author), St Marys Hosp, Rheumatol Unit, Praed St, London W2 1NY, England.							BULPITT KJ, 1989, J RHEUMATOL, V16, P677; GOLDEN MP, 1994, MEDICINE, V73, P246, DOI 10.1097/00005792-199409000-00003; SANCHEZ NP, 1985, ARCH DERMATOL, V121, P220, DOI 10.1001/archderm.121.2.220; SANDLER A, 1987, PEDIATR INFECT DIS J, V6, P422, DOI 10.1097/00006454-198704000-00019; WEIGAND DA, 1980, ARCH DERMATOL, V116, P1174, DOI 10.1001/archderm.116.10.1174	5	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					978	978		10.1016/S0140-6736(98)10477-4	http://dx.doi.org/10.1016/S0140-6736(98)10477-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459908				2022-12-28	WOS:000079421600014
J	Brearley, AJ				Brearley, AJ			Origin of graphitic carbon and pentlandite in matrix olivines in the Allende meteorite	SCIENCE			English	Article							DARK INCLUSIONS; SOLAR NEBULA; AQUEOUS ALTERATION; FAYALITIC OLIVINE; CHONDRITES; PHYLLOSILICATES; RIMS	Matrix olivines in the Allende carbonaceous chondrite are believed to have formed by condensation processes in the primitive solar nebula. However, transmission electron microscope observations of numerous matrix olivines show that they contain abundant, previously unrecognized, nanometer-sized inclusions of pentlandite and poorly graphitized carbon. Neither of these phases would have been stable at the high-temperature conditions required to condense iron-rich olivine in the solar nebula. The presence of these inclusions is consistent with formation of the olivines by parent body processes that involved overgrowth of fine-grained organic materials and sulfides in the precursor matrix materials.	Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA	University of New Mexico	Brearley, AJ (corresponding author), Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA.			Brearley, Adrian/0000-0002-7364-8815				AKAI J, 1988, GEOCHIM COSMOCHIM AC, V52, P1593, DOI 10.1016/0016-7037(88)90228-1; AKAI J, 1994, ANTARCT METEORITES, V7, P94; ASH RD, 1999, LUNAR PLANET SCI, V30; ASHWORTH JR, 1975, EARTH PLANET SC LETT, V27, P43, DOI 10.1016/0012-821X(75)90158-2; Brearley A.J., 1996, CHONDRULES PROTOPLAN, P137; Brearley AJ, 1997, SCIENCE, V276, P1103, DOI 10.1126/science.276.5315.1103; BREARLEY AJ, 1990, GEOCHIM COSMOCHIM AC, V54, P831, DOI 10.1016/0016-7037(90)90377-W; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; BUSECK PR, 1988, ORG GEOCHEM, V12, P221, DOI 10.1016/0146-6380(88)90260-4; Cassen P., 1996, CHONDRULES PROTOPLAN, P21; CLAYTON RN, 1997, WORKSH PAR BOD NEB 1, P10; Cronin JR., 1988, ORGANIC MATTER CARBO, P819; DURAND B, 1980, KEROGENS; Fischbach D. B., 1971, CHEM PHYS CARBON, V7, P1; FRANKLIN RE, 1951, ACTA CRYSTALLOGR, V4, P253, DOI 10.1107/S0365110X51000842; GREEN HW, 1971, SCIENCE, V172, P936, DOI 10.1126/science.172.3986.936; HYATSU R, 1980, SCIENCE, V208, P1515; Jarosewich E., 1987, SMITHSONIAN CONTRIB, V27, P1; KOJIMA T, 1995, METEORITICS, V30, P529; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; Krot AN, 1997, METEORIT PLANET SCI, V32, P31, DOI 10.1111/j.1945-5100.1997.tb01238.x; Kullerud G., 1963, CARNEGIE I ANN REPOR, V62, P175; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1239, DOI 10.1016/S0016-7037(67)80014-0; Lauretta DS, 1998, METEORIT PLANET SCI, V33, P821, DOI 10.1111/j.1945-5100.1998.tb01689.x; MACPHERSON GJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2267, DOI 10.1016/0016-7037(85)90227-3; PALME H, 1990, EARTH PLANET SC LETT, V101, P180, DOI 10.1016/0012-821X(90)90152-N; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; SMITH PPK, 1981, SCIENCE, V212, P322, DOI 10.1126/science.11536554; SWART PK, 1982, J GEOPHYS RES, V87, pA283, DOI 10.1029/JB087iS01p0A283; TORIUMI M, 1989, EARTH PLANET SC LETT, V92, P265, DOI 10.1016/0012-821X(89)90051-4; Weisberg MK, 1998, METEORIT PLANET SCI, V33, P1087, DOI 10.1111/j.1945-5100.1998.tb01714.x; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452	32	77	77	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1380	1382		10.1126/science.285.5432.1380	http://dx.doi.org/10.1126/science.285.5432.1380			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464092				2022-12-28	WOS:000082233500036
J	Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T				Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T			Altered cochlear fibrocytes in a mouse model of DFN3 nonsyndromic deafness	SCIENCE			English	Article							FACTOR BRN-2; DIFFERENTIATION; HYPOTHALAMUS; MUTATIONS; SURVIVAL	DFN3, an X chromosome-linked nonsyndromic mixed deafness, is caused by mutations in the BRN-4 gene, which encodes a POU transcription factor. Brn-4-deficient mice were created and found to exhibit profound deafness, No gross morphological changes were observed in the conductive ossicles or cochlea, although there was a dramatic reduction in endocochlear potential. Electron microscopy revealed severe ultrastructural alterations in cochlear spiral Ligament fibrocytes. The findings suggest that these fibrocytes, which are mesenchymal in origin and for which a role in potassium ion homeostasis has been postulated, may play a critical role in auditory function.	Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; Tohoku Univ, Sch Med, Dept Otorhinolaryngol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138655, Japan; Kansai Med Univ, Dept Anat, Moriguchi, Osaka 5708506, Japan	Japanese Foundation for Cancer Research; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; University of Tokyo; Kansai Medical University	Noda, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Minowa, Osamu/AAM-1238-2020; Noda, Tetsuo/B-1667-2016	Watanabe, Kenichi/0000-0002-5269-146X				Avraham KB, 1998, NAT MED, V4, P1238, DOI 10.1038/3215; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; DAVIS H, 1965, COLD SPRING HARB SYM, V30, P181, DOI 10.1101/SQB.1965.030.01.020; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; HONRUBIA V, 1969, J ACOUST SOC AM, V46, P388, DOI 10.1121/1.1911701; Katori Y, 1996, CELL TISSUE RES, V284, P473, DOI 10.1007/s004410050608; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; Phippard D, 1998, HEARING RES, V120, P77, DOI 10.1016/S0378-5955(98)00059-8; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHULTE BA, 1989, J HISTOCHEM CYTOCHEM, V37, P127, DOI 10.1177/37.2.2536055; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	18	159	164	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1408	1411		10.1126/science.285.5432.1408	http://dx.doi.org/10.1126/science.285.5432.1408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464101				2022-12-28	WOS:000082233500045
J	Boletis, JN; Ioannidis, JPA; Boki, KA; Moutsopoulos, HM				Boletis, JN; Ioannidis, JPA; Boki, KA; Moutsopoulos, HM			Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis	LANCET			English	Article							ERYTHEMATOSUS	Among 14 randomised patients with proliferative lupus nephritis, monthly intravenous immunoglobulin maintained remission over 18 months, similar to standard intravenous cyclophosphamide treatment. Pulsed immunoglobulin may be a useful alternative therapy in lupus nephritis.	Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece; Laikon Gen Hosp, Dept Nephrol, Athens, Greece; Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Tufts Univ, New England Med Ctr Hosp, Div Clin Care Res, Boston, MA 02111 USA	Athens Medical School; National & Kapodistrian University of Athens; Laiko General Hospital; University of Ioannina; Tufts Medical Center; Tufts University	Moutsopoulos, HM (corresponding author), Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece.		Ioannidis, John P. A./G-9836-2011					AUSTIN HA, 1994, KIDNEY INT, V45, P544, DOI 10.1038/ki.1994.70; AUSTIN HA, 1986, NEW ENGL J MED, V314, P314; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; CORVETTA A, 1989, CLIN EXP RHEUMATOL, V7, P295; WINDER A, 1993, J RHEUMATOL, V20, P495	5	106	114	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					569	570		10.1016/S0140-6736(99)01575-5	http://dx.doi.org/10.1016/S0140-6736(99)01575-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470708				2022-12-28	WOS:000081991000021
J	Bonn, M; Funk, S; Hess, C; Denzler, DN; Stampfl, C; Scheffler, M; Wolf, M; Ertl, G				Bonn, M; Funk, S; Hess, C; Denzler, DN; Stampfl, C; Scheffler, M; Wolf, M; Ertl, G			Phonon- versus electron-mediated desorption and oxidation of CO on Ru(0001)	SCIENCE			English	Article							SURFACE PHOTOCHEMISTRY; FEMTOSECOND; OXYGEN; FEMTOCHEMISTRY; CO/O-2/PT(111); ADSORPTION; CHEMISTRY; SUBSTRATE; DYNAMICS; PT(111)	Heating of a ruthenium surface on which carbon monoxide and atomic oxygen are coadsorbed leads exclusively to desorption of carbon monoxide. In contrast, excitation with femtosecond infrared laser pulses enables also the formation of carbon dioxide. The desorption is caused by coupling of the adsorbate to the phonon bath of the ruthenium substrate, whereas the oxidation reaction is initiated by hot substrate electrons, as evidenced by the observed subpicosecond reaction dynamics and density functional calculations. The presence of this laser-induced reaction pathway allows elucidation of the microscopic mechanism and the dynamics of the carbon monoxide oxidation reaction.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany	Max Planck Society; Fritz Haber Institute of the Max Planck Society	Bonn, M (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.		Wolf, Martin/Q-3548-2016; Scheffler, Matthias/O-4649-2016; Stampfl, Catherine M/C-7133-2018; Bonn, Mischa/H-7446-2012	Scheffler, Matthias/0000-0002-1280-9873; Stampfl, Catherine M/0000-0003-4407-1778; Bonn, Mischa/0000-0001-6851-8453; Hess, Christian/0000-0002-4738-7674				Anisimov S I, 1974, SOV PHYS JETP, V39, P375, DOI DOI 10.1016/J.JMATPROTEC.2009.05.031; Anisimov SI, 1997, P SOC PHOTO-OPT INS, V3093, P192, DOI 10.1117/12.271674; BENNDORF C, 1987, SURF SCI, V191, P455, DOI 10.1016/S0039-6028(87)81190-1; Bockstedte M, 1997, COMPUT PHYS COMMUN, V107, P187, DOI 10.1016/S0010-4655(97)00117-3; Bottcher A, 1997, J PHYS CHEM B, V101, P11185, DOI 10.1021/jp9726899; BRANDBYGE M, 1995, PHYS REV B, V52, P6042, DOI 10.1103/PhysRevB.52.6042; BUDDE F, 1991, PHYS REV LETT, V66, P3024, DOI 10.1103/PhysRevLett.66.3024; Busch DG, 1996, PHYS REV LETT, V77, P1338, DOI 10.1103/PhysRevLett.77.1338; CAVANAGH RR, 1993, J PHYS CHEM-US, V97, P786, DOI 10.1021/j100106a002; DAI HL, 1995, LASER SPECTROSCOPY P, P625; DELIWALA S, 1995, CHEM PHYS LETT, V242, P627; Finlay RJ, 1997, CHEM PHYS LETT, V274, P499, DOI 10.1016/S0009-2614(97)00708-2; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Her TH, 1998, J CHEM PHYS, V108, P8595, DOI 10.1063/1.476289; Ho W, 1998, ACCOUNTS CHEM RES, V31, P567, DOI 10.1021/ar9501784; HOFFMANN FM, 1991, SURF SCI, V253, P59, DOI 10.1016/0039-6028(91)90581-C; KAO FJ, 1993, PHYS REV LETT, V70, P4098, DOI 10.1103/PhysRevLett.70.4098; KOSTOV KL, 1992, SURF SCI, V278, P62, DOI 10.1016/0039-6028(92)90584-S; MADEY TE, 1970, J CHEM PHYS, V52, P5215, DOI 10.1063/1.1672766; MISEWICH JA, 1992, PHYS REV LETT, V68, P3737, DOI 10.1103/PhysRevLett.68.3737; NEUGEBAUER J, 1992, PHYS REV B, V46, P16067, DOI 10.1103/PhysRevB.46.16067; PRYBYLA JA, 1992, PHYS REV LETT, V68, P503, DOI 10.1103/PhysRevLett.68.503; Stampfl C, 1996, PHYS REV LETT, V77, P3371, DOI 10.1103/PhysRevLett.77.3371; Struck LM, 1996, PHYS REV LETT, V77, P4576, DOI 10.1103/PhysRevLett.77.4576; Troullier N., 1991, PHYS REV B, V43, P1993; Wintterlin J, 1997, SCIENCE, V278, P1931, DOI 10.1126/science.278.5345.1931; YATA M, 1995, SURF SCI, V328, P171, DOI 10.1016/0039-6028(95)00037-2	27	387	392	7	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1042	1045		10.1126/science.285.5430.1042	http://dx.doi.org/10.1126/science.285.5430.1042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446045				2022-12-28	WOS:000082033100038
J	Levine, RJ				Levine, RJ			The need to revise The declaration of of Helsinki	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; DEVELOPING-COUNTRIES; TRANSMISSION; TYPE-1		Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Levine, RJ (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH056826] Funding Source: NIH RePORTER; NIMH NIH HHS [P01 MH/DA 56 826-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Jonsen A.R., 1998, BIRTH BIOETHICS; Levine R J, 1988, Law Med Health Care, V16, P174; Levine RJ., 1996, ETHICS RES INVOLVING, P235; LEVINE RJ, 1988, ETHICS REGULATION CL; Levine Robert J, 1998, IRB, V20, P5, DOI 10.2307/3564021; Levit K R, 1985, Health Care Financ Rev, V7, P1; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Wilfert CM, 1999, LANCET, V353, P832, DOI 10.1016/S0140-6736(98)10414-2	14	126	129	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					531	534		10.1056/NEJM199908123410713	http://dx.doi.org/10.1056/NEJM199908123410713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441613				2022-12-28	WOS:000081962600013
J	Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH				Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH			A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation	NATURE			English	Article							TGF-BETA SUPERFAMILY; PROTEIN LIGASE; SIGNALING PATHWAYS; XENOPUS EMBRYO; C2 DOMAIN; DEGRADATION; RECEPTOR; ENCODES; SYSTEM; ACTS	The TGF-beta superfamily of proteins regulates many different biological processes, including cell growth, differentiation and embryonic pattern formation(1-3). TGF-beta-like factors signal across cell membranes through complexes of transmembrane receptors known as type I and type II serine/threonine-kinase receptors, which in turn activate the SMAD signalling pathway(4,5). On the inside of the cell membrane, a receptor-regulated class of SMADs are phosphorylated by the type-I-receptor kinase. In this way, receptors for different factors are able to pass on specific signals along the pathway: for example, receptors for bone morphogenetic protein (BMP) target SMADs 1, 5 and 8, whereas receptors for activin and TGF-beta target SMADs 2 and 3. Phosphorylation of receptor-regulated SMADs induces their association with Smad4, the 'common-partner' SMAD, and stimulates accumulation of this complex in the nucleus, where it regulates transcriptional responses. Here we describe Smurf1, a new member of the Hect family of E3 ubiquitin ligases. Smurf1 selectively interacts with receptor-regulated SMADs specific for the BMP pathway in order to trigger their ubiquitination and degradation, and hence their inactivation. In the amphibian Xenopus laevis, Smurf1 messenger RNA is localized to the animal pole of the egg; in Xenopus embryos, ectopic Smurf1 inhibits the transmission of BMP signals and thereby affects pattern formation. Smurf1 also enhances cellular responsiveness to the Smad2 (activin/TGF-beta) pathway. Thus, targeted ubipuitination of SMADs may serve to control both embryonic development and a wide variety of cellular responses to TGF-beta signals.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X8, Canada	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Thomsen, GH (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Kavsak, Pete/K-8089-2019; zhu, HAITAO/GVL-0589-2022; Wrana, Jeffrey/F-8857-2013		NICHD NIH HHS [R01 HD032429, R01 HD032429-04, R01 HD032429-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032429] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Candia AF, 1997, DEVELOPMENT, V124, P4467; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177	31	645	702	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					687	693		10.1038/23293	http://dx.doi.org/10.1038/23293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458166				2022-12-28	WOS:000082032900059
J	Bell, AC; West, AG; Felsenfeld, G				Bell, AC; West, AG; Felsenfeld, G			The protein CTCF is required for the enhancer blocking activity of vertebrate insulators	CELL			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER PROTEIN; HAIRY-WING PROTEIN; BETA-GLOBIN LOCUS; C-MYC GENE; DROSOPHILA-MELANOGASTER; CHROMATIN INSULATOR; TRANSCRIPTIONAL ACTIVITY; CHROMOSOMAL DOMAINS; PROMOTER	An insulator is a DNA sequence that can act as a barrier to the influences of neighboring cis-acting elements, preventing gene activation, for example, when located between an enhancer and a promoter. We have identified a 42 bp fragment of the chicken beta-globin insulator that is both necessary and sufficient for enhancer blocking activity in human cells. We show that this sequence is the binding site for CTCF, a previously identified eleven-zinc finger DNA-binding protein that is highly conserved in vertebrates. CTCF sites are present in all of the vertebrate enhancer-blocking elements we have examined. We suggest that directional enhancer blocking by CTCF is a conserved component of gene regulation in vertebrates.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Felsenfeld, G (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			West, Adam/0000-0003-3502-7804				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DORSETT D, 1993, GENETICS, V134, P1135; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; Gdula DA, 1997, GENETICS, V145, P153; Georgiev P, 1996, GENETICS, V142, P425; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; Robinett CC, 1997, MOL CELL BIOL, V17, P2866, DOI 10.1128/MCB.17.5.2866; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	38	825	881	0	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					387	396		10.1016/S0092-8674(00)81967-4	http://dx.doi.org/10.1016/S0092-8674(00)81967-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458613	Bronze			2022-12-28	WOS:000081950300013
J	Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V				Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V			Regulation of DLG localization at synapses by CaMKII-dependent phosphorylation	CELL			English	Article							TUMOR-SUPPRESSOR GENE; LONG-TERM POTENTIATION; PROTEIN-KINASE-II; SYNAPTIC BOUTON STRUCTURE; FASCICLIN-II; FUNCTIONAL COMPONENTS; POSTSYNAPTIC DENSITY; ADHESION MOLECULE; K+ CHANNELS; IN-VIVO	Discs large (DLG) mediates the clustering of synaptic molecules. Here we demonstrate that synaptic localization of DLG itself is regulated by CaMKII. We show that DLG and CaMKII colocalize at synapses and exist in the same protein complex. Constitutively activated CaMKII phenocopied structural abnormalities of dig mutant synapses and dramatically increased extra-junctional DLG. Decreased CaMKII activity caused opposite alterations. In vitro, CaMKII phosphorylated a DLG fragment with a stoichiometry close to one. Moreover, expression of site-directed dig mutants that blocked or mimicked phosphorylation had effects similar to those observed upon inhibiting or constitutively activating CaMKII. We propose that CaMKII-dependent DLG phosphorylation regulates the association of DLG with the synaptic complex during development and plasticity, thus providing a link between synaptic activity and structure.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Brandeis Univ, Volen Ctr Complex Syst, Dept Biol, Waltham, MA 02454 USA	University of Massachusetts System; University of Massachusetts Amherst; Brandeis University	Budnik, V (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	vbudnik@bio.umass.edu		Griffith, Leslie/0000-0003-3164-9876	NIGMS NIH HHS [R01 GM54408, R01 GM054408] Funding Source: Medline; NINDS NIH HHS [R01 NS30072, R01 NS030072, KO4 NS01786] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030072, K04NS001786] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAND AH, 1993, DEVELOPMENT, V118, P401; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; Davis GW, 1998, CURR OPIN NEUROBIOL, V8, P149, DOI 10.1016/S0959-4388(98)80018-4; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; Gramates LS, 1999, INT REV NEUROBIOL, V43, P93, DOI 10.1016/S0074-7742(08)60542-5; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; Guan B, 1996, CURR BIOL, V6, P695, DOI 10.1016/S0960-9822(09)00451-5; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jin R, 1998, J NEUROSCI, V18, P8955; KENNEDY M, 1997, TRENDS NEUROSCI, V20, P103; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; Wang Z, 1998, J NEUROCHEM, V71, P378; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	56	197	201	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					353	363		10.1016/S0092-8674(00)81964-9	http://dx.doi.org/10.1016/S0092-8674(00)81964-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458610	Bronze, Green Accepted			2022-12-28	WOS:000081950300010
J	Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M				Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M			Proton translocation by cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; OXYGEN; PUMP	Cell respiration in mitochondria and some bacteria is catalysed by cytochrome c oxidase, which reduces O-2 to water, coupled with translocation of four protons across the mitochondrial or bacterial membrane. The enzyme's catalytic cycle consists of a reductive phase, in which the oxidized enzyme receives electrons from cytochrome c, and an oxidative phase, in which the reduced enzyme is oxidized by O-2. Previous studies indicated that proton translocation is coupled energetically only to the oxidative phase, but this has been challenged. Here, with the purified enzyme inlaid in liposomes, we report time-resolved measurements of membrane potential, which show that hall: of the electrical charges due to proton-pumping actually cross the membrane during reduction after a preceding oxidative phase. pH measurements confirm that proton translocation also occurs during reduction, but only when immediately preceded by an oxidative phase. We conclude that all the energy for proton translocation is conserved in the enzyme during its oxidation by O-2. One half of it is utilized for proton-pumping during oxidation, but the other half is unlatched for this purpose only during re-reduction of the enzyme.	Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, FIN-00014 Helsinki, Finland; Univ Helsinki, Bioctr Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Wikstrom, M (corresponding author), Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, POB 8, FIN-00014 Helsinki, Finland.		Wikstrom, Marten KF/A-4403-2008	Verkhovskaya, Marina/0000-0001-8950-5256				ARMSTRONG F, 1983, BIOCHIM BIOPHYS ACTA, V722, P61, DOI 10.1016/0005-2728(83)90157-3; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; DRACHEV LA, 1974, NATURE, V249, P321, DOI 10.1038/249321a0; Gennis RB, 1998, P NATL ACAD SCI USA, V95, P12747, DOI 10.1073/pnas.95.22.12747; Hinkle P, 1970, J Bioenerg, V1, P45, DOI 10.1007/BF01516088; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1101, P188, DOI 10.1016/S0005-2728(05)80016-7; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; SOLIOZ M, 1982, J BIOL CHEM, V257, P1579; VERKHOVSKY MI, IN PRESS BIOCH BIOPH; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6	17	193	197	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					480	483		10.1038/22813	http://dx.doi.org/10.1038/22813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440381				2022-12-28	WOS:000081715000058
J	Maw, R; Wilks, J; Harvey, I; Peters, TJ; Golding, J				Maw, R; Wilks, J; Harvey, I; Peters, TJ; Golding, J			Early surgery compared with watchful waiting for glue ear and effect on language development in preschool children: a randomised trial	LANCET			English	Article							OTITIS-MEDIA; EARLY-CHILDHOOD; EFFUSION; LIFE	Background Otitis media with effusion (OME) is the most common cause of hearing loss in children and is generally treated by elective surgery. We compared in children with persistent OME the effect on speech and language development of immediate surgery (ventilation-tube insertion) and watchful waiting before surgery. Methods We did a randomised controlled trial with masked outcome assessment in Bristol Children's Hospital, Bristol, UK. We included 186 children born between April 1, 1991, and Dec 31, 1992, who had confirmed bilateral OME and bilateral hearing impairment of 25-70 dB of at least 3 months' duration. Children were randomly assigned surgery within 6 weeks (n=92), or 9 months of watchful waiting (n=90), after which bilateral tube insertion was done if required. We assessed hearing loss, expressive language, and verbal comprehension at 9 months and 18 months. Findings At 9 months, standardised scores for expressive language and verbal comprehension differed between groups with marginal significance after adjustment for baseline differences (p=0.04 and p=0.028, respectively). At 9 months, verbal comprehension and expressive language skills in the watchful-waiting group were 3.24 months behind those in the early-surgery group. The watchful-waiting group was delayed on these two measures compared with their age-expected levels. 18 months after randomisation, 85% of children in the watchful-waiting group had received surgery and groups did not differ significantly. Interpretation There is some benefit from ventilation-tube insertion for expressive language and verbal comprehension but the timing of surgery is not critical.	Univ Bristol, St Michaels Hosp, Dept Otolaryngol, Bristol BS8 2PR, Avon, England; Univ Bristol, St Michaels Hosp, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, St Michaels Hosp, Dept Paediat, Bristol BS8 2PR, Avon, England	University of Bristol; University of Bristol; University of Bristol	Maw, R (corresponding author), Univ Bristol, St Michaels Hosp, Dept Otolaryngol, Bristol BS8 2PR, Avon, England.			Peters, Tim/0000-0003-2881-4180; Golding, Jean/0000-0003-2826-3307				CHALMERS D, 1989, CLIN DEV MED, V108, P121; FIELLAUNIKOLAJSEN M, 1983, ACTA OTO-LARYNGOL, P1; FRIELPATTI S, 1990, J SPEECH HEAR RES, V33, P188, DOI 10.1044/jshr.3301.188; Griffiths R, 1984, ABILITIES YOUNG CHIL; LULOFF AK, 1993, RECENT ADV OTITIS ME, P531; PADEN EP, 1994, TOP LANG DISORD, V14, P72, DOI 10.1097/00011363-199402000-00008; RACH GH, 1991, CLIN OTOLARYNGOL, V16, P128, DOI 10.1111/j.1365-2273.1991.tb01960.x; REYNELL J, 1985, REYNELL DEV LANGUAGE; ROBERTS JE, 1988, J SPEECH HEAR DISORD, V53, P424, DOI 10.1044/jshd.5304.424; ROBERTS JE, 1991, J SPEECH HEAR RES, V34, P1158, DOI 10.1044/jshr.3405.1158; ROBERTS JE, 1986, PEDIATRICS, V78, P423; SCHILDER AGM, 1994, EAR HEARING, V15, P224, DOI 10.1097/00003446-199406000-00003; TEELE DW, 1984, PEDIATRICS, V74, P282; *U LEEDS, 1992, EFF HLTH CAR B; WALLACE IF, 1988, LARYNGOSCOPE, V98, P64; WRIGHT PF, 1988, J PEDIATR-US, V113, P581, DOI 10.1016/S0022-3476(88)80659-0	16	102	103	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					960	963		10.1016/S0140-6736(98)05295-7	http://dx.doi.org/10.1016/S0140-6736(98)05295-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459904				2022-12-28	WOS:000079421600010
J	Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M				Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M			Hip fractures in Finland between 1970 and 1997 and predictions for the future	LANCET			English	Article							POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; EPIDEMIOLOGY; TRENDS; AGE; ENGLAND; RATES	Background Hip fractures in elderly people are common worldwide, and the predicted ageing of populations is increasing the burden of these fractures on health-care systems. However, prediction of the true increases in number of patients needing treatment requires exact knowledge of whether the number of hip fractures is rising more rapidly than can be accounted for by demographic changes alone. We aimed to make such a prediction for people aged 50 years or more in Finland. Methods All patients aged 50 years or more, who were admitted to hospitals in Finland during 1970-97 for primary treatment of first hip fracture were selected from the National Hospital Discharge Register. The age-specific and age-adjusted fracture incidences were expressed as the number of patients per 100 000 individuals per year, and predicton of the number, and incidence of hip fractures in Finland (population 5 million) until the year 2030 was calculated with a regression model. Findings The number of hip fractures in Finnish people aged 50 or more rose during the study period, from 1857 in 1970 to 7122 in 1997. The corresponding fracture incidence (per 100 000 people) increased from 163 to 438. The age-adjusted incidence of hip fractures also showed a steady increase from 1970 to 1997. in women, from 292 to 467, and in men, from 112 to 233. If this trend continues, the number of hip fractures in Finland will be almost three-fold higher in the year 2030 than in 1997. Interpretation The number of hip fractures in elderly Finnish men and women is increasing at a rate that cannot be explained merely by demographic changes. The precise reasons for this are not known, but deterioration in age-adjusted bone-mineral density and strength, with accompanying increase in the age-adjusted incidence of injurious falls of the elderly, could partly account for the development.	UKK Inst Hlth Promot Res, FIN-33500 Tampere, Finland; Tampere Res Ctr Sports Med, Tampere, Finland; Accid & Trauma Res Ctr, Tampere, Finland; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Surg, Tampere, Finland	UKK Institute; Tampere University; Tampere University; Tampere University Hospital	Kannus, P (corresponding author), UKK Inst Hlth Promot Res, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.	klpeka@uta.fi						BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; BOYCE WJ, 1985, LANCET, V1, P150; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; EISKJAER S, 1992, ACTA ORTHOP SCAND, V63, P293, DOI 10.3109/17453679209154785; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; FENTONLEWIS A, 1981, BRIT MED J, V283, P1217; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; HOFFENBERG R, 1989, J ROY COLL PHYS LOND, V23, P8; HONKNEN R, 1990, HOSP DUE INJURIES FI; Jaglal SB, 1996, CAN J SURG, V39, P105; Kanis JA, 1993, OSTEOPOROSIS INT S1, V3, P10; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; LAU EMC, 1990, INT J EPIDEMIOL, V19, P1119, DOI 10.1093/ije/19.4.1119; LEE CM, 1993, ACTA ORTHOP SCAND, V64, P178, DOI 10.3109/17453679308994565; LEVY AR, 1995, AM J EPIDEMIOL, V142, P428, DOI 10.1093/oxfordjournals.aje.a117651; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MARTIN AD, 1991, CLIN ORTHOP RELAT R, P111; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; *OFF STAT FINL, 1998, STRUCT POP VIT STAT; *OFF STAT FINL, 1997, POP PROJ 1997 2030; PARKKARI J, 1994, CALCIFIED TISSUE INT, V55, P342, DOI 10.1007/BF00299311; SALMELA R, 1987, HOSPITAL, V79, P780; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; Thorngren K G, 1994, Disabil Rehabil, V16, P119; WALLACE WA, 1983, LANCET, V1, P1413	30	236	240	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					802	805		10.1016/S0140-6736(98)04235-4	http://dx.doi.org/10.1016/S0140-6736(98)04235-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459962				2022-12-28	WOS:000079089100012
J	Nathan, DG; Weatherall, DJ				Nathan, DG; Weatherall, DJ			Academia and industry: lessons from the unfortunate events in Toronto	LANCET			English	Editorial Material							THALASSEMIA; THERAPY		Dana Farber Inst Canc Res, Boston, MA 02115 USA; Univ Oxford, Inst Mol Med, Oxford OX3 9DS, England	Harvard University; Dana-Farber Cancer Institute; University of Oxford	Nathan, DG (corresponding author), Dana Farber Inst Canc Res, Boston, MA 02115 USA.							Buchwald M, 1999, NAT MED, V5, P2, DOI 10.1038/4667; NATHAN DG, 1995, NEW ENGL J MED, V332, P953, DOI 10.1056/NEJM199504063321411; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; Olivieri NF, 1997, BLOOD, V90, p264a; OLIVIERI NF, 1996, BLOOD S, V88, P310; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; 1998, N ENGL J MED, V339, P1710	9	31	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					771	772		10.1016/S0140-6736(99)00072-0	http://dx.doi.org/10.1016/S0140-6736(99)00072-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459956				2022-12-28	WOS:000079089100006
J	Man-Son-Hing, M; Laupacis, A; O'Connor, AM; Biggs, J; Drake, E; Yetisir, E; Hart, RG				Man-Son-Hing, M; Laupacis, A; O'Connor, AM; Biggs, J; Drake, E; Yetisir, E; Hart, RG		Stroke Prevention Atrial Fibrillation Investiga	A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WARFARIN; WOMEN	Context Decision aids are tools designed to help patients participate in the clinical decision-making process. Objective To determine whether use of an audiobooklet (AB) decision aid explaining the results of a clinical trial affected the decision-making process of study participants. Design Randomized controlled trial conducted from May 1997 to April 1998. Setting Fourteen centers that participated in the Stroke Prevention in Atrial Fibrillation (SPAF) III trial. Participants A total of 287 patients from the SPAF III aspirin cohort study, in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mg/d of aspirin and were followed up for a mean of 2 years, Intervention At the end of SPAF III, participants were randomized to be informed of the study results with usual care plus use of an AB (AB group) vs usual care alone (control group). The AB included pertinent information to help patients decide whether to continue taking aspirin or switch to warfarin. Main Outcome Measures Patients' ability to make choices regarding antithrombotic therapy, and 6-month adherence to these decisions. Their knowledge, expectations, decisional conflict (the amount of uncertainty about the course of action to take), and satisfaction with the decision-making process were also measured. Results More patients in the AB group made a choice about antithrombotic therapy than in the control group (99% vs 94%; P = .02). Patients in the AB group were more knowledgeable and had more realistic expectations about the risk of stroke and hemorrhage (in the AB group, 53% -80% correctly estimated different risks; in the control group, 16%-28% gave correct estimates). Decisional conflict and satisfaction were similar for the 2 groups. After 6 months, a similar percentage of patients were still taking their initial choice of antithrombotic therapy (95% vs 93%; P = .44). Conclusions For patients with atrial fibrillation who had participated in a major clinical trial, the use of an AB decision aid improved their understanding of the benefits and risks associated with different treatment options and helped them make definitive choices about which therapy to take. Further studies are necessary to evaluate the acceptability and impact of decision aids in other clinical settings.	Ottawa Civic Hosp, Geriatr Assessment Unit, Ottawa, ON K1Y 4E9, Canada; Ottawa Civic Hosp, Loeb Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Sch Nursing, Dept Med, Ottawa, ON K1N 6N5, Canada; Univ Texas, Dept Med, San Antonio, TX 78285 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Texas System	Man-Son-Hing, M (corresponding author), Ottawa Civic Hosp, Geriatr Assessment Unit, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	mhing@civich.ottawa.on.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 24224] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; Atrial Fibrillation Investigators, 1994, ARCH INTERN MED, V154, P2254; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Bunn H, 1996, Can J Nurs Res, V28, P13; DRAKE E, IN PRESS J GENET COU; FISET V, 1998, THESIS U OTTAWA ONTA; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; MORGAN MW, 1997, THESIS U TORONTO ONT; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Rothert ML, 1997, RES NURS HEALTH, V20, P377, DOI 10.1002/(SICI)1098-240X(199710)20:5<377::AID-NUR2>3.0.CO;2-L; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537	20	219	219	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					737	743		10.1001/jama.282.8.737	http://dx.doi.org/10.1001/jama.282.8.737			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463708	Bronze			2022-12-28	WOS:000082118800024
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1968: Har Khorana (b 1922); Robert Holley (1922-93); Marshall Nirenberg (b 1927)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					690	690		10.1016/S0140-6736(05)77679-0	http://dx.doi.org/10.1016/S0140-6736(05)77679-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466708				2022-12-28	WOS:000082214500071
J	Schwaiger, M; Melin, J				Schwaiger, M; Melin, J			Cardiological applications of nuclear medicine	LANCET			English	Article							CORONARY-ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; ISCHEMIC-HEART-DISEASE; MYOCARDIAL BLOOD-FLOW; PROGNOSTIC VALUE; VENTRICULAR DYSFUNCTION; VIABILITY ASSESSMENT; TL-201; REVASCULARIZATION; CARDIOMYOPATHY	Cardiovascular mortality is falling in most industrialised nations. Primarily responsible for this encouraging trend are preventive measures such as risk-factor modification but improved medical and surgical management have helped too. Clinical decision making in the patient with coronary heart disease demands techniques that not only describe coronary anatomy but also provide functional indices for early detection and to monitor the severity and extent of disease. Nuclear medicine methods can characterise non-invasively myocardial function, perfusion, and metabolism. Novel radiopharmaceuticals, improvements in imaging equipment, and extensive validation have contributed to the growing clinical acceptance of these techniques and to their cost-effective integration in the workup of patients with cardiovascular disease.	Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, D-81675 Munich, Germany; Catholic Univ Louvain, Clin Univ St Luc, Dept Internal Med, Div Nucl Med, Brussels, Belgium	Technical University of Munich; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwaiger, M (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany.	M.Schwaiger@lrz.tu-muenchen.de		schwaiger, markus/0000-0002-2305-7144				Bax JJ, 1997, J AM COLL CARDIOL, V30, P1451, DOI 10.1016/S0735-1097(97)00352-5; Beller GA, 1998, J AM COLL CARDIOL, V31, P1286; BERGMANN SR, 1989, J AM COLL CARDIOL, V14, P639, DOI 10.1016/0735-1097(89)90105-8; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BROWN KA, 1993, AM J CARDIOL, V71, P865, DOI 10.1016/0002-9149(93)90840-9; Campisi R, 1999, CIRCULATION, V99, P491, DOI 10.1161/01.CIR.99.4.491; Carrio I, 1998, J NUCL CARDIOL, V5, P551, DOI 10.1016/S1071-3581(98)90108-8; DICARLI MF, 1995, CIRCULATION, V92, P3436, DOI 10.1161/01.CIR.92.12.3436; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; EITZMAN D, 1992, J AM COLL CARDIOL, V20, P559, DOI 10.1016/0735-1097(92)90008-B; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOULD KL, 1978, AM J CARDIOL, V41, P267, DOI 10.1016/0002-9149(78)90165-0; Guethlin M, 1999, CIRCULATION, V99, P475, DOI 10.1161/01.CIR.99.4.475; Haas F, 1997, J AM COLL CARDIOL, V30, P1693, DOI 10.1016/S0735-1097(97)00375-6; Hachamovitch R, 1998, CIRCULATION, V97, P535; Iskander S, 1998, J AM COLL CARDIOL, V32, P57, DOI 10.1016/S0735-1097(98)00177-6; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Laine M, 1998, J CLIN INVEST, V101, P1156, DOI 10.1172/JCI1065; MACHECOURT J, 1994, J AM COLL CARDIOL, V23, P1096, DOI 10.1016/0735-1097(94)90597-5; MAISEY MN, 1990, EUR J NUCL MED, V16, P869, DOI 10.1007/BF01280254; MELIN JA, 1986, J NUCL MED, V27, P641; OHTANI H, 1990, AM J CARDIOL, V66, P394, DOI 10.1016/0002-9149(90)90692-T; Pagley PR, 1997, CIRCULATION, V96, P793; Pennell DJ, 1998, HEART, V80, P296, DOI 10.1136/hrt.80.3.296; POHOST GM, 1977, CIRCULATION, V55, P294, DOI 10.1161/01.CIR.55.2.294; PORT SC, 1995, J NUCL CARDIOL, V2, P551, DOI 10.1016/S1071-3581(05)80049-2; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Shaw LJ, 1999, J AM COLL CARDIOL, V33, P661, DOI 10.1016/S0735-1097(98)00606-8; SILSIZIAN V, 1996, J AM COLL CARDIOL, V27, P910; Stollfuss JC, 1998, EUR J NUCL MED, V25, P522, DOI 10.1007/s002590050253; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; UDELSON JE, 1994, CIRCULATION, V89, P2552, DOI 10.1161/01.CIR.89.6.2552; Underwood SR, 1999, EUR HEART J, V20, P157, DOI 10.1053/euhj.1998.1196; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; Wijns W, 1998, NEW ENGL J MED, V339, P173, DOI 10.1056/NEJM199807163390307; ZARET BL, 1973, NEW ENGL J MED, V288, P809, DOI 10.1056/NEJM197304192881602; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313	43	60	62	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					661	666		10.1016/S0140-6736(99)06057-2	http://dx.doi.org/10.1016/S0140-6736(99)06057-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466685				2022-12-28	WOS:000082214500045
J	Singer, M; Little, R				Singer, M; Little, R			ABC of intensive care - Cutting edge	BRITISH MEDICAL JOURNAL			English	Article									UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England; Univ Manchester, NW Injury Res Ctr, Manchester M13 9PL, Lancs, England	University of London; University College London; University of Manchester	Little, R (corresponding author), UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England.		Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350					0	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					501	504		10.1136/bmj.319.7208.501	http://dx.doi.org/10.1136/bmj.319.7208.501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454407	Green Published			2022-12-28	WOS:000082199600029
J	Everard, ML				Everard, ML			What link between early respiratory viral infections and atopic asthma?	LANCET			English	Editorial Material							SYNCYTIAL VIRUS-INFECTION; ACUTE BRONCHIOLITIS; RESPONSES; INFANTS; CELLS		Childrens Hosp, Dept Resp Med, Sheffield S10 2TH, S Yorkshire, England	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital	Everard, ML (corresponding author), Childrens Hosp, Dept Resp Med, Sheffield S10 2TH, S Yorkshire, England.							ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; CARLSEN KH, 1987, PEDIATR PULM, V3, P153, DOI 10.1002/ppul.1950030308; EVERAD ML, 1998, TXB PAEDIAT RESP MED; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; GARDNER PS, 1970, BMJ-BRIT MED J, V1, P327, DOI 10.1136/bmj.1.5692.327; MOK JYK, 1998, ARCH DIS CHILD, V59, P306; Noble V, 1997, ARCH DIS CHILD, V76, P315, DOI 10.1136/adc.76.4.315; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; SIGURS N, 1995, PEDIATRICS, V95, P500; SIMS DG, 1981, BRIT MED J, V282, P2086, DOI 10.1136/bmj.282.6282.2086; SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11; STOTT EJ, 1987, J VIROL, V61, P3855, DOI 10.1128/JVI.61.12.3855-3861.1987; Toms GL, 1996, ARCH DIS CHILD, V74, P126, DOI 10.1136/adc.74.2.126; WELLIVER RC, 1988, AM THORACIC SOC CONT, P21	14	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					527	528		10.1016/S0140-6736(99)00159-2	http://dx.doi.org/10.1016/S0140-6736(99)00159-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470690				2022-12-28	WOS:000081991000003
J	Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL				Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL			Incidence of weapon injuries not related to interfactional combat in Afghanistan in 1996: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FIREARM	Objective To examine the descriptive epidemiology of weapon injuries not directly attributable to combat during armed conflict Design Prospective cohort study. Setting Nangarhar region of Afghanistan, which experienced effective peace, intense fighting, and then peace over six months in 1996, Subjects 608 people admitted to Jalalabad hospital because of weapon injuries. Main outcome measures Estimated incidence of injuries from combat or otherwise (non-combat injury) before, during, and after the fall of Kabul. Results Incidence of non-combat injury was initially 65 per 100 000, During the intense military campaign for Kabul the incidence declined dramatically and then differentially increased dependent on injury subcategory-that is, whether injuries were accidental or intentional and whether they were inflicted by firearms or fragmenting munitions. Non-combat injuries accounted for 51% of weapon injuries observed over the study period. Civilians were more likely to have non-combat injuries than combat injuries. Conclusions Weapon injuries that are not attributable to combat are common. Social changes accompanying conflict and widespread availability of weapons may be predictive of use of weapons that persists independently of conflict.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Hlth Operat Div, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Peshawar, Pakistan; Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain	Autonomous University of Madrid	Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.	dmeddings@icrc.org		Michael, Markus/0000-0003-0482-4325				ADENIJI O, 1998, MORATORIUM LIGHT WEA, P85; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Bellah RN, 1995, BOST THEO I, V4, P1; BERMAN E, 1996, MANAGING ARMS PEACE, P57; CHACHIUA M, 1999, ARMS MANAGEMENT PROG; Coupland R. M., 1996, MED GLOBAL SURVIVAL, V3, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Cukier W, 1998, Chronic Dis Can, V19, P25; HIGDON S, 1996, ANGOLA CONFLICT RESO; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	16	19	20	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					415	417		10.1136/bmj.319.7207.415	http://dx.doi.org/10.1136/bmj.319.7207.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445923	Bronze, Green Published			2022-12-28	WOS:000082098900017
J	Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A				Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A			Control of the terminal step of intracellular membrane fusion by protein phosphatase 1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE PHOSPHATASES; YEAST VACUOLES; SEC18P NSF; T-SNARE; DOCKING; DISTINCT; KINASE; BINDS; ROLES	Intracellular membrane fusion is crucial for the biogenesis and maintenance of cellular compartments, for vesicular traffic between them, and for exo- and endocytosis. Parts of the molecular machinery underlying this process have been identified, but most of these components operate in mutual recognition of the membranes. Here it is shown that protein phosphatase 1 (PP1) is essential for bilayer mixing, the last step of membrane fusion, PP1 was also identified in a complex that contained calmodulin, the second known factor implicated in the regulation of bilayer mixing. The PP1-calmodulin complex was required at multiple sites of intracellular trafficking; hence, PP1 may be a general factor controlling membrane bilayer mixing.	Friedrich Miescher Lab, D-72076 Tubingen, Germany; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Univ So Denmark, Dept Mol Biol, Prot Interact Lab, DK-5230 Odense M, Denmark	Eberhard Karls University of Tubingen; University of Dundee; University of Southern Denmark	Mayer, A (corresponding author), Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.	andreas.mayer@tuebingen.mpg.de	Podtelejnikov, Alexandre/B-6120-2017; Mayer, Andreas/AAE-4315-2020; Mann, Matthias/A-3454-2013; Stark, Michael J. R./B-2815-2014	Podtelejnikov, Alexandre/0000-0002-8124-6584; Mayer, Andreas/0000-0001-6131-313X; Mann, Matthias/0000-0003-1292-4799; Stark, Michael J. R./0000-0001-9086-191X; Andrews, Paul/0000-0001-7699-5604	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS PD, UNPUB; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JONES EW, 1977, GENETICS, V85, P23; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MAYER A, IN PRESS CURR OPIN C; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	29	138	142	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1084	1087		10.1126/science.285.5430.1084	http://dx.doi.org/10.1126/science.285.5430.1084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446058				2022-12-28	WOS:000082033100051
J	Alton, EWFW; Stern, M; Farley, R; Jaffe, A; Chadwick, SL; Phillips, J; Davies, J; Smith, SN; Browning, J; Davies, MG; Hodson, ME; Durham, SR; Li, D; Jeffery, PK; Scallan, M; Balfour, R; Eastman, SJ; Cheng, SH; Smith, AE; Meeker, D; Geddes, DM				Alton, EWFW; Stern, M; Farley, R; Jaffe, A; Chadwick, SL; Phillips, J; Davies, J; Smith, SN; Browning, J; Davies, MG; Hodson, ME; Durham, SR; Li, D; Jeffery, PK; Scallan, M; Balfour, R; Eastman, SJ; Cheng, SH; Smith, AE; Meeker, D; Geddes, DM			Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial	LANCET			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NASAL EPITHELIUM; AIRWAY EPITHELIA; CHLORIDE SECRETION; RESPIRATORY-TRACT; IN-VIVO; ADENOVIRUS; EFFICIENCY; EFFICACY; SAFETY	Background We and others have previously reported significant changes in chloride transport after cationic-lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the nasal epithelium of patients with cystic fibrosis. We studied the safety and efficacy of this gene transfer to the lungs and nose of patients with cystic fibrosis in a double-blind placebo-controlled trial. Methods Eight patients with cystic fibrosis were randomly assigned DNA-lipid complex (active) by nebulisation into the lungs followed 1 week later by administration to the nose. Eight control patients followed the same protocol but with the lipid alone (placebo). Safety was assessed clinically, by radiography, by pulmonary function, by induced sputum, and by histological analysis. Efficacy was assessed by analysis of vector-specific CFTR DNA and mRNA, in-vivo potential difference, epifluorescence assay of chloride efflux, and bacterial adherence. Findings Seven of the eight patients receiving the active complex reported mild influenza-like symptoms that resolved within 36 h. Six of eight patients in both the active and placebo groups reported mild airway symptoms over a period of 12 h following pulmonary administration. No specific treatment was required for either event. Pulmonary administration resulted in a significant (p<0.05) degree of correction of the chloride abnormality in the patients receiving active treatment but not in those on placebo when assessed by in-vivo potential difference and chloride efflux. Bacterial adherence was also reduced. We detected no alterations in the sodium transport abnormality. A similar pattern occurred following-nasal administration. Interpretation Cationic-lipid-mediated CFTR gene transfer can significantly influence the underlying chloride defect in the lungs of patients with cystic fibrosis.	Natl Heart & Lung Inst, Imperial Coll, Dept Gene Therapy, London SW3 6LR, England; Royal Brompton Hosp, London SW3 6LY, England; Genzyme Corp, Framingham, MA USA	Imperial College London; Royal Brompton Hospital; Sanofi-Aventis; Genzyme Corporation	Alton, EWFW (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Dept Gene Therapy, London SW3 6LR, England.	e.alton@ic.ac.uk		Jaffe, Adam/0000-0002-1963-5415; Davies, Jane/0000-0003-3506-1199	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTON EWF, 1996, PAEDIAT PULMONOL S, V135, P240; ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V29, P290, DOI 10.1080/00039896.1974.10666589; Bellon G, 1997, HUM GENE THER, V8, P15, DOI 10.1089/hum.1997.8.1-15; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; Chadwick SL, 1997, GENE THER, V4, P937, DOI 10.1038/sj.gt.3300481; COUSWAY SP, 1994, THORAX, V49, P860; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Davies JC, 1997, AM J RESP CELL MOL, V16, P657, DOI 10.1165/ajrcmb.16.6.9191467; DAVIS PB, 1985, SEMIN RESPIR MED, V6, P261, DOI 10.1055/s-2007-1011505; Dorin JR, 1996, GENE THER, V3, P797; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; Gill DR, 1997, GENE THER, V4, P199, DOI 10.1038/sj.gt.3300391; HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487; Johnson LG, 1996, HUM GENE THER, V7, P51, DOI 10.1089/hum.1996.7.1-51; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Porteous DJ, 1997, GENE THER, V4, P210, DOI 10.1038/sj.gt.3300390; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; SCHWARZ MJ, 1995, HUM MUTAT, V6, P326, DOI 10.1002/humu.1380060406; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stern M, 1995, GENE THER, V2, P766; Wagner JA, 1998, LANCET, V351, P1702, DOI 10.1016/S0140-6736(05)77740-0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; Zabner J, 1997, J CLIN INVEST, V100, P1529, DOI 10.1172/JCI119676; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573	31	327	359	1	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					947	954		10.1016/S0140-6736(98)06532-5	http://dx.doi.org/10.1016/S0140-6736(98)06532-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459902				2022-12-28	WOS:000079421600008
J	Pocock, S; White, I				Pocock, S; White, I			Trials stopped early: too good to be true?	LANCET			English	Editorial Material							CLINICAL-TRIALS		Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Pocock, S (corresponding author), Univ London London Sch Hyg & Trop Med, Med Stat Unit, Keppel St, London WC1E 7HT, England.			White, Ian/0000-0002-6718-7661				ARMSTRONG PW, 1995, CIRCULATION, V91, P901, DOI 10.1161/01.CIR.91.3.901; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; FLEMING TR, 1993, CONTROL CLIN TRIALS, V14, P183, DOI 10.1016/0197-2456(93)90002-U; FREEDMAN LS, 1989, BRIT J CANCER, V59, P396, DOI 10.1038/bjc.1989.79; Lau WY, 1999, LANCET, V353, P797, DOI 10.1016/S0140-6736(98)06475-7; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Ware JH, 1989, STAT SCI, V4, P298, DOI DOI 10.1214/ss/1177012384	9	78	78	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					943	944		10.1016/S0140-6736(98)00379-1	http://dx.doi.org/10.1016/S0140-6736(98)00379-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459899				2022-12-28	WOS:000079421600005
J	Gueyffier, F; Bulpitt, C; Boissel, JP; Schron, E; Ekbom, T; Fagard, R; Casiglia, E; Kerlikowske, A; Coope, J				Gueyffier, F; Bulpitt, C; Boissel, JP; Schron, E; Ekbom, T; Fagard, R; Casiglia, E; Kerlikowske, A; Coope, J		INDANA Grp	Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials	LANCET			English	Article							ELDERLY TRIAL; SYSTOLIC HYPERTENSION; CLINICAL-TRIALS; BLOOD-PRESSURE; MORTALITY; METAANALYSIS; MORBIDITY; HYVET	Background Beneficial clinical effects of treatment with antihypertensive drugs have been shown in middle-aged patients and in those hypertensive patients over 60 years old, but whether treatment is beneficial in patients over 80 years old is not known. Methods We collected data from all participants aged 80 years and over in randomised controlled trials of antihypertensive drugs through direct contact with study investigators. Our primary outcome was fatal and non-fatal stroke. Secondary outcomes were death from all causes, cardiovascular death, fatal and non-fatal major coronary and cardiovascular events, and heart failure. Findings There were 57 strokes and 34 deaths among 874 actively treated patients, compared with 77 strokes and 28 stroke deaths among 796 controls, representing 1 non-fatal stroke prevented for about 100 patients treated each year. The meta-analysis of data from 1670 participants aged 80 years or older suggested that treatment prevented 34% (95% CI 8-52) of strokes. Rates of major cardiovascular events and heart failure were significantly decreased, by 22% and 39%, respectively. However, there was no treatment benefit for cardiovascular death, and a non-significant 6% (-5 to 18) relative excess of death from all causes. Interpretations The inconclusive findings for mortality contrast with the benefit of treatment for non-fatal events. Results of a large-scale specific trial are needed for definite conclusion that antihypertensive treatment is beneficial in very elderly hypertensive patients. Meanwhile, an age threshold beyond which hypertension should not be treated cannot be justified.	Univ Lyon 1, Lyon Hosp, Dept Clin Pharmacol, F-69622 Villeurbanne, France; Hammersmith Hosp, Imperial Coll Sch Med, London, England; NHLBI, NIH, Bethesda, MD 20892 USA; Dept Community Hlth Sci, Lund, Sweden; Hypertens & Cardiovasc Rehabil Unit, Louvain, Belgium; Univ Padua, Dept Clin & Expt Med, I-35100 Padua, Italy; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Bollington Med Ctr, Macclesfield, Cheshire, England	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Padua; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gueyffier, F (corresponding author), Serv Pharmacol Clin, EA 643,BP 3041, F-69394 Lyon 03, France.	fg@upcl.univ-lyon1.fr	Gueyffier, François/B-8545-2008	Gueyffier, François/0000-0002-9921-0977				AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1986, J HYPERTENS, V4, pS642; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1980, LANCET, V1, P1261; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BULPITT CJ, 1994, PHARMACOECONOMICS, V6, P523, DOI 10.2165/00019053-199406060-00006; BULPITT CJ, 1994, DRUG AGING, V5, P171, DOI 10.2165/00002512-199405030-00003; BULPITT CJ, 1994, J HUM HYPERTENS, V8, P631; BULPITT CJ, 1982, HYPERTENSIVE CARDIOV, P929; CARTER AB, 1970, LANCET, V1, P485; CASIGLIA E, 1994, JPN HEART J, V35, P589; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; CUCHERAT M, 1997, METAANALYSE ESSAIS T; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P490; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; FANSHEL S, 1970, OPER RES, V18, P1021, DOI 10.1287/opre.18.6.1021; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Gueyffier F, 1996, J HUM HYPERTENS, V10, P1; GUEYFFIER F, 1995, THERAPIE, V50, P353; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2362; KURAMOTO K, 1981, JPN HEART J, V22, P75; LENFANT C, 1997, WHL NEWSLETTER, V52, P1; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULROW C, 1998, HYPERTENSION MODULE; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; PERRY HM, 1989, STROKE, V20, P4, DOI 10.1161/01.STR.20.1.4; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	32	443	471	2	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					793	796		10.1016/S0140-6736(98)08127-6	http://dx.doi.org/10.1016/S0140-6736(98)08127-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459960	Green Submitted			2022-12-28	WOS:000079089100010
J	Baum, M; Houghton, J				Baum, M; Houghton, J			Contribution of randomised controlled trials to understanding and management of early breast cancer	BRITISH MEDICAL JOURNAL			English	Article							NEOADJUVANT CHEMOTHERAPY; ALTERNATIVE TREATMENTS; RADICAL-MASTECTOMY; CLINICAL-TRIAL; ADJUVANT; RADIOTHERAPY; CYCLOPHOSPHAMIDE; MORTALITY		UCL Royal Free & Univ Coll, Sch Med, CRC, London W1P 8AN, England; UCL Royal Free & Univ Coll, Canc Trials Ctr, London W1P 8AN, England	University of London; University College London; UCL Medical School; University of London; University College London	Baum, M (corresponding author), UCL Royal Free & Univ Coll, Sch Med, CRC, Macdonald Buchanan Bldg,John Astor House, London W1P 8AN, England.	mbaum@ucl.ac.uk						ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1998, LANCET, V352, P930; Abram P, 1996, J NATL CANCER I, V88, P1834; ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; BAUM M, 1992, ACTA ONCOL, V31, P251, DOI 10.3109/02841869209088911; BAUM M, 1983, LANCET, V2, P450; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BONADONNA G, 1985, LANCET, V1, P976; BONADONNA G, 1991, SEMIN ONCOL, V18, P515; Clarke M, 1998, LANCET, V351, P1451; COLE MP, 1975, HORMONES BREAST CANC, V55, P143; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; CUZICK J, 1985, LANCET, V2, P282; *EARL BREAST CANC, 1990, SYST OV ALL AV RAND, P1; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1991, BREAST, P1081; FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2827, DOI 10.1002/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO;2-I; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; FISHER B, 1980, CANCER, V46, P1, DOI 10.1002/1097-0142(19800701)46:1<1::AID-CNCR2820460102>3.0.CO;2-3; HARPER MJK, 1966, NATURE, V212, P87, DOI 10.1038/212087a0; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; Holmberg L, 1996, NAT MED, V2, P844, DOI 10.1038/nm0896-844; HOUGHTON J, 1994, WORLD J SURG, V18, P117, DOI 10.1007/BF00348201; HOUGHTON J, 1980, LANCET, V2, P55; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Mamounas EP, 1998, SEMIN ONCOL, V25, P31; NISSEN-MEYER R., 1967, EUR J CANCER, V3, P395, DOI 10.1016/0014-2964(67)90024-2; NISSENMEYER R, 1978, CANCER, V41, P2088, DOI 10.1002/1097-0142(197806)41:6<2088::AID-CNCR2820410604>3.0.CO;2-J; OVERGAARD M, 1988, ACTA ONCOL, V27, P707, DOI 10.3109/02841868809091773; PATERSON R, 1959, J FAC RADIOL, V10, P175; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RUHENS RD, 1977, ADJUVANT THERAPY CAN, P101; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; RUTQVIST LE, 1999, P AN M AM SOC CLIN, V18, pA67; SCHOLL SM, 1991, EUR J CANCER, V27, P1668, DOI 10.1016/0277-5379(91)90442-G	37	12	14	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					568	571		10.1136/bmj.319.7209.568	http://dx.doi.org/10.1136/bmj.319.7209.568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463904	Green Published			2022-12-28	WOS:000082347200033
J	Ghura, HS; Carmichael, AJ; Bairstow, D; Finney, R				Ghura, HS; Carmichael, AJ; Bairstow, D; Finney, R			Fatal erythroderma associated with pentostatin	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									N Tees Gen Hosp, Dept Dermatol, Stockton on Tees TS19 8PE, England; N Tees Gen Hosp, Dept Haematol, Stockton on Tees TS19 8PE, England	University Hospital of North Tees; University Hospital of North Tees	Ghura, HS (corresponding author), N Tees Gen Hosp, Dept Dermatol, Stockton on Tees TS19 8PE, England.							COOPMAN SA, 1991, ARCH DERMATOL, V127, P714, DOI 10.1001/archderm.127.5.714; KING LE, 1994, ARCH DERMATOL, V130, P1545; MCEVOY GK, 1997, AM HOSP FORMULARY SE; REATHNACH SM, 1992, ADVERSE DRUG REACTIO; SAVEN A, 1994, NEW ENGL J MED, V330, P691	5	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					549	549		10.1136/bmj.319.7209.549	http://dx.doi.org/10.1136/bmj.319.7209.549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463896	Green Published			2022-12-28	WOS:000082347200023
J	Laezza, F; Doherty, JJ; Dingledine, R				Laezza, F; Doherty, JJ; Dingledine, R			Long-term depression in hippocampal interneurons: Joint requirement for pre- and postsynaptic events	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA2+-PERMEABLE AMPA RECEPTORS; GYRUS IN-VITRO; RAT HIPPOCAMPUS; DENTATE GYRUS; POTENTIATION; EXPRESSION; CHANNELS; LOCALIZATION; SUBTYPES	Long-term depression (LTD) is a well-known form of synaptic plasticity of principal neurons in the mammalian brain. Whether such changes occur in interneurons is still controversial. CA3 hippocampal interneurons expressing Ca2+-permeable AMPA receptors exhibited LTD after tetanic stimulation of CA3 excitatory inputs. LTD was independent of NMDA receptors and required both Ca2+-influx through postsynaptic AMPA receptors and activation of presynaptic mGluR7-Like receptors. These results point to the capability of interneurons to undergo plastic changes of synaptic strength through joint activation of pre- and postsynaptic glutamate receptors.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Neurosci, Atlanta, GA 30322 USA	Emory University; Emory University	Dingledine, R (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.		Laezza, Fernanda/L-6019-2016; dingledine, Ray/F-5173-2011; Laezza, Fernanda/X-4076-2019	Laezza, Fernanda/0000-0003-1141-1852; Laezza, Fernanda/0000-0003-1141-1852; Dingledine, Ray/0000-0001-7128-4520				Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradley SR, 1996, J NEUROSCI, V16, P2044; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONN PJ, COMMUNICATION; Doherty J, 1997, J NEUROPHYSIOL, V77, P393, DOI 10.1152/jn.1997.77.1.393; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang LQ, 1997, NEUROREPORT, V8, P687, DOI 10.1097/00001756-199702100-00022; IINO M, 1994, NEUROSCI LETT, V173, P14, DOI 10.1016/0304-3940(94)90139-2; Isa T, 1996, NEUROREPORT, V7, P689, DOI 10.1097/00001756-199602290-00002; JACKSON H, 1988, TRENDS NEUROSCI, V11, P278, DOI 10.1016/0166-2236(88)90112-9; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Lissin DV, 1999, J NEUROSCI, V19, P1263; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Maccaferri G, 1998, SCIENCE, V279, P1368, DOI 10.1126/science.279.5355.1368; MACCAFERRI G, 1995, NEURON, V15, P135; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McMahon LL, 1997, NEURON, V18, P295, DOI 10.1016/S0896-6273(00)80269-X; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P2; Phillips T, 1997, NEUROREPORT, V8, P3349, DOI 10.1097/00001756-199710200-00031; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Tzounopoulos T, 1998, NEURON, V21, P837, DOI 10.1016/S0896-6273(00)80599-1; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; Wang Y, 1997, J NEUROPHYSIOL, V77, P812, DOI 10.1152/jn.1997.77.2.812; Washburn MS, 1997, J NEUROSCI, V17, P9393; Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; YOKI M, 1996, SCIENCE, V273, P645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	40	131	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1411	1414		10.1126/science.285.5432.1411	http://dx.doi.org/10.1126/science.285.5432.1411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464102				2022-12-28	WOS:000082233500046
J	Bucher, HC; Guyatt, GH; Cook, DJ; Holbrook, A; McAlister, FA				Bucher, HC; Guyatt, GH; Cook, DJ; Holbrook, A; McAlister, FA		Evidence Based Med Working Grp	Users' guides to the medical literature XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; HIV-INFECTED PATIENTS; BONE-MINERAL DENSITY; CONVERTING ENZYME-INHIBITOR; RANDOMIZED CONTROLLED TRIAL; COA REDUCTASE INHIBITOR; CD4 CELL COUNTS; CUBIC MILLIMETER; POSTMENOPAUSAL OSTEOPOROSIS; DOUBLE-BLIND		Univ Basel, Kantonsspital Basel, Med Poliklin, Basel, Switzerland; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Alberta Hosp, Div Gen Internal Med, Edmonton, AB T6G 2B7, Canada	University of Basel; McMaster University; University of Alberta	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				[Anonymous], 1996, Lancet, V348, P283; BakkerArkema RG, 1996, JAMA-J AM MED ASSOC, V275, P128, DOI 10.1001/jama.275.2.128; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; BrunVezinet F, 1997, LANCET, V350, P983, DOI 10.1016/S0140-6736(97)03380-1; Bucher HC, 1999, ARTERIOSCL THROM VAS, V19, P187, DOI 10.1161/01.ATV.19.2.187; Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CLENDENENINN N, 1998, 5 C RETR OPP INF CHI; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; *CONC COORD COMM, 1994, LANCET, V348, P871; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DREXLER H, 1989, CIRCULATION, V79, P491, DOI 10.1161/01.CIR.79.3.491; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; ETTINGER B, 1998, OSTEOPOROSIS INT S3, V8, P11; FISCHL M, 1998, 12 WORLD AIDS C GEN; FLEMING TR, 1994, STAT MED, V13, P1423, DOI 10.1002/sim.4780131318; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GILES TD, 1988, AM J MED, V85, P44, DOI 10.1016/0002-9343(88)90350-6; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Heinonen TM, 1996, CLIN THER, V18, P853, DOI 10.1016/S0149-2918(96)80045-2; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; Huang C, 1998, J BONE MINER RES, V13, P107, DOI 10.1359/jbmr.1998.13.1.107; JONES IR, 1990, DIABETES CARE, V13, P855, DOI 10.2337/diacare.13.8.855; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEWIS GR, 1989, AM J CARDIOL, V63, pD12, DOI 10.1016/0002-9149(89)90411-6; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MASSIE BM, 1993, CIRCULATION, V88, P492, DOI 10.1161/01.CIR.88.2.492; McAlister FA, 1998, CAN MED ASSOC J, V159, P488; McAlister FA, 1997, DRUGS, V54, P235, DOI 10.2165/00003495-199754020-00003; MCALISTER FA, IN PRESS JAMA; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Meunier PJ, 1998, OSTEOPOROSIS INT, V8, P4, DOI 10.1007/s001980050041; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Moore TJ, 1995, DEADLY MED; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Niebauer J, 1997, LANCET, V349, P966, DOI 10.1016/S0140-6736(97)22014-3; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; RIEGGER GAJ, 1991, EUR HEART J, V12, P705, DOI 10.1093/eurheartj/12.6.705; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Ruiz L, 1996, AIDS, V10, pF39, DOI 10.1097/00002030-199609000-00001; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SHEPHERD J, 1997, JAMA-J AM MED ASSOC, V277, P1159; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; SUETA CA, 1995, AM J CARDIOL, V75, pA34, DOI 10.1016/S0002-9149(99)80381-6; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Temple RJ, 1995, CLIN MEASUREMENT DRU, P57; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WINOCOUR PH, 1992, ATHEROSCLEROSIS, V93, P83, DOI 10.1016/0021-9150(92)90202-R; Yee KM, 1997, EUR HEART J, V18, P1860; Yerly S, 1998, ARCH INTERN MED, V158, P247, DOI 10.1001/archinte.158.3.247; 1981, CMAJ, V124, P985	81	240	250	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					771	778		10.1001/jama.282.8.771	http://dx.doi.org/10.1001/jama.282.8.771			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463714				2022-12-28	WOS:000082118800030
J	Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E				Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E		XEN 111 Study Grp	Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue	SCIENCE			English	Article							HUMAN-CELLS; NO EVIDENCE; INFECTION; XENOTRANSPLANTATION; CONNECTION; KIDNEYS; SAFETY	Pig organs may offer a solution to the shortage of human donor organs for transplantation, but concerns remain about possible cross-species transmission of porcine endogenous retrovirus (PERV). Samples were collected from 160 patients who had been treated with various Living pig tissues up to 12 years earlier. Reverse transcription-polymerase chain reaction (RT-PCR) and protein immunoblot analyses were performed on serum from all 160 patients. No viremia was detected in any patient. Peripheral blood mononuclear cells from 159 of the patients were analyzed by PCR using PERV-specific primers. No PERV infection was detected in any of the patients from whom sufficient DNA was extracted to allow complete PCR analysis (97 percent of the patients). Persistent microchimerism (presence of donor cells in the recipient) was observed in 23 patients for up to 8.5 years.	Imutran Ltd, Cambridge CB2 2YP, England; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, HIV & Retrovirol Branch, Atlanta, GA 30333 USA; Q One Biotech Ltd, Glasgow G20 0XA, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G20 0XA, Lanark, Scotland; Circe Biomed, Lexington, KY 40501 USA; Novartis Pharma, Basel, Switzerland; CDC, Atlanta, GA 30333 USA	Novartis; Centers for Disease Control & Prevention - USA; University of Glasgow; Novartis; Centers for Disease Control & Prevention - USA	Paradis, K (corresponding author), Imutran Ltd, POB 399, Cambridge CB2 2YP, England.							ABOUNA GM, 1970, LANCET, V2, P391; Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; BENVENISTE RE, 1975, P NATL ACAD SCI USA, V72, P4090, DOI 10.1073/pnas.72.10.4090; BIGGAR RJ, 1985, LANCET, V2, P520; Breimer ME, 1996, XENOTRANSPLANTATION, V3, P328, DOI 10.1111/j.1399-3089.1996.tb00155.x; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; GRANT RF, 1995, VIROLOGY, V207, P292, DOI 10.1006/viro.1995.1080; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; HOOVER EA, 1991, J AM VET MED ASSOC, V199, P1392; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; Long ZF, 1998, HUM GENE THER, V9, P1165, DOI 10.1089/hum.1998.9.8-1165; Martin U, 1998, LANCET, V352, P692, DOI 10.1016/S0140-6736(98)07144-X; Matthews AL, 1999, TRANSPLANTATION, V67, P939, DOI 10.1097/00007890-199904150-00002; Mullon C, 1999, Expert Opin Investig Drugs, V8, P229, DOI 10.1517/13543784.8.3.229; NIKONOV S, 1991, GRUDN SERDECH SOSUDI, V2, P42; *NUFF COUNC BIOETH, 1996, AN HUM TRANSPL ETH X; Onions D, 1998, TRENDS MICROBIOL, V6, P430, DOI 10.1016/S0966-842X(98)01386-9; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SONG IC, 1966, SURGERY, V59, P576; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Stoye J, 1998, LANCET, V352, P666, DOI 10.1016/S0140-6736(98)22035-6; Switzer WM, 1999, TRANSPLANTATION, V68, P183, DOI 10.1097/00007890-199907270-00003; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; WHITE D, 1995, NATURE, V378, P434, DOI 10.1038/378434b0; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; 1997, Patent No. 40167	28	576	618	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1236	1241		10.1126/science.285.5431.1236	http://dx.doi.org/10.1126/science.285.5431.1236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455044				2022-12-28	WOS:000082130200034
J	Yerushalmi-Rozen, R; Kerle, T; Klein, J				Yerushalmi-Rozen, R; Kerle, T; Klein, J			Alternative dewetting pathways of thin liquid films	SCIENCE			English	Article							POLYMER-FILMS; NUCLEAR-REACTION; MIXTURES; RUPTURE; DEFECTS	An alternative pathway for the initiation of dewetting in thin metastable films of partially miscible liquid mixtures is described. In this pathway, phase separation is followed by a dewetting process at the interface between the two phases. Dewetting proceeds (from the sample edges inward) as holes form. The initially smooth film breaks up into droplets at rates much faster than those allowed by classical rupture mechanisms. Marangoni flow appears to be responsible for the initiation of the flow of the dewetting front, and coupling between the flow in the two phases leads to accelerated hole formation.	Ben Gurion Univ Negev, Dept Chem Engn, IL-84105 Beer Sheva, Israel; Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel	Ben Gurion University; Weizmann Institute of Science	Yerushalmi-Rozen, R (corresponding author), Ben Gurion Univ Negev, Dept Chem Engn, IL-84105 Beer Sheva, Israel.			Yerushalmi - Rozen, Rachel/0000-0002-2240-0465				BINDER K, 1987, REP PROG PHYS, V50, P783, DOI 10.1088/0034-4885/50/7/001; BINDER K, 1983, J CHEM PHYS, V79, P6387, DOI 10.1063/1.445747; Bischof J, 1996, PHYS REV LETT, V77, P1536, DOI 10.1103/PhysRevLett.77.1536; BROCHARDWYART F, 1991, LANGMUIR, V7, P335, DOI 10.1021/la00050a023; BrochardWyart F, 1996, COLLOID POLYM SCI, V274, P70, DOI 10.1007/BF00658911; BRZOSKA JB, 1993, LANGMUIR, V9, P2220, DOI 10.1021/la00032a052; CHATURVEDI UK, 1990, APPL PHYS LETT, V56, P1228, DOI 10.1063/1.103332; Fanton X, 1998, LANGMUIR, V14, P2554, DOI 10.1021/la971292t; Herminghaus S, 1998, SCIENCE, V282, P916, DOI 10.1126/science.282.5390.916; Jacobs K, 1998, LANGMUIR, V14, P965, DOI 10.1021/la970954b; JOANNY JF, 1987, PHYSICOCHEM HYDRODYN, V9, P183; Kerle T, 1997, ACTA POLYM, V48, P548, DOI 10.1002/actp.1997.010481204; LEGER L, 1992, REP PROG PHYS, V55, P431, DOI 10.1088/0034-4885/55/4/001; Linde H, 1997, J COLLOID INTERF SCI, V188, P16, DOI 10.1006/jcis.1997.4660; REITER G, 1993, LANGMUIR, V9, P1344, DOI 10.1021/la00029a031; Scheffold F, 1996, J CHEM PHYS, V104, P8786, DOI 10.1063/1.471568; Stange TG, 1997, LANGMUIR, V13, P4459, DOI 10.1021/la962090k; WEISS P, 1999, SCI NEWS, V155, P28; WYART FB, 1990, CAN J PHYS, V68, P1084, DOI 10.1139/p90-151; Xie R, 1998, PHYS REV LETT, V81, P1251, DOI 10.1103/PhysRevLett.81.1251	20	86	86	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1999	285	5431					1254	1256		10.1126/science.285.5431.1254	http://dx.doi.org/10.1126/science.285.5431.1254			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455049				2022-12-28	WOS:000082130200039
J	Levi, M; ten Cate, H				Levi, M; ten Cate, H			Current concepts - Disseminated intravascular coagulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-NECROSIS-FACTOR; COLI SEPTIC SHOCK; ANTITHROMBIN-III; ESCHERICHIA-COLI; TISSUE FACTOR; DOUBLE-BLIND; PROTEIN-C; ENDOTHELIAL-CELLS; SEVERE SEPSIS		Univ Amsterdam, Acad Med Ctr F4, Dept Vasc Med & Internal Med, NL-1105 AZ Amsterdam, Netherlands; Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr F4, Dept Vasc Med & Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020; Cate, Hugo ten/AAM-4000-2021					Aboulafia DM, 1996, ANN VASC SURG, V10, P396, DOI 10.1007/BF02286787; AVVISATI G, 1989, LANCET, V2, P122; Baglin T, 1996, BMJ-BRIT MED J, V312, P683; Baudo F, 1998, INTENS CARE MED, V24, P336, DOI 10.1007/s001340050576; BAUER KA, 1987, BLOOD, V70, P343; Bergum P, 1998, BLOOD, V92, p669A; Bick RL, 1996, SEMIN THROMB HEMOST, V22, P69, DOI 10.1055/s-2007-998993; BICK RL, 1992, THROMB RES, V65, P785, DOI 10.1016/0049-3848(92)90116-R; BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; COLMAN RW, 1990, SEMIN ONCOL, V17, P172; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; CORRIGAN JJ, 1977, J PEDIATR-US, V91, P695, DOI 10.1016/S0022-3476(77)81017-2; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Eisele B, 1998, INTENS CARE MED, V24, P663, DOI 10.1007/s001340050642; Falanga A, 1998, BLOOD, V92, P143, DOI 10.1182/blood.V92.1.143.413k18_143_151; FEINSTEIN DI, 1982, BLOOD, V60, P284; FEINSTEIN DI, 1988, SEMIN THROMB HEMOST, V14, P351, DOI 10.1055/s-2007-1002795; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; GANDO S, 1995, CRIT CARE MED, V23, P1835, DOI 10.1097/00003246-199511000-00009; Gando S, 1996, THROMB HAEMOSTASIS, V75, P224; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Kazmers A, 1996, J VASC SURG, V23, P191, DOI 10.1016/S0741-5214(96)70263-X; Kessler CM, 1997, BLOOD, V89, P4393, DOI 10.1182/blood.V89.12.4393; Levi M, 1997, EUR J CLIN INVEST, V27, P3, DOI 10.1046/j.1365-2362.1997.570614.x; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LEVI M, 1999, IN PRESS THROMB HAEM; Mesters RM, 1996, BLOOD, V88, P881, DOI 10.1182/blood.V88.3.881.881; Muller-Berghaus G, 1998, CARDIOVASCULAR THROM, P781; NOSSEL HL, 1981, NATURE, V291, P165, DOI 10.1038/291165a0; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; REGOECZI E, 1969, BRIT J HAEMATOL, V17, P73, DOI 10.1111/j.1365-2141.1969.tb05665.x; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; RUGGENENTI P, 1997, KIDNEY INT S, V58, pS97; SAKURAGAWA N, 1993, THROMB RES, V72, P475, DOI 10.1016/0049-3848(93)90109-2; SARRIS AH, 1992, BLOOD, V79, P1305; SIBAI BM, 1984, OBSTET GYNECOL, V64, P319; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; Szlachetka D M, 1998, Neonatal Netw, V17, P7; SZLACHETKA DM, 1998, NEONATAL NETW, V17, P21; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; THIJS LG, 1993, INTENS CARE MED, V19, P8; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023; Wada H, 1996, AM J HEMATOL, V51, P255, DOI 10.1002/(SICI)1096-8652(199604)51:4<255::AID-AJH1>3.0.CO;2-V; WEINER CP, 1986, CLIN PERINATOL, V13, P705, DOI 10.1016/S0095-5108(18)30794-2	53	961	1008	1	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					586	592		10.1056/NEJM199908193410807	http://dx.doi.org/10.1056/NEJM199908193410807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451465				2022-12-28	WOS:000082061500007
J	Edejer, TTT				Edejer, TTT			North-South research partnerships: the ethics of carrying out research in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH RESEARCH; RESEARCH CAPACITY; CLINICAL RESEARCH; TRIALS		WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland	World Health Organization	Edejer, TTT (corresponding author), WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland.	tantorrest@who.ch		Edejer, Tessa/0000-0003-1068-332X				Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], 1996, LANCET, V347, P629, DOI 10.1016/S0140-6736(96)91193-9; [Anonymous], 1997, LANCET, V350, P897; [Anonymous], 1999, LANCET, V353, P1285; [Anonymous], INV HLTH RES DEV; [Anonymous], 1999, WORLD HLTH REPORT 19; CHRISTAKIS NA, 1992, SOC SCI MED, V35, P1079, DOI 10.1016/0277-9536(92)90220-K; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; DECOCK KM, 1995, BRIT MED J, V311, P860, DOI 10.1136/bmj.311.7009.860; Garner P, 1996, LANCET, V347, P1113; Halsey NA, 1998, BRIT MED J, V316, P627; Halsey NA, 1997, BRIT MED J, V315, P965, DOI 10.1136/bmj.315.7114.965; HALSTEAD SB, 1991, J CLIN EPIDEMIOL, V44, P579, DOI 10.1016/0895-4356(91)90222-U; KLEINMAN AM, 1979, I MED NAT AC SCI WOR; LANSANG MAD, 1994, ACTA TROP, V57, P139, DOI 10.1016/0001-706X(94)90004-3; Lurie P, 1998, LANCET, V351, P220, DOI 10.1016/S0140-6736(05)78167-8; Lurie P, 1998, BRIT MED J, V316, P626; Lurie P, 1999, LANCET, V353, P1878; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Mabey D, 1996, LANCET, V347, P1112; MainaAhlberg B, 1997, SOC SCI MED, V44, P1229, DOI 10.1016/S0277-9536(96)00311-5; *RAWOO, 1998, FRAM GHAN DUTCH PROG; SMITH P, 1997, LANCET, V350, P1546; Swiss Commission for Research Partnership with Developing Countries, 1998, GUID RES PARTN DEV C; TANNER M, 1994, ACTA TROP, V57, P153, DOI 10.1016/0001-706X(94)90006-X; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; TROSTLE J, 1992, SOC SCI MED, V35, P1379, DOI 10.1016/0277-9536(92)90041-N; TROSTLE J, 1992, SOC SCI MED, V35, P1321, DOI 10.1016/0277-9536(92)90035-O; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Wilfert CM, 1999, LANCET, V353, P1880, DOI 10.1016/S0140-6736(05)75082-0; Wilfert CM, 1999, LANCET, V353, P832, DOI 10.1016/S0140-6736(98)10414-2; Wolffers I, 1998, LANCET, V351, P1652, DOI 10.1016/S0140-6736(97)10237-9; *WORK GROUP PRIOR, IN PRESS HLTH POLICY; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Zarembo A., 1999, NEWSWEEK        0705, P25; 1999, COHRED NEWSLETTE JAN, P12	36	109	110	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	1999	319	7207					438	441		10.1136/bmj.319.7207.438	http://dx.doi.org/10.1136/bmj.319.7207.438			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445930	Green Published			2022-12-28	WOS:000082098900024
J	Griffiths, RD; Jones, C				Griffiths, RD; Jones, C			ABC of intensive care - Recovery from intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Whiston Hosp, Dept Med, Intens Care Res Grp, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Whiston Hospital	Griffiths, RD (corresponding author), Univ Liverpool, Whiston Hosp, Dept Med, Intens Care Res Grp, Liverpool L69 3BX, Merseyside, England.								0	88	92	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					427	429		10.1136/bmj.319.7207.427	http://dx.doi.org/10.1136/bmj.319.7207.427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445926	Green Published			2022-12-28	WOS:000082098900021
J	Kevles, DJ				Kevles, DJ			Eugenics and human rights	BRITISH MEDICAL JOURNAL			English	Article									CALTECH, Div Humanities, Pasadena, CA 91125 USA	California Institute of Technology	Kevles, DJ (corresponding author), CALTECH, Div Humanities, Pasadena, CA 91125 USA.							Broberg G., 1996, EUGENICS WELFARE STA; CHRISTIAN T, MENTALLY ILL HUMAN R; McLaren Angus, 1990, OUR OWN MASTER RACE, DOI DOI 10.3138/9781442623316	3	46	46	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					435	438		10.1136/bmj.319.7207.435	http://dx.doi.org/10.1136/bmj.319.7207.435			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445929	Green Published			2022-12-28	WOS:000082098900023
J	Herman-Giddens, ME; Brown, G; Verbiest, S; Carlson, PJ; Hooten, EG; Howell, E; Butts, JD				Herman-Giddens, ME; Brown, G; Verbiest, S; Carlson, PJ; Hooten, EG; Howell, E; Butts, JD			Underascertainment of child abuse mortality in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOMICIDE; YOUNGER; NEGLECT; COUNTY	Context Mortality figures in the United States are believed to underestimate the incidence of fatal child abuse. Objectives To describe the true incidence of fatal child abuse, determine the proportion of child abuse deaths missed by the vital records system, and provide estimates of the extent of abuse homicides in young children. Design and Setting Retrospective descriptive study of child abuse homicides that occurred over a 10-year period in North Carolina from 1985-1994. Cases The Medical Examiner Information System was searched for all cases of children younger than 11 years classified with International Classification of Diseases, Ninth Revision codes E960 to E969 as the underlying cause of death and homicide as the manner of death. A total of 273 cases were identified in the search and 259 cases were reviewed after exclusion of fetal deaths and deaths of children who were not residents of North Carolina. Main Outcome Measure Child abuse homicide. Results Of the 259 homicides, 220 (84.9%) were due to child abuse, 22 (8.5%) were not related to abuse, and the status of 17 (6.6%) could not be determined. The rate of child abuse homicide increased from 1.5 per 100 000 person-years in 1985 to 2.8 in 1994. Of all 259 child homicides, the state vital records system underrecorded the coding of those due to battering or abuse by 58.7%. Black children were killed at 3 times the rate of white children (4.3 per 100 000 vs 1.3 per 100 000). Males made up 65.5% (133/203) of the known probable assailants. Biological parents accounted for 63% of the perpetrators of fatal child abuse. From 1985 through 1996, 9467 homicides among US children younger than 11 years were estimated to be due to abuse rather than the 2973 reported. The ICD-9 cause of death coding underascertained abuse homicides by an estimated 61.6%. Conclusions Using medical examiner data, we found that significant underascertainment of child abuse homicides in vital records systems persists despite greater societal attention to abuse fatalities. Improved recording of such incidences should be a priority so that prevention strategies can be appropriately targeted and outcomes monitored, especially in light of the increasing rates.	Dept Hlth & Human Serv, Off Chief Med Examiner, Raleigh, NC USA; Dept Hlth & Human Serv, State Ctr Hlth Stat, Raleigh, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill	Herman-Giddens, ME (corresponding author), 1450 Russell Chapel Rd, Pittsboro, NC 27312 USA.	mherman-giddens@unc.edu			PHS HHS [R49-CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABEL EL, 1986, PEDIATRICS, V77, P709; BERGMAN AB, 1986, PEDIATRICS, V77, P113; *CDCP, 1992, MMWR CDC SURV SUMM, P2; *CDCP, 1996, EPIINF; COPELAND AR, 1985, AM J FOREN MED PATH, V6, P21, DOI 10.1097/00000433-198503000-00005; Durfee M., 1995, CHILD ABUSE REV, V4, P377; EWIGMAN B, 1993, PEDIATRICS, V91, P330; Herman-Giddens M E, 1991, N C Med J, V52, P634; HERMANGIDDENS M, 1996, CHILDHOOD FATALITIES, P54; HERMANGIDDENS M, 1997, CHILDHOOD FATALITIES, P34; KAPLUN D, 1976, AM J PSYCHIAT, V133, P809; MCCLAIN PW, 1994, ARCH PEDIAT ADOL MED, V148, P82, DOI 10.1001/archpedi.1994.02170010084020; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; MCCURDY K, 1994, J INTERPERS VIOLENCE, V9, P75, DOI 10.1177/088626094009001005; *NAT CTR HLTH STAT, 1990, INSTR CLASS MULT 2B; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; *PHS, 1988, INT CLASS DIS CLIN M; *SAS I INC, 1996, SAS SOL SYST; Showers J, 1985, Pediatr Emerg Care, V1, P66; *US ADV BOARD CHIL, 1995, NAT SHAM FAT CHILD A; WALLER AE, 1989, AM J PUBLIC HEALTH, V79, P310, DOI 10.2105/AJPH.79.3.310	21	122	122	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					463	467		10.1001/jama.282.5.463	http://dx.doi.org/10.1001/jama.282.5.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442662				2022-12-28	WOS:000081784900023
J	McConnell, J				McConnell, J			The real millennium bug	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568				Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					946	946		10.1016/S0140-6736(99)00090-2	http://dx.doi.org/10.1016/S0140-6736(99)00090-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459901				2022-12-28	WOS:000079421600007
J	Mingrone, G; Greco, AV; Castagneto, M; Gasbarrini, G				Mingrone, G; Greco, AV; Castagneto, M; Gasbarrini, G			A woman who left her wheelchair	LANCET			English	Article									Catholic Univ, Sch Med, Dept Internal Med, I-00168 Rome, Italy; Catholic Univ, Sch Med, Dept Surg, I-00168 Rome, Italy; Catholic Univ, Sch Med, CNR, Ctr Fisiopatol Shock, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Mingrone, G (corresponding author), Catholic Univ, Sch Med, Dept Internal Med, I-00168 Rome, Italy.		Mingrone, Geltrude/AAB-9681-2019					Black RM, 1996, CLIN PROBLEMS NEPHRO; CORAZZA GR, 1995, GASTROENTEROLOGY, V109, P122, DOI 10.1016/0016-5085(95)90276-7; RYAN JA, 1987, NUTR SUPPORT CRITICA, P183; Tataranni PA, 1996, NUTRITION, V12, P239, DOI 10.1016/S0899-9007(96)90849-7	4	22	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					806	806		10.1016/S0140-6736(98)10206-4	http://dx.doi.org/10.1016/S0140-6736(98)10206-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459963				2022-12-28	WOS:000079089100013
J	Williams, RB				Williams, RB			A 69-year-old man with anger and angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; SOCIAL SUPPORT; HEART-DISEASE; PSYCHOSOCIAL FACTORS; MOLECULAR-BIOLOGY; SMOKING CESSATION; MAJOR DEPRESSION; TOTAL MORTALITY; MENTAL STRESS		Duke Univ, Med Ctr, Behav Med Res Ctr, Durham, NC 27706 USA	Duke University	Williams, RB (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,LY318, Boston, MA 02215 USA.		Telch, Michael J/E-7027-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL36587, P01 HL036587] Funding Source: Medline; NIA NIH HHS [5P60-AG11268] Funding Source: Medline; NIMH NIH HHS [K05-MH79482] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS DO, 1994, PSYCHOSOM MED, V56, P316, DOI 10.1097/00006842-199407000-00007; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; BAREFOOT JC, 1991, HEALTH PSYCHOL, V10, P18, DOI 10.1037/0278-6133.10.1.18; BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; BAREFOOT JC, 1989, PSYCHOSOM MED, V51, P46, DOI 10.1097/00006842-198901000-00005; Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; Blumenthal JA, 1997, ARCH INTERN MED, V157, P2213, DOI 10.1001/archinte.157.19.2213; BLUMENTHAL JA, 1997, N C MED J, V58, P802; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; BURSHMAN BJ, 1999, J PERS SOC PSYCHOL, V76, P367; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; CUMMINGS NA, 1991, 11C9833449 HCFA; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FLEMING R, 1982, J HUM STRESS, V8, P14, DOI 10.1080/0097840X.1982.9936110; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; FUKUDO S, 1992, CIRCULATION, V85, P2045, DOI 10.1161/01.CIR.85.6.2045; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; Gidron Y, 1999, HEALTH PSYCHOL, V18, P416, DOI 10.1037/0278-6133.18.4.416; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; HARTKA E, 1991, BRIT J ADDICT, V86, P1283, DOI 10.1111/j.1360-0443.1991.tb01704.x; HLATKY MA, 1995, CIRCULATION, V92, P327, DOI 10.1161/01.CIR.92.3.327; HOLSBOER F, 1984, NEW ENGL J MED, V311, P1127; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; IRONSON G, 1992, AM J CARDIOL, V70, P281, DOI 10.1016/0002-9149(92)90605-X; Jiang W, 1996, JAMA-J AM MED ASSOC, V275, P1651, DOI 10.1001/jama.275.21.1651; KAPLAN GA, 1995, PSYCHOSOM MED, V57, P208, DOI 10.1097/00006842-199505000-00002; KAPLAN JR, 1991, CIRCULATION S6, V94, P23; KAWACHI I, 1994, CIRCULATION, V90, P2225, DOI 10.1161/01.CIR.90.5.2225; KRANTZ DS, 1994, AM HEART J, V128, P703, DOI 10.1016/0002-8703(94)90268-2; Krittayaphong R, 1996, CLIN J PAIN, V12, P126, DOI 10.1097/00002508-199606000-00007; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Luecken LJ, 1997, PSYCHOSOM MED, V59, P352, DOI 10.1097/00006842-199707000-00003; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Mittleman MA, 1997, ARCH INTERN MED, V157, P769, DOI 10.1001/archinte.157.7.769; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; POPE MK, 1991, PSYCHOSOM MED, V53, P386, DOI 10.1097/00006842-199107000-00004; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHERWITZ LW, 1992, AM J EPIDEMIOL, V136, P136, DOI 10.1093/oxfordjournals.aje.a116480; SCHNALL P, 1990, JAMA-J AM MED ASSOC, V263, P1971; Shapiro PA, 1999, AM HEART J, V137, P1100, DOI 10.1016/S0002-8703(99)70369-8; SHEKELLE RB, 1983, PSYCHOSOM MED, V45, P219; SIEGLER IC, 1992, AM J EPIDEMIOL, V136, P146, DOI 10.1093/oxfordjournals.aje.a116481; SLOAN RP, 1994, AM J CARDIOL, V74, P298, DOI 10.1016/0002-9149(94)90382-4; SMITH TW, 1989, J BEHAV MED, V12, P135, DOI 10.1007/BF00846547; SPIEGEL D, 1989, LANCET, V2, P888; Spiegel D, 1999, JAMA-J AM MED ASSOC, V282, P371, DOI 10.1001/jama.282.4.371; Suarez EC, 1997, PSYCHOSOM MED, V59, P481, DOI 10.1097/00006842-199709000-00004; Suarez EC, 1998, PSYCHOSOM MED, V60, P78, DOI 10.1097/00006842-199801000-00017; SUAREZ EC, 1991, ANN M SOC PSYCH RES; TOFLER GH, 1992, J AM COLL CARDIOL, V20, P1049, DOI 10.1016/0735-1097(92)90356-R; VEITH RC, 1994, ARCH GEN PSYCHIAT, V51, P411; Verrier Richard L., 1996, Cardiology Clinics, V14, P289; WILLIAMS CA, 1985, AM J PUBLIC HEALTH, V75, P483, DOI 10.2105/AJPH.75.5.483; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; WILLIAMS RB, 1993, JAMA-J AM MED ASSOC, V270, P1860, DOI 10.1001/jama.270.15.1860; Williams RB, 1997, ARCH GEN PSYCHIAT, V54, P543; Williams RB, 1998, JAMA-J AM MED ASSOC, V279, P1745, DOI 10.1001/jama.279.21.1745; WILLIAMS RB, 1980, PSYCHOSOM MED, V42, P539, DOI 10.1097/00006842-198011000-00002; WILLIAMS RB, 1994, PSYCHOSOM MED, V56, P308, DOI 10.1097/00006842-199407000-00006; WILLIAMS RB, 1993, ANGER KILLS 17 STRAT; Williams VP, 1997, LIFESKILLS 8 SIMPLE	64	6	6	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					763	770		10.1001/jama.282.8.763	http://dx.doi.org/10.1001/jama.282.8.763			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	228CJ	10463712				2022-12-28	WOS:000082118800028
J	Gifford, DR; Holloway, RG; Frankel, MR; Albright, CL; Meyerson, R; Griggs, RC; Vickrey, BG				Gifford, DR; Holloway, RG; Frankel, MR; Albright, CL; Meyerson, R; Griggs, RC; Vickrey, BG			Improving adherence to dementia guidelines through education and opinion leaders - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							DIAGNOSIS; NEUROLOGY; SOCIETY; CARE	Background: Educational methods that encourage physicians to adopt practice guidelines are needed. Objective: To evaluate an educational strategy to increase neurologists' adherence to specialty society-endorsed practice recommendations. Design: Randomized, controlled trial. Setting: Six urban regions in New York State. Participants: 417 neurologists. Intervention: The educational strategy promoted six recommendations for evaluation and management of dementia. It included a mailed American Academy of Neurology continuing medical education course, practice-based tools, an interactive evidence-based American Academy of Neurology-sponsored seminar led by local opinion leaders, and follow-up mailings. Measurements: Neurologists' adherence to guidelines was measured by using detailed clinical scenarios mailed to a baseline group 3 months before the intervention and to intervention and control groups 6 months after the intervention. In one region, patients' medical records were reviewed to determine concordance between neurologists' scenario responses and their actual care. Results: Compared with neurologists in the baseline and control groups, neurologists in the intervention group were more adherent to three of the six recommendations: neuroimaging for patients with dementia only when certain criteria are present (odds ratio, 4.1 [95% CI, 1.9 to 8.9]), referral of all patients with dementia and their families to the Alzheimer's Association (odds ratio, 2.8 [CI, 1.7 to 4.8]), and encouragement of all patients and their families to enroll in the Alzheimer's Association Safe Return Program (odds ratio, 10.8 [CI, 3.5 to 33.2]). For the other three recommendations, adherence did not differ between the intervention and the nonintervention groups. Agreement between scenario responses and actual care ranged from 27% to 99% for the six recommendations and was 95% or more for three of the recommendations. Conclusion: A multifaceted educational program can improve physician adoption of practice guidelines.	Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Rochester, Dept Neurol, Rochester, NY 14642 USA; CUNY Bernard M Baruch Coll, New York, NY 10010 USA; Albright Consulting, St Paul, MN USA; Univ Calif Los Angeles, Dept Neurol, Reed Neurol Res Ctr C128, Los Angeles, CA 90095 USA; Alzheimers Dis Res Ctr Calif, Los Angeles, CA USA	Brown University; University of Rochester; City University of New York (CUNY) System; Baruch College (CUNY); University of California System; University of California Los Angeles	Gifford, DR (corresponding author), Rhode Isl Hosp, Div Geriatr, 593 Eddy St, Providence, RI 02903 USA.	David_Gifford@brown.edu		Griggs, Robert/0000-0001-7988-4854	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS081764] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; [Anonymous], 1995, JAMA, V274, P1627; BALAS EA, 1995, MED CARE, V33, P687, DOI 10.1097/00005650-199507000-00005; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V258, P3411; BRODATY H, 1990, AUST NZ J PSYCHIAT, V24, P351, DOI 10.3109/00048679009077702; CLARFIELD AM, 1990, J FAM PRACTICE, V31, P405; CLARFIELD AM, 1991, CAN MED ASSOC J, V144, P851; COREYBLOOM J, 1995, NEUROLOGY, V45, P211, DOI 10.1212/WNL.45.2.211; COSTA PF, 1996, AHCPR PUBLICATION, V19; Davis D, 1996, J GEN INTERN MED, V11, P705, DOI 10.1007/BF02600164; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; *DEP HLTH, 1990, HLTH FAC SER; Gifford DR, 1996, J GEN INTERN MED, V11, P664, DOI 10.1007/BF02600157; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; HISS RG, 1978, P 17 ANN C RES MED E, P283; Holloway RG, 1999, CONTROL CLIN TRIALS, V20, P369, DOI 10.1016/S0197-2456(99)00006-9; HOLLOWAY RG, 1998, US NEUROLOGISTS 1996; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KATZMAN R, 1990, J FAM PRACTICE, V31, P401; KENT DL, 1994, ANN INTERN MED, V120, P872; KOSIK KS, 1996, CONTINUUM, V2; Kreger CG, 1996, NEW ENGL J MED, V334, P538; Lanska DJ, 1996, MAYO CLIN PROC, V71, P821, DOI 10.1016/S0025-6196(11)64850-7; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; MOHIDE EA, 1990, J AM GERIATR SOC, V38, P446, DOI 10.1111/j.1532-5415.1990.tb03544.x; MUNSAT TL, 1994, NEUROLOGY, V44, P771, DOI 10.1212/WNL.44.4.771; *OFF GER EXT CAR, 1989, DEM GUID DIAGN TREAT; OKAGAKI JF, 1994, NEUROLOGY, V44, P2203; PEABODY J, 1998, ASS HLTH SERV RES AN, V15, P202; PUTTERMAN C, 1995, NEW ENGL J MED, V333, P1208, DOI 10.1056/NEJM199511023331809; Rogers EM., 1983, DIFFUSION INNOVATION; RUSH AJ, 1993, AHCPR PUBLICATION, V5; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; THOMSON MA, 1999, COCHRANE LIB; *U HLTH SYST CONS, 1997, GUID PRIM CAR PRACT; *US DEP HHS, 1993, AHCPR PUBL; Vickrey BG, 1998, NEUROLOGY, V50, P1661, DOI 10.1212/WNL.50.6.1661; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	45	85	86	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					237	+		10.7326/0003-4819-131-4-199908170-00002	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454944				2022-12-28	WOS:000082012500001
J	Bartelink, H				Bartelink, H			Is neoadjuvant chemotherapy the answer for bladder cancer?	LANCET			English	Editorial Material							CISPLATIN; METHOTREXATE; VINBLASTINE; DOXORUBICIN		Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bartelink, H (corresponding author), Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands.							BOURHIS J, 1998, J CLIN ONCOL, V17, pA386; GHERSI D, 1995, BRIT J UROL, V75, P206; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; SCHER HI, 1988, J UROLOGY, V139, P470, DOI 10.1016/S0022-5347(17)42495-5; Shipley WU, 1997, INT J RADIAT ONCOL, V39, P937, DOI 10.1016/S0360-3016(97)00461-6; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; TANNOCK IF, 1990, SEMIN ONCOL, V17, P619; Thomas GM, 1999, NEW ENGL J MED, V340, P1198, DOI 10.1056/NEJM199904153401509	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					526	527		10.1016/S0140-6736(99)00210-X	http://dx.doi.org/10.1016/S0140-6736(99)00210-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470689				2022-12-28	WOS:000081991000002
J	Cuckle, H				Cuckle, H			Maternal age-standardisation of prevalence of Down's syndrome	LANCET			English	Editorial Material									Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Cuckle, H (corresponding author), Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England.							Carothers AD, 1999, J MED GENET, V36, P386; Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO;2-6; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; HOOK EB, 1994, SCREENING DOWNS SYND, P1; James RS, 1998, EUR J HUM GENET, V6, P207, DOI 10.1038/sj.ejhg.5200178; Mutton D, 1998, BRIT MED J, V317, P922; *OFF POP CENS SURV, 1990, BIRTH STAT SER FM1, P17; Penrose LS, 1933, J GENET, V27, P219, DOI 10.1007/BF02984413	8	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					529	530		10.1016/S0140-6736(99)00174-9	http://dx.doi.org/10.1016/S0140-6736(99)00174-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470692				2022-12-28	WOS:000081991000005
J	Turchin, P; Taylor, AD; Reeve, JD				Turchin, P; Taylor, AD; Reeve, JD			Dynamical role of predators in population cycles of a forest insect: An experimental test	SCIENCE			English	Article							SOUTHERN PINE-BEETLE; COLEOPTERA	Population cycles occur frequently in forest insects. Time-series analysis of fluctuations in one such insect, the southern pine beetle (Dendroctonus frontalis), suggests that beetle dynamics are dominated by an ecological process acting in a delayed density-dependent manner. The hypothesis that delayed density dependence in this insect results from its interaction with predators was tested with a long-term predator-exclusion experiment. Predator-imposed mortality was negligible during the increase phase, grew during the year of peak population, and reached a maximum during the period of population decline. The delayed nature of the impact of predation suggests that predation is an important process that contributes significantly to southern pine beetle oscillations.	Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Univ Hawaii, Dept Zool, Honolulu, HI 96822 USA; US Forest Serv, So Res Stn, USDA, Pineville, LA 71360 USA	University of Connecticut; University of Hawaii System; United States Department of Agriculture (USDA); United States Forest Service	Turchin, P (corresponding author), Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA.		Taylor, Andrew D/I-5040-2012					Anderson R. M., 1981, Theoretical ecology. Principles and application., P318; BERISFORD CW, 1980, USDA FOR SERV TECH B, V1631, P31; Berryman A. A., 1988, DYNAMICS FOREST INSE; Caughely G, 1981, THEORETICAL ECOLOGY, P132; EDELSTEINKESHET L, 1989, AM NAT, V133, P787, DOI 10.1086/284953; Elton CS, 1924, BR J EXP BIOL, V2, P119; GINZBURG LR, 1994, J ANIM ECOL, V63, P79, DOI 10.2307/5585; GODFRAY HCJ, 1989, J ANIM ECOL, V58, P153, DOI 10.2307/4992; GURNEY WSC, 1998, ECOLOGICAL DYNAMICS; HASSELL MP, 1981, THEORETICAL ECOLOGY, P105; Hudson PJ, 1998, SCIENCE, V282, P2256, DOI 10.1126/science.282.5397.2256; Hunter Alison F., 1998, Integrative Biology, V1, P166, DOI 10.1002/(SICI)1520-6602(1998)1:5<166::AID-INBI2>3.3.CO;2-B; KALKSTEIN LS, 1981, FOREST SCI, V27, P579; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; May R. M., 1981, THEOR ECOL-NETH, P78; May RM, 1981, THEORETICAL ECOLOGY, P5; MICHAELS PJ, 1984, FOREST SCI, V30, P143; MURDOCH WW, 1987, AM NAT, V129, P263, DOI 10.1086/284634; PAYNE TL, 1980, USDA FOREST SERVICE, V1631, P7; Pimm S.L., 1991, BALANCE NATURE; Reeve JD, 1997, OECOLOGIA, V112, P48, DOI 10.1007/s004420050282; Reeve JD, 1996, J ENTOMOL SCI, V31, P123, DOI 10.18474/0749-8004-31.1.123; Reeve JD, 1998, ECOL ENTOMOL, V23, P433, DOI 10.1046/j.1365-2311.1998.00143.x; Royama T., 1992, ANAL POPULATION ECOL; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; TURCHIN P, 1991, ENVIRON ENTOMOL, V20, P401, DOI 10.1093/ee/20.2.401	26	139	149	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1068	1071		10.1126/science.285.5430.1068	http://dx.doi.org/10.1126/science.285.5430.1068			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446053				2022-12-28	WOS:000082033100046
J	Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B				Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B			Trigger factor and DnaK cooperate in folding of newly synthesized proteins	NATURE			English	Article							HEAT-SHOCK GENE; ESCHERICHIA-COLI; RECOGNITION; CHAPERONES; ISOMERASE; MUTATIONS	The role of molecular chaperones in assisting the folding of newly synthesized proteins in the cytosol is poorly understood. In Escherichia coli, GroEL assists folding of only a minority of proteins(1) and the Hsp70 homologue DnaK is not essential for protein folding or cell viability at intermediate growth temperatures(2). The major protein associated with nascent polypeptides is ribosome-bound trigger factor(3,4), which displays chaperone and prolyl isomerase activities in vitro(3,5,6). Here we show that Delta tig::kan mutants lacking trigger factor have no defects in growth or protein folding. However, combined Delta tig::kan and Delta dnaK mutations cause synthetic lethality. Depletion of DnaK in the Delta tig::kan mutant results in massive aggregation of cytosolic proteins. In Delta tig::kan cells, an increased amount of newly synthesized proteins associated transiently with DnaK. These findings show in vivo activity for a ribosome-associated chaperone, trigger factor, in general protein folding, and functional cooperation of this protein with a cytosolic Hsp70. Trigger factor and DnaK cooperate to promote proper folding of a variety of E. coli proteins, but neither is essential for folding and viability at intermediate growth temperatures.	Inst Biochem & Mol Biol, D-79104 Freiburg, Germany		Bukau, B (corresponding author), Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.			Bukau, Bernd/0000-0003-0521-7199				BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	15	392	399	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					693	696		10.1038/23301	http://dx.doi.org/10.1038/23301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458167	Green Published			2022-12-28	WOS:000082032900060
J	Knopp, RH				Knopp, RH			Drug treatment of lipid disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; COA REDUCTASE INHIBITORS; TRIGLYCERIDE-RICH LIPOPROTEINS; AVERAGE CHOLESTEROL LEVELS; FAMILIAL HYPERCHOLESTEROLEMIA; COMBINED HYPERLIPIDEMIA; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; LOVASTATIN THERAPY		Univ Washington, NW Lipid Res Clin, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Knopp, RH (corresponding author), Univ Washington, NW Lipid Res Clin, Seattle, WA 98195 USA.		Abramowicz, Daniel/F-7578-2017	Abramowicz, Daniel/0000-0002-6556-9199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOWICZ M, 1998, MED LETT, V40, P117; ABRAMOWICZ M, 1996, MED LETT, V38, P67; ALBERS JJ, 1984, BIOCHIM BIOPHYS ACTA, V795, P293, DOI 10.1016/0005-2760(84)90078-X; ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; *AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS56; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1993, Am J Cardiol, V72, P1031; [Anonymous], 1993, Arch Intern Med, V153, P1321; ARAD Y, 1992, METABOLISM, V41, P487, DOI 10.1016/0026-0495(92)90206-P; ARAD Y, 1990, J LIPID RES, V31, P567; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; Auwerx J, 1996, ATHEROSCLEROSIS, V124, pS29, DOI 10.1016/0021-9150(96)05854-6; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; BakkerArkema RG, 1996, JAMA-J AM MED ASSOC, V275, P128, DOI 10.1001/jama.275.2.128; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V259, P2698; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN WV, 1986, ARTERIOSCLEROSIS, V6, P670, DOI 10.1161/01.ATV.6.6.670; BROYLES FE, 1995, AM J CARDIOL, V76, pA129, DOI 10.1016/S0002-9149(05)80035-9; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; BRUNZELL JD, 1982, MED CLIN N AM, V66, P455, DOI 10.1016/S0025-7125(16)31430-4; Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; Campeau L, 1997, NEW ENGL J MED, V336, P153; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CHAIT A, 1980, EUR J CLIN INVEST, V10, P17, DOI 10.1111/j.1365-2362.1980.tb00004.x; CHAMBLESS LE, 1990, AM J PUBLIC HEALTH, V80, P1200, DOI 10.2105/AJPH.80.10.1200; Cignarella A, 1998, ARTERIOSCL THROM VAS, V18, P1322, DOI 10.1161/01.ATV.18.8.1322; Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265; Coresh J, 1996, JAMA-J AM MED ASSOC, V276, P914, DOI 10.1001/jama.276.11.914; Coronary Drug Project Research Group, 1977, N Engl J Med, V296, P1185; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; *CTR HLTH STAT, 1995, MORT STAT, P1; Davidson MH, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(96)00742-4; DAVIGNON J, 1994, AM J CARDIOL, V73, P339, DOI 10.1016/0002-9149(94)90005-1; DAVIGNON J, 1992, CAN J CARDIOL, V8, P843; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DEGRAAF J, 1993, ARTERIOSCLER THROMB, V13, P712, DOI 10.1161/01.ATV.13.5.712; DENKE MA, 1995, ARCH INTERN MED, V155, P17, DOI 10.1001/archinte.155.1.17; DEVRIES ACJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P63, DOI 10.1016/0005-2760(93)90218-X; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FEHER MD, 1995, BRIT HEART J, V74, P14; Ferguson JJ, 1999, CIRCULATION, V99, P2968, DOI 10.1161/01.CIR.99.22.2968; FIELDING CJ, 1995, J LIPID RES, V36, P211; Frick MH, 1997, CIRCULATION, V96, P2137; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Ginsberg HN, 1997, ANN INTERN MED, V126, P912, DOI 10.7326/0003-4819-126-11-199706010-00012; GINSBURG HN, 1998, HARRISONS PRINCIPLES, V2, P2138; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1981, J LIPID RES, V22, P24; Grundy SM, 1998, CIRCULATION, V97, P1436; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HANSTON PD, 1998, DRUG INTERACTIONS NE, P103; HAVEL RJ, 1995, NEW ENGL J MED, V333, P467; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; HOKANSON JE, 1993, ARTERIOSCLER THROMB, V13, P427, DOI 10.1161/01.ATV.13.3.427; HSU I, 1995, ANN PHARMACOTHER, V29, P743, DOI 10.1177/106002809502907-818; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; IDE T, 1982, METABOLISM, V31, P1065, DOI 10.1016/0026-0495(82)90153-6; ILLINGWORTH DR, 1994, CLIN THER, V16, P366; ILLINGWOUTH DR, 1994, ARCH INTERN MED, V154, P1586, DOI 10.1001/archinte.154.14.1586; JAHN CE, 1985, GASTROENTEROLOGY, V89, P1266, DOI 10.1016/0016-5085(85)90642-0; Jen SL, 1997, CHUNG HUA HSUEH TSA, V59, P217; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KNOPP RH, 1994, ATHEROSCLEROSIS, V110, pS83, DOI 10.1016/0021-9150(94)05379-W; Knopp RH, 1998, METABOLISM, V47, P1097, DOI 10.1016/S0026-0495(98)90284-0; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; KNOPP RH, 1987, AM J MED, V83, P50, DOI 10.1016/0002-9343(87)90871-0; Knopp RH, 1997, JAMA-J AM MED ASSOC, V278, P1509, DOI 10.1001/jama.278.18.1509; KNOPP RH, 1994, ENDOCRINOLOGIST, V4, P286, DOI 10.1097/00019616-199407000-00008; KNOPP RH, 1987, AM J MED, V83, P75, DOI 10.1016/0002-9343(87)90875-8; KNOPP RH, 1994, AM J MED, V96, pS69, DOI 10.1016/0002-9343(94)90235-6; KNOPP RH, 1986, AM J MED, V81, P493, DOI 10.1016/0002-9343(86)90305-0; KNOPP RH, 1998, TXB CARDIOVASCULAR M, P195; KNOPP RH, 1989, ORAL CONTRACEPTION 1, P31; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Labarthe DR, 1996, CIRCULATION, V94, P2696, DOI 10.1161/01.CIR.94.11.2696; LATIES AM, 1990, NEW ENGL J MED, V323, P683; LEITERSDORF E, 1994, AM J MED, V96, P401, DOI 10.1016/0002-9343(94)90165-1; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; *LIP MET BRANCH DI, 1980, LIP RES CLIN POP STU, V1, P1; Llorente-Cortes V, 1998, ARTERIOSCL THROM VAS, V18, P738, DOI 10.1161/01.ATV.18.5.738; Mabuchi H, 1998, AM J CARDIOL, V82, P1489, DOI 10.1016/S0002-9149(98)00692-4; MABUCHI H, 1983, NEW ENGL J MED, V308, P609, DOI 10.1056/NEJM198303173081101; MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MCPHERSON R, 1993, J CLIN IMMUNOL, V13, P439, DOI 10.1007/BF00920019; Medical Economics, 1999, PHYS DESK REF, V53rd; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NIKKILA EA, 1977, METABOLISM, V26, P179, DOI 10.1016/0026-0495(77)90053-1; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; Oram JF, 1996, J LIPID RES, V37, P2473; PACKARD CJ, 1982, J LIPID RES, V23, P1081; Packard CJ, 1998, CIRCULATION, V97, P1440; PARTINEN M, 1994, AM J CARDIOL, V73, P876, DOI 10.1016/0002-9149(94)90814-1; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; *POST COR ART BYP, 1997, NEW ENGL J MED, V337, P1859; Rambjor GS, 1996, LIPIDS, V31, pS45, DOI 10.1007/BF02637050; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Retzlaff BM, 1997, J AM COLL NUTR, V16, P52, DOI 10.1080/07315724.1997.10718649; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; ROTH T, 1992, CLIN CARDIOL, V15, P426; RUBINS H, 1998, 71 ANN M AM HEART AS; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHONFELD G, 1994, ATHEROSCLEROSIS, V111, P161, DOI 10.1016/0021-9150(94)90090-6; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMIT WAJ, 1995, AM J CARDIOL, V76, pA126; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Stein, 1996, J Cardiovasc Pharmacol Ther, V1, P107; STONE NJ, 1994, MED CLIN N AM, V78, P117, DOI 10.1016/S0025-7125(16)30179-1; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TRAVIA D, 1995, J CLIN ENDOCR METAB, V80, P836, DOI 10.1210/jc.80.3.836; TRUSWELL AS, 1995, EUR J CLIN NUTR, V49, pS105; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Vaughan CJ, 1997, LANCET, V349, P214; VEGA GL, 1988, KIDNEY INT, V33, P1160, DOI 10.1038/ki.1988.125; VEGA GL, 1988, ATHEROSCLEROSIS, V70, P131; VGONTZAS AN, 1991, CLIN PHARMACOL THER, V50, P730, DOI 10.1038/clpt.1991.213; Walden CE, 1997, ARTERIOSCL THROM VAS, V17, P375, DOI 10.1161/01.ATV.17.2.375; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WHITE AA, 1995, STAT MED, V14, P697, DOI 10.1002/sim.4780140529; WIKLUND O, 1993, AM J MED, V94, P13, DOI 10.1016/0002-9343(93)90114-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551	142	649	688	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					498	511		10.1056/NEJM199908123410707	http://dx.doi.org/10.1056/NEJM199908123410707			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441607				2022-12-28	WOS:000081962600007
J	Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA				Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA			Structure of the DNA repair enzyme endonuclease IV and its DNA complex: Double-nucleotide flipping at abasic sites and three-metal-ion catalysis	CELL			English	Article							BASE EXCISION-REPAIR; MAJOR APURINIC ENDONUCLEASE; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; BACILLUS-CEREUS; EXONUCLEASE-III; SUBSTRATE-ANALOG; POLYMERASE-BETA; STRANDED-DNA	Endonuclease IV is the archetype for a conserved apurinic/apyrimidinic (AP) endonuclease family that primes DNA repair synthesis by cleaving the DNA backbone 5' of AP sites. The crystal structures of Endonuclease IV and its AP-DNA complex at 1.02 and 1.55 Angstrom resolution reveal how an alpha(8)beta(8) TIM barrel fold can bind dsDNA. Enzyme loops intercalate side chains at the abasic site, compress the DNA backbone, bend the DNA similar to 90 degrees, and promote double-nucleotide flipping to sequester the extrahelical AP site in an enzyme pocket that excludes undamaged nucleotides. These structures suggest three Zn2+ ions directly participate in phosphodiester bond cleavage and prompt hypotheses that double-nucleotide flipping and sharp bending by AP endonucleases provide exquisite damage specificity while aiding subsequent base excision repair pathway progression.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; SUNY Albany, Dept Biol Sci, Ctr Biochem & Biophys, Albany, NY 12222 USA	Scripps Research Institute; Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Tainer, JA (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46312] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Demple B, 1997, ENVIRON HEALTH PERSP, V105, P931, DOI 10.2307/3433306; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; HANSEN S, 1992, J MOL BIOL, V225, P543, DOI 10.1016/0022-2836(92)90938-G; HANSEN S, 1993, J MOL BIOL, V234, P179, DOI 10.1006/jmbi.1993.1572; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Krokan HE, 1997, BIOCHEM J, V325, P1; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; Masson JY, 1996, GENE, V179, P291, DOI 10.1016/S0378-1119(96)00375-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOL CD, 1998, NUCL ACID M, V12, P29; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; Ramotar D, 1998, BBA-GENE STRUCT EXPR, V1396, P15, DOI 10.1016/S0167-4781(97)00160-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Romier C, 1998, PROTEINS, V32, P414, DOI 10.1002/(SICI)1097-0134(19980901)32:4<414::AID-PROT2>3.3.CO;2-5; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SAPORITO SM, 1988, J BACTERIOL, V170, P5141, DOI 10.1128/jb.170.11.5141-5145.1988; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SHELDRICK GM, 1997, HIGH RESOLUTION STRU; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WEISS B, 1976, J BIOL CHEM, V251, P1896; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	60	242	246	2	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					397	408		10.1016/S0092-8674(00)81968-6	http://dx.doi.org/10.1016/S0092-8674(00)81968-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458614	Bronze			2022-12-28	WOS:000081950300014
J	Gokal, R; Mallick, NP				Gokal, R; Mallick, NP			Peritoneal dialysis	LANCET			English	Article							RENAL-TRANSPLANTATION; TECHNIQUE SURVIVAL; CAPD PATIENTS; HEMODIALYSIS; MULTICENTER; SELECTION; MORTALITY; ULTRAFILTRATION; CLEARANCE; REGISTRY	Peritoneal dialysis has now become an established form of renal replacement therapy; nearly half the patients on dialysis in the UK are treated in this way. Survival of patients is now equal to that with haemodialysis. However, long-term peritoneal dialysis (>8 years) is limited to a small percentage of patients because of dropout to haemodialysis for inherent complications of peritoneal dialysis-peritonitis, peritoneal access, inadequate dialysis, and patient-related factors. However, improvements in the understanding of the pathophysiological processes involving the peritoneal membrane have paved the way for advances in the delivery of adequate dialysis, more biocompatible dialysis fluids, and automated peritoneal dialysis. Other technical advances have led to a reduction in peritonitis. Peritoneal dialysis is an important dialysis modality and should be used as an integral part of RRT programmes.	Manchester Royal Infirm, Dept Renal Med, Manchester M13 9WL, Lancs, England	University of Manchester	Gokal, R (corresponding author), Manchester Royal Infirm, Dept Renal Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							[Anonymous], 1997, Am J Kidney Dis, V30, pS67; Blake PG, 1996, PERITON DIALYSIS INT, V16, P248; BRUNORI G, 1997, PERITON DIAL INT S1, V17, pS28; Buoncristiani U., 1980, INT J NEPHROL UROL A, V1, P50; BURTON PR, 1987, LANCET, V1, P1115; CAVALLI PL, 1989, ADV PERIT D, V5, P52; CHARYTAN C, 1986, ARCH INTERN MED, V146, P1138, DOI 10.1001/archinte.146.6.1138; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Coles GA, 1998, KIDNEY INT, V54, P2234, DOI 10.1046/j.1523-1755.1998.00183.x; Davies S J, 1996, Perit Dial Int, V16 Suppl 1, pS158; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; Diaz-Buxo JA, 1994, TXB PERITONEAL DIALY, P399; DISNEY APS, 1995, AM J KIDNEY DIS, V25, P165; FALLER B, 1984, PERITON DIALYSIS B, V4, P10; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; GOKAL R, 1987, LANCET, V2, P1105; Gokal R, 1996, PERITON DIALYSIS INT, V16, P553; GOKAL R, 1995, J ROY COLL PHYS LOND, V29, P190; Gokal R, 1998, PERITON DIALYSIS INT, V18, P11; Gokal R, 1996, Curr Opin Nephrol Hypertens, V5, P521, DOI 10.1097/00041552-199611000-00012; GOKAL R, 1993, KIDNEY INT, V43, pS23; Gokal R, 1996, Perit Dial Int, V16 Suppl 1, pS13; GUDEX CM, 1995, QUAL LIFE RES, V4, P359, DOI 10.1007/BF01593889; HABACH G, 1995, J AM SOC NEPHROL, V5, P1940; Harty J, 1996, AM J KIDNEY DIS, V28, P553, DOI 10.1016/S0272-6386(96)90467-9; Harty J, 1996, Perit Dial Int, V16 Suppl 1, pS147; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; HUTCHISON AJ, 1992, KIDNEY INT, V42, pS153; Keane WF, 1996, PERITON DIALYSIS INT, V16, P557; KESHAVIAH PR, 1989, PERITON DIALYSIS INT, V9, P257; KHANNA R, 1993, ESSENTIALS PERITONEA; KOPPLE JD, 1995, KIDNEY INT, V47, P1148, DOI 10.1038/ki.1995.164; LAMB EJ, 1997, KIDNEY INT, V51, P182; LUPO A, 1994, AM J KIDNEY DIS, V24, P826, DOI 10.1016/S0272-6386(12)80678-0; Maiorca R, 1996, PERITON DIALYSIS INT, V16, P276; MAIORCA R, 1991, PERITON DIALYSIS INT, V11, P118; MAIORCA R, 1994, TXB PERITONEAL DIALY, P669; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; Mallick NP, 1999, LANCET, V353, P737, DOI 10.1016/S0140-6736(97)09411-7; MAXWELL MH, 1959, JAMA-J AM MED ASSOC, V170, P917, DOI 10.1001/jama.1959.03010080025004; MISTRY CD, 1987, LANCET, V2, P178; MISTRY CD, 1991, SEMIN DIALYSIS, V4, P9, DOI 10.1111/j.1525-139X.1991.tb00401.x; Nakayama M, 1997, KIDNEY INT, V51, P182, DOI 10.1038/ki.1997.22; Nissenson AR, 1997, ASAIO J, V43, P143; Nolph KD, 1996, PERITON DIALYSIS INT, V16, P15; PIRAINO B, 1995, PERITON DIALYSIS INT, V15, P303; POPOVICH RP, 1976, ABSTR AM SOC ART INT, V5, P64; SERKES KD, 1990, PERITON DIALYSIS INT, V10, P15; TEEHAN BP, 1990, ADV PERIT D, V6, P181; TEEHAN BP, 1985, PERITON DIALYSIS B, V5, P152; Tenckhoff H, 1973, Proc Eur Dial Transplant Assoc, V10, P363; TERAOKA S, 1995, AM J KIDNEY DIS, V25, P151, DOI 10.1016/0272-6386(95)90640-1; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS B, V7, P128; YOUNG GA, 1991, AM J KIDNEY DIS, V17, P462, DOI 10.1016/S0272-6386(12)80642-1	56	95	98	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					823	828		10.1016/S0140-6736(98)09410-0	http://dx.doi.org/10.1016/S0140-6736(98)09410-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459977				2022-12-28	WOS:000079089100045
J	Williams, RS				Williams, RS			Apoptosis and heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1	1	24	29	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					759	760		10.1056/NEJM199909023411012	http://dx.doi.org/10.1056/NEJM199909023411012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471467				2022-12-28	WOS:000082291900012
J	Hartman, EE; Daley, J				Hartman, EE; Daley, J			A 45-year-old woman with premenstrual dysphoric disorder, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Parry BL, 1999, JAMA-J AM MED ASSOC, V281, P368, DOI 10.1001/jama.281.4.368	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					770	770		10.1001/jama.282.8.770	http://dx.doi.org/10.1001/jama.282.8.770			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463713				2022-12-28	WOS:000082118800029
J	Leach, JP				Leach, JP			Lest we forgive	BRITISH MEDICAL JOURNAL			English	Editorial Material													Leach, John Paul/AGU-8942-2022; Leach, John Paul/AGZ-0356-2022	Leach, John Paul/0000-0003-2086-9937; 					0	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					459	459		10.1136/bmj.319.7207.459	http://dx.doi.org/10.1136/bmj.319.7207.459			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445949	Green Published			2022-12-28	WOS:000082098900051
J	Stenseth, NC; Chan, KS; Tong, H; Boonstra, R; Boutin, S; Krebs, CJ; Post, E; O'Donoghue, M; Yoccoz, NG; Forchhammer, MC; Hurrell, JW				Stenseth, NC; Chan, KS; Tong, H; Boonstra, R; Boutin, S; Krebs, CJ; Post, E; O'Donoghue, M; Yoccoz, NG; Forchhammer, MC; Hurrell, JW			Common dynamic structure of Canada lynx populations within three climatic regions	SCIENCE			English	Article							TELECONNECTIONS; NUMBERS; PHASE	Across the boreal forest of Canada, Lynx populations undergo regular density cycles. Analysis of 21 time series from 1821 onward demonstrated structural similarity in these cycles within large regions of Canada. The observed population dynamics are consistent with a regional structure caused by climatic features, resulting in a grouping of Lynx population dynamics into three types (corresponding to three climatic-based geographic regions): Pacific-maritime, Continental, and Atlantic-maritime. A possible Link with the North Atlantic Oscillation is suggested.	Norwegian Acad Sci & Letters, Ctr Adv Study, Drammensveien 78, N-0271 Oslo, Norway; Univ Oslo, Dept Biol, Div Zool, N-0316 Oslo, Norway; Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA; London Sch Econ, Dept Stat, London WC2A 2AE, England; Univ Hong Kong, Dept Stat, Hong Kong, Peoples R China; Univ Toronto, Div Life Sci, Scarborough, ON M1C 1A4, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Dept Renewable Resources, Fish & Wildlife Branch, Mayo, YT Y0B 1M0, Canada; Norwegian Inst Nat Res, Polar Environm Ctr, Dept Arctic Ecol, N-9296 Tromso, Norway; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Natl Environm Res Inst, Dept Landscape Ecol, DK-8410 Ronde, Denmark; Natl Ctr Atmospher Res, Climate Anal Sect, Boulder, CO 80307 USA	University of Oslo; University of Iowa; University of London; London School Economics & Political Science; University of Hong Kong; University of Toronto; University Toronto Scarborough; University of Alberta; University of British Columbia; Norwegian Institute Nature Research; University of Cambridge; Aarhus University; National Center Atmospheric Research (NCAR) - USA	Stenseth, NC (corresponding author), Norwegian Acad Sci & Letters, Ctr Adv Study, Drammensveien 78, N-0271 Oslo, Norway.	n.c.stenseth@bio.uio.no	Forchhammer, Mads/I-7474-2013; Yoccoz, Nigel/C-8561-2014; Boutin, Stan A/A-2619-2014; Stenseth, Nils Chr./G-5212-2016; Yoccoz, Nigel Gille/A-1493-2008	Yoccoz, Nigel/0000-0003-2192-1039; Boutin, Stan A/0000-0001-6317-038X; Stenseth, Nils Chr./0000-0002-1591-5399; Hurrell, James Wilson/0000-0002-3169-6384				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Akaike H., 1973, P 2 INT S INF THEOR; Bailey R.G., 1998, ECOREGIONS ECOSYSTEM; Chan K. T., UNPUB; Cox DR, 1974, THEORETICAL STAT; Ecological Stratification Working Group, 1995, NAT EC FRAM CAN; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; Elton CS, 1924, BR J EXP BIOL, V2, P119; Forchhammer MC, 1998, P ROY SOC B-BIOL SCI, V265, P341, DOI 10.1098/rspb.1998.0301; Hurrell JW, 1996, GEOPHYS RES LETT, V23, P665, DOI 10.1029/96GL00459; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; MORAN PAP, 1953, AUST J ZOOL, V1, P163, DOI 10.1071/ZO9530163; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Post E, 1998, J ANIM ECOL, V67, P537, DOI 10.1046/j.1365-2656.1998.00216.x; Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621; Ranta E, 1997, ECOGRAPHY, V20, P454, DOI 10.1111/j.1600-0587.1997.tb00412.x; ROWE JW, 1972, PUBLICATION ENV CANA, V1300; Royama T., 1992, ANAL POPULATION ECOL; *STAT CAN, 1995, DOM BUR STAT 1965; Stenseth NC, 1998, P ROY SOC B-BIOL SCI, V265, P1957, DOI 10.1098/rspb.1998.0526; Stenseth NC, 1997, P NATL ACAD SCI USA, V94, P5147, DOI 10.1073/pnas.94.10.5147; Stenseth NC, 1998, NATURE, V394, P620, DOI 10.1038/29177; Stenseth NC, 1998, P NATL ACAD SCI USA, V95, P15430, DOI 10.1073/pnas.95.26.15430; Tong H, 1983, THRESHOLD MODELS NON; Tong H, 1990, NONLINEAR TIME SERIE; WALLACE JM, 1981, MON WEATHER REV, V109, P784, DOI 10.1175/1520-0493(1981)109<0784:TITGHF>2.0.CO;2; WALTERS H, 1985, VEGETATION EARTH ECO; WIKEN B, 1996, 14 CCEA	28	170	182	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1071	1073		10.1126/science.285.5430.1071	http://dx.doi.org/10.1126/science.285.5430.1071			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446054				2022-12-28	WOS:000082033100047
J	Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC				Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC			Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5 ' of RAG2	SCIENCE			English	Article							V(D)J RECOMBINATION; ACTIVATING GENES; IMMUNE-SYSTEM; LIGASE-IV; IN-VIVO; MICE; PROMOTER; REPAIR; TRANSPOSITION; REARRANGEMENT	RAG1 and RAG2 are essential for V(D)J recombination and Lymphocyte development. These genes are thought to encode a transposase derived from a mobile genetic element that was inserted into the vertebrate genome 450 million years ago. The regulation of RAG1 and RAG2 was investigated in vivo with bacterial artificial chromosome (BAC) transgenes containing a fluorescent indicator. Coordinate expression of RAG1 and RAG2 in B and T cells was found to be regulated by distinct genetic elements found on the 5' side of the RAG2 gene. This observation suggests a mechanism by which asymmetrically disposed cis DNA elements could influence the expression of the primordial transposon and thereby capture RAGs for vertebrate evolution.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; Rockefeller University; Fox Chase Cancer Center	Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019		NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown ST, 1997, J IMMUNOL, V158, P5071; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fuller K, 1997, MOL IMMUNOL, V34, P939, DOI 10.1016/S0161-5890(97)00000-X; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa T, 1996, BLOOD, V88, P3785, DOI 10.1182/blood.V88.10.3785.bloodjournal88103785; Kurioka H, 1996, MOL IMMUNOL, V33, P1059, DOI 10.1016/S0161-5890(96)00062-4; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1992, IMMUNOGENETICS, V35, P97, DOI 10.1007/BF00189518; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WONG Y, IN PRESS NATURE; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; YUESHENG L, 1996, IMMUNITY, V5, P527; ZARRIN AA, 1997, J IMMUNOL, V159, P4381; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	38	116	118	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1080	1084		10.1126/science.285.5430.1080	http://dx.doi.org/10.1126/science.285.5430.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446057				2022-12-28	WOS:000082033100050
J	Paus, R; Cotsarelis, G				Paus, R; Cotsarelis, G			The biology of hair follicles	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GROWTH-FACTOR RECEPTOR; DERMAL PAPILLA CELLS; NORMAL MURINE SKIN; STEM-CELLS; ANDROGENETIC ALOPECIA; CYCLE; MICE; EXPRESSION; MORPHOGENESIS; PATHOGENESIS		Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Univ Penn, Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA	University of Hamburg; University of Pennsylvania	Paus, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.		Paus, Ralf/F-6243-2011					Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Chuong C-M, 1998, MOL BASIS EPITHELIAL; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Danilenko DM, 1996, MOL MED TODAY, V2, P460, DOI 10.1016/1357-4310(96)10045-9; Dawber R., 1997, DIS HAIR SCALP; Eichmuller S, 1998, J HISTOCHEM CYTOCHEM, V46, P361, DOI 10.1177/002215549804600310; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gilliam AC, 1998, J INVEST DERMATOL, V110, P422, DOI 10.1046/j.1523-1747.1998.00162.x; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hansen LA, 1997, AM J PATHOL, V150, P1959; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEADINGTON JT, 1993, ARCH DERMATOL, V129, P356, DOI 10.1001/archderm.129.3.356; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Hembree JR, 1996, J CELL PHYSIOL, V167, P556, DOI 10.1002/(SICI)1097-4652(199606)167:3<556::AID-JCP19>3.0.CO;2-1; Hermes B, 1998, HAUTARZT, V49, P462, DOI 10.1007/s001050050771; Hibberts NA, 1998, J ENDOCRINOL, V156, P59, DOI 10.1677/joe.0.1560059; Holbrook K.A., 1991, PHYSL BIOCH MOL BIOL, P63; Hordinsky MK, 1996, DERMATOL CLIN, V14, P651, DOI 10.1016/S0733-8635(05)70391-0; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; JAWORSKY C, 1992, BRIT J DERMATOL, V127, P239, DOI 10.1111/j.1365-2133.1992.tb00121.x; Kaufman KD, 1996, DERMATOL CLIN, V14, P697, DOI 10.1016/S0733-8635(05)70396-X; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; KIM DK, 1995, J INVEST DERMATOL, V104, P411, DOI 10.1111/1523-1747.ep12665903; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Lin TYD, 1998, J INVEST DERMATOL, V111, P107, DOI 10.1046/j.1523-1747.1998.00227.x; Lindner G, 1997, AM J PATHOL, V151, P1601; Lyle S, 1998, J CELL SCI, V111, P3179; McGowan K, 1998, Subcell Biochem, V31, P173; Millar S, 1997, CYTOSKELETAL MEMBRAN, P87; Morris RJ, 1997, CANCER RES, V57, P3436; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; MURPHY GF, 1991, J CUTAN PATHOL, V18, P309, DOI 10.1111/j.1600-0560.1991.tb01541.x; Obana N, 1997, ENDOCRINOLOGY, V138, P356, DOI 10.1210/en.138.1.356; OLSEN EA, 1994, DISORDERS HAIR GROWT, P426; ORFANOS CE, 1988, Z HAUTKRANKHEITEN, V63, P23; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; Paus R, 1998, J INVEST DERMATOL, V111, P7, DOI 10.1046/j.1523-1747.1998.00243.x; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; PAUS R, 1997, SKIN IMMUNE SYSTEM, P377; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; SAWAYA ME, 1994, SKIN PHARMACOL, V7, P5; Sawaya ME, 1997, DERMATOL CLIN, V15, P37, DOI 10.1016/S0733-8635(05)70413-7; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; STARICCO RG, 1963, ANN NY ACAD SCI, V100, P239; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	55	819	885	6	119	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					491	497		10.1056/NEJM199908123410706	http://dx.doi.org/10.1056/NEJM199908123410706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441606				2022-12-28	WOS:000081962600006
J	Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN				Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN			Identification and cloning of a negative regulator of systemic acquired resistance, SNlI1, through a screen for suppressors of npr1-1	CELL			English	Article							TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; RETINOBLASTOMA PROTEIN; DISEASE RESISTANCE; GENE-EXPRESSION; KAPPA-B; ARABIDOPSIS; MUTANT; SIGNAL; TRANSCRIPTION	Systemic acquired resistance (SAR) is a plant immune response induced after a local infection by necrotizing pathogens. The Arabidopsis NPR1 gene is a positive regulator of SAR, essential for transducing the SAR signal salicylic acid (SA). Mutations in the NPR1 gene abolish the SA-induced expression of pathogenesis-related (PR) genes and resistance to pathogens. To identify additional regulators of SAR, we screened for suppressors of npr1-1. In the npr1-1 background, the sni1 (suppressor of npr1-1, inducible 1) mutant shows near wild-type levels of PR1 expression and resistance to pathogens after induction. Restoration of SAR in npr1-1 by the recessive sni1 mutation indicates that wild-type SNI1 may function as a negative regulator of SAR. We cloned the SNI1 gene and found that it encodes a leucine-rich nuclear protein.	Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA	Duke University	Dong, XN (corresponding author), Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA.	xdong@duke.edu						BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1996, GENETICS, V143, P973; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEFFERSON RA, 1987, EMBO J, V6, P3901; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEVINS JR, 1992, SCIENCE, V258, P424; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shah J, 1997, MOL PLANT MICROBE IN, V10, P69, DOI 10.1094/MPMI.1997.10.1.69; Sokal R. R., 1981, BIOMETRY; Stacey MG, 1999, PLANT CELL, V11, P349, DOI 10.1105/tpc.11.3.349; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523	46	190	206	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					329	339		10.1016/S0092-8674(00)81962-5	http://dx.doi.org/10.1016/S0092-8674(00)81962-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458608	Bronze			2022-12-28	WOS:000081950300008
J	Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP				Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP			Structure of the C-terminal domain of FliG, a component of the rotor in the bacterial flagellar motor	NATURE			English	Article							SALMONELLA-TYPHIMURIUM; TORQUE GENERATION; ESCHERICHIA-COLI; PROTEIN FLIG; BASAL-BODY; COMPLEX; SWITCH; MUTATIONS; ROTATION; RESIDUES	Many motile species of bacteria are propelled by flagella, which are rigid helical filaments turned by rotary motors in the cell membrane(1-3). The motors are powered by the transmembrane gradient of protons or sodium ions. Although bacterial flagella contain many proteins, only three-MotA, MotB and FliG-participate closely in torque generation. MotA, and MotB are ion-conducting membrane proteins that: form the stator of the motor. FliG is a component of the rotor, present in about 25 copies per flagellum. It is composed of an amino-terminal domain that functions in flagellar assembly and a carboxy-terminal domain (FliG-C) that functions specifically in motor rotation. Here we report the crystal structure of FliG-C from the hyperthermophilic eubacterium Thermotoga maritima, Charged residues that are important for function, and which interact with the stator protein MotA(4,5), duster along a prominent ridge on FliG-C. On the basic; of the disposition of these residues, we present a hypothesis for the orientation of FliG-C domains in the flagellar motor, and propose a structural model for the part of the rotor that interacts with the stator.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Blair, DF (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.							BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Braun TF, 1999, J BACTERIOL, V181, P3542, DOI 10.1128/JB.181.11.3542-3551.1999; BRUNGER AT, 1996, XPLOR VERSION 3 843; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; JONES CJ, 1990, J MOL BIOL, V212, P377, DOI 10.1016/0022-2836(90)90132-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Marykwas DL, 1996, J BACTERIOL, V178, P1289, DOI 10.1128/jb.178.5.1289-1294.1996; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452; Zhou JD, 1997, J MOL BIOL, V273, P428, DOI 10.1006/jmbi.1997.1316; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436	30	96	97	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					472	475		10.1038/22794	http://dx.doi.org/10.1038/22794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440379				2022-12-28	WOS:000081715000056
J	Price, CSC; Dyer, KA; Coyne, JA				Price, CSC; Dyer, KA; Coyne, JA			Sperm competition between Drosophila males involves both displacement and incapacitation	NATURE			English	Article							FEMALE RECEPTIVITY; MELANOGASTER; EVOLUTION	Females in almost all animal groups copulate with multiple males(1,2). This behaviour allows different males to compete for fertilization(3) and gives females the opportunity to mediate this competition(4). In many animals and most insects, the second male to copulate with a female typically sires most of her offspring(1,5,6). In Drosophila melanogaster, this second-male sperm precedence has long been studied(7-15) but, as in most species, its mechanism has remained unknown. Here we show, using labelled sperm in doubly mated females, that males can both physically displace and incapacitate stored sperm from earlier-mating males. Displacement occurs only if the second male transfers sperm to the female, and in only one of her three sperm-storage organs. Incapacitation can be caused by either fertile or spermless second males, but requires extended intervals between matings. Sperm from different males are not 'stratified' in the storage organs but mix freely. Many animal species may have multiple mechanisms of sperm competition like those observed here, and revealing these mechanisms is necessary to understand the genetic and evolutionary basis of second-male sperm precedence in animals.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Coyne, JA (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	j-coyne@uchicago.edu						[Anonymous], [No title captured]; Birkhead TR, 1992, SPERM COMPETITION BI; Birkhead TR, 1998, SPERM COMPETITION SE; Clark AG, 1998, GENETICS, V149, P1487; Clark AG, 1999, SCIENCE, V283, P217, DOI 10.1126/science.283.5399.217; Cochran W.G., 1967, STAT METHODS; COYNE JA, 1991, GENETICS, V129, P791; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; GILCHRIST AS, 1995, J INSECT PHYSIOL, V41, P1087, DOI 10.1016/0022-1910(95)00068-6; Gromko M.H., 1984, P371; GROMKO MH, 1993, ANIM BEHAV, V45, P253, DOI 10.1006/anbe.1993.1031; GROMKO MH, 1984, EVOLUTION, V38, P1273, DOI 10.1111/j.1558-5646.1984.tb05649.x; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; Imhof M, 1998, MOL ECOL, V7, P915, DOI 10.1046/j.1365-294x.1998.00382.x; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; Kaufmann P, 1942, AM NAT, V76, P445, DOI 10.1086/281068; KIEFER BI, 1966, GENETICS, V54, P1441; LEFEVRE G, 1962, GENETICS, V42, P1719; Lobashov ME, 1939, CR ACAD SCI URSS, V23, P827; NCHTSHEIM H, 1927, Z IND ABST VEREB S, V2, P1143; NEWPORT MEA, 1984, EVOLUTION, V38, P1261, DOI 10.1111/j.1558-5646.1984.tb05648.x; Nonidez JF, 1920, BIOL BULL-US, V39, P207, DOI 10.2307/1536488; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Price CSC, 1997, NATURE, V388, P663, DOI 10.1038/41753; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; SCOTT D, 1990, J INSECT PHYSIOL, V36, P451, DOI 10.1016/0022-1910(90)90063-L; SCOTT D, 1993, J INSECT PHYSIOL, V39, P201, DOI 10.1016/0022-1910(93)90089-A; Simmons L.W., 1998, P341, DOI 10.1016/B978-012100543-6/50035-0; Sokal RR, 1995, BIOMETRY	30	135	140	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					449	452		10.1038/22755	http://dx.doi.org/10.1038/22755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440373				2022-12-28	WOS:000081715000050
J	Donald, PR				Donald, PR			Children and tuberculosis: protecting the next generation?	LANCET			English	Article									Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa	Stellenbosch University	Donald, PR (corresponding author), Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, POB 19063, ZA-7505 Tygerberg, South Africa.	aec1@maties.sun.ac.za						BENTLEY FJ, 1954, TUBERCULOSIS CHILDHO, P232; Beyers N, 1996, S AFR MED J, V86, P40; FOURIE PB, 1999, TUBERCULOSIS CHILDRE, P27; FOX W, 1981, Bulletin of the International Union Against Tuberculosis, V56, P135; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; LINCOLN EM, 1951, AM REV TUBERC PULM, V64, P499; MITCHISON DA, 1982, B INT UNION TUBERC, V42, P140; RICH AR, 1951, PATHOGENESIS TUBERCU, P182; SETH V, 1991, TUBERCULOSIS CHILDRE, P1; van Helden PD, 1998, NOVART FDN SYMP, V217, P178, DOI 10.1002/0470846526.ch13	10	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1001	1002		10.1016/S0140-6736(99)02010-3	http://dx.doi.org/10.1016/S0140-6736(99)02010-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459927				2022-12-28	WOS:000079421600048
J	Greengold, NL				Greengold, NL			Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					716	717		10.1001/jama.282.8.716	http://dx.doi.org/10.1001/jama.282.8.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463694				2022-12-28	WOS:000082118800001
J	Levin, A				Levin, A			Nutrition and policy. 5: Who should teach patients about nutrition?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					317	318		10.7326/0003-4819-131-4-199908170-00101	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454963				2022-12-28	WOS:000082012500024
J	Margolis, D				Margolis, D			Neuroscience 2000: A new era of discovery	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					318	320		10.7326/0003-4819-131-4-199908170-00102	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454964				2022-12-28	WOS:000082012500025
J	Auperin, A; Arriagada, R; Pignon, JP; Le Pechoux, C; Gregor, A; Stephens, RJ; Kristjansen, PEG; Johnson, BE; Ueoka, H; Wagner, H; Aisner, J				Auperin, A; Arriagada, R; Pignon, JP; Le Pechoux, C; Gregor, A; Stephens, RJ; Kristjansen, PEG; Johnson, BE; Ueoka, H; Wagner, H; Aisner, J		Prophylactic Cranial Irradiation Overview Colla	Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAIN IRRADIATION; FOLLOW-UP; COMPLETE RESPONSE; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; CARCINOMA; TRIAL; CYCLOPHOSPHAMIDE; RADIOTHERAPY; METASTASES	Background Prophylactic cranial irradiation reduces the incidence of brain metastasis in patients with small-cell lung cancer. Whether this treatment, when given to patients in complete remission, improves survival is not known. We performed a metaanalysis to determine whether prophylactic cranial irradiation prolongs survival. Methods We analyzed individual data on 987 patients with small-cell lung cancer in complete remission who took part in seven trials that compared prophylactic cranial irradiation with no prophylactic cranial irradiation. The main end point was survival. Results The relative risk of death in the treatment group as compared with the control group was 0.84 (95 percent confidence interval, 0.73 to 0.97; P = 0.01), which corresponds to a 5.4 percent increase in the rate of survival at three years (15.3 percent in the control group vs. 20.7 percent in the treatment group). Prophylactic cranial irradiation also increased the rate of disease-free survival (relative risk of recurrence or death, 0.75; 95 percent confidence interval, 0.65 to 0.86; P < 0.001) and decreased the cumulative incidence of brain metastasis (relative risk, 0.46; 95 percent confidence interval, 0.38 to 0.57; P < 0.001). Larger doses of radiation led to greater decreases in the risk of brain metastasis, according to an analysis of four total doses (8 Gy, 24 to 25 Gy, 30 Gy, and 36 to 40 Gy) (P for trend = 0.02), but the effect on survival did not differ significantly according to the dose. We also identified a trend (P = 0.01) toward a decrease in the risk of brain metastasis with earlier administration of cranial irradiation after the initiation of induction chemotherapy. Conclusions Prophylactic cranial irradiation improves both overall survival and disease-free survival among patients with small-cell lung cancer in complete remission, (N Engl J Med 1999;341:476-84.) (C) 1999. Massachusetts Medical Society.	Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Radiat Oncol, F-94805 Villejuif, France; Inst Radiomed, Santiago, Chile; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; MRC, Canc Trials Off, Cambridge, England; Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; Natl Naval Med Ctr, Bethesda, MD USA; Okayama Univ, Sch Med, Okayama 700, Japan; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ S Florida, Res Inst, Tampa, FL 33682 USA; Canc Inst New Jersey, New Brunswick, NJ USA	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; University of Edinburgh; University of Copenhagen; Walter Reed National Military Medical Center; Okayama University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Pignon, JP (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, Rue Camille Desmoulins, F-94805 Villejuif, France.	jppignon@igr.fr		Arriagada, Rodrigo/0000-0002-3134-1735; PIGNON, Jean-Pierre/0000-0003-2047-1582; Stewart, Lesley/0000-0003-0287-4724				Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954; ALBAIN KS, 1990, J CLIN ONCOL, V8, P1563, DOI 10.1200/JCO.1990.8.9.1563; ARONEY RS, 1983, CANCER TREAT REP, V67, P675; ARRIAGADA R, 1994, ANTICANCER RES, V14, P333; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; ARRIAGADA R, 1992, J CLIN ONCOL, V10, P447, DOI 10.1200/JCO.1992.10.3.447; BEILER DD, 1979, INT J RADIAT ONCOL, V5, P941, DOI 10.1016/0360-3016(79)90598-4; CATANE R, 1981, INT J RADIAT ONCOL, V7, P105, DOI 10.1016/0360-3016(81)90066-3; COX JD, 1978, CANCER-AM CANCER SOC, V42, P1135, DOI 10.1002/1097-0142(197809)42:3<1135::AID-CNCR2820420316>3.0.CO;2-N; EAGAN RT, 1981, CANCER CLIN TRIALS, V4, P261; *EARL BREAST CANC, 1990, TREAT EARL BREAST CA, V1; FRYTAK S, 1989, AM J CLIN ONCOL-CANC, V12, P27, DOI 10.1097/00000421-198902000-00007; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; HANSEN HH, 1973, CANCER CHEMOTH REP 3, V4, P239; HANSEN HH, 1980, CANCER, V46, P279, DOI 10.1002/1097-0142(19800715)46:2<279::AID-CNCR2820460210>3.0.CO;2-W; HIRSCH FR, 1982, CANCER, V50, P2433, DOI 10.1002/1097-0142(19821201)50:11<2433::AID-CNCR2820501131>3.0.CO;2-E; JACKSON DV, 1977, JAMA-J AM MED ASSOC, V237, P2730, DOI 10.1001/jama.237.25.2730; Johnson BE, 1996, J CLIN ONCOL, V14, P806, DOI 10.1200/JCO.1996.14.3.806; JOHNSON BE, 1990, J CLIN ONCOL, V8, P48, DOI 10.1200/JCO.1990.8.1.48; KATSENIS AT, 1982, LUNG CANC ETIOLOGY E, P277; KOMAKI R, 1985, Cancer Treatment Symposia, V2, P35; KRISTJANSEN PEG, 1993, CANCER TREAT REV, V19, P3, DOI 10.1016/0305-7372(93)90023-K; Laplanche A, 1998, LUNG CANCER-J IASLC, V21, P193, DOI 10.1016/S0169-5002(98)00056-7; LEE JS, 1986, INT J RADIAT ONCOL, V12, P313, DOI 10.1016/0360-3016(86)90344-5; LISHNER M, 1990, J CLIN ONCOL, V8, P215, DOI 10.1200/JCO.1990.8.2.215; MAURER LH, 1980, CANCER, V45, P30, DOI 10.1002/1097-0142(19800101)45:1<30::AID-CNCR2820450107>3.0.CO;2-6; MOUNTAIN CF, 1982, 3 WORLD C LUNG CANC, P153; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; NIIRANEN A, 1989, ACTA ONCOL, V28, P501, DOI 10.3109/02841868909092258; OHONOSHI T, 1993, LUNG CANCER-J IASLC, V10, P47, DOI 10.1016/0169-5002(93)90308-K; PEREZ CA, 1981, CANCER, V47, P2407, DOI 10.1002/1097-0142(19810515)47:10<2407::AID-CNCR2820471015>3.0.CO;2-R; ROSEN ST, 1983, AM J MED, V74, P615, DOI 10.1016/0002-9343(83)91019-7; ROSENMAN J, 1982, INT J RADIAT ONCOL, V8, P1041, DOI 10.1016/0360-3016(82)90174-2; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SEYDEL HG, 1985, AM J CLIN ONCOL-CANC, V8, P218, DOI 10.1097/00000421-198506000-00005; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Suwinski R, 1998, INT J RADIAT ONCOL, V40, P797, DOI 10.1016/S0360-3016(97)00856-0; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; Wagner H, 1996, P AN M AM SOC CLIN, V15, P376	39	1162	1231	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					476	484		10.1056/NEJM199908123410703	http://dx.doi.org/10.1056/NEJM199908123410703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441603				2022-12-28	WOS:000081962600003
J	Plenz, D; Kital, ST				Plenz, D; Kital, ST			A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus	NATURE			English	Article							INTRACELLULAR ANALYSIS; FUNCTIONAL-ANATOMY; PARKINSONS-DISEASE; NEURONAL-ACTIVITY; MPTP MODEL; RAT; MONKEY; DISINHIBITION; STIMULATION; LESION	The subthalamic nucleus of the basal ganglia (STN) is important for normal movement(1,2) as well as in movement disorders(3-5). Lesioning(6) or deep-brain stimulation(7,8) of the STN can alleviate resting tremor in Parkinson's disease. The STN5 and its target nuclei(9,10) display synchronized oscillatory burst discharge at low frequencies, some of which correlate with tremor, but the mechanism underlying this synchronized bursting is unknown. Here we show that the excitatory STN and inhibitory, external globus pallidus (GPe) form a feedback system that engages in synchronized bursting. In mature organotypic cortex-striatum-STN-GPe cultures, neurons in the STN and GPe spontaneously produce synchronized oscillating bursts at 0.4, 0.8 and 1.8 Hz. Pallidal lesion abolishes this bursting, whereas cortical lesion favours bursting at 0.8 Hz. Pallidal bursts, although weaker than STN bursts, were required for synchronized oscillatory burst generation by recruitment of subthalmic rebound excitation. We propose that the STN and GPe constitute a central pacemaker modulated by striatal inhibition of GPe neurons. This pacemaker could be responsible for synchronized oscillatory activity in the normal and pathological basal ganglia.	Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Plenz, D (corresponding author), Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA.							ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALDRIDGE JW, 1991, BRAIN RES, V543, P123; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Chesselet MF, 1996, TRENDS NEUROSCI, V19, P417; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; FILION M, 1979, BRAIN RES, V178, P425, DOI 10.1016/0006-8993(79)90704-2; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hurtado JM, 1999, P NATL ACAD SCI USA, V96, P1674, DOI 10.1073/pnas.96.4.1674; KITA H, 1992, BRAIN RES, V589, P84, DOI 10.1016/0006-8993(92)91164-A; KITA H, 1983, BRAIN RES, V264, P255, DOI 10.1016/0006-8993(83)90823-5; KITAI ST, 1981, BRAIN RES, V214, P411, DOI 10.1016/0006-8993(81)91204-X; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; MATSUMURA M, 1992, J NEUROPHYSIOL, V67, P1615, DOI 10.1152/jn.1992.67.6.1615; NAKANISHI H, 1987, BRAIN RES, V437, P35, DOI 10.1016/0006-8993(87)91524-1; NINI A, 1995, J NEUROPHYSIOL, V74, P1800, DOI 10.1152/jn.1995.74.4.1800; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Plenz D, 1998, J COMP NEUROL, V397, P437, DOI 10.1002/(SICI)1096-9861(19980810)397:4<437::AID-CNE1>3.0.CO;2-2; Rodriguez MC, 1998, MOVEMENT DISORD, V13, P111; Ruskin DN, 1999, J NEUROPHYSIOL, V81, P2046, DOI 10.1152/jn.1999.81.5.2046; Shink E, 1996, NEUROSCIENCE, V73, P335, DOI 10.1016/0306-4522(96)00022-X; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P494, DOI 10.1152/jn.1994.72.2.494; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WURTZ RH, 1986, PROG BRAIN RES, V64, P175	30	529	537	2	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					677	682		10.1038/23281	http://dx.doi.org/10.1038/23281			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458164				2022-12-28	WOS:000082032900057
J	Joannides, R; Moore, N; de la Gueronniere, V; Thuillez, C				Joannides, R; Moore, N; de la Gueronniere, V; Thuillez, C			Effect of water on arteries	LANCET			English	Letter									Univ Bordeaux 2, Hosp Pellegrin Carreire, Dept Pharmacol, F-33076 Bordeaux, France; Univ Rouen, Dept Pharmacol, Rouen, France; Grp Danone, Paris, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Universite de Rouen Normandie; Danone Nutricia	Moore, N (corresponding author), Univ Bordeaux 2, Hosp Pellegrin Carreire, Dept Pharmacol, F-33076 Bordeaux, France.		Moore, Nicholas/B-2368-2013	Moore, Nicholas/0000-0003-1212-2817				Jordan J, 1999, LANCET, V353, P723, DOI 10.1016/S0140-6736(99)99015-3; Jordan J, 1999, LANCET, V353, P1971, DOI 10.1016/S0140-6736(05)77183-X; MOORE N, 1995, AM J HYPERTENS, V8, pA133; RETTIG R, 1989, BRAIN RES, V505, P251, DOI 10.1016/0006-8993(89)91451-0; Senard JM, 1999, LANCET, V353, P1971, DOI 10.1016/S0140-6736(05)77182-8	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					516	516		10.1016/S0140-6736(05)75553-7	http://dx.doi.org/10.1016/S0140-6736(05)75553-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465206				2022-12-28	WOS:000081896100060
J	Haerlin, B; Parr, D				Haerlin, B; Parr, D			How to restore public trust in science	NATURE			English	Editorial Material									Greenpeace Int, D-10115 Berlin, Germany; Greenpeace UK, London N1 2PN, England		Haerlin, B (corresponding author), Greenpeace Int, Chausseestr 131, D-10115 Berlin, Germany.							*EUR COMM DG XII, 1997, EUROBAROMETER, V46, P77; *ROYAL COMM ENV PO, 1998, ENV STAND; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194	3	60	62	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					499	499		10.1038/22867	http://dx.doi.org/10.1038/22867			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448847	Bronze			2022-12-28	WOS:000081854800020
J	Liu, JJ; Lindquist, S				Liu, JJ; Lindquist, S			Oligopeptide-repeat expansions modulate 'protein-only' inheritance in yeast	NATURE			English	Article							HUMAN PRION PROTEIN; DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROPAGATION; PSI; DETERMINANT; TRANSLATION; TERMINATION; HYPOTHESIS	The yeast [PSI+] element represents a new type of genetic inheritance, in which changes in phenotype are transmitted by a 'protein only' mechanism(1-3) reminiscent of the 'protein-only' transmission of mammalian prion diseases(1,4). The underlying molecular mechanisms for both are poorly understood and it is not clear how similar they might be. Sup35, the [PSI+] protein determinant, and PrP, the mammalian prion determinant, have different functions, different cellular locations and no sequence similarity; however, each contains five imperfect oligopeptide repeats-PQGGYQQYN in Sup35 and PHGGGWGQ in PrP5,6. Repeat expansions in PrP produce spontaneous prion diseases(7,8). Here we show that replacing the wild-type SUP35 gene with a repeat-expansion mutation induces new [PSI+] elements, the first mutation of its type among these newly described elements of inheritance. In vitro, fully denatured repeat-expansion peptides can adopt conformations rich in beta-sheets and form higher-order structures much more rapidly than wild-type peptides. Our results provide insight into the nature of the conformational changes underlying protein-based mechanisms of inheritance and suggest a link between this process and those producing neurodegenerative prion diseases in mammals.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave,MC1028, Chicago, IL 60637 USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Goldmann W, 1998, J GEN VIROL, V79, P3173, DOI 10.1099/0022-1317-79-12-3173; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; SERIO TR, IN PRESS METHODS ENZ; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	29	176	180	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					573	576		10.1038/23048	http://dx.doi.org/10.1038/23048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448860				2022-12-28	WOS:000081854800058
J	Kamau, PK				Kamau, PK			A case of mutual distrust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					410	410		10.1001/jama.282.5.410-b	http://dx.doi.org/10.1001/jama.282.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442643				2022-12-28	WOS:000081784900001
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1964: Konrad Bloch (b 1912) and Feodor Lynen (1911-79)	LANCET			English	Article									Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60612 USA.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					347	347		10.1016/S0140-6736(05)75261-2	http://dx.doi.org/10.1016/S0140-6736(05)75261-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440350				2022-12-28	WOS:000081646000074
J	Opie, LH				Opie, LH			Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium?	LANCET			English	Editorial Material							INFARCTION; MAGNESIUM		Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa.							Antman EM, 1996, CARDIOVASC DRUG THER, V10, P297; Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; CEREMUZYNSKI L, 1997, EUR HEART J, V18, pP1054; DEVILLALOBOS DH, 1995, LANCET, V345, P1552; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FATHORDOUBADI F, 1997, CIRCULATION, V96, P1074; GD Lopaschuk, 1998, METABOLIC APPROACHES, P44; JONASSEN AK, UNPUB; King LM, 1998, CARDIOVASC RES, V39, P381, DOI 10.1016/S0008-6363(98)00100-X; LAZAR HL, 1997, J THORACIC CARDIOVAS, V113, P345; Malmberg K, 1996, EUR HEART J, V17, P1337; OLDFIELD GS, 1986, J THORAC CARDIOV SUR, V91, P874; OPIE LH, 1995, LANCET, V345, P1520, DOI 10.1016/S0140-6736(95)91080-8; SHECHTER M, 1995, AM J CARDIOL, V75, P321, DOI 10.1016/S0002-9149(99)80546-3; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; STANLEY AW, 1975, AM J CARDIOL, V36, P929, DOI 10.1016/0002-9149(75)90085-5; Young LH, 1997, CIRCULATION, V95, P415	18	28	30	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					768	769		10.1016/S0140-6736(98)00385-7	http://dx.doi.org/10.1016/S0140-6736(98)00385-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459953				2022-12-28	WOS:000079089100003
J	Cohen, OJ; Fauci, AS				Cohen, OJ; Fauci, AS			Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable	LANCET			English	Editorial Material							ANTIRETROVIRAL THERAPY; INFECTION; INHIBITOR		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Cohen, OJ (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							BARTLETT JG, 1998, 12 INT C AIDS GEN SW; BAXTER JD, 1999, 6 C RETR OPP INF CHI; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; *DEP HLTH HUM SERV, 1998, ANN INTERN MED, V128, P1079; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Kelly JA, 1998, AIDS, V12, pF91, DOI 10.1097/00002030-199810000-00001; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	15	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					697	698		10.1016/S0140-6736(99)90106-X	http://dx.doi.org/10.1016/S0140-6736(99)90106-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475176				2022-12-28	WOS:000082233000004
J	White, HD				White, HD			Future of reperfusion therapy for acute myocardial infarction	LANCET			English	Editorial Material							INTRAVENOUS THROMBOLYTIC THERAPY; RETEPLASE; ALTEPLASE; PREDICTOR		Green Lane Hosp, Dept Cardiol, Auckland 1003, New Zealand		White, HD (corresponding author), Green Lane Hosp, Dept Cardiol, Auckland 1003, New Zealand.							[Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Ferguson JJ, 1998, CIRCULATION, V97, P1217; Gurbel PA, 1998, J AM COLL CARDIOL, V31, P1466, DOI 10.1016/S0735-1097(98)00172-7; *GUSTO ANG INV, 1993, NEW ENGL J MED, V330, P516; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; KONG DF, IN PRESS CIRCULATION; NEUHAUS KL, 1999, 48 ANN SCI SESS AM C; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; SIMOONS ML, 1988, LANCET, V1, P199; Stewart JT, 1998, J AM COLL CARDIOL, V31, P1499, DOI 10.1016/S0735-1097(98)00139-9; Topol E, 1997, NEW ENGL J MED, V337, P1118; van den Merkhof LFM, 1999, J AM COLL CARDIOL, V33, P1528, DOI 10.1016/S0735-1097(99)00038-8; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; White HD, 1997, CIRCULATION, V96, P2155; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	19	15	16	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					695	697		10.1016/S0140-6736(99)00263-9	http://dx.doi.org/10.1016/S0140-6736(99)00263-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475175				2022-12-28	WOS:000082233000003
J	Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H				Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H			Asteroidal water within fluid inclusion-bearing halite in an H5 chondrite, Monahans (1998)	SCIENCE			English	Article							CARBONACEOUS CHONDRITES; AQUEOUS ALTERATION; CONSTRAINTS; MINERALOGY; AGE	Crystals of halite and sylvite within the Monahans (1998) H5 chondrite contain aqueous fluid inclusions. The fluids are dominantly sodium chloride-potassium chloride brines. but they also contain divalent cations such as iron, magnesium, or calcium. Two possible origins for the brines are indigenous fluids flowing within the asteroid and exogenous fluids delivered into the asteroid surface from a salt-containing icy object.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Virginia Tech, Dept Geol Sci, Blacksburg, VA 24061 USA; Lockheed Martin Space Operat Co, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Virginia Polytechnic Institute & State University; Lockheed Martin	Zolensky, ME (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mail Code SN2, Houston, TX 77058 USA.		Bodnar, Robert J/A-1916-2009	Zolensky, Michael/0000-0002-3181-1303				BARBER DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P945, DOI 10.1016/0016-7037(81)90120-4; BERKLEY JL, 1978, GEOPHYS RES LETT, V5, P1075, DOI 10.1029/GL005i012p01075; BRIDGES JC, 1998, LUNAR PLANET SCI, V29; Browning L, 1998, METEORIT PLANET SCI, V33, P1213, DOI 10.1111/j.1945-5100.1998.tb01306.x; Chang L, 1996, ROCK FORMING MINER B, V5, P369; DAVIS DW, 1990, GEOCHIM COSMOCHIM AC, V54, P591, DOI 10.1016/0016-7037(90)90355-O; DUFRESNE ER, 1962, GEOCHIM COSMOCHIM AC, V26, P1085, DOI 10.1016/0016-7037(62)90047-9; Fieni C., 1978, METEORITICS, V13, P460; Garner E.L., 1975, LUNAR SCI C P, V6, P1845; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; LANGENAUER M, 1993, EARTH PLANET SC LETT, V120, P431, DOI 10.1016/0012-821X(93)90255-8; LAWLER JP, 1983, ECON GEOL, V78, P527, DOI 10.2113/gsecongeo.78.3.527; McSween H.Y., 1988, METEORITES EARLY SOL, P102; MCSWEEN HY, 1987, GEOCHIM COSMOCHIM AC, V51, P2469, DOI 10.1016/0016-7037(87)90298-5; MERNAGH TP, 1989, GEOCHIM COSMOCHIM AC, V53, P765, DOI 10.1016/0016-7037(89)90022-7; MINSTER JF, 1982, NATURE, V300, P414, DOI 10.1038/300414a0; NASSAU K, 1983, PHYSICS CHEM COLOR; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; Roedder E., 1984, FLUID INCLUSIONS; ROEDDER E, 1968, FLUID INCLUSION RES; RUDNICK RL, 1985, J GEOPHYS RES, V90, pC669, DOI 10.1029/JB090iS02p0C669; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; TARTER JG, 1981, THESIS ARIZONA STATE; WARNER JL, 1983, J GEOPHYS RES, V88, pA731, DOI DOI 10.1029/JB088IS02P0A731); Zolensky M., 1988, METEORITES EARLY SOL, P114; ZOLENSKY ME, 1989, ICARUS, V78, P411, DOI 10.1016/0019-1035(89)90188-7; ZOLENSKY ME, 1999, LUNAR PLANET SCI, V30	29	158	164	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1377	1379		10.1126/science.285.5432.1377	http://dx.doi.org/10.1126/science.285.5432.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464091				2022-12-28	WOS:000082233500035
J	Hochman, JS; Sleeper, LA; Webb, JG; Sanborn, TA; White, HD; Talley, JD; Buller, CE; Jacobs, AK; Slater, JN; Col, J; McKinlay, SM; LeJemtel, TH				Hochman, JS; Sleeper, LA; Webb, JG; Sanborn, TA; White, HD; Talley, JD; Buller, CE; Jacobs, AK; Slater, JN; Col, J; McKinlay, SM; LeJemtel, TH		SHOCK Investigators	Early revascularization in acute myocardial infarction complicated by cardiogenic shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSLUMINAL CORONARY ANGIOPLASTY; TISSUE-PLASMINOGEN-ACTIVATOR; GUSTO-I TRIAL; BALLOON COUNTERPULSATION; REPERFUSION THERAPY; NATIONAL REGISTRY; IMPROVES SURVIVAL; MORTALITY; STREPTOKINASE; THROMBOLYSIS	Background The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock. Methods Patients with shock due to left ventricular failure complicating myocardial infarction were randomly assigned to emergency revascularization (152 patients) or initial medical stabilization (150 patients). Revascularization was accomplished by either coronary-artery bypass grafting or angioplasty. Intraaortic balloon counterpulsation was performed in 86 percent of the patients in both groups. The primary end point was mortality from all causes at 30 days. Six-month survival was a secondary end point. Results The mean (+/-SD) age of the patients was 66+/-10 years, 32 percent were women, and 55 percent had been transferred from other hospitals. The median time to the onset of shock was 5.6 hours after infarction, and most infarcts were anterior in location. Ninety-seven percent of the patients assigned to revascularization underwent early coronary angiography, and 87 percent underwent revascularization; only 2.7 percent of the patients assigned to medical therapy crossed over to early revascularization without clinical indication. Overall mortality at 30 days did not differ significantly between the revascularization and medical-therapy groups (46.7 percent and 56.0 percent, respectively; difference, -9.3 percent; 95 percent confidence interval for the difference, -20.5 to 1.9 percent; P = 0.11). Six-month mortality was lower in the revascularization group than in the medical-therapy group (50.3 percent vs. 63.1 percent, P=0.027). Conclusions In patients with cardiogenic shock, emergency revascularization did not significantly reduce overall mortality at 30 days. However, after six months there was a significant survival benefit. Early revascularization should be strongly considered for patients with acute myocardial infarction complicated by cardiogenic shock. (N Engl J Med 1999;341:625-34.) (C) 1999, Massachusetts Medical Society.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; New England Res Inst, Watertown, MA 02172 USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; New York Hosp, Cornell Med Ctr, New York, NY USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Arkansas, Little Rock, AR 72204 USA; Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada; Boston Med Ctr, Boston, MA USA; Clin Univ St Luc, B-1200 Brussels, Belgium; Albert Einstein Coll Med, Bronx, NY 10467 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University; HealthCore, Inc; St. Paul's Hospital; University of Saskatchewan; Cornell University; NewYork-Presbyterian Hospital; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University of British Columbia; Boston Medical Center; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Yeshiva University; Albert Einstein College of Medicine	Hochman, JS (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, 1111 Amsterdam Ave, New York, NY 10025 USA.		Picard, Michael/F-1567-2013; Thompson, Christopher/F-3967-2010	Picard, Michael/0000-0002-9264-3243; Thompson, Christopher/0000-0001-9206-376X; Slater, James/0000-0003-3888-0317; Jacobs, Alice/0000-0002-2428-2458; Aylward, Philip/0000-0002-5358-8552; Hochman, Judith/0000-0002-5889-5981	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049970, R01HL050020] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50020-018Z, R01-HL49970] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antoniucci D, 1998, J AM COLL CARDIOL, V31, P294, DOI 10.1016/S0735-1097(97)00496-8; ARMITAGE P, 1957, BIOMETRIKA, V44, P9, DOI 10.1093/biomet/44.1-2.9; Barron HV, 1998, J AM COLL CARDIOL, V31, p135A, DOI 10.1016/S0735-1097(97)84290-8; Becker RC, 1996, J AM COLL CARDIOL, V27, P1321, DOI 10.1016/0735-1097(96)00008-3; Berger PB, 1997, CIRCULATION, V96, P122; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Betriu A, 1997, NEW ENGL J MED, V337, P287; BOLOOKI H, 1989, CIRCULATION S2, V76, P37; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; DUNKMAN WB, 1972, CIRCULATION, V46, P465, DOI 10.1161/01.CIR.46.3.465; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GUYTON RA, 1987, CIRCULATION, V76, P22; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HIMBERT D, 1994, AM J CARDIOL, V74, P492, DOI 10.1016/0002-9149(94)90910-5; Hochman JS, 1999, AM HEART J, V137, P313, DOI 10.1053/hj.1999.v137.95352; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; Hochman JS, 1998, CIRCULATION, V98, P778; HOCHMAN JS, 1998, TXB CARDIOVASCULAR M, P437; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KIRKLIN JK, 1985, CIRCULATION, V72, P175; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; Menon V, 1998, J AM COLL CARDIOL, V31, p136A, DOI 10.1016/S0735-1097(97)84292-1; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MOOSVI AR, 1992, J AM COLL CARDIOL, V19, P907, DOI 10.1016/0735-1097(92)90269-S; PREWITT RM, 1994, J AM COLL CARDIOL, V23, P794, DOI 10.1016/0735-1097(94)90770-6; Ross AM, 1998, CIRCULATION, V97, P1549, DOI 10.1161/01.CIR.97.16.1549; *SAS I, 1996, SAS SYST WIND VERS 6; *STAT SCI, 1995, S PLUS WIND VERS 3 3; STOMEL RJ, 1994, CHEST, V105, P997, DOI 10.1378/chest.105.4.997; SUBRAMANIAN VA, 1980, NEW YORK STATE J MED, V80, P947; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; Urban P, 1999, EUR HEART J, V20, P1030, DOI 10.1053/euhj.1998.1353; VERNA E, 1989, EUR HEART J, V10, P958, DOI 10.1093/oxfordjournals.eurheartj.a059420; YAMAMOTO H, 1992, JPN CIRC J, V56, P815, DOI 10.1253/jcj.56.815	38	1828	1922	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					625	634		10.1056/NEJM199908263410901	http://dx.doi.org/10.1056/NEJM199908263410901			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460813	Green Published, Green Submitted			2022-12-28	WOS:000082192500001
J	Rembacken, BJ; Snelling, AM; Hawkey, PM; Chalmers, DM; Axon, ATR				Rembacken, BJ; Snelling, AM; Hawkey, PM; Chalmers, DM; Axon, ATR			Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; 5-AMINOSALICYLIC ACID MESALAZINE; MAINTENANCE TREATMENT; DOUBLE-BLIND; SULFASALAZINE; OLSALAZINE; REMISSION; EFFICACY; STRAINS; SAFETY	Background Ulcerative colitis has been suggested to be caused by infection and there is circumstantial evidence linking Escherichia coli with the condition. Our aim was to find out whether the administration of a non-pathogenic strain of E coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E coli to standard medical therapy increased the chance of remission of active ulcerative colitis. Methods This was a single-centre, randomised, double dummy study in which 120 patients with active ulcerative colitis were invited to take part. 116 patients accepted; 59 were randomised to mesalazine and 57 to E coli. Atl patients also received standard medical therapy together with a 1-week course of oral gentamicin. After remission, patients were maintained on either mesalazine or E coli and followed up for a maximum of 12 months. A two-stage, conditional, intention-to-treat analysis was done. Findings 44 (75%) patients in the mesalazine group attained remission compared with 39 (68%) in the E coli group. Mean time to remission was 44 days (median 42) in the mesalazine group and 42 days (median 37) for those treated with E coli. In the mesalazine group, 32 (73%) patients relapsed compared with 26 (67%) in the E coli group. Mean duration of remission was 206 days in the mesalazine group (median 175) and 221 days (median 185) in the E coli group. Interpretation Our results suggest that treatment with a nonpathogenic E coli has an equivalent effect to mesalazine in maintaining remission of ulcerative colitis. The beneficial effect of live E coli may provide clues to the cause of ulcerative colitis.	Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England; Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England	Leeds General Infirmary; University of Leeds; University of Leeds	Rembacken, BJ (corresponding author), Gen Infirm, Ctr Digest Dis, Great George St, Leeds LS1 3EX, W Yorkshire, England.	BJR@thecafe.co.uk	Brunn, Anna/N-2524-2013					BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BENNET JD, 1989, LANCET, V1, P164; BLUM G, 1995, INFECTION, V23, P234, DOI 10.1007/BF01781204; BRANDWEIN SL, 1995, GASTROENTEROLOGY, V108, P787; BURKE DA, 1987, J CLIN PATHOL, V40, P782, DOI 10.1136/jcp.40.7.782; BURKE DA, 1988, BMJ-BRIT MED J, V297, P102, DOI 10.1136/bmj.297.6641.102; BURKE DA, 1990, ALIMENT PHARM THERAP, V4, P123; CHAPMAN RW, 1986, GUT, V27, P1210, DOI 10.1136/gut.27.10.1210; COOKE EM, 1968, J PATHOL BACTERIOL, V95, P101, DOI 10.1002/path.1700950112; COURTNEY MG, 1992, LANCET, V339, P1279, DOI 10.1016/0140-6736(92)91601-4; DICKINSON RJ, 1979, GUT, V20, P141, DOI 10.1136/gut.20.2.141; DICKINSON RJ, 1985, GUT, V26, P1380, DOI 10.1136/gut.26.12.1380; DISSANAYAKE AS, 1973, GUT, V14, P923, DOI 10.1136/gut.14.12.923; Fockens P, 1995, EUR J GASTROEN HEPAT, V7, P1025, DOI 10.1097/00042737-199511000-00003; GIAFFER MH, 1992, ALIMENT PHARM THERAP, V6, P479; GIAFFER MH, 1992, GUT, V33, P646, DOI 10.1136/gut.33.5.646; KIILERICH S, 1992, GUT, V33, P252, DOI 10.1136/gut.33.2.252; Kruis W, 1997, ALIMENT PHARM THER, V11, P853, DOI 10.1046/j.1365-2036.1997.00225.x; LOBO AJ, 1993, ALIMENT PHARM THERAP, V7, P155; MISIEWICZ JJ, 1965, LANCET, V1, P185; MORRISSEY PJ, 1995, CLIN IMMUNOL IMMUNOP, V76, pS48; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; RIJK MCM, 1992, AM J GASTROENTEROL, V87, P438; Riley SA, 1998, GUT, V42, P761, DOI 10.1136/gut.42.6.761; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; Sartor RB, 1996, CURR OPIN GASTROEN, V12, P327, DOI 10.1097/00001574-199607000-00003; SHORTER RG, 1970, GASTROENTEROLOGY, V58, P692; SUTHERLAND L, 1998, COCHRANE LIB CDROM O; SUTHERLAND LR, 1993, ANN INTERN MED, V118, P540, DOI 10.7326/0003-4819-118-7-199304010-00009; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; TEDESCO FJ, 1983, GASTROINTEST ENDOSC, V29, P195, DOI 10.1016/S0016-5107(83)72583-6; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; 1998, NOTES GUIDANCE STAT, P17	33	832	882	1	65	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					635	639		10.1016/S0140-6736(98)06343-0	http://dx.doi.org/10.1016/S0140-6736(98)06343-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466665				2022-12-28	WOS:000082214500012
J	Ryan, JM				Ryan, JM			Immersion deaths and swim failure - implications for resuscitation and prevention	LANCET			English	Editorial Material							SUBMERSION; CHILDREN; DROWN		Royal Sussex Cty Hosp, Dept Accid & Emergency Med, Brighton BN2 5BE, E Sussex, England	University of Brighton	Ryan, JM (corresponding author), Royal Sussex Cty Hosp, Dept Accid & Emergency Med, Brighton BN2 5BE, E Sussex, England.							BOLTE RG, 1988, JAMA-J AM MED ASSOC, V260, P377, DOI 10.1001/jama.260.3.377; FERGUSSON DM, 1984, NEW ZEAL MED J, V97, P777; GOODEN BA, 1992, MED J AUSTRALIA, V157, P629, DOI 10.5694/j.1326-5377.1992.tb137408.x; HASSALL IB, 1989, AUST PAEDIATR J, V25, P143; KEMP AM, 1991, BRIT MED J, V302, P931, DOI 10.1136/bmj.302.6782.931; KYRIACOU DN, 1994, PEDIATRICS, V94, P137; *OFF POP CENS SURV, 1988, REG DEATHS CAUS; WATERS DJ, 1994, ANN THORAC SURG, V57, P1018, DOI 10.1016/0003-4975(94)90229-1	8	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					613	613		10.1016/S0140-6736(99)00285-8	http://dx.doi.org/10.1016/S0140-6736(99)00285-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466657				2022-12-28	WOS:000082214500004
J	Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P				Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P			Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus	SCIENCE			English	Article							DENDRITIC CELLS; IMMUNE-RESPONSES; T-CELLS; HIV-1; REPLICATION; MACAQUES; SIV; PLASMA; SKIN; TRANSMISSION	The early events during infection with an immunodeficiency virus were followed by application of pathogenic simian immunodeficiency virus atraumatically to the tonsils of macaques. Analyses by virologic assays and in situ hybridization revealed that the infection started Locally in the tonsils, a mucosal-associated Lymphoid organ, and quickly spread to other Lymphoid tissues. At day 3, there were few infected cells, but then the number increased rapidly, reaching a high plateau between days 4 and 7. The infection was not detected in the dendritic cell-rich squamous epithelium to which the virus was applied; instead, it was primarily in CD4(+) tonsillar T cells, close to the specialized antigen-transporting epithelium of the tonsillar crypts. Transport of the virus and immune-activating stimuli across this epithelium would allow mucosal Lymphoid tissue to function in the atraumatic transmission of immunodeficiency viruses.	German Primate Ctr, D-37077 Gottingen, Germany; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Deutsches Primatenzentrum (DPZ); Rockefeller University; Bernhard Nocht Institut fur Tropenmedizin	Stahl-Hennig, C (corresponding author), German Primate Ctr, D-37077 Gottingen, Germany.		Abrams, William R/A-5782-2008; Steinman, Ralph/F-7729-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040874, R01AI042129, R01AI040877] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40877, AI 42129, AI 40874] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brandtzaeg P, 1987, IMMUNOLOGY EAR, V1987, P63; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Frankel SS, 1997, AM J PATHOL, V151, P89; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Ignatius R, 1998, J MED PRIMATOL, V27, P121, DOI 10.1111/j.1600-0684.1998.tb00236.x; Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Neildez O, 1998, VIROLOGY, V243, P12, DOI 10.1006/viro.1997.9026; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NORLEY SG, 1993, BIOLOGICALS, V21, P251, DOI 10.1006/biol.1993.1082; OWEN RL, 1990, SPRINGER SEMIN IMMUN, V12, P139; Pope M, 1997, AIDS RES HUM RETROV, V13, P819, DOI 10.1089/aid.1997.13.819; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; Ruprecht RM, 1998, AIDS RES HUM RETROV, V14, pS97; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; StahlHennig C, 1996, J GEN VIROL, V77, P2969, DOI 10.1099/0022-1317-77-12-2969; STAHLHENNIG C, 1992, VIROLOGY, V186, P588, DOI 10.1016/0042-6822(92)90025-K; TENNERRACZ K, 1988, AIDS, V2, P299, DOI 10.1097/00002030-198808000-00010; TENNERRACZ K, 1979, LAB INVEST, V41, P106; WINTHER B, 1994, ARCH OTOLARYNGOL, V120, P144; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	32	191	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1261	1265		10.1126/science.285.5431.1261	http://dx.doi.org/10.1126/science.285.5431.1261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455052				2022-12-28	WOS:000082130200042
J	Mulholland, K				Mulholland, K			Magnitude of the problem of childhood pneumonia	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; UPPER RIVER DIVISION; GAMBIAN CHILDREN; LOBAR PNEUMONIA; RURAL AREA; ETIOLOGY; MORTALITY; INFANT; BANGLADESH; PATTERN		WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Mulholland, K (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	mulhollande@who.ch						ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219, DOI 10.1017/S0021932000013390; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345, DOI 10.1080/02724936.1993.11747669; EVANS JR, 1981, NEW ENGL J MED, V305, P1117, DOI 10.1056/NEJM198111053051904; Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GRANT JP, 1996, STATE WORLDS CHILDRE; GRANT P, 1980, STATE WORLDS CHILDRE; GREENWOOD B, 1992, J INFECT DIS, V165, pS26, DOI 10.1093/infdis/165-Supplement_1-S26; GWATKIN DR, 1980, AM J PUBLIC HEALTH, V70, P1286, DOI 10.2105/AJPH.70.12.1286; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; KABIR M, 1995, J BIOSOC SCI, V27, P179, DOI 10.1017/S0021932000022689; Leowski J, 1986, World Health Stat Q, V39, P138; Lewis F L, 1944, Arch Dis Child, V19, P122; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Murray CJL, 1996, GLOBAL HLTH STAT; ORUBULOYE IO, 1975, POP STUD-J DEMOG, V29, P259, DOI 10.2307/2173511; PRESTON SH, 1976, MORTALITY PATTERNS N, P89; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; WARREN KS, 1988, SOC SCI MED, V26, P891, DOI 10.1016/0277-9536(88)90407-8; WHO (World Health Organization), 1978, PRIM HLTH CAR JOINT; World Bank, 1993, INV HLTH WORLD DEV R	29	74	80	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					590	592		10.1016/S0140-6736(98)10238-6	http://dx.doi.org/10.1016/S0140-6736(98)10238-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470718				2022-12-28	WOS:000081991000048
J	Horita, J; Berndt, ME				Horita, J; Berndt, ME			Abiogenic methane formation and isotopic fractionation under hydrothermal conditions	SCIENCE			English	Article							FISCHER-TROPSCH SYNTHESIS; MID-ATLANTIC RIDGE; CARBON-DIOXIDE; ZAMBALES OPHIOLITE; ORGANIC-COMPOUNDS; OCEANIC-CRUST; SERPENTINIZATION; REDUCTION; ORIGIN; GAS	Recently, methane (CH4) of possible abiogenic origin has been reported from many Localities within Earth's crust, However, little is known about the mechanisms of abiogenic methane formation, or about isotopic fractionation during such processes. Here, a hydrothermally formed nickel-iron alloy was shown to catalyze the otherwise prohibitively slow formation of abiogenic CH4 from dissolved bicarbonate (HCO3-) under hydrothermal conditions. Isotopic fractionation by the catalyst resulted in delta(13)C values of the CH4 formed that are as Low as those typically observed for microbial methane, with similarly high CH4/(C2H6 + C3H8) ratios. These results, combined with the increasing recognition of nickel-iron alloy occurrence in oceanic crusts, suggest that abiogenic methane may be more widespread than previously thought.	Oak Ridge Natl Lab, Div Chem & Analyt Sci, Oak Ridge, TN 37831 USA; Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Minnesota System; University of Minnesota Twin Cities	Horita, J (corresponding author), Oak Ridge Natl Lab, Div Chem & Analyt Sci, Oak Ridge, TN 37831 USA.							ABRAJANO TA, 1990, APPL GEOCHEM, V5, P625, DOI 10.1016/0883-2927(90)90060-I; ABRAJANO TA, 1988, CHEM GEOL, V71, P211, DOI 10.1016/0009-2541(88)90116-7; ALLEN DE, 1998, EOS, V79, pF58; Alt JC, 1998, J GEOPHYS RES-SOL EA, V103, P9917, DOI 10.1029/98JB00576; AZUMA M, 1990, J ELECTROANAL CHEM, V294, P299, DOI 10.1016/0022-0728(90)87154-C; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; Botz R, 1996, ORG GEOCHEM, V25, P255, DOI 10.1016/S0146-6380(96)00129-5; Charlou JL, 1996, J GEOPHYS RES-SOL EA, V101, P15899, DOI 10.1029/96JB00880; CHARLOU JL, 1993, J GEOPHYS RES-SOL EA, V98, P9625, DOI 10.1029/92JB02047; FROST BR, 1985, J PETROL, V26, P31, DOI 10.1093/petrology/26.1.31; GADALLA AM, 1988, CHEM ENG SCI, V43, P3049, DOI 10.1016/0009-2509(88)80058-7; GALIMOV EM, 1975, F682 NASA TT; GOLD T, 1993, US GEOLOGICAL SURVEY, V1570, P57; Gold T., 1979, J PETROL GEOL, V1, P3; Halas S, 1997, GEOCHIM COSMOCHIM AC, V61, P2691, DOI 10.1016/S0016-7037(97)00107-5; Hu GX, 1998, SCI CHINA SER D, V41, P202, DOI 10.1007/BF02932441; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; JANECKY DR, 1986, GEOCHIM COSMOCHIM AC, V50, P1357, DOI 10.1016/0016-7037(86)90311-X; JEFFREY AWA, 1988, CHEM GEOL, V71, P237, DOI 10.1016/0009-2541(88)90118-0; JENDEN JD, 1993, US GEOLOGICAL SURVEY, V1570, P31; KAI T, 1988, CAN J CHEM ENG, V66, P343, DOI 10.1002/cjce.5450660226; Kelley DS, 1996, J GEOPHYS RES-SOL EA, V101, P2943, DOI 10.1029/95JB02252; KELLEY DS, 1995, EOS, V76, pF675; KONNERUPMADSEN J, 1988, B MINERAL, V111, P567, DOI 10.3406/bulmi.1988.8103; KROLL VCH, 1997, J CATAL, V164, P387; Krot AN, 1997, GEOCHIM COSMOCHIM AC, V61, P219, DOI 10.1016/S0016-7037(96)00336-5; LANCET MS, 1970, SCIENCE, V170, P980, DOI 10.1126/science.170.3961.980; LEE MD, 1990, J CHEM ENG JPN, V23, P130, DOI 10.1252/jcej.23.130; MALININ SD, 1967, GEOCHEM INT, V4, P764; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Moody J.B., 1976, CAN MINERAL, V14, P462; Petersil'ye IA, 1979, GEOCHEM INT, V16, P50; Potter J, 1998, EUR J MINERAL, V10, P1167; RICHET P, 1977, ANNU REV EARTH PL SC, V5, P65, DOI 10.1146/annurev.ea.05.050177.000433; RONA PA, 1992, GEOLOGY, V20, P783, DOI 10.1130/0091-7613(1992)020<0783:HCSADA>2.3.CO;2; Rosing MT, 1999, SCIENCE, V283, P674, DOI 10.1126/science.283.5402.674; SATTERFIELD CN, 1986, IND ENG CHEM PROD RD, V25, P407, DOI 10.1021/i300023a007; SATTERFIELD CN, 1986, IND ENG CHEM PROD RD, V25, P401, DOI 10.1021/i300023a006; SHERWOOD B, 1988, CHEM GEOL, V71, P223, DOI 10.1016/0009-2541(88)90117-9; SHERWOODLOLLAR B, 1993, GEOCHIM COSMOCHIM AC, V57, P5087; SHOCK EL, 1993, GEOCHIM COSMOCHIM AC, V57, P3341, DOI 10.1016/0016-7037(93)90542-5; SHOCK EL, 1990, ORIGINS LIFE EVOL B, V20, P331, DOI 10.1007/BF01808115; SHOELL M, 1988, CHEM GEOL, V71, P1; SNOW JE, 1995, NATURE, V374, P413, DOI 10.1038/374413a0; SZATMARI P, 1989, AAPG BULL, V73, P989; WEATHERBEE GD, 1982, J CATAL, V77, P460, DOI 10.1016/0021-9517(82)90186-5; WELHAN JA, 1988, CHEM GEOL, V71, P183, DOI 10.1016/0009-2541(88)90114-3; WHITICAR MJ, 1990, ORG GEOCHEM, V16, P531, DOI 10.1016/0146-6380(90)90068-B; Yuen G.U., 1990, LUNAR PLANET SCI, V21, P1367	49	419	455	3	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1055	1057		10.1126/science.285.5430.1055	http://dx.doi.org/10.1126/science.285.5430.1055			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446049				2022-12-28	WOS:000082033100042
J	Clark, PJ; Eastell, R; Barker, ME				Clark, PJ; Eastell, R; Barker, ME			Zinc supplementation and bone growth in pubertal girls	LANCET			English	Article								We supplemented the diets of 47 peripubertal girls with zinc (15 mg/day) or placebo for 6 weeks. Zinc supplementation increased serum zinc. Insulin-like growth factor I and biochemical markers of bone turnover did not change, albeit dietary zinc was below the reference level (in 94% of individuals).	No Gen Hosp, Div Clin Sci, Ctr Human Nutr, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Barker, ME (corresponding author), No Gen Hosp, Div Clin Sci, Ctr Human Nutr, Sheffield S5 7AU, S Yorkshire, England.		Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366; Barker, Margo/0000-0002-1016-5787				BLOSTEINFUJJI A, 1997, AM J CLIN NUTR, V66, P369; Cadogan J, 1997, BMJ-BRIT MED J, V315, P1255, DOI 10.1136/bmj.315.7118.1255; Department of Health, 1991, DIET REF VAL FOOD EN; NAKAMURA T, 1993, J PEDIATR-US, V123, P65, DOI 10.1016/S0022-3476(05)81538-0; NINH NX, 1996, AM J CLIN NUTR, V63, P541	5	16	17	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					485	485		10.1016/S0140-6736(99)01290-8	http://dx.doi.org/10.1016/S0140-6736(99)01290-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465179				2022-12-28	WOS:000081896100019
J	Manassiev, N				Manassiev, N			Screening for ovarian cancer	LANCET			English	Letter											Manassiev, N (corresponding author), 58 Ollerton Rd, Birmingham B26 1PN, W Midlands, England.			Rosenthal, Adam/0000-0001-6924-0721; Menon, Usha/0000-0003-3708-1732				Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1; SELTZER V, 1995, JAMA-J AM MED ASSOC, V273, P491, DOI 10.1001/jama.1995.03520300065039	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					509	509		10.1016/S0140-6736(99)00142-7	http://dx.doi.org/10.1016/S0140-6736(99)00142-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465192	Bronze			2022-12-28	WOS:000081896100044
J	Banatvala, N; Peremitin, GG				Banatvala, N; Peremitin, GG			Tuberculosis, Russia, and the Holy Grail	LANCET			English	Article									MERLIN, London W1M 4HW, England; Tomsk Reg TB Dispensary, Tomsk, Russia		Banatvala, N (corresponding author), MERLIN, 14 David Mews, London W1M 4HW, England.			Banatvala, Nick/0000-0001-8130-154X				Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Drobniewski F, 1996, TUBERCLE LUNG DIS, V77, P297, DOI 10.1016/S0962-8479(96)90092-1; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671	3	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					999	1000		10.1016/S0140-6736(99)02059-0	http://dx.doi.org/10.1016/S0140-6736(99)02059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459925				2022-12-28	WOS:000079421600046
J	Chintu, C; Mwinga, A				Chintu, C; Mwinga, A			An African perspective on the threat of tuberculosis and HIV/AIDS - can despair be turned to hope?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS		Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia	University of Zambia	Chintu, C (corresponding author), Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia.	cchintu@zamnet.zm						Department for International Development, 1997, WHIT PAP INT DEV; DOLIN P, 1998, GENDER TUBERCULOSIS; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Zumla A, 1998, INT J TUBERC LUNG D, V2, P179	6	27	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					997	997		10.1016/S0140-6736(99)01141-1	http://dx.doi.org/10.1016/S0140-6736(99)01141-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459923				2022-12-28	WOS:000079421600044
J	Kelly, M				Kelly, M		Hlth Population Div Dept Int Dev	A donor's perspective on tuberculosis in international health	LANCET			English	Article									DFID, HPD, London SW1E 5JL, England		Kelly, M (corresponding author), DFID, HPD, 94 Victoria St, London SW1E 5JL, England.							Department for International Development, 1997, EL WORLD POV CHALL 2; *GLOB TUB PROGR, 1998, TUB GLOB SURV; *GLOB TUB PROGR, 1994, FRAM ESS TB CONTR; GWATKIN DR, 1998, 981 WHO TDR ER RD; Styblo K, 1991, TUBERCULOSIS CAN BE, V2, P60	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1006	1006						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459930				2022-12-28	WOS:000079421600051
J	Graham, WJ; Newell, ML				Graham, WJ; Newell, ML			Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; TO-CHILD TRANSMISSION; INFECTION; ZIDOVUDINE; MORBIDITY; HEALTH; IMPACT; TRIAL		Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland; UCL, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	University of Aberdeen; University of London; University College London	Graham, WJ (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Graham, Wendy/0000-0003-1473-5342				ABOUZAHR C, 1998, GLOBAL BURDEN DIS IN, V3, P111; [Anonymous], 1997, CONFR AIDS PUBL PRIO; [Anonymous], 1996, UNICEF REVISED 1990; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; BARNETT T, 1992, AIDS AFRICA; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DABIS F, 1995, AIDS, V9, P204, DOI 10.1097/00002030-199509020-00015; Diczfalusy E, 1994, World Health Forum, V15, P1; *EUR COLL STUD, 1997, BRIT J OBSTET GYNAEC, V105, P704; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Graham W, 1998, BRIT J OBSTET GYNAEC, V105, P375, DOI 10.1111/j.1471-0528.1998.tb10116.x; GRAHAM WJ, 1992, SOC SCI MED, V35, P967, DOI 10.1016/0277-9536(92)90236-J; Graham WJ, 1998, SOC SCI MED, V47, P1925, DOI 10.1016/S0277-9536(98)00334-7; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HANSLUWKA HE, 1985, SOC SCI MED, V20, P1207, DOI 10.1016/0277-9536(85)90374-0; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LOWBEER D, 1998, HLTH DIMENSIONS SEX, V3, P297; MAHLER H, 1987, LANCET, V1, P668; Mansergh G, 1998, JAMA-J AM MED ASSOC, V280, P30, DOI 10.1001/jama.280.1.30; Mayaud P, 1998, LANCET, V351, P29; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Murray C. J. L., 1998, GLOBAL BURDEN DIS IN, V3, P1; Newell ML, 1997, AIDS, V11, pS165; OVER M, 1993, 9 INT C AIDS 3 STD W; *PREV MAT MORT NET, 1995, SOC SCI MED, V40, P657; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; Strong MA, 1992, HLTH TRANSITION REV, V2, P215; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; *UNAIDS, 1998, REP GLOB HIV AIDS EP; VILLAR J, 1995, ACTA OBSTET GYNECOL, V76, P1; World Health Organization, 1997, MON REPR HLTH SEL SH; World Health Organization, 1997, COV MAT CAR LIST AV	36	40	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					836	839		10.1016/S0140-6736(98)12374-7	http://dx.doi.org/10.1016/S0140-6736(98)12374-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459980				2022-12-28	WOS:000079089100048
J	Nordesjo-Haglund, G; Lonnqvist, B; Lindberg, G; Hellstrom-Lindberg, E				Nordesjo-Haglund, G; Lonnqvist, B; Lindberg, G; Hellstrom-Lindberg, E			Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation	LANCET			English	Letter									Huddinge Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Huddinge, Sweden	Karolinska Institutet	Nordesjo-Haglund, G (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Huddinge, Sweden.							Brand RE, 1998, LANCET, V352, P1985, DOI 10.1016/S0140-6736(05)61330-X; Hecht JR, 1997, CANCER-AM CANCER SOC, V79, P1698, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1698::AID-CNCR9>3.0.CO;2-8; Nordesjo G, 1998, BONE MARROW TRANSPL, V21, pS89; PEETERS T, 1989, AM J PHYSIOL, V257, pG470, DOI 10.1152/ajpgi.1989.257.3.G470; SOUDAH HC, 1991, NEW ENGL J MED, V325, P1461, DOI 10.1056/NEJM199111213252102	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					846	846		10.1016/S0140-6736(05)76666-6	http://dx.doi.org/10.1016/S0140-6736(05)76666-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459993				2022-12-28	WOS:000079089100063
J	Kenney, N; Macfarlane, A				Kenney, N; Macfarlane, A			Identifying problems with data collection at a local level: survey of NHS maternity units in England	BRITISH MEDICAL JOURNAL			English	Article								Objectives To document the extent to which maternity data are collected and how they are recorded, and to identify problems that may affect their availability throughout the NHS. Methods Postal survey in September 1997 with structured questionnaires. Setting 207 NHS trusts with maternity units in England. Participants Heads of midwifery in maternity units. Main outcome measures Extent to which maternity data were routinely recorded, how they were recorded and evaluated, and to whom they were made available. Results 167 (81%) of questionnaires were returned, representing 166 trusts. Of these trusts, 165 collected greater than or equal to 17 of the 19 data items in HES maternity tail, and 158 collected greater than or equal to 40 of the 45 items selected from Korner dataset Only 18 collected all five items selected from the "indicators of success," and 17 did not collect any. In 58 of trusts data were primarily recorded on paper. A computerised maternity information system was used by 106 (63%) of trusts, but many recorded data on paper first. Thirty four did not audit data for accuracy. Most trusts analysed data not routinely collected at national level, but 18 did not analyse HES maternity tail and 17 did not analyse Korner data. Conclusions Improvement is needed in quality, completeness, and availability of maternity data at a national level, particularly if the NHS information strategy is to be successfully implemented. Although most of the data items in national datasets are recorded locally, variations in the way data are defined, recorded, and analysed and lack of linkage between computer systems restrict their access, availability, and use at local, district, and national levels.	Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England	University of Oxford	Macfarlane, A (corresponding author), Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England.							*AUD COMM, 1997, FIRST CLASS DEL IMPR; *AUD COMM, 1995, FOR YOUR INF STUD IN; BANFIELD PJ, 1992, CURRENT PERSPECTIVES, P367; BOWNS I, 1998, IMPROVING CLIN COMMU, P1; Bradshaw M G, 1997, J Nurs Manag, V5, P143, DOI 10.1046/j.1365-2834.1997.00009.x; BROWNBRIDGE G, 1988, MED CARE, V26, P474, DOI 10.1097/00005650-198805000-00004; CLEARY R, 1994, BRIT J OBSTET GYNAEC, V101, P1042, DOI 10.1111/j.1471-0528.1994.tb13579.x; *CLIN STAND ADV GR, 1995, WOM NORM LAB REP CLI; *DEP HLTH, 1997, STAT B NHS MAT STAT; *DEP HLTH, 1995, CONF ENQ STILLB DEAT; Department of Health, 1993, CHANGING CHILDBIRTH; Department of Health, 1997, NEW NHS MOD DEP; DOBSON P, 1995, BR J MIDWIFERY, V3, P487; HARTSHORN A, 1999, MATERNITY CARE DATA; *HC HLTH COMM, 1992, 2 REP MAT SERV, V1; Kenney N, 1997, Midwives (1995), V110, P204; KENNEY N, 1999, BR J MIDWIVES, V7, P120; KENNEY N, 1999, BR J MIDWIVES, V7, P49; KENNEY N, IN PRESS USE MATERNI; MACFARLANE A, 1995, COUNTING CHANGES CHI; Middle C, 1995, BRIT J OBSTET GYNAEC, V102, P970, DOI 10.1111/j.1471-0528.1995.tb10904.x; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; *NHS EX, 1996, BEN REAL MON MAT INF; *NHS EX, 1998, CLIN EFF IND CONS DO; *NHS EX, 1996, SEEING WOOD SPAR TRE; *NSH EX, 1998, INF HLTH INF STRAT M; Robertson H, 1995, INT J QUAL HEALTH C, V7, P391, DOI 10.1093/intqhc/7.4.391; Smith L, 1998, BRIT MED J, V316, P1710, DOI 10.1136/bmj.316.7146.1710; *STEER GROUP HLTH, 1985, SUPPL 1 4 REP SECR S; Walton I., 1995, MIDWIVES CHANGING CH; *WHO, 1977, INT CLASS DIS MAN IN, V1	31	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					619	622B		10.1136/bmj.319.7210.619	http://dx.doi.org/10.1136/bmj.319.7210.619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473480	Bronze, Green Published			2022-12-28	WOS:000082460300024
J	Micheli, F				Micheli, F			Eutrophication, fisheries, and consumer-resource dynamics in marine pelagic ecosystems	SCIENCE			English	Article							PLANKTONIC FOOD-WEB; NORTHERN BALTIC SEA; LONG-TERM TRENDS; TROPHIC INTERACTIONS; PHYTOPLANKTON BIOMASS; ESTUARINE ENCLOSURES; COASTAL WATERS; COMMUNITY; ZOOPLANKTON; NUTRIENT	Anthropogenic nutrient enrichment and fishing influence marine ecosystems worldwide by altering resource availability and food-web structure. Metaanalyses of 47 marine mesocosm experiments manipulating nutrients and consumers, and of time series data of nutrients, plankton, and fishes from 20 natural marine systems, revealed that nutrients generally enhance phytoplankton biomass and carnivores depress herbivore biomass. However, resource and consumer effects attenuate through marine pelagic food webs, resulting in a weak coupling between phytoplankton and herbivores. Despite substantial physical and biological variability in marine pelagic ecosystems, alterations of resource availability and consumers result in general patterns of community change.	Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA	National Center for Ecological Analysis & Synthesis	Micheli, F (corresponding author), Univ Pisa, Dipartimento Sci Uomo & Ambiente, I-56126 Pisa, Italy.			Micheli, Fiorenza/0000-0002-6865-1438				ABREU PC, 1994, ESTUARIES, V17, P575, DOI 10.2307/1352405; ALPINE AE, 1992, LIMNOL OCEANOGR, V37, P946, DOI 10.4319/lo.1992.37.5.0946; ANDERSSON L, 1988, ESTUAR COAST SHELF S, V26, P559, DOI 10.1016/0272-7714(88)90006-6; ARDITI R, 1989, J THEOR BIOL, V139, P311, DOI 10.1016/S0022-5193(89)80211-5; AUSTEN MC, 1991, J MAR BIOL ASSOC UK, V71, P179, DOI 10.1017/S0025315400037498; *BALT MAR ENV PROT, 1990, BALT SEA ENV P B, V35; BARBER RT, 1983, SCIENCE, V222, P1203, DOI 10.1126/science.222.4629.1203; BARETTABEKKER JG, 1994, MAR ECOL PROG SER, V106, P187, DOI 10.3354/meps106187; BARTLETT MS, 1946, J RES STAT SOC S, V8, P24; BOALCH GT, 1978, J MAR BIOL ASSOC UK, V58, P943, DOI 10.1017/S0025315400056873; Bonsdorff E, 1997, OCEANOL ACTA, V20, P319; Breitburg DL, 1999, LIMNOL OCEANOGR, V44, P837, DOI 10.4319/lo.1999.44.3_part_2.0837; Brett MT, 1996, P NATL ACAD SCI USA, V93, P7723, DOI 10.1073/pnas.93.15.7723; Brett MT, 1997, FRESHWATER BIOL, V38, P483, DOI 10.1046/j.1365-2427.1997.00220.x; Brett MT, 1997, SCIENCE, V275, P384, DOI 10.1126/science.275.5298.384; Brodeur RD, 1996, CAL COOP OCEAN FISH, V37, P80; CARPENTER SR, 1992, LIMNOL OCEANOGR, V37, P208, DOI 10.4319/lo.1992.37.1.0208; CORTEN A, 1990, NETH J SEA RES, V25, P227, DOI 10.1016/0077-7579(90)90024-B; CUSHING DH, 1998, ICES J MAR SCI, V21, P113; DEASON EE, 1982, J PLANKTON RES, V4, P219, DOI 10.1093/plankt/4.2.219; DICKSON RR, 1988, J PLANKTON RES, V10, P151, DOI 10.1093/plankt/10.1.151; DOERING PH, 1989, MAR ECOL PROG SER, V52, P287, DOI 10.3354/meps052287; FENCHEL T, 1988, ANNU REV ECOL SYST, V19, P19, DOI 10.1146/annurev.es.19.110188.000315; Fogarty MJ, 1998, ECOL APPL, V8, pS6, DOI 10.2307/2641359; FULTON RS, 1983, J EXP MAR BIOL ECOL, V72, P67, DOI 10.1016/0022-0981(83)90020-5; FULTON RS, 1984, OECOLOGIA, V62, P97, DOI 10.1007/BF00377381; FULTON RS, 1984, J PLANKTON RES, V6, P399, DOI 10.1093/plankt/6.3.399; GRANELI E, 1985, J EXP MAR BIOL ECOL, V85, P253, DOI 10.1016/0022-0981(85)90161-3; GRANELI E, 1993, J PLANKTON RES, V15, P213, DOI 10.1093/plankt/15.2.213; GROVER JP, 1995, AM NAT, V145, P746, DOI 10.1086/285766; Gurevitch J., 1993, DESIGN ANAL ECOLOGIC; Harris R.P., 1982, P353; Hedges L., 1985, STAT METHODS METANAL; HEIN M, 1995, J EXP MAR BIOL ECOL, V188, P167, DOI 10.1016/0022-0981(95)00002-9; Heiskanen AS, 1996, MAR ECOL PROG SER, V145, P195, DOI 10.3354/meps145195; HICKEL W, 1992, ICES MAR SC, V195, P249; HORSTED SJ, 1988, MAR ECOL PROG SER, V48, P217, DOI 10.3354/meps048217; Huxel GR, 1998, AM NAT, V152, P460, DOI 10.1086/286182; *ICES ADV COMM FIS, 1993, 196 ICES ADV COMM FI; JACOBSEN A, 1995, J EXP MAR BIOL ECOL, V187, P239, DOI 10.1016/0022-0981(94)00183-E; JAKOBSSON J, 1992, ICES MAR SC, V195, P291; Kivi K, 1996, MAR ECOL PROG SER, V136, P59, DOI 10.3354/meps136059; KONONEN K, 1988, KIELER MEERESFORSCH, V6, P281; KUIPER J, 1983, MAR ECOL PROG SER, V14, P9, DOI 10.3354/meps014009; Kuuppo P, 1998, ESTUAR COAST SHELF S, V46, P65, DOI 10.1006/ecss.1997.0258; KUUPPOLEINIKKI P, 1994, MAR ECOL PROG SER, V107, P89, DOI 10.3354/meps107089; LEGENDRE L, 1990, J PLANKTON RES, V12, P681, DOI 10.1093/plankt/12.4.681; LEIBOLD MA, 1989, AM NAT, V134, P922, DOI 10.1086/285022; McCann KS, 1998, P ROY SOC B-BIOL SCI, V265, P205, DOI 10.1098/rspb.1998.0283; MCCAULEY E, 1989, CAN J FISH AQUAT SCI, V46, P1171, DOI 10.1139/f89-152; MCCAULEY E, 1988, AM NAT, V134, P288; MCQUEEN DJ, 1990, FRESHWATER BIOL, V23, P613, DOI 10.1111/j.1365-2427.1990.tb00299.x; MillanNunez R, 1996, CAL COOP OCEAN FISH, V37, P241; Mittelbach G. G., 1988, SIZE STRUCTURED POPU, P217; MUCK P, 1989, PERUVIAN UPWELLING S; MURPHY GI, 1977, FISH POPULATION DYNA, P283; OKSANEN L, 1981, AM NAT, V118, P240, DOI 10.1086/283817; OLSSON P, 1992, J EXP MAR BIOL ECOL, V158, P249, DOI 10.1016/0022-0981(92)90230-8; Osenberg CW, 1997, AM NAT, V150, P798, DOI 10.1086/286095; PAERL HW, 1988, LIMNOL OCEANOGR, V33, P823, DOI 10.4319/lo.1988.33.4_part_2.0823; PAERL HW, 1990, MAR BIOL, V107, P247, DOI 10.1007/BF01319823; PINCKNEY JL, IN PRESS MAR ECOL PR; POLIS GA, 1992, TRENDS ECOL EVOL, V7, P151, DOI 10.1016/0169-5347(92)90208-S; Polis GA, 1996, AM NAT, V147, P813, DOI 10.1086/285880; Polis GA, 1997, ANNU REV ECOL SYST, V28, P289, DOI 10.1146/annurev.ecolsys.28.1.289; POMEROY LR, 1974, BIOL SCI, V24, P242; RIEMANN B, 1990, MAR ECOL PROG SER, V65, P159, DOI 10.3354/meps065159; RIEMANN B, 1988, MAR ECOL PROG SER, V48, P205, DOI 10.3354/meps048205; ROWE GT, 1981, COASTAL UPWELLING; SCHULZ S, 1991, INT REV GES HYDROBIO, V76, P351, DOI 10.1002/iroh.19910760308; SCHULZ S, 1990, LIMNOLOGICA, V20, P89; Shadish W., 1994, HDB RES SYNTHESIS, P265; Shapiro J., 1975, Proceedings of a Symposium on Water Quality and Management through Biological Control, Gainesville, 1975., P85; SHERMAN K, 1985, VARIABILITY MANAGEME, P33; Shiomoto A, 1997, MAR ECOL PROG SER, V150, P75, DOI 10.3354/meps150075; Sinovcic G, 1997, OCEANOL ACTA, V20, P201; SMITH PE, 1982, LIMNOL OCEANOGR, V27, P1; SONNTAG N C, 1979, Journal of Plankton Research, V1, P85, DOI 10.1093/plankt/1.1.85; SOUTHWARD AJ, 1988, ASPECTS LONG TERM CH, P415; SUVAPEPUN S, 1991, MAR POLLUT BULL, V23, P213, DOI 10.1016/0025-326X(91)90677-K; Uitto Anna, 1995, Aqua Fennica, V25, P23; *UN FAO, 1990, 63 UN FAO GEN FISH C; VIITASALO M, 1994, THESIS FINNISH I MAR; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Ware Daniel M., 1995, Canadian Special Publication of Fisheries and Aquatic Sciences, V121, P509; WASSMANN P, 1991, OCEANOGR MAR BIOL, V29, P87; Woehrling D, 1998, OCEANOL ACTA, V21, P113, DOI 10.1016/S0399-1784(98)80055-8; [No title captured]	89	222	228	1	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1396	1398		10.1126/science.285.5432.1396	http://dx.doi.org/10.1126/science.285.5432.1396			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464097				2022-12-28	WOS:000082233500041
J	Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK				Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK			Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids	SCIENCE			English	Article							EPOXYEICOSATRIENOIC ACIDS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; EXPRESSION; HEART	The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 epoxy-genases that have vasodilatory properties similar to that of endothelium-derived hyperpolarizing factor. The cytochrome P450 isoform CYP2J2 was cloned and identified as a potential source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytokine-induced endothelial cell adhesion molecule expression, and EETs prevented leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-kappa B and I kappa B kinase. The inhibitory effects of EETs were independent of their membrane-hyperpolarizing effects, suggesting that these molecules play an important nonvasodilatory role in vascular inflammation.	Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Virginia, Ctr Hlth Sci, Dept Biomed Engn, Charlottesville, VA 22908 USA; NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liao, JK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 75 Francis St, Boston, MA 02115 USA.		Zeldin, Darryl C/Y-7091-2018; TATSUTA, HARUKI/F-2997-2010	Zeldin, Darryl C/0000-0002-2087-7307; 	NHLBI NIH HHS [R01 HL052233, R01 HL052233-06, HL-52233, P01 HL048743-080008, P01 HL048743-090008, P01 HL048743, R01 HL052233-05, HL-58108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058108, R01HL052233, P01HL048743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DE CR, 1995, J CLIN INVEST, V96, P60; FARIN FM, 1994, TOXICOL APPL PHARM, V124, P1, DOI 10.1006/taap.1994.1001; Hoebel BG, 1998, CLIN EXP PHARMACOL P, V25, P826, DOI 10.1111/j.1440-1681.1998.tb02162.x; Kozak W, 1998, AM J PHYSIOL-REG I, V275, pR1031, DOI 10.1152/ajpregu.1998.275.4.R1031; LIAO J, UNPUB, P63509; LIN JHC, 1996, ENDOTHELIUM, V4, P219; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; Nakashima T, 1996, AM J PHYSIOL-REG I, V271, pR1274, DOI 10.1152/ajpregu.1996.271.5.R1274; Oltman CL, 1998, CIRC RES, V83, P932; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Rosolowsky M, 1996, BBA-LIPID LIPID MET, V1299, P267, DOI 10.1016/0005-2760(95)00216-2; VANROLLINS M, 1993, J LIPID RES, V34, P1931; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	20	955	1018	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1276	1279		10.1126/science.285.5431.1276	http://dx.doi.org/10.1126/science.285.5431.1276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455056	Green Accepted			2022-12-28	WOS:000082130200046
J	Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER				Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER			Synaptic function modulated by changes in the ratio of synaptotagmin I and IV	NATURE			English	Article							NEUROTRANSMITTER RELEASE; MUTATIONAL ANALYSIS; BINDING; DOMAIN; DROSOPHILA; VESICLES; PROTEINS; SENSOR; REGION; SNARE	Communication within the nervous system is mediated by Ca2+-triggered fusion of synaptic vesicles with the presynaptic plasma membrane. Genetic and biochemical evidence indicates that synaptotagmin I may function as a Ca2+ sensor in neuronal exocytosis because it can bind Ca2+ and penetrate into lipid bilayers(1-4). Chronic depolarization or seizure activity results in the upregulation of a distinct and unusual isoform of the synaptotagmin family, synaptotagmin IV (ref. 5). We have identified a Drosophila homologue of synaptotagmin IV that is enriched on synaptic vesicles and contains an evolutionarily conserved substitution of aspartate to serine that abolishes its ability to bind membranes in response to Ca2+ influx. Synaptotagmin IV forms hetero-oligomers with synaptotagmin I, resulting in synaptotagmin clusters that cannot effectively penetrate lipid bilayers and are less efficient at coupling Ca2+ to secretion in vivo: upregulation of synaptotagmin IV, but not synaptotagmin I, decreases evoked neurotransmission. These findings indicate that modulating the expression of synaptotagmins with different Ca2+-binding affinities can lead to heteromultimers that can regulate the efficiency of excitation-secretion coupling in vivo and represent a new molecular mechanism for synaptic plasticity.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Littleton, JT (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.			Rubin, Gerald/0000-0001-8762-8703; Chapman, Edwin/0000-0001-9787-8140; Littleton, J. Troy/0000-0001-5576-2887				BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	20	135	139	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					757	760		10.1038/23462	http://dx.doi.org/10.1038/23462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466723				2022-12-28	WOS:000082131100048
J	Liu, L; Wolf, R; Ernst, R; Heisenberg, M				Liu, L; Wolf, R; Ernst, R; Heisenberg, M			Context generalization in Drosophila visual learning requires the mushroom bodies	NATURE			English	Article							FLIGHT ORIENTATION; MELANOGASTER; BRAIN; EXPRESSION; GENE	The world is permanently changing, Laboratory experiments on learning and memory normally minimize this feature of reality, keeping all conditions except the conditioned and unconditioned stimuli as constant as possible(1). In the real world, however, animals need to extract from the universe of sensory signals the actual predictors of salient events by separating them from nonpredictive stimuli (context(2)), In principle, this can be achieved if only those sensory inputs that resemble the reinforcer in their temporal structure are taken as predictors. Here we study visual learning in the fly Drosophila melanogaster, using a flight simulator(3,4), and show that memory retrieval is, indeed, partially context-independent. Moreover, we show that the mushroom bodies, which are required for olfactory(5-7) but not visual or tactile learning(8), effectively support context generalization. In visual learning in Drosophila, it appears that a facilitating effect of context cues for memory retrieval is the default state, whereas making recall context-independent requires additional processing.	Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany	University of Wurzburg	Heisenberg, M (corresponding author), Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany.							ASHBURNER M, 1989, LAB MANUAL PROTOCOLL, P254; Barth M, 1997, LEARN MEMORY, V4, P219, DOI 10.1101/lm.4.2.219; BICKEL WK, 1985, J EXP ANAL BEHAV, V44, P245, DOI 10.1901/jeab.1985.44-245; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; BUCHNER E, 1988, CELL TISSUE RES, V253, P357, DOI 10.1007/BF00222292; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; deBelle JS, 1996, P NATL ACAD SCI USA, V93, P9875, DOI 10.1073/pnas.93.18.9875; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; ERBRE J, 1987, ANTHR BRAIN ITS EVOL; ERNST R, IN PRESS VIS RES; Guo A, 1996, LEARN MEMORY, V3, P49, DOI 10.1101/lm.3.1.49; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; Heisenberg M., 1984, STUDIES BRAIN FUNCTI, V12; Ito K, 1998, LEARN MEMORY, V5, P52; Li YS, 1997, J COMP NEUROL, V387, P631; MARTIN JR, 1998, DROSOPHILA MELANOGAS, V5, P179; Pavlov I.P., 1927, CONDITIONED REFLEXES; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Rybak J, 1998, LEARN MEMORY, V5, P133; SCHILDBERGER K, 1984, J COMP PHYSIOL, V154, P71, DOI 10.1007/BF00605392; SCHURMANN FW, 1974, EXP BRAIN RES, V19, P406, DOI 10.1007/BF00234464; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Tarpy R.M., 1997, CONT LEARNING THEORY; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Wolf R, 1998, LEARN MEMORY, V5, P166; WOLF R, 1991, J COMP PHYSIOL A, V169, P699	29	221	224	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					753	756		10.1038/23456	http://dx.doi.org/10.1038/23456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	228HM	10466722				2022-12-28	WOS:000082131100047
J	Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB				Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB			Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							LARGE BOWEL; ADENOCARCINOMA; LESIONS; CARCINOMA	Background: Pancreatic cancer, the fourth most common cause of cancer death in the United States, is hereditary in an estimated 10% of cases. Surveillance of patients with a familial predisposition for pancreatic cancer has not been systematically evaluated. Objective: To develop a surveillance program that can identify and treat patients who have precancerous conditions of the pancreas and a family history of pancreatic cancer. Design: Prospective cohort study. Setting: University medical center. Patients: 14 patients from three kindreds with a history of pancreatic cancer. Interventions: Endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were performed in all patients. Four affected patients were tested for the K-ras mutation. Main Outcome Measurement: Pancreatic dysplasia was determined by histologic evaluation. Results: Seven of the 14 patients were believed to have dysplasia on the basis of clinical history and abnormalities on endoscopic ultrasonography and ERCP and were referred for pancreatectomy. All 7 patients had histologic evidence of dysplasia in pancreatectomy specimens. Findings on endoscopic ultrasonography were subtle, nonspecific, and similar to those seen in patients with chronic pancreatitis. Findings on ERCP ranged from mild and focal side-branch duct irregularities and small sacculations to main-duct strictures and grapelike clusters of saccules. Some of these changes are typical of chronic pancreatitis, but others are more distinctive. Spiral computed tomography and serum tumor markers had low sensitivity in the detection of pancreatic dysplasia. Analysis for the K-ras mutation yielded positive results in 3 of 4 patients with dysplasia. Conclusions: Thorough screening of patients with a family history of pancreatic cancer is feasible. Clinical data combined with imaging studies (endoscopic ultrasonography and ERCP) can be used to identify high-risk patients who have dysplasia. The role of molecular genetic testing is uncertain at this time.	Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Brentnall, TA (corresponding author), Univ Washington, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA.	teribr@u.washington.edu						BARBOSA JJD, 1946, SURG GYNECOL OBSTET, V82, P527; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; BRENTNALL TA, 1995, CANCER RES, V55, P4264; BUSARD JM, 1950, ARCH SURG-CHICAGO, V60, P674, DOI 10.1001/archsurg.1950.01250010695003; CUBILLA AL, 1976, CANCER RES, V36, P2690; Enterline H T, 1976, Curr Top Pathol, V63, P95; EVANS JP, 1995, J MED GENET, V32, P330, DOI 10.1136/jmg.32.5.330; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; KLIMSTRA DS, 1994, INT J PANCREATOL, V16, P224; KLOPPEL G, 1980, VIRCHOWS ARCH A, V387, P221, DOI 10.1007/BF00430702; KOZUKA S, 1979, CANCER, V43, P1419, DOI 10.1002/1097-0142(197904)43:4<1418::AID-CNCR2820430431>3.0.CO;2-O; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LONGNECKER DS, 1994, INT J PANCREATOL, V16, P201; Lynch HT, 1996, SEMIN ONCOL, V23, P251; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; POUR P, 1977, AM J PATHOL, V88, P291; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wiersema M J, 1995, Gastrointest Endosc Clin N Am, V5, P487	18	290	301	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					247	+		10.7326/0003-4819-131-4-199908170-00003	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454945				2022-12-28	WOS:000082012500002
J	Chadwick, R				Chadwick, R			The Icelandic database - do modern times need modern sagas?	BRITISH MEDICAL JOURNAL			English	Article									Univ Cent Lancashire, Ctr Profess Eth, Preston PR1 2HE, Lancs, England	University of Central Lancashire	Chadwick, R (corresponding author), Univ Cent Lancashire, Ctr Profess Eth, Preston PR1 2HE, Lancs, England.							*COUNC EUR, 1997, R975 COUNC EUR; *COUNC EUR, 1997, R9718 COUNC EUR; Council of Europe, 2018, CONV PROT IND REG AU; GREELY H, 1999, COMMUNICATION   0514; *HUM GEN ORG ETH C, 1996, GENOME DIGEST    MAY, P2; LEWONTIN RC, 1999, NY TIMES        0123; McInnis MG, 1999, CLIN GENET, V55, P234, DOI 10.1034/j.1399-0004.1999.550404.x; *MIN HLTH, 1998, BILL HLTH SECT DAT; *UNESCO, 1997, UN DECL HUM GEN HUM	9	49	50	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					441	444		10.1136/bmj.319.7207.441	http://dx.doi.org/10.1136/bmj.319.7207.441			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445931	Green Published			2022-12-28	WOS:000082098900025
J	Staessen, JA; Thijs, L; Fagard, R; O'Brien, ET; Clement, D; de Leeuw, PW; Mancia, G; Nachev, C; Palatini, P; Parati, G; Tuomilehto, J; Webster, J				Staessen, JA; Thijs, L; Fagard, R; O'Brien, ET; Clement, D; de Leeuw, PW; Mancia, G; Nachev, C; Palatini, P; Parati, G; Tuomilehto, J; Webster, J		Systolic Hypertension Europe Trial Investigator	Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR MASS; WHITE-COAT; PROGNOSIS; PROTOCOL; VALUES	Context The clinical use of ambulatory blood pressure (BP) monitoring requires further validation in prospective outcome studies. Objective To compare the prognostic significance of conventional and ambulatory BP measurement in older patients with isolated systolic hypertension. Design Substudy to the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial, started in October 1988 with follow up to February 1999. The conventional BP at randomization was the mean of 6 readings (2 measurements in the sitting position at 3 visits 1 month apart). The baseline ambulatory BP was recorded with a noninvasive intermittent technique. Setting Family practices and outpatient clinics at primary and secondary referral hospitals, Participants A total of 808 older (aged greater than or equal to 60 years) patients whose untreated BP level on conventional measurement at baseline was 160 to 219 mm Hg systolic and less than 95 mm Hg diastolic. Interventions For the overall study, patients were randomized to nitrendipine (n = 415; 10-40 mg/d) with the possible addition of enalapril (5-20 mg/d) and/or hydrochlorothiazide (12.5-25.0 mg/d) or to matching placebos (n = 393), Main Outcome Measures Total and cardiovascular mortality, all cardiovascular end points, fatal and nonfatal stroke, and fatal and nonfatal cardiac end points. Results After adjusting for sex, age, previous cardiovascular complications, smoking, and residence in western Europe, a 10-mm Hg higher conventional systolic BP at randomization was not associated with a worse prognosis, whereas in the placebo group, a 10-mm Hg higher 24-hour BP was associated with an increased relative hazard rate (HR) of most outcome measures leg, HR, 1.23 [95% confidence interval {CI}, 1.00-1.50] for total mortality and 1.34 [95% CI, 1.03-1.75] for cardiovascular mortality). In the placebo group, the nighttime systolic BP (12 AM-6 AM) more accurately predicted end points than the daytime lever. Cardiovascular risk increased with a higher night-to-day ratio of systolic BP independent of the 24-hour BP (10% increase in night-to-day ratio; HR for all cardiovascular end points, 1.41; 95% CI, 1.03-1.94). At randomization, the cardiovascular risk conferred by a conventional systolic BP of 160 mm Hg was similar to that associated with a 24-hour daytime or nighttime systolic BP of 142 mm Hg (95% CI, 128-156 mm Hg), 145 mm Hg (95% CI, 126-164 mm Hg) or 132 mm Hg (95% CI, 120-145 mm Hg), respectively. In the active treatment group, systolic BP at randomization did not significantly predict cardiovascular risk, regardless of the technique of BP measurement. Conclusions In untreated older patients with isolated systolic hypertension, ambulatory systolic BP was a significant predictor of cardiovascular risk over and above conventional BP.	Univ Louvain, Lab Hypertens, Dept Mol & Cardiol Res, Hypertens & Cardiovasc Rehabil Unit, B-3000 Louvain, Belgium; Beaumont Hosp, Dublin, Ireland; Univ Ghent, Dept Cardiol, Ghent, Belgium; Univ Maastricht, Maastricht, Netherlands; Univ Milan, San Gerardo Hosp, Dept Internal Med, Monza, Italy; Alexandrovs Univ Hosp, Dept Internal Med, Sofia, Bulgaria; Univ Padua, Med Clin 1, Padua, Italy; Univ Milan, Ctr Clin Physiol & Hypertens, Milan, Italy; Natl Inst Publ Hlth, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland	KU Leuven; Ghent University; Maastricht University; San Gerardo Hospital; University of Milan; Medical University Sofia; University of Padua; University of Milan; Finland National Institute for Health & Welfare; University of Aberdeen	Staessen, JA (corresponding author), Univ Louvain, Lab Hypertens, Dept Mol & Cardiol Res, Hypertens & Cardiovasc Rehabil Unit, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Staessen, Jan A/A-1065-2011; de Leeuw, Peter W./J-4552-2016; Parati, Gianfranco/K-7151-2016	Staessen, Jan A/0000-0002-3026-1637; de Leeuw, Peter W./0000-0002-4949-5812; Parati, Gianfranco/0000-0001-9402-7439; Thijs, Lutgarde/0000-0002-8108-2356				Black HR, 1997, ARCH INTERN MED, V157, P2413; Dodt C, 1997, HYPERTENSION, V30, P71, DOI 10.1161/01.HYP.30.1.71; Emelianov, 1998, Blood Press Monit, V3, P173; Fagard R, 1996, J HYPERTENS, V14, P557, DOI 10.1097/00004872-199605000-00003; FAGARD R, 1995, J HYPERTENS, V13, P823, DOI 10.1097/00004872-199508000-00002; Fagard RH, 1997, J HYPERTENS, V15, P1493, DOI 10.1097/00004872-199715120-00018; Fagard RH, 1997, HYPERTENSION, V29, P22, DOI 10.1161/01.HYP.29.1.22; IMAI Y, 1996, BLOOD PRESS MONIT S, V1, pS51; Khattar RS, 1998, CIRCULATION, V98, P1892, DOI 10.1161/01.CIR.98.18.1892; MANCIA G, 1983, LANCET, V2, P695; Mancia G, 1997, CIRCULATION, V95, P1464; MANN S, 1985, CLIN EXP HYPERTENS A, V7, P279, DOI 10.3109/10641968509073547; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mulcahy, 1998, Blood Press Monit, V3, P29; OBRIEN E, 1990, J HYPERTENS, V8, P607, DOI 10.1097/00004872-199007000-00004; OBRIEN E, 1988, LANCET, V2, P397; Ohkubo T, 1998, HYPERTENSION, V32, P255, DOI 10.1161/01.HYP.32.2.255; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; Pickering, 1996, Blood Press Monit, V1, P151; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Staessen, 1996, Blood Press Monit, V1, P13; STAESSEN J, 1992, AM J HYPERTENS, V5, P386, DOI 10.1093/ajh/5.6.386; Staessen J, 1992, Aging (Milano), V4, P85; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 1999, HYPERTENSION, V33, P1476, DOI 10.1161/01.HYP.33.6.1476; STAESSEN JA, 1993, J HYPERTENS, V11, P443, DOI 10.1097/00004872-199304000-00016; Staessen JA, 1997, HYPERTENSION, V29, P30, DOI 10.1161/01.HYP.29.1.30; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STAESSEN JA, IN PRESS EUR J INTER; STAMLER J, 1991, HYPERTENSION, V18, P95, DOI 10.1161/01.HYP.18.3_Suppl.I95; Verdecchia P, 1997, HYPERTENSION, V29, P1218, DOI 10.1161/01.HYP.29.6.1218; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WHITE WB, 1993, HYPERTENSION, V21, P504, DOI 10.1161/01.HYP.21.4.504	34	1194	1234	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					539	546		10.1001/jama.282.6.539	http://dx.doi.org/10.1001/jama.282.6.539			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450715	Bronze			2022-12-28	WOS:000081919100027
J	Emery, J; Yaphe, J; Priest, P; Whiteman, D				Emery, J; Yaphe, J; Priest, P; Whiteman, D			Screening for ovarian cancer	LANCET			English	Letter									Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Emery, J (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England.		Yaphe, John/B-8034-2010; Menon, Usha/C-4716-2008; Whiteman, David C/P-2728-2014; Bourne, Tom/I-6478-2012	Yaphe, John/0000-0002-3131-9984; Menon, Usha/0000-0003-3708-1732; Whiteman, David C/0000-0003-2563-9559; Bourne, Tom/0000-0003-1421-6059				Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; Woodman R, 1999, BRIT MED J, V318, P1027, DOI 10.1136/bmj.318.7190.1027a	3	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					509	509		10.1016/S0140-6736(05)75538-0	http://dx.doi.org/10.1016/S0140-6736(05)75538-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465193				2022-12-28	WOS:000081896100045
J	McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M				McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M			Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; SMALL GTPASE RAB5; VESICLE DOCKING; SNARE COMPLEX; AMPA RECEPTORS; PROTEIN; TRANSPORT; ENDOSOME; EXOCYTOSIS; BINDING	SNAREs and Rab GTPases cooperate in vesicle transport through a mechanism yet poorly understood. We now demonstrate that the Rab5 effecters EEA1 and Rabaptin-5/Rabex-5 exist on the membrane in high molecular weight oligomers, which also contain NSF. Oligomeric assembly is modulated by the ATPase activity of NSF. Syntaxin 13, the t-SNARE required for endosome fusion, is transiently incorporated into the large oligomers via direct interactions with EEA1. This interaction is required to drive fusion, since both dominant-negative EEA1 and synthetic peptides encoding the MIE Zn2+ finger hinder the interaction and block fusion. We propose a novel mechanism whereby oligomeric EEA1 and NSF mediate the local activation of syntaxin 13 upon membrane tethering and, by analogy with viral fusion proteins, coordinate the assembly of a fusion pore.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Ioannina, Sch Med, Biol Chem Lab, Ioannina 45110, Greece; Alfred Hosp, Monash Med Sch, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Ioannina; Florey Institute of Neuroscience & Mental Health; Monash University	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Murphy, Carol/ABE-4282-2021; Teasdale, Rohan D/B-2538-2009; McBride, Heidi M./ABD-5774-2021; McBride, Heidi M/C-1162-2008; Teasdale, Rohan/AAD-6698-2019	Murphy, Carol/0000-0003-1353-8558; Teasdale, Rohan D/0000-0001-7455-5269; McBride, Heidi M./0000-0003-4666-2280; McBride, Heidi M/0000-0003-4666-2280; Teasdale, Rohan/0000-0001-7455-5269				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lin JW, 1998, NEURON, V21, P267, DOI 10.1016/S0896-6273(00)80534-6; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Markovic I, 1998, J CELL BIOL, V143, P1155, DOI 10.1083/jcb.143.5.1155; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	64	393	398	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					377	386		10.1016/S0092-8674(00)81966-2	http://dx.doi.org/10.1016/S0092-8674(00)81966-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458612	Bronze			2022-12-28	WOS:000081950300012
J	Pelli, DG				Pelli, DG			Visual science - Close encounters - An artist shows that size affects shape	SCIENCE			English	Editorial Material							NOISE		NYU, Dept Psychol, New York, NY 10003 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	New York University; New York University	Pelli, DG (corresponding author), NYU, Dept Psychol, New York, NY 10003 USA.							CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056; GRUSSER OJ, 1971, PATTERN RECOGN, P196; Harmon L D, 1973, Sci Am, V229, P71, DOI 10.1038/scientificamerican1173-70; HARMON LD, 1973, SCIENCE, V180, P1194, DOI 10.1126/science.180.4091.1194; James R. C., 1973, INTELLIGENT EYE, P14; Keuls E., 1978, PLATO GREEK PAINTING; MORRONE MC, 1983, NATURE, V305, P226, DOI 10.1038/305226a0	7	24	24	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					844	846		10.1126/science.285.5429.844	http://dx.doi.org/10.1126/science.285.5429.844			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10454935				2022-12-28	WOS:000081860900035
J	Neugebauer, R; Hoek, HW; Susser, E				Neugebauer, R; Hoek, HW; Susser, E			Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUTCH-HUNGER-WINTER; BIRTH COMPLICATIONS; VIOLENT CRIME; FOLLOW-UP; CHILDREN; PREGNANCY; BEHAVIOR; SCHIZOPHRENIA; ADOLESCENCE; STARVATION	Context Several observational epidemiological studies report an association of pregnancy and obstetric complications with development of antisocial personality disorder (ASPD) in offspring. However, the precise nature and timing of the hypothesized biological insults are not known. Objective To test whether severe maternal nutritional deficiency early in gestation is associated with risk for ASPD in offspring. Design and Setting Retrospective cohort study. From October 1944 to May 1945, the German army blockaded food supplies to the Netherlands, subjecting the western Netherlands first to moderate (official food rations, 4200-6300 kJ/d) then to severe (<4200 kJ/d) nutritional deficiency. The north and south were subjected to moderate nutritional deficiency only. Participants Dutch men born in large urban areas in 1944-1946 who were given psychiatric examinations for military induction at age 18 years (N = 100 543) were classified by the degree and timing of their prenatal exposure to nutritional deficiency based on their birthdate and birthplace. Main Outcome Measure Diagnosis of ASPD by psychiatric interview at time of medical examination for military induction, using the International Classification of Diseases, Sixth Revision (ICD-6). Results Men exposed prenatally to severe maternal nutritional deficiency during the first and/or second trimesters of pregnancy exhibited increased risk for ASPD (adjusted odds ratio [OR], 2.5; 95% confidence interval [CI], 1.5-4.2). Third-trimester exposure to severe nutritional deficiency and prenatal exposure to moderate nutritional deficiency were not associated with risk for ASPD. Conclusions Our data suggest that severe nutritional insults to the developing brain in utero may be capable of increasing the risk for antisocial behaviors in offspring. The possible implications of these findings for both developed countries and developing countries, where severe nutritional deficiency is widespread and often exacerbated by war, natural disaster, and forced migration, warrant study.	Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA; Columbia Univ, GH Sergievsky Ctr, Fac Med, New York, NY 10032 USA; Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Leiden Univ, Parnassia Hague Psychiat Inst, The Hague, Netherlands	Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Leiden University; Leiden University - Excl LUMC; Parnassia Psychiatric Institute	Neugebauer, R (corresponding author), Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, Box 53,722 W 168th St, New York, NY 10032 USA.			Hoek, Hans/0000-0001-6353-5465				[Anonymous], 1994, DIAGNOSTIC STAT MANU; Baker R. L., 1984, INFLUENCES HUMAN DEV; BRENNAN P, 1993, DEV TREATMENT CHILDH, P81; BRESLAU N, 1988, J AM ACAD CHILD PSY, V27, P605, DOI 10.1097/00004583-198809000-00015; BROWN AS, 1995, BRIT J PSYCHIAT, V166, P601, DOI 10.1192/bjp.166.5.601; Brown AS, 1997, EPIDEMIOLOGY, V8, P55, DOI 10.1097/00001648-199701000-00009; BUKA S L, 1988, Acta Paediatrica Japonica, V30, P537; BUKA SL, 1993, ARCH GEN PSYCHIAT, V50, P151; Burger G., 1948, MALNUTRITION STARVAT; CARP EAD, 1947, MED PSYCHOL PATHOP 3; COHEN P, 1989, CHILD DEV, V60, P701, DOI 10.2307/1130735; COHLER BJ, 1975, SOC BIOL, V22, P269, DOI 10.1080/19485565.1975.9988176; Elwood J. M., 1992, EPIDEMIOLOGY CONTROL; FIELD T, 1986, DEV PSYCHOBIOL, V21, P1152; GERSHON ES, 1995, ARCH GEN PSYCHIAT, V50, P900; GRAHAM GG, 1993, NEW ENGL J MED, V328, P1058, DOI 10.1056/NEJM199304083281429; GRIGOROIUSERBANESCU M, 1984, INT J BEHAV DEV, V7, P307, DOI 10.1177/016502548400700304; HALVERSON CF, 1976, CHILD DEV, V47, P281; Hoek HW, 1996, AM J PSYCHIAT, V153, P1637; HOSMER DW, 1989, APPL LOGISTIC REGRES; KANDEL E, 1991, CRIMINOLOGY, V29, P519, DOI 10.1111/j.1745-9125.1991.tb01077.x; KAPLAN HI, 1991, SYNOPSIS PSYCHIAT, P532; KATES RW, 1993, NEW ENGL J MED, V328, P1055, DOI 10.1056/NEJM199304083281428; Kline J.S., 1989, CONCEPTION BIRTH EPI; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LYONS MJ, 1995, ARCH GEN PSYCHIAT, V52, P906; MCGEE R, 1984, J CHILD PSYCHOL PSYC, V25, P573, DOI 10.1111/j.1469-7610.1984.tb00173.x; MEDNICK SA, 1988, BIOL CONTRIBUTIONS C; Neugebauer R, 1997, AM J PUBLIC HEALTH, V87, P726, DOI 10.2105/AJPH.87.5.726; OLDS H, 1998, JAMA-J AM MED ASSOC, V280, P1238; PAULHUS DL, 1986, J PERS SOC PSYCHOL, V50, P1235, DOI 10.1037/0022-3514.50.6.1235; Pine DS, 1997, AM J PUBLIC HEALTH, V87, P1303, DOI 10.2105/AJPH.87.8.1303; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Raine A, 1996, ARCH GEN PSYCHIAT, V53, P544; RAINE A, 1988, SOCIAL PSYCHOPHYSIOL, P231; RAINE A, PSYCHOPATHOLOGY CRIM; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Reiss A., 1993, UNDERSTANDING PREVEN; ROBINSON NM, 1965, PEDIATRICS, V35, P425; Rothman K., 1998, MODERN EPIDEMIOLOGY; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SCRIMSHAW NS, 1907, ANNU REV NUTR, V7, P1; SHAFFER D, 1985, CLIN GUIDE CHILD PSY, P29; SOUTH MA, 1985, TERATOLOGY, V31, P297, DOI 10.1002/tera.1420310216; STEIN Z, 1972, SCIENCE, V178, P708, DOI 10.1126/science.178.4062.708; Stein Z., 1975, FAMINE HUM DEV DUTCH; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; SZATMARI P, 1986, CAN J PSYCHIAT, V31, P513, DOI 10.1177/070674378603100606; WALDROP MF, 1978, SCIENCE, V199, P536; Wali Sima, 1995, WOMENS RIGHTS HUMAN, P335; WEISSMAN MM, 1996, PSYCHIATRY, P6; *WHO, 1948, MAN INT CLASS DIS IN; ZELDENRUST ELK, 1966, NED TIJDSCHR GENEES, V110, P1737; 1948, MANUAL INT CLASSIFIC	59	235	242	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					455	462		10.1001/jama.282.5.455	http://dx.doi.org/10.1001/jama.282.5.455			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442661				2022-12-28	WOS:000081784900022
J	Alberts, BM; Ayala, FJ; Botstein, D; Frank, E; Holmes, EW; Lee, RD; Macagno, ER; Marrack, P; Oparil, S; Orkin, SH; Rubenstein, AH; Slayman, CW; Sparling, PF; Squire, LR; von Hippel, PH; Yamamoto, KR				Alberts, BM; Ayala, FJ; Botstein, D; Frank, E; Holmes, EW; Lee, RD; Macagno, ER; Marrack, P; Oparil, S; Orkin, SH; Rubenstein, AH; Slayman, CW; Sparling, PF; Squire, LR; von Hippel, PH; Yamamoto, KR			Science policy - Proposed changes for NIH's Center for Scientific Review	SCIENCE			English	Editorial Material									NIH, Ctr Sci Review Advisory Comm, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Alberts, BM (corresponding author), NIH, Ctr Sci Review Advisory Comm, Bethesda, MD 20892 USA.		Holmes, Edward/GVR-9499-2022; Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687; von Hippel, Peter H./0000-0003-2512-8097				EHRENFELD E, COMMUNICATION	1	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					666	667		10.1126/science.285.5428.666	http://dx.doi.org/10.1126/science.285.5428.666			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454921				2022-12-28	WOS:000081765100026
J	Peveler, R; George, C; Kinmonth, AL; Campbell, M; Thompson, C				Peveler, R; George, C; Kinmonth, AL; Campbell, M; Thompson, C			Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MEDICATION; DEPRESSION; THERAPY	Objectives To evaluate two different methods of improving adherence to antidepressant drugs. Design Factorial randomised controlled single blind trial of treatment leaflet, drug counselling, both, or treatment as usual. Setting Primary care in Wessex Participants 250 patients starting treatment with tricyclic antidepressants. Main outcome measures Adherence to drug treatment (by confidential self report and electronic monitor); depressive symptoms and health status. Results 66 (63%) patients continued with drugs to 12 weeks in the counselled group compared with 42 (39%) of those who did not receiving counselling (odds ratio 2.1, 95% confidence interval 1.6 to 4.8; number needed to treat = 4). Treatment leaflets had no significant effect on adherence. No differences in depressive symptoms were found between treatment groups overall, although a significant improvement was found in patients with major depressive disorder receiving drug doses of at least 75 mg (depression score 4 (SD 3.7) counselling v 5.9 (SD 5.0) no counselling P = 0.038). Conclusions Counselling about drug treatment significantly improved adherence, but clinical benefit was seen only in patients with major depressive disorder receiving doses greater than or equal to 75 mg. Further research is required to evaluate the effect of this approach in combination with appropriate targeting of treatment and advice about dosage.	Univ Southampton, Royal S Hants Hosp, Mental Hlth Grp, Southampton SO14 0YG, Hants, England; Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England; Univ Cambridge, Inst Publ Hlth Med, Gen Practice & Primary Care Unit, Cambridge CB2 2SR, England; Univ Sheffield, No Gen Hosp, Sch Hlth & Related Res, Sheffield S5 7AU, S Yorkshire, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Cambridge; Northern General Hospital; University of Sheffield	Peveler, R (corresponding author), Univ Southampton, Royal S Hants Hosp, Mental Hlth Grp, Southampton SO14 0YG, Hants, England.							*AM PSYCH ASS, 1987, DSM, V3; [Anonymous], 1996, GLOBAL BURDEN DIS CO; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; GIBBS S, 1987, Pharmaceutical Medicine (London), V2, P23; GIBBS S, 1989, BRIT J CLIN PHARMACO, V27, P723, DOI 10.1111/j.1365-2125.1989.tb03434.x; GOLDBERG DP, 1988, J PSYCHOSOM RES, V32, P137, DOI 10.1016/0022-3999(88)90048-7; HAYNES RB, 1998, COCHRANE LIB; HOLLYMAN JA, 1988, J ROY COLL GEN PRACT, V38, P393; JOHNSON DAW, 1974, BRIT J PSYCHIAT, V125, P186, DOI 10.1192/bjp.125.2.186; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; Kemp R, 1996, BRIT MED J, V312, P345; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; MADDOX JC, 1994, J PSYCHOPHARMACOL, V8, P48, DOI 10.1177/026988119400800108; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; Spilker B., 1991, PATIENT COMPLIANCE M; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; WILKINSON G, 1993, PSYCHOL MED, V23, P229, DOI 10.1017/S0033291700039027; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	19	201	202	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					612	615		10.1136/bmj.319.7210.612	http://dx.doi.org/10.1136/bmj.319.7210.612			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473477	Bronze, Green Published			2022-12-28	WOS:000082460300021
J	Wu, NL; Wang, SY; Rusakova, IA				Wu, NL; Wang, SY; Rusakova, IA			Inhibition of crystallite growth in the sol-gel synthesis of nanocrystalline metal oxides	SCIENCE			English	Article							TIN OXIDE; SENSORS	Crystal growth upon firing of hydrous transition metal oxide gels can be effectively inhibited by replacing the surface hydroxyl group before firing with another functional group that does not condense and that can produce small, secondary-phase particles that restrict advancing of grain boundaries at elevated temperatures. Accordingly, fully crystallized SnO2, TiO2, and ZrO2 materials with mean crystallite sizes of similar to 20, 50, and 15 angstroms, respectively, were synthesized by replacing the hydroxyl group with methyl siloxyl before firing at 500 degrees C. An ultrasensitive SnO2-based chemical sensor resulting from the microstructural miniaturization was demonstrated.	Natl Taiwan Univ, Dept Chem Engn, Taipei 106, Taiwan; Univ Houston, Texas Ctr Superconduct, Houston, TX 77204 USA	National Taiwan University; University of Houston System; University of Houston	Wu, NL (corresponding author), Natl Taiwan Univ, Dept Chem Engn, Taipei 106, Taiwan.							ANTONELLI DM, 1995, ANGEW CHEM INT EDIT, V34, P2014, DOI 10.1002/anie.199520141; BONZI P, 1994, J MATER RES, V9, P1250, DOI 10.1557/JMR.1994.1250; Brinker C.J., 1990, SOL GEL SCI, P515; BURGGRAAF AJ, 1991, INORGANIC MEMBRANES, pCH2; COLES GSV, Patent No. 2177215; Jin CM, 1997, MRS BULL, V22, P39, DOI 10.1557/S0883769400034187; MILLER RGJ, 1969, INFRARED STRUCTURAL; NAKAJIMA A, 1993, J MATER SCI LETT, V12, P1778, DOI 10.1007/BF00517608; Qi LM, 1998, LANGMUIR, V14, P2579, DOI 10.1021/la971077c; SACHTLER WMH, Patent No. 5786294; Takahata K., 1988, CHEM SENSOR TECHNOLO, V1; TAKAHATA K, 1988, CHEM SENSOR TECHNOLO, V2; Wu NL, 1999, J AM CERAM SOC, V82, P67; Wu NL, 1996, J MATER RES, V11, P813, DOI 10.1557/JMR.1996.0098; 21104	15	351	365	3	186	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1375	1377		10.1126/science.285.5432.1375	http://dx.doi.org/10.1126/science.285.5432.1375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464090				2022-12-28	WOS:000082233500034
J	Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC				Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC			The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells	NATURE			English	Article							LYMPHOCYTE-ASSOCIATED ANTIGEN; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; HOMING RECEPTOR; E-SELECTIN; EXPRESSION; PHENOTYPE; SUBSETS; INTERLEUKIN-8; RECRUITMENT	Lymphocytes that are responsible for regional (tissue-specific) immunity home from the blood to the intestines, inflamed skin or other sites through a multistep process involving recognition of vascular endothelial cells and extravasation(1). Chemoattractant cytokine molecules known as chemokines(2) regulate this lymphocyte traffic, in part by triggering arrest (stopping) of lymphocytes rolling on endothelium(3-5). Here we shaw that many systemic memory T cells in blood carry the chemokine receptor CCR4 (ref. 6) and therefore respond to its ligands, the chemokines TARC and MDC. These cells include essentially all skin-homing cells expressing the cutaneous lymphocyte antigen and a subset of other systemic memory lymphocytes; however, intestinal (alpha 4 beta 7(+)) memory and naive T cells respond poorly. Immunohistochemistry reveals anti-TARC reactivity of venules and infiltration of many CCR4(+) lymphocytes in chronically inflamed skin, but not in the gastrointestinal lamina propria. Moreover, TARC induces integrin-dependent adhesion of skin (but not intestinal) memory T cells to the cell-adhesion molecule ICAM-1, and causes their rapid arrest under physiological now. Our results suggest that CCR4 and TARC are important in the recognition of skin vasculature by circulating T cells and in directing lymphocytes that are involved in systemic as opposed to intestinal immunity to their target tissues.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; LeukoSite Inc, Cambridge, MA 02142 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Haraldsen, Guttorm/W-4359-2019; Haraldsen, Guttorm/I-2680-2013	Campbell, James/0000-0003-4252-5182; Haraldsen, Guttorm/0000-0002-0064-9665				Anderson A O, 1993, Semin Immunol, V5, P271, DOI 10.1006/smim.1993.1031; Andrew DP, 1998, J IMMUNOL, V161, P5027; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Baekkevold ES, 1999, LAB INVEST, V79, P327; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Mackay CR, 1996, EUR J IMMUNOL, V26, P2433, DOI 10.1002/eji.1830261025; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SILBER A, 1994, J CLIN INVEST, V93, P1554, DOI 10.1172/JCI117134; Teraki Y, 1997, J IMMUNOL, V159, P6018; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Williams MB, 1997, J IMMUNOL, V159, P1746; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	30	674	698	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					776	780		10.1038/23495	http://dx.doi.org/10.1038/23495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466728				2022-12-28	WOS:000082131100053
J	Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL				Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL			Heparin is essential for the storage of specific granule proteases in mast cells	NATURE			English	Article							DIPEPTIDYL PEPTIDASE-I; MOLECULAR-CLONING; SERINE PROTEASES; MESSENGER-RNA; MOUSE; GENE; TRANSCRIPTION; EXPRESSION; SUBCLASS; SULFOTRANSFERASE	All mammals produce heparin, a negatively charged glycosaminoglycan that is a major constituent of the secretory granules of mast cells which are found in the peritoneal cavity and most connective tissues. Although heparin is one of the most studied molecules in the body, its physiological function has yet to be determined. Here we describe transgenic mice, generated by disrupting the N-deacetylase/N-sulphotransferase-2 gene(1,2), that cannot express fully sulphated heparin, The mast cells in the skeletal muscle that normally contain heparin lacked metachromatic granules and failed to store appreciable amounts of mouse mast-cell protease (mMCP)-4, mMCP-5 and carboxypeptidase A (mMC-CPA), even though they contained substantial amounts of mMCP-7, We developed mast cells from the bone marrow of the transgenic mice. Although these cultured cells contained high levels of various protease transcripts and had substantial amounts of mMCP-6 protein in their granules, they also failed to express mMCP-5 and mMC-CPA, Our data show that heparin controls, through a post-translational mechanism, the levels of specific cassettes of positively charged proteases inside mast cells.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02130 USA; VA Med Ctr, Boston, MA 02130 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ERIKSSON I, 1994, J BIOL CHEM, V269, P10439; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Gurish MF, 1997, BLOOD, V90, P382; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P16744; Huang CF, 1998, J IMMUNOL, V160, P1910; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, BIOSYNTHESIS HEPARIN, P159; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1982, J BIOL CHEM, V257, P253; STEVENS RL, 1986, J IMMUNOL, V137, P291; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054	30	341	348	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					769	772		10.1038/23481	http://dx.doi.org/10.1038/23481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466726				2022-12-28	WOS:000082131100051
J	Andersson, GBJ				Andersson, GBJ			Epidemiological features of chronic low-back pain	LANCET			English	Review							GENERAL-POPULATION; MEDICAL-SERVICES; FREQUENCY; INDUSTRY; INJURIES; WORKERS; CARE; COMPENSATION; RECURRENCE; PATTERNS	Although the literature is filled with information about the prevalence and incidence of back pain in general, there is less information about chronic back pain, partly because of a lack of agreement about definition. Chronic back pain is sometimes defined as back pain that lasts for longer than 7-12 weeks. Others define it as pain that lasts beyond the expected period of healing, and acknowledge that chronic pain may not have well-defined underlying pathological causes. Others classify frequently recurring back pain as chronic pain since it intermittently affects an individual over a long period. Most national insurance and industrial sources of data include only those individuals in whom symptoms result in loss of days at work or other disability. Thus, even less is known about the epidemiology of chronic low-back pain with no associated work disability or compensation. Chronic low-back pain has also become a diagnosis of convenience for many people who are actually disabled for socioeconomic, work-related, or psychological reasons. In fact, some people argue that chronic disability in back pain is primarily related to a psychosocial dysfunction. Because the validity and reliability of some of the existing data are uncertain, caution is needed in an assessment of the information on this type of pain.	Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA	Rush University	Andersson, GBJ (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.							ABENHAIM L, 1988, BRIT J IND MED, V45, P829; AFACAN AS, 1982, J SOC OCCUP MED, V32, P26; ANDERSON JAD, 1986, J SOC OCCUP MED, V36, P90; ANDERSSON GBJ, 1983, SPINE, V8, P880, DOI 10.1097/00007632-198311000-00011; Andersson Gunnar B. J., 1997, P93; BATTIE MC, 1990, J SPINAL DISORD, V3, P195; BATTIE MC, 1989, THESIS U GOTEBORG GO; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BIERINGSORENSEN F, 1989, DAN MED B, V29, P289; BIGOS SJ, 1986, SPINE, V11, P252, DOI 10.1097/00007632-198604000-00012; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; CHOLER U, 1985, 188 SPRI; Doorn JW., 1995, ACTA ORTHOP SCAND S, V263, P1; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FRYMOYER JW, 1987, CLIN ORTHOP RELAT R, P89; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1983, J BONE JOINT SURG AM, V65, P213, DOI 10.2106/00004623-198365020-00010; GREENOUGH CG, 1993, ACTA ORTHOP SCAND, V64, P1, DOI 10.3109/17453679309153927; GYNTELBERG F, 1974, DAN MED BULL, V21, P30; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HIRSCH C, 1969, CLIN ORTHOP RELAT R, P171; HULT L, 1954, Acta Orthop Scand Suppl, V17, P1; KOCH H, 1986, ADV DATA VITAL HLTH, V123; LANCOURT J, 1992, SPINE, V17, P629, DOI 10.1097/00007632-199206000-00002; LEAVITT F, 1992, SPINE, V17, P307, DOI 10.1097/00007632-199203000-00011; Magora A, 1970, IMS Ind Med Surg, V39, P504; MOENS GF, 1993, OCCUP MED-OXFORD, V43, P78, DOI 10.1093/occmed/43.2.78; NACHEMSON AL, 1991, CAUSES DIAGNOSIS TRE; NAGI SZ, 1973, J CHRON DIS, V26, P769, DOI 10.1016/0021-9681(73)90012-X; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; PRAEMER A, 1992, MUSCULOSKELETAL COND, P1; ROSSIGNOL M, 1988, J OCCUP ENVIRON MED, V30, P502, DOI 10.1097/00043764-198806000-00012; SANDER RA, 1986, SPINE, V11, P141, DOI 10.1097/00007632-198603000-00007; SHEKELLE PG, 1995, SPINE, V20, P1668, DOI 10.1097/00007632-199508000-00004; SPENGLER DM, 1986, SPINE, V11, P241, DOI 10.1097/00007632-198604000-00010; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; SVENSSON HO, 1982, SCAND J REHABIL MED, V14, P47; SVENSSON HO, 1988, SPINE, V13, P548, DOI 10.1097/00007632-198805000-00019; TAYLOR VM, 1994, SPINE, V19, P1207, DOI 10.1097/00007632-199405310-00002; VALKENBURG HA, 1982, S IDIOPATHIC LOW BAC, P9; VOLINN E, 1994, CLIN J PAIN, V10, P64, DOI 10.1097/00002508-199403000-00009; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227; WEBSTER BS, 1994, SPINE, V19, P1111, DOI 10.1097/00007632-199405001-00001	46	1951	2049	9	192	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					581	585		10.1016/S0140-6736(99)01312-4	http://dx.doi.org/10.1016/S0140-6736(99)01312-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470716				2022-12-28	WOS:000081991000046
J	Brocks, JJ; Logan, GA; Buick, R; Summons, RE				Brocks, JJ; Logan, GA; Buick, R; Summons, RE			Archean molecular fossils and the early rise of eukaryotes	SCIENCE			English	Article							WESTERN-AUSTRALIA; IRON-FORMATION; HAMERSLEY BASIN; HYDROCARBONS; MICROFOSSILS; ANTIQUITY; BACTERIA; PILBARA; LIFE	Molecular fossils of biological lipids are preserved in 2700-million-year-old shares from the Pilbara Craton, Australia. Sequential extraction of adjacent samples shows that these hydrocarbon biomarkers are indigenous and syngenetic to the Archean shales, greatly extending the known geological range of such molecules. The presence of abundant 2 alpha-methylhopanes, which are characteristic of cyanobacteria, indicates that oxygenic photosynthesis evolved well before the atmosphere became oxidizing. The presence of steranes, particularly cholestane and its 28- to 30-carbon analogs, provides persuasive evidence for the existence of eukaryotes 500 million to 1 billion years before the extant fossil record indicates that the lineage arose.	Univ Sydney, Sch Geosci, Sydney, NSW 2006, Australia; Australian Geol Survey Org, Canberra, ACT 2601, Australia	University of Sydney; Geoscience Australia	Brocks, JJ (corresponding author), Univ Sydney, Sch Geosci, Sydney, NSW 2006, Australia.		Summons, Roger Everett/AAL-3789-2020; Brocks, Jochen/E-3920-2012	Brocks, Jochen/0000-0002-8430-8744; Buick, Roger/0000-0003-0139-1659				ARNDT NT, 1991, AUST J EARTH SCI, V38, P261, DOI 10.1080/08120099108727971; BRATERMAN PS, 1983, NATURE, V303, P163, DOI 10.1038/303163a0; BUICK R, 1992, SCIENCE, V255, P74, DOI 10.1126/science.11536492; CLOUD PE, 1968, SCIENCE, V160, P729, DOI 10.1126/science.160.3829.729; Dutkiewicz A, 1998, NATURE, V395, P885, DOI 10.1038/27644; GRESSIER JM, 1996, THESIS U SYDNEY SYDN; HAN TM, 1992, SCIENCE, V257, P232, DOI 10.1126/science.1631544; Hayes J. M., 1983, EARTHS EARLIEST BIOS, P93; Hayes JM, 1994, NOBEL S, P220; Hoering T.C., 1965, CARNEGIE I WASHINGTO, V64, P215; HOERING TC, 1987, PRECAMBRIAN RES, V34, P247, DOI 10.1016/0301-9268(87)90003-9; Hoering TC, 1966, CARNEGIE I WASH YB, V65, P365; HOLLAND HD, 1990, AM J SCI, V290A, P1; KNOLL AH, 1995, EFFECTS PAST GLOBAL, P21; KOHL W, 1983, J GEN MICROBIOL, V129, P1629; Logan GA, 1999, GEOCHIM COSMOCHIM AC, V63, P1345, DOI 10.1016/S0016-7037(99)00033-2; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Logan GA, 1997, GEOCHIM COSMOCHIM AC, V61, P5391, DOI 10.1016/S0016-7037(97)00290-1; MANGO FD, 1991, NATURE, V352, P146, DOI 10.1038/352146a0; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; MORRIS RC, 1993, PRECAMBRIAN RES, V60, P243, DOI 10.1016/0301-9268(93)90051-3; NELSON DR, 1992, PRECAMBRIAN RES, V54, P231, DOI 10.1016/0301-9268(92)90072-V; OURISSON G, 1987, ANNU REV MICROBIOL, V41, P301, DOI 10.1146/annurev.mi.41.100187.001505; Peters K.E., 1993, BIOMARKER GUIDE; ROWLAND SJ, 1990, ORG GEOCHEM, V15, P9, DOI 10.1016/0146-6380(90)90181-X; SCHOPF JW, 1987, SCIENCE, V237, P70, DOI 10.1126/science.11539686; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; SMITH RE, 1982, J PETROL, V23, P75, DOI 10.1093/petrology/23.1.75; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; SUMMONS RE, 1990, AM J SCI, V290A, P212; SUMMONS RE, IN PRESS NATURE; Trendall AF, 1998, AUST J EARTH SCI, V45, P137, DOI 10.1080/08120099808728374; Walter M.R., 1983, EARTHS EARLIEST BIOS, P187; WIDDEL F, 1993, NATURE, V362, P834, DOI 10.1038/362834a0	34	853	923	12	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1033	1036		10.1126/science.285.5430.1033	http://dx.doi.org/10.1126/science.285.5430.1033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446042				2022-12-28	WOS:000082033100035
J	Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R				Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R			Time-dependent reorganization of brain circuitry underlying long-term memory storage	NATURE			English	Article							POSTERIOR CINGULATE CORTICES; POSITRON EMISSION TOMOGRAPHY; COGNITIVE NEUROSCIENCE; HIPPOCAMPAL-FORMATION; RETROGRADE-AMNESIA; EPISODIC MEMORY; CONSOLIDATION; MICE; PERSPECTIVE; RETRIEVAL	Retrogade amnesia observed following hippocampal lesions in humans and animals is typically temporally graded(1,2), with recent memory being impaired while remote memories remain intact, indicating that the hippocampal formation has a time-limited role in memory storage(3,4). However, this claim remains controversial because studies involving hippocampal lesions tell us nothing about the contribution of the hippocampus to memory storage if this region was present at the time of memory retrieval(5,6). We therefore used non-invasive functional brain imaging using (C-14)2-deoxyglucose uptake to examine how the brain circuitry underlying long-term memory storage is reorganized over time in an intact brain. Regional metabolic activity in the brain was mapped in mice tested at different times for retention of a spatial discrimination task. Here we report that increasing the retention interval from 5 days to 25 days resulted in both decreased hippocampal metabolic activity during retention testing and a loss of correlation between hippocampal metabolic activity and memory performance. Concomitantly, a recruitment of certain cortical areas was observed. These results indicate that there is a time-dependent reorganization of the neuronal circuitry underlying long-term memory storage, in which a transitory interaction between the hippocampal formation and the neocortex would mediate the establishment of long-lived cortical memory representations.	Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bontempi, B (corresponding author), Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, Ave Fac, F-33405 Talence, France.							Alkire MT, 1998, P NATL ACAD SCI USA, V95, P14506, DOI 10.1073/pnas.95.24.14506; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Bontempi B, 1996, EUR J NEUROSCI, V8, P2348, DOI 10.1111/j.1460-9568.1996.tb01198.x; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; CHO YH, 1993, J NEUROSCI, V13, P1759; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Dudai Y, 1996, NEURON, V17, P367, DOI 10.1016/S0896-6273(00)80168-3; FINCH DM, 1984, EXP NEUROL, V83, P468, DOI 10.1016/0014-4886(84)90116-X; Fink GR, 1996, J NEUROSCI, V16, P4275; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Knowlton BJ, 1998, CURR OPIN NEUROBIOL, V8, P293, DOI 10.1016/S0959-4388(98)80154-2; LEHMAN A, 1974, ATLAS STEREOTAXIQUE; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCINTOSH AR, 1994, J NEUROPHYSIOL, V72, P1717, DOI 10.1152/jn.1994.72.4.1717; MEUNIER M, 1991, BEHAV BRAIN RES, V44, P133, DOI 10.1016/S0166-4328(05)80018-X; Moscovitch M, 1998, CURR OPIN NEUROBIOL, V8, P297, DOI 10.1016/S0959-4388(98)80155-4; Nyberg L, 1996, J NEUROSCI, V16, P3753; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; Reed JM, 1998, J NEUROSCI, V18, P3943; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SIF J, 1989, NEUROSCI LETT, V101, P223, DOI 10.1016/0304-3940(89)90535-1; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	454	458	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					671	675		10.1038/23270	http://dx.doi.org/10.1038/23270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458162				2022-12-28	WOS:000082032900055
J	James, JH; Luchette, FA; McCarter, FD; Fischer, JE				James, JH; Luchette, FA; McCarter, FD; Fischer, JE			Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis	LANCET			English	Article							RAT SKELETAL-MUSCLE; SEVERE HEAD-INJURY; LACTIC-ACIDOSIS; AEROBIC GLYCOLYSIS; PLASMA-CATECHOLAMINES; POTASSIUM-TRANSPORT; GRADED-EXERCISE; TRAUMA PATIENTS; BLOOD LACTATE; SOLEUS MUSCLE	High blood lactate concentration (hyperlactacidaemia) in trauma or sepsis is thought to indicate tissue hypoxia and anaerobic glycolysis even when blood pressure, cardiac output, and urine output are within clinically acceptable ranges. However, mechanisms of lactate generation by well-oxygenated tissues have received little attention. Within cells, oxidative and glycolytic energy production can proceed In separate, independent compartments. In skeletal muscle and other tissues, aerobic glycolysis is linked to ATP provision for the Na+-H+ pump, the activity of which is stimulated by epinephrine. In injured patients, hypokalaemia may reflect increased Na+, K+-ATPase activity. We propose that increased blood lactate often reflects increased aerobic glycolysis in skeletal muscle secondary to epinephrine-stimulated Na+, K+-ATPase activity and not anaerobic glycolysis due to hypoperfusion. The hypothesis explains why hyperlactacidaemia often neither correlates with traditional indicators of perfusion nor diminishes with increased oxygen delivery. When other variables have returned to normal, continued attempts at resuscitation based on elevated blood lactate may lead to unnecessary use of blood transfusion and inotropic agents in an effort to increase oxygen delivery and lactate clearance.	Univ Cincinnati, Med Ctr, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	James, JH (corresponding author), Univ Cincinnati, Med Ctr, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	jamesjh@ucmail.uc.edu	Luchette, Fred/ABF-1710-2020	Luchette, Fred/0000-0002-8857-9111				ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; ASSADI FK, 1989, CLIN PEDIATR, V28, P258, DOI 10.1177/000992288902800603; Astiz ME, 1998, LANCET, V351, P1501, DOI 10.1016/S0140-6736(98)01134-9; Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9; BENEDICT CR, 1978, Q J MED, V47, P1; BORNEMANN M, 1986, ANN INTERN MED, V105, P880, DOI 10.7326/0003-4819-105-6-880; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; CLAUSEN T, 1983, ACTA MED SCAND, P111; CLAUSEN T, 1980, BRIT J PHARMACOL, V68, P749, DOI 10.1111/j.1476-5381.1980.tb10868.x; Clausen T, 1996, NEWS PHYSIOL SCI, V11, P24; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLUTTER WE, 1980, J CLIN INVEST, V66, P94, DOI 10.1172/JCI109840; DANIEL AM, 1978, SURG GYNECOL OBSTET, V147, P697; Day NPJ, 1996, LANCET, V348, P219, DOI 10.1016/S0140-6736(96)09096-4; Day NPJ, 1996, LANCET, V348, P902; DIETZ MR, 1980, J BIOL CHEM, V255, P2301; FLATMAN JA, 1979, NATURE, V281, P580, DOI 10.1038/281580a0; FRYBURG DA, 1995, AM J PHYSIOL-ENDOC M, V268, pE55, DOI 10.1152/ajpendo.1995.268.1.E55; GOODALL M, 1968, ANN NY ACAD SCI, V150, P685, DOI 10.1111/j.1749-6632.1968.tb14721.x; Gore DC, 1996, ANN SURG, V224, P97, DOI 10.1097/00000658-199607000-00015; GORE DC, 1991, ANN SURG, V213, P568, DOI 10.1097/00000658-199106000-00006; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HALMAGUI DF, 1971, EUR SURG RES, V3, P378, DOI 10.1159/000127584; HALMAGYI DF, 1967, J APPL PHYSIOL, V23, P171, DOI 10.1152/jappl.1967.23.2.171; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HUGHSON RL, 1995, J APPL PHYSIOL, V79, P1134, DOI 10.1152/jappl.1995.79.4.1134; Irving M H, 1968, Ann R Coll Surg Engl, V42, P367; James JH, 1996, J CLIN INVEST, V98, P2388, DOI 10.1172/JCI119052; LEWIS GP, 1975, HDB PHYSL ENDOCRINOL, V6, P309; LIDDELL MJ, 1979, SURG GYNECOL OBSTET, V149, P822; Luchette FA, 1998, J TRAUMA, V44, P796, DOI 10.1097/00005373-199805000-00010; Luchette FA, 1999, J TRAUMA, V46, P873, DOI 10.1097/00005373-199905000-00017; MAZZEO RS, 1989, J APPL PHYSIOL, V67, P1319, DOI 10.1152/jappl.1989.67.4.1319; Nielsen OB, 1996, ACTA PHYSIOL SCAND, V157, P199, DOI 10.1046/j.1365-201X.1996.d01-748.x; PARKER JC, 1967, J GEN PHYSIOL, V50, P893, DOI 10.1085/jgp.50.4.893; PAUL RJ, 1989, FASEB J, V3, P2298, DOI 10.1096/fasebj.3.11.2528493; PAUL RJ, 1979, SCIENCE, V206, P1414, DOI 10.1126/science.505014; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PODOLIN DA, 1991, J APPL PHYSIOL, V71, P1427, DOI 10.1152/jappl.1991.71.4.1427; POMERANZ S, 1989, ACTA NEUROCHIR, V97, P62, DOI 10.1007/BF01577741; Porter JM, 1998, J TRAUMA, V44, P908, DOI 10.1097/00005373-199805000-00028; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; Riley M, 1997, EUR J APPL PHYSIOL, V75, P14; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; STATEN MA, 1987, AM J PHYSIOL, V253, pE322, DOI 10.1152/ajpendo.1987.253.3.E322; Totaro RJ, 1997, CRIT CARE MED, V25, P1693, DOI 10.1097/00003246-199710000-00019; VANEK VW, 1994, SOUTHERN MED J, V87, P41, DOI 10.1097/00007611-199401000-00010; WOLFE RR, 1991, SURGERY, V110, P54	48	341	359	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					505	508		10.1016/S0140-6736(98)91132-1	http://dx.doi.org/10.1016/S0140-6736(98)91132-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465191				2022-12-28	WOS:000081896100043
J	Dabis, F; Msellati, P; Meda, N; Welffens-Ekra, C; You, B; Manigart, O; Leroy, V; Simonon, A; Cartoux, M; Combe, P; Ouangre, A; Ramon, R; Ky-Zerbo, O; Montcho, C; Salamon, R; Rouzioux, C; Van de Perre, P; Mandelbrot, L				Dabis, F; Msellati, P; Meda, N; Welffens-Ekra, C; You, B; Manigart, O; Leroy, V; Simonon, A; Cartoux, M; Combe, P; Ouangre, A; Ramon, R; Ky-Zerbo, O; Montcho, C; Salamon, R; Rouzioux, C; Van de Perre, P; Mandelbrot, L		DITRAME Study GRP	6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POSTNATAL TRANSMISSION; MOTHER; TYPE-1; INFECTION; ABIDJAN; INFANT	Background Zidovudine reduces the rate of vertical transmission of HIV in non-breastfed populations. We assessed the acceptability, tolerance, and 6-month efficacy of a short regimen of oral zidovudine in African populations practising breastfeeding. Methods A randomised double-blind placebo-controlled trial was carried out in public clinics of Abidjan, Cote d'Ivoire, and Bobo-Dioulasso, Burkina Faso. Eligible participants were women aged 18 years or older, who had confirmed HIV-1 infection and pregnancy of 36-38 weeks duration, and who gave written informed consent. Exclusion criteria were severe anaemia, neutropenia, abnormal liver function, and sickle-cell disease. Women were randomly assigned zidovudine (n=214; 300 mg twice daily until labour, 600 mg at beginning of labour, and 300 mg twice daily for 7 days post partum) or matching placebo (n=217). The primary outcome was the diagnosis of HIV-1 infection in the infant on the basis of sequential DNA PCR tests at days 1-8, 45, 90, and 180. We compared the probability of infection at a given age in the two groups. Analyses were by intention to treat. Findings Women were enrolled between September, 1995, and February, 1998, when enrolment to the placebo group was stopped. Analysis was based on 421 women and 400 lifeborn infants. Baseline demographic, clinical, and laboratory characteristics were similar in the two groups. The Kaplan-Meier probability of HIV infection in the infant at 6 months was 18.0% in the zidovudine group (n=192) and 27.5% in the placebo group (n=197; relative efficacy 0.38 [95% CI 0.05-0.60]; p=0.027). Adjustment for centre, period of recruitment, mode of delivery, maternal CD4-cell count, duration of labour, prolonged rupture of membranes, and duration of breastfeeding did not change the treatment effect. The proportions of women taking more than 80% of the planned maximum dose were 75% before delivery, 81% during labour, and 83% post partum, without statistical difference between the groups. No major adverse biological or clinical event was reported in excess among women and children of the zidovudine group. Interpretation A short course of oral zidovudine given during the peripartum period is well accepted and well tolerated, and provides a 38% reduction in early vertical transmission of HIV-1 infection despite breastfeeding.	Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France; ORSTOM Petit Bassam, Abidjan, Cote Ivoire; OCCGE, Ctr Muraz, Bobo Dioulasso, Burkina Faso; Ctr Hosp Univ Yopougon, Abidjan, Cote Ivoire; Program PACCI, CeDReS, Abidjan, Cote Ivoire; Univ Necker Enfants Malad, Ctr Hosp, Virol Lab, Paris, France; CHU Cochin Port Royal, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre Muraz; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Dabis, F (corresponding author), Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France.	Francois.dabis@dim.u-bordeaux2.fr	Leroy, Valeriane/GQB-1102-2022; Leroy, Valeriane/AAO-5175-2020; Leroy, Valeriane/F-8129-2013; Mandelbrot, Laurent/AAD-3554-2019; DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; Mandelbrot, Laurent/0000-0002-5883-7597; DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427; Odette, Ky-Zerbo/0000-0002-0018-1580				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Cartoux M, 1996, J ACQ IMMUN DEF SYND, V12, P290, DOI 10.1097/00042560-199607000-00009; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DABIS F, 1995, AIDS, V9, P204, DOI 10.1097/00002030-199509020-00015; Dabis F, 1995, AIDS, V9 Suppl A, pS67; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Marshall E, 1998, SCIENCE, V279, P1299, DOI 10.1126/science.279.5355.1299; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Meda N, 1998, INT J GYNECOL OBSTET, V61, P65, DOI 10.1016/S0020-7292(98)00016-2; Msellati P, 1998, AIDS, V12, P1257, DOI 10.1097/00002030-199810000-00026; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; MSELLATI P, IN PRESS AM J PUBLIC; Newell ML, 1998, AIDS, V12, P1571, DOI 10.1097/00002030-199813000-00003; Newell ML, 1997, AIDS, V11, pS165; Pocock SJ., 1983, CLIN TRIALS PRACTICA; Sangare L, 1997, INT J STD AIDS, V8, P646, DOI 10.1258/0956462971918797; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; Susser M, 1998, AM J PUBLIC HEALTH, V88, P547, DOI 10.2105/AJPH.88.4.547; SyllaKoko F, 1997, MED MALADIES INFECT, V27, P127, DOI 10.1016/S0399-077X(97)80083-2; Thorne C, 1998, BRIT J OBSTET GYNAEC, V105, P704; *UNAIDS, 1998, PREV HIV TRANSM MOTH; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP, P48; VANDEPERRE P, 1995, AM J OBSTET GYNECOL, V173, P483, DOI 10.1016/0002-9378(95)90270-8; VandePerre P, 1997, AIDS PATIENT CARE ST, V11, P4, DOI 10.1089/apc.1997.11.4; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P313; *WHO, 1998, 981 WHOFRHNUTCHD; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	36	381	388	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					786	792		10.1016/S0140-6736(98)11046-2	http://dx.doi.org/10.1016/S0140-6736(98)11046-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459959				2022-12-28	WOS:000079089100009
J	Martyn, CN; Cooper, C				Martyn, CN; Cooper, C			Prediction of burden of hip fracture	LANCET			English	Editorial Material							ENGLAND; TRENDS		Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Martyn, CN (corresponding author), Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Melton LJ, 1996, PUBLIC HEALTH REP, V111, P146; Osmond C, 1982, Stat Med, V1, P245, DOI 10.1002/sim.4780010306; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					769	770		10.1016/S0140-6736(98)00390-0	http://dx.doi.org/10.1016/S0140-6736(98)00390-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459954				2022-12-28	WOS:000079089100004
J	Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW				Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW			A population-based study of the clinical expression of the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; MUTATION ANALYSIS; EARLY DIAGNOSIS; TRANSFERRIN; SATURATION; PREDICTION; PREVALENCE; FIBROSIS; HFE	Background and Methods Hereditary hemochromatosis is associated with homozygosity for the C282Y mutation in the hemochromatosis (HFE) gene on chromosome 6, elevated serum transferrin saturation, and excess iron deposits throughout the body. To assess the prevalence and clinical expression of the HFE gene, we conducted a population-based study in Busselton, Australia. In 1994, we obtained blood samples for the determination of serum transferrin saturation and ferritin levels and the presence or absence of the C282Y mutation and the H63D mutation (which may contribute to increased hepatic iron levels) in 3011 unrelated white adults. We evaluated all subjects who had persistently elevated transferrin-saturation values (45 percent or higher) or were homozygous for the C282Y mutation. We recommended liver biopsy for subjects with serum ferritin levels of 300 ng per milliliter or higher. The subjects were followed for up to four years. Results Sixteen of the subjects (0.5 percent) were homozygous for the C282Y mutation, and 424 (14.1 percent) were heterozygous. The serum transferrin saturation was 45 percent or higher in 15 of the 16 who were homozygous; in 1 subject it was 43 percent. Four of the homozygous subjects had previously been given a diagnosis of hemochromatosis, and 12 had not. Seven of these 12 patients had elevated serum ferritin levels in 1994; 6 of the 7 had further increases in 1998, and 1 had a decrease, although the value remained elevated. The serum ferritin levels in the four other homozygous patients remained in the normal range. Eleven of the 16 homozygous subjects underwent liver biopsy; 3 had hepatic fibrosis, and 1, who had a history of excessive alcohol consumption, had cirrhosis and mild microvesicular steatosis. Eight of the 16 homozygous subjects had clinical findings that were consistent with the presence of hereditary hemochromatosis, such as hepatomegaly, skin pigmentation, and arthritis. Conclusions In a population of white adults of northern European ancestry, 0.5 percent were homozygous for the C282Y mutation in the HFE gene. However, only half of those who were homozygous had clinical features of hemochromatosis, and one quarter had serum ferritin levels that remained normal over a four-year period. (N Engl J Med 1999;341:718-24.) (C)1999, Massachusetts Medical Society.	Univ Western Australia, Dept Med, Fremantle, WA 6959, Australia; Fremantle Hosp, Dept Gastroenterol, Fremantle, WA, Australia; Busselton Populat Med Res Fdn, Perth, WA, Australia; Queen Elizabeth II Med Ctr, Pathctr, Nedlands, WA, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Univ Queensland, Brisbane, Qld, Australia	University of Western Australia; University of Western Australia; University of Western Australia; QIMR Berghofer Medical Research Institute; University of Queensland	Olynyk, JK (corresponding author), Univ Western Australia, Dept Med, POB 480, Fremantle, WA 6959, Australia.	jolynyk@cyllene.uwa.edu.au		Olynyk, John/0000-0003-0417-3411				Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; BASSETT ML, 1988, ANN NY ACAD SCI, V526, P274, DOI 10.1111/j.1749-6632.1988.tb55512.x; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; BEILBY J, 1992, CLIN CHEM, V38, P2078; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Cardoso EMP, 1998, J INTERN MED, V243, P203; Carella M, 1997, AM J HUM GENET, V60, P828; Cochran W.G., 1967, STAT METHODS; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Cullen LM, 1997, BLOOD, V90, P4236, DOI 10.1182/blood.V90.10.4236; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; JEFFREY GP, IN PRESS NAT GENET; Knuiman MW, 1997, J EPIDEMIOL COMMUN H, V51, P515, DOI 10.1136/jech.51.5.515; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; Mendler MH, 1998, HEPATOLOGY, V28, p419A; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Moirand R, 1999, GASTROENTEROLOGY, V116, P372, DOI 10.1016/S0016-5085(99)70134-4; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; OLYNYK JK, 1994, POSTGRAD MED, V96, P151, DOI 10.1080/00325481.1994.11945914; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Powell W.L., 1994, IRON METABOLISM HLTH; Robson KJH, 1997, GUT, V41, P841; Rossi E, 1999, J GASTROEN HEPATOL, V14, P427, DOI 10.1046/j.1440-1746.1999.01884.x; SEARLE J, 1994, PATHOLOGY LIVER, P224; SINGERSAM J, 1989, AMPL FOR PCR US; Welborn T A, 1968, Med J Aust, V2, P778	36	565	577	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					718	724		10.1056/NEJM199909023411002	http://dx.doi.org/10.1056/NEJM199909023411002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471457	Green Published			2022-12-28	WOS:000082291900002
J	Griffin, GE				Griffin, GE			Typhoid fever and childhood vaccine strategies	LANCET			English	Editorial Material									Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	St Georges University London	Griffin, GE (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.							Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Koff RS, 1999, NEW ENGL J MED, V340, P644, DOI 10.1056/NEJM199902253400810; LEVINE MM, 1997, NEW GENERATION VACCI, P437; LEVINE OS, 1997, NEW GENERATION VACCI, P69; *ROCK FDN, 1999, M VACC DEV DEL PARTN	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					698	699		10.1016/S0140-6736(99)90117-4	http://dx.doi.org/10.1016/S0140-6736(99)90117-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475177				2022-12-28	WOS:000082233000005
J	Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY				Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY			GTP binding by class II transactivator: Role in nuclear import	SCIENCE			English	Article							BARE LYMPHOCYTE SYNDROME; NUCLEOTIDE-BINDING; RAS P21; PROTEIN; CIITA; EXPRESSION; GENES; MHC; ACTIVATION; DEFICIENCY	Class II transactivator (CIITA) is a global transcriptional coactivator of human Leukocyte antigen-D (HLA-D) genes. CIITA contains motifs similar to guanosine triphosphate (CTP)-binding proteins. This report shows that CIITA binds GTP, and mutations in these motifs decrease its GTP-binding and transactivation activity. Substitution of these motifs with analogous sequences from Ras restores CIITA function. CIITA exhibits little GTPase activity, yet mutations in CIITA that confer GTPase activity reduce transcriptional activity. GTP binding by CIITA correlates with nuclear import. Thus, unlike other GTP-binding proteins, CIITA is involved in transcriptional activation that uses GTP binding to facilitate its own nuclear import.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		Harton, Jonathan/F-2848-2010; Harton, Jonathan A/AAW-5283-2021	Harton, Jonathan/0000-0002-0350-1877; Harton, Jonathan A/0000-0002-0350-1877; Der, Channing/0000-0002-7751-2747	NIAID NIH HHS [AI41751, AI45580, AI29564] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045580, R01AI029564] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COLLART FR, 1987, MOL CELL BIOL, V7, P3328, DOI 10.1128/MCB.7.9.3328; Crespo J. A., 1963, Revista del Museo arg Cienc nat Bernadino Rivadavia (Ecol), V1, P1; CRESSMAN DE, UNPUB; DAYTON JS, 1994, J IMMUNOL, V152, P984; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Foster R, 1996, MOL CELL BIOL, V16, P2689; Gu JJ, 1997, J BIOL CHEM, V272, P4458, DOI 10.1074/jbc.272.7.4458; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; HART PA, 1990, ONCOGENE, V5, P1099; HARTON JJ, UNPUB; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MONROE JG, 1983, J IMMUNOL, V130, P626; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	48	85	87	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1402	1405		10.1126/science.285.5432.1402	http://dx.doi.org/10.1126/science.285.5432.1402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464099				2022-12-28	WOS:000082233500043
J	Norton, JA; Fraker, DL; Alexander, HR; Venzon, DJ; Doppman, JL; Serrano, J; Goebel, SU; Peghini, PL; Roy, PK; Gibril, F; Jensen, RT				Norton, JA; Fraker, DL; Alexander, HR; Venzon, DJ; Doppman, JL; Serrano, J; Goebel, SU; Peghini, PL; Roy, PK; Gibril, F; Jensen, RT			Surgery to cure the Zollinger-Ellison syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOMATOSTATIN RECEPTOR SCINTIGRAPHY; ENDOCRINE NEOPLASIA TYPE-1; DUODENAL GASTRINOMAS; SURGICAL-MANAGEMENT; PROVOCATIVE TESTS; LONG-TERM; RESECTION; LOCALIZATION; SECRETIN; EXCISION	Background and Methods The role of surgery in patients with the Zollinger-Ellison syndrome is controversial. To determine the efficacy of surgery in patients with this syndrome, we followed 151 consecutive patients who underwent laparotomy between 1981 and 1998. Of these patients, 123 had sporadic gastrinomas and 28 had multiple endocrine neoplasia type 1 with an imaged tumor of at least 3 cm in diameter. Tumor-localization studies and functional localization studies were performed routinely. All patients underwent surgery according to a similar operative protocol, and all patients who had surgery after 1986 underwent duodenotomy. Results The 151 patients underwent 180 exploratory operations. The mean (+/-SD) follow-up after the first operation was 8+/-4 years. Gastrinomas were found in 140 of the patients (93 percent), including all of the last 81 patients to undergo surgery. The tumors were located in the duodenum in 74 patients (49 percent) and in the pancreas in 36 patients (24 percent); however, primary tumors were found in lymph nodes in 17 patients (11 percent) and in another location in 13 patients (9 percent). The primary location was unknown in 24 patients (16 percent). Among the patients with sporadic gastrinomas, 34 percent were free of disease at 10 years, as compared with none of the patients with multiple endocrine neoplasia type 1. The overall 10-year survival rate was 94 percent. Conclusions All patients with the Zollinger-Ellison syndrome who do not have multiple endocrine neoplasia type 1 or metastatic disease should be offered surgical exploration for possible cure. (N Engl J Med 1999;341:635-44.) (C) 1999, Massachusetts Medical Society.	NIDDK, NIH, Digest Dis Branch, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA; NCI, Surg Metab Sect, Surg Branch, Bethesda, MD 20892 USA; NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA; NIH, Dept Diagnost Radiol, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Jensen, RT (corresponding author), NIDDK, NIH, Digest Dis Branch, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.		Venzon, David J/B-3078-2008	Roy, Praveen/0000-0002-2033-7087	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053200, Z01DK053200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander HR, 1998, ANN SURG, V228, P228, DOI 10.1097/00000658-199808000-00013; BENYA RV, 1994, AM J MED, V97, P436, DOI 10.1016/0002-9343(94)90323-9; Cadiot G, 1999, GASTROENTEROLOGY, V116, P286, DOI 10.1016/S0016-5085(99)70124-1; DEVENEY CW, 1983, ANN SURG, V198, P546, DOI 10.1097/00000658-198310000-00015; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FISHBEYN VA, 1993, ANN INTERN MED, V119, P199, DOI 10.7326/0003-4819-119-3-199308010-00004; Fraker Douglas L., 1997, P1678; FRUCHT H, 1989, ANN INTERN MED, V111, P713, DOI 10.7326/0003-4819-111-9-713; Gibril F, 1997, GASTROENTEROLOGY, V112, P567, DOI 10.1053/gast.1997.v112.pm9024311; Gibril F, 1996, ANN INTERN MED, V125, P26, DOI 10.7326/0003-4819-125-1-199607010-00005; HIRSCHOWITZ BI, 1995, FRONTIERS GASTROINTE, V523, P360; HOWARD TJ, 1990, ANN SURG, V211, P9, DOI 10.1097/00000658-199001000-00002; Jaskowiak NT, 1996, SURGERY, V120, P1055, DOI 10.1016/S0039-6060(96)80055-9; Jensen Robert T., 1993, P931; Jensen RT, 1998, J INTERN MED, V243, P477; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MACFARLANE MP, 1995, SURGERY, V118, P973, DOI 10.1016/S0039-6060(05)80102-3; MALAGELADA JR, 1983, GASTROENTEROLOGY, V84, P1524; MATON PN, 1989, GASTROENTEROLOGY, V97, P468, DOI 10.1016/0016-5085(89)90085-1; MCCARTHY DM, 1980, NEW ENGL J MED, V302, P1344, DOI 10.1056/NEJM198006123022404; METZ DC, 1993, WORLD J SURG, V17, P468, DOI 10.1007/BF01655106; METZ DC, 1995, FRONT GASTROINT RES, V23, P240; MIGNON M, 1995, FRONT GASTROINT RES, V23, P223; NORTON JA, 1986, ANN SURG, V204, P468, DOI 10.1097/00000658-198610000-00015; NORTON JA, 1992, ANN SURG, V215, P8, DOI 10.1097/00000658-199201000-00012; Ohrvall U, 1997, CANCER, V80, P2490; ORBUCH M, 1995, FRONT GASTROINT RES, V23, P268; PERRIER ND, 1995, SURGERY, V118, P957, DOI 10.1016/S0039-6060(05)80100-X; PISEGNA JR, 1992, GASTROENTEROLOGY, V102, P767, DOI 10.1016/0016-5085(92)90157-T; Proye C, 1998, WORLD J SURG, V22, P643, DOI 10.1007/s002689900447; STABILE BE, 1985, AM J SURG, V149, P144, DOI 10.1016/S0002-9610(85)80024-6; STADIL F, 1995, FRONT GASTROINT RES, V23, P333; STRADER DB, 1995, FRONT GASTROINT RES, V23, P282; SUGG SL, 1993, ANN SURG, V218, P138, DOI 10.1097/00000658-199308000-00004; THOM AK, 1992, SURGERY, V112, P1002; Thompson NW, 1998, J INTERN MED, V243, P495; THOMPSON NW, 1993, WORLD J SURG, V17, P455, DOI 10.1007/BF01655104; WEBER HC, 1995, GASTROENTEROLOGY, V108, P1637, DOI 10.1016/0016-5085(95)90124-8; Wu PC, 1997, SURGERY, V122, P1176, DOI 10.1016/S0039-6060(97)90224-5; Yu F, 1999, J CLIN ONCOL, V17, P615, DOI 10.1200/JCO.1999.17.2.615	40	330	342	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					635	644		10.1056/NEJM199908263410902	http://dx.doi.org/10.1056/NEJM199908263410902			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460814				2022-12-28	WOS:000082192500002
J	Davies, M				Davies, M			New diagnostic criteria for diabetes - are they doing what they should?	LANCET			English	Editorial Material							RISK-FACTORS; POPULATION; GLUCOSE; ASSOCIATION; DISEASE		Leicester Royal Infirm, Dept Endocrinol & Diabet, Leicester LE1 5WW, Leics, England	University of Leicester	Davies, M (corresponding author), Leicester Royal Infirm, Dept Endocrinol & Diabet, Leicester LE1 5WW, Leics, England.			Davies, Melanie/0000-0002-9987-9371				Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Gavin JR, 1997, DIABETES CARE, V20, P1183; Hanefeld M, 1996, DIABETOLOGIA, V39, P1577, DOI 10.1007/s001250050617; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; JANGHORBANI M, 1994, J CLIN EPIDEMIOL, V47, P379; JARRETT RJ, 1979, DIABETOLOGIA, V16, P25, DOI 10.1007/BF00423146; Ramachandran A, 1998, DIABETES CARE, V21, P666, DOI 10.2337/diacare.21.4.666; Shaw JE, 1998, DIABETES, V47, pA150; Wahl PW, 1998, LANCET, V352, P1012, DOI 10.1016/S0140-6736(98)04055-0; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; *WHO STUD GROUP, 1985, WHO TECHN REP SER, V727	12	28	33	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					610	611		10.1016/S0140-6736(99)90129-0	http://dx.doi.org/10.1016/S0140-6736(99)90129-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466655				2022-12-28	WOS:000082214500002
J	Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF				Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF			Population based study of social and productive activities as predictors of survival among elderly Americans	BRITISH MEDICAL JOURNAL			English	Article							TIME PHYSICAL-ACTIVITY; ALL-CAUSE MORTALITY; MIDDLE-AGED MEN; CARDIOVASCULAR-DISEASE; PLASMA-FIBRINOGEN; COLLEGE ALUMNI; OLDER ADULTS; RISK-FACTORS; HEALTH; DETERMINANTS	Objectives To examine any association between social, productive, and physical activity and 13 year survival in older people. Design Prospective cohort study with annual mortality follow up. Activity and other measures were assessed by structured interviews at baseline in the participants' homes. Proportional hazards models were used to model survival from time of initial interview. Setting City of New Haven, Connecticut, United States. Participants 2761 men and women from a random population sample of 2812 people aged 65 and older. Main outcome measure Mortality from all causes during 13 years of follow up. Results All three types of activity were independently associated with survival after age, sex, race/ethnicity, marital status, income, body mass index; smoking functional disability and history of cancer, diabetes, stroke, and myocardial infarction were controlled for. Conclusions Social and productive activities that involve little or no enhancement, of fitness lower the risk of all cause mortality as much as fitness activities do. This suggests that in addition to increased cardiopulmonary fitness, activity may confer survival benefits through psychosocial pathways. Social and productive activities that require less physical exertion may complement exercise programmes and may constitute alternative interventions for frail elderly people.	Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Rush Presbyterian St Lukes Med Ctr, Rush Inst Healthy Aging, Chicago, IL 60612 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06504 USA	Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Yale University	Glass, TA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA.			Glass, Thomas/0000-0003-4399-612X	NIA NIH HHS [N01-AG-02105, R01-AG-11042, R29-AG-10170] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG010170, N01AG002105, R01AG011042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADELMANN PK, 1994, J GERONTOL, V49, pS277, DOI 10.1093/geronj/49.6.S277; BERKMAN L, 1979, AM J EPIDEMIOL, V2, P186; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; Bygren LO, 1996, BRIT MED J, V313, P1577, DOI 10.1136/bmj.313.7072.1577; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; GOLDBERG L, 1985, MED CLIN N AM, V69, P41; HELMERT U, 1994, INT J EPIDEMIOL, V23, P285, DOI 10.1093/ije/23.2.285; HERBERT TB, 1994, PSYCHOSOM MED, V56, P337, DOI 10.1097/00006842-199407000-00009; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; KANNEL WB, 1986, AM HEART J, V112, P820, DOI 10.1016/0002-8703(86)90480-1; Kaplan GA, 1996, AM J EPIDEMIOL, V144, P793, DOI 10.1093/oxfordjournals.aje.a009003; KAPLAN GA, 1988, AM J EPIDEMIOL, V128, P370, DOI 10.1093/oxfordjournals.aje.a114977; LaVange L M, 1996, Stat Methods Med Res, V5, P311, DOI 10.1177/096228029600500306; Mendes de Leon CF, 1996, J GERONTOL PSYCHOL S, V51, P183; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; ORTHGOMER K, 1993, PSYCHOSOM MED, V55, P37, DOI 10.1097/00006842-199301000-00007; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PHILLIPS DP, 1988, LANCET, V2, P728; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; ROSENGREN A, 1993, BRIT MED J, V306, P243, DOI 10.1136/bmj.306.6872.243; Rowe JW, 1997, SCIENCE, V278, P367, DOI 10.1126/science.278.5337.367; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WELIN L, 1992, J EPIDEMIOL COMMUN H, V46, P127, DOI 10.1136/jech.46.2.127; YAMANOUCHI K, 1992, J APPL PHYSIOL, V73, P2241, DOI 10.1152/jappl.1992.73.6.2241; YATES EF, 1988, EMERGENT THEORIES AG, P90; ZIMMER Z, 1995, GERONTOLOGIST, V35, P463, DOI 10.1093/geront/35.4.463	33	560	567	1	38	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					478	483		10.1136/bmj.319.7208.478	http://dx.doi.org/10.1136/bmj.319.7208.478			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454399	Green Published, Bronze			2022-12-28	WOS:000082199600018
J	Greengold, NL				Greengold, NL			On the road	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Zynx Hlth Inc, Beverly Hills, CA 90212 USA		Greengold, NL (corresponding author), Zynx Hlth Inc, 9100 Wilshire Blvd,Suite 655, Beverly Hills, CA 90212 USA.	Greengold@Zynx.com							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					307	308		10.7326/0003-4819-131-4-199908170-00011	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454952				2022-12-28	WOS:000082012500008
J	Brennan, TA				Brennan, TA			Proposed revisions to the Declaration of Helsinki - Will they weaken the ethical principles underlying human research?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSMISSION PREVENTION TRIALS; DEVELOPING-COUNTRIES; AFRICA		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; Bayer R, 1998, AM J PUBLIC HEALTH, V88, P567, DOI 10.2105/AJPH.88.4.567; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; BRENNAN TA, 1991, JUST DOCTORING MED E; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Council for International Organizations of Medical Sciences, 1991, INT GUID ETH REV EP; de Zoysa I, 1998, AM J PUBLIC HEALTH, V88, P571, DOI 10.2105/AJPH.88.4.571; Glantz LH, 1998, HASTINGS CENT REP, V28, P38, DOI 10.2307/3528268; KAHN J, 1999, LANCET           MAY; Katz J, 1972, EXPT HUMAN BEINGS AU; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; *NAT COMM PROT HUM, 1983, BELM REP ETH PRINC G; ROTHMAN DJ, 1982, HASTINGS CENT REP, V12, P5, DOI 10.2307/3561798; Stolberg Sheryl Gay, 1998, N Y Times Web, pA21; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Wilfert CM, 1999, LANCET, V353, P832, DOI 10.1016/S0140-6736(98)10414-2; Wilkinson D, 1999, BRIT MED J, V318, P479, DOI 10.1136/bmj.318.7182.479	18	84	89	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					527	531		10.1056/NEJM199908123410712	http://dx.doi.org/10.1056/NEJM199908123410712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441612				2022-12-28	WOS:000081962600012
J	Koff, RS				Koff, RS			Advances in the treatment of chronic viral hepatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERFERON; COMBINATION; RIBAVIRIN		MetroWest Med Ctr, Dept Med, Framingham, MA 01702 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Koff, RS (corresponding author), MetroWest Med Ctr, Dept Med, 115 Lincoln St, Framingham, MA 01702 USA.							Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Malaguarnera M, 1996, PHARMACOTHERAPY, V16, P609; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; Wong JB, 1998, JAMA-J AM MED ASSOC, V280, P2088, DOI 10.1001/jama.280.24.2088	12	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					511	512		10.1001/jama.282.6.511	http://dx.doi.org/10.1001/jama.282.6.511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450697				2022-12-28	WOS:000081919100001
J	Chappuis, PO; Narod, SA; Foulkes, WD				Chappuis, PO; Narod, SA; Foulkes, WD			Screening for ovarian cancer	LANCET			English	Letter									McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet & Oncol, Montreal, PQ H3G 1A4, Canada; Univ Toronto, Ctr Res Womens Hlth, Toronto, ON, Canada	McGill University; McGill University; University of Toronto	Chappuis, PO (corresponding author), McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada.		Narod, Steven A/AAA-6112-2022; Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Eisen A, 1998, J NATL CANCER I, V90, P797, DOI 10.1093/jnci/90.11.797; Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					509	510		10.1016/S0140-6736(05)75539-2	http://dx.doi.org/10.1016/S0140-6736(05)75539-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465194				2022-12-28	WOS:000081896100046
J	Kornberg, RD; Lorch, YL				Kornberg, RD; Lorch, YL			Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome	CELL			English	Review							RNA-POLYMERASE-II; CHROMATIN STRUCTURE; HISTONE ACETYLATION; REMODELING FACTOR; TRANSCRIPTIONAL ACTIVATION; REPEATING UNIT; CORE PARTICLE; YEAST GCN5P; DNASE-I; COMPLEX		Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu						Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BRAM S, 1971, J MOL BIOL, V55, P325; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DANNA JA, 1974, BIOCHEMISTRY-US, V13, P4987, DOI 10.1021/bi00721a018; DELANGE RJ, 1969, J BIOL CHEM, V244, P5669; EDWARDS PA, 1969, BIOCHEM J, V114, P227, DOI 10.1042/bj1140227; FINCH JT, 1977, NATURE, V269, P29, DOI 10.1038/269029a0; FINCH JT, 1975, P NATL ACAD SCI USA, V72, P3320, DOI 10.1073/pnas.72.9.3320; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HUBERMAN JA, 1973, ANNU REV BIOCHEM, V42, P355, DOI 10.1146/annurev.bi.42.070173.002035; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KELLEY RI, 1973, BIOCHEM BIOPH RES CO, V54, P1588, DOI 10.1016/0006-291X(73)91168-6; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Kossel A, 1884, Z PHYSL CHEM, P511; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; LU Q, 1995, EMBO J, V14, P4738, DOI 10.1002/j.1460-2075.1995.tb00155.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OLINS AL, 1974, SCIENCE, V183, P330, DOI 10.1126/science.183.4122.330; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PHILLIPS DM, 1965, BIOCHEM J, V94, P127, DOI 10.1042/bj0940127; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; Prunell A, 1998, BIOPHYS J, V74, P2531, DOI 10.1016/S0006-3495(98)77961-5; PRUNELL A, 1978, PHILOS T ROY SOC B, V283, P269, DOI 10.1098/rstb.1978.0023; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; ROARK DE, 1974, BIOCHEM BIOPH RES CO, V59, P542, DOI 10.1016/S0006-291X(74)80014-8; SAHASRABUDDHE CG, 1974, J BIOL CHEM, V249, P152; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SPADAFORA C, 1976, FEBS LETT, V69, P281, DOI 10.1016/0014-5793(76)80704-1; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6; VANHOLDE KE, 1975, 10TH P FEBS M, P57; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; VARSHAVSKY AJ, 1979, CELL, V16, P453, DOI 10.1016/0092-8674(79)90021-7; WILLIAMSON R, 1970, J MOL BIOL, V51, P157, DOI 10.1016/0022-2836(70)90277-9; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; WOODCOCK CLF, 1976, CHROMOSOMA, V58, P33, DOI 10.1007/BF00293438; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89	102	1305	1356	3	133	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					285	294		10.1016/S0092-8674(00)81958-3	http://dx.doi.org/10.1016/S0092-8674(00)81958-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458604	Bronze			2022-12-28	WOS:000081950300004
J	Ing, AJ; Ngu, MC				Ing, AJ; Ngu, MC			Cough and gastro-oesophageal reflux	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; DIAGNOSTIC EVALUATION; KEY COMPONENTS; THERAPY; FREQUENCY; SPECTRUM		Concord Hosp, Dept Thorac Med, Concord, NSW, Australia; Concord Hosp, Dept Gastroenterol, Concord, NSW, Australia	Concord Repatriation General Hospital; Concord Repatriation General Hospital	Ing, AJ (corresponding author), Concord Hosp, Dept Thorac Med, Concord, NSW, Australia.			Ing, Alvin/0000-0002-6391-020X				Allen CJ, 1998, THORAX, V53, P963, DOI 10.1136/thx.53.11.963; *AM COLL CHEST PHY, 1998, CHEST, V114, pS133; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; GIUDICELLI R, 1990, ANN CHIR, V47, P552; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; ING A J, 1992, American Review of Respiratory Disease, V145, pA11; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294, DOI 10.1164/ajrccm/140.5.1294; MEIER JH, 1994, DIGEST DIS SCI, V39, P2127, DOI 10.1007/BF02090360; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; WARING JP, 1995, DIGEST DIS SCI, V40, P1093	13	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					944	946		10.1016/S0140-6736(98)00354-7	http://dx.doi.org/10.1016/S0140-6736(98)00354-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459900				2022-12-28	WOS:000079421600006
J	Lau, WY; Leung, TWT; Ho, SKW; Chan, M; Machin, D; Lau, J; Chan, ATC; Yeo, W; Mok, TSK; Yu, SCH; Leung, NWY; Johnson, PJ				Lau, WY; Leung, TWT; Ho, SKW; Chan, M; Machin, D; Lau, J; Chan, ATC; Yeo, W; Mok, TSK; Yu, SCH; Leung, NWY; Johnson, PJ			Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial	LANCET			English	Article							MULTIVARIATE-ANALYSIS; CURATIVE RESECTION; IODIZED OIL; RECURRENCE; PROGNOSIS; INJECTION; THERAPY	Background Resection of hepatocellular carcinoma is potentially curative, but local recurrence is common. In this prospective randomised trial, we aimed to find out if one dose of postoperative adjuvant intra-arterial iodine-131-labelled lipiodol could reduce the rate of local recurrence and increase disease-free and overall survival. Methods Patients who underwent curative resection for hepatocellular carcinoma and recovered within 6 weeks were randomly assigned one 1850 MBq dose of I-131-lipiodol or no further treatment (controls). We compared rates of recurrence and disease-free and overall survival (the primary endpoints) between the two groups by intention to treat. We planned an interim analysis when 30 patients (both groups together) had been followed up for a median of 2 years, with the intention of stopping early if the between-group difference in disease-free survival was significant (p=0.029). Findings Between April, 1992, and August, 1997, we recruited 43 patients: 21 received intra-arterial I-131-lipiodol and 22 received no adjuvant treatment. During a median follow-up of 34.6 (range 14.1-69.7) months, there were six (28.5%) recurrences among the 21 patients in the adjuvant treatment, compared with 13 (59%) in the controls (p=0.04). Median disease-free survival in the treatment and control groups was 57.2 (0.4-69.7) and 13.6 (2.1-68.3) months, respectively (p=0.037). 30-year overall survival in the treatment and control groups was 86.4% and 46.3%, respectively, (p=0.039). The interim analysis showed a significant increase in disease-free survival in the treatment group compared with the controls (p=0.01), so we closed the trial early. I-131-lipiodol had no significant toxic effects. respectively a significant toxic effects. Interpretation In patients with hepatocellular carcinoma, one 1850 MBq dose of intra-arterial I-131-lipiodol given after curative resection significantly decreases the rate of recurrence and increases disease-free and overall survival.	Chinese Univ Hong Kong, Dept Surg, Hong Kong SAR, Peoples R China; Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong SAR, Peoples R China; Chinese Univ Hong Kong, Dept Diagnost Radiol & Organ Imaging, Hong Kong SAR, Peoples R China; Chinese Univ Hong Kong, Dept Med, Hong Kong SAR, Peoples R China; Chinese Univ Hong Kong, Ctr Clin Trials & Epidemiol Res, Hong Kong SAR, Peoples R China; Natl Med Res Council, Clin Trials & Epidemiol Res Unit, Singapore, Singapore	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Leung, TWT (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong SAR, Peoples R China.	waitongleung@cuhk.edu.hk	Yu, Simon Chun Ho/D-1046-2011; Mok, Tony Shu Kam/B-2310-2019; Chan, Anthony Tak Cheung/R-3940-2018; Yeo, Winnie/R-4792-2018	Yu, Simon Chun Ho/0000-0002-8715-5026; Mok, Tony Shu Kam/0000-0002-8251-0551; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Yeo, Winnie/0000-0002-0863-8469				BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; IKEDA K, 1993, CANCER, V71, P19, DOI 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I; IZUMI R, 1994, HEPATOLOGY, V20, P295, DOI 10.1002/hep.1840200205; LAI EC, 1993, ARCH SURG-CHICAGO, V133, P183; LEE NW, 1982, WORLD J SURG, V6, P66, DOI 10.1007/BF01656375; LEUNG NWY, 1992, CANCER, V70, P40, DOI 10.1002/1097-0142(19920701)70:1<40::AID-CNCR2820700107>3.0.CO;2-P; Leung W.T., 1997, P AN M AM SOC CLIN, V16, P988; LEUNG WT, 1994, J NUCL MED, V35, P1313; MADSEN MT, 1988, J NUCL MED, V29, P1038; Maini CL, 1996, CLIN NUCL MED, V21, P221, DOI 10.1097/00003072-199603000-00008; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAGAO T, 1990, ANN SURG, V211, P28, DOI 10.1097/00000658-199001000-00005; NG IOL, 1995, CANCER, V76, P2443, DOI 10.1002/1097-0142(19951215)76:12<2443::AID-CNCR2820761207>3.0.CO;2-F; OKAYASU I, 1988, AM J CLIN PATHOL, V90, P536, DOI 10.1093/ajcp/90.5.536; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Raoul JL, 1997, HEPATOLOGY, V26, P1156; TAKENAKA K, 1995, AM J SURG, V169, P400, DOI 10.1016/S0002-9610(99)80184-6; Yamamoto M, 1996, BRIT J SURG, V83, P336, DOI 10.1002/bjs.1800830313; YAMANAKA N, 1990, CANCER, V65, P1104, DOI 10.1002/1097-0142(19900301)65:5<1104::AID-CNCR2820650511>3.0.CO;2-G; YOO HS, 1994, CANCER CHEMOTH PHARM, V33, pS128, DOI 10.1007/BF00686684	21	329	346	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					797	801		10.1016/S0140-6736(98)06475-7	http://dx.doi.org/10.1016/S0140-6736(98)06475-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459961				2022-12-28	WOS:000079089100011
J	Ausejo, M; Saenz, A; Ba'Pham; Kellner, JD; Johnson, DW; Moher, D; Klassen, TP				Ausejo, M; Saenz, A; Ba'Pham; Kellner, JD; Johnson, DW; Moher, D; Klassen, TP			The effectiveness of glucocorticoids in treating croup: meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIALS; STEROID TREATMENT; CLINICAL-TRIALS; QUALITY; BIAS	Objective To determine the effectiveness of glucocorticoid treatment in children with croup. Design Meta-analysis of randomised controlled trials that examine the effectiveness of glucocorticoid treatment in children with croup. Main outcome measures Score on scale measuring severity of croup, use of cointerventions (adrenaline (epinephrine), antibiotics, or supplemental glucocorticoids), length of stay in accident and emergency or in hospital, and rate of hospitalisation. Results Twenty four studies met the inclusion criteria. Glucocorticoid treatment was associated with an improvement in the croup severity score at 6 hours with an effect size of -1.0 (95% confidence interval -1.5 to -0.6) and at 12 hours -1.0 (-1.6 to -0.4); at 24 hours this improvement was no longer significant (-1.0, - 2.0 to 0.1). There was a decrease in the number of adrenaline treatments needed in children treated with glucocorticoids: a decrease of 9% (95% confidence interval 2% to 16%) among those treated with budesonide and of 12% (4% to 20%) among those treated with dexamethasone. There was also a decrease in the length of time spent in accident and emergency (-11 hours, 95% confidence interval -18 to 4 hours), and for inpatients hospital stay was reduced by 16 hours (-31 to 1 hour). Publication bias seems to play a part in these results. Conclusions Dexamethasone and budesonide are effective in relieving the symptoms of croup as early as 6 hours after treatment Fewer cointerventions are used and the length of time spent in hospital is decreased in patients treated with glucocorticoids.	Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON K1H 8L1, Canada; Univ Calgary, Alberta Childrens Hosp, Dept Pediat, Calgary, AB T2T 5C7, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; Alberta Childrens Hospital; University of Calgary	Klassen, TP (corresponding author), Univ Alberta, Dept Pediat, Walter C Mackenzie Hlth Sci Ctr 2C3 67, Edmonton, AB T6G 2R7, Canada.		; Kellner, James Duncan/D-6358-2011	Moher, David/0000-0003-2434-4206; Kellner, James Duncan/0000-0002-9083-2980				BARTKO JJ, 1994, STAT MED, V13, P737, DOI 10.1002/sim.4780130534; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; DENNY FW, 1983, PEDIATRICS, V71, P871; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Geelhoed GC, 1996, ANN EMERG MED, V28, P621, DOI 10.1016/S0196-0644(96)70084-7; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; Hedges LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364; Hedges LV, 1995, STAT METHODS METAANA; HENRICKSON KJ, 1994, CLIN INFECT DIS, V18, P770, DOI 10.1093/clinids/18.5.770; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KAIRYS SW, 1989, PEDIATRICS, V83, P683; Klassen T, 1995, ARCH PEDIAT ADOLESC, V149, P60; Klassen TP, 1998, CAN MED ASSOC J, V159, P1121; LIGHT RJ, 1984, SUMMING UP SCI REV R; MARTENSSON B, 1960, Acta Otolaryngol Suppl, V158, P62; Marx A, 1997, J INFECT DIS, V176, P1423, DOI 10.1086/514137; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; NOVIK A, 1960, Acta Otolaryngol Suppl, V158, P20; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SKOLNIK NS, 1989, AM J DIS CHILD, V143, P1045, DOI 10.1001/archpedi.1989.02150210079022; SUSSMAN S, 1964, PEDIATRICS, V34, P851; Taylor S., 1998, TRIM FILL SIMPLE FUN; TO T, 1994, CLIN INVEST MED, V17, pA25; WAIISMAN Y, 1992, PEDIATRICS, V89, P302; WESTLEY CR, 1978, AM J DIS CHILD, V132, P484, DOI 10.1001/archpedi.1978.02120300044008	28	61	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					595	600		10.1136/bmj.319.7210.595	http://dx.doi.org/10.1136/bmj.319.7210.595			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473471	Bronze, Green Published			2022-12-28	WOS:000082460300013
J	van Harten, PN; Hoek, HW; Kahn, RS				van Harten, PN; Hoek, HW; Kahn, RS			Fortnightly review - Acute dystonia induced by drug treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEUROLEPTIC-INDUCED DYSTONIA; CURACAO EXTRAPYRAMIDAL SYNDROMES; ANTICHOLINERGIC PROPHYLAXIS; TARDIVE-DYSKINESIA; SCHIZOPHRENIA; AKATHISIA; SYMPTOMS; COCAINE; MANIA; RISK		Psychiat Ctr Zon & Schild, Psychiat Residency Programme, NL-3800 DB Amersfoort, Netherlands; Parnassia Leiden Univ, NL-2555 VZ The Hague, Netherlands; Univ Utrecht Hosp, Dept Psychiat, NL-3584 CX Utrecht, Netherlands	Leiden University; Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center	van Harten, PN (corresponding author), Psychiat Ctr Zon & Schild, Psychiat Residency Programme, Utrechtseweg 266, NL-3800 DB Amersfoort, Netherlands.	zonenschild.a-opl@wxs.nl		Hoek, Hans/0000-0001-6353-5465				ADDONIZIO G, 1988, AM J PSYCHIAT, V145, P869; AGUILAR EJ, 1994, AM J PSYCHIAT, V151, P1819; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ARANA GW, 1988, AM J PSYCHIAT, V145, P993; Arnt J, 1998, NEUROPSYCHOPHARMACOL, V18, P63, DOI 10.1016/S0893-133X(97)00112-7; AYD FJ, 1961, JAMA-J AM MED ASSOC, V175, P1054, DOI 10.1001/jama.1961.03040120016004; BATEMAN DN, 1985, BRIT MED J, V291, P930, DOI 10.1136/bmj.291.6500.930; Benjamin S, 1992, MOVEMENT DISORDERS N, P111; BINDER RL, 1981, AM J PSYCHIAT, V138, P1243; CARDOSO FEC, 1993, MOVEMENT DISORD, V8, P175, DOI 10.1002/mds.870080210; CASEY DE, 1994, DSM 4 SOURCE BOOK, V1, P545; CASEY DE, 1992, DRUG INDUCED MOVEMEN, P21; Gill HS, 1997, J CLIN PSYCHOPHARM, V17, P377, DOI 10.1097/00004714-199710000-00007; Gjerden Pal, 1998, Tidsskrift for den Norske Laegeforening, V118, P53; Heath HW, 1997, CLIN PEDIATR, V36, P57, DOI 10.1177/000992289703600109; HORIGUCHI J, 1989, ACTA PSYCHIAT SCAND, V80, P521, DOI 10.1111/j.1600-0447.1989.tb03016.x; JOHNSON DAW, 1973, BRIT J PSYCHIAT, V123, P519, DOI 10.1192/bjp.123.5.519; KEEPERS GA, 1991, AM J PSYCHIAT, V148, P85; KEEPERS GA, 1983, ARCH GEN PSYCHIAT, V40, P1113; KEEPERS GA, 1987, J CLIN PSYCHOPHARM, V7, P342; KHANNA R, 1992, AM J PSYCHIAT, V149, P511; LANG AE, 1995, CAN J NEUROL SCI, V22, P136, DOI 10.1017/S031716710004021X; Lang AE, 1992, DRUG INDUCED MOVEMEN, P339; LopezAlemany M, 1997, J NEUROL, V244, P131, DOI 10.1007/s004150050062; Mazurek MF, 1996, AM J PSYCHIAT, V153, P708; NASRALLAH HA, 1988, AM J PSYCHIAT, V145, P1455; PRIORI A, 1995, MOVEMENT DISORD, V10, P353, DOI 10.1002/mds.870100323; RUPNIAK NMJ, 1986, PSYCHOPHARMACOLOGY, V88, P403; Sproule BA, 1997, CLIN PHARMACOKINET, V33, P454, DOI 10.2165/00003088-199733060-00004; Van Harten P. N., 1996, Schizophrenia Research, V19, P195; van Harten PN, 1998, AM J PSYCHIAT, V155, P565, DOI 10.1176/ajp.155.4.565; van Harten PN, 1998, J CLIN PSYCHIAT, V59, P128, DOI 10.4088/JCP.v59n0307; Volkow ND, 1998, AM J PSYCHIAT, V155, P344; Zemishlany Z, 1996, INT CLIN PSYCHOPHARM, V11, P199, DOI 10.1097/00004850-199609000-00007	34	126	130	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	1999	319	7210					623	626		10.1136/bmj.319.7210.623	http://dx.doi.org/10.1136/bmj.319.7210.623			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473482	Green Published			2022-12-28	WOS:000082460300026
J	Jana, N; Vasishta, K; Saha, SC; Ghosh, K				Jana, N; Vasishta, K; Saha, SC; Ghosh, K			Obstetrical outcomes among women with extrapulmonary tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY TUBERCULOSIS; PREGNANCY	Background The prevalence of tuberculosis, especially extrapulmonary tuberculosis, is increasing worldwide. Because information on the outcome of pregnancy among women with extrapulmonary tuberculosis is limited, we studied the course of pregnancy and labor and the perinatal outcome in these women and their infants. Methods From 1983 to 1993, we followed 33 pregnant women who had extrapulmonary tuberculosis (12 with tuberculous lymphadenitis and 9 with intestinal, 7 with skeletal, 2 with renal, 2 with meningeal, and 1 with endometrial tuberculosis) through their deliveries. Of the 33, 29 received antituberculosis treatment during pregnancy. The antenatal complications, intrapartum events, and perinatal outcomes were compared with those among 132 healthy pregnant women without tuberculosis who were matched for age, parity, and socioeconomic status. Results Tuberculous lymphadenitis did not affect the course of pregnancy or labor or the perinatal outcome. However, as compared with the control women, the 21 women with tubercular involvement of other extrapulmonary sites had higher rates of antenatal hospitalization (24 percent vs. 2 percent, P< 0.001), infants with low Apgar scores (less than or equal to 6) soon after birth (19 percent vs. 3 percent, P=0.01), and low-birth-weight (<2500 g) infants (33 percent vs. 11 percent, P=0.01). Conclusions Extrapulmonary tuberculosis that is confined to the lymph nodes has no effect on obstetrical outcomes, but tuberculosis at other extrapulmonary sites does adversely affect the outcome of pregnancy. (N Engl J Med 1999;341:645-9.) (C) 1999, Massachusetts Medical Society.	Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India; Mem Hosp, Dept Obstet & Gynaecol, Darlington, Durham, England; W Middlesex Univ Hosp, Dept Obstet & Gynaecol, Isleworth, Middx, England	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Imperial College London	Vasishta, K (corresponding author), Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India.		JANA, NARAYAN/AAE-5437-2020					BROOKS JH, 1986, BRIT J OBSTET GYNAEC, V93, P1009, DOI 10.1111/j.1471-0528.1986.tb08027.x; CASPER GR, 1995, AUST NZ J OBSTET GYN, V35, P398, DOI 10.1111/j.1479-828X.1995.tb02151.x; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P1083; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DAVIES PDO, 1993, THORAX, V48, P193, DOI 10.1136/thx.48.3.193; DWYER DE, 1987, AUST NZ J MED, V17, P507, DOI 10.1111/j.1445-5994.1987.tb00110.x; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GOVENDER S, 1989, S AFR MED J, V75, P190; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; KINGDOM JCP, 1989, BRIT J OBSTET GYNAEC, V96, P233, DOI 10.1111/j.1471-0528.1989.tb01668.x; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LAU SK, 1991, J LARYNGOL OTOL, V105, P558, DOI 10.1017/S0022215100116603; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1954, AM J OBSTET GYNECOL, V67, P605, DOI 10.1016/0002-9378(54)90050-2; SIMPSON ML, 1989, ORTHOPAEDIC INFECT D, P205; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TULI SM, 1991, TUBERCULOSIS SKELETA, P162; VARMA TR, 1991, INT J GYNECOL OBSTET, V35, P1, DOI 10.1016/0020-7292(91)90056-B; *WHO, 1993, TREATM TUB GUID NAT, P3; 1985, INDIAN J TUBERC, V32, P115	22	76	80	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					645	649		10.1056/NEJM199908263410903	http://dx.doi.org/10.1056/NEJM199908263410903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460815	Bronze			2022-12-28	WOS:000082192500003
J	Schachter, J; West, SK; Mabey, D; Dawson, CR; Bobo, L; Bailey, R; Vitale, S; Quinn, TC; Sheta, A; Sallam, S; Mkocha, H; Mabey, D; Faal, H				Schachter, J; West, SK; Mabey, D; Dawson, CR; Bobo, L; Bailey, R; Vitale, S; Quinn, TC; Sheta, A; Sallam, S; Mkocha, H; Mabey, D; Faal, H			Azithromycin in control of trachoma	LANCET			English	Article							SINGLE-DOSE AZITHROMYCIN; CONTROLLED TRIAL; CHAIN-REACTION; INFECTION; TANZANIA; CHILDREN	Background Trachoma is the leading cause of preventable blindness. Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline. We assessed the potential of community-wide azithromycin treatment for trachoma control. Methods Pairs of villages in trachoma endemic areas of Egypt, The Gambia, and Tanzania were matched on trachoma rates in 1-10-year-old children. Villages were randomly assigned community-wide oral azithromycin treatment (three doses with intervals of 1 week) or treatment with 1% topical tetracycline (once daily for 6 weeks). Clinical examinations were done at baseline, 2-4.5 months, and 12-14 months after treatment. Chlamydia trachomatitis was identified by ligase chain reaction (LCR). Analyses were by intention to treat. Univariate comparisons and multivariate analyses were used to compare outcomes. Findings LCR positivity was correlated with clinical severity, but about 30% of Egyptian and Gambian villagers with no active disease were LCR positive. Village-wide LCR positivity ranged from 16.5% (Tanzania) to 43.6% (Egypt). Treatment compliance was over 90% except in the tetracycline treatment village in Egypt. Of the participants initially LCR positive, 866 (95%) of 924 who received at least one azithromycin dose and 482 (82%) of 587 who received 28 days or more topical tetracycline, were negative at follow-up. At 1 year, village-wide LCR positivity rates were substantially lower than at baseline with both treatments; the decreases were greater with azithromycin than with tetracycline (93% vs 77% in Egypt, 78 vs 66% in The Gambia, 64 vs 55% in Tanzania). Similarly, greater reduction in clinical activity occurred after azithromycin. In multivariate analyses, factors associated with being LCR positive at 1 year were: not receiving azithromycin; age under 10 years; and LCR positivity at baseline. Interpretation Community-wide treatment with oral azithromycin markedly reduces C trachomatis infection and clinical trachoma in endemic areas and may be an important approach to control of trachoma.	Univ Calif San Francisco, Dept Lab Med, Chlamydia Res Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Wilmer Eye Inst, Baltimore, MD USA; Johns Hopkins Univ, Dept Paediat Infect Dis, Baltimore, MD USA; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Alexandria, Fac Med, Dept Ophthalmol, Alexandria, Egypt; Univ Alexandria, High Inst Publ Hlth, Dept Epidemiol, Alexandria, Egypt; NIAID, Bethesda, MD 20892 USA; Cent Eye Hlth Fdn, Kongwa Trachoma Project, Kongwa, Tanzania; Minist Hlth, Natl Eye Care Programme, Banjul, Gambia	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of London; London School of Hygiene & Tropical Medicine; Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Alexandria University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schachter, J (corresponding author), Univ Calif San Francisco, Dept Lab Med, Chlamydia Res Lab, Box 0842, San Francisco, CA 94143 USA.	jsch@itsa.ucsf.edu	Quinn, Thomas/A-2494-2010	Mabey, David/0000-0002-0031-8276; vitale, susan/0000-0002-5972-6848	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000358, Z01AI000358] Funding Source: NIH RePORTER; PHS HHS [P01 A135682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; DAWSON CR, 1982, B WORLD HEALTH ORGAN, V60, P347; DAWSON CR, 1985, REV INFECT DIS, V7, P768; Dawson CR, 1981, GUIDE TRACHOMA CONTR; MABEY D, 1998, CHLAMYDIAL INFECT, P351; MALATY R, 1981, J INFECT DIS, V143, P853, DOI 10.1093/infdis/143.6.853; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; SCHACHTER J, 1998, CHLAMYDIAL INFECT, P347; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; *WHO, 1996, WHOPBL9656; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	222	224	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					630	635		10.1016/S0140-6736(98)12387-5	http://dx.doi.org/10.1016/S0140-6736(98)12387-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466664				2022-12-28	WOS:000082214500011
J	Crevoisier, GB; Fabre, P; Corpart, JM; Leibler, L				Crevoisier, GB; Fabre, P; Corpart, JM; Leibler, L			Switchable tackiness and wettability of a liquid crystalline polymer	SCIENCE			English	Article							DYNAMIC CONTACT-ANGLE; MECHANICAL-PROPERTIES; ADHESION; MONOLAYERS; FILMS; TACK	The spreading velocity of liquids on the surface of a liquid crystalline polymer can be tremendously affected by a slight temperature change. indeed, a bulk transition between a highly ordered smectic and an isotropic phase induces a sharp change from a rigid to a soft behavior, with consequent effects on the tack properties of the liquid crystalline polymer and on the dewetting dynamics of a liquid on its surface.	Elf Atochem, CNRS, UMR 167, F-92303 Levallois, France; Elf Atochem, Serv Agents Interfaces, F-92303 Levallois, France	Centre National de la Recherche Scientifique (CNRS)	Crevoisier, GB (corresponding author), Elf Atochem, CNRS, UMR 167, 95 Rue Danton, F-92303 Levallois, France.							Andrieu C, 1996, J ADHESION, V58, P15, DOI 10.1080/00218469608014397; BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039; BROCHARD F, 1988, CR ACAD SCI II, V306, P1143; BROCHARDWYART F, 1987, CR ACAD SCI II, V304, P553; Carre A, 1996, NATURE, V379, P432, DOI 10.1038/379432a0; Clarke R., 1993, ADHES AGE, P39; Creton C, 1996, J POLYM SCI POL PHYS, V34, P545, DOI 10.1002/(SICI)1099-0488(199602)34:3<545::AID-POLB13>3.0.CO;2-I; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; Kasemura T, 1996, POLYMER, V37, P3659, DOI 10.1016/0032-3861(96)00177-2; Langmuir I, 1920, T FARADAY SOC, V15, P0062, DOI 10.1039/tf9201500062; Long D, 1996, LANGMUIR, V12, P5221, DOI 10.1021/la9604700; Mansky P, 1997, SCIENCE, V275, P1458, DOI 10.1126/science.275.5305.1458; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; PITTMAN AG, 1972, FLUOROPOLYMERS, V25; REDON C, 1991, PHYS REV LETT, V66, P6; ROTTINK JBH, 1993, POLYM BULL, V31, P221, DOI 10.1007/BF00329969; Shanahan MER, 1996, J ADHESION, V57, P179, DOI 10.1080/00218469608013651; SHANAHAN MER, 1995, LANGMUIR, V11, P1396, DOI 10.1021/la00004a055; SHANAHAN MER, 1988, J PHYS D APPL PHYS, V21, P981, DOI 10.1088/0022-3727/21/6/019; VANDAMME HS, 1986, J COLLOID INTERF SCI, V114, P167, DOI 10.1016/0021-9797(86)90248-1; YAMAGUCHI T, 1992, MOL CRYST LIQ CRYST, V214, P1, DOI 10.1080/10587259208037277; ZOSEL A, 1985, COLLOID POLYM SCI, V263, P541, DOI 10.1007/BF01421887	22	241	246	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1246	1249		10.1126/science.285.5431.1246	http://dx.doi.org/10.1126/science.285.5431.1246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455047	Green Submitted			2022-12-28	WOS:000082130200037
J	Gwatkin, DR; Guillot, M; Heuveline, P				Gwatkin, DR; Guillot, M; Heuveline, P			The burden of disease among the global poor	LANCET			English	Article							MORTALITY; DISABILITY; PATTERNS	Background Global and regional estimates show that noncommunicable diseases in old age are rising in importance relative to other causes of ill health as populations age, and as progress continues against communicable diseases among infants and children. However, these estimates, which cover population groups at all income levels, do not accurately reflect conditions that prevail among the poor. We estimated the burden of disease among the 20% of the global population living in countries with the lowest per capita incomes, compared with the 20% of the world's people living in the richest countries. Methods Estimates for the global poorest and richest 20% were prepared for 1990 for deaths and disability-adjusted life years (DALYs), by a procedure used in a prominent recent study of the global disease burden. Projected mortality rates in the year 2020 were established for the world's poorest and richest 20% under various assumptions about the future rate of decline in communicable and noncommunicable diseases. Findings In 1990, communicable diseases caused 59% of death and disability among the world's poorest 20%. Among the world's richest 20%, on the other hand, noncommunicable diseases caused 85% of death and disability. A raised baseline rate of communicable disease decline between 1990 and 2020 would increase life-expectancy among the world's poorest 20% around ten times as much as it would the richest 20% (4.1 vs 0.4 years). However, the poorest 20% would gain only around a quarter to a third as much as the richest 20% from a similar increase in noncommunicable diseases (1.4 vs 5.3 years). As a result, a faster decline in communicable diseases would decease the poor-rich gap in 2020, but under an accelerated rate of overall decline in noncommunicable diseases, the poor-rich gap would widen. Interpretation Our estimates are crude, but despite their limitations, they give a more accurate picture of changes in attributable mortality among the world's poor than do the global averages in current use.	World Bank, Int Hlth Policy Program, Washington, DC 20433 USA; Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USA; Univ Chicago, Chicago, IL 60637 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA	The World Bank; University of Pennsylvania; University of Chicago; University of Chicago	Gwatkin, DR (corresponding author), World Bank, Int Hlth Policy Program, 1818 H St NW, Washington, DC 20433 USA.							[Anonymous], INV HLTH RES DEV; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Bulatao RA, 1993, EPIDEMIOLOGICAL TRAN, P42; Editorial, 1997, LANCET, V349, P1263; Feachem RGA, 1992, HLTH ADULTS DEV WORL; GWATKIN DR, 1999, WORLD BANK GLOB FOR; HAKULINEN T, 1986, INT J EPIDEMIOL, V15, P226, DOI 10.1093/ije/15.2.226; HEUVELINE P, 1998, M POP ASS AM CHIC IL; Jamison D.T., 1993, DIS CONTROL PRIORITI; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Preston SH, 1976, MORTALITY PATTERNS N; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; *WOLD BANK, 1997, SECT STRAT HLTH NUTR; *WORLD BANK, 1993, WORLD DEV REP 1993 I	17	138	140	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					586	589		10.1016/S0140-6736(99)02108-X	http://dx.doi.org/10.1016/S0140-6736(99)02108-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470717				2022-12-28	WOS:000081991000047
J	Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP				Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP			Quaternary structure of the insulin-insulin receptor complex	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; BINDING; DOMAIN; IMAGES; FAMILY; SITE	The three-dimensional (3D) structure of the intrinsically dimeric insulin receptor bound to its ligand, insulin, was determined by electron cryomicroscopy. Gold-labeled insulin served to locate the insulin-binding domain. The 3D structure was then fitted with available known high-resolution domain substructures to obtain a detailed contiguous model for this heterotetrameric transmembrane receptor. The 3D reconstruction indicates that the two alpha subunits jointly participate in insulin binding and that the kinase domains in the two beta subunits are in a juxtaposition that permits autophosphorylation of tyrosine residues in the first step of insulin receptor activation.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Yip, CC (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHRISTENSEN C, 1998, J BIOL CHEM, V273, P17780; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEMEYTS P, 1993, EXP CLIN ENDOCRINOL, V101, P17; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGERTON RF, 1996, ELECT ENERGY LOSS SP, P145; FABRY M, 1992, J BIOL CHEM, V267, P8950; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; FARROW NA, 1993, ULTRAMICROSCOPY, V52, P141, DOI 10.1016/0304-3991(93)90185-Z; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GEIGER R, 1971, Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, V352, P1487, DOI 10.1515/bchm2.1971.352.2.1487; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; MURRAYRUST J, 1992, BIOESSAYS, V14, P325, DOI 10.1002/bies.950140507; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SCHAFFER L, 1993, EXP CLIN ENDOCRINOL, V101, P7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Smith GD, 1996, PROTEIN SCI, V5, P1502, DOI 10.1002/pro.5560050806; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; UILRICH A, 1990, CELL, V61, P203; WHITE MF, 1994, J BIOL CHEM, V269, P1; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105	28	106	113	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1077	1080		10.1126/science.285.5430.1077	http://dx.doi.org/10.1126/science.285.5430.1077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446056				2022-12-28	WOS:000082033100049
J	de Lange, T; Jacks, T				de Lange, T; Jacks, T			For better or worse? Telomerase inhibition and cancer	CELL			English	Review							MOUSE CELLS LACKING; HUMAN FIBROBLASTS; RNA COMPONENT		Rockefeller Univ, New York, NY 10021 USA; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	Rockefeller University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	de Lange, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0	21	105	114	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					273	275		10.1016/S0092-8674(00)81955-8	http://dx.doi.org/10.1016/S0092-8674(00)81955-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458601	Bronze			2022-12-28	WOS:000081950300001
J	Pym, AS; Cole, ST				Pym, AS; Cole, ST			PostDOTS, postgenomics: the next century of tuberculosis control	LANCET			English	Article							VACCINE		Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Univ Liverpool, Wellcome Trust Trop Ctr, Liverpool L69 3BX, Merseyside, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Liverpool	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, 28 Rue Dr Roux, F-75724 Paris 15, France.			Pym, Alexander/0000-0002-6260-8180				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; India Single-lesion Multicentre Trial Group, 1997, Indian Journal of Leprosy, V69, P121; Jacobs GG, 1997, TUBERCLE LUNG DIS, V78, P159, DOI 10.1016/S0962-8479(97)90022-8; Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; Murray PJ, 1996, P NATL ACAD SCI USA, V93, P934, DOI 10.1073/pnas.93.2.934; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STRAUS SJE, 1998, SCIENCE, V276, P707; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; *WHO GLOB TUB PROG, 1998, WHOTB98237; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1004	1005		10.1016/S0140-6736(99)02118-2	http://dx.doi.org/10.1016/S0140-6736(99)02118-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459929				2022-12-28	WOS:000079421600050
J	Tobin, EH				Tobin, EH			Prosthetic joint infections: controversies and clues	LANCET			English	Editorial Material							ULTRACLEAN AIR		Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA	Albany Medical College	Tobin, EH (corresponding author), Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA.							BACKE HA, 1996, CLIN ORTHOP RELAT R, V331, P125; BARRACK RL, 1997, CLIN ORTHOP RELAT R, V345, P8; Berbari EF, 1998, CLIN INFECT DIS, V27, P1247, DOI 10.1086/514991; BLASER J, 1995, ANTIMICROB AGENTS CH, V39, P1134, DOI 10.1128/AAC.39.5.1134; Christensen Gordon D., 1994, P45; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DUNCAN CP, 1994, J BONE JOINT SURG AM, V76A, P1742, DOI 10.2106/00004623-199411000-00020; Lachiewicz PF, 1996, J BONE JOINT SURG AM, V78A, P749, DOI 10.2106/00004623-199605000-00015; LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10; NORDEN C, 1994, INFECT BONES JOINTS, P291; Proctor Richard A., 1994, P79; Segreti J, 1998, CLIN INFECT DIS, V27, P711, DOI 10.1086/514951; STECKELBERGJM, 1994, INFECT ASS INDWELLIN, P259; TAYLOR GJS, 1993, J BONE JOINT SURG BR, V75, P503, DOI 10.1302/0301-620X.75B3.8496233; Tunney MM, 1998, J BONE JOINT SURG BR, V80B, P568, DOI 10.1302/0301-620X.80B4.8473; Zimmerli W, 1998, JAMA-J AM MED ASSOC, V279, P1537, DOI 10.1001/jama.279.19.1537	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					770	771		10.1016/S0140-6736(99)00071-9	http://dx.doi.org/10.1016/S0140-6736(99)00071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459955				2022-12-28	WOS:000079089100005
J	[Anonymous]				[Anonymous]			Canadian doctors' threatened walk out averted	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					534	534						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463882				2022-12-28	WOS:000082347200007
J	North, CS; Nixon, SJ; Shariat, S; Mallonee, S; McMillen, JC; Spitznagel, EL; Smith, EM				North, CS; Nixon, SJ; Shariat, S; Mallonee, S; McMillen, JC; Spitznagel, EL; Smith, EM			Psychiatric disorders among survivors of the Oklahoma City bombing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SHORT-TERM; DISASTER; PSYCHOPATHOLOGY; RISK	Context Disasters expose unselected populations to traumatic events and can be used to study the mental health effects. The Oklahoma City, Okla, bombing is particularly significant for the study of mental health sequelae of trauma because its extreme magnitude and scope have been predicted to render profound psychiatric effects on survivors. Objective To measure the psychiatric impact of the bombing of the Alfred P. Murrah Federal Building in Oklahoma City on survivors of the direct blast, specifically examining rates of posttraumatic stress disorder (PTSD), diagnostic comorbidity, functional impairment, and predictors of postdisaster psychopathology. Design, Setting, and Participants Of 255 eligible adult survivors selected from a confidential registry, 182 (71%) were assessed systematically by interviews approximately 6 months after the disaster. between August and December 1995. Main Outcome Measurer Diagnosis of 8 psychiatric disorders, demographic data, level of functioning treatment, exposure to the event. involvement of family and friends, and physical injuries, as ascertained by the Diagnostic Interview Schedule/Disaster Supplement, Results Forty-five percent of the subjects had a postdisaster psychiatric disorder and 34.3% had PTSD. Predictors included disaster exposure, female sex (for any postdisaster diagnosis, 55% vs 34% for men; chi(1)(2) = 8.27; P = .004), and predisaster psychiatric disorder (for PTSD, 45% vs 26% for those without predisaster disorder; chi(1)(2) = 6.86; P = .009). Onset of PTSD was swift, with 76% reporting same-day onset. The relatively uncommon avoidance and numbing symptoms virtually dictated the diagnosis of PTSD (94% meeting avoidance and numbing criteria had full PTSD diagnosis) and were further associated with psychiatric comorbidity, functional impairment, and treatment received. Intrusive reexperience and hyperarousal symptoms were nearly universal, but by themselves were generally unassociated with other psychopathology or impairment in functioning. Conclusions Our data suggest that a focus on avoidance and numbing symptoms could have provided an effective screening procedure for PTSD and could have identified most psychiatric cases early in the acute postdisaster period. Psychiatric comorbidity further identified those with functional disability and treatment need. The nearly universal yet distressing intrusive reexperience and hyperarousal symptoms in the majority of nonpsychiatrically ill persons may be addressed by nonmedical interventions of reassurance and support.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63110 USA; Washington Univ, Dept Math & Stat, St Louis, MO 63110 USA; Univ Oklahoma Hlth Sci, Dept Psychiat & Behav Sci, Oklahoma City, OK USA; Oklahoma State Dept Hlth, Oklahoma City, OK USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center	North, CS (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 4940 Childrens Pl, St Louis, MO 63110 USA.		Nixon, Sara Jo/L-1369-2014	Nixon, Sara Jo/0000-0003-1179-2851	NIMH NIH HHS [MH40025] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040025] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P247; American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th, P427; BRESLAU N, 1992, AM J PSYCHIAT, V149, P671; Bromet EJ, 1982, J PREV PSYCHIATRY, V1, P225; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; Grace MC, 1993, INT HDB TRAUMATIC ST, P441; HOCKING F, 1970, DIS NERV SYST, V31, P542; KASL SV, 1981, AM J PUBLIC HEALTH, V71, P472, DOI 10.2105/AJPH.71.5.472; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KESSLER RC, 1997, ANN M INT SOC TRAUM; LOPEZIBOR JJ, 1985, BRIT J PSYCHIAT, V147, P352, DOI 10.1192/bjp.147.4.352; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; MCFARLANE AC, 1989, BRIT J PSYCHIAT, V154, P221, DOI 10.1192/bjp.154.2.221; MCFARLANE AC, 1986, J NERV MENT DIS, V147, P4; MCMILLEN JC, IN PRESS J TRAUMA ST; MOORE HE, 1959, SOC FORCES, V38, P135, DOI 10.2307/2573933; Newman J. P., 1987, ANN M INT SOC TRAUM; Nixon SJ, 1998, J PERS INTERPERS LOS, V3, P99, DOI 10.1080/10811449808414432; North C.S., 1989, J TRAUMA STRESS, V2, P353, DOI DOI 10.1002/JTS.2490020309; North CS, 1997, AM J PSYCHIAT, V154, P1696, DOI 10.1176/ajp.154.12.1696; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; NORTH CS, 1989, HOSP COMMUNITY PSYCH, V40, P1293; NORTH CS, 1995, BAILLIERES CLIN PSYC, V1, P225; *OK DEP HLTH, 1999, 1995 OKL CIT BOMB IN; RAMSAY R, 1990, J PSYCHOSOM RES, V34, P355, DOI 10.1016/0022-3999(90)90059-D; RBINS LN, 1986, DISASTER STRESS STUD, P22; Robins L., 1983, DIAGNOSTIC INTERVIEW; ROBINS LN, 1981, NIMH DIAGN INT SCHED; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Shore J. H., 1986, DISASTER STRESS STUD, P77; Sloan P, 1988, J TRAUMA STRESS, V1, P211, DOI DOI 10.1002/JTS.2490010208; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SMITH EM, 1993, J SOC BEHAV PERS, V8, P353; STEINGLASS P, 1990, J APPL SOC PSYCHOL, V20, P1746, DOI 10.1111/j.1559-1816.1990.tb01509.x; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb05251.x; Weisaeth L., 1985, PSYCHIAT STATE ART, P299	36	596	607	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					755	762		10.1001/jama.282.8.755	http://dx.doi.org/10.1001/jama.282.8.755			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	228CJ	10463711	Bronze			2022-12-28	WOS:000082118800027
J	Hoyle, J; Rowe-Jones, C				Hoyle, J; Rowe-Jones, C			Charles Peter Broad - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					522	522		10.1136/bmj.319.7208.522	http://dx.doi.org/10.1136/bmj.319.7208.522			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454420	Green Published			2022-12-28	WOS:000082199600065
J	Mushtaq, I; Logan, S; Morris, M; Johnson, AW; Wade, AM; Kelly, D; Clayton, PT				Mushtaq, I; Logan, S; Morris, M; Johnson, AW; Wade, AM; Kelly, D; Clayton, PT			Screening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometry	BRITISH MEDICAL JOURNAL			English	Article							EXTRAHEPATIC BILIARY ATRESIA; BILE-ACID PATTERNS; NEONATAL HEPATITIS; BLOOD SPOTS; SERUM; JAUNDICE; SURGERY; FOLLOW; BABIES; LIFE	Objective To assess the feasibility of screening for cholestatic hepatobiliary disease and extrahepatic biliary atresia by using tandem mass spectrometry to measure conjugated bile acids in dried blood spots obtained from newborn infants at 7-10 days of age for the Guthrie test. Setting Three tertiary referral clinics and regional neonatal screening laboratories. Design Unused blood spots from the Guthrie test were retrieved for infants presenting with cholestatic hepatobiliary disease and from the two cards stored on either side of each card from an index child. Concentrations of conjugated bile acids measured by tandem mass spectrometry in the two groups were compared. Main outcome measures Concentrations of glycodihydroxycholanoates, glycotrihydroxycholanoates, taurodihydroxycholanoates, and taurotrihydroxycholanoates. Receiver operator curves were plotted to determine which parameter (or combination of parameters) would best predict the cases of cholestatic hepatobiliary disease and extrahepatic biliary atresia. The sensitivity and specificity at a selection of cut off values for each bile acid species and for total bile acid concentrations for the detection of the two conditions were calculated. Results 218 children with cholestatic hepatobiliary disease were eligible for inclusion in the study. Two children without a final diagnosis and five who presented at < 14 days of age were excluded. Usable blood spots were obtained from 177 index children and 708 comparison children. Mean concentrations of all four bile acid species were significantly raised in children with cholestatic hepatobiliary disease and extrahepatic biliary atresia compared with the unaffected children (P < 0.0001). Of 177 children with cholestatic hepatobiliary disease, 104 (59%) had a total bile acid concentration >33 mu mol/l (97.5th centile value for comparison group). Of the 61 with extrahepatic biliary atresia, 47 (77%) had total bile acid concentrations > 33 mu mol/l. Taurotrihydroxycholanoate and total bile acid concentrations were the best predictors of both conditions. For all cholestatic hepatobiliary disease, a cut off level of total bile acid concentration of 30 mu mol/l gave a sensitivity of 62% and a specificity of 96%, while the corresponding values for extrahepatic biliary atresia were 79% and 96%. Conclusion Most children who present With extrahepatic biliary atresia and other forms of cholestatic hepatobiliary disease have significantly raised concentrations of conjugated bile acids as measured by tandem mass spectrometry at the time when samples are taken for the Guthrie test Unfortunately the separation between the concentrations in these infants and those in the general population is not sufficient to make mass screening for cholestatic hepatobiliary disease a feasible option with this method alone.	UCL, Inst Child Hlth, Biochem Unit, London WC1N 1EH, England; Inst Child Hlth, Epidemiol & Biostat Unit, London, England; Micromass UK Ltd, Manchester M23 9LZ, Lancs, England; Childrens Hosp, Liver Unit, Birmingham B16 8ET, W Midlands, England	University of London; University College London; University of London; University College London	Clayton, PT (corresponding author), UCL, Inst Child Hlth, Biochem Unit, London WC1N 1EH, England.	P.Clayton@ich.ucl.ac.uk	Clayton, Peter T/C-1523-2008	Clayton, Peter/0000-0001-7592-4302; Logan, Stuart/0000-0002-9279-261X; Morris, Michael/0000-0003-4265-8479				BARNES S, 1981, J CLIN INVEST, V68, P775, DOI 10.1172/JCI110314; DECONTI RW, 1992, PEDIAT SURG INT, V7, P737; DICK MC, 1985, ARCH DIS CHILD, V60, P512, DOI 10.1136/adc.60.6.512; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hennekens C.H., 1987, EPIDEMIOLOGY MED; JAVITT NB, 1977, J PEDIATR-US, V90, P736, DOI 10.1016/S0022-3476(77)81238-9; KELLY DA, 1995, BRIT MED J, V310, P1172, DOI 10.1136/bmj.310.6988.1172; LOGAN S, 1993, LANCET, V342, P256, DOI 10.1016/0140-6736(93)91814-3; MACKIERNAN PJ, 1995, BRIT PAEDIAT SURVEIL, V4, P3; MATHEW PM, 1981, ARCH DIS CHILD, V56, P949, DOI 10.1136/adc.56.12.949; MATSUI A, 1985, J PEDIATR-US, V107, P255, DOI 10.1016/S0022-3476(85)80140-2; MATSUI A, 1993, SCREENING, V2, P201; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; MIELIVERGANI G, 1989, LANCET, V1, P421; Mills KA, 1998, PEDIATR RES, V43, P361, DOI 10.1203/00006450-199803000-00009; MOWAT AP, 1995, ARCH DIS CHILD, V72, P90, DOI 10.1136/adc.72.1.90; OHI R, 1990, J PEDIATR SURG, V25, P442, DOI 10.1016/0022-3468(90)90390-U; Rashed MS, 1997, CLIN CHEM, V43, P1129; SENGER H, 1986, BIOMED BIOCHIM ACTA, V45, P931; TAZAWA Y, 1984, J PEDIATR GASTR NUTR, V3, P394, DOI 10.1097/00005176-198406000-00016; WINFIELD CR, 1978, ARCH DIS CHILD, V53, P506, DOI 10.1136/adc.53.6.506	21	72	80	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					471	477		10.1136/bmj.319.7208.471	http://dx.doi.org/10.1136/bmj.319.7208.471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454398	Green Published, Bronze			2022-12-28	WOS:000082199600015
J	Vogt, PH				Vogt, PH			Risk of neurodegenerative diseases in children conceived by intracytoplasmic sperm injection?	LANCET			English	Editorial Material							BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; DOMINANT CEREBELLAR-ATAXIA; POLYGLUTAMINE EXPANSION; INFERTILE MEN; CAG REPEAT; TRANSACTIVATION; GLUTAMINE; MUTATIONS		Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Vogt, PH (corresponding author), Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany.							Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; Butler R, 1998, HUM MOL GENET, V7, P121, DOI 10.1093/hmg/7.1.121; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Djian P, 1998, CELL, V94, P155, DOI 10.1016/S0092-8674(00)81415-4; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PUSCHECK EE, 1994, FERTIL STERIL, V62, P1035; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; Tincello DG, 1997, MOL HUM REPROD, V3, P941, DOI 10.1093/molehr/3.11.941; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; WARNER CL, 1990, ARCH NEUROL-CHICAGO, V47, P1117, DOI 10.1001/archneur.1990.00530100087018; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	18	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					611	612		10.1016/S0140-6736(99)80147-0	http://dx.doi.org/10.1016/S0140-6736(99)80147-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466656				2022-12-28	WOS:000082214500003
J	Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E				Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E			Salt tolerance conferred by overexpression of a vacuolar Na+/H+ antiport in Arabidopsis	SCIENCE			English	Article							ION-TRANSPORT; TONOPLAST VESICLES; EXCHANGER; MEMBRANE; YEAST	Agricultural productivity is severely affected by soil salinity, One possible mechanism by which plants could survive salt stress is to compartmentalize sodium ions away from the cytosol. Overexpression of a vacuolar Na+/H+ antiport from Arabidopsis thaliana in Arabidopsis plants promotes sustained growth and development in soil watered with up to 200 millimolar sodium chloride. This salinity tolerance was correlated with higher-than-normal levels of AtNHX1 transcripts, protein, and vacuolar Na+/H+ (sodium/proton) antiport activity, These results demonstrate the feasibility of engineering salt tolerance in plants.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto	Blumwald, E (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.		Blumwald, Eduardo/Y-2751-2019					APSE MP, 1998, P 11 INT WORKSH PLAN, P84; Barkla BJ, 1996, ANNU REV PLANT PHYS, V47, P159, DOI 10.1146/annurev.arplant.47.1.159; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; Blumwald E, 1997, ADV BOT RES, V25, P401, DOI 10.1016/S0065-2296(08)60159-7; BLUMWALD E, 1987, PLANT PHYSIOL, V85, P30, DOI 10.1104/pp.85.1.30; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; DARLEY CP, 1998, P 11 INT WORKSH PLAN, P8; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Glenn EP, 1999, CRIT REV PLANT SCI, V18, P227, DOI 10.1016/S0735-2689(99)00388-3; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Johnson C.B., 1981, PHYSL PROCESSES LIMI, P271; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; PLANT PJ, 1994, J MEMBRANE BIOL, V140, P1; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998	18	1381	1657	15	352	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1256	1258		10.1126/science.285.5431.1256	http://dx.doi.org/10.1126/science.285.5431.1256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455050				2022-12-28	WOS:000082130200040
J	Schrier, RW; Abraham, WT				Schrier, RW; Abraham, WT			Mechanisms of disease - Hormones and hemodynamics in heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ATRIAL-NATRIURETIC-FACTOR; CONVERTING-ENZYME-INHIBITION; LEFT-VENTRICULAR DYSFUNCTION; OUTPUT CARDIAC-FAILURE; NEPHROTIC SYNDROME; WATER-EXCRETION; NECROSIS-FACTOR; SODIUM; VASOPRESSIN; CIRRHOSIS		Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA; Univ Cincinnati, Coll Med, Sect Heart Failure & Cardiac Transplantat, Cincinnati, OH USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Ohio; University of Cincinnati	Schrier, RW (corresponding author), Univ Colorado, Sch Med, Dept Med, Box B-178,4200 E 9th Ave, Denver, CO 80262 USA.							Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1; Abraham W. T., 1997, Journal of the American College of Cardiology, V29, p169A; Abraham William T., 1997, P127; ABRAHAM WT, 1992, J AM SOC NEPHROL, V2, P1697; ABRAHAM WT, 1995, HEPATOLOGY, V22, P737, DOI 10.1002/hep.1840220308; Allison NL, 1988, VASOPRESSIN CELLULAR, P207; ARDAILLOU, 1993, J HYPERTENS S, V11, pS43; BALL SG, 1993, LANCET, V342, P821; BELLOREUSS E, 1976, J CLIN INVEST, V57, P1104, DOI 10.1172/JCI108355; BOEKSTEGERS P, 1994, SHOCK, V1, P237, DOI 10.1097/00024382-199404000-00001; BOLAND DG, 1998, CONGEST HEART FAIL, V0004, P00023; CARMINES PK, 1989, AM J PHYSIOL, V256, pF1015, DOI 10.1152/ajprenal.1989.256.6.F1015; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; DREXLER H, 1990, CIRC RES, V66, P1371, DOI 10.1161/01.RES.66.5.1371; DUNN BR, 1986, CIRC RES, V59, P237, DOI 10.1161/01.RES.59.3.237; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GAUER OH, 1954, J CLIN INVEST, V33, P287, DOI 10.1172/JCI102897; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GILMORE JP, 1964, CIRC RES, V14, P301, DOI 10.1161/01.RES.14.4.301; HENSEN J, 1991, AM J NEPHROL, V11, P441, DOI 10.1159/000168356; Hjalmarson A, 1999, LANCET, V353, P2001; ISHIKAWA S, 1986, KIDNEY INT, V30, P49, DOI 10.1038/ki.1986.149; JOHNSTON CI, 1986, J CARDIOVASC PHARM, V8, pS96, DOI 10.1097/00005344-198600087-00019; KIM JK, 1989, KIDNEY INT, V35, P799, DOI 10.1038/ki.1989.55; Lechat P, 1999, LANCET, V353, P9; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MEYERS BD, 1975, CIRC RES, V37, P101; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAITOH M, 1994, AM J PHYSIOL-HEART C, V267, pH2245, DOI 10.1152/ajpheart.1994.267.6.H2245; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; OELKERS W, 1988, HYPERTENSION, V12, P462, DOI 10.1161/01.HYP.12.4.462; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PHILLIPS PA, 1985, CLIN SCI, V68, P669, DOI 10.1042/cs0680669; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; PITT B, IN PRESS N ENGL J ME; RAKUSAN K, 1992, CIRCULATION, V86, P38, DOI 10.1161/01.CIR.86.1.38; SAITO Y, 1987, BIOCHEM BIOPH RES CO, V148, P211, DOI 10.1016/0006-291X(87)91097-7; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SATOH S, 1981, ARCH INT PHARMACOD T, V254, P304; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SCHRIER RW, 1991, EUR J GASTROEN HEPAT, V3, P721; SCHRIER RW, 1990, ANN INTERN MED, V113, P155, DOI 10.7326/0003-4819-113-2-155; SCHRIER RW, 1973, J CLIN INVEST, V52, P502, DOI 10.1172/JCI107207; SCHRIER RW, 1989, NEW ENGL J MED, V320, P676; SCHRIER RW, 1992, J R COLL PHYSICIANS, V26, P4295; SCHRIER RW, 1979, AM J PHYSIOL, V236, P321; SEIBOLD A, 1993, ANN NY ACAD SCI, V689, P570, DOI 10.1111/j.1749-6632.1993.tb55596.x; SUKI WN, 1989, ARCH INTERN MED, V149, P669, DOI 10.1001/archinte.149.3.669; Supaporn T, 1996, KIDNEY INT, V50, P1718, DOI 10.1038/ki.1996.491; SZATALOWICZ VL, 1981, NEW ENGL J MED, V305, P263, DOI 10.1056/NEJM198107303050506; WALSHE JJ, 1979, ANN INTERN MED, V91, P47, DOI 10.7326/0003-4819-91-1-47; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312	62	807	863	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					577	585		10.1056/NEJM199908193410806	http://dx.doi.org/10.1056/NEJM199908193410806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451464				2022-12-28	WOS:000082061500006
J	Genest, J; Lavoie, MA				Genest, J; Lavoie, MA			Homozygous familial hypercholesterolemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Montreal Heart Inst, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Genest, J (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					490	490		10.1056/NEJM199908123410705	http://dx.doi.org/10.1056/NEJM199908123410705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441605				2022-12-28	WOS:000081962600005
J	Wald, NJ; Watt, HC; Hackshaw, AK				Wald, NJ; Watt, HC; Hackshaw, AK			Integrated screening for Down's syndrome based on tests performed during the first and second trimesters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCHAL-TRANSLUCENCY THICKNESS; MATERNAL SERUM; FETAL TRISOMIES; INHIBIN-A; PREGNANCY; RISK; AGE; TRISOMY-21; GESTATION; MARKER	Background Both first-trimester screening and second-trimester screening for Down's syndrome are effective means of selecting women for chorionic-villus sampling or amniocentesis, but there is uncertainty about which screening method should be used in practice. We propose a new screening method in which measurements obtained during both trimesters are integrated to provide a single estimate of a woman's risk of having a pregnancy affected by Down's syndrome. Methods We used data from published studies of various screening methods employed during the first and second trimesters. The first-trimester screening consisted of measurement of serum pregnancy-associated plasma protein A in 77 pregnancies affected by Down's syndrome and 383 unaffected pregnancies and measurements of nuchal translucency obtained by ultrasonography in 326 affected and 95,476 unaffected pregnancies. The second-trimester tests were various combinations of measurements of serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin, and inhibin A in 77 affected and 385 unaffected pregnancies. Results When we used a risk of 1 in 120 or greater as the cutoff to define a positive result on the integrated screening test, the rate of detection of Down's syndrome was 85 percent, with a false positive rate of 0.9 percent. To achieve the same rate of detection, current screening tests would have higher false positive rates (5 to 22 percent). If the integrated test were to replace the triple test (measurements of serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin), currently used with a 5 percent false positive rate, for screening during the second trimester, the detection rate would be higher (85 percent vs. 69 percent), with a reduction of four fifths in the number of invasive diagnostic procedures and consequent losses of normal fetuses. Conclusions The integrated test detects more cases of Down's syndrome with a much lower false positive rate than the best currently available test. (N Engl J Med 1999;341:461-7.) (C) 1999, Massachusetts Medical Society.	St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, Charterhouse Sq, London EC1M 6BQ, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BRIZOT ML, 1995, BRIT J OBSTET GYNAEC, V102, P127, DOI 10.1111/j.1471-0528.1995.tb09065.x; BRIZOT ML, 1994, OBSTET GYNECOL, V84, P918; Canick JA, 1998, PRENATAL DIAG, V18, P413; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO;2-U; Hackshaw AK, 1996, LANCET, V348, P1740, DOI 10.1016/S0140-6736(05)65871-0; Haddow JE, 1998, LANCET, V352, P336, DOI 10.1016/S0140-6736(98)22031-9; Haddow JE, 1998, J MED SCREEN, V5, P115, DOI 10.1136/jms.5.3.115; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; LAM YH, 1998, ULTRASOUND OBSTET S1, V12, pA62; Nicolaides KH, 1998, PRENATAL DIAG, V18, P519, DOI 10.1002/(SICI)1097-0223(199805)18:5<519::AID-PD398>3.0.CO;2-U; Nicolaides KH, 1996, LANCET, V347, P906, DOI 10.1016/S0140-6736(96)91391-4; NIELSON JP, 1997, LANCET, V350, P754; Noble PL, 1995, ULTRASOUND OBST GYN, V6, P390, DOI 10.1046/j.1469-0705.1995.06060390.x; Onda T, 1998, PRENATAL DIAG, V18, P956, DOI 10.1002/(SICI)1097-0223(199809)18:9<956::AID-PD370>3.3.CO;2-I; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROYSTON P, 1992, STAT MED, V11, P257, DOI 10.1002/sim.4780110211; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Wald N J, 1996, J Med Screen, V3, P185; Wald N J, 1997, J Med Screen, V4, P181; WALD NJ, 1988, BRIT MED J, V297, P1029; Wald NJ, 1997, PRENATAL DIAG, V17, P821, DOI 10.1002/(SICI)1097-0223(199709)17:9<821::AID-PD154>3.3.CO;2-X; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; Wald NJ, 1996, PRENATAL DIAG, V16, P143, DOI 10.1002/(SICI)1097-0223(199602)16:2<143::AID-PD825>3.0.CO;2-F; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; Wald NJ, 1997, PRENATAL DIAG, V17, P285, DOI 10.1002/(SICI)1097-0223(199703)17:3<285::AID-PD71>3.0.CO;2-A; WALD NJ, 1994, PRENATAL DIAG, V14, P707, DOI 10.1002/pd.1970140810; Wald NJ, 1998, J MED SCREEN, V5, P110; Wald NJ, 1998, J MED SCREEN, V5, P166	30	377	396	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					461	467		10.1056/NEJM199908123410701	http://dx.doi.org/10.1056/NEJM199908123410701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441601				2022-12-28	WOS:000081962600001
J	Davis, RL; Rubanowice, D; Shinefield, HR; Lewis, N; Gu, D; Black, SB; DeStefano, F; Gargiullo, P; Mullooly, JP; Thompson, RS; Chen, RT				Davis, RL; Rubanowice, D; Shinefield, HR; Lewis, N; Gu, D; Black, SB; DeStefano, F; Gargiullo, P; Mullooly, JP; Thompson, RS; Chen, RT		Ctr Dis Control and Prevention Vaccine Safety D	Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TETANUS-PERTUSSIS IMMUNIZATIONS; PRETERM INFANTS; PRIMARY-CARE; DIPHTHERIA; SERVICES; VACCINE	Context Studies have noted that health care professionals may not conform to proper immunization schedules for premature and low-birth-weight infants in the United States. Little is known about the success of current efforts to immunize these high-risk infants. Objective To describe current immunization practices for premature and low-birthweight infants and ascertain risk factors for poor immunization status, using large population-based data sources. Design and Setting Cohort and case-control analyses of immunization data tracked from March 1991 through March 1997 for 3 large health maintenance organizations (HMOs) participating in the Centers for Disease Control and Prevention's Vaccine Safety Datalink project, Participants A total of 11 580 low-birth-weight and premature infants were enrolled from birth to age 2 months; 6832 of these were continuously enrolled from birth to age 24 months. At age 2 months, there were 173 373 full-term, normal-birthweight infants enrolled as controls; at age 24 months, there were 103 324. Main Outcome Measures Age-specific immunization status by prematurity and birth weight(<1500 g, 1500-2500 g, born at <38 weeks' gestation with birth weight of >2500 g, or full-term with normal birth weight) and patient characteristics associated with up-to-date status. Results At each age, infants weighing less than 1500 g at birth had lower up-to-date immunization levels than other infants. At age 6 months, 52% to 65% of infants weighing less than 1500 g were up-to-date at each of the 3 HMOs compared with 69% to 73% of those weighing 1500 to 2500 g, 66% to 80% of premature infants weighing more than 2500 g, and 65% to 76% of full-term, normal-birth-weight infants, By age 24 months, 78% to 86% of infants weighing less than 1500 g were up-to-date, significantly less than heavier infants, who had levels of 84% to 89%, Well-child preventive care strongly predicted immunization status, while concomitant pulmonary disease did not. Conclusions Our data suggest that infants born prematurely are vaccinated at levels approaching that of the general population, but levels of vaccination for Very low-birth-weight infants lag slightly behind.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Immunizat Studies Program, Seattle, WA 98101 USA; Grp Hlth Cooperat Puget Sound, Dept Prevent Care, Seattle, WA 98101 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA; No Calif Kaiser Permanente Med Ctr, Dept Res, Oakland, CA USA; Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; NW Kaiser Permanente, Portland, OR USA	Group Health Cooperative; Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kaiser Permanente; Emory University; Centers for Disease Control & Prevention - USA; Kaiser Permanente	Davis, RL (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Immunizat Studies Program, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367	PHS HHS [200-95-0947] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altman D. G., 1991, PRACTICAL STAT MED R, DOI [10.1201/9780429258589, DOI 10.1201/9780429258589]; BERNBAUM JC, 1985, J PEDIATR-US, V107, P184, DOI 10.1016/S0022-3476(85)80122-0; Bordley WC, 1996, PEDIATRICS, V97, P467; Breslow NE, 1980, STAT METHODS CANC RE, V2; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; Conway S P, 1987, Lancet, V2, P1326; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Davis R L, 1997, HMO Pract, V11, P13; Harris JR, 1998, AM J PREV MED, V14, P9; LANGKAMP DL, 1993, AM J PERINAT, V10, P187; LANGKAMP DL, 1992, PEDIATRICS, V89, P52; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; LONG SS, 1997, PRINCIPLES PRACTICE, P976; Magoon M W, 1995, J Perinatol, V15, P222; ORENSTEIN WA, 1994, PEDIATRICS, V94, P545; PETER G, 1997, 1997 RED BOOK REPORT, P48; PROBER CG, 1997, PRINCIPLES PRACTICE, P603; PULLAN C R, 1989, Archives of Disease in Childhood, V64, P1438; RODEWALD LE, 1995, ARCH PEDIAT ADOL MED, V149, P393, DOI 10.1001/archpedi.1995.02170160047007; ROPER J, 1988, ARCH DIS CHILD, V63, P518, DOI 10.1136/adc.63.5.518; SHACKELFORD PG, 1997, PRINCIPLES PRACTICE, P596; SMOLEN P, 1983, J PEDIATR-US, V103, P917, DOI 10.1016/S0022-3476(83)80714-8; Thompson RS, 1996, MILBANK Q, V74, P469, DOI 10.2307/3350390; VOHR BR, 1986, PEDIATRICS, V77, P569	24	54	55	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					547	553		10.1001/jama.282.6.547	http://dx.doi.org/10.1001/jama.282.6.547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450716	Bronze			2022-12-28	WOS:000081919100028
J	Chowdhury, AMR				Chowdhury, AMR			Success with the DOTS strategy	LANCET			English	Article									BRAC, Dhaka 1212, Bangladesh	Bangladesh Rural Advancement Committee BRAC	Chowdhury, AMR (corresponding author), BRAC, 75 Mohakhall, Dhaka 1212, Bangladesh.							Chowdhury A.M.R., 1996, SIMPLE SOLUTION TEAC; Chowdhury AMR, 1997, LANCET, V350, P169, DOI 10.1016/S0140-6736(96)11311-8; CHOWDHURY AMR, 1991, IUATLD NEWSLETTER, P1; CHOWDHURY AMR, IN PRESS TUBERCULOSI; GRANGE JM, 1997, LANCET, V350, P158; LOVELL CH, 1992, BREAKING CYCLE PROVE	6	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1003	1004		10.1016/S0140-6736(99)02119-4	http://dx.doi.org/10.1016/S0140-6736(99)02119-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459928				2022-12-28	WOS:000079421600049
J	Grange, JM; Zumla, A				Grange, JM; Zumla, A			Paradox of the global emergency of tuberculosis	LANCET			English	Article									UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, London W1P 6DB, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	University of London; University College London; UCL Medical School; Imperial College London	Zumla, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, 46 Cleveland St, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				Department for International Development, 1997, WHIT PAP INT DEV; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; Kochi A, 1997, WORLD HEALTH FORUM, V18, P225; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; 1998, INT J TUBERC LUNG DI, V2, P1044	5	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					996	996		10.1016/S0140-6736(99)01196-4	http://dx.doi.org/10.1016/S0140-6736(99)01196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459922				2022-12-28	WOS:000079421600043
J	Williams, A				Williams, A			How the defibrillator saved a patient's life	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					638	638		10.1136/bmj.319.7210.638	http://dx.doi.org/10.1136/bmj.319.7210.638			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473487	Green Published			2022-12-28	WOS:000082460300033
J	Hatlebakk, JG; Hyggen, A; Madsen, PH; Walle, PO; Schulz, T; Mowinckel, P; Bernklev, T; Berstad, A				Hatlebakk, JG; Hyggen, A; Madsen, PH; Walle, PO; Schulz, T; Mowinckel, P; Bernklev, T; Berstad, A		Norwegian Heartburn Study Grp	Heartburn, treatment in primary care: randomised, double blind study for 8 weeks	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROESOPHAGEAL REFLUX DISEASE; BARRETTS-ESOPHAGUS; CISAPRIDE; OMEPRAZOLE; SYMPTOMS; RANITIDINE; RELIEF	Objective To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients. Design Randomised, double blind, placebo controlled study. Setting 65 primary care practices in Norway. Participants 483 untreated patients with complaints of heartburn greater than or equal to 3 days a week, with at most grade 1 reflux oesophagitis. Interventions Omeprazole 20 mg once daily, cisapride 20 mg twice daily, or placebo for 8 weeks. Main outcome measures Adequate central of heartburn, defined as less than or equal to 1 day of the past 7 days with no more chan mild heartburn after 4 weeks of treatment. Results In the all patients treated analysis, adequate control of heartburn was achieved in 71%, of patients taking omeprazole, 22% taking cisapride, and 18% caking placebo after 4 weeks of treatment (omeprazole v cisapride and placebo, P < 0.0001; cisapride v placebo, non-significant). Results were comparable in patients with or without reflux oesophagitis. In patients treated with omeprazole only, symptom control aas achieved significantly more often in patients positive for Helicobacter pylori. Antacid use was 2-3 times greater in patients taking cisapride or placebo than in those taking omeprazole. Relief of non-reflux symptoms did not significantly differ between the three groups. Significantly more patients ticking cisapride reported adverse events than those taking omeprazole or placebo. Conclusions Omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo.	Univ Bergen, Haukeland Sykehus, Dept Med, N-5021 Bergen, Norway; Astra Norge, N-1471 Skarer, Norway; Lyshovden Legekontor, N-5148 Fyllingsdalen, Norway; Aust Agder Cent Hosp, N-4800 Arendal, Norway	University of Bergen; Haukeland University Hospital	Hatlebakk, JG (corresponding author), Univ Bergen, Haukeland Sykehus, Dept Med, N-5021 Bergen, Norway.	jan.hatlebakk@haukeland.no						Armstrong D, 1996, GASTROENTEROLOGY, V111, P85, DOI 10.1053/gast.1996.v111.pm8698230; BOST R, 1992, EUR J GASTROEN HEPAT, V4, P323; CAMERON AJ, 1995, GASTROENTEROLOGY, V108, pA65, DOI 10.1016/0016-5085(95)22922-1; Carlsson R, 1998, EUR J GASTROEN HEPAT, V10, P119, DOI 10.1097/00042737-199802000-00004; Castell DO, 1998, AM J GASTROENTEROL, V93, P547; CASTELL DO, 1998, PRACT GASTROENTEROL, V22, P18; CECCATELLI P, 1988, GUT, V29, P631, DOI 10.1136/gut.29.5.631; DEMICCO M, 1992, Gastroenterology, V102, pA59; FARUQUI S, 1992, Gastroenterology, V102, pA66; GALMICHE JP, 1990, DIGEST DIS SCI, V35, P649, DOI 10.1007/BF01540415; Galmiche JP, 1997, ALIMENT PHARM THER, V11, P765, DOI 10.1046/j.1365-2036.1997.00185.x; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; Hatlebakk JG, 1997, SCAND J GASTROENTERO, V32, P1100, DOI 10.3109/00365529709002988; Heading RC, 1998, EUR J GASTROEN HEPAT, V10, P87, DOI 10.1097/00042737-199801000-00016; HOLLOWAY RH, 1989, GUT, V30, P1187, DOI 10.1136/gut.30.9.1187; JANISCH HD, 1988, HEPATO-GASTROENTEROL, V35, P125; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; KHOURY R, 1998, AM J GASTROENTEROL, V93, P1619; Leite LP, 1997, DIGEST DIS SCI, V42, P1859, DOI 10.1023/A:1018802908358; MADDERN GJ, 1991, GUT, V32, P470, DOI 10.1136/gut.32.5.470; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; SCHOEMAN MN, 1995, GASTROENTEROLOGY, V108, P83, DOI 10.1016/0016-5085(95)90011-X; Venables TL, 1997, SCAND J GASTROENTERO, V32, P965, DOI 10.3109/00365529709011211; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X	24	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					550	553		10.1136/bmj.319.7209.550	http://dx.doi.org/10.1136/bmj.319.7209.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463897	Bronze, Green Published			2022-12-28	WOS:000082347200024
J	Simeone, DM; Pranikoff, T				Simeone, DM; Pranikoff, T			Mesenteric cyst	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Michigan, Ann Arbor, MI 48109 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA	University of Michigan System; University of Michigan; Wake Forest University; Wake Forest Baptist Medical Center	Simeone, DM (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.								0	4	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					659	659		10.1056/NEJM199908263410905	http://dx.doi.org/10.1056/NEJM199908263410905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460817				2022-12-28	WOS:000082192500005
J	Danielsson, T; Rossner, S; Westin, A				Danielsson, T; Rossner, S; Westin, A			Open randomised trial of intermittent very low energy diet together with nicotine gum for stopping smoking in women who gained weight in previous attempts to quit	BRITISH MEDICAL JOURNAL			English	Article							BODY-WEIGHT; CESSATION; SMOKERS; PATCHES; OBESITY; VLCD	Objective To determine whether attempts to prevent weight gain will increase success rates for stopping smoking. Design 16 week, open, randomised study with I year follow up, Setting Obesity unit. Subjects 287 female smokers who had quit smoking before but started again because of weight concerns. Intervention Combination of a standard smoking cessation programme with nicotine gum and a behavioural weight control programme including a very low energy diet. A control group was treated with the identical programme but without the diet. Main outcome measure Sustained cessation of smoking. Results After 16 weeks, 68/137 (50%) women had stopped smoking in the diet group versus 53/150 (35%) in the control group (P = 0.01). Among these women, weight fell by mean 2.1 (95% confidence interval 2.9 to 1.3) kg in the diet group but increased by 1.6 (0.9 to 2.3) kg in die control group (P < 0.001). After 1 year the success rates in the diet and control groups were 38/137 (28%) and 24/150 (16%) respectively (P < 0.05), but: there tvas no statistical difference in weight gain. Conclusions Combining the smoking cessation programme with an intervention to control weight helped women to stop smoking and control weight.	Karolinska Hosp, Obes Unit, S-17176 Stockholm, Sweden; Pharmacia & Upjohn Inc, Consumer Healthcare, S-25109 Helsingborg, Sweden	Karolinska Institutet; Karolinska University Hospital; Pfizer; Pharmacia Corporation	Danielsson, T (corresponding author), Huddinge Univ Hosp, Obes Unit, S-14186 Huddinge, Sweden.							*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P244; ATKINSON RL, 1993, JAMA-J AM MED ASSOC, V270, P967, DOI 10.1001/jama.1993.03510080071034; ATKINSON RL, 1989, MED EVALUATION MONIT, P273; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; Fiore MC, 1996, AHCPR PUBLICATION, V96-0692; FLEGAL KM, 1995, NEW ENGL J MED, V333, P1165, DOI 10.1056/NEJM199511023331801; GALEAZZI RL, 1985, EUR J CLIN PHARMACOL, V28, P301, DOI 10.1007/BF00543327; GRUNBERG NE, 1982, ADDICT BEHAV, V7, P317, DOI 10.1016/0306-4603(82)90001-6; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; KLESGES RC, 1991, J CONSULT CLIN PSYCH, V59, P899, DOI 10.1037/0022-006X.59.6.899; LEISCHOW SJ, 1991, BRIT J ADDICT, V86, P577; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; PIRIE PL, 1992, HEALTH PSYCHOL, V11, P53; Rossner S, 1997, INT J OBESITY, V21, P22, DOI 10.1038/sj.ijo.0800355; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; RYTTIG KR, 1995, J INTERN MED, V238, P299, DOI 10.1111/j.1365-2796.1995.tb01202.x; RYTTIG KR, 1997, INT J OBESITY, V21, P674; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SILAGY C, 1997, COCHRANE LIB; SPRING B, 1995, AM J CLIN NUTR, V62, P1181, DOI 10.1093/ajcn/62.6.1181; SPRING B, 1992, INT J OBES RELAT S3, V16, P19; TUOMILEHTO J, 1986, ADDICT BEHAV, V11, P1, DOI 10.1016/0306-4603(86)90002-X; *US PHS, 1990, DHHS CDC PUBL, P469; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106	26	47	48	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					490	493		10.1136/bmj.319.7208.490	http://dx.doi.org/10.1136/bmj.319.7208.490			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454403	Bronze, Green Published			2022-12-28	WOS:000082199600024
J	Kay, S				Kay, S			Brachial palsies from obstetric procedures	LANCET			English	Editorial Material							PLEXUS INJURIES		St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Kay, S (corresponding author), St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England.							Bager B, 1997, ACTA PAEDIATR, V86, P1214, DOI 10.1111/j.1651-2227.1997.tb14849.x; BIRCH R, 1993, J BONE JOINT SURG BR, V75, P346, DOI 10.1302/0301-620X.75B3.8496196; CLARKE HM, 1995, HAND CLIN, V11, P563; GJORUP L, 1966, ACTA NEUROL SCAN S18, V42, P1; Kay SPJ, 1998, BRIT J PLAST SURG, V51, P43, DOI 10.1054/bjps.1997.0166; Mallet J, 1972, REV CHIR ORTHOP S1, V58, P115; Narakas AO., 1987, PARALYSED HAND, P116; Smith B, 1996, BYTE, V21, P145; Tassin GA, 1987, MICRORECONSTRUCTION, P529; TASSIN JL, 1983, THESIS U PARIS 7; Waters PM, 1999, J BONE JOINT SURG AM, V81A, P649, DOI 10.2106/00004623-199905000-00006	11	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					614	615		10.1016/S0140-6736(99)00222-6	http://dx.doi.org/10.1016/S0140-6736(99)00222-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466658				2022-12-28	WOS:000082214500005
J	Tipton, M; Eglin, C; Gennser, M; Golden, F				Tipton, M; Eglin, C; Gennser, M; Golden, F			Immersion deaths and deterioration in swimming performance in cold water	LANCET			English	Article							THERMAL RESPONSES; EXERCISE; LEG	Background General hypothermia (deep body temperature <35 degrees C) has been implicated in immersion-related deaths, but many deaths occur too quickly for it to be involved. We investigated changes in swimming capability in cold water to find out whether such changes could lead to swim failure and drowning. Methods Ten volunteers undertook three self paced breaststroke swims in a variable-speed swimming flume, in water at 25 degrees C, 18 degrees C, and 10 degrees C, for a maximum of 90 min, During each swim, we measured oxygen consumption, rectal temperature, swim speed and angle, and stroke rate and length. Swim failure was defined as being unable to keep feet off the bottom of the flume. Findings All ten swimmers completed 90 min swims at 25 degrees C, eight completed swims at 18 degrees C, and five at 10 degrees C. In 10 degrees C water, one swimmer reached swim failure after 61 min and four were withdrawn before 90 min with rectal temperatures of 35 degrees C when they were close to swim failure. Swimming efficiency and length of stroke decreased more and rate of stroke and swim angle increased more in 10 degrees C water than in warmer water. These variables seemed to characterise impending swim failure. Interpretation Impaired performance and initial cardiorespiratory responses to immersion probably represent the major dangers to immersion victims. Consequently, treatment should be aimed at symptoms resulting from near-drowning rather than severe hypothermia.	Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England; Natl Def Res Estab, Dept Naval Med, Harsfjarden, Sweden	University of Portsmouth	Tipton, M (corresponding author), Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England.	michael.tipton@port.ac.uk		Eglin, Clare Mary/0000-0002-3848-6515; Tipton, Michael/0000-0002-7928-8451				DULAC S, 1987, INT J SPORTS MED, V8, P352, DOI 10.1055/s-2008-1025683; GLASER EM, 1951, J PHYSIOL-LONDON, V115, pP14; Golden F, 1981, HYPOTHERMIA ASHORE A; GOLDEN FS, 1987, J PHYSIOL-LONDON, V391, P399, DOI 10.1113/jphysiol.1987.sp016744; GOLDEN FS, 1986, J PHYSIOL-LONDON, V378, pP94; Golden FS, 1997, BRIT J ANAESTH, V79, P214, DOI 10.1093/bja/79.2.214; GOLDEN FSC, 1982, J PHYSIOL-LONDON, V330, pP60; HOLMER I, 1974, ACTA PHYSIOL SCAND, P1; HOLMER I, 1974, J APPL PHYSIOL, V37, P702, DOI 10.1152/jappl.1974.37.5.702; Home Office, 1977, REP WORK PART WAT SA; HUTCHINSON P, 1998, STAYING ALIVE    SPR, P12; KEATINGE WR, 1969, BRIT MED J, V1, P480, DOI 10.1136/bmj.1.5642.480; NADEL ER, 1974, J APPL PHYSIOL, V36, P465, DOI 10.1152/jappl.1974.36.4.465; PUGH LGC, 1967, BRIT MED J, V2, P333, DOI 10.1136/bmj.2.5548.333; *ROSPA, 1988, DROWN UK 1987; *ROYAL COLL PHYS L, 1966, REP COMM ACC HYP; Scheffe H, 1959, ANAL VARIANCE; TIPTON MJ, 1989, CLIN SCI, V77, P581, DOI 10.1042/cs0770581; TONER MM, 1984, J APPL PHYSIOL, V56, P1355, DOI 10.1152/jappl.1984.56.5.1355	19	51	51	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					626	629		10.1016/S0140-6736(99)07273-6	http://dx.doi.org/10.1016/S0140-6736(99)07273-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466663				2022-12-28	WOS:000082214500010
J	Hull, CM; Johnson, AD				Hull, CM; Johnson, AD			Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; SEXUAL DEVELOPMENT; HOMOLOG; FUNGUS	Candida albicans, the most prevalent fungal pathogen in humans, is thought to lack a sexual cycle. A set of C. albicans genes has been identified that corresponds to the master sexual cycle regulators a1, alpha 1, and alpha 2 of the Saccharomyces cerevisiae mating-type (MAT) Locus. The C. albicans genes are arranged in a way that suggests that these genes are part of a mating type-like Locus that is similar to the mating-type Loci of other fungi. In addition to the transcriptional regulators a1, alpha 1, and alpha 2, the C. albicans mating type-like Locus contains several genes not seen in other fungal MAT Loci, including those encoding proteins similar to poly(A) polymerases, oxysterol binding proteins, and phosphatidylinositol kinases.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre AD, 1995, INT J AVIAT PSYCHOL, V5, P1, DOI 10.1207/s15327108ijap0501_1; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; Casselton LA, 1998, MICROBIOL MOL BIOL R, V62, P55, DOI 10.1128/MMBR.62.1.55-70.1998; Chibana H, 1998, GENETICS, V149, P1739; Coppin E, 1997, MICROBIOL MOL BIOL R, V61, P411, DOI 10.1128/.61.4.411-428.1997; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Diener AC, 1996, GENETICS, V143, P769; FONZI WA, 1993, GENETICS, V134, P717; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HULL CM, UNPUB; Jin YS, 1999, MOL CELL BIOL, V19, P585; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; Keogh RS, 1998, YEAST, V14, P443, DOI 10.1002/(SICI)1097-0061(19980330)14:5<443::AID-YEA243>3.0.CO;2-L; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; Odds FC., 1988, CANDIDA CANDIDOSIS; Raymond M, 1998, MOL MICROBIOL, V27, P587, DOI 10.1046/j.1365-2958.1998.00704.x; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; Sharon A, 1996, MOL GEN GENET, V251, P60, DOI 10.1007/BF02174345; Turgeon BG, 1998, ANNU REV PHYTOPATHOL, V36, P115, DOI 10.1146/annurev.phyto.36.1.115	22	278	319	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1271	1275		10.1126/science.285.5431.1271	http://dx.doi.org/10.1126/science.285.5431.1271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455055				2022-12-28	WOS:000082130200045
J	Ankersmit, HJ; Tugulea, S; Spanier, T; Weinberg, AD; Artrip, JH; Burke, EM; Flannery, M; Mancini, D; Rose, EA; Edwards, NM; Oz, MC; Itescu, S				Ankersmit, HJ; Tugulea, S; Spanier, T; Weinberg, AD; Artrip, JH; Burke, EM; Flannery, M; Mancini, D; Rose, EA; Edwards, NM; Oz, MC; Itescu, S			Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device	LANCET			English	Article							FLOW CYTOMETRIC DETECTION; PHOSPHATIDYLSERINE EXPRESSION; HIV-INFECTION; ANNEXIN-V; RECIPIENTS; TRANSPLANTATION; APOPTOSIS; EXPERIENCE; INDIVIDUALS; BRIDGE	Background Cardiac transplantation is a limited option for end-stage heart failure because of the shortage of donor organs. Left-ventricular assist devices (LVADs) are currently under investigation as permanent therapy for end-stage heart failure, but long-term successful device implantation is limited because of a high rate of serious infections. To examine the relation between LVAD-related infection and host immunity, we investigated immune responses in LVAD recipients. Methods We compared the rate of candidal infection in 78 patients with New York Heart Association class IV heart failure who received either an LVAD (n=40) or medical management (controls, n=38). Fluorochrome-labelled monoclonal antibodies were used in analyses of T-cell phenotype. Analysis of T-cell function included intradermal responses to recall antigens and proliferative responses after stimulation by phytohaemagglutinin, monoclonal antibodies to CD3, and mixed lymphocyte culture. We measured T-cell apoptosis in vivo by annexin V binding, and confirmed the result by assessment of DNA fragmentation. Activation-induced T-cell death was measured after T-cell stimulation with antibodies to CD3. All immunological tests were done at least 1 month after LVAD implantation. Between-group comparisons were by Kaplan-Meier actuarial analysis and Students t test. Findings By 3 months after implantation of LVAD, the risk of developing candidal infection was 28% in LVAD recipients, compared with 3% in controls (p=0.003). LVAD recipients had cutaneous anergy to recall antigens and lower (<70%) T-cell proliferative responses than controls after activation via the T-cell receptor complex (p<0.001). T cells from LVAD recipients had higher surface expression of CD95 (Fas) (p<0.001) and a higher rate of spontaneous apoptosis (p<0.001) than controls. Moreover, after stimulation with antibodies to CD3, CD4 T-cell death increased by 3.2-fold in LVAD recipients compared with only 1.2-fold in controls (p<0.05). Interpretation LVAD implantation results in an aberrant state of T-cell activation, heightened susceptibility of CD4 T cells to activation-induced cell death, progressive defects in cellular immunity, and increased risk of opportunistic infection.	Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Itescu, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, 630 W 168th St, New York, NY 10032 USA.		Rose, Eric/AAJ-2281-2020	Ankersmit, Hendrik Jan/0000-0002-8761-3517				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Argenziano M, 1997, J HEART LUNG TRANSPL, V16, P822; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; DASSE KA, 1987, T AM SOC ART INT ORG, V33, P418; Didisheim P, 1994, ASAIO J, V40, P230, DOI 10.1097/00002480-199404000-00020; Fischer SA, 1997, CLIN INFECT DIS, V24, P18, DOI 10.1093/clinids/24.1.18; FRAZIER OH, 1992, ANN THORAC SURG, V102, P578; Goldstein D J, 1995, ASAIO J, V41, P873, DOI 10.1097/00002480-199510000-00010; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Hermann M, 1997, CIRCULATION, V95, P814; HOGNES JR, 1991, ARTIFICIAL HEART PRO, P1; Holman WL, 1996, ANN THORAC SURG, V61, P366, DOI 10.1016/0003-4975(95)01021-1; Itescu S, 1998, CIRCULATION, V98, P786, DOI 10.1161/01.CIR.98.8.786; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Massad MG, 1997, ANN THORAC SURG, V64, P1120, DOI 10.1016/S0003-4975(97)00807-2; MCBRIDE LR, 1987, T AM SOC ART INT ORG, V33, P201; MCCARTHY PM, 1991, J THORAC CARDIOV SUR, V102, P578; McCarthy PM, 1996, ANN THORAC SURG, V61, P359, DOI 10.1016/0003-4975(95)00990-6; MENCONI MJ, 1992, J CARDIAC SURG, V7, P177, DOI 10.1111/j.1540-8191.1992.tb00794.x; Michalopoulos A, 1998, EUR J SURG, V164, P217; Oz MC, 1997, CIRCULATION, V95, P1844; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; ROBINS JP, 1997, CURRENT PROTOCOLS CY, V2; ROBINS JP, 1997, CURRENT PROTOCOLS CY, V1; ROSE EA, 1994, CIRCULATION, V50, P1187; SAFRIT JT, 1995, CURR OPIN IMMUNOL, V7, P456, DOI 10.1016/0952-7915(95)80088-3; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Spanier T, 1996, J THORAC CARDIOV SUR, V112, P1090, DOI 10.1016/S0022-5223(96)70111-3; SPANIER TB, 1996, CIRCULATION S8, V94, P1704; SPANIER TB, 1997, J HEART LUNG TRANSPL, V17, P80; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; *US DEP HHS, 1990, ANN REP US SCI REG O; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WAGNER WR, 1993, CIRCULATION, V88, P2023, DOI 10.1161/01.CIR.88.5.2023; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; Weyand M, 1997, TRANSPLANT P, V29, P3327, DOI 10.1016/S0041-1345(97)00932-9	40	135	136	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					550	555		10.1016/S0140-6736(98)10359-8	http://dx.doi.org/10.1016/S0140-6736(98)10359-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470699	hybrid			2022-12-28	WOS:000081991000012
J	Licht, S; Wang, BH; Ghosh, S				Licht, S; Wang, BH; Ghosh, S			Energetic iron(VI) chemistry: The super-iron battery	SCIENCE			English	Article							OXIDATION; ELECTROCHEMISTRY; FERRATE(VI)	Higher capacity batteries based on an unusual stabilized iron(VI) chemistry are presented. The storage capacities of alkaline and metal hydride batteries are largely cathode limited, and both use a potassium hydroxide electrolyte. The new batteries are compatible with the alkaline and metal hydride battery anodes but have higher cathode capacity and are based on available, benign materials. Iron(VI/III) cathodes can use low-solubility K2FeO4 and BaFeO4 salts with respective capacities of 406 and 313 milliampere-hours per gram. Super-iron batteries have a 50 percent energy advantage compared to conventional alkaline batteries. A cell with an iron(VI) cathode and a metal hydride anode is significantly (75 percent) rechargeable.	Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Licht, S (corresponding author), Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel.		Ghosh, Susanta/AAU-5849-2020	Ghosh, Susanta/0000-0002-5461-2446; Wang, Baohui/0000-0003-2547-9954				CHEN JS, 1993, J ELECTROCHEM SOC, V140, P1205, DOI 10.1149/1.2220958; DAHN JR, 1995, SCIENCE, V270, P590, DOI 10.1126/science.270.5236.590; Delaude L, 1996, J ORG CHEM, V61, P6360, DOI 10.1021/jo960633p; Dhar SK, 1997, J POWER SOURCES, V65, P1, DOI 10.1016/S0378-7753(96)02599-2; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Idota Y, 1997, SCIENCE, V276, P1395, DOI 10.1126/science.276.5317.1395; Johnson MD, 1996, CHEM COMMUN, P965, DOI 10.1039/cc9960000965; Johnson MD, 1996, INORG CHEM, V35, P6795, DOI 10.1021/ic960480o; Licht S, 1998, J PHYS CHEM B, V102, P6780, DOI 10.1021/jp981048q; McLaughin C.W., 1985, P C WAT CHLOR CHEM E, P1285; OVSHINSKY SR, 1993, SCIENCE, V260, P176, DOI 10.1126/science.260.5105.176; PERAMUNAGE D, 1993, SCIENCE, V261, P1029, DOI 10.1126/science.261.5124.1029; Reddington E, 1998, SCIENCE, V280, P1735, DOI 10.1126/science.280.5370.1735; RONG Z, 1997, SCIENCE, V276, P926; Sharma VK, 1997, ENVIRON SCI TECHNOL, V31, P2486, DOI 10.1021/es960755z; VEPREKSISKA J, CHEM IND, V548, P67	16	217	264	12	186	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1039	1042		10.1126/science.285.5430.1039	http://dx.doi.org/10.1126/science.285.5430.1039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446044				2022-12-28	WOS:000082033100037
J	Mooij, JE; Orlando, TP; Levitov, L; Tian, L; van der Wal, CH; Lloyd, S				Mooij, JE; Orlando, TP; Levitov, L; Tian, L; van der Wal, CH; Lloyd, S			Josephson persistent-current qubit	SCIENCE			English	Article							QUANTUM COMPUTATION; INFORMATION; JUNCTIONS; COMPUTER; LOGIC	A qubit was designed that can be fabricated with conventional electron beam Lithography and is suited for integration into a Large quantum computer. The qubit consists of a micrometer-sized Loop with three or four Josephson junctions; the two qubit states have persistent currents of opposite direction. Quantum superpositions of these states are obtained by pulsed microwave modulation of the enclosed magnetic flux by currents in control Lines. A superconducting flux transporter allows for controlled transfer between qubits of the flux that is generated by the persistent currents, leading to entanglement of qubit information.	Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, Delft Inst Microelect & Submicron Technol, NL-2600 GA Delft, Netherlands; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Delft University of Technology; Delft University of Technology; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Mooij, JE (corresponding author), Delft Univ Technol, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.		van der Wal, Caspar H./D-9206-2013; Tian, Lin/I-3314-2013; Mooij, Johan/B-1371-2012	van der Wal, Caspar H./0000-0002-9843-3220; Tian, Lin/0000-0001-6281-1034; 				Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; Averin DV, 1998, SOLID STATE COMMUN, V105, P659, DOI 10.1016/S0038-1098(97)10001-1; BENNETT CH, 1995, PHYS TODAY, V48, P24, DOI 10.1063/1.881452; Bocko MF, 1997, IEEE T APPL SUPERCON, V7, P3638, DOI 10.1109/77.622206; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; ELION WJ, 1994, NATURE, V371, P594, DOI 10.1038/371594a0; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Ioffe LB, 1999, NATURE, V398, P679, DOI 10.1038/19464; Joyez P, 1998, PHYS REV LETT, V80, P1956, DOI 10.1103/PhysRevLett.80.1956; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; KUZMIN LS, 1991, PHYS REV LETT, V67, P2890, DOI 10.1103/PhysRevLett.67.2890; LLOYD S, 1995, SCI AM, V273, P140, DOI 10.1038/scientificamerican1095-140; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; ORLANDO TP, UNPUB; Shnirman A, 1998, PHYS REV B, V57, P15400, DOI 10.1103/PhysRevB.57.15400; Shnirman A, 1997, PHYS REV LETT, V79, P2371, DOI 10.1103/PhysRevLett.79.2371; Spiller TP, 1996, P IEEE, V84, P1719, DOI 10.1109/5.546399; TESCHE CD, 1990, PHYS REV LETT, V64, P2358, DOI 10.1103/PhysRevLett.64.2358; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710	23	1087	1162	8	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1036	1039		10.1126/science.285.5430.1036	http://dx.doi.org/10.1126/science.285.5430.1036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446043	Green Submitted			2022-12-28	WOS:000082033100036
J	Painter, MJ; Scher, MS; Stein, AD; Armatti, S; Wang, ZM; Gardiner, JC; Paneth, N; Minnigh, B; Alvin, J				Painter, MJ; Scher, MS; Stein, AD; Armatti, S; Wang, ZM; Gardiner, JC; Paneth, N; Minnigh, B; Alvin, J			Phenobarbital compared with phenytoin for the treatment of neonatal seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EFFICACY; BRAIN; RAT	Background Seizures occur in 1 to 2 percent of neonates admitted to an intensive care unit. The treatment is usually with either phenobarbital or phenytoin, but the efficacy of the two drugs has not been compared directly. Methods From 1990 to 1995, we studied 59 neonates with seizures that were confirmed by electroencephalography. The neonates were randomly assigned to receive either phenobarbital or phenytoin intravenously, at doses sufficient to achieve free plasma concentrations of 25 mu g per milliliter for phenobarbital and 3 mu g per milliliter for phenytoin. Neonates whose seizures were not controlled by the assigned drug were then treated with both drugs. Seizure control was assessed by electroencephalographic criteria. Results Seizures were controlled in 13 of the 30 neonates assigned to receive phenobarbital (43 percent) and 13 of the 29 neonates assigned to receive phenytoin (45 percent; P = 1.00). When combined treatment is considered, seizure control was achieved in 17 (57 percent) of the neonates assigned to receive phenobarbital first and 18 (62 percent) of those assigned to receive phenytoin first (P = 0.67). The severity of the seizures was a stronger predictor of the success of treatment than was the assigned agent. Neonates with mild seizures or with seizures that were decreasing in severity before treatment were more likely to have their seizures end, regardless of the treatment assignment. Conclusions Phenobarbital and phenytoin are equally but incompletely effective as anticonvulsants in neonates. With either drug given alone, the seizures were controlled in fewer than half of the neonates. (N Engl J Med 1999;341:485-9.) (C) 1999, Massachusetts Medical Society.	Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA; Magee Womens Hosp, Pittsburgh, PA USA; Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Stat & Probabil, E Lansing, MI 48824 USA; Pharmakon Labs, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Michigan State University; Michigan State University	Painter, MJ (corresponding author), Childrens Hosp Pittsburgh, 1 Childrens Pl, Pittsburgh, PA 15213 USA.		Scher, Mark Steven/AAX-8358-2021; GARDINER, JOSEPH/AAN-9697-2021	GARDINER, JOSEPH/0000-0003-2605-6478; Stein, Aryeh/0000-0003-1138-6458	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026946] Funding Source: NIH RePORTER; NINDS NIH HHS [NS R01 26946-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRE M, 1986, EUR J CLIN PHARMACOL, V30, P585, DOI 10.1007/BF00542419; DESHMUKH A, 1986, AM J DIS CHILD, V140, P1042, DOI 10.1001/archpedi.1986.02140240088032; DIAZ J, 1977, BIOL NEONATE, V32, P77; FARWELL JR, 1992, NEW ENGL J MED, V326, P144; GAL P, 1982, NEUROLOGY, V32, P1401, DOI 10.1212/WNL.32.12.1401; GAMSTORP I, 1982, UPSALA J MED SCI, V87, P143, DOI 10.3109/03009738209178419; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; LOCKMAN LA, 1979, NEUROLOGY, V29, P1445, DOI 10.1212/WNL.29.11.1445; Massingale T W, 1993, J Perinatol, V13, P107; MIZRAHI EM, 1987, NEUROLOGY, V37, P1837, DOI 10.1212/WNL.37.12.1837; PAINTER MJ, 1978, J PEDIATR-US, V92, P315, DOI 10.1016/S0022-3476(78)80034-1; PAINTER MJ, 1994, J CLIN PHARMACOL, V34, P312, DOI 10.1002/j.1552-4604.1994.tb01999.x; SCHER MS, 1989, PEDIATR NEUROL, V5, P17, DOI 10.1016/0887-8994(89)90004-0; SCHER MS, 1994, J EPILEPSY, V7, P273, DOI 10.1016/0896-6974(94)90056-6; SEAY AR, 1977, ARCH NEUROL-CHICAGO, V34, P381, DOI 10.1001/archneur.1977.00500180075017; SVENNINGSEN NW, 1982, ARCH DIS CHILD, V57, P176, DOI 10.1136/adc.57.3.176; Thong Y H, 1974, Med Ann Dist Columbia, V43, P63; VANORMAN CB, 1985, CAN J NEUROL SCI, V12, P95; Wasterlain CG, 1997, EPILEPSIA, V38, P728, DOI 10.1111/j.1528-1157.1997.tb01244.x	19	373	384	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					485	489		10.1056/NEJM199908123410704	http://dx.doi.org/10.1056/NEJM199908123410704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441604				2022-12-28	WOS:000081962600004
J	Teng, E; Squire, LR				Teng, E; Squire, LR			Memory for places learned long ago is intact after hippocampal damage	NATURE			English	Article							TOPOGRAPHIC DISORIENTATION; RETROGRADE-AMNESIA; LESIONS; MONKEYS; HUMANS; RATS	The hippocampus is part of a system of structures in the medial temporal lobe that are essential for memory(1-3). One influential view of hippocampal function emphasizes its role in the acquisition and retrieval of spatial knowledge(4,5). By this view, the hippocampus constructs and stores spatial maps and is therefore essential for learning and remembering places, including those learned about long ago. We tested a profoundly amnesic patient (E.P.), who has virtually complete bilateral damage to the hippocampus and extensive damage to adjacent structures in the medial temporal lobe. We asked him to recall the spatial layout of the region where he grew up, from which he moved away more than 50 years ago. E.P. performed as well as or better than age-matched control subjects who grew up in the same region and also moved away. In contrast, E.P. has no knowledge of his current neighbourhood, to which he moved after he became amnesic. Our results show that the medial temporal lobe is not the permanent repository of spatial maps, and support the view that the hippocampus and other structures in the medial temporal lobe are essential for the formation of long-term declarative memories, both spatial and non-spatial, but not for the retrieval of very remote memories, either spatial or non-spatial(3,6).	Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Squire, LR (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Batschelet E, 1965, STAT METHODS ANAL PR; BOTTINI G, 1990, NEUROPSYCHOLOGIA, V28, P309, DOI 10.1016/0028-3932(90)90024-I; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; dellaRocchetta AI, 1996, CORTEX, V32, P727, DOI 10.1016/S0010-9452(96)80042-6; DERENZI E, 1977, J NEUROL NEUROSUR PS, V40, P498, DOI 10.1136/jnnp.40.5.498; Hamann SB, 1997, BEHAV NEUROSCI, V111, P850, DOI 10.1037/0735-7044.111.4.850; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Pai MC, 1997, J FORMOS MED ASSOC, V96, P660; PATERSON A, 1945, BRAIN, V68, P188, DOI 10.1093/brain/68.3.188; Reed JM, 1997, BEHAV NEUROSCI, V111, P1163, DOI 10.1037/0735-7044.111.6.1163; Reed JM, 1998, J NEUROSCI, V18, P3943; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Takahashi N, 1997, NEUROLOGY, V49, P464, DOI 10.1212/WNL.49.2.464; Wechsler D., 1997, WECHSLER MEMORY SCAL, Vthird	28	256	260	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					675	677		10.1038/23276	http://dx.doi.org/10.1038/23276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458163				2022-12-28	WOS:000082032900056
J	Valagussa, F; Franzosi, MG; Geraci, E; Mininni, N; Nicolosi, GL; Santini, M; Tavazzi, L; Vecchio, C; Marchioli, R; Bomba, E; Chieffo, C; Maggioni, AP; Schweiger, C; Tognoni, G; Barzi, F; Flamminio, AV; Marfisi, RM; Olivieri, M; Pera, C; Polidoro, A; Santoro, E; Zama, R; Pagliaro, L; Correale, E; Del Favero, A; Loi, U; Marubini, E; Campolo, L; Casari, A; Di Minno, G; Donati, MB; Galli, M; Gattone, M; Garattini, S; Mancini, M; Marino, P; Santoro, GM; Scardulla, C; Specchia, G; Cericola, A; Di Gregorio, D; Di Mascio, R; Levantesi, G; Mantini, L; Mastrogiuseppe, G; Tucci, C; Mocarelli, P; Baldinelli, R; Ceriotti, F; Colonna, A; Cortese, C; Fortunato, G; Franzini, C; Gonano, F; Graziani, MS				Valagussa, F; Franzosi, MG; Geraci, E; Mininni, N; Nicolosi, GL; Santini, M; Tavazzi, L; Vecchio, C; Marchioli, R; Bomba, E; Chieffo, C; Maggioni, AP; Schweiger, C; Tognoni, G; Barzi, F; Flamminio, AV; Marfisi, RM; Olivieri, M; Pera, C; Polidoro, A; Santoro, E; Zama, R; Pagliaro, L; Correale, E; Del Favero, A; Loi, U; Marubini, E; Campolo, L; Casari, A; Di Minno, G; Donati, MB; Galli, M; Gattone, M; Garattini, S; Mancini, M; Marino, P; Santoro, GM; Scardulla, C; Specchia, G; Cericola, A; Di Gregorio, D; Di Mascio, R; Levantesi, G; Mantini, L; Mastrogiuseppe, G; Tucci, C; Mocarelli, P; Baldinelli, R; Ceriotti, F; Colonna, A; Cortese, C; Fortunato, G; Franzini, C; Gonano, F; Graziani, MS		GISSI-Prevenzione Investigators	Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial	LANCET			English	Article							CORONARY HEART-DISEASE; RAT CARDIAC MYOCYTES; RANDOMIZED CONTROLLED TRIAL; LOW-DENSITY-LIPOPROTEIN; FISH CONSUMPTION; LONG-CHAIN; CARDIOVASCULAR-DISEASE; ANTIOXIDANT VITAMINS; ALPHA-TOCOPHEROL; RISK	Background There is conflicting evidence on the benefits of foods rich in vitamin E (alpha-tocopherol), n-3 polyunsaturated fatty acids (PUFA), and their pharmacological substitutes. We investigated the effects of these substances as supplements in patients who had myocardial infarction. Methods From October, 1993, to September, 1995, 11324 patients surviving recent (less than or equal to 3 months) myocardial infarction were randomly assigned supplements of n-3 PUFA (Ig daily, n=2836), vitamin E (300 mg daily, n=2830), both (n=2830), or none (control, n=2828) for 3.5 years. The primary combined efficacy endpoint was death, non-fatal myocardial infarction, and stroke. Intention-to-treat analyses were done according to a factorial design (two-way) and by treatment group (four-way). Findings Treatment with n-3 PUFA, but not vitamin E, significantly lowered the risk of the primary endpoint (relative risk decrease 10% [95% CI 1-18] by two-way analysis, 15% [2-26] by four-way analysis). Benefit was attributable to a decrease in the risk of death (14% [3-24] two-way, 20% [6-33] four-way) and cardiovascular death (17% [3-29] two-way, 30% [13-44] four-way). The effect of the combined treatment was similar to that for n-3 PUFA for the primary endpoint (14% [1-26]) and for fatal events (20% [5-33]). Interpretation Dietary supplementation with n-3 PUFA led to a clinically important and satistically significant benefit. Vitamin E had no benefit. Its effects on fatal cardiovascular events require further exploration.	Consorzio Mario Negri Sud, GISSI Prevenz Coordinating Ctr, I-66030 Santa Maria Imbaro, Italy	Consorzio Mario Negri Sud	Marchioli, R (corresponding author), Consorzio Mario Negri Sud, GISSI Prevenz Coordinating Ctr, I-66030 Santa Maria Imbaro, Italy.		Nicolosi, Gian Luigi/AAT-9893-2020; Garattini, Silvio/AAA-6390-2020; Donati, Maria Benedetta/K-6606-2016; Tavazzi, Luigi/ABD-5119-2020; Ceriotti, Ferruccio/S-9457-2019; Barzi, Federica/AAI-7465-2021	Nicolosi, Gian Luigi/0000-0002-2218-2808; Garattini, Silvio/0000-0003-0647-9297; Donati, Maria Benedetta/0000-0003-1747-5443; Tavazzi, Luigi/0000-0003-0336-8356; Barzi, Federica/0000-0001-7427-0167				Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1976, ACTA MED SCAND, V200, P69; BURR ML, 1989, LANCET, V2, P757; BYAR DP, 1985, CANCER TREAT REP, V69, P1055; Christensen JH, 1997, AM J CARDIOL, V79, P1670, DOI 10.1016/S0002-9149(97)00220-8; CHRISTENSEN JH, 1995, NUTR RES, V15, P1, DOI 10.1016/0271-5317(95)91647-U; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DEVITA C, 1990, LANCET, V335, P289, DOI 10.1016/0140-6736(90)90104-D; deWaart FG, 1997, ATHEROSCLEROSIS, V133, P255, DOI 10.1016/S0021-9150(97)00137-8; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FVILLMAN GE, 1999, CIRCULATION, V99, P2452; Graziani MS, 1997, EUR J CLIN CHEM CLIN, V35, P311; *GRUPP IT STUD SOP, 1993, G ITAL CARDIOL, V23, P1053; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KANG JX, 1994, P NATL ACAD SCI USA, V91, P9886, DOI 10.1073/pnas.91.21.9886; KANG JX, 1995, BIOCHEM BIOPH RES CO, V208, P629, DOI 10.1006/bbrc.1995.1385; KANG JX, 1995, P NATL ACAD SCI USA, V92, P3997, DOI 10.1073/pnas.92.9.3997; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; MACMAHON S, 1995, LANCET, V765, P225; Marchioli R, 1993, G Ital Cardiol, V23, P933; Marchioli R, 1996, LANCET, V348, P1582, DOI 10.1016/S0140-6736(05)66192-2; Marchioli R, 1996, LANCET, V347, P467; MARCHIOLI R, IN PRESS PHARM RES; Marubini E, 1995, ANAL SURVIVAL DATA C; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MCLENNAN PL, 1993, AM J CLIN NUTR, V57, P207, DOI 10.1093/ajcn/57.2.207; MEYDANI M, 1991, J NUTR, V121, P484, DOI 10.1093/jn/121.4.484; Mitchinson MJ, 1999, LANCET, V353, P381, DOI 10.1016/S0140-6736(05)74955-2; Ness A, 1999, LANCET, V353, P1017, DOI 10.1016/S0140-6736(05)70733-9; Omenn G S, 1995, Ann Epidemiol, V5, P333, DOI 10.1016/1047-2797(95)90014-4; Porkkala-Sarataho EK, 1998, AM J CLIN NUTR, V68, P1034, DOI 10.1093/ajcn/68.5.1034; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rodriguez BL, 1996, CIRCULATION, V94, P952, DOI 10.1161/01.CIR.94.5.952; SANTORO E, 1993, CONTROLLED CLIN TRIA, V14, P430; SELLMAYER A, 1995, AM J CARDIOL, V76, P974, DOI 10.1016/S0002-9149(99)80276-8; Simopoulos AP, 1997, CAN J PHYSIOL PHARM, V75, P234, DOI 10.1139/cjpp-75-3-234; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; SUZUKAWA M, 1995, J AM COLL NUTR, V14, P46; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Weber P, 1997, NUTRITION, V13, P450, DOI 10.1016/S0899-9007(97)00110-X; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182; XIAO YF, 1995, P NATL ACAD SCI USA, V92, P11000, DOI 10.1073/pnas.92.24.11000; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680	60	3060	3245	3	127	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					447	455						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465168				2022-12-28	WOS:000081896100008
J	Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA				Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA			Essential role for oncogenic Ras in tumour maintenance	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TRANSGENIC MICE; FACTOR EXPRESSION; UP-REGULATION; ANGIOGENESIS; MELANOMA; CELLS; INDUCTION; HYPOXIA	Advanced malignancy in tumours represents the phenotypic endpoint of successive genetic lesions that affect the function and regulation of oncogenes and tumour-suppressor genes(1). The established tumour is maintained through complex and poorly understood host-tumour interactions that guide processes such as angiogenesis and immune sequestration. The many different genetic alterations that accompany tumour genesis raise questions as to whether experimental cancer-promoting mutations remain relevant during tumour maintenance. Here we show thar melanoma genesis and maintenance are strictly dependent upon expression of H-Ras(V12G) in a doxycycline-inducible H-Ras mouse melanoma model null for the tumour suppressor INK4a. Withdrawal of doxycycline and H-Ras(V12G) down-regulation resulted in clinical and histological regression of primary and explanted tumours. The initial stages of regression involved marked apoptosis in the tumour cells and host-derived endothelial cells. Although the regulation of vascular endothelial growth factor (VEGF) was found td be Ras-dependent in vitro, the failure of persistent endogenous and enforced VEGF expression to sustain tumour viability indicates that the tumour-maintaining actions of activated Ras extend beyond the regulation of VEGF expression in vivo. Our results provide genetic evidence that H-Ras(V12G) is important in both the genesis and maintenance of solid tumours.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Regeneron	DePinho, RA (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X				Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BIRD IN, 1993, IMMUNOLOGY, V80, P553; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DOHERTY PC, 1994, CIBA F SYMP, V187, P245; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gause PR, 1997, MOL CARCINOGEN, V20, P78, DOI 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Larcher F, 1996, CANCER RES, V56, P5391; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TRAWEEK ST, 1991, AM J CLIN PATHOL, V96, P25, DOI 10.1093/ajcp/96.1.25; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9	25	698	748	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					468	472		10.1038/22788	http://dx.doi.org/10.1038/22788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440378				2022-12-28	WOS:000081715000055
J	Ell, PJ				Ell, PJ			Bright future for nuclear medicine	LANCET			English	Editorial Material									UCL, Sch Med, Inst Nucl Med, London W1N 8AA, England	University of London; University College London; UCL Medical School	Ell, PJ (corresponding author), UCL, Sch Med, Inst Nucl Med, Mortimer St, London W1N 8AA, England.								0	1	1	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					616	616		10.1016/S0140-6736(99)00286-X	http://dx.doi.org/10.1016/S0140-6736(99)00286-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466660				2022-12-28	WOS:000082214500007
J	Thacher, TD				Thacher, TD			Nutritional rickets	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Jos, Teaching Hosp, Jos, Nigeria	University of Jos	Thacher, TD (corresponding author), Univ Jos, Teaching Hosp, Jos, Nigeria.			Thacher, Tom/0000-0002-7644-8173					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					576	576		10.1056/NEJM199908193410805	http://dx.doi.org/10.1056/NEJM199908193410805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451463	Bronze			2022-12-28	WOS:000082061500005
J	Coutsoudis, A; Pillay, K; Spooner, E; Kuhn, L; Coovadia, HM				Coutsoudis, A; Pillay, K; Spooner, E; Kuhn, L; Coovadia, HM			Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; INFECTION; PLASMA; RISK	Background The observation that mother-to-child transmission of HIV-1 can occur through breastfeeding has resulted in policies that recommend avoidance of breastfeeding by HIV-1-infected women in the developed world and under specific circumstances in developing countries. We compared transmission rates in exclusively breastfed, mixed-fed, and formula-fed (never breastfed) infants to assess whether the pattern of breastfeeding is a critical determinant of early mother-to-child transmission of HIV-1. Methods We prospectively assessed infant-feeding practices of 549 HIV-1-infected women who were part of a vitamin A intervention trial in Durban, South Africa. The proportions of HIV-1-infected infants at 3 months (estimated by use of Kaplan-Meier life tables) were compared in the three different feeding groups, HIV-1 infection was defined by a positive RNA-PCR test. Findings At 3 months, 18.8% (95% CI 12.6-24.9) of 156 never-breastfed children were estimated to be HIV-1 infected compared with 21.3% (17.2-25.5) of 393 breastfed children (p=0.5). The estimated proportion (Kaplan-Meier) of infants HIV-1 infected by 3 months was significantly lower for those exclusively breastfed to 3 months than in those who received mixed feeding before 3 months (14.6% [7.7-21.4] vs 24.1% [19.0-29.2], p=0.03) After adjustment for potential confounders (maternal CD4-cell/CD8-cell ratio, syphilis screening test results, and preterm delivery), exclusive breastfeeding carried a significantly lower risk of HIV-1 transmission than mixed feeding (hazard ratio 0.52 [0.28-0.98]) and a similar risk to no breastfeeding (0.85 [0.51-1.42]). Interpretations Our findings have important implications for prevention of HIV-1 infection and infant-feeding policies in developing countries and further research is essential. In the meantime, breastfeeding policies for HIV-l-infected women require urgent review. If our findings are confirmed, exclusive breastfeeding may offer HIV-l-infected women in developing countries an affordable, culturally acceptable, and effective means of reducing mother-to-child transmission of HIV-1 while maintaining the overwhelming benefits of breastfeeding.	Univ Natal, Sch Med, Dept Paediat & Child Hlth, ZA-4013 Congella, South Africa; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA	University of Kwazulu Natal; Columbia University	Coutsoudis, A (corresponding author), Univ Natal, Sch Med, Dept Paediat & Child Hlth, Private Bag 7,, ZA-4013 Congella, South Africa.			Spooner, Elizabeth/0000-0002-1498-8131				Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; FABER M, 1997, S AFR J FOOD SCI NUT, V9, P43; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Karlsson K, 1997, PEDIATR INFECT DIS J, V16, P963, DOI 10.1097/00006454-199710000-00012; KOVAR MG, 1984, PEDIATRICS, V74, P615; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LABBOCK M, 1997, BREASTFEEDING CHILD; LAGAMMA EF, 1985, AM J DIS CHILD, V139, P385, DOI 10.1001/archpedi.1985.02140060067031; LAWRENCE RA, 1994, BREASTFEEDING GUIDE; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NEWBURG DS, 1992, PEDIATR RES, V31, P22, DOI 10.1203/00006450-199201000-00004; PLANCHON SM, 1994, J IMMUNOL, V153, P5730; PREBLE EA, 1995, LINKAGES PROJECT; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; UDALL JN, 1981, PEDIATR RES, V15, P245, DOI 10.1203/00006450-198103000-00009; *UNAIDS, 1998, HIV INF FEED REV HIV; Wahl S M, 1997, Oral Dis, V3 Suppl 1, pS64	26	362	370	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					471	476		10.1016/S0140-6736(99)01101-0	http://dx.doi.org/10.1016/S0140-6736(99)01101-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465172				2022-12-28	WOS:000081896100012
J	McCarthy, M				McCarthy, M			Caveat doctor	LANCET			English	Editorial Material									Lancet, New York, NY 10010 USA		McCarthy, M (corresponding author), Lancet, New York, NY 10010 USA.							Stryer D, 1996, J GEN INTERN MED, V11, P575, DOI 10.1007/BF02599024	1	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					446	446		10.1016/S0140-6736(99)00266-4	http://dx.doi.org/10.1016/S0140-6736(99)00266-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465167				2022-12-28	WOS:000081896100007
